Criterion,Intent
Ability and willingness to adhere to the study visit schedule and all protocol requirements,able-to-comply
Ability and willingness to comply with the requirements of the study protocol,able-to-comply
"Ability and willingness to comply with the requirements of the study protocol. When it is determined by the study investigator that a potential research participant is cognitively impaired, a surrogate consent from a caregiver or legally-authorized representative will be obtained. Caregiver or legally-authorized representative will ensure that they comply with the protocol in order for the subject to be considered eligible.",able-to-comply
"Ability and willingness to comply with the study protocol procedures, including PRO measures.",able-to-comply
Ability to adhere to the study visit schedule and other protocol requirements,able-to-comply
Ability to complete questionnaires by themselves or with assistance.,able-to-comply
"Ability to comply with study visits, treatment, procedures, PK and PD sample collection, and required study follow-up.",able-to-comply
"Ability to comply with study visits, treatment, procedures, PK and pharmacodynamic sample collection, and required study follow-up.",able-to-comply
Ability to comply with the protocol.,able-to-comply
Ability to comply with the treatment schedule,able-to-comply
"Ability to comply with the treatment, evaluations and required study follow-up.",able-to-comply
"Ability to comply with treatment, PK and test schedules",able-to-comply
Ability to follow protocol procedures.,able-to-comply
Ability to tolerate sedation and or general anesthesia if required.,able-to-comply
Ability to tolerate thin liquids by mouth at the time of enrollment.,able-to-comply
Ability to understand and follow the breathing instructions involved in the respiratory gating procedure or to tolerate compression sufficient to reduce fiducial motion to <= 5mm.,able-to-comply
Able and willing to complete the entire study,able-to-comply
Able and willing to complete the entire study according to the study schedule.,able-to-comply
Able to adhere to the study visit schedule and other protocol requirements.,able-to-comply
Able to comply with protocol requirements and follow-up procedures.,able-to-comply
Able to comply with study procedures,able-to-comply
Able to comply with study requirements,able-to-comply
"Able to comply with the study protocol and procedures, in the investigator&rsquo;s judgment.",able-to-comply
Able to comply with the treatment schedule.,able-to-comply
"able to tolerate a confined area (ie, not claustrophobic)",able-to-comply
Able to tolerate a ultrasound guided biopsy,able-to-comply
Able to tolerate apheresis,able-to-comply
"Able to tolerate apheresis, including placement of temporary apheresis line if required",able-to-comply
Able to tolerate daily supplementation of calcium and vitamin D,able-to-comply
Able to tolerate feeds either orally or via tube gastrostomy or enterostomy.,able-to-comply
Able to tolerate general or spinal anesthesia.,able-to-comply
Able to tolerate HFRT (e.g. lie flat and hold position for treatment),able-to-comply
Able to tolerate PET/MRI with intravenous contrast administration and must complete the applicable MRI screening evaluation form,able-to-comply
"Able to tolerate the conditions required to perform imaging studies (e.g., lying flat for at least 1 hour).",able-to-comply
Able to tolerate the supine position as required for the radiation treatment unit and able to tolerate rotation needed for treatment delivery,able-to-comply
"Any medical condition, which would make the imaging studies unsafe or poorly tolerated",able-to-comply
"Any uncontrolled significant medical, psychiatric or surgical condition (active infection, unstable angina pectoris, cardiac arrhythmia, poorly controlled hypertension, poorly controlled diabetes mellitus [HbA1c >= 9%], uncontrolled congestive heart disease, etc.) or laboratory findings that, in the opinion of the investigator, might jeopardize the patient's safety or that would limit compliance with the objectives and assessments of the study. Note: the patient should be able to tolerate high volume load.",able-to-comply
Are able and willing to make themselves available for the duration of the study and are willing to follow study procedures.,able-to-comply
Are able to comply with the requirements of the entire study,able-to-comply
Are physically unable to tolerate flexible bronchoscopy or moderate sedation as determined by the bronchoscopist,able-to-comply
Are reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures.,able-to-comply
Are unwilling or unable to comply with procedures required in this protocol,able-to-comply
Are unwilling or unable to comply with procedures required in this protocol.,able-to-comply
"Are unwilling or unable to participate in, or do not have adequate tissue for participation in the genetic and biomarker portion of the study.",able-to-comply
Are willing or able to comply with procedures required in this protocol.,able-to-comply
"As determined by the enrolling physician or protocol designee, ability of the subject to understand and comply with study procedures for the entire length of the study.",able-to-comply
"As determined by the enrolling physician or protocol designee, willingness and ability of the subject to understand and comply with study procedures",able-to-comply
"As determined by the enrolling physician, ability of the subject to understand and comply with study procedures for the entire length of the study.",able-to-comply
Assessed by the Investigator to be unable or unwilling to comply with the requirements of the protocol.,able-to-comply
"Be able to comply with all study-related procedures, medication use, and evaluations",able-to-comply
Be able to comply with the requirements of the entire study.,able-to-comply
Can tolerate 18F-fluciclovine PET/CT exam (can lie on her back for the duration of the scan).,able-to-comply
"Capable of understanding the investigative nature, potential risks, and benefits of the study.",able-to-comply
Clinically significant psychiatric illness/social situations thatwould limit compliance with study requirements.,able-to-comply
"Contraindication to or inability to tolerate MRI with endorectal coil (e.g. severe claustrophobia, presence of cardiac pacemaker, aneurysm clip, severe or painful hemorrhoids, rectal stricture)",able-to-comply
Contraindication to or inability to tolerate MRIs,able-to-comply
Donor must be willing and able to undergo PBSC collection.,able-to-comply
Expected non-compliance.,able-to-comply
"Has a primary informal caregiver (as defined by an unpaid individual who provides the patient with emotional, physical, and/or practical support) who is willing and able to participate in the study",able-to-comply
Has insurance coverage or is willing to pay for protocol therapy (rituximab x 4 or Zevalin x 1),able-to-comply
Have access or willing to set up access to Duke MyChart.,able-to-comply
Have voluntarily agreed to provide written informed consent and demonstrated willingness and ability to comply with all aspects of the protocol.,able-to-comply
If the patient's treatment visit schedule is too infrequent to meet the study visit timeline requirements,able-to-comply
"In the investigator's opinion, the patient has the ability to communicate satisfactorily with the investigator and the study team, to participate fully in the study, and comply with all requirements.",able-to-comply
"In the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)",able-to-comply
"Inability for the subject to complete protocol requirements, such as geographic considerations, psychiatric disorders, or other compliance concerns",able-to-comply
Inability to attend full course of radiotherapy or follow-up visits,able-to-comply
Inability to comply with medical therapy or follow-up,able-to-comply
Inability to comply with protocol mandated hospitalization and restrictions,able-to-comply
Inability to comply with protocol/procedures.,able-to-comply
Inability to comply with protocol-mandated hospitalization and activities restrictions.,able-to-comply
Inability to comply with study and follow-up procedures,able-to-comply
Inability to comply with study and/or follow-up procedures,able-to-comply
Inability to comply with study or follow-up testing and procedures.,able-to-comply
Inability to comply with study procedures,able-to-comply
Inability to comply with study-related procedures,able-to-comply
Inability to comply with visit schedule or other protocol requirements.,able-to-comply
Inability to tolerate 18F-fluciclovine PET/CT exam,able-to-comply
Inability to tolerate additional imaging time in the opinion of the investigator or treating physician.,able-to-comply
Inability to tolerate anesthesia,able-to-comply
"Inability to tolerate at least one modality of diagnostic anatomic imaging, such as CT or MRI",able-to-comply
Inability to tolerate bronchoscopy.,able-to-comply
Inability to tolerate imaging procedures in the opinion of an investigator or treating physician,able-to-comply
Inability to tolerate MRI with contrast.,able-to-comply
Inability to tolerate or complete the HRA procedure,able-to-comply
Inability to tolerate or undergo PET/MRI or PET/CT,able-to-comply
Inability to tolerate prolonged Trendelenburg position as deemed by anesthesiology,able-to-comply
inability to tolerate sedated upper endoscopy due to cardio-pulmonary instability or other significant medical issues,able-to-comply
Inability to tolerate stationary position during HIFU,able-to-comply
Inability to tolerate stationary position during HIFU.,able-to-comply
Inability to tolerate thromboprophylaxis,able-to-comply
Inability to tolerate thromboprophylaxis.,able-to-comply
Individuals must be able to comply with the requirements of REVLIMID Risk Evaluation and Mitigation Strategy (REMS)®,able-to-comply
Individuals who are not able or willing to tolerate the required prolonged stationary position during treatment (approximately 2 hrs.),able-to-comply
Is unable to tolerate a contrast enhanced computed tomography (CT) or magnetic resonance imaging (MRI) for staging/restaging purposes,able-to-comply
"Judgement by the Investigator or Medical Monitor that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions, and requirements",able-to-comply
"Judgment by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions and requirements",able-to-comply
"Judgment by the Investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions and requirements.",able-to-comply
"Judgment by the Investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions, and requirements.",able-to-comply
"Known medical, psychiatric, substance abuse, or cognitive disorder that may compromise the patient's ability to understand the patient information, give informed consent, comply with the study protocol or complete the study.",able-to-comply
Limitation of the patient's ability to comply with treatment or follow-up requirements; and,able-to-comply
"Medical, psychiatric, cognitive or other conditions that compromise the patient's ability to understand the patient information, to give informed consent, to comply with the study protocol or to complete the study",able-to-comply
"Medical, psychiatric, cognitive or other conditions that may compromise the patient's ability to understand the patient information, give informed consent, comply with the study protocol or complete the study.",able-to-comply
Medically and psychologically fit and willing to donate,able-to-comply
Must be able to comply with study protocol procedures.,able-to-comply
Must be able to comply with the study and follow-up requirements.,able-to-comply
Must be able to schedule and tolerate additional PET/CT imaging following therapy,able-to-comply
"Must be able to tolerate additional blood draws before, during, and after the radioembolization therapy procedure.",able-to-comply
Must be able to tolerate CT and/or MRI with contrast,able-to-comply
Must be able to tolerate the confinement of an MRI procedure,able-to-comply
Must be willing and able to accept at least one leukapheresis procedure,able-to-comply
Must be willing to take effective antiretroviral therapy if indicated,able-to-comply
Must be willing to take effective antiretroviral therapy if indicated.,able-to-comply
Newly diagnosed MCL: Patients must be willing to receive transfusions of blood products,able-to-comply
Not willing to give longitudinal blood specimens for research use or not willing to allow access to medical records for non-clinical purposes.,able-to-comply
"Participant agrees to, and be capable of, adhering to the study visit schedule and other protocol requirements, including follow-up for survival.",able-to-comply
"Participant is not able to tolerate supine position on PET/CT bed for the duration of the PET/CT acquisitions, is not cooperative, or needs continuous nursing (e.g. patient from Intensive Care Unit) or is unable to attend full course of follow up visits",able-to-comply
"Participant must be willing to comply with study and/or follow-up procedures, including willingness to be followed for one year post-HCT",able-to-comply
"Participants must be willing and able to comply with scheduled visits, treatment schedule, and laboratory testing.",able-to-comply
Participants who are unable to undergo an MRI,able-to-comply
Patient has a caretaker willing to assist with study compliance,able-to-comply
Patient is able and willing to adhere to the study visit schedule and other protocol requirements,able-to-comply
Patient is able and willing to use the Medication Event Monitoring System (MEMS) TrackCap (e.g. not using a pillbox).,able-to-comply
"Patient is unable to tolerate MRI (foreign body; i.e. pacemaker or other implanted device; claustrophobia; inability to tolerate rectal coil, etc.…)",able-to-comply
"Patient is unable to tolerate remaining still on the bed of the PET camera, due to physical limitations or claustrophobia.",able-to-comply
"Patient is unwilling or unable to comply with scheduled visits, drug administration plan, laboratory tests, or other study procedures and study restrictions.",able-to-comply
Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up.,able-to-comply
Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations.,able-to-comply
Patient must be able to adhere to the study visit schedule and other protocol requirements.,able-to-comply
"Patient must be able to communicate with the investigator, to comply with the requirements of the study procedures, and is willing to remain at the clinical site during the study duration.",able-to-comply
Patient must be able to tolerate PET/CT or PET/MR imaging,able-to-comply
Patient unable to comply with Optune device treatment or the study follow- up schedule,able-to-comply
Patient unable to have an MRI,able-to-comply
Patient willing to complete a medication diary,able-to-comply
Patients able to tolerate PET/MRI scans,able-to-comply
Patients are unable or unwilling to comply with the requirements of clinical trial,able-to-comply
Patients must be able and willing to receive anticoagulation prophylactically versus therapeutically as clinically indicated,able-to-comply
Patients must be able to adhere to the study visit schedule and other protocol requirements.,able-to-comply
Patients must be able to tolerate CT or magnetic resonance (MR) imaging including contrast agents as required for the treatment and the protocol,able-to-comply
Patients must be willing and able to complete study-required procedures,able-to-comply
"Patients must be willing and able to comply with scheduled visits, treatment plan, and laboratory tests.",able-to-comply
Patients must be willing to receive transfusions of blood products,able-to-comply
Patients must fulfill all the following requirements to enter the study:,able-to-comply
Patients must voluntarily sign and date informed consent forms that state his or her willingness to comply with all study procedures and availability for the duration of the study.,able-to-comply
Patients of both sexes must be willing to practice birth control from the time of enrollment on this study and for four months after receiving the protocol treatment.,able-to-comply
Patients should have the ability and willingness to comply with the study and follow-up procedures.,able-to-comply
Patients that cannot tolerate additional imaging procedures following therapy,able-to-comply
Patients that cannot tolerate MRI,able-to-comply
Patients that cannot tolerate the additional blood draws required for this study,able-to-comply
Patients unable to receive contrast enhanced brain magnetic resonance imaging (MRI),able-to-comply
Patients unable to undergo an MRI with contrast,able-to-comply
"Patients unable to undergo gadolinium contrast-enhanced MRI or receive IV contrast for any reason (e.g., due to pacemaker, ferromagnetic implants, claustrophobia, extreme obesity, hypersensitity).",able-to-comply
Patients unable to undergo MRI imaging,able-to-comply
Patients unable to undergo MRI of the prostate.,able-to-comply
Patients unwilling or unable to comply with the protocol.,able-to-comply
"Patients unwilling or unable to undergo magnetic resonance (MR) imaging, including patients with contraindications to MRI, such as cardiac pacemakers or non-compatible intracranial vascular clips",able-to-comply
"Patients unwilling or unable to undergo MR imaging, including patients with contra-indications to MRI, such as cardiac pacemakers or non-compatible intracranial vascular clips.",able-to-comply
Patients unwilling or unable to undergo pelvic MRI,able-to-comply
Patients unwilling to comply with the protocol,able-to-comply
Patients who are able to tolerate flexible bronchoscopy,able-to-comply
Patients who are deemed unable to safely undergo or tolerate flexible bronchoscopy,able-to-comply
Patients who are unable to tolerate anesthesia or sedation,able-to-comply
Patients who are unable to tolerate general anesthesia according to the anesthesiologist,able-to-comply
Patients who are unable to undergo MRI,able-to-comply
Patients who cannot tolerate intravesical dosing or intravesical surgical manipulation,able-to-comply
Patients who cannot tolerate the vaginal ultrasound procedure.,able-to-comply
"Patients will undergo CT imaging of the chest, abdomen, and pelvis to evaluate lung and liver metastases within 30 days of registration; for patients who cannot tolerate CT contrast or have hepatic steatosis that reduces the sensitivity of CT, MRI of the liver will be performed",able-to-comply
Patients willing to comply with study requirements,able-to-comply
"Perspective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics).",able-to-comply
"Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)",able-to-comply
"Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics).",able-to-comply
"psychiatric conditions e.g. patients unlikely to comply with the protocol, e.g. mental condition rendering the patient unable to understand the nature, scope, and possible consequences of participating in the study",able-to-comply
Psychiatric illness / social situations that would limit compliance with study requirements,able-to-comply
Psychiatric illness or social situation that would limit the patient's ability to tolerate and/or comply with study requirements.,able-to-comply
Psychiatric illness or social situations that would limit compliance with study requirements,able-to-comply
Psychiatric illness or social situations that would preclude study compliance.,able-to-comply
Psychiatric illness/social situation that would preclude compliance with study requirements,able-to-comply
Psychiatric illness/social situations,able-to-comply
Psychiatric illness/social situations that would limit compliance with study requirements,able-to-comply
Psychiatric illness/social situations that would limit compliance with study requirements and ability to comprehend the investigational nature of the study and provide informed consent.,able-to-comply
Psychiatric illness/social situations that would limit compliance with study requirements.,able-to-comply
Psychiatric illness/social situations that would limit the patient s ability to tolerate and/or comply with study requirements.,able-to-comply
"RECIPIENT: Participant must be willing to comply with study and/or follow-up procedures, including willingness to be followed for one year post-HCT",able-to-comply
"RECIPIENT: Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)",able-to-comply
"Refusal or inability to tolerate the scanning procedure (e.g., due to claustrophobia)",able-to-comply
Severe psychiatric illness/social situations or cognitive impairment that would limit the patient s ability to tolerate and/or comply with study requirements,able-to-comply
Signed an informed consent form (ICF) indicating that the subject understands the purpose of and procedures required for the study and is willing to participate in the study; subjects must be willing and able to adhere to the prohibitions and restrictions specified in this protocol (Section 4.3),able-to-comply
Stated willingness to comply with all study procedures and availability for the duration of the Study,able-to-comply
Stated willingness to comply with all study procedures and be available for the duration of the study.,able-to-comply
Stated willingness to comply with study procedures and duration.,able-to-comply
STEP 1: If patient says 'Yes' to  I choose to take part in the imaging study and will have the diffusion weighted magnetic resonance imaging (MRI) scans : patients must be able to tolerate MRI scans:,able-to-comply
Subject is able to tolerate endoscopy,able-to-comply
Subject is unable or unwilling to participate in a study related procedure,able-to-comply
Subject is unable or unwilling to undergo protocol required thromboembolism prophylaxis.,able-to-comply
"Subject is willing and able to adhere to the study visit schedule and other protocol requirements within this protocol and for a subject randomized to Treatment Arm A, subject agrees to continued follow-up for up to 15 years as mandated by the regulatory guidelines for gene therapy trials.",able-to-comply
"Subject is willing and able to comply with scheduled visits, treatment plans, laboratory tests and other procedures (including bone marrow assessments).",able-to-comply
Subject is willing and able to comply with study procedures based on the judgement of the investigator or protocol designee.,able-to-comply
Subject is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits as well as follow up examinations.,able-to-comply
Subject is willing or able to comply with procedures required in this protocol. Disease Activity,able-to-comply
Subject must be able to comply with all study-related procedures and medication use.,able-to-comply
Subject must be willing and able to adhere to the prohibitions and restrictions specified in this protocol.,able-to-comply
Subject not able or willing to tolerate the required prolonged stationary supine position during treatment,able-to-comply
Subjects is willing and able to comply with study procedures based on the judgement of the investigator or protocol designee.,able-to-comply
"Subjects must be willing and able to comply with scheduled visits, treatment schedule, laboratory tests and other requirements of the study.",able-to-comply
Subjects should be able and willing to comply with protocol visits and procedures.,able-to-comply
Subjects should be willing and able to comply with the study schedule and protocols.,able-to-comply
"Systemic staging including CT that covers the chest, liver and adrenal glands or a PET/CT; MRI of the brain is required and must be negative for metastatic spread. If a patient is unable to tolerate MRI or has a contraindication to MRI, a head CT scan with and without contrast is acceptable",able-to-comply
"The patient is able to adhere to the study visit schedule and other protocol requirements, including follow-up for survival assessment.",able-to-comply
The patient is unable or unwilling to take folic acid or vitamin B12 supplementation,able-to-comply
The patient is unwell or unable to participate in all required study evaluations and procedures,able-to-comply
The patient must be able to tolerate SPECT/CT and PET/CT imaging. This includes:,able-to-comply
"The subject must have the ability to understand and comply with study procedures for the entire length of the study, as determined by the treating physician or protocol designee.",able-to-comply
Tolerated previous transrectal ultrasound guided biopsy procedure under local anesthetic,able-to-comply
Tumor sample requirements:,able-to-comply
Unable for any reason to undergo MRI of the brain,able-to-comply
Unable or unwilling to abide by the study protocol or cooperate fully with the investigator or designee,able-to-comply
Unable or unwilling to tolerate an intracranial MRI,able-to-comply
Unable or unwilling to undergo MRI,able-to-comply
Unable or unwilling to undergo MRI if indicated,able-to-comply
Unable to comply with study investigations (in the judgment of the investigator),able-to-comply
"Unable to comply with the requirements of the protocol, or unable to provide adequate informed consent in the opinion of the principal investigator",able-to-comply
Unable to lie comfortably on a bed inside the MR-PET,able-to-comply
Unable to lie flat during or tolerate PET/CT,able-to-comply
"Unable to lie flat during or tolerate PET/MRI, PET/CT or SBRT.",able-to-comply
"Unable to lie flat, still or tolerate a PET scan",able-to-comply
"Unable to lie flat, still or tolerate a PET scan.",able-to-comply
"Unable to lie flat, still or tolerate a PET/CT scan.",able-to-comply
"Unable to lie flat, still, or tolerate a PET/CT scan",able-to-comply
Unable to lie supine for 1-hour imaging with PET,able-to-comply
Unable to tolerate a contrast enhanced computed tomography (CT) or magnetic resonance imaging (MRI) for staging/restaging purposes,able-to-comply
Unable to tolerate anesthesia or sedation,able-to-comply
Unable to tolerate PET scan (i.e. if the patient is claustrophobic or unable to lie still for 30-60 minutes),able-to-comply
Unable to tolerate prone positioning,able-to-comply
Unable to tolerate the expected radiation therapy prescription,able-to-comply
Unable to tolerate up to 90 min of PET/CT imaging per imaging session.,able-to-comply
Unable to tolerate up to 90 min of PET/MR imaging per imaging session.,able-to-comply
Unable to undergo brain MRI,able-to-comply
Unable to undergo contract MRI of the brain,able-to-comply
Unable to undergo contrast MRI of the brain,able-to-comply
Unable to undergo magnetic resonance imaging (MRI),able-to-comply
"Unable to undergo MRI due to presence of errant metal, cardiac pacemakers, pain pumps or other MRI incompatible devices (MRI group only)",able-to-comply
Unable to undergo MRI of the spine,able-to-comply
Unable to undergo MRI:,able-to-comply
Unable to undergo PET imaging due to pre-existing comorbidities and/or claustrophobia,able-to-comply
Unwilling or unable to comply with study procedures (including follow-up procedures).,able-to-comply
Unwilling or unable to comply with the protocol.,able-to-comply
Unwilling or unable to comply with the trial protocol.,able-to-comply
Unwilling or unable to follow protocol requirements,able-to-comply
Unwilling or unable to follow protocol requirements.,able-to-comply
Unwilling or unable to participate in all required study evaluations and procedures.,able-to-comply
Unwillingness or inability to comply with procedures required in this protocol,able-to-comply
Unwillingness or inability to comply with procedures required in this protocol.,able-to-comply
Willing and able to comply with all aspects of the protocol.,able-to-comply
Willing and able to comply with clinic visits and study-related procedures,able-to-comply
Willing and able to comply with scheduled visits and study procedures.,able-to-comply
"Willing and able to comply with scheduled visits, drug administration plan, imaging studies, laboratory tests, other study procedures, and study restrictions including mandatory prophylaxis for Pneumocystis jirovecii pneumonia (PJP)",able-to-comply
"Willing and able to comply with scheduled visits, treatment plan and laboratory tests",able-to-comply
"Willing and able to comply with scheduled visits, treatment plan and laboratory tests.",able-to-comply
"Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.",able-to-comply
Willing and able to comply with study and follow-up procedures,able-to-comply
Willing and able to comply with study procedures and follow-up.,able-to-comply
Willing and able to participate in all required evaluations and procedures in this study including swallowing CBT-101 in accordance administration schedule outlined.,able-to-comply
"Willing and able to participate in all required study evaluations and procedures including receiving IV administration of study drug and admission to the hospital, when required, for at least 24 hrs during administration of study drug",able-to-comply
Willing and able to register into and comply with the mandatory requirements of Celgene's REVLIMID (lenalidomide) Risk Evaluation and Mitigation Strategies (REMS&trade;) program,able-to-comply
Willing and able to tolerate brain MRI's with contrast,able-to-comply
Willing and able to tolerate exhaled breath collection.,able-to-comply
Willing and able to understand the nature of this study and to comply with the study and follow-up procedures.,able-to-comply
Willing to adhere to the prohibitions and restrictions specified in this protocol,able-to-comply
Willing to agree to periodic contact with a member of the study team during the period that the cancer has not recurred and/or has not become platinum resistant,able-to-comply
Willing to be randomized,able-to-comply
Willing to be randomized to placebo for one year,able-to-comply
Willing to complete follow-up serial blood samples post-operatively.,able-to-comply
Willing to follow the requirements of the Pomalyst REMS program.,able-to-comply
"Willing to limit daily alcohol intake to the following: one 12-oz glass of beer, one 6-oz glass of wine, or one 1.5-oz portion of 80-proof alcohol.",able-to-comply
Willing to maintain adherence to combination antiretroviral therapy,able-to-comply
Willing to receive a tetanus vaccination if subject has not had one within the past year.,able-to-comply
Willing to return to Mayo clinic for follow up,able-to-comply
Willing to return to Mayo Clinic Rochester for follow-up.,able-to-comply
"Willingness and ability of the subject to comply with scheduled visits, drug administration plan, protocol-specified laboratory tests, other study procedures, and study restrictions.",able-to-comply
Willingness and ability of the subject to comply with study activities.,able-to-comply
Willingness and ability to comply with all study procedures,able-to-comply
"Willingness and ability to comply with scheduled visits, drug administration plan, protocol-specified laboratory tests, other study procedures, and study restrictions.",able-to-comply
"Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures",able-to-comply
"Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests, and other trial procedures",able-to-comply
"Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests, and other trial procedures.",able-to-comply
"Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other procedures.",able-to-comply
"Willingness and ability to comply with study and follow-up procedures, and give written informed consent.",able-to-comply
Willingness and ability to comply with study and follow-up procedures.,able-to-comply
Willingness and ability to comply with study procedures and follow-up examination.,able-to-comply
Willingness and ability to comply with trial and follow-up procedures and provide written informed consent.,able-to-comply
"Willingness and ability to comply with trial and follow-up procedures, and give written informed consent",able-to-comply
"Willingness and ability to comply with trial and follow-up procedures, give written informed consent.",able-to-comply
Willingness and ability to participate in all required evaluations and procedures in this study protocol including swallowing capsules without difficulty,able-to-comply
Willingness and capability to comply with the requirements of the study,able-to-comply
"Willingness to avoid exposing breast skin to natural or artificial sunlight (i.e., tanning beds) for the duration of the study.",able-to-comply
"Willingness to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.",able-to-comply
Willingness to follow the requirements of the intravenous ascorbic acid program schedule,able-to-comply
Willingness to follow the requirements of the intravenous ascorbic acid program schedule.,able-to-comply
"women who are unable to tolerate study constraints, frail, or unable to cooperate",able-to-comply
Women who are unable to tolerate study constraints.,able-to-comply
Ability of patient or Legally Authorized Representative (LAR) to understand and the willingness to sign a written informed consent document,able-to-consent
Ability of patient or Legally Authorized Representative (LAR) to understand and the willingness to sign a written informed consent document.,able-to-consent
Ability of patient to provide informed consent.,able-to-consent
Ability of subject or Legally Authorized Representative (LAR) to understand and sign the written informed consent document.,able-to-consent
Ability of subject or Legally Authorized Representative (LAR) to understand and the willingness to sign a written informed consent document,able-to-consent
Ability of subject or Legally Authorized Representative (LAR) to understand and the willingness to sign a written informed consent document.,able-to-consent
Ability of subject or parent/guardian to understand and the willingness to sign a written informed consent document,able-to-consent
Ability of subject to understand and the willingness to sign a written informed consent document.,able-to-consent
Ability to consent.,able-to-consent
Ability to give informed consent,able-to-consent
Ability to give informed consent.,able-to-consent
"Ability to give written, informed consent prior to any study-specific Screening procedures, with the understanding that the consent may be withdrawn by the patient at any time without prejudice",able-to-consent
"Ability to give written, informed consent prior to any study-specific screening procedures, with the understanding that the consent may be withdrawn by the patient at any time without prejudice.",able-to-consent
Ability to provide consent.,able-to-consent
Ability to provide informed consent,able-to-consent
Ability to provide informed consent and adhere to the required follow-up,able-to-consent
Ability to provide informed consent.,able-to-consent
Ability to provide informed written consent,able-to-consent
Ability to provide informed written consent and be able to adhere to the study visit schedule and other protocol requirements.,able-to-consent
Ability to provide informed written consent.,able-to-consent
Ability to provide the written informed consent and can understand and comply with the requirements of the study.,able-to-consent
Ability to provide written consent.,able-to-consent
Ability to provide written informed consent,able-to-consent
Ability to provide written informed consent and to understand and comply with the requirements of the study,able-to-consent
Ability to provide written informed consent for the protocol and understand the investigational nature of the study.,able-to-consent
Ability to provide written informed consent which must be obtained prior to any screening procedures and according to local guidelines,able-to-consent
Ability to provide written informed consent.,able-to-consent
Ability to read and understand and willing to sign a written informed consent form.,able-to-consent
"Ability to read, understand and evaluate study materials and willingness to sign a written informed consent document",able-to-consent
"Ability to read, understand, and sign a written informed consent approved by each institutional IRB. Alternatively, patients with legal guardians who can read, understand, and sign written informed consent may also enroll.",able-to-consent
Ability to sign and date the consent form.,able-to-consent
"Ability to understand a written informed consent document, and the willingness to sign it.",able-to-consent
Ability to understand and provide informed consent,able-to-consent
Ability to understand and provide informed consent.,able-to-consent
Ability to understand and sign a written informed consent,able-to-consent
Ability to understand and the willingness to sign a written informed consent document,able-to-consent
Ability to understand and the willingness to sign a written informed consent document (adult subject or parent/legal guardian of minor subject),able-to-consent
Ability to understand and the willingness to sign a written informed consent document (all cohorts),able-to-consent
Ability to understand and the willingness to sign a written informed consent document and to undergo tumor biopsies in the expansion phase.,able-to-consent
Ability to understand and the willingness to sign a written informed consent document that is approved by the local institutional review board and HIPAA authorization for the release of personal health information.,able-to-consent
Ability to understand and the willingness to sign a written informed consent document.,able-to-consent
"Ability to understand and the willingness to sign a written informed consent document; if a patient has impaired decision-making capacity, a legally authorized representative, patients will be allowed to participate",able-to-consent
Ability to understand and the willingness to sign a written informed consent document; patients must have signed informed consent to participate in the trial,able-to-consent
Ability to understand and the willingness to sign a written informed consent.,able-to-consent
Ability to understand and the willingness to sign a written informed consent/assent document,able-to-consent
Ability to understand and the willingness to sign a written informed consentdocument.,able-to-consent
Ability to understand and the willingness to sign an informed consent document,able-to-consent
Ability to understand and the willingness to sign an Institutional Review Board (IRB) approved written informed consent document.,able-to-consent
Ability to understand and the willingness to sign an Institutional Review Board (IRB)-approved informed consent document (either directly or via a legally authorized representative),able-to-consent
Ability to understand and to sign a written informed consent document,able-to-consent
Ability to understand and voluntarily give informed consent.,able-to-consent
Ability to understand and willing to sign a written informed consent document,able-to-consent
Ability to understand and willingness to sign a written informed consent and HIPAA consent document,able-to-consent
Ability to understand and willingness to sign a written informed consent and HIPAA consent document. LARs are allowed to sign on patient's behalf with proper documentation.,able-to-consent
Ability to understand and willingness to sign a written informed consent document,able-to-consent
Ability to understand and willingness to sign a written informed consent document (I-SPY 2 TRIAL Screening Consent).,able-to-consent
Ability to understand and willingness to sign a written informed consent document (I-SPY 2 TRIAL Treatment Consent),able-to-consent
Ability to understand and willingness to sign a written informed consent form (the consent form must be signed by the patient prior to any study-specific procedures).,able-to-consent
Ability to understand and willingness to sign a written informed consent.,able-to-consent
"Ability to understand and willingness to sign an IRB approved written informed consent document (or that of legally authorized representative, if applicable).",able-to-consent
Ability to understand and willingness to sign Institutional Review Board (IRB)-approved informed consent.,able-to-consent
"Ability to understand and/or the willingness of the patient (or parent or legally authorized representative, if minor) to provide informed consent, using an institutionally approved informed consent procedure.",able-to-consent
Ability to understand the protocol and provide informed consent,able-to-consent
Ability to understand the purpose and risks of the study and provide signed and dated ICF and authorization to use protected health information.,able-to-consent
Ability to understand the purpose and risks of the study and provide signed and dated informed consent and authorization to use protected health information,able-to-consent
Ability to understand the purpose and risks of the study and provide signed and dated informed consent and authorization to use protected health information (in accordance with national and local subject privacy regulations),able-to-consent
Ability to understand the purpose and risks of the study and provide signed and dated informed consent and authorization to use protected health information (in accordance with national and local subject privacy regulations).,able-to-consent
Ability to understand the purpose and risks of the study and provide signed and dated informed consent and authorization to use protected health information.,able-to-consent
"Ability to understand the requirements of the study, provide written informed consent and authorization of use and disclosure of protected health information, and agreement to abide by the study restrictions and to return to the clinic for the required assessments.",able-to-consent
"Ability to understand, and willingness to sign, a written informed consent document.",able-to-consent
Able and willing to provide informed consent,able-to-consent
"Able and willing to provide written, signed informed consent (assent as appropriate)",able-to-consent
Able to and provides IRB approved study specific written informed consent.,able-to-consent
Able to comprehend the investigational nature of the protocol and provide informed consent,able-to-consent
Able to comprehend the investigational nature of the protocol and provide informed consent.,able-to-consent
Able to give consent,able-to-consent
Able to give informed consent,able-to-consent
Able to give informed consent.,able-to-consent
Able to provide informed consent,able-to-consent
Able to provide informed consent to the donation process,able-to-consent
Able to provide informed written consent.,able-to-consent
Able to provide written informed consent,able-to-consent
Able to provide written informed consent.,able-to-consent
Able to sign informed consent.,able-to-consent
"Able to understand and comply with the study procedures, understand the risks involved in the study, and provide written informed consent before any study-specific procedure is performed.",able-to-consent
"Able to understand and has provided written informed consent. A legally authorized representative may consent on behalf of a participant who is otherwise unable to provide informed consent, if acceptable to and approved by the site and/or site's Institutional Review Board (IRB)/Independent Ethics Committee (IEC).",able-to-consent
"Able to understand and has provided written informed consent. A legally authorized representative may consent on behalf of a participant who is otherwise unable to provide informed consent, if acceptable to and approved by the site and/or site's IRB/IEC.",able-to-consent
Able to understand and have provided written informed consent.,able-to-consent
Able to understand and provide a signed informed consent that fulfills the relevant Institutional Review Board (IRB) or Independent Ethics Committee (IEC) guidelines.,able-to-consent
Able to understand and sign an informed consent form (ICF),able-to-consent
Able to understand and sign the Informed Consent Document.,able-to-consent
Able to understand and voluntarily sign a written informed consent before any screening procedures.,able-to-consent
Able to understand and voluntarily sign an informed consent form,able-to-consent
Able to understand and voluntarily sign consent prior to any study related assessments or procedures,able-to-consent
Able to understand and voluntarily sign the informed consent form.,able-to-consent
"Able to understand and willing to sign an Institutional Review Board (IRB) approved written informed consent document (or that of legally authorized representative, if applicable).",able-to-consent
Able to understand and willing to sign an IRB approved written informed consent document.,able-to-consent
Able to understand and willing to sign an IRB-approved written informed consent document.,able-to-consent
Able to understand and willing to sign the ICF.,able-to-consent
Able to understand and willing to sign the Informed Consent Form,able-to-consent
Able to understand and willingness to sign a written informed consent,able-to-consent
Able to understand the nature of this trial and provide written informed consent,able-to-consent
Able to understand the study procedures and agree to participate in the study by providing written informed consent,able-to-consent
"Adult patients must be able to understand and sign a written informed consent. For pediatric patients, the parent/legal guardian or representative must be able to understand and sign a written informed consent. Assent, when appropriate, will be obtained according to institutional guidelines.",able-to-consent
"Aility to provide written informed consent in accordance with federal, local, and institutional guidelines",able-to-consent
"All individuals or legally appointed representatives/caregivers, must personally sign and date the Institutional Review Board (IRB)/Independent Ethics Committee (IEC) approved consent form before initiating any study specific procedures or activities.",able-to-consent
All participants must be able to understand and willing to sign an informed consent document.,able-to-consent
"All participants will undergo standard written informed consent procedures as dictated by the City of Hope Human Research Protections Office prior to performing any screening procedures that are not part of standard-of-care; informed consent will be obtained by the principal investigator, collaborating investigators, or other Institutional Review Board (IRB) designated personnel who will meet the training requirements established by the IRB; with the support of research personnel, he/she will explain the nature, duration, purpose of the study, potential risks, alternatives and potential benefits, and all other information contained in the informed consent document; in addition, they will review the experimental subject's bill of rights and the Health Insurance Portability and Accountability Act (HIPAA) research authorization form; prospective research participants will be informed that they may withdraw from the study at any time and for any reason without prejudice; prospective research participants will be afforded sufficient time to consider whether or not to participate in the research",able-to-consent
All patients and/or their parents or legal guardians must have the ability to understand and the willingness to sign a written informed consent,able-to-consent
"All patients and/or their parents or legal guardians must provide written informed consent, with assent provided if applicable",able-to-consent
All patients and/or their parents or legal guardians must sign a written informed consent.,able-to-consent
"All patients and/or their parents or legally authorized representatives must sign a written informed consent; assent, when appropriate, will be obtained according to institutional guidelines",able-to-consent
All patients must be informed of the investigational nature of this study and have given written consent in accordance with institutional and federal guidelines,able-to-consent
All subjects must have the ability to understand and the willingness to sign a written informed consent,able-to-consent
All subjects must have the ability to understand and the willingness to sign a written informed consent document,able-to-consent
"All subjects must have the ability to understand and the willingness to sign a written informed consent; they are to give voluntary written informed consent before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care",able-to-consent
"Altered mental status, or any psychiatric condition that would prohibit the understanding or rendering of informed consent",able-to-consent
Any perceived inability to directly (and without the means of a legal guardian) provide informed consent,able-to-consent
Are able and willing to sign an informed consent.,able-to-consent
Are unable to give informed consent,able-to-consent
Be able to consent long-term follow-up protocol PA17-0483,able-to-consent
Be able to sign informed consent,able-to-consent
Be able to understand and give informed consent,able-to-consent
"Be able to understand the study procedures, agree to participate in the study program, and voluntarily provide written Informed Consent.",able-to-consent
Be adequately informed about the study and fully consent to participation as demonstrated by signing the written informed consent form before any screening procedure.,able-to-consent
Be willing and able to provide written consent/assent for the trial.,able-to-consent
Be willing and able to provide written informed consent for the trial.,able-to-consent
Be willing and able to provide written informed consent/assent for the trial,able-to-consent
Be willing and able to provide written informed consent/assent for the trial.,able-to-consent
"Be willing and able to provide written informed consent/assent for the trial. The subject may also provide consent/assent for Future Biomedical Research. However, the subject may participate in the main trial without participating in Future Biomedical Research.",able-to-consent
Be willing and able to sign written informed consent for the trial.,able-to-consent
Be willing and able to understand and give written informed consent and comply with all study related procedures,able-to-consent
Be willing and able to understand and give written informed consent and comply with all study related procedures.,able-to-consent
"Besides these basic criteria, any criterion as outlined below under inclusion eligibility criteria for full study and exclusion criteria already known to prohibit the patient's participation in the study should be considered. No study-related procedures will be performed that are not covered by the prescreening informed consent form (ICF).",able-to-consent
"Can give signed informed consent, as indicated in Appendix 2, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and this protocol.",able-to-consent
Capable and willing to provide informed consent,able-to-consent
Capable of giving signed informed consent,able-to-consent
"Capable of giving signed informed consent as described in Appendix 1, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.",able-to-consent
"Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol",able-to-consent
Capable of giving written informed consent.,able-to-consent
Capable of providing informed consent,able-to-consent
Capable of providing valid informed consent.,able-to-consent
Capable of understanding and complying with the protocol requirements and has signed the informed consent document.,able-to-consent
Capable of understanding and complying with the protocol requirements and must have signed the informed consent document.,able-to-consent
Cohort TBI: Documented written informed consent of participant,able-to-consent
Consent by legal authorized representative is not permitted in this study,able-to-consent
Consent obtained and able to provide blood samples.,able-to-consent
Consent obtained.,able-to-consent
Consent: Voluntary written consent (adult or legally authorized representative; or parental/guardian),able-to-consent
Dementia or altered mental status that would preclude sufficient understanding to provide informed consent,able-to-consent
Dementia or altered mental status that would prohibit the understanding and giving of informed consent.,able-to-consent
Dementia or significantly altered mental status that would prohibit the understanding or rendering of informed consent and compliance with the requirements of this protocol,able-to-consent
"Dementia, altered mental status, or any psychiatric condition that would prohibit the understanding or rendering of informed consent",able-to-consent
"Documented (signed) informed consent; the patient, family member and transplant staff physician (physician, nurse, and social worker) meet at least once prior to starting the transplant procedure; during this meeting all pertinent information with respect to risks and benefits to donor and recipient will be presented; alternative treatment modalities will be discussed; the risks are explained in detail in the enclosed consent forms",able-to-consent
Documented informed consent,able-to-consent
Documented informed consent of participant and/or legally authorized representative,able-to-consent
Documented informed consent of the participant and/or legally authorized representative,able-to-consent
Documented informed consent of the participant and/or legally authorized representative.,able-to-consent
Documented informed consent of the participant and/or the legally authorized representative,able-to-consent
Documented informed consent of the participant or legally authorized representative,able-to-consent
Documented informed consent/assent of the participant or legally responsible guardian,able-to-consent
Documented willingness and ability to sign an informed consent of the participant and/or legally authorized representative.,able-to-consent
DONOR: Ability to comprehend the investigational nature of the study and provide informed consent,able-to-consent
DONOR: Must be able to understand and sign informed consent,able-to-consent
Donors must be capable of giving informed consent,able-to-consent
Each patient must be willing to participate as a research subject and must sign an informed consent form.,able-to-consent
Each patient's parents or legal guardians must sign a written informed consent,able-to-consent
"Each subject (or legally authorized representative if allowed per local regulations) must be willing and able to adhere to the study visit schedule, understand and comply with other protocol requirements, and provide written informed consent and authorization to use protected health information.",able-to-consent
"Each subject must sign an informed consent form (ICF) indicating that he or she understands the purpose of and procedures required for the study is willing to participate in the study, including the requirement to provide information during the Follow-up period.",able-to-consent
Either the subject or his/her legally authorized representative be willing and able to provide written informed consent for the trial,able-to-consent
Evidence of a personally signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the study; patients with mental capacity which requires the presence of a legally authorized representative will be excluded from the study,able-to-consent
Evidence of a personally signed informed consent document.,able-to-consent
"Evidence of a personally signed informed consent indicating that the subject is aware of the neoplastic nature of the disease and has been informed of the procedures to be followed, the experimental nature of the therapy, alternatives, potential risks and discomforts, potential benefits, and other pertinent aspects of study participation.",able-to-consent
FOR TISSUE COLLECTION TO ESTABLISH PDX (PART 1): Understand and voluntarily sign an Institutional Review Board (IRB)-approved informed consent form.,able-to-consent
Fully understand the study and voluntarily sign the ICF,able-to-consent
Has provided signed written informed consent,able-to-consent
Has provided written informed consent prior to completing any study procedures.,able-to-consent
"Has the ability to give informed consent, or for cognitively or decisionally impaired individuals (vulnerable population), the availability of a family member or guardian to give consent and assist in the consent process",able-to-consent
Have given written informed consent prior to any study-specific procedures,able-to-consent
"Have read and signed the Institutional Review Board (IRB) approved informed consent form (ICF) prior to any study related procedure. (In the event that the patient is rescreened for study participation or a protocol amendment alters the care of an ongoing patient, a new ICF must be signed.)",able-to-consent
"Have read and signed the Institutional Review Board (IRB)-approved informed consent form (ICF) prior to any study related procedure. (In the event that the patient is rescreened for study participation or a protocol amendment alters the care of an ongoing patient, a new ICF must be signed).",able-to-consent
"Have read and signed the IRB-approved informed consent form prior to any study related procedure. (In the event that the patient is re-screened for study participation or a protocol amendment alters the care of an ongoing patient, a new informed consent form must be signed.)",able-to-consent
Have signed an Institutional Review Board (IRB)/Independent Ethics Committee(IEC)-approved informed consent form prior to any study-specific evaluation,able-to-consent
Have signed an Institutional Review Board/Independent Ethics Committee-approved informed consent form prior to any study-specific evaluation,able-to-consent
"Inability of the participant (or parent, guardian, or legally authorized representative) to comprehend or unwilling to sign the ICF.",able-to-consent
Inability of the patient to consent themselves for this study,able-to-consent
Inability or unwillingness of research participant or legal guardian / representative to give written informed consent.,able-to-consent
Inability or unwillingness of research participant or legal guardian to consent,able-to-consent
Inability or unwillingness of research participant or legal guardian/representative to give written informed consent.,able-to-consent
"Inability or unwillingness of research participant, parent, or legal guardian/representative to give written informed consent.",able-to-consent
Inability to obtain informed consent,able-to-consent
Inability to obtain informed consent from patient or surrogate,able-to-consent
Inability to provide informed consent,able-to-consent
Informed Consent,able-to-consent
Informed consent (and assent as applicable) obtained from patient/guardian.,able-to-consent
Informed consent and HIPAA authorization for release of personal health information obtained.,able-to-consent
"Informed consent explained to, understood and signed by patient/guardian. Patient/guardian given copy of informed consent.",able-to-consent
"Informed consent explained to, understood by and signed by patient or guardian.",able-to-consent
"Informed consent explained to, understood by and signed by patient/guardian (and donor, where applicable). Patient/guardian given copy of informed consent.",able-to-consent
"Informed consent explained to, understood by and signed by patient/guardian. Patient/guardian given copy of informed consent.",able-to-consent
"Informed consent explained to, understood by and signed by patient/guardian; patient/guardian given copy of informed consent.",able-to-consent
"Informed consent explained to, understood by, and signed by patient/guardian. Patient/guardian given copy of informed consent.",able-to-consent
Informed consent from patient or legal guardian (if patient is minor),able-to-consent
Informed consent given.,able-to-consent
Informed consent must be obtained according to St. Jude guidelines before enrollment into study,able-to-consent
Informed consent must be obtained by local PI or his/her designee according to ICH/Good Clinical Practice and local guidelines before enrollment into study,able-to-consent
Informed Consent must be obtained prior to initiating conditioning therapy.,able-to-consent
Informed consent must be obtained.,able-to-consent
Informed consent must be signed by donor,able-to-consent
"Informed Consent Patients and/or their parents or legal guardians must be capable of understanding the investigational nature, potential risks and benefits of the study. All patients and/or their parents or legal guardians must sign a written informed consent. Age appropriate assent will be obtained per institutional guidelines. To allow non-native speaking patients to participate in this study, bilingual health services will be provided in the appropriate language, when feasible, according to individual institutional practices and guidelines",able-to-consent
"Informed consent signed by participant, parent, or guardian according to the guidelines of the institutional review board.",able-to-consent
Informed consent to undergo cell procurement understood by and signed by the subject or legally authorized representative; subject and/or legally authorized representative given a copy of informed consent form for cell procurement.,able-to-consent
"Informed Consent: All patients or their legal guardians (if the patient is < 18 years old) must sign an IRB-approved document of informed consent to demonstrate their understanding of the investigational nature and the risks of this study before any protocol-related studies are performed. When appropriate, pediatric subjects will be included in all discussions.",able-to-consent
"Informed Consent: Provision of signed and dated written informed consent (parent/legal guardian if patient < 18 years of age) and assent (from patients aged > 7 years) prior to any study specific procedures, sampling and analyses, including screening evaluations.",able-to-consent
"Institutional Review Board/Independent Ethics Committee (IRB/IEC) approved written informed consent and privacy language as per national regulations (e.g., Health Insurance Portability and Accountability Act Authorization (HIPAA) for US sites) obtained from the participant or legally authorized representative prior to any study-related procedures (including withdrawal of prohibited medication, if applicable).",able-to-consent
"Is able to understand and voluntarily sign a written informed consent and is willing and able to comply with the protocol requirements including scheduled visits, treatment plan, laboratory tests and other study procedures.",able-to-consent
Is able to understand and voluntarily sign a written informed consent form and is willing and able to comply with protocol requirements.,able-to-consent
Is unable or unwilling to sign informed consent.,able-to-consent
Is willing and able to provide written Informed consent and comply with the requirements of the study,able-to-consent
"Mentally competent, ability to understand and willingness to sign the informed consent form.",able-to-consent
Must be able to give informed consent or have an appropriate representative available to do so.,able-to-consent
Must be able to give informed consent; subjects unable to give informed consent will not be eligible for this study,able-to-consent
"Must be fully informed about their illness and the investigational nature of the study protocol (including foreseeable risks and possible side effects), and must sign an informed consent",able-to-consent
Must be willing and able to provide written informed consent,able-to-consent
"Must give IRB approved, study specific, informed consent",able-to-consent
Must have provided informed consent for study participation (see Section 15.3) before performance of any study-specific procedures or tests.,able-to-consent
Newly diagnosed MCL: Understand and voluntarily sign an IRB-approved informed consent form,able-to-consent
Participant has given voluntary written informed consent.,able-to-consent
"Participant has the ability and the willingness to sign the informed consent document (for adults only, for participants with mild cognitive abilities may use a legally authorized representative)",able-to-consent
"Participant must be aware of the nature of her malignancy, understand the study requirements and risks and be able and willing to sign a written informed consent document.",able-to-consent
Participant or legal representative must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedure,able-to-consent
Participants must be able to understand and be willing to sign a written informed consent document.,able-to-consent
Participants must have signed and dated an Institutional Review Board (IRB)/Independent Ethics Committee (IEC) approved written informed consent form in accordance with regulatory and institutional guidelines. This must be obtained before the performance of any protocol related procedures that are not part of normal participant care.,able-to-consent
"Patient (or parent or legally authorized representative, if minor) is able to understand and willing to provide informed consent, using an institutionally approved informed consent procedure.",able-to-consent
Patient able to provide written informed consent for the long-term follow-up (LTFU) gene therapy study.,able-to-consent
Patient able to provide written informed consent.,able-to-consent
"Patient and,or parent,guardian able to give informed consent.",able-to-consent
Patient consent must be appropriately obtained in accordance with applicable local and regulatory requirements. Each patient must sign a consent form prior to enrollment in the trial to document their willingness to participate. A similar process must be followed for sites outside of Canada as per their respective cooperative group's procedures.,able-to-consent
Patient has provided written informed consent.,able-to-consent
Patient has signed the Informed Consent (ICF) prior to any screening procedures being performed and is able to comply with protocol requirements.,able-to-consent
Patient is able to provide written consent on their own behalf,able-to-consent
Patient must be able to understand and willing to sign Institutional Review Board (IRB)-approved informed consent.,able-to-consent
"Patient must be able to understand the nature of the study and provide a signed and dated, written informed consent prior to any study specific procedures, sampling or analyses.",able-to-consent
Patient must be capable and willing to provide informed written consent for study participation.,able-to-consent
"Patient must be capable of understanding the investigational nature of this study, potential risks and benefits of the study, and be able to provide a valid informed consent.",able-to-consent
"Patient must be willing and capable of giving written Informed Consent, adhering to dosing and visit schedules and meeting all study requirements.",able-to-consent
Patient must have given written informed consent,able-to-consent
"Patient must have signed informed consent and, if required by local regulations, assent as age appropriate, obtained prior to participation in any study screening procedures.",able-to-consent
Patient must provide study specific informed consent prior to study entry.,able-to-consent
Patient must provide voluntary written informed consent prior to the performance of any research related tests or procedures.,able-to-consent
"Patient must sign an Informed Consent form indicating that the patient understands the purpose of and procedures required for the study and is willing to participate in the study. In case a patient is incapable of giving consent, the patient's legally authorized representative (as defined by local regulation) must give consent. However, should the patient in any manner indicate the will not to participate this takes precedence and must be respected.",able-to-consent
Patient or appointed surrogate decision-maker or legally authorized representative must have ability to understand the purpose and risks of the study and willingness to provide a signed and dated informed consent form (ICF) and authorization to use protected health information (in accordance with national and local subject privacy regulations).,able-to-consent
Patient or guardian able to sign informed consent,able-to-consent
"Patient or his or her legal representative has the ability to read, understand, and provide written informed consent for the initiation of any study-related procedures",able-to-consent
"Patient or his or her legal representative has the ability to read, understand, and provide written informed consent for the initiation of any study-related procedures.",able-to-consent
Patient or legally authorized representative able to sign informed consent,able-to-consent
Patient or parent/guardian capable of providing informed consent,able-to-consent
Patient or parent/guardian capable of providing informed consent.,able-to-consent
Patient or patient's guardian is able to give informed consent,able-to-consent
Patient or patient's legal representative able to sign informed consent,able-to-consent
Patient or patient's legal representative must provide written informed consent,able-to-consent
Patient or patient's representative is willing and able to provide written informed consent,able-to-consent
Patient provides informed consent to participate in the study.,able-to-consent
Patient unable to provide written consent on their own behalf,able-to-consent
"Patients at Mayo Clinic Arizona are not required to consent to the Registry or onto the Pancreas SPORE, IRB 354-06.",able-to-consent
Patients declining to consent for treatment,able-to-consent
Patients must be able to understand and be willing to sign a written informed consent.,able-to-consent
Patients must be able to understand and sign an Informed Consent Form.,able-to-consent
Patients must be able to understand and sign Informed Consent Form.,able-to-consent
Patients must be able to understand and to sign a written consent document.,able-to-consent
Patients must be able to understand and willing to sign a written informed consent document.,able-to-consent
"Patients must be aware of the neoplastic nature of his/her disease and willingly provide written, informed consent after being informed of the procedure to be followed, the nature of the therapy, alternatives, potential benefits, side-effects, risks, and discomforts",able-to-consent
Patients must be capable of and willing to sign an informed consent.,able-to-consent
Patients must be capable of understanding and providing a written informed consent,able-to-consent
Patients must be informed of the investigational nature of this study and all patients and/or their parents or legal guardians (for patients < 18 years of age) must sign and give written informed consent and assent (where appropriate) in accordance with institutional and federal guidelines.,able-to-consent
Patients must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines,able-to-consent
Patients must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines.,able-to-consent
"Patients must be willing to give written consent before performance of any study related procedures not part of standard medical care, with the understanding that consent may be withdrawn by the patient at any time without prejudice to future medical care",able-to-consent
Patients must give informed consent,able-to-consent
Patients must give written informed consent. A copy of the signed informed consent form (ICF) will be retained in the patient's chart.,able-to-consent
Patients must have the ability to give informed consent,able-to-consent
Patients must have the ability to give informed consent.,able-to-consent
Patients must have the ability to understand and sign an approved ICF.,able-to-consent
Patients must have the ability to understand and the willingness to sign a written informed consent prior to registration,able-to-consent
Patients must have the ability to understand and the willingness to sign a written informed consent prior to registration on study,able-to-consent
Patients must have the ability to understand and willingness to sign a written informed consent prior to registration on study.,able-to-consent
Patients must provide signed ICF.,able-to-consent
Patients must provide written informed consent.,able-to-consent
Patients must sign a study-specific informed consent prior to study entry.,able-to-consent
Patients must sign an informed consent document,able-to-consent
"Patients must sign an informed consent document indicating that they understand the purpose of and procedures required for the study, including biomarkers, and are willing to participate in the study",able-to-consent
Patients must sign an informed consent indicating that they are aware this is a research study and have been told of its possible benefits and toxic side effects. Patients will be given a copy of the consent form.,able-to-consent
"Patients must sign an informed consent, and be mentally responsible.",able-to-consent
Patients must sign Institutional Review Board (IRB) approved study specific informed consent,able-to-consent
Patients must sign IRB approved study specific informed consent.,able-to-consent
Patients must sign written informed consent,able-to-consent
Patients or legal guardians must sign an informed consent indicating that they are aware this is a research study and have been told of its possible benefits and toxic side effects. Patients or their guardians will be given a copy of the consent form.,able-to-consent
Patients or legal guardians must sign an informed consent.,able-to-consent
"Patients or the patient's legally authorized guardian must be fully informed about their illness and the investigational nature of this protocol (including foreseeable risks and possible side effects), and must sign an informed consent in accordance with the institutional policies approved by the U.S. Department of Health and Human Services.",able-to-consent
Patients or their legally authorized representative must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines,able-to-consent
Patients or their legally authorized representative must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines.,able-to-consent
Patients or their legally authorized representative must provide written informed consent,able-to-consent
Patients unable or unwilling to provide informed consent,able-to-consent
Patients who have any debilitating medical or psychiatric illness which would preclude their giving informed consent or their receiving optimal treatment and follow-up.,able-to-consent
"Patients with psychological, familial, social, or geographic factors that otherwise preclude them from giving informed consent, following the protocol, or potentially hamper compliance with study treatment and follow-up",able-to-consent
Patients with reproductive potential must agree to use medically approved contraceptive precautions during the trial and for 3 months following the last dose of study drug.,able-to-consent
Prior consent to have tumors used for unspecified future research,able-to-consent
Provide a signed and dated ICF document prior to initiation of any treatment-relatedstudy-specific procedures,able-to-consent
Provide a signed and dated informed consent form prior to initiation of study-specific procedures.,able-to-consent
Provide informed written consent,able-to-consent
Provide informed written consent.,able-to-consent
Provide signed informed consent,able-to-consent
Provide signed IRB approved informed consent in accordance with institutional guidelines.,able-to-consent
Provide signed written informed consent.,able-to-consent
Provide written informed consent,able-to-consent
Provide written informed consent (either by the patient or his/her legal representative). Consent from a legally acceptable representative of a deceased patient will be obtained for enrollment into the study and sample collection,able-to-consent
"Provide written informed consent prior to any study related procedure. (In the event that the patient is re-screened for study participation or a protocol amendment alters the care of an ongoing patient, a new informed consent form must be signed.)",able-to-consent
Provide written informed consent prior to any study-specific screening procedures.,able-to-consent
Provide written informed consent to participate on the study,able-to-consent
Provide written informed consent.,able-to-consent
"Provide written, informed consent to participate in the study and follow the study procedures.",able-to-consent
Provided written informed consent.,able-to-consent
Provides signed informed consent before initiation of any study-specific procedures or treatment.,able-to-consent
Provision of a signed informed consent prior to any protocol specific procedures. Patients already receiving LOXO-292 who enroll in this protocol must be reconsented and sign the consent form for this expanded access protocol.,able-to-consent
Provision of informed consent prior to any study specific procedures.,able-to-consent
"Provision of signed and dated ICF to agree to participate, at time of withdrawal or completion of this study, in Fate Therapeutics' long-term, non-interventional, observation study, FT-003.",able-to-consent
Provision of signed and dated informed consent form (ICF),able-to-consent
Provision of signed and dated written genetic informed consent prior to collection of sample for genetic analysis The ICF process is described in Appendix A 3.,able-to-consent
"Provision of signed and dated written ICF prior to any mandatory study specific procedures, sampling, and analyses",able-to-consent
Provision of signed and dated written ICF prior to collection of sample for genetic analysis,able-to-consent
"Provision of signed and dated written informed consent form (ICF) and any locally required authorization (eg, Health Insurance Portability and Accountability Act in the US, EU Data Privacy Directive in the EU) obtained from the patient/legal representative prior to any mandatory study-specific procedures, sampling, and analyses, including screening evaluations.",able-to-consent
"Provision of signed and dated written informed consent prior to any study specific procedures, sampling, and analyses.",able-to-consent
"Provision of signed and dated, written informed consent prior to any study-specific procedures, sampling and analyses.",able-to-consent
Provision of written informed consent,able-to-consent
Recipient ability to understand and provide informed consent,able-to-consent
RECIPIENT: All subjects must have the ability to understand and the willingness to sign a written informed consent,able-to-consent
REGISTRATION STEP 2-RANDOMIZATION: Patients must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines,able-to-consent
Relapsed/refractory MCL: Understand and voluntarily sign an Institutional Review Board (IRB)-approved informed consent form,able-to-consent
Sign (or their legally-acceptable representatives must sign) an informed consent document indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study.,able-to-consent
"Sign (or their legally-acceptable representatives must sign) an informed consent document indicating that they understand the purpose of and procedures required for the study, including biomarkers, and are willing to participate in the study",able-to-consent
"Sign (or their legally-acceptable representatives must sign) an informed consent document indicating that they understand the purpose of and procedures required for the study, including biomarkers, and are willing to participate in the study.",able-to-consent
Signed and dated informed consent document for study participation.,able-to-consent
Signed and dated informed consent document for study participation.Written informed consent to enroll in the CAR T-cell therapy trial must be obtained prior to lymphodepletion.,able-to-consent
Signed and dated informed consent document indicating that the participant (or legally acceptable representative) has been informed of all pertinent aspects of the trial,able-to-consent
Signed and dated informed consent document indicating that the patient (or legally acceptable representative) has been informed of all pertinent aspects of the trial prior to the start of entrectinib treatment.,able-to-consent
Signed and dated informed consent document obtained prior to initiation of any study-specific procedure and treatment (by the subject or a legally acceptable representative as per the local regulations),able-to-consent
Signed and dated informed consent document obtained prior to initiation of any study-specific procedure and treatment (by the subject or a legally acceptable representative as per the local regulations).,able-to-consent
Signed informed consent,able-to-consent
Signed informed consent (and assent when applicable).,able-to-consent
Signed Informed Consent (ICF) and is able to comply with protocol requirements.,able-to-consent
Signed informed consent form,able-to-consent
Signed informed consent form (ICF),able-to-consent
Signed informed consent form by patients and/or patients' parents/legal guardians and age appropriate assent form by the patients obtained before any study specific procedure,able-to-consent
Signed informed consent form for PROACT,able-to-consent
Signed informed consent form must be obtained prior to any study procedure.,able-to-consent
Signed Informed Consent Form(s).,able-to-consent
Signed Informed Consent Form.,able-to-consent
Signed informed consent must be obtained prior to participation in the study.,able-to-consent
Signed informed consent obtained prior to any study-specific procedures and treatment.,able-to-consent
Signed informed consent obtained prior to initiation of any study-specific procedures and treatment.,able-to-consent
"Signed informed consent prior to the performance of any study-specific procedures, including fresh tumor biopsies.",able-to-consent
Signed informed consent to provide blood sample(s) for specific correlative assays.,able-to-consent
"Signed informed consent, and assent if applicable. Consent may be signed prior to completion of family typing but patients will only be considered evaluable upon confirmation that there is no suitable HLA-identical or 1 allele or antigen mismatched related donor available.",able-to-consent
Signed informed consent.,able-to-consent
Signed Main Informed Consent Form obtained prior to any study specific assessments and procedures,able-to-consent
Signed Preliminary Informed Consent Form obtained prior to any study specific assessments and procedures,able-to-consent
Signed study specific informed consent,able-to-consent
Signed Written Informed Consent,able-to-consent
Signed written informed consent granted prior to initiation of any study-specific procedures,able-to-consent
Signed written informed consent granted prior to initiation of any study-specific procedures.,able-to-consent
Signed written informed consent in accordance to ICH-GCP and national/local regulation before any protocol-related procedures that are not part of normal patient care.,able-to-consent
signed written informed consent obtained prior to study procedures,able-to-consent
Signed written informed consent obtained prior to study procedures.,able-to-consent
Signed written pre-registration informed consent document,able-to-consent
"Signed, informed consent",able-to-consent
"Signed, written IRB-approved informed consent",able-to-consent
"Signed, written IRB-approved informed consent.",able-to-consent
Subject and/or legally authorized representative has signed the informed consent form for this study,able-to-consent
Subject capable of providing written informed consent prior to initiation of any study procedures; subjects able to understand and comply with planned study procedures and be available for all study visits,able-to-consent
Subject has consented to provide at least 10 unstained tumor slides (or equivalent tumor tissue blocks) for retrospective testing of HRAS gene tumor status except in cases of anaplastic thyroid cancer. Provision of tumor slides is not required for cases of anaplastic thyroid cancer.,able-to-consent
Subject has provided informed consent prior to initiation of any study-specific activities/procedures,able-to-consent
Subject has provided informed consent prior to initiation of any study-specific activities/procedures.,able-to-consent
Subject has voluntarily agreed to participate by giving written informed consent in accordance with ICH/GCP guidelines and applicable local regulations.,able-to-consent
"Subject is capable of understanding and complying with parameters as outlined in the protocol and able to sign and date the informed consents, approved by the Institutional Review Board (IRB), prior to the initiation of any screening or study-specific procedures.",able-to-consent
Subject is willing to consent to study-required blood draws.,able-to-consent
Subject must be able to understand and sign written informed consent.,able-to-consent
Subject must understand and voluntarily sign an ICF prior to any study-related assessments/procedures being conducted.,able-to-consent
"Subject or legal representative has ability to read, understand and provide written informed consent for study related procedures",able-to-consent
Subject or subject's legally acceptable representative has provided informed consent.,able-to-consent
Subject or subject's representative is willing and able to provide written informed consent,able-to-consent
Subject understands the study procedures and is able to provide informed consent to participate in the study and authorization for release of relevant protected health information to the study Investigator.,able-to-consent
Subject/legal representative willing and able to provide written informed consent,able-to-consent
"Subjects must be able to provide written, informed consent",able-to-consent
Subjects must be able to sign (or their legally-acceptable representatives must sign) an informed consent indicating that they understand the rational of the study and can participate in all study procedures.,able-to-consent
Subjects must have signed and dated an IRB-approved written informed consent form in accordance with regulatory and institutional guidelines. This must be obtained before the performance of any protocol-related procedures that are not part of normal subject care.,able-to-consent
Subjects must have the ability to understand and the willingness to sign a written informed consent document,able-to-consent
Subjects must have the ability to understand and the willingness to sign a written informed consent document.,able-to-consent
"Subjects must voluntarily sign and date an informed consent, approved by an Independent Ethics Committee (IEC)/Institutional Review Board (IRB), prior to the initiation of any screening or study-specific procedures.",able-to-consent
"Subjects must voluntarily sign and date an informed consent, approved by an Independent Ethics Committee (IEC)/Institutional Review Board (IRB), prior to the initiation of any screening or study-specific procedures. Demographic and Laboratory Assessments",able-to-consent
Subjects or their legal representative must be able to understand and provide written informed consent,able-to-consent
"Sweden Specific requirement: In case a patient is incapable of giving consent, in addition to the legally authorized representative, the patient's next of kin must give consent to the participation of the patient.",able-to-consent
the ability and willingness to sign an informed consent,able-to-consent
"The participant (or legally acceptable representative if applicable) provides written informed consent for the study. The participant may also provide consent for Future Biomedical Research. However, the participant may participate in the main study without participating in Future Biomedical Research.",able-to-consent
The participant (or legally acceptable representative if applicable) provides written informed consent for the trial prior to the initiation of any study procedures. The participant must be capable of understanding and complying with protocol requirements.,able-to-consent
The participant (or legally acceptable representative if applicable) provides written informed consent for the trial.,able-to-consent
The participant must sign the ICF prior to the performance of any study related procedures that are not considered part of standard of care.,able-to-consent
The participant provides written informed consent/assent for the trial.,able-to-consent
The patient can understand and is willing to sign a written informed consent document.,able-to-consent
The patient has signed informed consent prior to initiation of any study-specific procedures or treatment.,able-to-consent
"The patient is capable of understanding and complying with the protocol and has signed the informed consent document. A signed informed consent form must be obtained before any study-specific procedures are performed. Standard procedures performed as part of the practice of medicine prior to consent (e.g., imaging, physical exam) can be used to determine eligibility if completed within 28 days prior to the initial dose of study drug.",able-to-consent
The patient must have signed and dated an Institutional Review Board (IRB)-approved consent form that conforms to federal and institutional guidelines,able-to-consent
The patient must have signed and dated an Institutional Review Board (IRB)-approved consent form that conforms to federal and institutional guidelines.,able-to-consent
The patient must have signed and dated an IRB-approved consent form that conforms to federal and institutional guidelines.,able-to-consent
The patient must provide study-specific informed consent prior to study entry.,able-to-consent
The patient must provide written informed consent.,able-to-consent
The patient or a legally authorized representative must provide study-specific informed consent and authorization permitting release of personal health information prior to study entry.,able-to-consent
The patient or a legally authorized representative must provide study-specific informed consent prior to Step 1 registration.,able-to-consent
The patient or a legally authorized representative must provide study-specific informed consent prior to study entry,able-to-consent
"The patient or a legally authorized representative must provide study-specific informed consent prior to study entry and, for patients treated in the U.S., authorization permitting release of personal health information.",able-to-consent
"The patient or a legally authorized representative must provide study-specific informed consent prior to study entry and, for patients treated in the United States (U.S.), authorization permitting release of personal health information.",able-to-consent
The patient or a legally authorized representative must provide study-specific informed consent prior to study entry.,able-to-consent
The subject is capable of understanding and complying with the protocol requirements and has signed the informed consent document.,able-to-consent
Unable or unwilling to sign consent,able-to-consent
Unable or unwilling to sign consent.,able-to-consent
Unable or unwilling to sign the consent form,able-to-consent
Unable to comprehend or unwilling to sign the informed consent form (ICF).,able-to-consent
Unable to give written informed consent,able-to-consent
unable to provide informed consent,able-to-consent
Unable to provide written consent,able-to-consent
Unable to sign informed consent form.,able-to-consent
Unable to understand the investigational nature of the study or give informed consent.,able-to-consent
Unable to understand the purpose and risks of the study and to provide a signed and dated informed consent for (ICF) and authorization to use protected health information (in accordance with national and local subject privacy regulations),able-to-consent
Unable to understand the purpose and risks of the study and to provide a signed and dated informed consent form (ICF),able-to-consent
Unable to understand the purpose and risks of the study and to provide a signed and dated informed consent form (ICF) and authorization to use protected health information (in accordance with national and local subject privacy regulations),able-to-consent
Unable to understand the purpose and risks of the study and to provide a signed and dated informed consent form (ICF) and authorization to use protected health information (in accordance with national and local subject privacy regulations).,able-to-consent
Understand and voluntarily sign an informed consent document.,able-to-consent
Understand and voluntarily sign an informed consent form,able-to-consent
Understand and voluntarily sign an informed consent form.,able-to-consent
Understand and voluntarily sign an Institutional Review Board (IRB) approved informed consent form (ICF).,able-to-consent
Understand and voluntarily sign an institutional review board (IRB)-approved informed consent form,able-to-consent
Understand and voluntarily sign an Institutional Review Board (IRB)-approved informed consent form.,able-to-consent
"Voluntarily agree to participate by giving written informed consent/assent for the trial. The subject may also provide consent/assent for Future Biomedical Research. However, the subject may participate in the main trial without participating in Future Biomedical Research.",able-to-consent
Voluntarily sign informed consent form(s),able-to-consent
Voluntarily sign informed consent form(s) (ICFs).,able-to-consent
Voluntarily sign informed consent form(s) prior to any study-related assessments/procedures being conducted.,able-to-consent
Voluntarily sign informed consent form.,able-to-consent
Voluntary signed and dated IRB/IEC approved written informed consent form in accordance with regulatory and local guidelines.,able-to-consent
"Voluntary signed Institutional Review Board (IRB)-approved informed consent before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care",able-to-consent
Voluntary written consent,able-to-consent
"Voluntary written consent (adult or parent/guardian with presentation of the minor information sheet, if appropriate)",able-to-consent
Voluntary written consent (adult or parental/guardian),able-to-consent
Voluntary written consent (using assent form if donor < 18 years of age),able-to-consent
"Voluntary written consent must be given before performance of any study related procedure not part of standard medical care, with the understanding that consent may be withdrawn by the patient at any time without prejudice to future medical care",able-to-consent
"Voluntary written consent must be given before performance of any study related procedure not part of standard medical care, with the understanding that consent may be withdrawn by the patient at any time without prejudice to future medical care.",able-to-consent
"Voluntary written consent obtained prior to the performance of any study-related procedure that is not a part of standard medical care, with the understanding that consent may be withdrawn by the patient at any time without prejudice to future medical care.",able-to-consent
Voluntary written consent signed (adult or parental) before performance of any study-related procedure not part of normal medical care.,able-to-consent
Voluntary written informed consent,able-to-consent
"Voluntary written informed consent before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the patient at any time without prejudice to future medical care.",able-to-consent
"Voluntary written informed consent before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care",able-to-consent
Voluntary written informed consent before performance of any study-related procedure not part of normal medical care.,able-to-consent
"Voluntary written informed consent before performance of any study-specific procedure not part of routine medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care. Subjects must be able to understand and be willing to sign the written informed consent form.",able-to-consent
"Voluntary written informed consent must be obtained before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care",able-to-consent
Willing and able to comply with the study procedure and sign a written informed consent,able-to-consent
"Willing and able to give written, informed consent.",able-to-consent
Willing and able to provide signed informed consent.,able-to-consent
Willing and able to provide written informed consent,able-to-consent
Willing and able to provide written informed consent and comply with the requirements of the trial.,able-to-consent
Willing and able to provide written informed consent/assent for the trial.,able-to-consent
Willing and able to sign an informed consent and comply with the protocol.,able-to-consent
Willing to provide informed consent for participation in the study.,able-to-consent
Willing to provide informed written consent,able-to-consent
Willing to provide voluntary written informed consent before performance of any study related procedure not part of normal medical care,able-to-consent
"Willing to sign consent onto the Mayo Clinic Radiotherapy Patient Outcomes Registry and Biobanking study, IRB 15-0001361,2 and consent on to the Pancreas SPORE, IRB 354-062.",able-to-consent
Willing to sign Informed Consent,able-to-consent
Willingness to sign the healthy volunteer informed consent form.,able-to-consent
"Written and voluntary informed consent understood, signed and dated.",able-to-consent
"Written and voluntary informed consent understood, signed and dated. Amendment 4, 11 June 2018",able-to-consent
Written and voluntary informed consent.,able-to-consent
Written consent (adult or parent/guardian),able-to-consent
Written informed consent,able-to-consent
"Written informed consent and any locally required authorization (eg, data privacy) obtained from the subject/legal representative prior to performing any protocol-related procedures, including screening evaluations",able-to-consent
"Written informed consent and any locally required authorization obtained from the subject prior to performing any protocol-related procedures, including screening evaluation.",able-to-consent
"Written informed consent and HIPAA authorization for release of personal health information explained to, understood by and signed by the subject or legally authorized representative.",able-to-consent
Written informed consent and HIPAA authorization for release of personal health information of subject or subject's legally authorized representative.,able-to-consent
Written informed consent and HIPAA authorization for release of personal health information prior to registration. NOTE: HIPAA authorization may be included in the informed consent or obtained separately.,able-to-consent
Written informed consent and HIPAA authorization for release of personal health information.,able-to-consent
Written informed consent and HIPAA authorization for release of personal health information. NOTE: HIPAA authorization may be included in the informed consent or obtained separately.,able-to-consent
Written informed consent and HIPAA authorization for release of personal health information. Subjects or their Legally Authorized Representative must sign a consent to undergo cell procurement. Written informed consent to enroll in the CAR T-cell therapy trial must be obtained prior to lymphodepletion.,able-to-consent
"Written informed consent explained to, understood by and signed by the subject or legally authorized representative; subject and/or legally authorized representative given a copy of informed consent form.",able-to-consent
Written informed consent for clinical trial enrollment and mandatory consent for any biopsies as well as HIPAA authorization for release of personal health information.,able-to-consent
Written informed consent for full study.,able-to-consent
Written informed consent for prescreening.,able-to-consent
Written informed consent given.,able-to-consent
"Written informed consent in accordance with federal, local, and institutional guidelines. The patient must provide informed consent prior to the first screening procedure.",able-to-consent
Written informed consent must be obtained prior to any procedures.,able-to-consent
Written informed consent must be obtained prior to any screening procedures,able-to-consent
Written informed consent must be obtained prior to any screening procedures.,able-to-consent
Written informed consent must be obtained prior to any study procedures.,able-to-consent
Written informed consent obtained prior to any screening procedures,able-to-consent
"Written informed consent obtained prior to any screening procedures and in accordance with federal, local, and institutional guidelines.",able-to-consent
Written informed consent obtained to participate in the study and HIPAA authorization for release of personal health information.,able-to-consent
Written informed consent prior to completing any study-specific procedure,able-to-consent
Written informed consent provided,able-to-consent
Written informed consent.,able-to-consent
Written informed consent/assent prior to any study-specific procedures.,able-to-consent
"A formalin fixed tissue block or 15 slides of tumor sample (archival or fresh) must be available for performance of correlative studies. NOTE: Patients must be willing to have a tumor biopsy if prior tissue or adequate archival tissue is not available (i.e.,post-enrollment and prior to treatment).",able-to-provide-samples
A formalin fixed tissue block or at least 15 slides of tumor sample (archival or fresh) must be available for performance of correlative studies. NOTE: Patient must be willing to have a pre-treatment tumor biopsy if adequate archival tissue is not available.,able-to-provide-samples
A formalin fixed tissue block or equivalent of 24 slides of the tumor sample for analyses by Adaptive Sequenta and NeoGenomics must be available for analysis.,able-to-provide-samples
A formalin-fixed tissue block or 15 slide of tumor sample (archival or fresh) must be available for performance of correlative studies.,able-to-provide-samples
"A tumor biopsy sample (either archival or fresh) must be collected from all patients from either the primary tumor or a metastatic site (if clinically feasible) for determination of expression of BCL-2 by central laboratory testing for patient eligibility purposes and for exploratory research on biomarkers. The tumor specimen must contain adequate evaluable tumor cells ( >= 20% tumor cells) to enable BCL-2 IHC and other relevant biomarker analysis. Samples can be in a tissue block (preferred) or prepared as 20 unstained serial slides, and should be accompanied by an associated pathology report. If a tumor sample is not available, a fresh biopsy must be collected. The specimen must be a formalin-fixed, paraffin-embedded (FFPE) tumor specimen, or another appropriate fixative must be used (notation of the type of fixative should be included). Cytological or fine-needle aspiration samples are not acceptable.",able-to-provide-samples
"Able to adhere to the study visit schedule and other protocol requirements including willing to provide blood, baseline bone marrow aspirate, and control deoxyribonucleic acid (DNA) samples for correlative research purposes.",able-to-provide-samples
Able to provide a tumor biopsy sample (fresh strongly preferred or else archival).,able-to-provide-samples
Accessible tumor that can be safely accessed for multiple core biopsies and patient is willing to provide tissue from newly obtain biopsies before and during treatment.,able-to-provide-samples
Adequate tissue from diagnostic biopsy; formalin fixed tissue block or 20 slides of tumor sample (archival or fresh) must be available for performance of correlative studies,able-to-provide-samples
Adequate tumor tissue (archival or fresh) must be available for correlative studies.,able-to-provide-samples
Agreement to allow the use of archival tissue from diagnostic tumor biopsies,able-to-provide-samples
Agreement to allow the use of archival tissue from diagnostic tumor biopsies will be retrieved and submitted post-enrollment,able-to-provide-samples
Agreement to allow the use of archival tissue from pre-ASCT tumor biopsies,able-to-provide-samples
Agreement to provide mandatory archival tissue or fresh biopsy,able-to-provide-samples
Agreement to provide mandatory archival tissue or fresh biopsy.,able-to-provide-samples
All participants: archived tumor tissue (if available).,able-to-provide-samples
"Archival tissue must be available and identified during screening and shipped prior to Day -21. If archival tissue is not available and the subject is not undergoing a standard of care biopsy, the subject must undergo a research biopsy to obtain fresh tissue prior to start of treatment.",able-to-provide-samples
"Archival tissue must be available for submission in all patients for histopathology review, though participation in correlative substudies is optional.",able-to-provide-samples
Archival tissue or optional tumor biopsy (fresh tissue).,able-to-provide-samples
Archived formalin-fixed paraffin-embedded (FFPE) tumor tissue specimen from the original diagnostic biopsy is available for submission OR,able-to-provide-samples
"Archived tumor specimens: Excess tumor tissue must be available for research purposes. This will include tumor tissue sufficient to make >= 10 five-micron sections; more tumor tissue is preferred. Freshly acquired tumor specimens: As part of a clinically indicated biopsy procedure, an additional 1-3 cores or tissue fragments will be obtained by core needle or surgical biopsy for research purposes and FFPE.",able-to-provide-samples
"Availability of additional tumor tissue for further biomarker analysis (e.g. next-generation sequencing for tumor DNA, ribonucleic acid (RNA) expression profiling, immunohistochemistry of important markers such as PD-L1) to better understand the mode of action of the study drug. Or, if additional tumor tissue is not available, willingness to provide fresh biopsy tissue (if deemed as no additional risk to the patient by the investigator). This tissue (archival or fresh) will only have to be provided after treatment start. This tumor tissue sample must consist of actual biopsy material from either the primary tumor or a metastatic lesion. Core needle biopsies are allowed, fineneedle aspirates are allowed as long as the content of tumor cells is at least 20% (see Section 9.7.1 and the lab manual).",able-to-provide-samples
"Availability of archival formalin-fixed, paraffin-embedded block containing tumor tissue, or slides, or a fresh/recent tumor biopsy prior to avelumab treatment for subjects in Phase 2",able-to-provide-samples
Availability of archival or freshly collected tumor tissue before study enrolment,able-to-provide-samples
Availability of archival tissue confirming diagnosis.,able-to-provide-samples
Availability of archival tissue for correlative analysis.,able-to-provide-samples
Availability of formalin-fixed paraffin-embedded (FFPE) tumor tissue block (or minimum 10 freshly cut unstained slides if block is not available),able-to-provide-samples
Availability of formalin-fixed paraffin-embedded (FFPE) tumor tissue block (or minimum 10 freshly cut unstained slides if block is not available).,able-to-provide-samples
Availability of fresh or archived tumor tissue for immunohistochemical studies,able-to-provide-samples
Availability of fresh tumor tissue and/or archival tumor tissue at Screening,able-to-provide-samples
Availability of fresh tumor tissue and/or archival tumor tissue at Screening.,able-to-provide-samples
Availability of fresh tumor tissue and/or archival tumor tissue for central pathology(obtained within 5 years of the consent date) at Screening,able-to-provide-samples
Availability of pretreatment tumor tissue.,able-to-provide-samples
"Availability of tissue for correlative studies; patients must have at least 6-8 unstained slides of archived formalin-fixed, paraffin-embedded tumor tissue available; if not enough archived tissue is available, a fresh tumor biopsy prior to study initiation is mandatory; for patients who have undergone a fresh baseline biopsy at baseline, the archived tissue is not mandatory",able-to-provide-samples
"Availability of tumor specimens is optional for patients in dose escalation cohorts and mandatory for patients in the confirmation phase. In the confirmation phase, an archived formalin-fixed, paraffin-embedded tumor tissue block sufficient in size to allow for sectioning of at least 15 slides should be provided if available from the most recent primary or metastatic tumor biopsy or resection prior to start of study therapy. If such an archived sample is not available, a fresh tumor sample must be obtained prior to enrollment. If blocks cannot be provided, then at least 10, but preferably 15, freshly prepared slides must be provided. Core needle or excision biopsies are required.",able-to-provide-samples
Availability of tumor tissue biopsy for analysis of mesothelin expression. Archival tissue is preferred and a biopsy should only be obtained based on investigator's judgment that there is no additional risk to the patient's safety. This tumor tissue sample must consist of actual biopsy material from either the primary tumor or a metastatic lesion. Fine-needle aspirates will not be acceptable to fulfill this requirement.,able-to-provide-samples
Available archived tissue from the initial breast primary (formalin fixed paraffin embedded [FFPE] tissue is acceptable; fresh frozen tissue is preferred if available),able-to-provide-samples
Available representative tissue (from fresh or formalin fixed paraffin embedded tissue) from the most recent biopsy or archival tumor tissue for Clonotype evaluation for minimal residual disease (MRD) testing.,able-to-provide-samples
Available tissue to perform protein and genomic analysis,able-to-provide-samples
Available tumor tissue and peripheral blood samples for exome and transcriptome sequencing.,able-to-provide-samples
"Baseline tumor tissue, either fresh (preferred) or from paraffin block/unstained slides if contemporary biopsy is unsafe or not otherwise obtainable from the primary tumor site or metastatic site to be available for use on correlative studies",able-to-provide-samples
"Be willing to provide a tissue sample for pre-treatment intra-tumoral assessment of proinflammatory and immunosuppressive factors. Preferably, tumor biopsies will be collected at the time of screening or newly obtained tissue can be used (no intervening treatment [local or systemic] involving the site of tissue biopsy once tissue biopsy is obtained up to the time of trial enrollment).",able-to-provide-samples
Be willing to provide a tumor biopsy sample for the study,able-to-provide-samples
Be willing to provide tissue,able-to-provide-samples
Be willing to provide tissue from a fresh core or excisional biopsy (performed as standard of care) of a tumor lesion prior to starting study therapy or from archival tissue of a biopsy that was performed after the most recent systemic therapy. Exception can be granted by the principal investigator (PI) if a biopsy is not feasible and/or safe,able-to-provide-samples
Be willing to provide tissue from a fresh core or excisional biopsy of a tumor lesion prior to starting study therapy or from archival tissue of a biopsy that was performed after the most recent systemic therapy. Exception can be granted by the PI if a biopsy is not feasible and/or safe,able-to-provide-samples
Be willing to provide tissue from a newly obtained core needle or excisional biopsy. Newly-obtained is defined as a specimen obtained up to and including 90 days prior to treatment day 1. Subjects for whom newly obtained samples cannot be provided may be enrolled only with agreement by the overall PI.,able-to-provide-samples
Be willing to provide tissue from a newly obtained core or excisional biopsy of a tumor lesion prior to starting study therapy or from archival tissue of a biopsy that was performed after the most recent systemic therapy,able-to-provide-samples
Be willing to provide tissue from a newly obtained core or excisional biopsy of a tumor lesion. Be willing to provide fine-needle aspiration (FNA) of a tumor lesion. Newly-obtained is defined as a specimen obtained up to 6 weeks (42 days) prior to initiation of treatment on Day 1. Subjects for whom newly-obtained samples cannot be provided (e.g. inaccessible or subject safety concern) may submit an archived specimen only upon agreement from the Sponsor.,able-to-provide-samples
Be willing to provide tissue from a newly obtained core or excisional biopsy of a tumor lesion. Be willing to provide FNA of a tumor lesion. Newly-obtained is defined as a specimen obtained up to 6 weeks (42 days) prior to initiation of treatment on Day 1. Subjects for whom newly-obtained samples cannot be provided (e.g. inaccessible or subject safety concern) may submit an archived specimen only upon agreement from the Sponsor.,able-to-provide-samples
Be willing to provide tissue from a newly obtained core or excisional biopsy of a tumor lesion. Newly-obtained is defined as a specimen obtained up to 6 weeks (42 days) prior to initiation of treatment on day 1. Subjects for whom newly-obtained samples cannot be provided (e.g. inaccessible or subject safety concern) may submit an archived specimen.,able-to-provide-samples
"Be willing to provide tissue from a newly obtained core or excisional biopsy of a tumor lesion. Newly-obtained is defined as a specimen obtained up to 6 weeks (42 days) prior to initiation of treatment on Day 1. Subjects for whom newly-obtained samples cannot be provided (e.g. inaccessible or subject safety concern) may submit an archived specimen or leukemic blood sample, only upon written agreement from the Study PI.",able-to-provide-samples
Cohort 6: A tissue sample must be provided after osimertinib progression,able-to-provide-samples
Cohort 7: Either tissue or plasma samples are acceptable for enrollment,able-to-provide-samples
Cohort B: An archival tumor tissue sample or tumor tissue from a fresh core or excisional biopsy from soft tissue is required.,able-to-provide-samples
"Cohorts C & D: Subjects with soft tissue disease must provide a core or excisional biopsy from a soft tissue lesion if clinically accessible. In addition to the biopsy an archival specimen should also be provided if one is available. The biopsy must be performed within 1 year of screening and after developing mCRPC. If soft tissue disease cannot be biopsied then an archival specimen is required. For subjects with bone metastasis only, an archival tumor tissue specimen must be provided.",able-to-provide-samples
Confirmed availability of archival or freshly collected tumor tissue before study enrollment.,able-to-provide-samples
Diagnostic archival tissue available for review and correlative studies,able-to-provide-samples
"For patients enrolled via local molecular testing, an archival or fresh tumor tissue (unless medically contraindicated) is required to be submitted for independent central molecular testing at Ignyta's CLIA laboratory post-enrollment",able-to-provide-samples
FOR TISSUE COLLECTION TO ESTABLISH PDX (PART 1): Confirmed MCL tissue diagnosis.,able-to-provide-samples
"FOR TISSUE COLLECTION TO ESTABLISH PDX (PART 1): Patients must be willing to allow residual tissue to be collected for both in vitro, in vivo (PDX) testing and molecular profiling.",able-to-provide-samples
FOR TISSUE COLLECTION TO ESTABLISH PDX (PART 1): Reasonable expectation that the patient can wait 3-6 months for generation of PDX data for subsequent treatment selection.,able-to-provide-samples
"Formalin fixed, paraffin embedded tumor sample from the primary cancer must be sent for central testing.",able-to-provide-samples
"Formalin-fixed, paraffin embedded (FFPE) tissue blocks are preferred to slides",able-to-provide-samples
Fresh or archived tumor tissue sample available for target expression analysis. [Phase 1b only: Subjects' tumor tissue must test positive for target expression.],able-to-provide-samples
"Fresh tumour tissue for central pathology review must be provided as an adjunct to participation in this study. Should it not be possible to obtain a fresh tumour tissue sample, archival paraffin embedded tumour tissue acquired <= 3 years prior to screening for this protocol must be available for this purpose.",able-to-provide-samples
Group 2 patients should have archived or fresh tumor tissue available from the non-craniotomy site and will have fresh tumor tissue available from the planned craniotomy.,able-to-provide-samples
"Has confirmed metastatic TNBC as locally determined according to the American Society of Clinical Oncology-College of American Pathologists (ASCO-CAP) guidelines on a newly obtained core or excisional biopsy from a metastatic, not previously irradiated, tumor lesion.",able-to-provide-samples
Has existing archived tissue and is willing to consent to providing sample for correlative research purposes.,able-to-provide-samples
"Have provided a tumor tissue sample either collected from a newly obtained tumor tissue biopsy or an archival tissue specimen. Subjects for whom newly obtained samples cannot be provided (e.g,. inaccessible or subject safety concern) may submit an archived biopsy specimen. Formalin-fixed paraffin embedded (FFPE) block specimens are preferred to 20 unstained slides. Additional samples may be requested if tumor tissue provided is not adequate for quality and/or quantity as assessed by the central laboratory.",able-to-provide-samples
Have provided archival tumor tissue sample or newly obtained core or excisional biopsy of a tumor lesion not previously irradiated,able-to-provide-samples
"Have provided archival tumor tissue sample or newly obtained core or excisional biopsy of a tumor lesion not previously irradiated. Formalin-fixed, paraffin embedded (FFPE) tissue blocks are preferred to slides. Newly obtained biopsies are preferred to archived tissue. Newly-obtained is defined as a specimen obtained up to 6 weeks (42 days) prior to initiation of treatment on day 1. Subjects for whom newly-obtained samples cannot be provided (e.g. inaccessible or subject safety concern) may submit an archived specimen. Note: If submitting unstained cut slides, newly cut slides should be submitted to the testing laboratory within 14 days from the date slides are cut",able-to-provide-samples
Have provided archival tumor tissue sample or newly obtained core or excisional biopsy of a tumor lesion not previously irradiated. Newly obtained biopsies are preferred to archival tissue. Repeat samples may be required if adequate tissue is not provided.,able-to-provide-samples
Have provided tissue from an archival tissue sample or newly obtained core or excisional biopsy of a tumor lesion obtained within 28 days prior to study enrollment.,able-to-provide-samples
"If patients have been biopsied or submitted archived tumor tissue obtained within the last 6 months for assessment with the MATCH assays, patients may receive non-protocol treatment after biopsy/tissue submission (if clinically indicated) until they receive notification of results however, lack of response must be documented prior to registration to step 1; new non-protocol treatment will NOT be permitted as intervening therapy after registration to Step 0; for patients entering step 0 with assay results from outside laboratories, no systemic treatment is allowed after step 0 registration; the decision to stop the intervening nonprotocol treatment will be left up to the treating physician if patient has an aMOI; waiting periods as described will apply",able-to-provide-samples
"If the site is unable to confirm during screening that sufficient archival biopsy is available, the subject must consent to a pretreatment biopsy for inclusion in this study",able-to-provide-samples
"In the expansion part all patients must provide a mandatory fresh biopsy (FFPE tissue blocks/slides) at screening (aspirates are not acceptable) which contains tumor tissue and is taken after failure/stop of last prior treatment. Documentation of the fresh FFPE biopsy shipment must be submitted to the Sponsor as a part of eligibility package prior to administration of first dose of enapotamab vedotin. In case it is not feasible to meet the required criteria for fresh tumor biopsy, the sponsor medical officer's approval of enrollment is needed. Furthermore, the latest available archival tumor tissue sample must be collected if available.",able-to-provide-samples
Inability to provide blood sample.,able-to-provide-samples
Is able to provide a core or excisional tumor biopsy for biomarker analysis from an archival (within 3 months) or newly obtained biopsy at screening,able-to-provide-samples
"Mandatory provision of an archived tumor tissue block <= 6 months old (or a minimum of 6 newly cut unstained slides; if available, up to 20 newly cut slides are encouraged) (refer to the Laboratory Manual for details). If archival tumor block or slides are both unavailable, cell blocks from fine needle aspirate (FNA) samples will be accepted.",able-to-provide-samples
Must be willing to provide pre- and post-infusion blood samples for exploratory analyses.,able-to-provide-samples
Must be willing to undergo an incisional or excisional lymph node or tissue biopsy or to provide a lymph node or tissue biopsy from the most recent available archival tissue.,able-to-provide-samples
"Must be willing to undergo an incisional, excisional, or core needle lymph node or tissue biopsy or provide a lymph node or tissue biopsy from the most recent available archival tissue.",able-to-provide-samples
Must have available and willing to submit pre-systemic treatment DLBCL tumor biopsy tissue/slides for central pathology review.,able-to-provide-samples
Must have tumor tissue from transurethral resection of the bladder tumor (TURBT) available for submission that is sufficient for COXEN testing and must agree to submission of 20 (10 micron) slides plus 2 (5 micron) slides from the start and end of the 20 slides for a total of 22 unstained slides.,able-to-provide-samples
Newly obtained biopsies are preferred to archived tissue,able-to-provide-samples
outside diagnostic material is acceptable as long as peripheral blood and/or bone marrow slides are reviewed at the study institution and cytogenetic/molecular information is available,able-to-provide-samples
"Paraffin tissue samples obtained by transurethral resection of muscle-invasive bladder tumor, upper tract resection, or radical cystectomy/nephrectomy/ureterectomy/nephroureterectomy must be available.",able-to-provide-samples
Part 1 enrichment patients must have MTC or a RET-altered solid tumor per local assessment of tumor tissue and/or blood.,able-to-provide-samples
"Part C: Archived paraffin-embedded tissue (20 unstained slides or a tumor block) from a prior resection must be available as a control for correlative studies; if tissue blocks or slides are unavailable, the study chair must be notified prior to enrollment",able-to-provide-samples
Participants in Dose Optimization (excluding AML): pre- and on-treatment fresh tissue biopsies. (Note: fresh tissue biopsies will be optional for participants with solid tumor or NHL in Dose Escalation and will be collected only if consent is provided),able-to-provide-samples
"Participants should be able to submit up to 20 unstained formalin-fixed, paraffinembedded (FFPE) slides from the initial tissue diagnosis prior to study registration for confirmation of diagnosis and correlative studies",able-to-provide-samples
Parts H and I: Must be able and willing to undergo mandatory tumor biopsies prior to study treatment and at the time of discontinuation from study treatment. Tumor tissue obtained from a prior biopsy may be permitted for the pretreatment sample after discussion and agreement between Lilly CRP and investigator if a patient has not received any therapies for the disease between the time the biopsy was obtained and the time of treatment start. The decision to use a tumor tissue sample from a prior biopsy will be documented in writing.,able-to-provide-samples
Pathological diagnosis should be obtained by incisional or excisional tissue biopsy; core biopsy is permissible if obtaining an incisional or excisional is not possible and if the grade can be assessed on the core biopsy. A core biopsy can also be used if deemed in the best interest of the patient in the opinion of the investigator,able-to-provide-samples
"Patient agrees to provide tumor tissue (archived, if available or a fresh biopsy) for RET status confirmation and is willing to consider an on-treatment tumor biopsy, if considered safe and medically feasible by the treating Investigator. For Part 2, Group 6, patients are required to undergo a pretreatment biopsy to define baseline RET status in tumor tissue.",able-to-provide-samples
Patient agrees to the collection of formalin fixed paraffin embedded block or slides from archival diagnostic samples or a pre-treatment tumor biopsy,able-to-provide-samples
"Patient has adequate tumor tissue obtained from a biopsy or surgical procedure to enable molecular profiling for retrospective central laboratory confirmation of the mutation. If tissue is not available, the patient must have biopsy accessible disease and must be willing to undergo a biopsy to provide an appropriate tissue sample prior to receiving treatment in the study.",able-to-provide-samples
Patient is agreeable to allow tumor (from peripheral blood) and normal tissue (from saliva) samples to be submitted for complete exome and transcriptome sequencing.,able-to-provide-samples
"Patient is agreeable to allow tumor (from peripheral blood, lymph node, or effusion) and normal tissue (from saliva) samples to be submitted for complete exome and transcriptome sequencing.",able-to-provide-samples
"Patient is willing to undergo a pre-treatment tumor biopsy, unless an appropriate archival tumor tissue (obtained after most recent disease progression) is available. Additionally, patient must be willing to undergo 1 on-treatment biopsy, provided it is deemed safe and feasible by the Investigator.",able-to-provide-samples
"Patient must agree to the collection of formalin fixed paraffin-embedded (FFPE) blocks or slides from archival diagnostic histology samples, or a fresh pre-treatment biopsy will be accepted.",able-to-provide-samples
Patient must be willing to provide mandatory bone marrow and blood samples for research.,able-to-provide-samples
"Patient must consent to provision of, and Investigator(s) must confirm access to and agree to submit a representative, formalin fixed, paraffin block of tumor tissue to be used for correlative marker assays. Submission of the tissue does not have to occur prior to enrollment.",able-to-provide-samples
"Patient must consent to provision of, and investigator(s) must confirm access to and agree to submit to the CCTG Central Tumour Bank, a representative formalin fixed paraffin block of tumour tissue in order that the specific correlative marker assays described in the protocol may be conducted.",able-to-provide-samples
Patient must have archived formalin-fixed paraffin-embedded (FFPE) tumor tissue specimen from the original diagnostic biopsy available for submission to Adaptive Biotechnologies for ClonoSEQ ID molecular marker identification of unique clonal immunoglobulin deoxyribonucleic acid (DNA) sequence,able-to-provide-samples
"Patient must have available archival tumor tissue obtained <= 6 months before the screening, or have fresh tumor tissue biopsy obtained during the screening.",able-to-provide-samples
Patients enrolled in the phase 2 portion of the study will be required to have archival tumor tissue available for analysis and be willing to have a tumor biopsy at baseline (after registration and prior to starting study treatment) and at Cycle 1 Day 2.,able-to-provide-samples
Patients must be able to provide an archived tumor tissue sample or newly obtained core or excisional biopsy of a tumor lesion.,able-to-provide-samples
"Patients must be offered participation in specimen banking as outlined in Section 15.3. With patient consent, pretreatment specimens must be collected and submitted via the SWOG Specimen Tracking System as outlined in Section 15.3.",able-to-provide-samples
"Patients must be offered participation in specimen banking for future research. With patient's consent, specimens must be submitted as outlined in Section 15.2.",able-to-provide-samples
"Patients must be offered participation in specimen submission for future research. With patient's consent, specimens must be submitted as outlined in Section 15.3 and Section 15.4.",able-to-provide-samples
"Patients must be offered participation in specimen submission for future research; with patient's consent, specimens must be submitted as outlined",able-to-provide-samples
Patients must be offered the opportunity to participate in specimen banking for future studies to include translational medicine studies,able-to-provide-samples
Patients must be offered the opportunity to participate in specimen banking for future studies.,able-to-provide-samples
Patients must be offered the opportunity to participate in specimen submission for banking as outlined in Section 15.1.,able-to-provide-samples
Patients must be offered the opportunity to participate in translational medicine studies and specimen banking for future studies as outlined in Section 15.0.,able-to-provide-samples
"Patients must have a formalin-fixed paraffin-embedded (FFPE) tissue block (from primary or metastatic tumor) available and must have provided informed consent for the release of the FFPE tissue block for subgroup analysis at the end of the study. If an archival tumor tissue sample is not available, a fresh tumor biopsy will be performed.",able-to-provide-samples
"Patients must have access to archival tumor tissue for proposed correlative studies; these may be derived from transurethral resection of bladder tumors (TURBT), cystectomy, or biopsy; if archival tissue is not available for proposed correlatives, patients may be enrolled at the discretion of the study principal investigator (PI) (SKP)",able-to-provide-samples
"Patients must have blood and tissue specimens collected prior to registration and submitted for translational medicine; Note that patients without adequate diagnostic specimens will not be eligible; with patient consent, residuals from the mandatory submission will be banked for future research",able-to-provide-samples
Patients must have paraffin tissue from the diagnostic or relapse biopsy available to be submitted for central pathology review,able-to-provide-samples
Patients must have specimens submitted for blinatumomab immunogenicity assessment. Collection of pretreatment specimens must be completed up to 28 days prior to registration to S1318. Specimens must be submitted to LabConnect as outlined in Section 15.2.,able-to-provide-samples
Patients must have specimens submitted for FLT3 testing for randomization stratification. Collection of pretreatment specimens must be completed within 1 day of registration to Step 1. Specimens must be submitted via the SWOG Specimen Tracking System as outlined in Section 15.2. FLT3 results will be used for stratification purposes at the time of randomization. E-mail notification of randomization assignment must be received prior to Step 2 registration.,able-to-provide-samples
Patients must have sufficient diagnostic tissue specimens collected prior to registration.,able-to-provide-samples
"Patients must have tissue specimens collected prior to registration; patients must be offered participation in biobanking of residual specimens; with patient consent, residuals from the mandatory submission will be banked for future research",able-to-provide-samples
Patients must submit specimens for MRD as outlined in Section 15.1,able-to-provide-samples
Patients should be willing to provide a representative tumor specimen obtained from metastatic disease if clinically feasible. This is a recommended but optional research biopsy.,able-to-provide-samples
Patients with no archival tissue available must be agreeable to fresh biopsy at baseline.,able-to-provide-samples
"Patients with solid tumors (with the exception of glial tumors and tumors that are anatomically inaccessible) must have an archival tumor biopsy sample as long as no anticancer therapy was administered since the sample was collected; otherwise, a current biopsy is required. In the case of glial tumors and anatomically inaccessible tumors, the most recent archival tissue is required.",able-to-provide-samples
Pretreatment cytogenetics must be performed on all patients as outlined in Section 15.4. Collection of pretreatment specimens must be completed within 42 days prior to randomization (registration Step 2). Reports of the results must be submitted as outlined in Sections 14.4 and 15.4.,able-to-provide-samples
Pretreatment tumor tissue will be assessed for adequate tumor content prior to participants receiving study treatment. Pretreatment tissue must be collected and confirmed for adequate tissue quantity (20 slides) and quality (100 viable tumor cells and 20% tumor content) during the screening period prior to first dose of study treatment. Participants who had a biopsy after signing consent which confirmed diagnosis but did not yield sufficient tissue for all correlative studies may be allowed after discussion with the BMS Medical Monitor.,able-to-provide-samples
Provision of suitable tumor tissue for the analysis of Axl kinase expression and PD-L1 expression.,able-to-provide-samples
"Provision of tumor tissue sample, when available, from original diagnosis obtained before initiation of chemoradiotherapy",able-to-provide-samples
Representative baseline tumor tissue sample is available (Parts A-K),able-to-provide-samples
"Strongly encouraged: representative pretreatment tumor specimen for exploratory biomarker research (see Section 4.5.6 for information on tumor specimens) The pretreatment tissue sample should be submitted before or within 4 weeks after randomization; however, patients may be enrolled into the study before the pretreatment tumor tissue sample is submitted. Patients without archival tissue are strongly encouraged to undergo a tumor biopsy.",able-to-provide-samples
"Subject has consented to provide at least 10 unstained tumor slides from an archival formalin-fixed, paraffin-embedded (FFPE) tumor block or the entire tissue block for retrospective testing of genetic abnormalities and gene expression profiles. If archival tissue is not available, Subject must consent to tumor biopsy.",able-to-provide-samples
Subject must be able to provide an evaluable core or incisional/excisional biopsy prior to the start of treatment.,able-to-provide-samples
"Subject must be willing to provide a fresh biopsy sample during Screening (and Pre-treatment Screening, if required).",able-to-provide-samples
Subjects for whom newly-obtained samples cannot be provided (e.g. inaccessible or subject safety concern) may submit an archived specimen,able-to-provide-samples
"Subjects with lymphoma: must have archival tissue available for analysis of CD22 expression, or must be willing to undergo a biopsy of easily accessible disease.",able-to-provide-samples
"Submit adequate archival tissue specimen (25+ unstained slides or 2 tissue blocks) from a biopsy performed after progression of disease on most recent therapy OR subject is willing to undergo a new core or excisional biopsy to obtain evaluable tumor tissue sample for immunohistochemical assessment and sequencing for B2M loss; repeat samples may be required if adequate tissue is not provided, however, patients may still be considered for enrollment on a case by case basis following consultation with the principal investigator (PI)",able-to-provide-samples
Submit an evaluable baseline tumor sample for PD-L1 analysis (either a newly obtained or archival tumor sample) as specified in the Procedure Manual.,able-to-provide-samples
"Tissue (or lymph node biopsy for rrcHL participants) available from an archival tissue sample or, if appropriate, a newly obtained core or excisional biopsy of a tumor lesion not previously irradiated",able-to-provide-samples
Tissue and plasma samples for mutation confirmation:,able-to-provide-samples
"Tissue available from the diagnostic biopsy in the form of blocks, tissue cores, or slides available for submission to central pathology is required for all participants enrolled to this study; formalin-fixed paraffin-embedded tissue from diagnostic tissue is acceptable and recommended; submission of the institutional diagnostic slides is also preferred for all participants enrolled in the study",able-to-provide-samples
Tissue or Programmed death-ligand 1 (PD-L1) results available,able-to-provide-samples
"Tumor tissue (a minimum of 10 and up to 15 unstained slides, or paraffin block, ideally from the patient's most recent biopsy, must be made available prior to the first dose of study therapy.",able-to-provide-samples
Tumor tissue for retrospective central pathology review and correlative studies must be provided.,able-to-provide-samples
Tumor tissue samples must be available for submission to the sponsor prior to study treatment.,able-to-provide-samples
"Type 1 specimen collection: Patients undergoing a clinically directed tissue biopsy or tissue collection who are willing to have additional specimens taken for research during the same procedure. Sites for tissue acquisition may include the breast, skin/chest wall, lymph node/soft tissue, liver, bone, lung, brain, pleural fluid, and ascites as needed for routine clinical care.",able-to-provide-samples
"Type 2 specimen collection: Patients underging a tissue biopsy or tissue collection for research purposes only. Sites for tissue acquisition include the breast, skin/chest wall, lymph node/soft tissue, liver, bone, pleural fluid, and ascites. Research directed lung biopsies and brain biopsies are not permitted. Procedures for tissue acquisition are restricted to those performed under local anesthesia or IV conscious sedation; biopsies that require general anesthesia are not permitted in this situation.",able-to-provide-samples
Will provide bone marrow aspirate sample for correlative research purposes.,able-to-provide-samples
"Willing to provide archive tissue samples for correlative research purposes (See Sections 4.0, 6.0 and 17.0.)",able-to-provide-samples
willing to provide archived or fresh tumor tissue samples that are sufficient for comprehensive genomic and/or proteomic analyses at baseline,able-to-provide-samples
Willing to provide blood and saliva samples for correlative research purposes,able-to-provide-samples
Willing to provide blood and tissue for correlative research purposes.,able-to-provide-samples
Willing to provide blood and tissue samples for mandatory correlative research purposes.,able-to-provide-samples
Willing to provide blood samples at baseline for correlative research purposes and tissue for central pathology review,able-to-provide-samples
Willing to provide blood samples for correlative research purposes,able-to-provide-samples
"Willing to provide blood samples for correlative research purposes (see Sections 6, 14 and 17).",able-to-provide-samples
Willing to provide blood samples for correlative research purposes.,able-to-provide-samples
Willing to provide blood samples for mandatory correlative research purposes.,able-to-provide-samples
Willing to provide blood samples for translational research purposes,able-to-provide-samples
Willing to provide bone marrow and blood samples for correlative research purposes,able-to-provide-samples
Willing to provide bone marrow and blood samples for planned research,able-to-provide-samples
"Willing to provide bone marrow aspirate and core, and blood samples for correlative research purposes",able-to-provide-samples
"Willing to provide bone marrow aspirate and core, and blood samples for correlative research purposes.",able-to-provide-samples
Willing to provide bone marrow samples under Institutional Review Board (IRB)#521-93 for correlative research purposes,able-to-provide-samples
"Willing to provide bone marrow, tissue, and blood samples for correlative research purposes",able-to-provide-samples
Willing to provide existing relapse-confirmatory DLBCL tumor sample,able-to-provide-samples
Willing to provide longitudinal blood samples per Control Specimen Collection Calendar for correlative studies (for comparison to specimens from patients treated on the trial).,able-to-provide-samples
Willing to provide mandatory biological specimens for research purposes,able-to-provide-samples
Willing to provide mandatory biological specimens for research purposes (See Section 14.0).,able-to-provide-samples
Willing to provide mandatory tissue and blood for correlative research purposes.,able-to-provide-samples
"Willing to provide mandatory tissue and blood samples for correlative research purposes (see Sections 6.0, 14.0, and 17.0)",able-to-provide-samples
Willing to provide mandatory tissue and blood samples for research purposes.,able-to-provide-samples
"Willing to provide mandatory tissue samples (if sufficient tissue available), bone marrow and blood samples for research purposes.",able-to-provide-samples
Willing to provide mandatory tissue samples for research purposes.,able-to-provide-samples
Willing to provide samples for planned research.,able-to-provide-samples
Willing to provide tissue and blood samples for correlative research purposes,able-to-provide-samples
Willing to provide tissue and blood samples for correlative research purposes (see Section 10).,able-to-provide-samples
"Willing to provide tissue and blood samples for correlative research studies (see Sections 6.0, 14.0 and 17.0).",able-to-provide-samples
"Willing to provide tissue and blood samples for mandatory correlative research purposes (see Sections 6.0, 14.0 and 17.0).",able-to-provide-samples
Willing to provide tissue and blood samples for research purposes,able-to-provide-samples
Willing to provide tissue for central review blood samples for correlative research purposes,able-to-provide-samples
Willing to provide tissue for correlative research purposes,able-to-provide-samples
Willing to provide tissue samples for correlative research purposes,able-to-provide-samples
Willing to provide tumor biopsy sample,able-to-provide-samples
"Willing to submit tissue, blood, and urine for required correlative research",able-to-provide-samples
Willing to undergo a biopsy of a metastatic site of breast disease for central laboratory determination of ER and correlative research purposes.,able-to-provide-samples
Willingness to participate in collection of pharmacokinetic samples,able-to-provide-samples
Willingness to provide all biologic specimens as required by the protocol,able-to-provide-samples
"Willingness to provide and there is confirmed availability of pre-existing diagnostic or resected tumor samples, such as paraffin-embedded sections. Providing fresh tumor biopsy is optional for subjects in dose escalation cohorts.",able-to-provide-samples
Willingness to provide biologic samples for correlative research purposes,able-to-provide-samples
Willingness to provide biological samples required for the duration of the study including a fresh tumor biopsy sample (See Table 1).,able-to-provide-samples
Willingness to provide blood and new tumor biopsy samples for research purposes if on the expansion phase of the study.,able-to-provide-samples
Willingness to provide blood and tissue samples for correlative research purposes (see Sections 14.0 and 17.0).,able-to-provide-samples
"Willingness to provide consent for biopsy samples (In Part A, fresh pre-treatment biopsies will be requested from subjects with safely accessible lesions. For subjects who cannot provide a fresh pre-treatment biopsy, an archival specimen will be required. In Part B, fresh pre-treatment biopsies will be required from subjects with safely accessible lesions. Archival specimens will be requested).",able-to-provide-samples
Willingness to provide mandatory 24 hour urine collection samples for research purposes.,able-to-provide-samples
Willingness to provide mandatory biological specimens for research purposes.,able-to-provide-samples
Willingness to provide mandatory blood and tissue specimens for correlative research.,able-to-provide-samples
Willingness to provide mandatory blood sample and bone marrow aspirate for research purposes.,able-to-provide-samples
Willingness to provide mandatory blood samples for research purposes,able-to-provide-samples
Willingness to provide mandatory blood specimens and bone marrow specimens for correlative research,able-to-provide-samples
Willingness to provide mandatory blood specimens and mandatory tissue specimens for correlative research.,able-to-provide-samples
Willingness to provide mandatory tissue specimens for correlative research,able-to-provide-samples
Willingness to provide mandatory tissue specimens for correlative research.,able-to-provide-samples
Willingness to provide mandatory tumor tissue and/or blood specimens for correlative research,able-to-provide-samples
Willingness to provide mandatory tumor tissue specimens for correlative research,able-to-provide-samples
Willingness to provide paraffin-embedded tissue blocks of ovarian cancer,able-to-provide-samples
"Willingness to provide pre-treatment (or recent archival w/o intervening therapy), and on-treatment tumor samples by core needle or excisional surgical biopsy",able-to-provide-samples
Willingness to provide tissue and blood samples for correlative research purposes,able-to-provide-samples
Willingness to provide tumor biopsies.,able-to-provide-samples
"Willingness to undergo a pretreatment bone marrow biopsy and/or aspirate (as appropriate to disease), or archival sample obtained since completion of most recent therapy (as appropriate to subjects with existing bone marrow disease or for whom bone marrow examination is a component of disease status assessment). If a biopsy is not possible or contraindicated, or the tissue requirement cannot be satisfied, this requirement may be waived with approval from the medical monitor.",able-to-provide-samples
Ability to adhere to dose and visit schedules.,able-to-return
Able and willing to return to enrolling institution for follow-up (during the active monitoring phase of the study).,able-to-return
Available to return to Mayo Clinic in within 6 weeks post-treatment for assessment,able-to-return
"During the Active Monitoring Phase of a study (i.e., active treatment and observation), participants must be willing to return to the consenting institution for follow-up",able-to-return
Patient has the initiative and means to be compliant with the protocol and be within geographical proximity to make the required study visits,able-to-return
Subject likely to not be available to complete all protocol required study visits or procedures ,able-to-return
Willing to return for follow-up,able-to-return
Willing to return to consenting institution for follow-up at 6 months,able-to-return
"Willing to return to enrolling institution for all study visits (immunizations, blood draws, etc).",able-to-return
Willing to return to enrolling institution for follow-up,able-to-return
Willing to return to enrolling institution for follow-up (during the active monitoring phase of the study [i.e. active treatment and observation]),able-to-return
Willing to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study),able-to-return
Willing to return to enrolling institution for follow-up (during the active monitoring phase of the study).,able-to-return
Willing to return to enrolling institution for follow-up (during the treatment and observation phases of the study),able-to-return
Willing to return to enrolling institution for follow-up (during the treatment phase of the study).,able-to-return
Willing to return to enrolling institution for follow-up 2-4 weeks after treatment discontinuation.,able-to-return
"Willing to return to enrolling institution for follow-up during the active monitoring phase of the study, i.e. active treatment and observation",able-to-return
Willing to return to enrolling institution for follow-up during the Active Treatment Phase of the trial.,able-to-return
Willing to return to enrolling institution for follow-up during the active treatment. Event monitoring following completion of therapy may occur outside the enrolling institution.,able-to-return
Willing to return to enrolling institution for follow-up for a minimum of 1 year.,able-to-return
"Willing to return to enrolling institution for follow-up or have a local physician willing to submit response and outcome data; Note: any and all therapy, potentially in its entirety, may be conducted outside of the Mayo Clinic",able-to-return
Willing to return to enrolling institution for follow-up.,able-to-return
Willing to return to Mayo Clinic enrolling institution for follow-up,able-to-return
Willing to return to Mayo Clinic institution for follow-up during the Active Monitoring Phase of the study.,able-to-return
Willing to return to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study),able-to-return
Willing to return to the enrolling institution for follow-up (during active treatment and active monitoring phase of the study),able-to-return
Willing to return to the enrolling institution for follow-up (during active treatment and active monitoring phase of the study).,able-to-return
"Willing to return to the enrolling institution for follow-up (during the Active Monitoring Phase of the study); Note: during the Active Monitoring Phase of a study (i.e., active treatment and observation), participants must be willing to return to the consenting institution for follow-up",able-to-return
"Willing to travel to a radioimmunotherapy site for Zevalin, if necessary",able-to-return
"Willing to undergo monthly follow-up assessment, either in person at the enrolling institution or by telephone",able-to-return
Willingness to return to enrolling institution for follow-up,able-to-return
Willingness to return to enrolling institution for follow-up (during the active monitoring phase of the study),able-to-return
Willingness to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study).,able-to-return
"Willingness to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study; i.e., active treatment and clinical follow-up).",able-to-return
Willingness to return to enrolling institution for follow-up.,able-to-return
Willingness to return to Mayo Clinic enrolling institution for follow-up,able-to-return
Willingness to return to Mayo Clinic for follow-up (during the Active Monitoring Phase of the study).,able-to-return
"Willingness to return to Mayo Clinic in Rochester, Minnesota for follow-up.",able-to-return
"Willingness to return to Mayo Clinic Rochester or another participating institution for follow-up; patients who are randomized to Arm B (cytotoxic chemotherapy) may receive chemotherapy at any oncology clinic able to provide the protocol-directed therapy and willing to send laboratory data to the participating institution; however, patients must be willing to return to the participating institution every two months for evaluation; patients who are randomized to Arm A must be willing to receive all treatment and follow-up at a participating institution",able-to-return
Willingness to return to the enrolling institution for follow up,able-to-return
"[Cohort B] Patients with gastrointestinal (GI) tract disease causing the inability to take oral medication, malabsorption syndrome, a requirement for intravenous (IV) alimentation, prior surgical procedures affecting absorption, uncontrolled inflammatory GI disease (e.g., Crohn's disease, ulcerative colitis)",absorb
A condition that would interfere with enteric absorption.,absorb
Able to tolerate oral medications and no GI illnesses that would preclude absorption of olaparib,absorb
Active gastrointestinal disease or other malabsorption syndromes,absorb
Active gastrointestinal disease or other malabsorption syndromes that would impact drug absorption.,absorb
"Active malabsorption syndrome at time of consent (ie. Crohn's disease, major bowel resection leading to permanent malabsorption).",absorb
"Any clinically significant concomitant disease or condition that could interfere with-or for which the treatment might interfere with the conduct of the study or the absorption of oral medications or that would pose an unacceptable risk to the patients in this study, in the opinion of the Principal Investigator",absorb
Any clinically significant gastrointestinal (GI) abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach and/or bowels.,absorb
"Any clinically significant gastrointestinal abnormalities that may alter absorption, such as malabsorption syndrome, chronic gastrointestinal disease, or major resection of the stomach and/or bowels that could preclude adequate absorption of the study medication.",absorb
Any coexistent medical condition interfering with drug absorption,absorb
"Any contraindication to oral agents or significant nausea and vomiting, malabsorption, or significant small bowel resection that, in the opinion of the Investigator, would preclude adequate absorption",absorb
"Any gastrointestinal condition causing malabsorption or obstruction (eg, celiac sprue, gastric bypass surgery, strictures, adhesions, history of small bowel resection, blind loop syndrome)",absorb
Any gastrointestinal disorder expected to limit absorption of IRX4204 or erlotinib.,absorb
Any GI disorder that may affect absorption of oral medications,absorb
"Any GI disorder that may affect absorption of oral medications, such as malabsorption syndrome or status post-major bowel resection",absorb
"Any history or presence of poorly controlled gastrointestinal disorders that could affect the absorption of the study drug (e.g. Crohn?s disease, ulcerative colitis, chronic diarrhea, malabsorption)",absorb
"Any history or presence of poorly controlled gastrointestinal disorders that could affect the absorption of the study drug (e.g. Crohn's disease, ulcerative colitis, chronic diarrhea, malabsorption)",absorb
Any malabsorption condition,absorb
"Any medical condition or diagnosis that would likely impair absorption of an orally administered drug (e.g. gastrectomy, ileal bypass, chronic diarrhea, gastroparesis)",absorb
Any underlying condition that would significantly interfere with the absorption of an oral medication,absorb
"Chronic diarrhea or malabsorptive diseases (e.g., Crohn's disease)",absorb
"Clinically active existing gastrointestinal disease affecting drug absorption, such as celiac disease or Crohn's disease",absorb
"Clinically significant gastrointestinal conditions or disorders that may interfere with study drug absorption, including prior gastrectomy",absorb
Clinically significant malabsorption syndrome.,absorb
Current or recent (within 3 months of study treatment administration) gastrointestinal disease that could interfere with absorption of orally administered systemic treatments (sub protocol c),absorb
Dose Optimization combination cohorts only: Participant has malabsorption syndrome or other condition that precludes enteral route of administration.,absorb
"For ABBV-181 plus venetoclax therapy (Part 3), participants with a known gastrointestinal disorder (i.e.: malabsorption syndrome), complication (i.e.: dysphagia) or surgery that could make consumption or absorption of oral medication problematic are also excluded.",absorb
"Gastro-intestinal abnormalities, including bowel obstruction, inability to take oral medication, requirement for intravenous (IV) alimentation, active peptic ulcer or prior surgical procedures or bowel resection affecting absorption.",absorb
Gastrointestinal abnormality that would affect absorption of SGN-2FF,absorb
"Gastrointestinal ailments that may alter the absorption of oral medications (i.e. bowel obstruction, short-gut syndrome).",absorb
Gastrointestinal condition that may affect drug absorption,absorb
Gastrointestinal conditions affecting absorption,absorb
"Gastrointestinal disease (e.g., Crohn's disease, ulcerative colitis, or short gut syndrome) or other malabsorption syndromes that would impact drug absorption.",absorb
Gastrointestinal disorder or abnormality that would interfere with absorption of the study drug.,absorb
Gastrointestinal disorder or procedure which is expected to interfere significantly with absorption of study treatment.,absorb
Gastrointestinal disorder that may affect absorption of study treatment,absorb
Gastrointestinal disorders or abnormalities that would interfere with absorption of the study drug,absorb
Gastrointestinal disorders that would interfere with drug absorption,absorb
"Gastrointestinal malabsorption, gastrointestinal anastomosis, or any other condition that might affect the absorption of lenvatinib or everolimus",absorb
"Gastrointestinal tract disease or any other reasons resulting in an inability to take oral medication or a requirement for intravenous (IV) alimentation, prior surgical procedures affecting absorption, active peptic ulcer disease or chronic diarrhea",absorb
"Gastrointestinal tract disease resulting in an inability to take oral medication or a requirement for IV alimentation, prior surgical procedures affecting absorption, or active peptic ulcer disease. Patients with nasogastric tube (NG-tube), J-tube, or G-tube will not be allowed to participate.",absorb
"Gastrointestinal tract disease resulting in an inability to take oral medication or a requirement for IV alimentation, prior surgical procedures affecting absorption, or active peptic ulcer disease. Patients with NG-tube, J-tube, or G-tube will not be allowed to participate.",absorb
GI condition that might limit absorption of oral agents,absorb
"has a significant chronic or recent acute gastrointestinal disorder with diarrhea as a major symptom (e.g., Crohn's disease, malabsorption, or >= grade 2 diarrhea of any etiology at baseline)",absorb
"Has any condition that would preclude adequate absorption of DS-3032b, including refractory nausea and vomiting, malabsorption, biliary shunt, significant bowel resection, and/or graft-versus-host disease (GVHD) affecting the gut.",absorb
Has malabsorption due to prior gastrointestinal (GI) surgery or GI disease,absorb
"Has refractory GI disease with refractory nausea/vomiting, inflammatory bowel disease, or bowel resection that would prevent absorption",absorb
"Has refractory GI disease with refractory nausea/vomiting, inflammatory bowel disease, or bowel resection that would prevent absorption of oral agents",absorb
Have a condition that limits the ingestion or absorption of drugs administered by mouth,absorb
Have a history of gastric bypass surgery or severe malabsorption that may interfere with the absorption of the study agents,absorb
Have a history of gastrointestinal disorders (medical disorders or extensive surgery) that may interfere with the absorption of the study agents,absorb
"Have a serious preexisting medical condition that, in the opinion of the investigator would preclude participation in the study (for example a GI disorder causing clinically significant symptoms such as nausea, vomiting, and diarrhea, or malabsorption syndrome) or that would result in a life expectancy of less than 1 year",absorb
Have gastrointestinal illness or disorder that could affect oral absorption of TAK-788.,absorb
"History of a malabsorption syndrome or uncontrolled nausea, vomiting, or diarrhea that may interfere with the absorption of oral study medication in the opinion of the investigator.",absorb
"History of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess within 28 days or manifestations of malabsorption due to prior gastrointestinal (GI) surgery or GI disease that may alter the absorption of MLN0128 (TAK-228)",absorb
History of bowel obstruction or malabsorption syndromes (within the last 3 months) which might limit the absorption of the study drug,absorb
"History of malabsorption or uncontrolled vomiting or diarrhea, or any other disease significantly affecting gastrointestinal function that could interfere with absorption of oral medications.",absorb
History of malabsorption syndrome or other condition that would interfere with enteral absorption,absorb
History of malabsorption syndrome or other condition that would interfere with enteral absorption.,absorb
History of prior surgical procedures affecting absorption,absorb
Illnesses that could affect oral absorption.,absorb
Impaired gastrointestinal absorption,absorb
Impaired gastrointestinal function (GI) or GI disease that may significantly alter the absorption of oral medications,absorb
"Impaired gastrointestinal function or poorly controlled gastrointestinal disease that may significantly alter the absorption of oral BYL719 (e.g. Crohn's disease, ulcerative colitis, malabsorption syndrome, small bowel resection, uncontrolled nausea or vomiting, or grade >= 3 diarrhea of any etiology) based on treating physician assessment",absorb
"Impaired GI function or GI disease that may significantly impair absorption (e.g., inflammatory bowel disease (IBD), malabsorption syndrome, small bowel resection, uncontrolled vomiting or diarrhea)",absorb
Impairment of gastrointestinal (GI) function or disease that may significantly alter the absorption of the study drugs,absorb
"Impairment of gastrointestinal (GI) function or GI disease that could significantly alter the absorption of CPI-0610 and/or ruxolitinib, including any unresolved nausea, vomiting, or diarrhea that is CTCAE grade > 1",absorb
Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of panobinostat,absorb
"Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of the study drugs (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection).",absorb
"Impairment of gastrointestinal function or gastrointestinal disease (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection that under the judgment of the PI may impair absorption of study drugs).",absorb
Impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of aspirin.,absorb
"Impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of capecitabine/temozolomide (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome or substantial small bowel resection)",absorb
"Impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of oral LGK974 (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, small bowel resection)",absorb
"Impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of study medication (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome or small bowel resection associated with malabsorption)",absorb
Impairment of gastrointestinal function or GI disease that may significantly alter the absorption of oral combination partners,absorb
Impairment of gastrointestinal function or GI disease that may significantly alter the absorption of oral combination partners.,absorb
"Impairment of gastro-intestinal function or GI disease that may significantly alter the absorption of palbociclib, such as history of GI surgery which may result in intestinal blind loops and patients with clinically significant gastroparesis, short bowel syndrome, unresolved nausea, vomiting, active inflammatory bowel disease or diarrhea of CTCAE Grade > 1.",absorb
"Impairment of gastrointestinal function or who have gastrointestinal disease that may significantly alter the absorption of study drugs (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea or malabsorption syndrome).",absorb
Impairment of GI function or GI disease that may significantly alter the absorption of INC280,absorb
"Impairment of GI function or GI disease that may significantly alter the absorption of INC280 (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, or malabsorption syndrome)",absorb
Impairment of GI function or GI disease that may significantly alter the absorption of venetoclax.,absorb
"Inability to take oral medication or significant nausea and vomiting, malabsorption, or significant small bowel resection that, in the opinion of the Investigator, would preclude adequate absorption",absorb
Incidence of gastrointestinal disease that may significantly alter the absorption of ACY 241.,absorb
Incidence of gastrointestinal disease that may significantly alter the oral absorption of Pomalidomide.,absorb
"Is unable to take oral medications, malabsorption syndrome or any other uncontrolled gastrointestinal condition (e.g., nausea, diarrhea or vomiting) that might impair the bioavailability of tazemetostat",absorb
"Is unable to take oral medications, or has a malabsorption syndrome or any uncontrolled gastrointestinal condition (e.g., nausea, diarrhea or vomiting) that would limit compliance with study requirements.",absorb
Known disorder affecting gastrointestinal absorption,absorb
Known fat malabsorption diseases that may affect skin carotenoid status.,absorb
Known impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral everolimus,absorb
Major resection of the stomach or small bowel that could affect the absorption of capecitabine,absorb
"Malabsorption issues (e.g., gastric bypass or gastrectomy patients)",absorb
Malabsorption syndrome,absorb
Malabsorption syndrome or other GI illness that could affect oral absorption of the study drug,absorb
Malabsorption syndrome or other illness that could affect oral absorption.,absorb
"Malabsorption syndrome, ulcerative colitis, inflammatory bowel disease, resection of the stomach or small bowel, or other disease or condition significantly affecting gastrointestinal function",absorb
Malabsorption syndrome.,absorb
Maldigestion/malabsorption syndrome pre-dating the diagnosis of pancreatic cancer.,absorb
"Manifestations of malabsorption due to prior gastrointestinal (GI) surgery, GI disease, or for an unknown reason that may alter the absorption of MLN0128 (TAK-228)",absorb
"Manifestations of malabsorption due to prior gastrointestinal (GI) surgery, GI disease, or for an unknown reason that may alter the absorption of MLN0128. In addition, patients with enteric stomata are also excluded.",absorb
"Manifestations of malabsorption due to prior gastrointestinal (GI) surgery, GI disease, or for an unknown reason that may alter the absorption of TAK-228. In addition, subjects with enteric stomata are also excluded.",absorb
"Manifestations of malabsorption due to prior gastrointestinal surgery, gastrointestinal disease, or for some other reason that may alter the absorption of MLN0128 or MLN1117. In addition, participants with enteric stomata are also excluded.",absorb
"Medical condition that, in the opinion of the investigator, may interfere with oral drug absorption",absorb
Must not have a gastrointestinal condition that would interfere with absorption,absorb
"No history of serious digestive and/or absorptive problems, including inflammatory bowel disease and chronic diarrhea that preclude adherence to the study diet.",absorb
"No known gastrointestinal (GI) disease or GI procedures that could interfere with the oral absorption or tolerance of alisertib; examples include, but are not limited to partial gastrectomy, history of small intestine surgery, and celiac disease",absorb
"or any form of chronic GI disease resulting in disturbed gut function, diarrhea, and malabsorption.",absorb
Participant has a malabsorption syndrome or other condition that precludes enteral route of administration.,absorb
"Participants must not have any clinically significant gastrointestinal abnormalities that in the opinion of the treating investigator may alter absorption of oral medications, such as malabsorption syndrome or major resection of the stomach or bowels.",absorb
"Participants with impairment of GI function or GI disease that may significantly alter the absorption of dabrafenib and trametinib in the opinion of the treating investigator (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, small bowel resection).",absorb
"Participants with known, uncontrolled malabsorption syndromes.",absorb
Participants with malabsorption syndrome or any other condition that precludes enteral administration.,absorb
"Patient has impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of orally administered medication (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, or malabsorption syndrome).",absorb
Patient has impairment of GI function or GI disease that may significantly alter the absorption of the study drugs,absorb
"Patient is unable to take drugs orally due to disorders or diseases that may affect gastrointestinal function, such as inflammatory bowel diseases (e.g., Crohn's disease, ulcerative colitis) or malabsorption syndrome, or procedures that may affect gastrointestinal function, such as gastrectomy, enterectomy, or colectomy",absorb
Patient must be able to take oral medications. Patients may not have any impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of the study drug.,absorb
"Patient with impaired gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral BYL719 (e.g. ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection).",absorb
"Patient with impaired gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral drug (e.g. ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection)",absorb
"Patients are excluded from Cohort 2 should they have pre-existing duodenal stent and/or any gastrointestinal disorder or defect that would, in the opinion of the investigator, interfere with absorption of rucaparib.",absorb
"Patients may not have any impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of blinded drug (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection)",absorb
"Patients must be able to take oral medications; patients must not have any impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of protocol treatment (e.g. ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome or small bowel resection)",absorb
Patients must be able to tolerate oral medications and not have gastrointestinal illnesses that would preclude absorption of cediranib or olaparib,absorb
"Patients must be able to tolerate oral medications by mouth, and not have a gastrointestinal illness that would preclude absorption of olaparib",absorb
Patients must NOT have absorption issues that would limit the ability to absorb study agents,absorb
Patients must not have clinically significant malabsorption syndrome or history,absorb
Patients that have a malabsorption syndrome or other illness which could affect oral absorption,absorb
Patients with any condition likely to interfere with absorption of the study medication.,absorb
Patients with any medical or surgical conditions that would interfere with gastrointestinal absorption of the study drug are not eligible,absorb
Patients with any medical or surgical conditions that would interfere with gastrointestinal absorption of the study drug are not eligible.,absorb
"Patients with gastrointestinal (GI) tract disease causing the inability to take oral medication, malabsorption syndrome, requirement for intravenous alimentation, prior surgical procedures affecting absorption, uncontrolled inflammatory GI disease (e.g., Crohn's disease, ulcerative colitis)",absorb
Patients with gastrointestinal impairment that would affect the absorption of enzalutamide or previous history of colitis,absorb
"Patients with GI tract disease resulting in an inability to take oral medication, malabsorption syndrome, a requirement for IV alimentation, prior surgical procedures affecting absorption, uncontrolled inflammatory GI disease (e.g., Crohn's, ulcerative colitis).",absorb
Patients with hypercalcemia and/or any condition resulting in malabsorption,absorb
Patients with impaired gastrointestinal absorption for whatever reason,absorb
Patients with malabsorption in the small intestine or other conditions that would preclude administration of oral medication.,absorb
"Persistent diarrhea or malabsorption >= NCI CTCAE Grade 2, despite medical management",absorb
Personal history of any condition that may impair absorption of enzalutamide.,absorb
"Preexisting duodenal stent and/or any gastrointestinal disorder or defect that would, in the opinion of the investigator, interfere with absorption of rucaparib",absorb
"Pre-existing duodenal stent and/or any other gastrointestinal disorder or defect that would, in the opinion of the Investigator, interfere with absorption of rucaparib",absorb
"Presence of a malabsorption syndrome, gastrointestinal disorder, or gastrointestinal surgery that could affect the absorption of axitinib",absorb
"Presence of active gastrointestinal (GI) disease or other condition that will interfere significantly with the absorption, distribution, metabolism, or excretion of X-396.",absorb
"Presence of active gastrointestinal disease or other condition that will interfere significantly with the absorption, distribution, metabolism, or excretion of drugs",absorb
"Presence of active malabsorption disorder (e.g., flare episodes documented within the preceding 3 months, presence of symptoms requiring daily medications for control) or history of extensive small bowel resection",absorb
Presence of conditions that will interfere significantly with the absorption of drugs.,absorb
Presence of gastrointestinal disease that would significantly affect compound absorption.,absorb
Previous bowel resection anticipated to affect drug absorption,absorb
"Prior gastric surgery, small bowel resection, or other conditions that may impede adequate absorption of oral study drug",absorb
"Prior surgery or gastrointestinal dysfunction that may affect drug absorption (eg, gastric bypass surgery, gastrectomy)",absorb
"Refractory nausea and vomiting, chronic gastrointestinal diseases (e.g., inflammatory bowel disease), or significant bowel resection that would preclude adequate ingestion and absorption of an oral agent",absorb
"Refractory nausea and vomiting, malabsorption, external biliary shunt, or significant bowel resection that would preclude absorption of vismodegib",absorb
"Significant chronic gastrointestinal disorder with diarrhea as a major symptom (e.g., Crohn's disease, malabsorption, or Grade >= 2 National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events Version 4.0 [CTCAE v.4.0] diarrhea of any etiology at baseline).",absorb
Significant malabsorption syndrome or inability to tolerate oral medications,absorb
Subject has a known gastrointestinal disorder that in the opinion of the treating investigator is concerning for malabsorption of oral medications.,absorb
Subject has a malabsorption syndrome or other condition that precludes enteral route of administration,absorb
"Subject is known to have dysphagia, short-gut syndrome, gastroparesis, or other conditions that limit the ingestion or gastrointestinal absorption of drugs administered orally",absorb
"Subjects must have no barriers to taking oral medications, for example uncontrolled nausea, vomiting, diarrhea at baseline, lack of physical integrity of the upper gastrointestinal tract, or malabsorption syndrome.",absorb
"Subjects with gastrointestinal (GI) tract disease causing the inability to take oral medication, malabsorption syndrome, requirement for intravenous alimentation, prior surgical procedures affecting absorption, uncontrolled inflammatory GI disease (e.g., Crohn's disease, ulcerative colitis)",absorb
Suspected malabsorption or obstruction; note: use of pancreatic enzyme supplements is allowed to control malabsorption,absorb
The subject is able to tolerate oral medications and no evidence of ongoing malabsorption,absorb
Unable to take oral medications or any medical condition that would interfere with the absorption of study medication capsules.,absorb
Uncontrolled malabsorption syndrome significantly affecting gastrointestinal function,absorb
Acceptable liver and renal function:,adequatefunction
Acceptable liver function:,adequatefunction
"Acceptable organ function, as evidenced by the following laboratory data during Screening period:",adequatefunction
Acceptable renal function:,adequatefunction
Acute worsening of renal function (CrCl < 30 ml/min) directly related to myeloma relapse,adequatefunction
Adequate baseline organ function:,adequatefunction
Adequate bone marrow and organ function as defined by the following laboratory values <= 14 days prior to registration:,adequatefunction
"Adequate bone marrow reserve, hepatic, and renal function, defined by",adequatefunction
Adequate hepatic function assessed by:,adequatefunction
Adequate hepatic function within 28 days before randomization defined as follows:,adequatefunction
Adequate hepatic function within 60 days prior to Step 1 registration defined as follows:,adequatefunction
"Adequate hepatic function, defined as:",adequatefunction
"Adequate hepatic, bone marrow, and renal function:",adequatefunction
Adequate laboratory values at Screening:,adequatefunction
Adequate liver function as defined by the following criteria:,adequatefunction
Adequate liver function as demonstrated by:,adequatefunction
Adequate Liver Function Defined As:,adequatefunction
Adequate marrow function as defined by the following:,adequatefunction
Adequate organ and marrow function as defined below:,adequatefunction
"Adequate organ and marrow function, as defined below. Criteria a, b, c, and f cannot be met with transfusions, infusions, or growth factor support administered within 14 days of starting the first dose.",adequatefunction
"Adequate organ and marrow function, based upon meeting all of the following laboratory criteria within 14 days before first dose of study treatment:",adequatefunction
Adequate organ and marrow functions as determined per protocol-defined criteria,adequatefunction
Adequate organ function <= 21 days prior to registration:,adequatefunction
Adequate organ function as defined below within 8 weeks of pre-registration:,adequatefunction
Adequate organ function as defined below:,adequatefunction
Adequate organ function as defined by the following criteria:,adequatefunction
Adequate organ function as defined by the following laboratory values at screening:,adequatefunction
Adequate organ function within 14 days of study registration defined as:,adequatefunction
Adequate organ function within 3 weeks prior to first study drug administration as evidenced by:,adequatefunction
Adequate organ functions as indicated by the following laboratory values (based on screening visit values from the central laboratory).,adequatefunction
Adequate renal and liver function defined as the following:,adequatefunction
Adequate renal function defined as:,adequatefunction
Adequate renal function within 14 days prior to registration defined as follows:,adequatefunction
Adequate renal function:,adequatefunction
"Adequate renal, hepatic, pulmonary and cardiac function defined as:",adequatefunction
All diseases: The following laboratory values obtained <= 14 days prior to registration:,adequatefunction
Any of the following laboratory abnormalities:,adequatefunction
Demonstrates adequate organ fuction. The following laboratory values obtained <= 14 days prior to re-registration:,adequatefunction
For AML only The following laboratory values obtained <= 14 days prior to registration,adequatefunction
For TCL only: The following laboratory values obtained <= 14 days prior to registration,adequatefunction
Have acceptable liver function:,adequatefunction
Have acceptable renal function:,adequatefunction
Have adequate organ and marrow function as defined below:,adequatefunction
Have adequate organ function confirmed by the following clinical laboratory values obtained within 14 days prior to the first dose of study drug:,adequatefunction
"Have adequate organ function, including:",adequatefunction
Have an acceptable liver function defined as:,adequatefunction
Have an acceptable renal function defined as:,adequatefunction
Hepatic function as follows:,adequatefunction
Impaired hepatic or renal function as demonstrated by any of the following laboratory values:,adequatefunction
Laboratory values ( <= 14 days prior to registration),adequatefunction
Laboratory values <= 14 days prior to registration:,adequatefunction
Laboratory values as follows:,adequatefunction
Laboratory values at screening outside the protocol-defined range.,adequatefunction
Must have adequate organ function as demonstrated by the following:,adequatefunction
Normal organ and marrow function as defined below (test results can be used if done within 30 days of consenting to treatment phase):,adequatefunction
Out of range lab values as defined in protocol,adequatefunction
Out of range lab values as defined:,adequatefunction
"Palpable hepatomegaly with impairment of liver function, ascites, and/or portal hypertension.",adequatefunction
"Participants must have adequate organ function, as defined by the following:",adequatefunction
Participants must have normal organ and marrow function as defined below:,adequatefunction
Participants must have normal organ as defined below:,adequatefunction
Patient enrolled prior to chemotherapy must have adequate organ function as indicated by the following laboratory values:,adequatefunction
Patient has adequate bone marrow and coagulation function as shown by the following laboratory values:,adequatefunction
Patient has adequate liver function as shown by:,adequatefunction
Patient has adequate renal function:,adequatefunction
Patient must have adequate organ and marrow function as defined below:,adequatefunction
Patients must have adequate liver function:,adequatefunction
Patients must have adequate organ and marrow function less than or equal to 28 days prior to Registration as defined below:,adequatefunction
Patients must have adequate organ function as defined by the following criteria within 2 weeks prior to randomization: NOTE: It is strongly encouraged that these tests take place no more than one week prior to randomization to meet the 2 week requirement for randomization:,adequatefunction
Patients must have adequate renal function as evidenced by ONE of the following:,adequatefunction
Patients must have normal organ and marrow function as definded below within less than or equal to 14 days prior to randomization:,adequatefunction
"Patients must have normal organ and marrow function as defined below (labs within one week of registration if patient postop, otherwise within two weeks of registration):",adequatefunction
Patients must have normal organ and marrow function as described below:,adequatefunction
Renal,adequatefunction
Renal function as follows:,adequatefunction
Renal:,adequatefunction
Required Initial Laboratory Values:,adequatefunction
Subject with any of the following laboratory abnormalities at screening:,adequatefunction
Subject with any of the following laboratory abnormalities:,adequatefunction
The following laboratory values in specified ranges:,adequatefunction
The following laboratory values obtained <= 14 days prior to registration:,adequatefunction
The following laboratory values obtained <= 14 days prior to Cycle 1/Day 1 dosing:,adequatefunction
The following laboratory values obtained <= 14 days prior to randomization.,adequatefunction
The following laboratory values obtained <= 14 days prior to registration.,adequatefunction
The following laboratory values obtained <= 14 days prior to study day 1.,adequatefunction
"The following laboratory values obtained <= 21 days prior to registration; complete blood count (CBC), sodium, potassium, aspartate aminotransferase (AST), bilirubin and creatinine are to be obtained pre-study; Note: treatment initiation and dosing modification should be performed at the individual investigators discretion and be consistent with the product label and their medical practice",adequatefunction
The following laboratory values obtained <= 7 days prior to registration,adequatefunction
The following laboratory values obtained <= 7 days prior to registration.,adequatefunction
The following laboratory values obtained after completion of NAC but <= 14 days prior to registration:,adequatefunction
"The patient has adequate baseline organ function, including cardiac, renal, and hepatic function:",adequatefunction
< 70 years of age:,agegender
>= 18 years of age and <= 80 years of age.,agegender
>= 18 years of age.,agegender
>= 18 years old,agegender
>= 18years of age,agegender
">= 70 years of age at the time of informed consent, OR 65-69 years of age with comorbidities precluding autologous stem cell transplantation",agegender
18 years of age or older,agegender
18-81 years of age,agegender
Adult (age >= 18 years),agegender
Adult and adolescent (age >= 12 years) subjects.,agegender
"Adult male or female, and at least 18 years old.",agegender
Adults >= 18 years of age,agegender
Age < 75 years with at least 1 of the following co-morbidities:,agegender
Age > 18 and < 70 years of age.,agegender
Age > 18 years old,agegender
Age > 65 years,agegender
Age >= 14 years ( >= 18 years in Germany),agegender
Age >= 18,agegender
Age >= 18 years,agegender
Age >= 18 years and < 65 years.,agegender
Age >= 18 years and <= 80 years old.,agegender
Age >= 18 years at diagnosis.,agegender
Age >= 18 years at the time of signing Informed Consent Form,agegender
Age >= 18 years at the time of signing the informed consent.,agegender
Age >= 18 years at time of signing Informed Consent Form,agegender
Age >= 18 years at time of signing Informed Consent Form.,agegender
Age >= 18 years of age.,agegender
Age >= 18 years old,agegender
Age >= 18 years on day of signing informed consent.,agegender
Age >= 18 years.,agegender
Age >= 21 years,agegender
Age >= 40 years in NOMAD study.,agegender
Age >= 60 years,agegender
Age >= 60 years OR,agegender
"Age >= 60 years, or",agegender
Age >= 60; or,agegender
"Age >= 75 years, or",agegender
Age 18 >= years at the time of study registration.,agegender
Age 18 or older,agegender
age 18 years or older,agegender
Age 18 years or older.,agegender
"Age 40 years or older. This age cutoff is justified because breast cancers in women under the age of 40 are known to have a significantly higher risk of IBTR presumably due to underlying biologic differences [104, 105].",agegender
Age eighteen years or older on the day of consent.,agegender
Age is >= 18 years.,agegender
Age Patients must be > 365 days and < 31 years of age,agegender
Age Patients must be >= 1 year and < 22 years of age at the time of enrollment.,agegender
Aged 18 years or older at the time of consent.,agegender
At least 18 years of age.,agegender
Be >= 18 years of age,agegender
Be >= 18 years of age on day of signing informed consent.,agegender
Be >= 18 years of age on the day of signing informed consent.,agegender
"Be 18 years of age or older on the day of signing the informed consent, and able and willing to comply with all trial procedures.",agegender
Be 18 years or older and 80 years or younger on the day of signing consent,agegender
Be at least 18 years of age,agegender
Be between the ages of >= 18 and <= 65 years,agegender
Between the ages of 18 and 70 years of age (inclusive) at time of enrollment,agegender
Both men and women are allowed.,agegender
Female >= 18 years of age.,agegender
Female age >= 18 years.,agegender
Female patient volunteers aged 18 years and older,agegender
Female sex.,agegender
Females >= 18 years of age.,agegender
Females age >= 18 years old,agegender
Females age >= 18 years.,agegender
Females age 18-90,agegender
Is aged >= 18 years,agegender
"Is male or female, aged 18 years or older at the time of consent; preferably non-Asian.",agegender
Male >= 18 years of age at the time the informed consent form is signed,agegender
Male and female participants at least 18 years of age at the time of signing the informed consent form (ICF); a legally minor participant from Japan needs written parental consent.,agegender
"Male and female patients of any race, 18 years or older",agegender
"Male and female patients, 18 - 75 years of age.",agegender
Male DCIS.,agegender
Male gender,agegender
Male or female 18 years of age or older,agegender
Male or female patients >= 18 years of age.,agegender
Male or female patients aged >= 18 years at time of informed consent.,agegender
Male or female patients aged 18 years or older.,agegender
Male or female subject >= 18 years.,agegender
Male or female subjects; age >= 18 years (all countries except Japan) or >= 20 years (Japan only) at the time of screening.,agegender
"Male or female, age >= 18 years (age limit may be higher if legally required in a country).",agegender
"Male or female, age >= 18 years old at the time of consent.",agegender
Male patients,agegender
Male subjects must:,agegender
Male subjects.,agegender
Male/female participants who are at least 18 years of age on the day of signing,agegender
Male/female subjects who are at least 18 years of age on the day of signing the informed consent.,agegender
"Males and Females, ages 18 or age of majority or older at the time of consent",agegender
"Males and females, ages 18 years or older at the time of consent",agegender
"Males and females,age 1 year(365 days) to < 18 (17 years and 364 days) years.",agegender
Men and women who are >= 18 years old at signing of informed consent.,agegender
"Men and women, aged 18 or older.",agegender
"Men are excluded from this study since DCIS of the breast is exceedingly rare in men, and there are no data regarding skin penetration of 4-OHT though male chest wall skin (which is thicker and hairier than female chest wall skin).",agegender
Must be at least 18 years old,agegender
Patient >= 18 years of age.,agegender
Patient is >= 18 years of age.,agegender
Patient is an adult male or female >= 18 years old at the time of consent and has signed informed consent (ICF) before any trial related activities and according to local guidelines.,agegender
Patient is at least 18 years of age.,agegender
Patient must be female,agegender
"Patient must be female >= 18 years of age, able to understand the study procedures, and agree to participate in the study by providing written informed consent.",agegender
Patients age 18 years and greater and able to give informed consent,agegender
Patients must be >= 18 years of age.,agegender
"Patients must be >= 2 and <= 30 years of age at the time of study entry for all strata except upper age limit of <= 18 years of age for MTC, RCC and HCC.",agegender
Patients must be 18 years of age or older.,agegender
Patients must be at least >= 18 years of age.,agegender
Patients must be at least 18 years old.,agegender
Patients must be female.,agegender
"Pediatric Patients (age 12-17), the following must have been obtained within 14 days prior to registration:",agegender
Subject is >= 18 years of age at the time of signing the informed consent form (ICF).,agegender
Subject is >= 18 years to <= 75 years of age and has voluntarily agreed to participate by giving written informed consent in accordance with ICH GCP Guidelines and applicable local regulations.,agegender
Subject is at least 18 years of age.,agegender
Subject is male or female > 18 years of age.,agegender
Subject must be >= 18 years of age and satisfy the legal age of consent in the jurisdiction in which the study is being conducted.,agegender
Subjects must be >= 18 years of age at the time of signing the Informed Consent Form (ICF); and must voluntarily sign an ICF; and able to meet all study requirements,agegender
The patient is >= 18 years old.,agegender
The patient is a woman of at least 18 years of age.,agegender
The patient must be >= 18 years old.,agegender
The patient must be female.,agegender
Women >= 18 years old.,agegender
Women of age >= 18 years.,agegender
Albumin > 2.5 g/dL,albumin
Albumin > 3.0 g/dL,albumin
Albumin > 3.0 g/dL (3.0 g/dL is equivalent to 30 g/L) .,albumin
Albumin >= 2.5 g/dL,albumin
Albumin >= 2.8 g/dL,albumin
Albumin >= 3 g/dL.,albumin
Albumin >= 3.0 g/dL within 2 weeks prior to registration,albumin
Albumin >= 3.0 grams/decilitre.,albumin
Albumin less than 3 g/dL (pancreatic cancer arms only),albumin
Albumin levels should be > 25 g/L (CTCAE G2 intermediate) to allow inclusion,albumin
Normal serum albumin,albumin
serum albumin > 28 g/L,albumin
Serum Albumin > 3.0 g/dL,albumin
Serum albumin >= 2.8 g/dL,albumin
Serum albumin >= 25 g/L (2.5 g/dL),albumin
Serum albumin >= 3.0 g/dL,albumin
Serum albumin >= 3.0 g/dL within 90 days prior to Step 1 registration,albumin
Serum albumin >= 3.2 g/dL (or >= 32 g/L) in the absence of receipt of (IV) albumin within the previous 72 hours.,albumin
Serum albumin 2.5 g/dL.,albumin
"A history of allergic reactions attributed to compounds of similar chemical or biologic composition to defactinib, pembrolizumab, gemcitabine, or other agents used in the study.",allergyhypersensitivity
"A history of allergic reactions attributed to compounds of similar chemical or biologic composition to palbociclib, letrozole, trastuzumab, any other aromatase inhibitor, any other monoclonal antibody, or other agents used in the study.",allergyhypersensitivity
A history of hypersensitivity to other humanized monoclonal antibodies.,allergyhypersensitivity
"A known history of allergy to docetaxel, Cremophor or polysorbate 80 (Tween 80)",allergyhypersensitivity
"Allergy or hypersensitivity to components of the KO-947 formulation, e.g. dextrose, hydroxypropyl beta cyclodextrin, acetic acid, sodium acetate and water for injection.",allergyhypersensitivity
Allergy to iodine. Note: This does not include reactions to intravenous contrast materials,allergyhypersensitivity
"Allergy to iodine. Note: This does not include reactions to intravenous contrast materialsKnown allergy to any of the study medications, their analogues or excipients in the various formulations.",allergyhypersensitivity
Allergy to iodine; (NOTE: this does not include reactions to intravenous contrast materials),allergyhypersensitivity
Allergy to iodine; Note: this does not include reactions to intravenous contrast materials,allergyhypersensitivity
Allergy to iodine; this does not include reactions to intravenous contrast materials.,allergyhypersensitivity
Allergy to measles vaccine or history of severe reaction to prior measles vaccination.,allergyhypersensitivity
Any prior hypersensitivity or adverse reaction to GM-CSF.,allergyhypersensitivity
"Any serious known immediate or delayed hypersensitivity reaction(s) to GSK525762 or fulvestrant, or idiosyncrasy to drugs chemically related to the investigational drugs.",allergyhypersensitivity
Contraindication to furosemide administration including prior allergy or adverse reaction to furosemide or sulfa drugs.,allergyhypersensitivity
Current evidence of hypersensitivity requiring systemic steroids at doses > 20 mg/day prednisone equivalent.,allergyhypersensitivity
Documented chlorhexidine gluconate allergy,allergyhypersensitivity
Has a known severe hypersensitivity ( >= Grade 3) to any of the study chemotherapy agents and/or to any of their excipients.,allergyhypersensitivity
"Has a known severe hypersensitivity ( >= Grade 3) to pembrolizumab, its active substance and/or any of its excipients.",allergyhypersensitivity
Has had a severe hypersensitivity reaction to treatment with another monoclonal antibody.,allergyhypersensitivity
Has severe hypersensitivity ( >= Grade 3) to any of the components or excipients used in the study treatments.,allergyhypersensitivity
"Has severe hypersensitivity ( >= Grade 3) to pembrolizumab, MK-4280, or lenvatinib and/or any of its excipients.",allergyhypersensitivity
"Have a history of severe adverse reaction (eg, hypersensitivity reaction, anaphylaxis) to sulfonamides",allergyhypersensitivity
"History of a hypersensitivity reaction to fingolimod or any of the excipients including rash, urticarial, and angioedema upon treatment initiation.",allergyhypersensitivity
"History of a serious or life-threatening allergic reaction to local anesthetics (e.g., lidocaine, xylocaine) used during a biopsy procedure",allergyhypersensitivity
History of allergic reaction attributed to compounds of similar or biologic composition to inotuzumab ozogamicin or other agents in the study.,allergyhypersensitivity
History of allergic reactions attributed to compounds of chemical or biologic composition similar to palbociclib.,allergyhypersensitivity
History of allergic reactions attributed to compounds of similar chemical or biologic composition to ABT-888 and atezolizumab.,allergyhypersensitivity
History of allergic reactions attributed to compounds of similar chemical or biologic composition to cabozantinib or nivolumab.,allergyhypersensitivity
"History of allergic reactions attributed to compounds of similar chemical or biologic composition to CB-839 HCl, carfilzomib, or dexamethasone.",allergyhypersensitivity
History of allergic reactions attributed to compounds of similar chemical or biologic composition to durvalumab or any excipient or any egg products.,allergyhypersensitivity
"History of allergic reactions attributed to compounds of similar chemical or biologic composition to M6620 (VX-970), carboplatin, gemcitabine or to these specific compounds.",allergyhypersensitivity
History of allergic reactions attributed to compounds of similar chemical or biologic composition to metformin.,allergyhypersensitivity
History of allergic reactions attributed to compounds of similar chemical or biologic composition to navitoclax or sorafenib,allergyhypersensitivity
History of allergic reactions attributed to compounds of similar chemical or biologic composition to olaparib and AT13387 used in study.,allergyhypersensitivity
History of allergic reactions attributed to compounds of similar chemical or biologic composition to olaparib or abiraterone.,allergyhypersensitivity
History of allergic reactions attributed to compounds of similar chemical or biologic composition to other agents used in study.,allergyhypersensitivity
History of allergic reactions attributed to compounds of similar chemical or biologic composition to PD 0332991 or other agents used in the study.,allergyhypersensitivity
History of allergic reactions attributed to compounds of similar chemical or biologic composition to ruxolitinib or other agents used in this study.,allergyhypersensitivity
History of allergic reactions attributed to compounds of similar chemical or biologic composition to Study Agent or accompanying supportive medications.,allergyhypersensitivity
"History of allergic reactions attributed to compounds of similar chemical or biologic composition to veliparib and MM-398; if patients have a history of allergic reactions to compounds resembling MM-398, they will be excluded from participating in the FMX MRI study, if applicable.",allergyhypersensitivity
"History of allergic reactions attributed to compounds of similar chemical or biologic composition to VX-970, cisplatin, or gemcitabine",allergyhypersensitivity
History of allergic reactions attributed to compounds of similar chemical or biologic composition to VX-970.,allergyhypersensitivity
History of allergic reactions attributed to tamoxifen or compounds of similar chemical or biologic composition.,allergyhypersensitivity
"History of allergic reactions/hypersensitivity attributed to compounds of similar chemical or biologic composition to tamoxifen, anastrozole, or fulvestrant or any of their ingredients.",allergyhypersensitivity
History of allergy or hypersensitivity to study treatment components.,allergyhypersensitivity
History of allergy to apixaban or Factor Xa inhibitors,allergyhypersensitivity
History of allergy to study treatments or any of its components of the study arm that,allergyhypersensitivity
History of allergy to study treatments or any of its components of the study arm that participant is enrolling,allergyhypersensitivity
History of any significant drug allergy (such as anaphylaxis or hepatotoxicity,allergyhypersensitivity
"History of any significant treatment allergy (such as anaphylaxis or hepatotoxicity) to prior anti-cancer immune-modulating therapies (eg, checkpoint inhibitors and T-cell co-stimulatory antibodies).",allergyhypersensitivity
"History of hypersensitivity or anaphylactoid reactions to pneumococcal vaccine or any component of the formulation, including diphtheria toxoid.",allergyhypersensitivity
"History of hypersensitivity to any of the study drugs, or their excipients, or a history of severe hypersensitivity to any other antigen.",allergyhypersensitivity
History of hypersensitivity to iodine,allergyhypersensitivity
"History of serious or life-threatening allergic reaction to local anesthetics (i.e. lidocaine, xylocaine)",allergyhypersensitivity
History of severe allergic anaphylactic reactions to chimeric or humanized antibodies or fusion proteins,allergyhypersensitivity
History of severe allergic or anaphylactic reactions to monoclonal antibody therapy (or recombinant antibody-related fusion proteins).,allergyhypersensitivity
"History of severe allergic reactions or intolerability attributed to compounds of similar chemical or biologic composition to neratinib (all cohorts), capecitabine for Cohorts 3A/3B, and T-DM1 for Cohorts 4A-4C",allergyhypersensitivity
"History of severe allergic, anaphylactic reactions to chimeric or humanized antibodies or fusion proteins",allergyhypersensitivity
"History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins",allergyhypersensitivity
History of severe hypersensitivity reaction to aminoglycosides or any of the agents used in this study,allergyhypersensitivity
History of severe hypersensitivity reaction to any monoclonal antibody.,allergyhypersensitivity
Hypersensitivity or history of allergic reactions to cisplatin or to any of the excipients listed below or other platinum containing compounds:,allergyhypersensitivity
"Hypersensitivity to CBT-101, excipients of the drug product, or other components of the study treatment regimen.",allergyhypersensitivity
Hypersensitivity to gemcitabine or to any of the excipients listed below:,allergyhypersensitivity
Hypersensitivity to pembrolizumab or any of its excipients.,allergyhypersensitivity
"Hypersensitivity to pembrolizumab, binimetinib, or any excipients of either drug.",allergyhypersensitivity
Hypersensitivity to Ruxolitinib or any of its excipients.,allergyhypersensitivity
"Hypersensitivity to trastuzumab, murine proteins or any of the excipients listed in the Herceptin or biosimilar trastuzumab label.",allergyhypersensitivity
Is known to be hypersensitive to any of the components or metabolites of 9-ING-41 or to the excipients used in its formulation,allergyhypersensitivity
"Known allergies, hypersensitivity, or intolerance to corticosteroids, monoclonal antibodies or human proteins, or their excipients (refer to respective package inserts or Investigator's Brochure), or known sensitivity to mammalian-derived products. Known allergies, hypersensitivity, or intolerance to trial drugs.",allergyhypersensitivity
"Known allergies, hypersensitivity, or intolerance to protein-based therapies or with a history of any significant drug allergy (e.g., anaphylaxis, hepatotoxicity, immune-mediated thrombocytopenia or anemia).",allergyhypersensitivity
Known allergy or hypersensitivity to any component of the atezolizumab formulation,allergyhypersensitivity
Known allergy or hypersensitivity to any component of the chemotherapy regimen the patient will be assigned to,allergyhypersensitivity
Known allergy or hypersensitivity to any component of the investigational drug product. Patients with history of Stevens-Johnson syndrome on a prior TKI are excluded.,allergyhypersensitivity
Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients,allergyhypersensitivity
Known allergy or hypersensitivity to any of the study drugs or their excipients,allergyhypersensitivity
Known allergy or hypersensitivity to any of the study treatments or any of the study treatment excipients. Prior/concomitant therapy,allergyhypersensitivity
Known allergy or hypersensitivity to study drug formulation(s),allergyhypersensitivity
Known allergy or hypersensitivity to study drug formulations.,allergyhypersensitivity
"Known allergy or hypersensitivity to the components of the atezolizumab formulation or to any of the study drugs or excipients, (e.g., Cremophor EL).",allergyhypersensitivity
Known allergy to any of the formulation components of Oraxol (oral paclitaxel or HM30181A) or pembrolizumab,allergyhypersensitivity
"Known allergy to any of the study medications or their analogues, or excipients in the various formulations.",allergyhypersensitivity
"Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent",allergyhypersensitivity
Known allergy to hyaluronidase.,allergyhypersensitivity
Known history of hypersensitivity to any components of the MSB2311 product.,allergyhypersensitivity
Known hypersensitivity allergy or contraindication to biopharmaceuticals produced in Chinese hamster ovary cells or any component of the PD-1/PD-L1 inhibitor formulation,allergyhypersensitivity
Known hypersensitivity or allergic reaction to platinum containing compounds.,allergyhypersensitivity
"Known hypersensitivity or development of erythema nodosum if characterized by a desquamating rash while taking thalidomide, lenalidomide, pomalidomide or similar drug. Known allergy to any of the study medications, their analogues, or excipients in the various formulations of the agents.",allergyhypersensitivity
"Known hypersensitivity or severe reaction to pemigatinib, gemcitabine, cisplatin, or their excipients (refer to the IB and commercially available product information sheets).",allergyhypersensitivity
Known hypersensitivity reaction to GM-CSF.,allergyhypersensitivity
Known hypersensitivity to 5-fluorouracil/leucovorin.,allergyhypersensitivity
Known hypersensitivity to any component of bevacizumab.,allergyhypersensitivity
Known hypersensitivity to any component of study drug,allergyhypersensitivity
"Known hypersensitivity to any component of the IP, required combination therapy, or loperamide.",allergyhypersensitivity
"Known hypersensitivity to any components of pracinostat, AZA, or mannitol",allergyhypersensitivity
Known hypersensitivity to any excipient contained in the drug formulation of SGN-LIV1A.,allergyhypersensitivity
Known hypersensitivity to any involved study drug or any of its formulation components.,allergyhypersensitivity
"Known hypersensitivity to any of the components of the investigational agent, LOXO-292 or Ora-Sweet® SF and OraPlus®, for patients who will receive LOXO-292 suspension.",allergyhypersensitivity
Known hypersensitivity to any of the excipients of ribociclib,allergyhypersensitivity
"Known hypersensitivity to any of the study medications (fulvestrant, venetoclax) or to any of the excipients",allergyhypersensitivity
Known hypersensitivity to biopharmaceutical agents produced in Chinese hamster ovary cells,allergyhypersensitivity
Known hypersensitivity to celecoxib or sulfonamides.,allergyhypersensitivity
Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies.,allergyhypersensitivity
Known hypersensitivity to Chinese hamster ovary cell products or to any component of the atezolizumab formulation,allergyhypersensitivity
Known hypersensitivity to fruquintinib or any of its excipients.,allergyhypersensitivity
Known hypersensitivity to immunoglobulins or to any components of the study drug.,allergyhypersensitivity
Known hypersensitivity to irinotecan.,allergyhypersensitivity
Known hypersensitivity to olanzapine,allergyhypersensitivity
Known hypersensitivity to paclitaxel (Taxol) or products containing Cremophor EL (polyoxyethylated castor oil).,allergyhypersensitivity
"Known hypersensitivity to palbociclib, letrozole, fulvestrant, goserelin (if applicable) or to any of their excipients",allergyhypersensitivity
Known hypersensitivity to the components of niraparib components or their formulation excipients,allergyhypersensitivity
Known hypersensitivity to the components of the study therapy or its analogs.,allergyhypersensitivity
Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to IGF or methotrexate.,allergyhypersensitivity
"Known or suspected hypersensitivity to azacitidine, pembrolizumab or the excipients of any of the study drugs (including mannitol). Known or suspected hypersensitivity to monoclonal antibodies.",allergyhypersensitivity
Known prior severe hypersensitivity reaction to monoclonal antibodies (grade >= 3 by NCI CTCAE v4.03 criteria).,allergyhypersensitivity
"Known severe hypersensitivity (Grade >= 3 National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0 [NCI-CTCAE 5.0]) to investigational product (M7824) or any components in their formulations, any history of anaphylaxis, or recent, within 5 months, history of uncontrolled asthma.",allergyhypersensitivity
No history of allergic reaction attributed to compounds of similar chemical or biological composition to cabozantinib/placebo,allergyhypersensitivity
"No known allergy to 5-fluorouracil, oxaliplatin, or leucovorin",allergyhypersensitivity
"No known history of severe allergic anaphylactic reactions to chimeric, human or humanized antibodies, or fusion proteins",allergyhypersensitivity
No known hypersensitivity to Chinese hamster ovary (CHO) cell products or any component of the atezolizumab formulation,allergyhypersensitivity
No known serious or severe hypersensitivity reaction to naloxegol or any of its excipients. See list of excipients in Section 10.1.,allergyhypersensitivity
Part B only: Known hypersensitivity to trastuzumab.,allergyhypersensitivity
Patient does not have a known allergy to compounds of similar or biologic composition as triapine.,allergyhypersensitivity
Patient has a known history of hypersensitivity to defibrotide or any of its excipients. Patient has a known hypersensitivity to agent(s) (or excipients of agent[s]) within the immunoprophylaxis regimens allowed by the protocol and also to be part of the patient's planned immunoprophylaxis regimen (refer to the approved product label and reference therapy section for additional details).,allergyhypersensitivity
Patient has a prior allergy or intolerance of ketoconazole,allergyhypersensitivity
Patient has an allergy or intolerance to sulfites,allergyhypersensitivity
"Patient has known hypersensitivity to alpelisib, fulvestrant or letrozole.",allergyhypersensitivity
Patient has known hypersensitivity to poziotinib or has a history of allergic reactions attributed to chemically similar compounds or other tyrosine kinase inhibitors (TKIs).,allergyhypersensitivity
Patient has previously received treatment with SL-401 or has a known hypersensitivity to any components of the drug product.,allergyhypersensitivity
Patient must NOT have a history of allergic reaction attributable to compounds of similar chemical or biologic composition to 18F-FES,allergyhypersensitivity
"Patients must NOT have a history of allergic reactions attributed to compounds of similar chemical or biochemical composition to cisplatin, etoposide, temozolomide or capecitabine.",allergyhypersensitivity
Patients must not have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to nivolumab,allergyhypersensitivity
Patients must not have a known hypersensitivity to olaparib or any of the excipients of the product.,allergyhypersensitivity
Patients must not have any history of hypersensitivity to any drugs or metabolites of midostaurin,allergyhypersensitivity
Patients who have severe hypersensitivity to irinotecan hydrochloride (HCl).,allergyhypersensitivity
"Patients with known hypersensitivity to any of the excipients of INC280 (crospovidone, mannitol, microcrystalline cellulose, povidone, sodium lauryl sulfate, magnesium stearate, colloidal silicon dioxide, and various coating premixes).",allergyhypersensitivity
"Previously identified allergy or hypersensitivity to components of the study treatment formulations (Note: patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency, or glucose-galactose malabsorption should not take cabozantinib and are also excluded).",allergyhypersensitivity
Previously identified allergy or hypersensitivity to components of the study treatment formulations.,allergyhypersensitivity
"Prior allergic reactions to drugs containing Cremophor, such as teniposide or cyclosporine, or study drugs involved in this protocol, or to a monoclonal antibody or prior hypersensitivity to platinum-containing agents.",allergyhypersensitivity
Prior severe allergic reactions to a monoclonal antibody or hypersensitivity to pembrolizumab or any of its excipients.,allergyhypersensitivity
"Severe hypersensitivity reaction to apixaban (e.g., anaphylactic reactions)",allergyhypersensitivity
"Subject has known allergies or hypersensitivity to mAbs or human proteins, or their excipients or known sensitivity to mammalian-derived products.",allergyhypersensitivity
"Subject has known allergies, hypersensitivity, or intolerance to JNJ-61186372 or its excipients (refer to Investigator's Brochure).8",allergyhypersensitivity
"Subject has known hypersensitivity or severe reaction to any of the active substances or excipients in INCB053914, cytarabine, azacitidine, ruxolitinib, or similar compounds as appropriate to the relevant treatment group.",allergyhypersensitivity
"Subject has known immediate or delayed hypersensitivity, intolerance or contraindication to any component of study treatment.",allergyhypersensitivity
Subject with history of severe allergic or anaphylactic reactions or hypersensitivity to recombinant proteins or excipients in the investigational product (see luspatercept IB).,allergyhypersensitivity
Subject with history of severe allergic or anaphylactic reactions or hypersensitivity to recombinant proteins or excipients in the investigational product (see luspatercept Investigator's Brochure (IB)).,allergyhypersensitivity
"Subject with known hypersensitivity to any component of bb2121 product, cyclophosphamide, fludarabine, and/or tocilizumab or hypersensitivity to the excipients contained in the formulation of DARA, POM, LEN, IXA, BTZ or dex.",allergyhypersensitivity
"Subject with known hypersensitivity to any component of bb2121 product, cyclophosphamide, fludarabine, and/or tocilizumab.",allergyhypersensitivity
"Subjects who have exhibited allergic reactions to tipifarnib or structural compounds similar to tipifarnib or to the drug product excipients. This includes hypersensitivity to imidazoles, such as clotrimazole, ketoconazole, miconazole and others in this drug class. Subjects with hypersensitivity to these agents will be excluded from enrolment.",allergyhypersensitivity
"Subjects with known hypersensitivity to any component of bb21217 product, cyclophosphamide, fludarabine or tociluzimab.",allergyhypersensitivity
Suspected/known hypersensitivity to IFN-&alpha;2b.,allergyhypersensitivity
"The patient has a history of drug-related anaphylactic reactions, severe allergic reactions, or an atopic diagnosis related to skin or severe reactions related to a drug. Likewise, patients with an active diagnosis of uncontrolled airway hyperactivity, uncontrolled asthma, or asthma requiring oral corticosteroids will be excluded.",allergyhypersensitivity
Alkaline phosphatase (ALP) <= 2.5x ULN or < 5x ULN if bone metastases are present,alp
Alkaline phosphatase (ALP) <= 5 x ULN,alp
Alkaline phosphatase < 2 x ULN ( < 5 x ULN if considered due to tumor),alp
Alkaline phosphatase < 2.5 x ULN ( < 5 x ULN if considered due to tumor),alp
Alkaline phosphatase < 2.5 X upper limit of normal,alp
Alkaline Phosphatase < 5 x ULN.,alp
Alkaline Phosphatase <= 2.5 x ULN,alp
alkaline phosphatase <= 2.5 x ULN ( <= 5 x ULN for patients with documented liver involvement or bone metastases),alp
Alkaline phosphatase <= 2.5 x ULN.,alp
Alkaline phosphatase <= 3 x ULN or <= 5 x ULN if bone or liver metastasis is present,alp
Alkaline phosphatase > 2.5 x ULN,alp
alkaline phosphatase must be <= 3 x ULN for the lab; and,alp
"Alkaline Phosphatase, AST and ALT <= 3 X ULN ( < 5 x ULN is acceptable if liver has tumor involvement)",alp
Obtained <= 14 days prior to registration: Alkaline phosphatase <= 3 x ULN,alp
Patients must have alkaline phosphatase <= 2.5 x IULN within 14 days prior to registration.,alp
Absolute neutrophil (ANC) count greater than 1000/ µL.,anc
"Absolute neutrophil count (ANC) _ 1.2x10^9/L (1,200/mm3)",anc
"Absolute neutrophil count (ANC) < 1,000/µL",anc
"Absolute neutrophil count (ANC) < 1,000/_L (1.0x10^9/L)",anc
Absolute neutrophil count (ANC) < 1.0 x 10/L,anc
Absolute neutrophil count (ANC) < 1.0x10^9/L.,anc
"Absolute Neutrophil Count (ANC) > 1,000/mm3",anc
Absolute Neutrophil Count (ANC) > 1500/uL,anc
"Absolute neutrophil count (ANC) >= 1,000 cell/mm^3 without growth factor support",anc
"Absolute neutrophil count (ANC) >= 1,000 cell/mm^3 without growth factor support, obtained <= 14 days prior to registration",anc
"Absolute neutrophil count (ANC) >= 1,000 cell/mm3 without growth factor support",anc
"Absolute neutrophil count (ANC) >= 1,000 mm^3",anc
"Absolute neutrophil count (ANC) >= 1,000/mm^3.",anc
"Absolute Neutrophil Count (ANC) >= 1,200/mm3.",anc
"Absolute Neutrophil Count (ANC) >= 1,500 /μl without the use of hematopoietic growth factors",anc
"Absolute neutrophil count (ANC) >= 1,500 /mcL",anc
"absolute neutrophil count (ANC) >= 1,500 cells/μl without the use of hematopoietic growth factors; and",anc
"Absolute Neutrophil Count (ANC) >= 1,500/mcL",anc
"Absolute Neutrophil Count (ANC) >= 1,500/mm^3",anc
"Absolute Neutrophil Count (ANC) >= 1,500/mm3",anc
"Absolute neutrophil count (ANC) >= 1,500/ul within 14 days prior to registration.",anc
"Absolute neutrophil count (ANC) >= 1,500/ul without the use of hematopoietic growth factors (within 14 days of treatment initiation)",anc
"Absolute neutrophil count (ANC) >= 1.0x10^9/L (if G-CSF or GM-CSF has been administered within 1 week of screening, must reassess ANC after 1-week washout to confirm no dependence on growth factors)",anc
absolute neutrophil count (ANC) >= 1.0x10^9/L (without growth factor support),anc
Absolute neutrophil count (ANC) >= 1.0x10^9/L without hematopoietic growth factor support,anc
absolute neutrophil count (ANC) >= 1.5 * 109/Litre,anc
Absolute neutrophil count (ANC) >= 1.5 X 10^9/L,anc
Absolute Neutrophil count (ANC) >= 1.5x10^9/L (without GCSF support),anc
Absolute neutrophil count (ANC) >= 1.5x10^9/L without growth factor support,anc
absolute neutrophil count (ANC) >= 1000 cells/mm3,anc
Absolute neutrophil count (ANC) >= 1000/mm^3,anc
Absolute neutrophil count (ANC) >= 1000/mm^3 obtained <= 14 days prior to registration,anc
Absolute neutrophil count (ANC) >= 1000/mm_ (without the use of growth factors),anc
Absolute neutrophil count (ANC) >= 1500 cells/_L,anc
Absolute neutrophil count (ANC) >= 1500 cells/mm3,anc
Absolute neutrophil count (ANC) >= 1500 uL,anc
Absolute neutrophil count (ANC) >= 1500/µL,anc
Absolute neutrophil count (ANC) >= 1500/_L (1.5x10^9/L).,anc
Absolute neutrophil count (ANC) >= 1500/mcL,anc
Absolute neutrophil count (ANC) >= 1500/mm^3,anc
Absolute neutrophil count (ANC) >= 1500/mm^3 or >= 1.5 x 10^9/L.,anc
Absolute neutrophil count (ANC) >= 1500/mm3 or >= 1.5x10^9/L,anc
"Absolute neutrophil count (ANC) >= 1500/mm3 or >= 1.5x10^9/L, without biologic response modifiers, such as granulocyte colony-stimulating factor (G-CSF), within 21 days before the start of screening (see Section 8.1).",anc
Absolute neutrophil count (ANC) >= 500 cells/mm3,anc
Absolute Neutrophil Count (ANC) >= 900 K/mm3,anc
Absolute neutrophil count (ANC) must be >= 1.5x10^9/L,anc
"Absolute neutrophil count [ANC] >= 1,500 cells/mm3 or >= 1.5 bil/L",anc
Absolute neutrophil count < 1.0x10^9/L.,anc
"Absolute Neutrophil Count > 1,500 cells/mm3",anc
Absolute neutrophil count > 1500/μL,anc
"Absolute neutrophil count >= 1,000 cells/mm3 without growth factors (within 14 days of enrollment).",anc
"Absolute neutrophil count >= 1,500/_L ( >= 1.5x10^9/L)",anc
"Absolute neutrophil count >= 1,500/mcL (subjects may be treated with hematopoietic growth factors to achieve or maintain this level)",anc
"Absolute neutrophil count >= 1,500/mcL without the use of hematopoietic growth factors (within 28 days prior to administration of ABT-888)",anc
"Absolute neutrophil count >= 1,500/mcL without the use of hematopoietic growth factors.",anc
absolute neutrophil count >= 1.0x10^9/L,anc
Absolute neutrophil count >= 1.0x10^9/L (1000 per mm3),anc
Absolute neutrophil count >= 1.5 X 10^9/L,anc
Absolute neutrophil count >= 1000 cells/mm3,anc
"Absolute neutrophil count >= 1000/mm3 (i.e., >= 1.0x10^9/L by International Units [IU])",anc
Absolute neutrophil count >= 1500 cells/mm3.,anc
Absolute neutrophil count >= 1500/mm^3,anc
Absolute neutrophil count >= 1500/mm3 (without hematopoietic growth factor support).,anc
Absolute neutrophil count: >= 1.5x10^9/L (1500/mm3),anc
Absolute neutrophils (x 109/L) | < 1.0 | < 1.0 | < 0.5 in the 2 weeks before screening.,anc
ANC <= 1500/mm3,anc
"ANC > 1,500 cells/μl without the use of hematopoietic growth factors; and",anc
"ANC >= 1,000/_L",anc
ANC >= 1500 cells/_L.,anc
ANC >= 1500/mm3,anc
ANC must be >= 1200/mm3,anc
Neutrophils < 1x10^9/L,anc
Neutrophils >= 1000/_L:,anc
Obtained <= 14 days prior to registration: Absolute neutrophil count (ANC) >= 1000/mm_,anc
Obtained <= 14 days prior to registration: Absolute neutrophil count (ANC) >= 1500/mm^3,anc
Patient has an absolute neutrophil count (ANC) >= 0.5x10^9/L.,anc
Patient's absolute neutrophil count (ANC) level must be > 1500/mm^3 within 2 weeks prior to registration,anc
Patient's ANC level must be > 1500/mm^3 within 2 weeks prior to registration,anc
"Patients must have adequate marrow function as evidenced by ANC >= 750/mcl and platelets >= 50,000/mcl within 28 days prior to registration.",anc
"Patients must have adequate marrow function as evidenced by ANC >= 750/mcl and platelets >= 75,000/mcl within 28 days prior to registration.",anc
Peripheral absolute neutrophil count (ANC) >= 1000/μL,anc
Peripheral absolute neutrophil count (ANC) >= 750/μL,anc
Active severe angina pectoris prior to registration,angina
angina,angina
Angina pectoris,angina
Angina pectoris <= 6 months,angina
No unstable angina or MI within 6 months of registration,angina
Onset of unstable angina within six months of signing the ICF.,angina
Patients with known unstable angina pectoris,angina
Presence of current angina,angina
Severe or unstable angina pectoris,angina
severe/unstable angina,angina
Uncontrolled angina within the past 3 months,angina
Unstable angina,angina
Unstable angina (symptoms of angina at rest) or new-onset angina <= 6 months before the start of anetumab ravtansine,angina
Unstable angina (symptoms of angina at rest) or new-onset angina within < 6 months before the start of study treatment.,angina
Unstable angina <= 12 months prior to registration,angina
Unstable angina pectoris,angina
Unstable angina within 6 months prior to screening,angina
unstable angina.,angina
"Unstable or poorly controlled angina pectoris, including the Prinzmetal variant of angina pectoris.",angina
"Able to receive concurrent prophylactic anticoagulation therapy (e.g., low-dose aspirin [81 mg] daily or an alternative prophylaxis [e.g., warfarin or low molecular weight heparin])",aspirinwarfarin
"Able to take aspirin (325 mg) daily as prophylactic anticoagulation. Subjects intolerant to aspirin may use warfarin, novel oral anticoagulants, or low dose molecular weight heparin.",aspirinwarfarin
Able to take aspirin (81 or 325 mg) daily as prophylactic anticoagulation (patients intolerant to ASA may use warfarin or low molecular weight heparin).,aspirinwarfarin
Able to take aspirin (81 or 325 mg) daily or an anticoagulant (as determined by treating physician) as prophylactic anticoagulation,aspirinwarfarin
"Able to take aspirin (81mg or 325mg) daily, warfarin, low molecular weight heparin, or equivalent anticoagulation as prophylactic medication.",aspirinwarfarin
Acceptable coagulation status:,aspirinwarfarin
"Coagulopathy, including the use of Coumadin or heparin anticoagulants that cannot be discontinued for the cryoablation procedure.",aspirinwarfarin
Have acceptable coagulation status:,aspirinwarfarin
On anticoagulation and unable to discontinue temporarily,aspirinwarfarin
Require therapy with warfarin or other coumarin derivatives (non-coumarin anticoagulants are allowed),aspirinwarfarin
These patients would not need the aspirin with the lenalidomide unless clinically indicated,aspirinwarfarin
Willing and able to take aspirin (81 mg) daily as prophylactic anticoagulation,aspirinwarfarin
Alanine aminotransferase (ALT) <= 3 x ULN,astalt
"Alanine aminotransferase (ALT) >= 3 x ULN, or if subject has known liver metastases, ALT >= 7 x ULN.",astalt
Alanine aminotransferase (ALT) 3 x ULN.,astalt
Alanine aminotransferase (ALT) and (aspartate aminotransferase) AST <= 3x institutional upper limit of normal (ULN),astalt
alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 1.5 x ULN or < 3 x ULN with documented liver metastases,astalt
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 3.0 x upper limit of normal.,astalt
alanine aminotransferase (ALT) and aspartate aminotransferase (AST) <= 1.5x ULN or <= 3x ULN if liver metastases present,astalt
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) <= 2 times upper limit of normal (ULN),astalt
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) <= 2.5 x the upper limit of normal (ULN) ( <= 5 x ULN if considered due to primary or metastatic liver involvement),astalt
"Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) <= 2.5 x ULN for subjects with hepatic metastases, ALT and AST <= 5 x ULN",astalt
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) <= 2.5 x ULN in patients without liver metastases or <= 5 x ULN for patients with liver metastases.,astalt
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) <= 2.5 x ULN or <= 5 x upper limits of normal (ULN) if liver metastases are present,astalt
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) <= 2.5 x ULN within 14 days prior to registration.,astalt
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) <= 2.5 x upper limit of normal (ULN) or <= 5 x ULN if liver metastases are present,astalt
"Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) <= 3 times the ULN; if liver tumor/ metastases are present, then <= 5 x ULN is allowed.",astalt
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) <= 3 x ULN,astalt
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) <= 3 x ULN or < 5 x ULN if liver involvement,astalt
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) <= 3x,astalt
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) <= 3x institutional upper limit of normal (ULN),astalt
Alanine aminotransferase (ALT) and Aspartate transaminase (AST) 3 x ULN ( <= 5 x ULN for patients with liver involvement),astalt
alanine aminotransferase (ALT) level <= 2.5 * ULN,astalt
Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) <= 3.0 x ULN OR <= 5.0 x ULN for patients with liver metastases.,astalt
Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 1.5 x ULN in patients without hepatic metastases; ALT or AST > 3 x ULN in patients with hepatic metastases,astalt
Alanine aminotransferase (ALT) or aspartate transaminase (AST) <= 3 x upper limit of normal (ULN),astalt
Alanine aminotransferase (ALT)(SGPT) <= 3 x ULN,astalt
Alanine aminotransferase (ALT)/Serum Glutamic Pyruvic Transaminase (SGPT),astalt
Alanine aminotransferase (ALT)/Serum Glutamic Pyruvic Transaminase (SGPT) <= 3x ULN,astalt
"alanine aminotransferase (ALT, SGPT) <= 3.5 x upper limit of normal (ULN)",astalt
Alanine aminotransferase [ALT/SGPT] <= 3x UNL ( <= 5x UNL if liver metastases present),astalt
Alanine aminotransferase < 3 x upper limit of normal (ULN),astalt
Alanine aminotransferase and aspartate aminotransferase <= 3x ULN,astalt
"Alanine transaminase (ALT) <= 3 x ULN, except for patients with liver metastasis, who may only be included if ALT <= 5 x ULN",astalt
Alanine transaminase (ALT) 2.5 x ULN (5 x ULN for patients with liver involvement),astalt
Alanine transaminase (ALT)/aspartate transaminase (AST) >= 2.5 x upper limit of normal (ULN),astalt
Alanine transaminase and aspartate transaminase <= 2.5 x ULN,astalt
"ALT (SGPT) and/or AST (SGOT) <= 3x upper limit of normal (ULN), or <= 4 x ULN (if upon judgment of the treating physician, it is believed to be due to extramedullary hematopoiesis [EMH] related to MF)",astalt
ALT < 2.5 x ULN (5.0 x ULN in the presence of liver metastasis),astalt
ALT <= 2.5 x ULN OR < 5 x ULN is acceptable for subjects with documented liver metastases/tumor infiltration,astalt
ALT <= 3 institutional ULN OR <= 5 x ULN in presence of liver metastases,astalt
ALT > 3 x ULN,astalt
"ALT and AST <= 2.5 x upper limit of normal (ULN), with the following exception:",astalt
ALT and AST <= 3 x ULN,astalt
"ALT, AST, and ALP <= 3 x upper limit of normal (ULN). ALP <= 5 x ULN with documented bone metastases.",astalt
"Aminotransferase (ALT) <= 3.0 x ULN, <= 5.0 x ULN for patients with metastatic disease to the liver",astalt
Aspartate aminotransferase (AST or SGOT) and alanine aminotransferase (ALT or SGPT) <= 3 x institutional ULN ( <= 5 x ULN if liver metastases are present).,astalt
Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) <= 3 x ULN,astalt
Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) <= 3.0 x upper limit of normal (ULN),astalt
Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and Alanine aminotransferase (ALT) (serum glutamic-pyruvic transaminase [SGPT]) <= 2.5 X ULN OR <= 5 X ULN for subjects with liver metastases,astalt
Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) < 2.5 x institutional upper limit of normal,astalt
Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) <= 2.5 x institutional ULN,astalt
Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) <= 3 x ULN.,astalt
Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) <= 3 x institutional ULN.,astalt
Aspartate aminotransferase (AST) (SGOT) or alanine transaminase (ALT) (SGPT) £1.5 x institutional ULN,astalt
Aspartate aminotransferase (AST) <= 2 x ULN,astalt
Aspartate aminotransferase (AST) <= 3 x ULN.,astalt
Aspartate aminotransferase (AST) <= 8 x upper limit of normal (ULN).,astalt
"Aspartate aminotransferase (AST) >= 3 x upper limit of normal (ULN), or if subject has known liver metastases, AST >= 7 x ULN.",astalt
Aspartate aminotransferase (AST) 3 x ULN.,astalt
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT),astalt
aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3 x upper limit of normal (ULN).,astalt
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) <= 2.5 times ULN (except patients with known liver involvement of their advanced solid malignancy or NHL who must have their AST and ALT <= 5.0 times ULN).,astalt
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) <= 2.5 x ULN,astalt
Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) <= 2.5 X ULN OR <= 5 X ULN for subjects with liver metastases,astalt
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) <= 2.5 x ULN without liver metastases ( <= 5 x ULN if liver metastases are present),astalt
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) <= 3 x the upper limit of normal (ULN),astalt
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) <= 3 x ULN,astalt
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) <= 3.0 x upper limit of normal (ULN),astalt
"Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) <= 3.0 xupper limit of normal (ULN); if liver function abnormalities are due to underlying liver metastasis, AST and ALT <= 5 x ULN.",astalt
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) <= 5 x ULN,astalt
Aspartate aminotransferase (AST) and/or Alanine aminotransferase (ALT) > 3 x institutional ULN or > 5 x ULN if liver metastases are present,astalt
aspartate aminotransferase (AST) level <= 2.5 * ULN,astalt
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) < 2.5 x ULN within 90 days prior to Step 1 registration,astalt
"Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) <= 3 x upper limit of normal (ULN); in patients with known hepatic involvement, AST or ALT <= 5 x ULN are allowed",astalt
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 3 x the upper limit of normal (ULN) if no hepatic metastases are present; > 5 x ULN if hepatic metastases are present.,astalt
Aspartate aminotransferase (AST) or alanine transaminase (ALT) > 3.0 x upper limit of normal (ULN),astalt
Aspartate aminotransferase (AST) or alanine transaminase (ALT) > 3.0 x upper limit of normal (ULN).,astalt
Aspartate aminotransferase (AST)(serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT)(serum glutamate pyruvate transaminase [SGPT]) <= 2.5 x institutional upper limit of normal ( <= 5 x upper limit of normal [ULN] is acceptable if liver metastases are present).,astalt
"Aspartate aminotransferase (AST), alanine aminotransferase (ALT) <= 3 x upper limit of normal (ULN), unless suspected leukemic involvement of the liver.",astalt
Aspartate aminotransferase (AST)/ alanine aminotransferase (ALT) <= 3 x ULN,astalt
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) <= 2.5 x the upper limit of normal (ULN),astalt
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) <= 2.5 x upper limit of normal (ULN),astalt
"Aspartate aminotransferase (AST)/serum glutamic-oxalacetic transaminase (SGOT) and alanine aminotransferase (ALT)/serum glutamic-pyruvic transaminase (SGPT) < 2.5 x ULN, or, in the presence of documented liver metastases, <= 5 x ULN.",astalt
Aspartate aminotransferase (AST)/serum glutamic-oxaloacetic transaminase (SGOT) and alanine aminotransferase (ALT)/serum glutamate pyruvate transaminase (SGPT) <= 3 x ULN,astalt
"Aspartate aminotransferase (AST)/serum glutamic-oxaloacetic transaminase (SGOT) and alanine aminotransferase (ALT)/serum glutamic-pyruvic transaminase (SGPT) <= 3 x ULN, obtained <= 14 days prior to registration",astalt
"aspartate aminotransferase (AST, SGOT) <= 2.5 x ULN",astalt
Aspartate aminotransferase [AST/SGOT] <= 3x upper normal limit [UNL],astalt
"Aspartate aminotransferase and alanine aminotransferase <= 2.5x ULN, unless liver metastases are present, in which case they must be <= 5x ULN",astalt
Aspartate transaminase (AST) <= 3 x ULN,astalt
Aspartate transaminase (AST) <= 3 x ULN ( <= 5 x ULN for patients with liver involvement),astalt
Aspartate transaminase (AST) <= 3 x ULN ( <= 5 x ULN if liver metastases present),astalt
"Aspartate transaminase (AST) <= 3 x ULN, <= 5.0 x ULN for patients with metastatic disease to the liver",astalt
"Aspartate transaminase (AST) <= 3 x ULN, except for patients with liver metastasis, who may only be included if AST <= 5 x ULN",astalt
Aspartate transaminase (AST) and alanine aminotransferase (ALT) <= 1.5 x ULN,astalt
Aspartate transaminase (AST) and alanine transaminase (ALT) 2.5 x ULN or 5 x ULN for patients with liver metastases,astalt
aspartate transaminase (AST) and/or alanine aminotransferase (ALT) <= 2.5 X ULN ( <= 5 X ULN if with liver involvement),astalt
Aspartate transaminase (AST) and/or alanine transaminase (ALT) <= 2.5 x ULN or <= 5 x ULN for patients with liver metastases.,astalt
Aspartate transaminase (AST)(SGOT) <= 3 x ULN,astalt
"aspartate transaminase (AST)/alanine transaminase (ALT), <= 3 x ULN (5 <= x ULN in the presence of hepatic metastases or if this elevation is solely due to ASM/MCL).",astalt
AST (SGOT) / ALT (SGPT) <= 1.5x institutional ULN unless liver metastases are present in which case it must be <= 5x ULN,astalt
AST (SGOT) and ALT (SGPT) < 2.5 x ULN ( < 5 x ULN for participants with liver metastases),astalt
AST (SGOT) and ALT (SGPT) <= 1.5 x ULN.,astalt
AST (SGOT) and ALT (SGPT) <= 2.5 x ULN or < 5 x ULN if organ involvement.,astalt
AST (SGOT) and ALT (SGPT) <= 2.5 x ULN OR <= 5 x ULN for subjects with liver metastases,astalt
"AST (SGOT) and ALT (SGPT) <= 3 x ULN; if liver metastases are present, then <= 5 x ULN is allowed.",astalt
AST (SGOT) or ALT (SGPT) <= 3.0 X ULN Note: patients enrolled after chemotherapy do not have to meet the above criteria,astalt
"AST (SGOT), ALT (SGPT) <= 2.5 x upper limit of normal (ULN)",astalt
"AST (SGOT)/ALT (SGPT) <= 2.5 x upper limit of normal (ULN), Document State: Effective (Controlled) Page 20 of 56",astalt
AST < 2.5 x ULN (5.0 x ULN in the presence of liver metastasis),astalt
AST < 3 x ULN,astalt
AST <= 3 times ULN (5 times ULN if direct liver involvement by lymphoma),astalt
AST <= 3 x ULN,astalt
"AST and alanine aminotransferase (ALT) <= 3 x ULN; if liver metastases are present, then <= 5 x ULN is allowed.",astalt
AST and ALT < 2.5 X upper limit of normal,astalt
AST and ALT <= 2 x upper limit of normal (ULN),astalt
AST and ALT <= 2.5 times the upper limit of normal (ULN).,astalt
AST and ALT <= 2.5 x the upper limit of normal,astalt
AST and ALT <= 2.5 x ULN ( <= 5 x ULN if liver metastases are present),astalt
"AST and ALT <= 2.5 x ULN, alkaline phosphatase <= 2.5 x ULN",astalt
AST and ALT <= 2.5 x upper limit of normal (ULN),astalt
AST and ALT <= 3 x ULN ( <= 5 x ULN for subjects with liver metastases),astalt
AST and ALT <= 3.0 x ULN,astalt
AST and ALT <= 5 x ULN,astalt
AST and ALT: <= 3x ULN or <= 5 x ULN for patients with liver metastases.,astalt
AST must be <= 3 x ULN for the lab.,astalt
AST or ALT < 1.5 x the upper limit of institutional normal,astalt
AST or ALT > 1.5 x ULN,astalt
AST or ALT at screening > 3.0 x upper limit of normal (ULN) unless considered due to leukemic organ involvement.,astalt
AST(SGOT)/ and ALT(SGPT) < 2.5 X institutional upper limit normal,astalt
AST(SGOT)/ALT(SGPT) < 2.5 X institutional upper limit of normal,astalt
AST(SGOT)/ALT(SGPT) <= 2 x institutional upper limit of normal (ULN),astalt
AST(SGOT)/ALT(SGPT) <= 2.0 x institutional upper limit of normal,astalt
AST(SGOT)/ALT(SGPT) <= 2.5 times the laboratory upper limit of normal,astalt
"AST(SGOT)/ALT(SGPT) <= 2.5 x IULN, or <= 5.0 x IULN if due to liver involvement by tumor",astalt
AST(SGOT)/ALT(SGPT) <= 2.5 x IULN.,astalt
"AST(SGOT)/ALT(SGPT) <= 3 X institutional ULN without liver metastases, or <= 5X institutional ULN with liver metastases",astalt
AST(SGOT)/ALT(SGPT) <= 3 x institutional upper limit of normal,astalt
AST(SGOT)/ALT(SGPT) <= 3 x upper limit of normal (ULN) if no liver metastasis; <= 5 x upper ULN if liver metastasis present,astalt
"AST, ALT, and ALP <= 2.5xupper limit of normal (ULN)",astalt
AST/ALT <= 2.5 x upper limits of normal (ULN),astalt
AST/ALT <= 3.0 x ULN.,astalt
AST/SGOT <= 2.5 x upper limit of normal (ULN)* *For patients with liver metastasis: <= 5 x upper limit of normal (ULN),astalt
"For participants with liver involvement in their tumor, AST <= 5.0 * ULN and ALT <= 5.0 * ULN is acceptable.",astalt
Have an alanine aminotransferase (ALT)/aspartate aminotransferase (AST) level <= 5 times upper limit of normal (ULN),astalt
"In absence of liver metastases, serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) <= 2.5 x ULN or <= 5 x upper limit of normal (ULN) if hepatic metastases are present",astalt
Obtained <= 14 days prior to registration: Alanine aminotransferase (ALT) <= 2 x ULN ( <= 5 x ULN for patients with liver involvement),astalt
Obtained <= 14 days prior to registration: Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) <= 2.5 x ULN,astalt
Obtained <= 14 days prior to registration: Aspartate transaminase (AST) <= 2 x ULN ( <= 5 x ULN for patients with liver involvement),astalt
Obtained <= 14 days prior to registration: Serum glutamic-oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) and serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) <= 3 x ULN or SGOT (AST) and SGPT (ALT) <= 5 x ULN is acceptable if liver has tumor involvement,astalt
Patients must have AST and ALT <= 2.5 x institutional upper limit of normal (IULN),astalt
Patients with documented liver metastases: AST and/or ALT <= 5.0 x ULN,astalt
Serum alanine transaminase (ALT)/aspartate aminotransferase (AST) <= 2.5 x the upper limit of normal (ULN),astalt
Serum ALT < 2.5 x upper limits of normal (ULN),astalt
Serum ALT/AST <= 2.5 x ULN,astalt
Serum ALT/AST <= 2.5 x ULN (upper limit normal),astalt
Serum aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 2.5 x upper limit of normal (ULN),astalt
Serum aspartate transaminase (AST) and serum alanine transaminase (ALT) < 2.0 x ULN or <= 5 X ULN for subjects with liver metastases.,astalt
Serum Aspartate Transaminase (AST) and Serum Alanine Transaminase (ALT) <= 2.5 x upper limit of normal (ULN),astalt
Serum aspartate transaminase (AST; serum glutamic oxaloacetic transaminase (SGOT)) and serum alanine transaminase (ALT; serum glutamic pyruvic transaminase (SGPT)) <= 3.0 x upper limit of normal (ULN); <= 5.0 x ULN if liver metastases are present,astalt
Serum aspartate transaminase (AST; serum glutamic oxaloacetic transaminase[SGOT]) and serum alanine transaminase (ALT; serum glutamic pyruvic transaminase [SGPT]) < 2.5 x upper limit of normal (ULN),astalt
Serum AST and/or alanine aminotransferase (ALT) < 3 x institutional upper limit of normal (ULN).,astalt
Serum AST and/or ALT < 3 x institutional ULN.,astalt
Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) <= 10 x upper limit of normal (ULN) for age.,astalt
Serum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) <= 1.5 x ULN,astalt
Serum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) and serum glutamic pyruvic transaminase (SGPT) (alanine aminotransferase [ALT]) <= 3 x ULN or SGOT (AST) and SGPT (ALT) <= 5 x ULN is acceptable if liver has tumor involvement,astalt
Serum glutamic oxaloacetic transaminase (SGOT)/aspartate aminotransferase (AST) or serum glutamic pyruvic transaminase (SGPT)/alanine aminotransferase (ALT) >= 2.0 x upper limit of normal (ULN),astalt
SGOT (AST) <= 1.5 x ULN,astalt
SGOT (AST) <= 2 x ULN,astalt
SGOT (AST) <= 2.5 x ULN,astalt
"SGOT (AST) and SGPT (ALT) <= 2.5x ULN with the following exception; Patients with liver metastases AST, ALT <= 5x ULN",astalt
SGOT <= 1.5 x ULN,astalt
SGOT <= 2.5 x ULN,astalt
"SGPT (ALT) <= 135 U/L (3x ULN) (for the purpose of this study, the ULN for SGPT is 45 U/L)",astalt
"SGPT (ALT) <= 5 x ULN for age. For the purpose of this study, the ULN for ALT will be 45 U/L.",astalt
SGPT <= 2.5 x ULN,astalt
The patient has an aspartate aminotransferase (AST)/serum glutamic-oxaloacetic transaminase (SGOT) and alanine aminotransferase (ALT)/serum glutamic-pyruvic transaminase (SGPT) <= 2.5 X institutional ULN.,astalt
Active and uncontrolled autoimmune cytopenia(s),autosteroid
Active and uncontrolled autoimmune hemolytic anemia (AIHA) or autoimmune thrombocytopenia (ITP) requiring daily prednisone dose of >= 20 mg,autosteroid
"Active autoimmune cytopenias (for 2 or more weeks), including autoimmune hemolytic anemia (AIHA) and idiopathic thrombocytopenic purpura. Pregnancy or breastfeeding. Medical, psychological, or social condition that, in the opinion of the investigator, may increase the patient's risk, interfere with the patient's participation in the study or hinder evaluation of study results.",autosteroid
Active autoimmune disease,autosteroid
"Active autoimmune disease or a documented history of autoimmune disease, except vitiligo or resolved childhood asthma/atopy.",autosteroid
Active autoimmune disease or documented history of autoimmune disease.,autosteroid
"Active autoimmune disease requiring immunosuppressive therapy, unless considered by the PI or designee to be eligible",autosteroid
Active autoimmune disease requiring immunosuppressive therapy.,autosteroid
Active autoimmune disease requiring systemic immunosuppressive therapy,autosteroid
Active autoimmune disease requiring systemic treatment within the past 3 months or a documented history of clinically severe autoimmune disease/syndrome difficult to control in the past; EXCEPTIONS:,autosteroid
"Active autoimmune disease such as Crohn's disease, rheumatoid arthritis, Sjogrens' disease, systemic lupus erythematosis, or similar conditions requiring systemic treatment within the past 3 months or a documented history of clinically severe autoimmune disease/syndrome difficult to control in the past",autosteroid
"Active autoimmune disease that has required systemic treatment in past 2 years; replacement therapy (such as thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is acceptable",autosteroid
Active autoimmune disease that has required systemic treatment in the past 2 years (replacement therapies for hormone deficiencies are allowed). Hemolytic anemia associated with the lymphoma does not exclude a patient from the study.,autosteroid
"Active autoimmune disease that might deteriorate when receiving an immuno-stimulatory agent; patients with diabetes type I, vitiligo, psoriasis, or hypo- or hyperthyroid diseases not requiring immunosuppressive treatment are eligible",autosteroid
Active autoimmune disease that required systemic treatment in the past.,autosteroid
"Active autoimmune disease that required systemic treatment in the past. Patients who have not required systemic treatment for at least two years may be enrolled if permission is provided after discussion with the Medical Monitor (replacement therapy, e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, is not considered a form of systemic treatment, and is allowed).",autosteroid
"Active autoimmune disease, except for vitiligo, type 1 diabetes mellitus, asthma, atopic dermatitis, or endocrinopathies manageable by hormone replacement; other autoimmune conditions may be allowable at the discretion of the principal investigator.",autosteroid
Active autoimmune diseases requiring systemic treatments,autosteroid
Active autoimmune disorder (with the exception of autoimmune hemolytic anemia or ITP),autosteroid
Active autoimmune or auto-inflammatory ocular disease within 6 months,autosteroid
Active life-threatening autoimmune disease,autosteroid
"Active neurological autoimmune or inflammatory disorders not related to B cell NHL (eg: Guillain-Barre syndrome, Amyotrophic Lateral Sclerosis)",autosteroid
"Active or history of autoimmune disease or immune deficiency, including, but not limited to, myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, antiphospholipid antibody syndrome, Wegener granulomatosis, Sjögren's syndrome, Guillain-Barré syndrome, or multiple sclerosis), with the following exceptions: Patients with a history of autoimmune-related hypothyroidism who are on thyroid replacement hormone are eligible for the study. Patients with controlled Type 1 diabetes mellitus who are on an insulin regimen are eligible for the study. Patients with eczema, psoriasis, lichen simplex chronicus, or vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis are excluded) are eligible for the study provided all of following conditions are met:",autosteroid
"Active or prior documented autoimmune disease within the past 2 years. NOTE: Patients with vitiligo, Grave's disease, or psoriasis not requiring systemic treatment (within the past 2 years) are not excluded. Patients with hypothyroidism as a result of irradiation or thyroidectomy are also not excluded.",autosteroid
Active or prior history of pneumonitis that required corticosteroids,autosteroid
"Active, known, or suspected autoimmune disease",autosteroid
"Active, known, or suspected autoimmune disease or immunosuppressive conditions with the exception of vitiligo, type 1 diabetes, residual autoimmune-related hypothyroidism requiring hormone replacement, or psoriasis not requiring systemic treatment.",autosteroid
"Active, known, or suspected autoimmune disease or infection",autosteroid
"Active, known, or suspected autoimmune disease that requires systemic treatment (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs)",autosteroid
"Active, suspected or prior documented autoimmune disease, clinically significant cardiovascular disease or clinically uncontrolled hypertension.",autosteroid
Active/uncontrolled autoimmune disease,autosteroid
Adrenal replacement doses > 10 mg daily prednisone equivalents in the absence of active autoimmune disease,autosteroid
"An active, known or suspected autoimmune disease; the following are exceptions:",autosteroid
"Any active autoimmune disease or a documented history of autoimmune disease (excluded/exception to the rule: subjects with vitiligo or resolved childhood asthma/atopy, type I diabetes mellitus, subjects with hypothyroidisms stable on hormone replacement, Sjorgen‟s syndrome, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger).",autosteroid
Any active autoimmune disease or documented history of autoimmune disease.,autosteroid
Any condition requiring systemic treatment with corticosteroids ( > 10 mg daily prednisone or equivalent) or other immunosuppressive medications within 14 days prior to first dose of study drug. Inhaled or topical steroids and adrenal replacement steroid doses > 10 mg daily prednisone or equivalent are permitted in the absence of active autoimmune disease.,autosteroid
"Any condition requiring systemic treatment with either corticosteroids ( > 10 mg daily prednisone equivalents) or other systemic immunosuppressive medications within 14 days of study drug administration; inhaled or topical steroids and adrenal replacement doses < 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease; patients are permitted to use topical, ocular, intra-articular, intranasal, and inhalational corticosteroids (with minimal systemic absorption)' physiologic replacement doses of systemic corticosteroids are permitted, even if < 10 mg/day prednisone equivalents; a brief course of corticosteroids for prophylaxis (e.g., contrast dye allergy) or for treatment of non-autoimmune conditions (e.g., delayed-type hypersensitivity reaction caused by contact allergen) is permitted",autosteroid
"Any syndrome that requires ongoing systemic treatment with either corticosteroids ( > 10 mg daily prednisone equivalents) or other immunosuppressive medications within 7 days of study drug administration. Of note: Inhaled or topical steroids, and adrenal replacement doses are permitted",autosteroid
at least 3 days between last corticosteroids and study treatment start,autosteroid
At least 7 das post last systemic corticosteroids administration (unless physiologic replacement dosing),autosteroid
"at the time CR/CRu is determined, the patient should not have used corticosteroids for at least two weeks",autosteroid
Autoimmune anemia or thrombocytopenia that is poorly responsive to corticosteroids,autosteroid
"Autoimmune disease requiring treatment within the last 5 years including systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, Sjӧgren's syndrome, autoimmune thrombocytopenia, uveitis, or other if clinically significant",autosteroid
"Autoimmune disease requiring treatment within the last 5 years including systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, Sjogren's syndrome, autoimmune thrombocytopenia, uveitis, or other if clinically significant",autosteroid
"Autoimmune disease with the exception of controlled/treated hypothyroidism, disease-related immune thrombocytopenic purpura, or hemolytic anemia",autosteroid
autoimmune vasculitis,autosteroid
Chronic inhaled steroid use,autosteroid
Chronic use of corticosteroids in excess of prednisone 30 mg/day or its equivalent,autosteroid
"clinical history, prior diagnosis, or overt evidence of autoimmune disease",autosteroid
"Cohort I, Ph-negative Patients Only: It is preferred, but not required, that corticosteroids and hydroxyurea should start only after all diagnostic samples have been obtained; however, if the patient was previously on corticosteroids and/or hydroxyurea, this is allowable provided that the patient still has measurable disease at time of the bone marrow aspirate",autosteroid
Concomitant therapy with immunosuppressive or immunomodulatory agents; chronic use of systemic corticosteroids. Previous history of corticosteroid use is acceptable. Use of corticosteroids after initial registration is acceptable if tapered at least one week before NeoVax administration.,autosteroid
"Concurrent medical condition requiring the use of immunosuppressive medications, or systemic corticosteroids; systemic corticosteroids must be discontinued at least 4 weeks prior to dosing. Inhaled or intranasal corticosteroids (with minimal systemic absorption) may be continued if the subject is on a stable dose. Non-absorbed intra-articular steroid injections will be permitted; or use of other investigational drugs (drugs not marketed for any indication) within 30 days prior to study drug administration. Use of steroids as prophylactic treatment for subjects with contrast allergies to diagnostic imaging contrast dyes will be permitted.",autosteroid
"Concurrent systemic immunosuppressant therapy other than corticosteroids (e.g., cyclosporine A, tacrolimus, etc.) within 28 days of the first dose of study drug.",autosteroid
Concurrent use of corticosteroids.,autosteroid
Condition requiring systemic treatment with either corticosteroids ( > 10 mg daily prednisone or equivalent) or other immunosuppressive medications within 14 days of study drug administration; exceptions are:,autosteroid
Continuous use of steroid containing inhalers?,autosteroid
Continuous use of topical steroid creams/ointments?,autosteroid
Corticosteroid therapy at the time the patient enters the protocol; NOTE: patients using prednisone or its equivalent for adrenal failure or using <= 10mg of prednisone/day for other benign causes are accepted,autosteroid
Corticosteroid use <= 2 weeks prior to registration,autosteroid
"Corticosteroid use <= 2 weeks prior to registration; NOTE: patients must be off corticosteroids for at least 2 weeks prior to registration; this includes oral, IV, subcutaneous, or inhaled route of administration; patients on chronic corticosteroid for adrenal insufficiency or other reasons may enroll if they receive less than 10 mg/day of prednisone (or equivalent)",autosteroid
"Corticosteroid use > 30 mg/day of prednisone or equivalent, for purposes other than lymphoma symptom control",autosteroid
"Corticosteroid use within 1 week prior to first dose of study drug, with the exception of inhaled, topical, or other local administrations. Patients requiring systemic steroids at daily doses > 20 mg prednisone (or corticosteroid equivalent), or those who are administered steroids for leukemia control or white blood cell (WBC)-count-lowering are excluded",autosteroid
"Corticosteroids and/or hydroxyurea, as well as any of the other therapies mentioned (with the exception of IV cyclophosphamide), may continue to be administered, at physician discretion, until 1 day prior to blinatumomab administration",autosteroid
"Corticosteroids: at the time of consent and enrollment to regimen specific subprotocols, patients receiving corticosteroids who have not been on a stable or decreasing dose of corticosteroid for at least 7 days prior to enrollment to the subprotocol will not be eligible; if used to modify immune adverse events related to prior therapy, >= 14 days must have elapsed since last dose of corticosteroid",autosteroid
"Corticosteroids: if used to modify immune adverse events related to prior therapy, >= 14 days must have elapsed since last dose of corticosteroid",autosteroid
Corticosteroids: Patients receiving corticosteroids who have not been on a stable or decreasing dose of corticosteroid for at least 7 days prior to enrollment are not eligible. Corticosteroids must be held for 24 hours prior to initiation of study therapy.,autosteroid
Current evidence of hypersensitivity or other underlying illness requiring systemic corticosteroids at doses > 20 mg/day prednisone equivalent,autosteroid
Current or history of systemic autoimmune disease requiring systemic therapy,autosteroid
"Current or prior use of immunosuppressive medication within 28 days before the first dose of Durvalumab, with the exceptions of intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of prednisone, or an equivalent corticosteroid.",autosteroid
"Current or prior use of immunosuppressive medication within 28 days before the first dose of PDR001, with the exception of intranasal/inhaled corticosteroids or systemic corticosteroids at physiological doses (not exceeding equivalent of 10 mg/day of prednisone) ",autosteroid
Current use of systemic corticosteroids > 0.5 mg/kg/day,autosteroid
Current use of systemic corticosteroids at a dose equivalent to 0.5 mg/kg/day of prednisone or higher.,autosteroid
Current use of systemic corticosteroids at doses >= 10mg/day prednisone or its equivalent; those receiving < 10mg/day may be enrolled at discretion of investigator,autosteroid
Current use of systemic corticosteroids greater than ( > ) 20 milligrams (mg) prednisone per day (or equivalent); or prior anti-cancer therapy to include: radioimmunoconjugate within 12 weeks; mAb or antibody-drug conjugate within 4 weeks; or radiotherapy/chemotherapy/hormone therapy/targeted small-molecule therapy within 2 weeks prior to Day 1 of Cycle 1,autosteroid
Current use of systemic corticosteroids more than 0.5 mg/kg/day,autosteroid
Currently taking corticosteroids ( > 0.5 mg/kg/day prednisone or equivalent) for therapy of GVHD.,autosteroid
Currently taking corticosteroids (greater than 0.5 mg/kg/day prednisone or equivalent).,autosteroid
"Cytotoxic or lymphotoxic agents (including prednisone > 5 mg/day or equivalent corticosteroid) within 1 week prior to leukapheresis; physiologic corticosteroid replacement, and topical or inhaled corticosteroids are not excluded",autosteroid
Date of last dose of steroid containing medicines:,autosteroid
Date of last steroid containing medicines:,autosteroid
Dependence on corticosteroids,autosteroid
Diagnosis of a condition requiring systemic treatment with either corticosteroids ( > 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration. Inhaled or topical steroids and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease.,autosteroid
Diagnosis of immunosuppression or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment. The use of physiologic doses of corticosteroids may be approved after consultation with the Sponsor.,autosteroid
Disease is well controlled at baseline and requires only low-potency topical corticosteroids,autosteroid
ELIGIBILITY FOR LYMPHODEPLETION CHEMOTHERAPY: Absence of active autoimmune disease requiring ongoing systemic immunosuppressive therapy,autosteroid
ELIGIBILITY FOR LYMPHODEPLETION CHEMOTHERAPY: Patients must require no corticosteroid therapy or dose of less than 15 mg per day of prednisone or the equivalent; pulsed corticosteroid dose for disease control is acceptable until the day before the start of lymphodepletion,autosteroid
"For all patients, receipt of systemic physiologic replacement steroids, topical and/or inhaled corticosteroids is acceptable.",autosteroid
Has active autoimmune disease that has required systemic treatment in the past 2 years.,autosteroid
"Has active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease [eg, colitis or Crohn's disease], diverticulitis [with the exception of diverticulosis], systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome [granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc]). The following are exceptions to this criterion:",autosteroid
"Has an active autoimmune disease or history of autoimmune disease such as hepatitis, hypophysitis, nephritis, hyperthyroidism or hypothyroidism, interstitial lung disease, colitis",autosteroid
Has an active autoimmune disease that has required systemic treatment in past 2 years,autosteroid
Has an active autoimmune disease that has required systemic treatment in the past 2 years.,autosteroid
"Has an active, known, or suspected autoimmune disease",autosteroid
"Have an active, known or suspected autoimmune disease.",autosteroid
History of autoimmune disease,autosteroid
"History of autoimmune disease (eg, Crohn's, rheumatoid arthritis, systemic lupus) resulting in end organ injury or requiring systemic immunosuppression/systemic disease modifying agents within the last 2 years. Patients with a history of autoimmune-related hypothyroidism on a stable dose of thyroid replacement hormone and patients with controlled type 1 diabetes mellitus on a stable insulin regimen may be eligible for this study",autosteroid
"History of autoimmune disease (i.e. rheumatoid arthritis, systemic lupus erythematosus) with requirement of immunosuppressive medication within 6 months.",autosteroid
History of autoimmune disease requiring systemic immunosuppressive therapy.,autosteroid
History of autoimmune disease resulting in end organ injury or requiring systemic immunosuppression/systemic disease modifying agents within the last 24 months.,autosteroid
"History of autoimmune disease resulting in end-organ injury unless attributable to CLL (eg, idiopathic thrombocytopenic purpura (ITP), autoimmune hemolytic anemia (AIHA))",autosteroid
History of known or suspected autoimmune disease,autosteroid
"History of or current active autoimmune diseases, including but not limited to inflammatory bowel diseases, rheumatoid arthritis, autoimmune thyroiditis, autoimmune hepatitis, systemic sclerosis, systemic lupus erythematosus, autoimmune vasculitis, autoimmune neuropathies, or type 1 insulin dependent diabetes mellitus.",autosteroid
History of severe autoimmune disease that in the opinion of the investigator would interfere with patient safety or compliance on trial.,autosteroid
"History or risk of autoimmune disease, including, but not limited to, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjogren's syndrome, Bell's palsy, Guillain-Barre syndrome, multiple sclerosis, autoimmune thyroid disease, vasculitis, or glomerulonephritis",autosteroid
Intermittent use of bronchodilators or local steroid injections,autosteroid
Known current or prior autoimmune disease with the exception of vitiligo,autosteroid
Low dose steroid use for appetite,autosteroid
"May not have primary immunodeficiency or history of autoimmune disease (e.g. Crohns, rheumatoid arthritis, systemic lupus) resulting in end organ injury or requiring systemic immunosuppression/systemic disease modifying agents within the last 2 years",autosteroid
"May not have primary immunodeficiency or history of systemic autoimmune disease (e.g. Crohns, rheumatoid arthritis, systemic lupus) resulting in end organ injury or requiring systemic immunosuppression/systemic disease modifying agents within the last 2 years.",autosteroid
Must not have current use of systemic corticosteroids at doses >= 10 mg prednisone daily or its equivalent; those receiving < 10mg daily may be enrolled at discretion of the Investigator,autosteroid
"Must not have required the use of additional immunosuppression other than corticosteroids for the management of an AE, not have experienced recurrence of an AE if re-challenged, and not currently require maintenance doses of > 10 mg prednisone or equivalent per day.",autosteroid
No active auto-immune disease and not on therapy for auto-immune disease. Patients with a history of autoimmune-related hypothyroidism on a stable dose of thyroid replacement hormone are eligible. Patients who have adrenal insufficiency and hypophysitis from prior immunotherapy if they are on stable medical replacement doses are eligible.,autosteroid
"No active autoimmune disease that has required systemic treatment in past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs); replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment; subjects with vitiligo or resolved childhood asthma/atopy would be an exception to this rule; subjects that require intermittent use of bronchodilators, local steroid injections or inhaled or topical steroids would not be excluded from the study; subjects with hypothyroidism stable on hormone replacement or Sjogren's syndrome will not be excluded from the study",autosteroid
No current or prior autoimmune disease with the exception of vitiligo and autoimmune alopecia (Arm B only),autosteroid
"No current use of systemic corticosteroids at physiologic doses > 10 mg/day of dexamethasone or equivalent are permitted. Patients receiving current systemic steroids must be on a stable steroid dose (i.e., less than or equal to 10 mg/day of dexamethasone or equivalent at the same dose for at least 7 days). Patients who recently discontinued systemic steroids must have completed them at least 7 days prior to entry.",autosteroid
Patients must not have any known autoimmune disease,autosteroid
"Patients receiving corticosteroids who have not been on a stable or decreasing dose of corticosteroid for at least 7 days prior to enrollment are not eligible; if used to modify immune adverse events related to prior therapy, >= 14 days must have elapsed since last dose of corticosteroid",autosteroid
Patients receiving systemic corticosteroids.,autosteroid
Patients requiring corticosteroid therapy at a dose of 15 mg or more per day of prednisone or the equivalent; pulsed corticosteroid dose for disease control is acceptable,autosteroid
"Patients should be excluded if they have a condition requiring systemic treatment with either corticosteroids ( > 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration. Inhaled or topical steroids and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease. Note: Subjects are permitted to use topical, ocular, intra-articular, intranasal, and inhalational corticosteroids (with minimal systemic absorption). Physiologic replacement doses of systemic corticosteroids are permitted, even if > 10 mg/day prednisone equivalents. A brief course of corticosteroids for prophylaxis (eg, contrast dye allergy) or for treatment of non-autoimmune conditions (eg, delayed-type hypersensitivity reaction caused by contact allergen) is permitted.",autosteroid
Patients should not have an autoimmune disorder that requires active immunosuppression,autosteroid
Patients with active known autoimmune disease are ineligible,autosteroid
"Patients with active, known, or suspected autoimmune disease, except in these conditions:",autosteroid
Patients with any autoimmune disease or a history of autoimmune disease,autosteroid
Previous use of corticosteroids is allowed,autosteroid
Received systemic immunosuppressive agents (except prescribed corticosteroids at doses <= 20 mg/day prednisone equivalent) within 2 weeks before the start of treatment,autosteroid
RECIPIENT: Diagnosis with autoimmune disease,autosteroid
Requires immunosuppressive doses of corticosteroid therapy ( > 10 mg/day prednisone equivalents) for >= 2 weeks prior to registration,autosteroid
Requires ongoing need for corticosteroid treatment.,autosteroid
Stable dose of replacement steroid for adrenal insufficiency or low doses for non-malignant disease,autosteroid
Steroid injections for joint disease,autosteroid
Subjects that require intermittent use of bronchodilators or local steroid injections would not be excluded from the study,autosteroid
Subjects with active autoimmune disease or a syndrome that requires systemic corticosteroids,autosteroid
"Subjects with active, known or suspected autoimmune disease. Subjects with vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll.",autosteroid
Systemic corticosteroid therapy at a prednisone dose > 20mg/day (or equivalent) within 14 days prior to study enrollment,autosteroid
Systemic treatment with corticosteroids or other immunosuppressive medications within 1 week of enrollment,autosteroid
Temporary steroid use for computed tomography (CT) imaging in setting of contrast allergy,autosteroid
Therapeutic doses of corticosteroids (defined as > 20 mg/day prednisone or equivalent) within 7 days prior to leukapheresis,autosteroid
"Therapeutic doses of corticosteroids within 14 days prior to study entry, defined as > 20mg/day pf prednisone, or equivalent. Topical and/or inhaled steroids are permitted.",autosteroid
Topical steroid,autosteroid
Use of immunosuppressive medications within 4 weeks or systemic corticosteroids within 2 weeks prior to study treatment.,autosteroid
Use of immunosuppressive or immune-modulating therapies that may have immunosuppressive effects,autosteroid
"Use of immunosuppressive, or immune-modulating therapies that may have immunosuppressive effects .",autosteroid
bilirubin < 1.5 X ULN,bilirubin
Bilirubin <= 1.5 mg/dL (or <= 26 _mol/L).,bilirubin
Bilirubin <= 1.5 times upper limit of normal,bilirubin
Bilirubin <= 1.5 times upper limit of normal (NCI-CTCAE Grade 2 baseline),bilirubin
"Bilirubin <= 1.5 times x upper limit of normal (ULN); if liver metastases are present, then <= 2 x ULN is allowed. Criteria does not apply to subjects with Gilbert's syndrome diagnosed as per institutional guidelines.",bilirubin
Bilirubin <= 1.5 x institutional upper limit of normal (ULN),bilirubin
Bilirubin <= 1.5 x ULN ( < 2 x ULN if hyperbilirubinemia is due to Gilbert's syndrome),bilirubin
"Bilirubin <= 1.5 x ULN, except in patients diagnosed with Gilbert's syndrome, direct bilirubin <= 2 x ULN",bilirubin
Bilirubin <= 1.5 x ULN; does not apply to subjects with Gilbert's syndrome diagnosed as per institutional guidelines.,bilirubin
Bilirubin <= 1.5x upper limit of normal (ULN) *Patients receiving immunotherapy should have a bilirubin level < 3.0x ULN.,bilirubin
Bilirubin <= 2.0 x upper limits of normal (ULN),bilirubin
Bilirubin <= 2.5 x ULN within 14 days prior to registration.,bilirubin
Bilirubin > 1.5 x ULN,bilirubin
Bilirubin for patients w/Gilbert&rsquo;s <= 3.0 x ULN.,bilirubin
Bilirubin total <= 1.5 x ULN,bilirubin
Bilirubin Total bilirubin <= 1.5 X ULN OR Direct bilirubin <= ULN for subjects with total bilirubin levels > 1.5 x ULN OR total bilirubin <= 2 X ULN if liver metastases are present,bilirubin
Bilirubin within normal institutional limits (or < 2X the upper limit of normal (ULN) in those with Gilbert's disease),bilirubin
Direct bilirubin < 3.0 mg/dL,bilirubin
Direct bilirubin <= 1.5 x ULN,bilirubin
Direct bilirubin <= 1.5 x upper limit of normal (ULN),bilirubin
"Direct bilirubin <= 1.5 x upper limit of normal (ULN) for age, and",bilirubin
Direct bilirubin <= 3 x upper limit of normal (ULN) for age.,bilirubin
"Direct bilirubin <= 3 x upper limit of normal (ULN), unless suspected leukemic involvement of the liver.",bilirubin
Direct bilirubin >= 2 x ULN,bilirubin
Direct bilirubin >= 2 x ULN:,bilirubin
Direct or total bilirubin < 1.5 x ULN (unless related to Gilbert's or Meulengracht's syndrome); the values must be obtained within 48 hours prior to randomization,bilirubin
"Except in the case of Gilbert disease, in which case total bilirubin must be <= 3 x ULN",bilirubin
"Have a total bilirubin level <= 2.0 mg/dL (unless secondary to Gilbert syndrome, hemolysis, or leukemia)",bilirubin
Obtained <= 14 days prior to registration: Total bilirubin <= 1.5 x upper limit of normal (ULN),bilirubin
"Obtained <= 14 days prior to registration: Total bilirubin <= 1.5 x upper limit of normal (ULN) (in patients with well-documented Gilbert's syndrome and the total bilirubin is grade 1, then direct bilirubin value must be <= 1.0 mg/dL)",bilirubin
Obtained <= 14 days prior to registration: Total bilirubin <= 1.5 x upper limit of normal (ULN) or direct bilirubin <= ULN,bilirubin
OR Direct bilirubin <= ULN for subjects with total bilirubin levels > 1.5 x ULN,bilirubin
Patients must have total bilirubin < 2.0 x Institutional Upper Limit of Normal (IULN) within 14 days prior to registration.,bilirubin
Patients must have total bilirubin <= 1.5 x IULN,bilirubin
Patients must have total bilirubin <= 2.0 x IULN within 14 days prior to registration.,bilirubin
Patients must have total bilirubin <= 2.5 x IULN,bilirubin
Patients with previously documented Gilbert syndrome who may have a bilirubin < 5 x ULN,bilirubin
Serum bilirubin < 1.5 times upper limit of normal (ULN),bilirubin
"Serum bilirubin <= 1.5 x ULN, with the following exception:",bilirubin
serum bilirubin <= 1.5 x upper limit of normal (ULN) or <= 3 x ULN for patients with Gilbert's disease,bilirubin
Serum bilirubin <= 1.5x ULN with the following exception: Patients with known Gilbert disease: serum bilirubin level <= 3x ULN,bilirubin
serum bilirubin <= 1.5x upper limit of normal (ULN),bilirubin
Serum direct bilirubin < 2 mg/dl or serum total bilirubin <= 3,bilirubin
Serum direct bilirubin <= 1.5 times the upper limit of normal (ULN) ( <= 3 x ULN if this elevation is solely due to ASM/MCL),bilirubin
Serum total bilirubin <= 1.5 mg/dL,bilirubin
Serum total bilirubin <= 1.5 X ULN,bilirubin
"Serum total bilirubin <= 1.5 x ULN (Note: In subjects with Gilbert's syndrome, if total bilirubin is > 1.5 x ULN, measure direct and indirect bilirubin and if direct bilirubin is <= 1.5 x ULN, subject is eligible) within 90 days prior to Step 1 registration",bilirubin
Serum total bilirubin <= 1.5 x ULN (subjects with Gilbert's syndrome may have a bilirubin > 1.5 x ULN),bilirubin
Serum total bilirubin > 1.5 x ULN or > 3.0 mg/dL for subjects with documented Gilbert's syndrome,bilirubin
Serum total bilirubin > 1.5 x upper limit of normal (ULN),bilirubin
Serum total bilirubin and alkaline phosphatase > 1.5 x ULN,bilirubin
"TBL <= 1.5 x ULN (unless consistent with Gilbert's syndrome [ratio between total and direct bilirubin > 5], for which TBL <= 3.0 x ULN is allowed)",bilirubin
The patient has a total bilirubin level <= 2 mg/dL.,bilirubin
Total and direct bilirubin within normal range,bilirubin
Total bilirubin,bilirubin
Total bilirubin ( <= 1.5 mg/dl) unless history of Gilbert's syndrome,bilirubin
Total bilirubin (TBIL) < 1.5 X ULN (except subjects with Gilbert's syndrome),bilirubin
total bilirubin (TBIL) < 1.5 x ULN (unless considered due to Gilbert's syndrome).,bilirubin
Total bilirubin (TBL) <= 2.0 x ULN (Upper Limit of Normal),bilirubin
"Total bilirubin (TBL) <= 2.5 mg/dL, except for participants with Gilbert's syndrome.",bilirubin
Total bilirubin < 1.5 mg/dL,bilirubin
Total bilirubin < 1.5 times the upper limit of normal (ULN) (except patients with Gilbert's syndrome [hereditary indirect hyperbilirubinemia] who must have a total bilirubin of <= 3 times ULN),bilirubin
"total bilirubin < 1.5 x ULN (upper limit of normal), unless due to Gilbert's syndrome",bilirubin
Total Bilirubin < 1.5 x ULN or direct bilirubin < ULN for participants with total bilirubin levels > 1.5 x ULN,bilirubin
total bilirubin < 1.5 x ULN unless considered due to Gilbert's disease,bilirubin
"Total bilirubin < 1.5 x ULN, except for patients with Gilbert's disease who are eligible if total bilirubin <= 3mg/dL.",bilirubin
Total bilirubin < 1.5 x upper limit of normal (ULN) (or < 3 x ULN for subjects with Gilbert's syndrome),bilirubin
"Total bilirubin < 1.5 x upper limit of normal (ULN) or if total bilirubin is > 1.5 x ULN, the direct bilirubin must be <= 2.0 mg/dL",bilirubin
Total Bilirubin < 1.5 x upper limits of normal (ULN),bilirubin
Total bilirubin < 2 x upper limit of normal (ULN) or < 3 x ULN for patients with Gilbert-Meulengracht Syndrome,bilirubin
total bilirubin < 2.0 mg/dL,bilirubin
Total bilirubin < 2.0 mg/dL (or < 3.0 mg/dL for subjects with documented Gilbert's syndrome),bilirubin
"Total bilirubin < 2.5 x ULN, AST/SGOT < 5 x ULN.",bilirubin
Total bilirubin < 3 mg/dL,bilirubin
Total Bilirubin <= 1.2 x upper limit of normal (ULN) Unless due to Gilbert's disease,bilirubin
Total bilirubin <= 1.5 mg/dL or direct bilirubin <= 0.4 mg/dL,bilirubin
"Total bilirubin <= 1.5 mg/dl, except in subjects with Gilbert's syndrome.",bilirubin
Total bilirubin <= 1.5 times the upper limit of normal (ULN),bilirubin
Total bilirubin <= 1.5 upper limit of normal (ULN),bilirubin
"total bilirubin <= 1.5 x institutional upper limit of normal (IULN) *(except patients with Gilbert's Syndrome, who must have a direct bilirubin < 1.5 mg/dL), and SGOT (AST) and SGPT (ALT) <= 8 x IULN.",bilirubin
"Total bilirubin <= 1.5 x institutional upper limit of normal (ULN) (however, patients with known Gilbert disease who have serum bilirubin level <= 3 x ULN may be enrolled).",bilirubin
Total bilirubin <= 1.5 x IULN; no prior history of Gilbert's syndrome,bilirubin
Total bilirubin <= 1.5 x the institutional upper limit of normal (ULN). For patients with known Gilbert's Syndrome <= 3 x ULN is permitted,bilirubin
Total bilirubin <= 1.5 x the upper limit of normal,bilirubin
Total bilirubin <= 1.5 x the upper limit of normal (ULN). Documented Gilbert syndrome is allowed if total bilirubin <= 2 x ULN.,bilirubin
"Total bilirubin <= 1.5 x the upper limit of normal. For patients with Gilbert&rsquo;s disease, <= 3 mg/dL ( <= 51.3 µmol/L).",bilirubin
Total bilirubin <= 1.5 x the upper limit of the normal range (ULN),bilirubin
"Total bilirubin <= 1.5 x the upper limit of the normal range (ULN) or if total bilirubin is > 1.5 x ULN, the direct bilirubin must be <= 2.0 mg/dL",bilirubin
Total bilirubin <= 1.5 x ULN,bilirubin
Total bilirubin <= 1.5 x ULN (except in subjects with Gilbert Syndrome who must have a total bilirubin < 3.0x ULN),bilirubin
Total bilirubin <= 1.5 x ULN (for subjects with Gilbert's disease <= 3 x ULN).,bilirubin
Total bilirubin <= 1.5 x ULN *Patients with documented Gilbert's disease may have bilirubin up to 2.5 mg/dL,bilirubin
Total bilirubin <= 1.5 x ULN in the absence of Gilbert's syndrome <= 3 x ULN if the patient has Gilbert's syndrome,bilirubin
Total bilirubin <= 1.5 x ULN or direct bilirubin <= 1.5 x ULN when total bilirubin is > 1.5 x ULN,bilirubin
Total bilirubin <= 1.5 x ULN or Direct bilirubin <= ULN for participants with total bilirubin levels >= 1.5 x ULN,bilirubin
Total bilirubin <= 1.5 x ULN OR Direct bilirubin <= ULN for subjects with total bilirubin levels > 1.5 x ULN,bilirubin
Total bilirubin <= 1.5 x ULN OR direct bilirubin within normal limits for participants with total bilirubin levels > 1.5 x ULN,bilirubin
"Total bilirubin <= 1.5 x ULN unless due to Gilbert&rsquo;s syndrome, in which case the direct bilirubin must be <= 1.5 X ULN",bilirubin
"Total bilirubin <= 1.5 x ULN, or <= 3.0 mg/dL for patients with Gilbert's syndrome.",bilirubin
Total Bilirubin <= 1.5 x ULN.,bilirubin
Total bilirubin <= 1.5 x ULN. Isolated bilirubin > 1.5 X ULN is acceptable if bilirubin is fractionated and direct bilirubin < 35% or subject has a diagnosis of Gilbert's syndrome,bilirubin
Total bilirubin <= 1.5 x ULN; if patient has known Gilbert's syndrome direct bilirubin <= 3.0 x ULN,bilirubin
"Total bilirubin <= 1.5 x ULN; or <= 2x ULN (if upon judgment of the treating physician, it is believed to be due to EMH related to MF)",bilirubin
Total bilirubin <= 1.5 x ULN; patients with a documented history of Gilbert syndrome and in whom total bilirubin elevations are accompanied by elevated indirect bilirubin are eligible.,bilirubin
Total bilirubin <= 1.5 x ULN; subjects with Gilbert's syndrome can enroll if conjugated bilirubin is within normal limits,bilirubin
Total bilirubin <= 1.5 x Upper Limit Normal (ULN).,bilirubin
Total bilirubin <= 1.5 x upper limit of normal (ULN),bilirubin
"total bilirubin <= 1.5 x upper limit of normal (ULN) (however, patients with known Gilbert disease who have serum bilirubin level <= 3 X ULN may be enrolled)",bilirubin
"Total bilirubin <= 1.5 x upper limit of normal (ULN) (patients with Gilbert's syndrome may have serum bilirubin > 1.5 x ULN) (NOTE: If patient has liver involvement by tumor, total bilirubin must be within normal range)",bilirubin
Total bilirubin <= 1.5 x upper limit of normal (ULN) except in the case of Gilbert disease,bilirubin
Total bilirubin <= 1.5 x upper limit of normal (ULN) except subjects with documented Gilbert's syndrome who must have a baseline total bilirubin <= 3.0 mg/dL,bilirubin
Total bilirubin <= 1.5 x upper limit of normal (ULN) for age,bilirubin
Total bilirubin <= 1.5 x upper limit of normal (ULN) or direct bilirubin <= ULN,bilirubin
"Total bilirubin <= 1.5 x upper limit of normal (ULN) unless due to Gilbert?s syndrome, in which case the direct bilirubin must be <= 1.5 X ULN, obtained <= 14 days prior to registration",bilirubin
Total bilirubin <= 1.5 x upper limit of normal (ULN) unless due to Gilbert's syndrome,bilirubin
"Total bilirubin <= 1.5 x upper limit of normal (ULN), ( <= 3 x ULN if Gilbert's disease)",bilirubin
"Total bilirubin <= 1.5 x upper limit of normal (ULN), except for patients with known Gilbert's syndrome.",bilirubin
Total bilirubin <= 1.5 x upper limit of normal (ULN).,bilirubin
"Total bilirubin <= 1.5 x upper limit of normal (ULN). If patient has known Gilbert's syndrome, direct bilirubin <= 2.0 x ULN.",bilirubin
Total bilirubin <= 1.5 x upper limit of normal (ULN). Patients with known history of Gilbert Syndrome and total bilirubin < 2x ULN and normal AST/ALT are eligible.,bilirubin
Total bilirubin <= 1.5 x upper limit of normal range (ULN),bilirubin
Total bilirubin <= 1.5x institutional ULN (except for participants with Gilbert's syndrome who must have normal direct bilirubin),bilirubin
Total bilirubin <= 1.5x institutional ULN (except participants with Gilbert's Syndrome who must have normal direct bilirubin),bilirubin
Total bilirubin <= 1.5x ULN except in patients with Gilbert's syndrome. Patients with Gilbert's syndrome may enroll if direct bilirubin <= 1.5 x ULN of the direct bilirubin,bilirubin
"Total bilirubin <= 1.5x ULN, except in patients with Gilbert's syndrome. Patients with Gilbert's syndrome may enroll if direct bilirubin is <=.5x ULN for the direct bilirubin",bilirubin
"Total bilirubin <= 2 mg/dL; if hepatic metastases are present, <= 2.5x ULN",bilirubin
Total bilirubin <= 2 x ULN,bilirubin
Total bilirubin <= 2 x upper limit of normal (ULN),bilirubin
Total bilirubin <= institutional upper limit of normal (IULN),bilirubin
Total bilirubin <= institutional upper limit of normal (ULN),bilirubin
Total bilirubin <= institutional upper limit of normal (ULN) or <= 1.5 X institutional ULN (if the patient has liver metastases).,bilirubin
Total bilirubin <= ULN,bilirubin
Total bilirubin <= upper limit of normal (ULN).,bilirubin
Total bilirubin <= upper normal institutional limits,bilirubin
total bilirubin <= upper normal institutional limits (except for patients with Gilbert's Disease who are eligible despite elevated serum bilirubin level),bilirubin
Total bilirubin <= upper normal limit,bilirubin
Total bilirubin <=.5 x ULN,bilirubin
"Total bilirubin > 1.5 x institutional upper limit of normal (ULN) (in case of known Gilbert's syndrome, > 2x ULN)",bilirubin
Total bilirubin > 1.5 x ULN (Patients with a history of Gilbert's syndrome may participate if total bilirubin is less than or equal to 1.5 x ULN and the AST/ALT and alkaline phosphatase meet the protocol-specified levels for eligibility),bilirubin
Total bilirubin > 1.5 x ULN; > 3 x ULN with direct bilirubin > 1.5 x ULN in presence of Gilbert's disease.,bilirubin
Total bilirubin > ULN (except total bilirubin > ULN is acceptable if direct bilirubin is <= 1.2 x ULN. Subjects with Gilbert's syndrome who have total bilirubin <= 2 x ULN may be enrolled with medical monitor approval),bilirubin
Total bilirubin > upper limit of normal (ULN; except total bilirubin > ULN is acceptable if direct bilirubin is <= 1.2 x ULN. Subjects with Gilbert's syndrome who have total bilirubin <= 2 x ULN may be enrolled with medical monitor approval),bilirubin
Total bilirubin >= 1.5 mg/dL not related to hemolysis or Gilbert's disease,bilirubin
"Total bilirubin >= 100,000/microliter <= 1.5 x institutional upper limit of normal (ULN)",bilirubin
Total bilirubin 2 x ULN.,bilirubin
Total bilirubin below normal institutional upper limit of normal (ULN).,bilirubin
total bilirubin level <= 1.5 * upper limit of normal (ULN),bilirubin
Total bilirubin level of <= 1.5 x ULN,bilirubin
Total bilirubin must be < 2 X ULN within 2 weeks prior to registration,bilirubin
total bilirubin must be <= ULN (upper limit of normal) for the lab unless the patient has a bilirubin elevation > ULN to 1.5 x ULN due to Gilbert's disease or similar syndrome involving slow conjugation of bilirubin; and,bilirubin
Total bilirubin of < upper limit of normal (ULN),bilirubin
Total bilirubin ULN,bilirubin
Total Bilirubin Within normal institutional limits,bilirubin
"Total bilirubin within normal institutional limits, unless participant has Gilbert's disease, for which bilirubin must be <= 2.0 x ULN",bilirubin
total bilirubin within normal laboratory limits,bilirubin
"Total bilirubin, AST (SGOT) and ALT (SGPT): If no known liver metastases: Total bilirubin < 1.5 x institutional upper limit of normal (ULN), AST/SGOT < 2 x ULN.",bilirubin
"Total bilirubin: <= 1.5 x ULN (in case of known Gilbert's syndrome, < 2 x ULN is allowed)",bilirubin
Total Serum Bilirubin <= 1.5 x ULN,bilirubin
"Total serum bilirubin <= 1.5 x ULN, with the following exception:",bilirubin
"Total serum bilirubin <= 1.5 x ULN. In subjects with Gilbert's syndrome, if direct bilirubin is <= 1.5 x ULN, subject may be eligible)",bilirubin
Total serum bilirubin <= 2.0 x ULN; patients with a known history of Gilbert's syndrome and/or isolated elevations of indirect bilirubin are eligible,bilirubin
Total serum bilirubin <= ULN (except for patients with Gilbert&rsquo;s syndrome who may only be included if the total bilirubin is <= 3.0 x ULN or direct bilirubin <= 1.5 x ULN.,bilirubin
Total serum bilirubin <= ULN; or total bilirubin <= 3.0 x ULN with direct bilirubin within normal range in patients with documented Gilbert's Syndrome.,bilirubin
Total serum bilirubin level <= 1.5 x ULN; Direct bilirubin <= ULN for subjects with total bilirubin > 1.5 x ULN (patients with isolated indirect bilirubin elevations and a history of Gilbert's Syndrome are eligible),bilirubin
A known bleeding diathesis,bleeding
Bleeding >= Grade 2 in the past 3 months.,bleeding
"Bleeding disorder (eg, factor deficiency, coagulopathy) or history of significant bruising or bleeding following IM injections or blood draws",bleeding
"Bleeding disorder (eg., factor deficiency, coagulopathy) or history of significant bruising or bleeding following IM injections or blood draws Complete inclusion and exclusion criteria are listed in the clinical study protocol.",bleeding
Clinically significant bleeding event within prior 6 months,bleeding
"Clinically significant bleeding event within the last 3 months, unrelated to trauma, or underlying condition that would be expected to result in a bleeding diathesis.",bleeding
"Clinically significant bleeding event, as judged by investigator, within prior 6 months",bleeding
"Clinically significant gastrointestinal abnormalities that may increase the risk for gastrointestinal bleeding including, but not limited to:",bleeding
"Clinically significant hematuria, hematemesis, or hemoptysis of > 0.5 teaspoon (2.5 ml) of red blood, or other history of significant bleeding (e.g., pulmonary hemorrhage) within 1 months before start of study treatment",bleeding
"Clinically significant hematuria, hematemesis, or hemoptysis of > 0.5 teaspoon (2.5 ml) of red blood, or other history of significant bleeding (e.g., pulmonary hemorrhage) within 12 weeks before first dose.",bleeding
"Clinically significant hematuria, hematemesis, or hemoptysis of > 0.5 teaspoon (2.5 mL) of red blood, or other history of significant bleeding (eg, pulmonary hemorrhage) within 12 weeks before first dose.",bleeding
Clinically significant hemoptysis or tumor bleeding within 2 weeks prior to the first dose of study drug.,bleeding
Disseminated intravascular coagulopathy with active bleeding or signs of thrombosis,bleeding
Documented or known bleeding disorder.,bleeding
evidence of active bleeding or bleeding diathesis,bleeding
Evidence of bleeding diathesis or clinically significant coagulopathy.,bleeding
Evidence of coagulopathy or bleeding diathesis,bleeding
Gastric or esophageal varices that are untreated or incompletely treated with bleeding or high risk for bleeding. Subjects treated with adequate endoscopic therapy (according to institutional standards) without any episodes of recurrent GI bleeding requiring transfusion or hospitalization for at least 6 months prior to study entry are eligible.,bleeding
History of active bleeding within the last 3 months prior to screening requiring transfusion.,bleeding
"History of bleeding diathesis (e.g. hemophilia, von Willebrand disease)",bleeding
History of clinically significant bleeding or known platelet or coagulation disorder,bleeding
History of gastrointestinal bleeding episode occurring within the prior 6 months.,bleeding
History of hemolytic anemia or bleeding diathesis,bleeding
"History of significant bleeding disorders, vasculitis, or a significant bleeding episode from the GI tract within 3 months prior to study randomization.",bleeding
Increased Risk of bleeding: including a history of a bleeding diathesis and/or known history of severe thrombocytopenia.,bleeding
"Known bleeding disorder which, in the opinion of the Investigator, would prohibit administration of fulvestrant if that would be SOC choice for the subject",bleeding
Known inherited bleeding disorder or coagulopathy,bleeding
"No clinically significant gastrointestinal abnormalities that may increase the risk for gastrointestinal bleeding within 6 months of registration including, but not limited to: active peptic ulcer, known endoluminal metastatic lesion(s) with history of bleeding, inflammatory bowel disease, or other gastrointestinal conditions with increased risk of perforation",bleeding
No clinically significant GI bleeding within 6 months of registration,bleeding
"Patient has acute bleeding that is clinically significant within 24 hours before the start of study treatment, defined as either of the following (a or b):",bleeding
Patient has conditions that have a high risk of clinically significant bleeding after administration of anti-VEGF agents:,bleeding
"Patients who have a history or current evidence of bleeding disorder, i.e., any hemorrhage/bleeding event of CTCAE Grade >= 2 within 28 days before the start of study treatment.",bleeding
"Patients with a clinically significant bleeding episode as judged by the investigator within 3 months of registration are not eligible, except patients who suffer bleeding due to trauma.",bleeding
"Recent or ongoing clinically significant gastrointestinal disorder (e.g., malabsorption, bleeding, inflammation, emesis, diarrhea > grade 1).",bleeding
Subject has an underlying condition predisposing them to bleeding or currently exhibits signs of clinically significant bleeding,bleeding
Subject with a major bleeding event (defined as symptomatic bleeding in a critical area or organ and/or bleeding causing a decrease in Hgb of >= 2 g/dL or leading to transfusion of >= 2 units of packed red cells) in the last 6 months prior to enrollment.,bleeding
"Subjects with history of known bleeding disorder(s) including clinically significant hemorrhage (e.g., GI, neurologic), within the past 6 months.",bleeding
"[Cohort B] WBC < 10,000 / uL on day of first therapy, cytoreduction may be achieved using hydroxyurea",blood-count
Adequate hematology (white blood cell [WBC] 3500 cells/mm3 or,blood-count
Circulating WBC count must not be above 20 x10^9/L within 7 days prior to first dose of study agent,blood-count
Circulating white blood cell (WBC) count must not be above 20 x10^9/L within 7 days prior to first dose of study agent,blood-count
"Circulating white blood cells > 25,000 /µl. Hydroxyurea to control peripheral blood leukemic cell counts, within 24 hours of study day 1 is permitted.",blood-count
"Leukocytes (WBCs) >= 3,000/uL",blood-count
"Leukocytes (white blood cell [WBC]) >= 3,000/microliter",blood-count
"leukocytes : >= 3,000/mcL",blood-count
"Leukocytes ? 2,000/mcL",blood-count
"leukocytes <= 3,000/mcL",blood-count
"Leukocytes > 3,000/uL",blood-count
"Leukocytes > 3,000/mcL",blood-count
"Leukocytes > 3,000/microliter",blood-count
"Leukocytes > 3,000/microliter (mcL)",blood-count
"Leukocytes > 3,000/micro-liter (mcl)",blood-count
"Leukocytes > 3,000/uL",blood-count
"Leukocytes >= 1,500/mcL",blood-count
Leukocytes >= 1500/mcL,blood-count
Leukocytes >= 2 x 10^9/L,blood-count
"Leukocytes >= 2,000/mcL",blood-count
"Leukocytes >= 2,000/mcL (within 10 days of treatment initiation)",blood-count
"Leukocytes >= 2,000/mm3",blood-count
"Leukocytes >= 2,000/ul",blood-count
"Leukocytes >= 2,000/uL.",blood-count
"Leukocytes >= 2,500/mcL",blood-count
"Leukocytes >= 2,500/microliter",blood-count
Leukocytes >= 3 x 10^9/L,blood-count
"Leukocytes >= 3,000 cells/mm^3",blood-count
"Leukocytes >= 3,000/ mm^3",blood-count
"Leukocytes >= 3,000/µL",blood-count
"leukocytes >= 3,000/mcL",blood-count
"Leukocytes >= 3,000/mcL (measured within 14 days prior to administration of study treatment)",blood-count
"leukocytes >= 3,000/mcL (microliter)",blood-count
"Leukocytes >= 3,000/mcL (no more than 7 days before starting study treatment)",blood-count
"Leukocytes >= 3,000/mcL (obtained within 14 days prior to randomization)",blood-count
"Leukocytes >= 3,000/mcl (within 14 days prior to enrollment)",blood-count
"Leukocytes >= 3,000/mcL (within 2 weeks prior to screening and within 4 weeks prior to treatment step registration)",blood-count
"Leukocytes >= 3,000/mcL (within 2 weeks prior to screening step registration and within 4 weeks prior to treatment step registration)",blood-count
"Leukocytes >= 3,000/mcL (within 28 days prior to administration of ABT-888)",blood-count
"Leukocytes >= 3,000/mcL (within 28 days prior to administration of study treatment)",blood-count
"Leukocytes >= 3,000/microliter",blood-count
"Leukocytes >= 3,000/microliter (mcL)",blood-count
"Leukocytes >= 3,000/microliters (mcL)",blood-count
"Leukocytes >= 3,000/mL",blood-count
"Leukocytes >= 3,000/mm^3",blood-count
"Leukocytes >= 3,000/mm^3 .",blood-count
"Leukocytes >= 3,000/mm3",blood-count
"Leukocytes >= 3,000/uL",blood-count
Leukocytes >= 3.0 x 10^9/L (obtained <= 14 days prior to registration),blood-count
Leukocytes >= 3000 mcL,blood-count
Leukocytes >= 3000/µL,blood-count
Leukocytes >= 3000/L,blood-count
Leukocytes >= 3000/mcL (within 10 days of treatment initiation),blood-count
"Leukocytes 4500 - 11,000 uL",blood-count
leukocytes greater than or equal to 2500mcL,blood-count
"leukocytes greater than or equal to 3,000/mcL",blood-count
leukocytes greater than or equal to 3000/mcL,blood-count
leukocytes greater than or equal to 750/mcL*,blood-count
Leukocytes no lower limit,blood-count
"Leukocytes: >= 2,000/mcL",blood-count
"Leukocytes: >= 3,000/mm^3",blood-count
Leukocytes: >= 4*10^9/L,blood-count
"Leukocytosis ( > 13,000) with absolute monocytosis ( > 1,000)",blood-count
Normal WBC ( > 3000/mm3).,blood-count
"Obtained within 14 days prior to the first study treatment (cycle 1, day 1): White blood cell (WBC) counts > 2500/uL",blood-count
Other unfavorable karyotype OR leukocytes >= 40 x 10(9) /L and,blood-count
"PARTICIPANTS NOT ON THE HODGKIN LYMPHOMA EXPANSION COHORT: Leukocytes >= 2,000/mm^3 (within 2 weeks prior to enrollment)",blood-count
"Patients with WBC count above 20 x10^9/L may be eligible if they start steroids or hydroxyurea per institutional guidelines, but they must discontinue before day 1 of study drug",blood-count
"Peripheral blood white blood count (WBC) greater than 2,000 per microliter (required for collection of dendritic cell precursors)",blood-count
Peripheral white blood cell (WBC) >= 2000/mm3,blood-count
"Peripheral White Blood Cell (WBC) count > 30,000 /µL in the 48 hours prior to first BST-236 dose administration. Hydroxyurea administration or leukapheresis is permitted to meet this criterion",blood-count
"Peripheral white blood cell (WBC) count 30,000/µL For cyto-reduction, hydroxyurea is allowed during screening and up to Cycle 1, Days 1-14, to reduce WBC count to < 30,000 µL prior to Day 1. After Cycle 1, Day 14, hydroxyurea is prohibited.",blood-count
Proliferative disease (WBC > 30x10^9/L) confirmed prior to first dose of ONO-7475,blood-count
"STEP 1: Leukocytes >= 3,000/mm^3 (within less than or equal to 14 days prior to randomization)",blood-count
total leukocytes > 3x10^3/μL.,blood-count
"Total WBC >= 2,000 cells/mm3 without growth factors within 1 week of the initiation of treatment",blood-count
Total White Blood Cell count (WBC) < 25x10^9/L prior to first infusion. Prior or concurrent treatment with hydroxyurea to achieve this level is allowed.,blood-count
"WBC (white blood cells) > 3,000/mm3",blood-count
"WBC < 2,000/mm3",blood-count
"WBC < 4,000 or > 30,000/mm3 or requires cytoreductive therapy to maintain WBC < 30,000/mm3.",blood-count
"WBC <= 25,000 cells/mm3 (25x10^9/L); use of leukapheresis or hydroxyurea before study drug initiation is allowed to achieve this entry criterion.",blood-count
WBC <= 3x10^³/mm³,blood-count
"WBC <= 50,000/µL (use of hyroxyurea is permitted)",blood-count
"WBC > 2,500 cells/mm3",blood-count
"WBC > 2,500/mcL",blood-count
WBC > 2500 cells/mm3,blood-count
WBC > 3000/mm^3,blood-count
WBC > 3000/mm3,blood-count
"WBC >= 1,500/mcL",blood-count
"WBC >= 2,000/µL",blood-count
"WBC >= 2,000/ul",blood-count
WBC >= 2.5 and <= 15.0x10^9/L,blood-count
WBC >= 2.5x10^9/L,blood-count
WBC >= 2000/µL ( >= 2 x 10^9/L),blood-count
WBC >= 2000/uL,blood-count
"WBC >= 3,000/ L",blood-count
"WBC >= 3,000/µL",blood-count
WBC >= 3.0 10^9/L,blood-count
WBC >= 3.0 109/L,blood-count
WBC >= 3.0 K/uL,blood-count
WBC >= 3.0 x 10^9/L (x 10^3/mm^3),blood-count
WBC >= 300 x 10^9/L AND/OR prednisone poor response,blood-count
WBC >= 3000/mm3,blood-count
"WBC >= 4,000/µl, platelets >= 100,000/µl",multlabs
WBC count > 2500/uL,blood-count
"WBC count > 30,000/mcL at diagnosis",blood-count
"WBC count >= 100,000 cells/µL at diagnosis",blood-count
WBC count >= 3 x 10^9/L,blood-count
WBC count >= 3000/µL,blood-count
WBC counts > 2500/µL,blood-count
WBC counts > 2500/uL,blood-count
WBC counts greater than 2500/µL,blood-count
WBC greater than or equal to 1500/microL,blood-count
WBC greater than or equal to 3000/mm(3),blood-count
WBC greater than or equal to 3000/mm^3,blood-count
WBC greater than or equal to 3000/mm3,blood-count
White blood cell (WBC ) >= 2000/uL (obtained within 14 days prior to randomization/registration),blood-count
White blood cell (WBC) ( > 3000/mm(3)).,blood-count
"White blood cell (WBC) < 3,500/mm^3",blood-count
White blood cell (WBC) <= 2000/uL (prior to cyclophosphamide and T cell infusions).,blood-count
White blood cell (WBC) > 2.5 B/L (10^9/L),blood-count
White blood cell (WBC) > 2000/uL (stable off any growth factor within 4 weeks of first study treatment administration),blood-count
"White blood cell (WBC) > 3,000/mm��??",blood-count
"White blood cell (WBC) > 50,000/mcL",blood-count
"White blood cell (WBC) >= 2,500 cells/µL",blood-count
"White blood cell (WBC) >= 2,500/mm^3",blood-count
White blood cell (WBC) >= 2000 cells/µL,blood-count
White blood cell (WBC) >= 2000/µL,blood-count
White blood cell (WBC) >= 2000/mm^3.,blood-count
white blood cell (WBC) >= 2000/uL,blood-count
White blood cell (WBC) >= 2000/uL (within 2 weeks prior to randomization),blood-count
White blood cell (WBC) >= 2000/uL (within 30 days before study registration),blood-count
White blood cell (WBC) >= 3 K/mm^3,blood-count
White blood cell (WBC) >= 3 x 10^9/L.,blood-count
"White blood cell (WBC) >= 3,000 K/mm3",blood-count
"White blood cell (WBC) >= 3,000/mcL",blood-count
White blood cell (WBC) >= 3000/mm^3,blood-count
White blood cell (WBC) >= 50 x 10^3/µL,blood-count
"white blood cell (WBC) count ( >= 2,000/uL)",blood-count
"White blood cell (WBC) count < 3,500 cells/mm3",blood-count
"White blood cell (WBC) count < 30,000 /mcL",blood-count
White blood cell (WBC) count <= 20 x 10E3/µL,blood-count
"White blood cell (WBC) count > 3,000/µL",blood-count
"White blood cell (WBC) count >= 2500/ul, obtained within 14 days prior to initiation of study treatment",blood-count
White blood cell (WBC) count >= 3 x 10^9/L.,blood-count
"White blood cell (WBC) count >= 3,000/mm3 within 3 weeks prior to registration",blood-count
"White blood cell (WBC) count >= 3,000/mm3 within 3 weeks prior to registration.",blood-count
White blood cell (WBC) count >= 3000 cells/mm^3,blood-count
White blood cell (WBC) count >= 3000 cells/mm3,blood-count
"White blood cell (WBC) count 3,000/mL",blood-count
White blood cell (WBC) count no greater than 25x10^9/L at time of start of study drug (venetoclax or gilteritinib). Note: Hydroxyurea is permitted from screening through completion of Cycle 1 in order to meet this criterion.,blood-count
White blood cell (WBC) count of > 3000/ul,blood-count
White blood cell (WBC) counts > 2500/microL,blood-count
"White blood cell (WBC) counts > 2500/uL (obtained within 14 days prior to the first study treatment [PD window, day 1])",blood-count
White blood cell (WBC) counts > 2500/uL.,blood-count
"White blood cell >= 2,000 /mm3",blood-count
"White blood cell count (WBC) < 2,000/µL",blood-count
White blood cell count (WBC) > 2.5 k/mm3,blood-count
White blood cell count (WBC) > 3 x 10^9/L,blood-count
"White blood cell count (WBC) >= 3,000/mcL (within 28 days prior to administration of study treatment)",blood-count
"White Blood Cell Count (WBC) >= 3,000/mm3",blood-count
"White blood cell count (WBC) >= 3,000/ul",blood-count
"White blood cell count (WBC) >= 3,500/ul",blood-count
White blood cell count (WBC) >= 3.0x10^9/L,blood-count
"White blood cell count (WBC) >= 4,000/mm��??",blood-count
White Blood Cell Count (WBC) Criteria,blood-count
White blood cell count >= 2500/mm^3 ( >= 2.5 GI/L),blood-count
White blood cell count >= 2500/mm3 ( >= 2.5 GI/L).,blood-count
White blood cell counts (WBC) > 2500/uL,blood-count
"White blood cells (WBC) > 15,000 cells/mcL (15 cells x 10^9/L) at screening",blood-count
"White blood cells (WBC) > 15,000 cells/mcL at screening",blood-count
White blood cells (WBC) > 3 x 10^9/L (within 28 days prior to administration of study treatment),blood-count
"White blood cells (WBC) > 3x10^9/L (unless due to bone marrow infiltration by tumor, in which case WBC > 2x10^9/L is allowed)",blood-count
White blood cells (WBC) >= 2.0 X 10^9/L (within 28 days of first study treatment),blood-count
White blood cells (WBC) >= 2000 /uL (within one week prior to registration),blood-count
White blood cells (WBC) >= 2000/mm^3,blood-count
White blood cells (WBC) >= 2000/uL,blood-count
"white blood cells (WBC) >= 3,000/μL",blood-count
"White blood cells (WBC) >= 3,000/ul",blood-count
White Blood Cells (WBC) >= 3.0x10^9/L,blood-count
White blood cells (WBC) >= 3000/mm^3,blood-count
"White blood cells (WBC) greater than 15,000 cells/mcL (15 cells x 10^9/L) at screening (hydroxyurea is permitted to enable eligibility).",blood-count
White blood cells (WBCs) >= 2000/μL,blood-count
White blood cells >= 3000 cells/μL,blood-count
White blood count (WBC) > 100 x 10^9/L,blood-count
White blood count (WBC) >= 2000 /mcL,blood-count
White blood count (WBC) >= 2000/uL,blood-count
"Within 2 weeks prior to initiation of study treatment: Leukocytes >= 3,000/mcL",blood-count
"Within 90 days before enrollment: Leukocytes: >= 3,000/mm^3",blood-count
A body mass index (BMI) >= 25,bmi
"Are centrally obese with the following criteria (determined by study team at eligibility screening): body mass index (BMI) > 30 kg/m^2 (calculated using height and weight) or body fat > 30% (estimated by bioelectrical impedance), and waist circumference > 35 inches (in)",bmi
Are morbidly obese with body mass index (BMI) > 40,bmi
BMI (Body Mass Index) less than 30,bmi
BMI < 16 (malnutrition),bmi
BMI < 18 or > 45 kg/m2(16),bmi
BMI < 25 kg/m^2,bmi
BMI <= 29.9 kg/m^2,bmi
BMI > 22 and <= 35.,bmi
BMI > 24 kg/m2,bmi
BMI > 25 kg/m2,bmi
BMI > 30.,bmi
BMI > 40,bmi
BMI > 40 kg/m2,bmi
BMI >= 18.5,bmi
BMI >= 19,bmi
BMI >= 24 kg/m2,bmi
BMI >= 25 kg/m^2,bmi
BMI >= 25 kg/m2,bmi
BMI 18 to 32 kg/m2.,bmi
BMI 20-35 kg/m2,bmi
BMI between 18 and 40 kg/m2,bmi
BMI between 25.0 to < 40 kg/m2 (allows for use of assessments such as DXA to be included),bmi
Body mass index (BMI) < 25,bmi
Body mass index (BMI) > 20,bmi
Body mass index (BMI) > 25.0 (overweight and obese),bmi
Body mass index (BMI) >= 18.5,bmi
Body mass index (BMI) >= 35 mg/m^2 <= 56 days prior to registration,bmi
Body mass index (BMI) greater than or equal to 30.0.,bmi
Body Mass Index (BMI) less than 32,bmi
Body mass index (BMI) of 25 or higher,bmi
Has a BMI (Body Mass Index) of 30 or higher,bmi
Malnutrition defined as BMI < 16.,bmi
morbid obesity,bmi
morbid obesity (BMI > 40),bmi
Morbidly obese as defined by a body mass index (BMI) >= 40.,bmi
Obese (defined as BMI 30 - < 50 kg/m2),bmi
Obesity > BMI 30 or any physical or neurological disability that would preclude patients from participating in physical therapy,bmi
Obesity that limits obtainment of acceptable images,bmi
Overweight or obese ( > 25 kg/m^2),bmi
Patient BMI greater than or equal to 21,bmi
Patient BMI less than 21,bmi
"Patients for whom a PET/MRI is technically not feasible (e.g. breast volume, obesity, > body mass index (BMI) 36)",bmi
Patients must have BMI >= 30.,bmi
Patients who may not fit on a 35 x 35 detector (BMI > 35),bmi
Patients with BMI > 35,bmi
Patients with body mass index (BMI) greater than 40.0.,bmi
Subjects have a BMI greater than 18.,bmi
Subjects have a BMI greater than 22.,bmi
The patients has a body mass index (BMI) > 40,bmi
Body weight < 40 kg,body-weight
Body weight > 30 kg,body-weight
Body weight > 30 kg at screening,body-weight
Body weight > 30kg,body-weight
Body weight >= 35 kg.,body-weight
Body weight >= 40 kg,body-weight
Body WT > 30 kg,body-weight
Girth and weight must be suitable to enter the gantry,body-weight
Patients greater than or equal to 12 and less than 18 years of age should weigh at least 40 kilograms (kg); there is no weight requirement for adult subjects.,body-weight
Patients with a weight of < 39 kg,body-weight
The kilogram weight is the patient's actual body weight with an upper limit of 140% of the IBW.,body-weight
there is no weight requirement for adult subjects,body-weight
Weight < 45 kg,body-weight
Weight < 70kg for cord blood transplantation,body-weight
Weight over 40 kg,body-weight
Weight over 40 kilograms (kg),body-weight
Breast conserving surgery and indications for whole breast radiotherapy.,breast-conserving-surgery
Patient desires breast conserving therapy.,breast-conserving-surgery
Patients must be undergoing breast conserving therapy,breast-conserving-surgery
Patients must have been treated by Breast Conserving Surgery (BCS) or mastectomy.,breast-conserving-surgery
"Patients treated by Breast Conserving Surgery and SLNB alone must have only 1-2 positive axillary nodes (macrometastases, > 2 mm)*.",breast-conserving-surgery
"Patients treated by Breast Conserving Surgery or mastectomy and axillary dissection must have 1-3 positive axillary nodes (macrometastases, > 2 mm).",breast-conserving-surgery
Planned breast surgery and indications for whole breast radiotherapy.,breast-conserving-surgery
"All patients must have undergone modified radical mastectomy (with negative margins on ink) with pathologic nodal evaluation (from level I and II axillary lymph node dissection) at least 3 weeks and no more than 12 weeks prior to randomization, unless they receive additional chemotherapy after mastectomy (see Section 5.2c). Patients must not have gross residual tumor or positive microscopic margins after mastectomy.",breast-surgery
All tumor removed by either a modified radical mastectomy or a segmental mastectomy (lumpectomy).,breast-surgery
All women who undergo breast conserving therapy must receive concomitant radiotherapy. Radiation after mastectomy is to be administered according to prespecified institutional guidelines. Radiation must be completed at least 21 days prior to registration.,breast-surgery
"For patients who have undergone lumpectomy, any type of mastectomy and any type of reconstruction (including no reconstruction) are allowed.",breast-surgery
"For patients who have undergone lumpectomy, there are no breast size limitations.",breast-surgery
"For patients who undergo lumpectomy, the margins of the resected specimen or re-excision must be histologically free of invasive tumor and DCIS as determined by the local pathologist. Additional operative procedures may be performed to obtain clear margins. If tumor is still present at the resected margin after re-excision(s), the patient must undergo total mastectomy to be eligible. (Patients with margins positive for LCIS are eligible without additional resection.)",breast-surgery
"For patients who undergo mastectomy, the margins must be histologically free of residual (microscopic or gross) tumor.",breast-surgery
History of mastectomy or implants,breast-surgery
Lumpectomy performed prior to study entry,breast-surgery
Negative inked histologic margins from mastectomy pathology (no invasive cells at margin).,breast-surgery
"No significant post mastectomy complications in the ipsilateral or contralateral breast requiring an unplanned re-operation or admission for IV antibiotics. Re-operation for margins evaluation, nodal completion and routine reconstruction is acceptable.",breast-surgery
Patient must have undergone immediate reconstruction at the time of mastectomy or be planning to undergo reconstruction within 18 months after radiation.,breast-surgery
Patient who have undergone either a total mastectomy or a lumpectomy are eligible. (Patients who have had a nipple-sparing mastectomy are eligible.),breast-surgery
Patients must have been treated by BCS or mastectomy.,breast-surgery
"Patients treated by BCS or mastectomy and axillary dissection must have 1-3 positive axillary nodes (macrometastases, > 2 mm).",breast-surgery
"Patients treated by mastectomy and SLNB alone must have only 1 positive axillary node (macrometastases, > 2 mm).",breast-surgery
Planned breast procedure other than mastectomy,breast-surgery
Planned mastectomy,breast-surgery
Post-mastectomy with or without reconstruction,breast-surgery
"Surgical margins must be clear of invasive carcinoma. If there is microscopic residual ductal in situ disease present at lumpectomy or total mastectomy margins, further excision is highly recommended. If further excision is not undertaken, the subject may still be entered on study, provided that in addition to breast or chest wall irradiation, a boost to the tumor bed is delivered. In situ lobular disease at the margin is acceptable.",breast-surgery
The definition of control is definitive surgery by excision or mastectomy (+/- radiotherapy) per institution preference,breast-surgery
The maximum time requirement between surgery and randomization must be:,breast-surgery
"The patient's primary surgical treatment is lumpectomy and a simultaneous SLNB or ALND is planned as part of the patient's therapy; or, the patient's primary surgical treatment is mastectomy and a simultaneous ALND is planned as part of the patient's therapy as part of the same procedure.",breast-surgery
Without a history of mastectomy or implants,breast-surgery
All patients must be surgical candidates for complete hysterectomy and bilateral salpingo-oophorectomy and pelvic and aortic lymphadenectomy.,bso-hysterectomy
All patients must have undergone complete hysterectomy and bilateral salpingo-oophorectomy at the time of original therapy for their uterine carcinoma,bso-hysterectomy
All patients must have undergone hysterectomy. Bilateral salpingooophorectomy is strongly encouraged but not mandatory.,bso-hysterectomy
Candidate for a total hysterectomy with or without bilateral salpingo?oophorectomy,bso-hysterectomy
"Have a hysterectomy and/or bilateral oophorectomy, bilateral salpingectomy or bilateral tubal ligation/occlusion, at least 6 weeks prior to Step 2 registration; OR",bso-hysterectomy
Have had or are scheduled to undergo a hysterectomy and/or salpingo-oophorectomy,bso-hysterectomy
"Histological evidence of newly diagnosed Stage III or IV or recurrent endometrial carcinoma who have had definitive surgery for endometrial cancer (at least hysterectomy and bilateral salpingo-oophorectomy). Pathologic documentation of the recurrence (i.e., biopsy) will be performed per standard of care, at the treating physician's discretion. If a subject with recurrence is undergoing a biopsy for clinical indications and is willing and able, an optional collection of 3 frozen tissue cores of the recurrence site is requested for correlative analysis.",bso-hysterectomy
"If either a bilateral salpingo-oophorectomy or nodal dissection was not performed, post-operative pre-treatment CT/MRI is required and must not demonstrate evidence suggestive of metastatic disease (adnexa, nodes, intraperitoneal disease). Post-operative, pre-treatment CT/MRI must be performed if a pelvic and para-aortic nodal dissection was not performed.",bso-hysterectomy
Is scheduled to undergo preventative salpingo-oophorectomy for high risk of ovarian cancer not earlier than 24 hours and not later than 5 days following the second BR55 CEUS examination,bso-hysterectomy
Is scheduled to undergo salpingo-oophorectomy for suspected ovarian cancer not earlier than 24 hours and not later than 30 days following BR55 administration,bso-hysterectomy
Patients must have undergone a bilateral salpingo-oophorectomy,bso-hysterectomy
"Patients must have undergone surgical staging with at least hysterectomy, removal of cervix, bilateral (if both are present) salpingo-oophorectomy, and either sentinel lymph node assessment or complete pelvic +/- aortic lymphadenectomy. Secondary staging is allowed to determine stage. Patients with isolated tumor cells in sentinel lymph nodes are eligible (considered N0i) as long as there is no evidence of micro- or macro-metastases in any lymph nodes",bso-hysterectomy
Prior bilateral salpingo-oophorectomy.,bso-hysterectomy
Scheduled to undergo a hysterectomy and/or bilateral salpingo-oophorectomy,bso-hysterectomy
Scheduled to undergo a hysterectomy and/or salpingo-oophorectomy,bso-hysterectomy
Scheduled to undergo a hysterectomy or salpingo-oophorectomy,bso-hysterectomy
Surgery consisted of Total Abdominal or Laparoscopic Hysterectomy and Bilateral Salpingo Oophorectomy (TH-BSO) with or without lymph node dissection.,bso-hysterectomy
Surgery must have included a hysterectomy and bilateral salpingooophorectomy. Pelvic lymph node sampling and para-aortic lymph node sampling are optional.,bso-hysterectomy
"(#4, continued): AML patients:",cancertype
"(#4, continued): MDS patients:",cancertype
A confirmed myelodysplastic syndrome (MDS) with:,cancertype
Active hematologic malignancy,cancertype
Acute biphenotypic leukemia,cancertype
Acute biphenotypic leukemia or,cancertype
Acute leukemias:,cancertype
Acute lymphoblastic leukemia,cancertype
Acute lymphoblastic leukemia (ALL),cancertype
Acute lymphocytic leukemia (ALL),cancertype
Acute lymphocytic leukemia:,cancertype
Acute myelogenous leukemia,cancertype
Acute myelogenous leukemia (AML),cancertype
Acute myelogenous leukemia:,cancertype
Acute myeloid leukemia,cancertype
Acute myeloid leukemia (AML),cancertype
Advanced prostate cancer,cancertype
Advanced Renal Cell Carcinoma,cancertype
ALL,cancertype
"All B-ALL patients must have detectable disease by morphology, flow cytometry, cytogenetic analysis (e.g. polymerase chain reaction [PCR], fluorescence in situ hybridization [FISH], karyotyping) or imaging (positron emission tomography [PET]-computed tomography [CT])",cancertype
AML arising after documented MPD is excluded,cancertype
AML favorable or intermediate ELN risk,cancertype
AML patients who are unlikely to demonstrate rapid progression such that they would be unable to complete the first cycle of therapy.,cancertype
AML patients who either have:,cancertype
AML patients:,cancertype
Any advanced malignant hepatic tumor(s),cancertype
"Any detectable ALL (by flow cytometry, cytogenetics, or PCR techniques) as per clinical indication.",cancertype
"Any detectable ALL (by flow cytometry, cytogenetics, or polymerase chain reaction (PCR) techniques) as per clinical indication.",cancertype
Any of the following hematologic malignancies:,cancertype
Any of the following hematological malignancies:,cancertype
Any solid tumors with masses that are accessible,cancertype
Any stage for pancreatic cancer and,cancertype
Arm A: Solid Tumor,cancertype
atypical MDS/myeloproliferative syndromes,cancertype
Basal or squamous cell carcinoma of the skin,cancertype
Biopsy proven prostate cancer,cancertype
Biopsy proven Renal neoplasm,cancertype
Biopsy-proven neuroendocrine tumor.,cancertype
Biopsy-proven prostate cancer.,cancertype
Biopsy-proven small lymphocytic lymphoma or,cancertype
Biphenotypic or bilineal acute leukemia,cancertype
Bladder Cancer,cancertype
"Bone marrow dysplasia, myelodysplasia",cancertype
Breast cancer,cancertype
Breast cancer determined to be:,cancertype
Breast cancer tissue diagnosis,cancertype
Breast cancer:,cancertype
"breast, ovarian, and other solid cancers",cancertype
Burkitt lymphoma,cancertype
Burkitt type leukemia,cancertype
Carcinoma of the lung,cancertype
Cervical cancer,cancertype
Cervical carcinoma,cancertype
Chronic lymphocytic leukemia,cancertype
Chronic lymphocytic leukemia (CLL),cancertype
Chronic myelocytic leukemia (CML):,cancertype
Chronic Myelogenous leukemia,cancertype
Chronic myelogenous leukemia (CML),cancertype
Chronic myeloid leukemia,cancertype
Chronic myeloid leukemia (CML) in any phase,cancertype
Chronic myeloid leukemia (CML):,cancertype
chronic myelomonocytic leukemia,cancertype
Chronic myelomonocytic leukemia (CMML),cancertype
Clinically localized prostate cancer:,cancertype
CLL or SLL diagnosis according to iwCLL criteria,cancertype
CLL-must have either,cancertype
CML in blast crisis,cancertype
CML in refractory blast crisis,cancertype
Cohort 1: HER2 IHC 2+/FISH- breast cancer,cancertype
Cohort 4: HNSCC,cancertype
Cohort A. Acute lymphoblastic leukemia,cancertype
COHORT A: multiple myeloma,cancertype
Colon/rectal carcinoma,cancertype
colorectal cancer,cancertype
Confirmed diagnosis of CMML,cancertype
Criteria for NHL:,cancertype
Current diagnosis of colorectal cancer,cancertype
"Diagnosed with histologically confirmed metastatic solid tumor - cancer of the lung (small cell or non small cell), prostate (adenocarcinoma), colorectum, kidney (renal cell carcinoma), pancreas (adenocarcinoma),or malignant melanoma, metastatic Ewing's sarcoma, or metastatic epithelial neoplasms and adenocarcinoma of unknown primary, and disease confirmed to be metastatic and unresectable for which standard curative or beneficial treatments are no longer effective",cancertype
Diagnosed with prostate cancer,cancertype
Diagnosis Leukemia,cancertype
Diagnosis of acute leukemia,cancertype
Diagnosis of Acute Myeloid Leukemia (AML),cancertype
Diagnosis of AML according to WHO 2008 criteria,cancertype
Diagnosis of AML according to WHO criteria 2016.,cancertype
Diagnosis of AML within the recent 2 months,cancertype
Diagnosis of cervical esophageal carcinoma.,cancertype
Diagnosis of chronic lymphocytic leukemia,cancertype
Diagnosis of colorectal cancer or any cancer,cancertype
Diagnosis of Multiple Myeloma,cancertype
Diagnosis of myelodysplastic syndrome,cancertype
Diagnosis of myelodysplastic syndrome (MDS),cancertype
Diagnosis of myelodysplastic syndrome (MDS).,cancertype
Diagnosis of Myelodysplastic Syndrome.,cancertype
Diagnosis of prostate cancer,cancertype
"Diagnosis of PTCL according to the most recent edition of the World Health Organization (WHO) Classification of Tumors of Hematopoietic or Lymphoid Tissues, as follows:",cancertype
Diagnosis other than multiple myeloma,cancertype
Documented diagnosis of multiple myeloma,cancertype
Dose Escalation: all solid tumor types,cancertype
Endometrial cancer,cancertype
Evaluable MM with at least one of the following:,cancertype
Evidence of extravesical bladder cancer,cancertype
Extramedullary MM,cancertype
FNA alone to diagnose the breast cancer.,cancertype
FOR AML ONLY: No ANC restriction,cancertype
For AML subjects:,cancertype
For AML:,cancertype
For CML patients either:,cancertype
For Colorectal Cancer Participants:,cancertype
For Gastric Cancer Participants:,cancertype
For lymphoma patients:,cancertype
For MDS patients,cancertype
For Ovarian Cancer Participants:,cancertype
For patients with solid tumors:,cancertype
gallbladder cancer,cancertype
gastric cancer,cancertype
gastrointestinal and genitourinary cancers,cancertype
Germ cell or hematologic malignancies.,cancertype
Has breast cancer with lobular histology.,cancertype
Has diagnosis of endometrial cancer,cancertype
"Has histologically or cytologically confirmed, locally advanced, metastatic cancer meeting the following criteria:",cancertype
Have had CRC screening in the previous 12 months,cancertype
Have hematological malignancy,cancertype
Have synchronous primary endometrial cancer,cancertype
Head and neck squamous cell carcinoma,cancertype
Hepatocellular carcinoma,cancertype
Hereditary colorectal cancer syndromes,cancertype
"High risk AML, including any of the following:",cancertype
Histologic evidence of neuroendocrine or small cell carcinoma of the prostate,cancertype
Histologic evidence of small cell carcinoma (morphology alone - immunohistochemical evidence of neuroendocrine differentiation without morphologic evidence is not exclusionary).,cancertype
"Histologic or cytologic confirmation of lung cancer (squamous, adenocarcinoma or small cell lung cancer)",cancertype
Histological confirmation of breast cancer,cancertype
Histological diagnosis of breast adenocarcinoma,cancertype
Histological Diagnosis: Patients must have a histologically documented peritoneal carcinomatosis from either colorectal or appendiceal adenocarcinoma.,cancertype
Histologically confirmed adult acute lymphoblastic leukemia,cancertype
"Histologically confirmed breast cancer, including 1 of the following subtypes:",cancertype
"Histologically confirmed high grade serous or endometrioid ovarian, peritoneal or fallopian tube malignancy that is metastatic and for which curative measures do not exist. The histology can be confirmed from tissue that was taken at the time of diagnosis. A biopsy at the time of recurrence prior to enrollment on study is not required.",cancertype
Histologically confirmed invasive cancer of the breast,cancertype
Histologically confirmed neurotropic primary melanoma,cancertype
Histologically confirmed prostate cancer,cancertype
histologically confirmed prostate cancer.,cancertype
Histologically confirmed prostate cancer. Small cell/neuroendocrine differentiated allowed but not required for study participation.,cancertype
Histologically confirmed renal cell carcinoma,cancertype
Histologically confirmed solid tumor or hematologic malignancy,cancertype
"Histologically confirmed squamous, adenosquamous, or adenocarcinoma of the cervix with any/all of the following high-risk features after surgery:",cancertype
Histologically confirmed urothelial carcinoma of the bladder,cancertype
"Histologically confirmed, locally confined adenocarcinoma of the prostate",cancertype
"Histologically or cytological confirmed diagnosis of metastatic or locally advanced, unresectable pancreatic adenocarcinoma (excluding other pancreatic malignancies for example, acinar cell carcinomas, adenosquamous carcinomas, and neuroendocrine islet cell neoplasms).",cancertype
"Histologically or cytologically confirmed adenocarcinoma of the prostate at initial biopsy, without neuroendocrine differentiation, signet cell, or small cell features",cancertype
Histologically or cytologically confirmed adenocarcinoma of the prostate previously treated with surgery and/or radiotherapy.,cancertype
Histologically or cytologically confirmed adenocarcinoma of the prostate. No evidence of neuroendocrine differentiation or small cell features.,cancertype
Histologically or cytologically confirmed carcinoma of the prostate (excluding neuroendocrine differentiation or squamous cell histology),cancertype
Histologically- or cytologically- confirmed CRC.,cancertype
Histologically or cytologically documented small cell lung cancer (SCLC),cancertype
Histologically proven prostate adenocarcinoma,cancertype
Histologically-confirmed primary uveal melanoma.,cancertype
HNSCC,cancertype
Hodgkin disease:,cancertype
Hodgkin Lymphoma,cancertype
Hodgkin lymphoma (HL),cancertype
Hodgkin lymphomas,cancertype
Hodgkin's disease,cancertype
Hodgkin's Lymphoma,cancertype
Hormone unresponsive breast cancer,cancertype
Imaging showing possible pancreatic cancer,cancertype
Immunophenotyping consistent with CLL defined as:,cancertype
Inflammatory/inoperable breast cancer.,cancertype
"Institutional confirmation of Mullerian epithelial adenocarcinoma on core biopsy (not cytology or fine needle aspiration) or laparoscopic biopsy; (for phase II of the study formalin-fixed paraffin-embedded [FFPE] tissue should be available for laboratory analysis); patients with the following histologic epithelial cell types are eligible: high grade serous carcinoma, high grade endometrioid carcinoma, clear cell carcinoma, or a combination of these",cancertype
Juvenile myelomonocytic leukemia,cancertype
Juvenile myelomonocytic leukemia (JMML),cancertype
Kidney cancer,cancertype
"Known anal, vulvar, cervical, or penile cancer",cancertype
Known bladder cancer,cancertype
Known breast cancer,cancertype
Known CNS lymphoma or leukemia,cancertype
Known FR-negative ovarian cancer,cancertype
Known meningeal involvement of multiple myeloma.,cancertype
Known prostate cancer,cancertype
Leukemia,cancertype
Low-risk prostate cancer after curative surgery,cancertype
Low-risk prostate cancer on active surveillance,cancertype
Lung cancer,cancertype
Lymphoid blast crisis of CML,cancertype
Lymphoma,cancertype
Lymphoma (Hodgkin and non-Hodgkin),cancertype
Lymphomas with leukemic expression.,cancertype
Lymphoplasmocytic lymphoma,cancertype
male patients with breast cancer,cancertype
Males with breast cancer,cancertype
Malignant melanoma (other than in situ),cancertype
malignant mesothelioma,cancertype
Mantle cell lymphoma,cancertype
Mantle cell lymphoma (MCL),cancertype
MDS,cancertype
MDS patients:,cancertype
MDS should be classified as:,cancertype
Medical clearance by their breast cancer surgeon,cancertype
Medullary renal cell carcinoma,cancertype
Mesothelioma,cancertype
Mixed lineage or biphenotypic acute leukemia,cancertype
Morphologically unclassifiable lymphoma.,cancertype
Multiple myeloma,cancertype
Multiple myeloma (MM),cancertype
multiple myeloma as per IMWG 2014 definition,cancertype
Multiple Myeloma criteria:,cancertype
Multiple myeloma meeting the following criteria:,cancertype
Multiple myeloma with IgM subtype,cancertype
Multiple myeloma.,cancertype
Myelodysplasia,cancertype
Myelodysplastic syndrome,cancertype
Myelodysplastic syndrome (MDS),cancertype
"Myelodysplastic syndrome (MDS), unclassifiable",cancertype
Myelodysplastic syndromes,cancertype
Myelodysplastic/Myeloproliferative Disease,cancertype
Myelodysplatic Syndrome,cancertype
Myeloma eligibility criteria are the following:,cancertype
Myeloproliferative and myelodysplasia syndromes:,cancertype
Myeloproliferative disease.,cancertype
Myeloproliferative disorder,cancertype
Myeloproliferative disorders/myelofibrosis,cancertype
Myeloproliferative neoplasm,cancertype
Myelosplastic syndrome and/or pre-leukemia at any stage,cancertype
New breast cancer diagnosis,cancertype
no diagnosis of breast cancer,cancertype
no histological confirmation of breast cancer,cancertype
Non Hodgkin Lymphoma,cancertype
Non-Hodgkin lymphoma,cancertype
Non-Hodgkin lymphoma (NHL),cancertype
Non-Hodgkin's lymphoma,cancertype
Non-Hodgkin's Lymphoma (NHL),cancertype
NSCLC and gastric adenocarcinoma subjects must have tissue available for HA-selection and PD-L1 testing.,cancertype
Other Solid Tumor,cancertype
Ovarian cancer,cancertype
pancreatic cancer,cancertype
pancreatic cancer recurrence,cancertype
Pancreatic carcinoma,cancertype
Pancreatic tumor size <= 5cm,cancertype
Pancreatic tumors of endocrine or mixed origin.,cancertype
Participants with AML must not have:,cancertype
Participants with CLL:,cancertype
Pathologically confirmed NHL.,cancertype
Pathologically confirmed non-small lung cancer,cancertype
Patient has chronic myelogenous leukemia.,cancertype
"Patient has symptomatic MM, as defined by any of the following:",cancertype
Patient must have cervical cancer,cancertype
Patient must have endometrial cancer,cancertype
Patient must have fallopian tube cancer,cancertype
Patient must have ovarian cancer,cancertype
Patient with AML according to 2016 WHO criteria.,cancertype
Patients must have a histologically documented diagnosis of soft tissue sarcoma,cancertype
Patients must have an acceptable MDS subtype:,cancertype
Patients must have hepatocellular carcinoma.,cancertype
"Patients must have mCRC and, if MSI status is known, non-high MSI status.",cancertype
"Patients must not have testicular involvement; if clinical or ultrasound findings are equivocal, biopsy must be performed; all tests for establishing testicular involvement must be completed within 14 days prior to registration",cancertype
patients with advanced malignant hepatic tumors,cancertype
Patients with cervical esophageal carcinoma,cancertype
Patients with histologically confirmed prostate cancer.,cancertype
Patients with islet cell/neuroendocrine or papillary cystic neoplasm,cancertype
Patients with known diagnosis of breast cancer,cancertype
Patients with lung cancer,cancertype
Patients with MDS,cancertype
Patients with myelodysplastic syndrome,cancertype
Patients with myelodysplastic syndromes (MDS):,cancertype
Patients with neuroendocrine or small cell features are not eligible.,cancertype
Patients with NSCLC LM who are unable to undergo collection of CSF.,cancertype
Patients with previous breast cancer,cancertype
Patients with primary brain tumors.,cancertype
Patients with solitary plasmacytoma,cancertype
Patients with symptomatic MM as defined by IMWG requiring anti-myeloma therapy.,cancertype
Penile carcinoma,cancertype
Phase 2 expansion: Gastric Cancer,cancertype
Phase 2 expansion: MSI high CRC,cancertype
Phase 2 expansion: Ovarian cancer,cancertype
Phase 2 expansion: RCC,cancertype
Phase 2 expansion: SCCHN,cancertype
Phase II Component Advanced RCC associated with,cancertype
Philadelphia-like ALL,cancertype
Plasma cell myeloma,cancertype
Preceding myelodysplastic syndrome (MDS),cancertype
Precursor T-cell lymphoma or leukemia,cancertype
Pre-existing myelodysplastic syndrome:,cancertype
Previous breast cancer,cancertype
Previous diagnosis of CRC,cancertype
Previous diagnosis of lung cancer,cancertype
Previous excisional biopsy of the breast cancer,cancertype
Previous excisional biopsy of the breast cancer.,cancertype
Previous myPlan Lung Cancer test performed,cancertype
Previously diagnosed with lung cancer,cancertype
Prostate Cancer,cancertype
Prostate cancer (PC)-SPES,cancertype
Prostate cancer:,cancertype
r/r CD19+ B-cell NHL that is histologically confirmed by archived tumor biopsy tissue from last relapse and corresponding pathology report. The following types of lymphoma are included:,cancertype
RCC Subpopulation A (1L):,cancertype
renal cell cancer associated with HLRCC.,cancertype
Renal cell carcinoma,cancertype
RENAL CELL CARCINOMA (1L):,cancertype
RENAL CELL CARCINOMA (RCC):,cancertype
Renal insufficiency (attributable to MM),cancertype
Renal insufficiency (attributable to myeloma),cancertype
Self-reported diagnosis of breast cancer,cancertype
Siewert-Stein Type III carcinomas of the stomach.,cancertype
small bowel cancer,cancertype
Small cell prostate cancer,cancertype
Small lymphocytic lymphoma,cancertype
Small lymphocytic lymphoma (SLL),cancertype
Soft tissue sarcomas including but not limited to Ewing's sarcoma and Rhabdomyosarcoma,cancertype
Subjects must have CLL or SLL,cancertype
Subjects that have breast cancer,cancertype
Subjects that have colorectal cancer,cancertype
Subjects with ALL,cancertype
Subjects with lymphoma,cancertype
Subjects with Myelodysplastic Syndrome (MDS):,cancertype
Subjects without a diagnosis of prostate cancer,cancertype
Suspected malignancy of prostate cancer,cancertype
Symptoms clinically consistent with lung cancer.,cancertype
Synchronous contra-lateral lung cancer,cancertype
The diagnosis of DLBCL/HGBCL and assessment of DEL/DHL will be performed per standardized guidelines at local institutions and patients will be enrolled based on local determination,cancertype
Thyroid Carcinoma,cancertype
transformation to acute leukemia,cancertype
Uncommon or rare subtypes of breast cancer.,cancertype
Urothelial Bladder Cancer Expansion Cohort,cancertype
Uveal or ocular malignant melanoma,cancertype
Waldenstr??m's macroglobulinemia,cancertype
Waldenstrom's macroglobulinemia,cancertype
"A marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a QTc interval > 480 milliseconds (ms) (CTCAE grade 1) using Fredericia's QT correction formula (i.e., QTcF).",cardio
"Active coronary artery disease requiring treatment, myocardial infarction within the prior year, New York Heart Association grade III or greater congestive heart failure, cerebro-vascular attack within the prior year, or current serious cardiac arrhythmia requiring medication except atrial fibrillation.",cardio
"Active heart disease including but not limited to symptomatic congestive heart failure (NYHA class 3 or 4), symptomatic coronary artery disease, symptomatic angina pectoris, or symptomatic myocardial infarction.",cardio
Active heart failure of New York Heart Association (NYHA) Functional Capacity Class III or IV or Objective Assessment C or D (Section 21.8),cardio
"Active uncontrolled cardiac disease, including cardiomyopathy, congestive heart failure (New York Heart Association functional classification of >= 2), unstable angina (symptomatic angina pectoris within the past 180 days that required the initiation of or increase in anti-anginal medication or other intervention), myocardial infarction within 12 months of enrollment, or ventricular arrhythmia (except for benign premature ventricular contractions). For patients with lung cancer, the following are additionally excluded: conduction abnormality requiring a pacemaker; supraventricular and/or nodal arrhythmias not controlled with medication; valvular disease with documented compromise in cardiac function; symptomatic pericarditis; any history of myocardial infarction documented by elevated cardiac enzymes or persistent regional wall abnormalities on assessment of LV function; any history of documented congestive heart failure and/or cardiomyopathy.",cardio
Acute myocardial infarction prior to registration,cardio
Acute myocardial infarction within six months of the signing the ICF.,cardio
"Adverse cardiac history (unstable angina, myocardial infarction less than 4 months, New York Heart Association [NYHA] class III or IV congestive heart failure [CHF], ejection fraction [EF] < 40%, uncontrolled arrhythmias).",cardio
"Angina pectoris requiring anti-anginal medication, serious cardiac arrhythmia not controlled by adequate medication, severe conduction abnormality, or clinically significant valvular disease",cardio
"Any condition (in the past 3 months) that would interfere with the determination of safety or efficacy of entrectinib: myocardial infarction, unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident or transient ischemic attack, stroke, symptomatic bradycardia, or uncontrolled arrhythmias requiring medication.",cardio
"Any history of clinically relevant coronary artery disease or myocardial infarction within the last 3 years, New York Heart Association (NYHA) grade III or greater congestive heart failure, cerebro-vascular attack within the prior year, or current serious cardiac arrhythmia requiring medication except atrial fibrillation.",cardio
"Any of the following cardiovascular events within 6 months prior to study entry: myocardial infarction, malignant hypertension, severe/unstable angina, symptomatic congestive heart failure, cerebral vascular accident, or transient ischemic attack",cardio
Arterial thrombotic or embolic events such as cerebrovascular accident (including ischemic attacks) or hemoptysis within 6 months before start of study drug.,cardio
Atrial fibrillation documented within 2 weeks prior to first dose of study drug,cardio
Atrial fibrillation on anti-coagulants,cardio
Atrial fibrillation or other cardiac arrhythmia requiring therapy.,cardio
Atrial fibrillation/flutter,cardio
"Baseline ECG QTc > 470 msec (applying Fridericia correction), defined as the average of individual baseline ECGs.",cardio
Baseline prolongation of QT/QTc interval (repeated demonstration of QTc >= 450 msec for men and 470 msec for women),cardio
Baseline prolongation of the rate-corrected QT interval based on repeated demonstration of QTcF > 450 ms in males or > 470 ms in females or history of long QT interval corrected (QTc) syndrome.,cardio
Baseline QTc exceeding 450 msec (using the Bazett's formula) and/or patients receiving class 1A or class III antiarrythmic agents.,cardio
Baseline QTC interval >= 500 ms (on EKG).,cardio
Cardiac arrhythmia,cardio
Cardiac arrhythmia (Grade 2 or higher [NCI CTCAE version 4.03]) or clinically significant ECG abnormalities,cardio
Cardiac arrhythmias requiring anti-arrhythmic medications (Subjects with rate controlled atrial fibrillation for > 1 month prior to first dose of study treatment are eligible).,cardio
Cardiac disease (history of and/or active disease) that would preclude the use of the drugs included in the treatment regimens; this includes but is not confined to:,cardio
Cardiac disease that would preclude the use of any of the drugs included in the GI002 treatment regimen. This includes but is not limited to:,cardio
"Cardiac or cardiac repolarization abnormality, including any of the following:",cardio
"Cardiac syncope, uncompensated NYHA Class 3 or 4 congestive heart failure, myocardial infarction within the previous six months, unstable angina pectoris, clinically significant repetitive ventricular arrhythmias despite antiarrhythmic treatment, severe orthostatic hypotension, or clinically important autonomic disease",cardio
"Cardiovascular disease including unstable angina, therapy for life-threatening ventricular arrhythmia, or myocardial infarction, stroke, or congestive heart failure within the last 6 months.",cardio
Cardiovascular disorders including:,cardio
Clarification: Subjects with atrial fibrillation controlled for > 30 days prior to dosing are eligible,cardio
Class II-IV heart failure (as defined by New York Heart Association) or a cardiac ejection fraction measurement of less than 50% at baseline,cardio
"Clinically severe cardiovascular disease (e.g., uncontrolled congestive heart failure, uncontrolled angina, history of myocardial infarction within the 6 months, unstable angina or stroke within 30 days of study entry, uncontrolled hypertension or clinically significant arrhythmias not controlled by medication).",cardio
Clinically significant cardiac disease defined by CHF NewYork Heart Association (NYHA) > Class 1; uncontrolledclinically significant arrhythmia in last 6 months; AcuteCoronary Syndrome (ACS) (angina or myocardial infarction) inlast 6 months,cardio
"Clinically significant cardiac illness including New York Heart Association (NYHA) Class III or Class IV heart failure (Appendix III), unstable angina pectoris, myocardial infarction within the past 6 months, or >= Grade 3 cardiac arrhythmias noted <= 14 days prior to registration.",cardio
"Clinically significant cardiac illness including New York Heart Association (NYHA) class III or class IV heart failure, unstable angina pectoris, myocardial infarction within the past 6 months, or >= grade 3 cardiac arrhythmias noted <= 14 days prior to registration",cardio
"Clinically significant cardiac illness including New York Heart Association (NYHA) class III or class IV heart failure, unstable angina pectoris, myocardial infarction within the past 6 months, or >= grade 3 cardiac arrhythmias noted <= 14 days prior to registration.",cardio
"Clinically significant cardiovascular disease, including but not limited to acute myocardial infarction or coronary artery bypass surgery within 6 months prior to enrollment, severe or unstable angina pectoris, New York Heart Association Class III/IV congestive heart failure, ventricular arrhythmias requiring treatment, or left ventricular ejection fraction (LVEF) < 50%",cardio
"Clinically significant cardiovascular/cerebrovascular disease as follows: cerebral vascular accident/stroke ( < 6 months prior to enrollment), myocardial infarction ( < 6 months prior to enrollment), unstable angina, congestive heart failure ( >= New York Heart Association Classification Class II), or serious cardiac arrhythmia.",cardio
"Clinically significant heart disease (e.g., symptomatic congestive heart failure; uncontrolled arrhythmia, or hypertension; history of labile hypertension or poor compliance with an antihypertensive regimen).",cardio
"Clinically significant or active cardiovascular disease, including:",cardio
"Clinically significant or uncontrolled cardiac disease, including unstable angina, acute myocardial infarction within 6 months from Day 1 of study treatment administration, New York Heart Association Class III and IV congestive heart failure, and uncontrolled arrhythmia (participants with pacemaker or with atrial fibrillation and well controlled heart rate are allowed).",cardio
clinically significant valvular disease,cardio
clinically significant valvular heart disease,cardio
"Clinically significant, uncontrolled heart disease and/ or cardiac repolarization abnormalities including any of the following:",cardio
"Clinically unstable cardiac disease, including unstable atrial fibrillation, symptomatic bradycardia, unstable congestive heart failure, active myocardial ischemia, or indwelling temporary pacemaker",cardio
clinically-significant cardiac arrhythmias,cardio
congestive heart failure,cardio
Congestive heart failure (CHF) New York Heart Association (NYHA) Class II-IV or history of CHF NYHA Class III or IV.,cardio
Congestive heart failure (CHF): New York Heart Association (NYHA) Class III (moderate) or Class IV (severe) at the time of screening,cardio
"Congestive heart failure (defined as New York Heart Association Class III or IV), myocardial infarction, unstable angina, coronary angioplasty, coronary stenting, coronary artery bypass graft, cerebrovascular accident or hypertensive crisis within 6 months prior to administration of first dose of study treatment",cardio
Congestive heart failure (New York Heart Association Class III or IV),cardio
congestive heart failure (New York Heart Association Classification >= Class II).,cardio
Congestive heart failure >= Class 3 based on New York Heart Association Functional Classification,cardio
Congestive heart failure defined as New York Heart Association (NYHA) class III-IV (Attachment 2) or Hospitalization for CHF (any NYHA class) within 6 months of study Day 1,cardio
"Congestive heart failure New York Heart Association Class 3 or 4, unstable angina pectoris, serious cardiac arrhythmias.",cardio
Congestive heart failure of New York Heart Association (NYHA) class III or IV,cardio
Congestive heart failure of New York Heart Association (NYHA) Class III or IV (see Appendix 16.2).,cardio
Congestive heart failure requiring medical therapy,cardio
Congestive heart failure requiring use of ongoing maintenance therapy for life-threatening ventricular arrhythmias,cardio
Congestive heart failure with New York Heart Association class III or IV; moderate to severe objective evidence of cardiovascular disease,cardio
Corrected QT (QTc) > 470 milliseconds (msec) on a 12-lead ECG obtained during the Screening period,cardio
"Corrected QT (QTc) > 470 milliseconds (msec) on a 12-lead ECG obtained during the screening period; Note: If a machine reading is above this value, the ECG should be reviewed by a qualified reader and confirmed on a subsequent ECG",cardio
Corrected QT (QTc) interval <= 480 ms.,cardio
Corrected QT (QTc) interval > 470 msec.,cardio
Corrected QT (QTc) interval > 480 msec on baseline electrocardiogram (EKG),cardio
Corrected QT interval (QTc) < 480 ms (as calculated by the Fridericia correction formula).,cardio
Corrected QT Interval (QTc) > 470 milliseconds (msec) on a 12-lead ECG obtained during the screening period,cardio
Corrected QT interval (QTc) > 480 ms determined by the electrocardiogram (ECG) recorder's algorithm on the screening ECG.,cardio
Corrected QT interval (QTc) > 480 msecs using Bazett's formula.,cardio
Corrected QT interval (QTc) > 500 msec within 1 mo before randomization.,cardio
"Demonstrates a QTc interval > 450 ms for men or > 470 ms for women, or known history of congenital QT-prolongation or Torsade de pointes (TdP).",cardio
Documented history of prolonged QTc interval <= 6 months prior to registration,cardio
Documented myocardial infarction <= 6 months prior to registration (pretreatment ECG evidence of infarct only will not exclude patients),cardio
Electrocardiogram (ECG) showing clinically significant abnormality at Screening or showing a QTc interval >= 450 msec in males and >= 470 msec infemales ( >= 4 80 msec for subjects with Bundle Branch Block (BBB) overconsecutive ECGs).,cardio
"Evidence of current uncontrolled cardiovascular conditions, including cardiac arrhythmias, congestive heart failure, angina, or myocardial infarction within the past 6 months. Note: Prior to study entry, any ECG abnormality at screening must be documented by the investigator as not medically relevant.",cardio
"Evidence of current uncontrolled cardiovascular conditions, including cardiac arrhythmias, congestive heart failure, angina, or myocardial infarction within the past 6 months; Note: prior to study entry, any electrocardiogram (ECG) abnormality at screening must be documented by the investigator as not medically relevant",cardio
"Evidence of current uncontrolled cardiovascular conditions, including hypertension, cardiac arrhythmias, congestive heart failure, unstable angina, or myocardial infarction within the past 6 months.",cardio
"Evidence of current uncontrolled cardiovascular conditions, including uncontrolled hypertension, uncontrolled cardiac arrhythmias, symptomatic congestive heart failure, unstable angina, or myocardial infarction within the past 6 months.",cardio
"Evidence of current uncontrolled cardiovascular conditions, including uncontrolled hypertension, uncontrolled cardiac arrhythmias, uncontrolled congestive heart failure, unstable angina, or myocardial infarction within the past 6 months; Note: prior to study entry, any electrocardiogram (ECG) abnormality at screening must be documented by the investigator as not medically relevant",cardio
"For Cohorts 4A, 4B, and 4C: Patients with myocardial infarction or cardiomyopathy onset within the last 6 months are excluded",cardio
"For Part G: Have a baseline electrocardiogram (ECG) (obtained from Day -14 to Day -1) with any of the following abnormal findings: ventricular arrhythmia, evidence of acute myocardial ischemia, heart block (of any degree), or QTc prolongation (defined as Bazett-corrected QT interval >= 450 milliseconds).",cardio
"For Parts F and H: Cardiac disease including myocardial infarction within 6 months, unstable angina, or New York Heart Association (NYHA) Grade II or greater functional impairment.",cardio
"Grade 3 a fib defined as symptomatic and incompletely controlled medically, or controlled with device (e.g. pacemaker), or ablation and",cardio
"Grade 3 a fib defined as symptomatic and incompletely controlled medically, or controlled with device (e.g., pace maker), or ablation",cardio
"Has a medical history of myocardial infarction within 6 months, symptomatic congestive heart failure.",cardio
Has clinically significant heart disease that affects normal activities.,cardio
Has had myocardial infarction within 6 months prior to Cycle 1 or uncontrolled angina within 6 months prior to Cycle 1,cardio
"Has other significant cardiac disease, such as:",cardio
"Has significant cardiovascular impairment within 12 months of the first dose of study drug: such as history of congestive heart failure greater than New York Heart Association (NYHA) Class II, unstable angina, myocardial infarction or cerebrovascular accident (CVA) stroke, cardiac arrhythmia associated with hemodynamic instability, or a left ventricular ejection fraction (LVEF) below the institutional normal range as determined by multigated acquisition scan (MUGA) or echocardiogram.",cardio
"Has significant cardiovascular impairment: history of congestive heart failure greater than New York Heart Association (NYHA) Class II, unstable angina, or stroke within 6 months of the first dose of 9-ING-41, or cardiac arrhythmia requiring medical treatment detected at screening",cardio
"Have clinically significant cardiac disease, including:",cardio
"Have New York Heart Association (NYHA) Class III or IV, cardiac disease, myocardial infarction within the past 6 months prior to Day 1, unstable arrhythmia, or evidence of ischemia on electrocardiogram (ECG) or during Cardiac Stress Testing within 14 days prior to Day (Appendix C)",cardio
"Heart disease as evidenced by myocardial infarction, or aterial thrombotic events in the past 6 months",cardio
Heart valve disease,cardio
"History of acute coronary syndromes (including myocardial infarction unstable angina, coronary artery bypass grafting, coronary angioplasty, or stenting) <= 6 months; OR",cardio
"History of acute coronary syndromes (including unstable angina and myocardial infarction), coronary angioplasty, or stenting within the past 3 months. Subjects with a history of stent placement requiring ongoing antithrombotic therapy (e.g., clopidogrel, prasugrel) will not be permitted to enroll.",cardio
"History of any one of the following cardiovascular conditions within the 6 months prior to initial Screening: Class III or IV heart failure as defined by the New York Heart Association (NYHA), myocardial infarction, unstable angina, uncontrolled or symptomatic atrial arrhythmias, any ventricular arrhythmias, or other clinically significant cardiac disease",cardio
"History of arterial thrombosis (eg, stroke or transient ischemic attack) in the past 6 months prior to study day 1",cardio
History of cardiac disease:,cardio
"History of cardiac disease: congestive heart failure (CHF) Class II or higher according to the New York Heart Association (NYHA); active coronary artery disease, myocardial infarction within 6 months prior to study entry; unevaluated new onset angina within 3 months or unstable angina (angina symptoms at rest) or cardiac arrhythmias requiring anti arrhythmic therapy (beta blockers or digoxin are permitted).",cardio
"History of cerebral vascular accident, unstable angina, myocardial infarction, or ventricular arrhythmia within the last 6 months",cardio
"History of clinically significant or uncontrolled cardiac disease, including recent (within last 12 months) unstable angina or acute myocardial infarction, or New York Heart Association Class III or IV congestive heart failure, or clinically significant arrhythmias not controlled by medication. Subjects with a pacemaker and well-controlled rhythm for at least 1 month before the first dose of study drug will be allowed.",cardio
"History of congestive heart failure <= 84 days (3 months), unless ejection fraction > 40%",cardio
History of documented congestive heart failure (New York Heart Association functional classification III-IV),cardio
"History of myocardial infarction <= 12 months prior to registration, severe/unstable angina, systematic congestive heart failure (CHF) New York Heart Association classification III or IV or CHF requiring use of ongoing maintenance therapy for life-threatening ventricular arrhythmias",cardio
"History of myocardial infarction <= 168 days (6 months) prior to Pre-registration, or congestive heart failure requiring use of ongoing maintenance therapy for life threatening ventricular arrhythmias.",cardio
"History of myocardial infarction <= 6 months prior to registration, or congestive heart failure requiring use of ongoing maintenance therapy for life-threatening ventricular arrhythmias.",cardio
"History of myocardial infarction <= 6 months, current symptomatic CHF or LVEF < 40% or > grade 2 diastolic dysfunction, with no symptoms or signs of heart failure.",cardio
"History of myocardial infarction <= 6 months, or congestive heart failure requiring use of ongoing maintenance therapy for life-threatening ventricular arrhythmias",cardio
"History of myocardial infarction <= 6 months, or congestive heart failure requiring use of ongoing maintenance therapy for life-threatening ventricular arrhythmias.",cardio
History of myocardial infarction or decompensated congestive heart failure (CHF) within the last 6 months,cardio
History of myocardial infarction within the last 6 months.,cardio
"History of myocardial infarction, acute coronary syndrome, or coronary angioplasty/stenting/bypass within the last 6 months; or",cardio
"History of myocardial infarction, cardiac angioplasty or stenting, unstable angina, or other clinically significant cardiac disease within 12 months of enrollment",cardio
"History of myocardial infarction, unstable angina, cardiac or other vascular stenting, angioplasty, or cardiac surgery <= 6 months prior to registration",cardio
History of NCI CTCAE (Version 4.0) Grade >= 3 symptomatic congestive heart failure (CHF) or NYHA criteria Class >= II,cardio
History of NCI CTCAE v5.0 Grade >= 3 symptomatic congestive heart failure or New York Heart Association criteria Class >= II,cardio
"History of non-pharmacologically induced prolonged QTc interval (e.g., repeated demonstration of a QTc interval > 500 milliseconds from ECGs performed at least 24 hours apart).",cardio
History of or active atrial fibrillation or supraventricular tachycardia,cardio
"History of other clinically significant heart disease (eg, cardiomyopathy, congestive heart failure with New York Heart Association functional classification III to IV, myocarditis, pericarditis, or significant pericardial effusion)",cardio
"History of other clinically significant heart disease (eg, cardiomyopathy, congestive heart failure with New York Heart Association functional classification III to IV, pericarditis, significant pericardial effusion, or myocarditis)",cardio
"History of other clinically significant heart disease (eg, cardiomyopathy, congestive heart failure with New York Heart Association functional classification III-IV, pericarditis, significant pericardial effusion, or myocarditis)",cardio
"History of significant cardiac disease, cardiac risk factors, or uncontrolled arrhythmias.",cardio
"History of unstable angina pectoris, symptomatic pericarditis, myocardial infarction, coronary artery bypass grafting or coronary angioplasty <= 12 months prior to registration",cardio
"History or evidence of any other clinically-significant disorder, condition or disease (eg, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia requiring therapy at time of screening) with the exception of those outlined above that, in the opinion of the investigator or Amgen medical monitor, if consulted, would pose a risk to subject safety or interfere with the study evaluation, procedures or completion.",cardio
"History or evidence of cardiac risk including any of the following: history or evidence of current clinically significant uncontrolled arrhythmias or arrhythmia requiring treatment with the exceptions of atrial fibrillation and paroxysmal supraventricular tachycardia; history of acute coronary syndromes within 6 months prior to the first dose of study therapy (including myocardial infarction and unstable angina, coronary angioplasty, or stenting); history of uncontrolled hypertension; or any history of congestive heart failure with most recent ejection fraction < 45% (screening LVEF assessment without history of CHF is not required).",cardio
History or evidence of cardiovascular risk including any of the following:,cardio
History or evidence of current >= Class II congestive heart failure as defined by New York Heart Association (NYHA).,cardio
History or evidence of current >= class II congestive heart failure as defined by the New York Heart Association (NYHA) functional classification system,cardio
"History or presence of an abnormal ECG that, in the investigator's opinion, is clinically meaningful. Screening QTc interval > 470 milliseconds is excluded. For subjects with an intraventricular conduction delay (QRS interval 120 msec), the JTc interval may be used in place of the QTc with sponsor approval. Subjects with left bundle branch block are excluded. QTc prolongation due to a pacemaker may enroll if the JT is normal or with MM approval.",cardio
"History or presence of an abnormal ECG, which, in the investigator's opinion, is clinically meaningful. A screening QTcF interval > 480 milliseconds is excluded. For participants with an interventricular conduction delay (QRS interval > 120 ms), the JTc interval may be used in place of the QTc with sponsor approval (the JTc must be <= 340 milliseconds if JTc is used in place of the QTc).",cardio
"History or presence of an abnormal electrocardiography (ECG) that, in the investigator's opinion, is clinically meaningful. Screening QTc interval > 480 milliseconds is excluded (corrected by Fridericia). In the event that a single QTc is > 480 milliseconds, the subject may enroll if the average QTc for the 3 ECGs is < 480 milliseconds. For subjects with an intraventricular conduction delay (QRS interval > 120 msec), the JTc interval may be used in place of the QTc with sponsor approval. The JTc must be < 340 milliseconds if JTc is used in place of QTc. Subjects with left bundle branch block are excluded.",cardio
"History or presence within the last 12 months of myocardial infarction, clinically relevant valvular heart disease, or congestive heart failure within the last 12 months",cardio
Impaired cardiac function or clinically significant cardiac disease including the following:,cardio
Known cardiac arrhythmia,cardio
Known hereditary predisposition to bleeding or thrombosis; History of arterioembolic event including a stroke or myocardial infarction,cardio
"Mean corrected QT interval (QTc) using the Fridericia method (QTcF) > 480 msec or any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as hypokalemia, congenital long QT syndrome, family history of long QT syndrome, or unexplained sudden death under 40 years of age in a first-degree relative.",cardio
Myocardial Infarction,cardio
Myocardial infarction (MI) or congestive heart failure defined as Class II to IV per the New York Heart Association (NYHA) classification within 6 months of the first dose of ARQ 087 (MI that occurred > 6 months prior to the first dose of ARQ 087 will be permitted),cardio
myocardial infarction < 6 months prior to study entry.,cardio
Myocardial infarction <= 168 days (6 months) prior to registration,cardio
Myocardial infarction or coronary artery bypass graft (CABG) 6 months prior to enrollment,cardio
Myocardial infarction or stroke less than or equal to 6 months prior to registration.,cardio
Myocardial infarction or stroke/transient ischemic attack within the past 6 months,cardio
Myocardial infarction or stroke/transient ischemic attack within the past 6 months ii) Uncontrolled angina within the past 3 months,cardio
Myocardial infarction or unstable angina <= 6 months prior to registration,cardio
Myocardial infarction or unstable angina within <= 6 months of randomization,cardio
"Myocardial infarction within 6 months before date of randomization, or unstable or uncontrolled disease/condition related to or affecting cardiac function (eg, unstable angina, congestive heart failure, New York Heart Association Class III-IV)",cardio
Myocardial infarction within 6 months of study day 1,cardio
Myocardial infarction within 6 months prior to screening,cardio
"Myocardial infarction within ONE months prior to enrollment or has New York Heart Association (NYHA - appendix IV) Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities. Prior to study entry, any ECG abnormality at screening has to be documented by the investigator as not medically relevant.",cardio
"Myocardial infarction, severe/unstable angina, symptomatic congestive heart failure (New York Heart Association [NYHA] Class III or IV (see Appendix D, New York Heart Association [NYHA] Classification) within the previous 2 months; if > 2 months, cardiac function must be within normal limits and the patient must be free of cardiac-related symptoms.",cardio
"Myocardial infarction, unstable angina, stroke, TIA, decompensated heart failure requiring hospitalization or Class III/IV heart failure < 6 months prior to registration.",cardio
New York Heart Association (NYHA) Class III or IV congestive heart failure,cardio
"New York Heart Association class III or IV heart disease, active ischemia or any other uncontrolled cardiac condition such as angina pectoris, clinically significant cardiac arrhythmia requiring therapy, uncontrolled hypertension or congestive heart failure.",cardio
"New York Heart Association Class III or IV, cardiac disease, myocardial infarction within the past 6 months, unstable arrhythmia, or evidence of ischemia on ECG.",cardio
New York Heart Association class II-IV congestive heart failure (Serious cardiac arrhythmia requiring medication),cardio
"New York Heart Association classification III or IV congestive heart failure, known symptomatic coronary artery disease, symptoms of coronary artery disease on systems review, or known cardiac arrhythmias (atrial fibrillation or supraventricular tachycardia [SVT])",cardio
New York Heart Association classification IV cardiovascular disease or symptomatic class III disease (Appendix III).,cardio
New York Heart Association Grade >= 2 congestive heart failure,cardio
No acute congestive heart failure,cardio
No class III or IV congestive heart failure (CHF) within 6 months of registration,cardio
No clinically significant cardiac arrhythmia within 6 months of registration,cardio
"No clinically significant cardiac arrhythmias, stroke or myocardial infarction within 6 months prior to enrollment",cardio
No history of any prior stroke (hemorrhagic or ischemic).,cardio
No history of atrial fibrillation or myocardial infarction.,cardio
"No history of congenital prolonged QTc syndrome, NYHA Class III or IV congestive heart failure (CHF)",cardio
"No history of myocardial infarction <= 6 months prior to pre-registration or New York Heart Association (NYHA) Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities.",cardio
"No history of myocardial infarction <= 6 months prior to registration. No current symptomatic congestive heart failure, uncontrolled angina or uncontrolled cardiac arrhythmias.",cardio
"No ongoing cardiac dysrythmias of Grade >= 2 NCI CTCAE version 4.0, uncontrolled atrial fibrillation (any grade), or QTc interval > 470 msec.",cardio
"No uncontrolled or severe cardiac disease (history of diagnosis of unstable angina, myocardial infarction, symptomatic congestive heart failure, serious uncontrolled cardiac arrhythmia [including atrial flutter/fibrillation], requirement for inotropic support or use of devices for cardiac conditions [pacemakers/defibrillators]). Baseline ejection fraction (by nuclear imaging or echocardiography) must be >= 50%.",cardio
"NYHA Class III or IV heart failure 1094P17AUG.003 Amendment 2 - August 22, 2017",cardio
"NYHA II, III, IV heart failure",cardio
"ongoing cardiac dysrhythmias of NCI CTCAE grade >= 2 or prolongation of the QTcF interval to > 450 msec for males, and < 470 msec for females.",cardio
Other cardiac arrhythmia not controlled with medication,cardio
"Participant has had a myocardial infarction within 6 months prior to registration or New York Heart Association (NYHA) Class III or IV heart failure (APPENDIX D), uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia.",cardio
Patient has a history of congestive heart failure (CHF) Class III/IV according to the New York Heart Association (NYHA) Functional Classification or serious cardiac arrhythmias requiring treatment.,cardio
Patient has any of the following cardiac abnormalities (as determined by treating MD):,cardio
"Patient has clinically significant cardiovascular disease (e.g., uncontrolled or any New York Heart Association Class 3 or 4 congestive heart failure, uncontrolled angina, history of myocardial infarction, unstable angina, or stroke within 6 months prior to study entry, uncontrolled hypertension or clinically significant arrhythmias not controlled by medication).",cardio
"Patient has clinically significant, uncontrolled, cardiovascular disease including congestive heart failure Grade III or IV according to the New York Heart Association (NYHA) classification; myocardial infarction or unstable angina within the previous 6 months, uncontrolled hypertension, or clinically significant, uncontrolled arrhythmias, including bradyarrhythmias that may cause QT prolongation (eg, Type II second degree heart block or third degree heart block).",cardio
"Patient must have no history of recent myocardial infarction (within three months), uncontrolled congestive heart failure, or uncontrolled cardiac arrhythmia",cardio
Patients must have an electrocardiogram (EKG) fewer than 6 days prior to enrollment on the dasatinib arm; patients who have had cardiac assessments by echocardiogram or radionuclide scan at the beginning of induction do not need to have these repeated prior to study entry; correct QT interval (QTc) < 450 msec on baseline electrocardiogram as measured by the Frederica or Bazett formula,cardio
Patients must have corrected QT (QTc) interval < 500/msec (by Bazett's formula) on baseline ECG,cardio
"Patients must not have a history of a resting ECG indicating uncontrolled, potentially reversible cardiac conditions (such as unstable ischemia, uncontrolled symptomatic arrhythmia, congestive heart failure, QTcF prolongation > 500 ms, electrolyte disturbances) or congenital long QCYP3T syndrome.",cardio
"Patients must not have active uncontrolled infection, symptomatic congestive heart failure, unstable angina pectoris or cardiac arrhythmia.",cardio
Patients must not have NYHA Class III or IV heart failure or myocardial infarction within 6 months prior to registration.,cardio
Patients should not have New York Heart Association classification III or IV heart failure at baseline.,cardio
Patients with a history of known coronary artery disease or a myocardial infarction within 12 months prior to pre-registration,cardio
Patients with a history of myocardial infarction that is < 3 months prior to registration.,cardio
Patients with a history of stroke who have not experienced a stroke or transient ischemic attack in the past 2 years and have no residual neurologic deficits as judged by the investigator are allowed,cardio
"Patients with a known history of serious cardiac arrhythmias requiring treatment (exception: controlled atrial fibrillation, paroxysmal supraventricular tachycardia)",cardio
Patients with a prolonged corrected QT interval (QTc) interval ( >= 450 ms),cardio
"Patients with a significant cardiovascular disease or condition, including:",cardio
Patients with active coronary artery disease,cardio
Patients with any class of New York Heart Association (NYHA) congestive heart failure (CHF) or heart failure with preserved ejection fraction (HFPEF),cardio
"Patients with chronic, rate-controlled atrial arrhythmias who do not have other cardiac abnormalities are eligible.",cardio
"Patients with clinically significant cardiac disease (New York Heart Association Classification III or IV (see Appendix A) and cardiac arrhythmias not well controlled with medication), or myocardial infarction within the previous six months.",cardio
Patients with paroxysmal atrial fibrillation or grade < 3 atrial fibrillation for period of at least 6 months are permitted to enroll provided that their rate is controlled on a stable regimen,cardio
Patients with significant cardiac history including:,cardio
permanent atrial fibrillation (a fib) defined as a fib >= 6 months,cardio
"Permanent atrial fibrillation (a fib), defined as continuous a fib for >= 6 months",cardio
"Permanent atrial fibrillation, defined as continuous atrial fibrillation for >= 6 months",cardio
"Permanent atrial fibrillation, defined as continuous atrial fibrillation lasting for >= 6 months",cardio
"Persistent atrial fibrillation, defined as sustained atrial fibrillation lasting > 7 days and/or requiring cardioversion in the 4 weeks before randomization",cardio
Planned concomitant use of medications known to prolong the QT/QTc interval.,cardio
Poorly controlled cardiac arrhythmia despite medication (patient with rate controlled,cardio
"Previous cerebrovascular accident, transient ischemic attack, or sub-arachnoids",cardio
Prior symptomatic congestive heart failure,cardio
Prolongation of QTc interval to > 480 ms.,cardio
"Prolonged QTcF interval > 480 msec or clinically significant cardiac arrhythmia or electrophysiologic disease (eg, placement of implantable cardioverter defibrillator or atrial fibrillation with uncontrolled rate).",cardio
QTc >= 450ms.,cardio
QTc Agents: Patients who are receiving drugs that prolong QTc are not eligible.,cardio
QTc interval <= 450 msec for men or <= 470 msec for women within 2 weeks of registration.,cardio
QTc interval > 450 msec for male subjects; QTc interval > 470 msec for female subjects,cardio
"QTc interval > 480 msec, Brugada syndrome or known history of QTc prolongation or Torsade de Pointes.",cardio
"QTc prolongation > 480 msec, as calculated by either the Bazett or Fridericia formula, as per institutional standard.",cardio
"Received treatment for unstable angina within the prior year, myocardial infarction within the prior year, cerebro-vascular attack within the prior year, history of New York Heart Association grade III or greater congestive heart failure, or current serious cardiac arrhythmia requiring medication except atrial fibrillation.",cardio
"Severe or uncontrolled cardiac disease requiring treatment, congestive heart failure (New York Heart Association) NYHA III or IV, unstable angina pectoris even if medically controlled, history of myocardial infarction during the last 6 months, serious arrhythmias requiring medication (with exception of atrial fibrillation or paroxysmal supraventricular tachycardia).",cardio
Severe valvular disease assessed by transthoracic echocardiogram.,cardio
Severe valvular disease.,cardio
Severe valvular heart disease,cardio
"Significant active cardiac disease within 6 months prior to enrollment in Part A or randomization in Part B , including but not limited to New York Heart Association class 4 cardiac heart failure, unstable angina, myocardial infarction",cardio
"Significant cardiovascular disease (New York Heart Association Class II or greater), myocardial infarction within the 3 months prior to study entry, unstable angina, or cerebral vascular accident / stroke ( < 6 months prior to enrollment), or serious uncontrolled cardiac arrhythmia requiring medication / active intervention, corrected QT interval [QTc] prolongation of >= 470ms and/or prior diagnosis of congenital long QT syndrome.",cardio
"Significant cardiovascular disease (such as New York Heart Association Class II or greater cardiac disease, myocardial infarction, carotid artery disease requiring intervention or treatment, or cerebrovascular accident) within 12 months prior to initiation of study treatment, or unstable arrhythmia or unstable angina within 3 months prior to initiation of study treatment",cardio
"Significant cardiovascular disease (such as New York Heart Association Class II or greater cardiac disease, myocardial infarction, or cerebrovascular accident) within 3 months prior to initiation of study treatment, unstable arrhythmia, or unstable angina",cardio
"Significant cardiovascular disease (such as, but not limited to, New York Heart Association Class III or IV cardiac disease, myocardial infarction within the last 6 months, unstable arrhythmias, or unstable angina) that may limit a patient's ability to adequately respond to a CRS event:",cardio
"Significant cardiovascular disease such as symptomatic congestive heart failure (New York Heart Association Class III or IV), symptomatic coronary artery disease, myocardial infarction within the last 6 months, unstable arrhythmia requiring treatment, unstable angina, or prolonged QTc interval > 480 milliseconds (Grade 2 or higher) (QTc interval calculation at the discretion of the Investigator)",cardio
"Significant cardiovascular disease, such as New York Heart Association cardiac disease (Class II or greater), myocardial infarction, or cerebrovascular accident within 3 months prior to initiation of study treatment, unstable arrhythmia, or unstable angina",cardio
"Significant history of uncontrolled cardiac disease defined as uncontrolled hypertension, unstable angina, myocardial infarction within the last 4 months, and uncontrolled congestive heart failure.",cardio
"Significant symptoms (Grade >= 2) relating to left ventricular dysfunction, cardiac arrhythmia, or cardiac ischemia",cardio
Significant valvular disease; severe regurgitation or stenosis by imaging independent of symptom control with medical intervention; or history of valve replacement.,cardio
"Stroke (including TIA), myocardial infarction, or other ischemic event within 6 mo before randomization.",cardio
"stroke (including TIA, or other ischemic event)",cardio
Subject does not have a history of chronic New York Heart Association (NYHA) class IV heart failure.,cardio
"Subject has a history of class III or IV congestive heart failure (CHF) or severe nonischemic cardiomyopathy, unstable or poorly controlled angina, myocardial infarction, or ventricular arrhythmia within the previous 6 months prior to randomization.",cardio
Subject has a history of major cardiac abnormalities.,cardio
"Subject has clinically significant cardiac disease, including:",cardio
"Subject with a history of Class III or IV congestive heart failure (CHF) or severe nonischemic cardiomyopathy, unstable or poorly controlled angina, myocardial infarction, or ventricular arrhythmia within the previous 6 months prior to starting study treatment.",cardio
"Subjects must not have conditions associated with increased risk of metformin associated lactic acidosis, including New York Heart Association Class III or IV congestive heart failure, history of acidosis of any type, alcoholic liver disease, or habitual intake of 3 or more alcoholic beverages per day.",cardio
"Subjects with a history of class III or IV congestive heart failure or severe non-ischemic cardiomyopathy, unstable or poorly controlled angina, myocardial infarction, or ventricular arrhythmia within the previous 6 months.",cardio
"Subjects with history of myocardial infarction, transient ischemic attack, or stroke in the past 6 months.",cardio
Symptomatic chronic heart failure history or current evidence of clinically significant cardiac arrhythmia and/or conduction abnormality < 6 months prior to screening; except atrial fibrillation and paroxysmal supraventricular tachycardia.,cardio
Symptomatic congestive heart failure,cardio
Symptomatic congestive heart failure (New York Heart Association > Class II) (Appendix F),cardio
Symptomatic congestive heart failure as defined by the New York Heart Association (NYHA) (see Appendix III; does not exclude Class III CHF),cardio
"Symptomatic congestive heart failure, unstable angina pectoris, serious cardiac arrhythmias",cardio
"Testing for LVEF is not required for pre-registration, but patient must not have a recent LVEF < LLN or have symptoms of congestive heart failure.",cardio
The use of concomitant medications that prolong the QT/QTc intervals.,cardio
transient ischemic attack,cardio
Transient ischemic attack > 1 month prior to screening is allowed.,cardio
Transmural myocardial infarction within the last 4 months prior to Step 1 registration.,cardio
Transmural myocardial infarction within the last 6 months.,cardio
Treatment with medications known to cause QTc interval prolongation within the washout periods described in Appendix E unless approved by the Amgen medical monitor.,cardio
Uncontrolled arrhythmias; any Class 3-4 cardiac diseases as defined by the New York Heart Association (NYHA) functional classification (Appendix E),cardio
uncontrolled congestive heart failure or acute myocardial infarction within the previous six months,cardio
uncontrolled symptomatic cardiac arrhythmia,cardio
"Uncontrolled, clinically significant cardiac arrhythmias",cardio
Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months,cardio
Unstable angina or acute myocardial infarction <= 3 months prior to C1D1,cardio
"Unstable cardiac dysrhythmias or persistent prolongation of the corrected QT interval (QTc) (Fridericia) to > 500 msec for males or > 480 msec for females, based on ECG at screening (patients with stable atrial fibrillation on treatment are allowed provided they do not meet any other cardiac or prohibited drug exclusion criterion)",cardio
"Before diagnosing CLL or SLL, mantle cell lymphoma must be excluded by demonstrating a negative FISH analysis for t(11;14)(IgH/CCND1) on peripheral blood or tissue biopsy or negative immunohistochemical stains for cyclin D1 on involved tissue biopsy.",cll-not-mantle
"Before diagnosing CLL or SLL, mantle cell lymphoma must be excluded by demonstrating a negative fluorescent in situ hybridization (FISH) analysis for t(11;14)(immunoglobulin H [IgH]/cyclin D 1 [CCND1]) on peripheral blood or tissue biopsy or negative immunohistochemical stains for cyclin D1 on tissue biopsy",cll-not-mantle
"Before diagnosing CLL or SLL, mantle cell lymphoma must be excluded by demonstrating a negative fluorescent in situ hybridization (FISH) analysis for t(11;14)(immunoglobulin H [IgH]/cyclin D 1 [CCND1]) on peripheral blood or tissue biopsy or negative immunohistochemical stains for cyclin D1 on involved tissue biopsy",cll-not-mantle
"Before diagnosing CLL or SLL, mantle cell lymphoma must be excluded by demonstrating a negative fluorescent in situ hybridization (FISH) analysis for t(11;14)(immunoglobulin H [IgH]/cyclin D1 [CCND1]) on peripheral blood or tissue biopsy or negative immunohistochemical stains for cyclin D1 on involved tissue biopsy",cll-not-mantle
"Before diagnosing CLL or SLL, mantle cell lymphoma must be excluded with  a negative fluorescent in situ hybridization (FISH) analysis for t(11;14)(immunoglobulin H [IgH]/cyclin D1 [CCND1]) on peripheral blood or tissue biopsy or negative immunohistochemical stains for cyclin D1 on involved tissue biopsy",cll-not-mantle
"Before diagnosing CLL or SLL, MCL must be excluded by demonstrating a negative fluorescent in situ hybridization (FISH) analysis for t(11;14)(immunoglobulin H [IgH]/cyclin D1 [CCND1]) on peripheral blood or tissue biopsy or negative immunohistochemical stains for cyclin D1 on involved tissue biopsy",cll-not-mantle
"CLL cells on immunophenotype (performed locally) must reveal a clonal B-cell population, which express the B cell surface markers of CD19 and CD20, as well as the T-cell antigen CD5. Patients with bright surface immunoglobulin expression or lack of CD23 expression in > 10% of cells must lack t(11;14) translocation by interphase cytogenetics.",cll-not-mantle
"Diagnosed with CLL/SLL based on the standard histologic and immunophenotypic criteria described in the WHO classification of lymphoid malignancies, including immunophenotypic confirmation that the tumor cells co-express B cell antigens CD19/20 and CD5. Mantle cell lymphoma should be excluded based on positive staining of the tumor cells for CD23, or the absence of staining of the tumor cells for cyclin D1 or the absence of t(11;14). This diagnosis should be confirmed at a Dana-Farber/Harvard Cancer Center institution within approximately one month after the subject is registered.",cll-not-mantle
"Histologically or flow cytometry confirmed diagnosis of B-CLL/small lymphocytic lymphoma (SLL) according to National Cancer Institute - Working Group (NCI-WG) 1996 guidelines. Patients who lack CD23 expression on their leukemia cells should be examined for (and found NOT to have) either t(11;14) or cyclin D1 overexpression, to rule out mantle cell lymphoma.",cll-not-mantle
Mantle cell lymphoma must be excluded by demonstrating a negative FISH analysis for t(11;14)(IgH/CCND1) before diagnosing CLL or SLL,cll-not-mantle
Mantle cell lymphoma must be excluded by demonstrating a negative FISH analysis for t(11;14)(IgH/CCND1) on peripheral blood or tissue biopsy or negative immunohistochemical stains for cyclin D1 on involved tissue biopsy before diagnosing CLL or SLL.,cll-not-mantle
Negative fluorescent in situ hybridization (FISH) analysis for t(11;14)(IgH/CCND1) on peripheral blood or tissue biopsy (e.g. marrow aspirate) or negative immunohistochemical stains for cyclin D1 staining on involved tissue biopsy (e.g. marrow aspirate or lymph node biopsy).,cll-not-mantle
"Negative fluorescent in situ hybridization (FISH) analysis for t(11;14)(IgH/CCND1) on peripheral blood or tissue biopsy (e.g., marrow aspirate) or negative immunohistochemical stains for cyclin D1 staining on involved tissue biopsy (e.g., marrow aspirate or lymph node biopsy.",cll-not-mantle
"Patients who have histologically or flow cytometry confirmed diagnosis of B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma (B-CLL/SLL) according to NCI-WG 1996 guidelines. The malignant B cells must co-express CD5 with CD19 or CD20. Patients who lack CD23 expression on their leukemia cells should be examined for (and found NOT to have) either t(11;14) or cyclin D1 overexpression, to rule out mantle cell lymphoma. Patients with CLL who have progressed on prior ibrutinib therapy will be eligible. Patients with B-cell prolymphocytic leukemia and patients with Richter's transformation of CLL/SLL are NOT eligible.",cll-not-mantle
"Phase II part of the study: histologically or flow cytometry confirmed diagnosis of BCLL/SLL according to NCI-WG 1996 guidelines; patients who lack CD23 expression on their leukemia cells should be examined for (and found NOT to have) either t(11;14) or cyclin D1 overexpression, to rule out mantle cell lymphoma",cll-not-mantle
"Phase II portion of the study - histologically or flow cytometry confirmed diagnosis of BCLL/SLL according to NCI-WG 1996 guidelines; patients who lack CD23 expression on their leukemia cells should be examined for (and found NOT to have) either t(11;14) or cyclin D1 overexpression, to rule out mantle cell lymphoma",cll-not-mantle
"?��?��????��?��??? Patients with a history of CNS involvement of lymphoma are eligible, provided they received treatment greater than 30 days prior to cycle 1 day 1 and there is no evidence of involvement on most recent assessment",cnsbrain
A history of treated CNS leukemia or lymphoma will be allowed if recent imaging and CSF studies confirm the absence of active CNS disease at the time of study entry,cnsbrain
Active central nervous system (CNS) involvement by lymphoma,cnsbrain
"Active central nervous system (CNS) involvement by lymphoma, including parenchymal and/or lymphomatous meningitis. Subjects with prior CNS involvement by lymphoma must have a baseline magnetic resonance imaging (MRI) and lumbar puncture at screening that demonstrate no active lymphoma in the CNS.",cnsbrain
"Active central nervous system (CNS) involvement by lymphoma, including untreated symptomatic epidural disease",cnsbrain
Active central nervous system (CNS) involvement of Non-Hodgkin's Lymphoma (NHL),cnsbrain
Active central nervous system (CNS) involvement of the underlying malignancy,cnsbrain
Active central nervous system (CNS) lymphoma or cerebrospinal fluid involvement with malignant lymphoma cells that requires therapy,cnsbrain
Active central nervous system leukemia,cnsbrain
"Active central nervous system metastases. Patients with a history of brain metastases may be eligible, provided they have been definitively treated and are clinically stable, after discussion with sponsor. Treated or untreated leptomeningeal disease is not permitted.",cnsbrain
Active central nervous system or meningeal involvement by lymphoma. Subjects with untreated brain metastases or central nervous system (CNS) disease will be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events. Patients with a history of CNS or meningeal involvement must be in a documented remission by cerebrospinal fluid evaluation and contrast-enhanced MRI imaging for at least 90 days prior to registration.,cnsbrain
Active central nervous system or meningeal involvement by lymphoma; patients with a history of central nervous system (CNS) or meningeal involvement must be in a documented remission by cerebrospinal fluid (CSF) evaluation and contrast-enhanced magnetic resonance imaging (MRI) imaging for at least 91 days prior to registration,cnsbrain
Active central nervous system tumor or metastases,cnsbrain
Active CNS disease as identified by positive CSF cytospin at time of enrollment,cnsbrain
Active CNS leukemia,cnsbrain
Active CNS lymphoma.,cnsbrain
Active meningeal or central nervous system disease,cnsbrain
Active or untreated brain metastases,cnsbrain
Active uncontrolled CNS metastases.,cnsbrain
"Active untreated brain or leptomeningeal metastases; in patients with treated central nervous system (CNS) metastases, eligible if symptoms controlled for at least 4 weeks; dexamethasone allowed if total daily dose does not exceed 2 mg",cnsbrain
All patients on Cohort 4A will not have received prior radiation or surgery to their brain. Prior systemic therapy aimed to treat disease in the brain is allowed (i.e. prior systemic standard therapy or protocol systemic therapy for brain mets),cnsbrain
"Any active central nervous system (CNS) lesion (i.e., those with radiographically unstable, symptomatic lesions) and/or leptomeningeal metastases",cnsbrain
brain metastases,cnsbrain
"Brain metastases per MRI or CT at any time prior to registration. NOTE: patients that have had primary therapy for brain metastasis (i.e. surgical resection, whole brain radiation, or SRT even if stable) are not eligible.",cnsbrain
"Brain metastases requiring focal or whole brain radiation will be excluded, as these lesions cannot be biopsied and can have life expectancies < 6 months.",cnsbrain
"Brain metastases, leptomeningeal disease or bone metastases",cnsbrain
Brain or central nervous system (CNS) metastases,cnsbrain
Central nervous system (CNS) disease (including meningeal involvement) by MRI or cerebrospinal fluid exam.,cnsbrain
Central nervous system (CNS) involvement by lymphoma at time of enrollment.,cnsbrain
Central nervous system (CNS) involvement.,cnsbrain
Central nervous system (CNS) lymphoma,cnsbrain
"Central nervous system (CNS) lymphoma; active brain or leptomeningeal metastases, as indicated by positive cytology from lumbar puncture or computed tomography (CT) scan/magnetic resonance imaging (MRI).",cnsbrain
Central nervous system (CNS) metastases or seizure disorder,cnsbrain
Central nervous system involvement,cnsbrain
Central nervous system metastases,cnsbrain
Central Nervous System: Patients with a history of CNS involvement by lymphoma or with relapsed primary CNS lymphoma will be eligible for Cy/TBI arm. Patients with active CNS disease are eligible if they have completed a standard treatment for CNS lymphoma and have no evidence of progressive CNS disease at the time of enrollment,cnsbrain
Clinically stable CNS tumor at the time of screening and not receiving steroids and/or enzyme-inducing anti-epileptic medications for brain metastases,cnsbrain
"CNS involvement of leukemia or lymphoma that is symptomatic and in the opinion of the investigator, cannot be controlled during the interval between enrollment and CAR T cell infusion",cnsbrain
CNS lymphoma,cnsbrain
"CNS lymphoma; active brain or leptomeningeal metastases, as indicated by positive cytology from lumbar puncture or CT scan/magnetic resonance imaging (MRI).",cnsbrain
cns metastases,cnsbrain
CNS metastasis is allowed if the metastasis is treated and there are no signs of progression following treatment. The potential participant must be off steroids for at least 3 days and be stable.,cnsbrain
"CNS: 1-4 brain metastases of maximum size 3cm in longest diameter. However, these should be treated with standard-of-care SRS and will not be defined as target lesions for purposes of this protocol.",cnsbrain
"Concurrent therapy for extramedullary leukemia or central nervous system (CNS) lymphoma: concurrent therapy or prophylaxis for testicular leukemia, CNS leukemia, and CNS lymphoma including standard intrathecal chemotherapy and/or radiation therapy will be allowed as clinically indicated",cnsbrain
Current or history of central nervous system (CNS) lymphoma,cnsbrain
Current or history of CNS lymphoma,cnsbrain
Current or past history of central nervous system (CNS) lymphoma,cnsbrain
Cytologic or unequivocal radiographic confirmation of leptomeningeal metastasis by dural puncture and/or neuroimaging with or without known brain metastasis,cnsbrain
Diagnosis of primary central nervous system (CNS) lymphoma,cnsbrain
Documented central nervous system (CNS) metastases or liver metastasis,cnsbrain
Evaluation of cerebrospinal fluid is only required if CNS involvement by leukemia is suspected during screening,cnsbrain
Evidence of central nervous system metastases.,cnsbrain
Exception: Adequately treated brain metastases documented by baseline computed tomography (CT) or magnetic resonance imaging (MRI) scan that have not progressed since previous scans and do not require corticosteroids (except prednisone <= 5 mg/day or equivalent) for management of CNS symptoms. A repeated CT or MRI following the identification of CNS metastases (obtained at least 2 weeks after definitive therapy) must document adequately treated brain metastases,cnsbrain
Exhibits clinical signs of meningeal involvement of MM.,cnsbrain
"For Cohort A, participants must have histologically confirmed non-CNS primary solid tumors or lymphoma based upon biopsy or surgery at initial diagnosis and/or relapse/progression. The only exception to histologic confirmation is for patients with retinoblastoma.",cnsbrain
Has known active and untreated brain (CNS) metastases and/or carcinomatous meningitis. Subjects with previously treated brain metastases may participate.,cnsbrain
"Has known active central nervous system (CNS) disease and/or lymphomatous involvement. Subjects with previously treated CNS lymphoma and/or lymphomatous meningitis may participate provided they are stable (without evidence of progression by imaging for at least four weeks prior to the first dose of trial treatment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and are not using steroids for at least 7 days prior to trial treatment",cnsbrain
Has known active central nervous system (CNS) involvement.,cnsbrain
Has known active central nervous system (CNS) lymphoma,cnsbrain
"Has known active central nervous system (CNS) lymphoma or lymphomatous meningitis. Subjects with previously treated brain metastases may participate provided they are stable (without evidence of progression by imaging for at least four weeks prior to the first dose of trial treatment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and are not using steroids for at least 7 days prior to trial treatment",cnsbrain
"Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis; subjects with previously treated brain metastases may participate if they are stable, and have no evidence of new or enlarging brain metastases, and are not using steroids for at least 7 days prior to trial treatment",cnsbrain
Has known active CNS lymphoma and/or lymphomatous meningitis,cnsbrain
"Has known active CNS lymphoma and/or lymphomatous meningitis. Participants with previously treated brain metastases may participate provided they are radiologically stable, i.e. without evidence of progression for at least 4 weeks by repeat imaging (note that the repeat imaging should be performed during study screening), clinically stable and without requirement of steroid treatment for at least 14 days prior to first dose of study treatment.",cnsbrain
"Has known active intraparenchymal lymphomatous central nervous system (CNS) lesions and/or lymphomatous meningitis. Subjects with previously treated CNS involvement by lymphoma may participate provided they are stable (without evidence of progression by imaging for at least four weeks prior to the first dose of trial treatment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain lesions, and are not using steroids for at least 7 days prior to trial treatment.",cnsbrain
"Has known symptomatic rapidly progressive brain metastases or leptomeningeal involvement as assessed by CT scan or MRI. Patients with stable asymptomatic brain metastases or leptomeningeal disease or slowly progressive disease are eligible provided that they have not required new treatments for this disease in a 28-day period before the first dose of study drug, and anticonvulsants and steroids are at a stable dose for a period of 14 days prior to the first dose of study drug",cnsbrain
Have a primary central nervous system (CNS) lymphoma.,cnsbrain
Have active central nervous system (CNS) leukemia,cnsbrain
Have clinical evidence or history of central nervous system metastasis,cnsbrain
"Have lymphomatous involvement of the CNS that is symptomatic or requires therapy. However, subjects who have completed treatment for lymphoma involving the CNS and have no further evidence of disease in the CNS may be enrolled in this study.",cnsbrain
Have stable CNS disease on the Computed tomography (CT) or magnetic resonance imaging (MRI) scan within 4 weeks before signing the informed consent compared with prior neuro-imaging.,cnsbrain
Histologically documented PCNSL or histologically documented systemic diffuse large B-cell lymphoma (DLBCL).,cnsbrain
History of carcinomatous meningitis,cnsbrain
History of hemorrhagic CNS metastases,cnsbrain
History of leptomeningeal disease,cnsbrain
"History or clinical evidence of central nervous system (CNS) metastases or leptomeningeal carcinomatosis, except for individuals who have previously treated CNS metastases, are asymptomatic, and have had no requirement for steroids or anti-seizure medication for <= 6 months prior to randomization. Note: Screening with CNS imaging studies (computed tomography [CT] or magnetic resonance imaging [MRI]) is required only if clinically indicated or if the subject has a history of CNS metastases.",cnsbrain
"History or evidence upon physical examination of central nervous system (CNS) disease including primary brain tumor; seizures not controlled with standard medical therapy; and history of cerebrovascular accident (CVA, stroke), transient ischemic attack (TIA), or subarachnoid hemorrhage within 6 months of enrollment.",cnsbrain
However patients with metastatic CNS tumors may participate in this study if the patient is:,cnsbrain
"If a known history of brain metastases, either treated with radiation therapy or untreated, the metastatic disease must be stable in the judgment of the Principal Investigator and must not require ongoing treatment with corticosteroids or anticonvulsants",cnsbrain
"If signs or symptoms suggest suspected CNS metastases, a brain MRI must be performed to confirm absence of CNS disease prior to receiving study drug.",cnsbrain
Individual has no known presence or history of central nervous system (CNS) involvement by lymphoma.,cnsbrain
"Individuals with detectable cerebrospinal fluid malignant cells, brain metastases, or a history of CNS lymphoma",cnsbrain
"Individuals with detectable cerebrospinal fluid malignant cells, brain metastases, or active CNS lymphoma",cnsbrain
"Individuals with detectable cerebrospinal fluid malignant cells, or brain metastases, or with a history of central nervous system (CNS) lymphoma or primary CNS lymphoma, cerebrospinal fluid malignant cells or brain metastases",cnsbrain
"Known active central nervous system (CNS) involvement by lymphoma, including parenchymal and/or lymphomatous meningitis",cnsbrain
"Known active central nervous system (CNS) leukemia, as defined by unequivocal morphologic evidence of lymphoblasts in the cerebrospinal fluid (CSF), use of CNS-directed local treatment for active disease within the prior 28 days, symptomatic CNS leukemia (i.e., cranial nerve palsies or other significant neurologic dysfunction) within 28 days; patients may have history of CNS leukemic involvement if definitively treated with prior therapy and no evidence of active disease (defined as >= 2 consecutive spinal fluid assessments with no evidence of disease) at the time of registration; prophylactic intrathecal chemotherapy is not a criterion for exclusion",cnsbrain
Known active central nervous system metastases and/or lymphomatous meningitis; patients with isolated cerebrospinal fluid (CSF) involvement detectable by flow cytometry are eligible if clinically asymptomatic and if abnormal B cells are reported to be less than 3% by flow cytometry; subjects with previously treated central nervous system (CNS) disease may participate provided:,cnsbrain
Known active CNS metastases and/or carcinomatous meningitis.,cnsbrain
Known brain metastases (unless previously treated and well controlled for a period of at least 3 months).,cnsbrain
Known brain metastases. Patients with known brain metastases must be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events.,cnsbrain
Known central nervous system (CNS) involvement by lymphoma.,cnsbrain
Known central nervous system (CNS) leukemia.,cnsbrain
known central nervous system (CNS) lymphoma involvement,cnsbrain
"Known central nervous system (CNS) metastases requiring treatment, such as surgery, radiation or steroids.",cnsbrain
Known central nervous system involvement by multiple myeloma.,cnsbrain
"Known cerebral metastases, central nervous system (CNS), or epidural tumor.",cnsbrain
Known CNS involvement by lymphoma,cnsbrain
Known CNS lymphoma involvement,cnsbrain
Known CNS lymphoma.,cnsbrain
"Known CNS metastases or history of uncontrolled seizures. Participants with treated brain metastases are eligible if there is no evidence of progression for at least 4 weeks after CNS-directed treatment, as ascertained by clinical examination and brain imaging (MRI or CT scan) during the screening period, and they are on stable or decreasing dose of corticosteroids for at least 1 week.",cnsbrain
Known evidence of active cerebral/meningeal disease; patients may have history of central nervous system (CNS) leukemic involvement if definitively treated with prior therapy and no evidence of active disease (defined as >= 2 consecutive spinal fluid assessments with no evidence of disease) at that time of registration,cnsbrain
Known lymphomatous involvement of the CNS,cnsbrain
Known lymphomatous involvement of the CNS.,cnsbrain
Known or suspected Central Nervous System (CNS) leukemia involvement,cnsbrain
Known parenchymal brain metastasis,cnsbrain
Known untreated or active CNS metastases (progressing or requiring anticonvulsants or corticosteroids for symptomatic control) Patients who have had previous treatment of brain metastases with surgery or radiotherapy may be eligible provided they meet all of the following criteria:,cnsbrain
"Known, untreated brain metastasis. Patients with signs or symptoms of brain metastasis must have a CT or MRI performed within 4 weeks prior to randomization to specifically exclude the presence of radiographically-detected brain metastases",cnsbrain
Leptomeningeal dissemination of brain metastases,cnsbrain
Leptomeningeal metastases,cnsbrain
Medically apparent central nervous system(CNS) lymphoma or leptomeningeal disease,cnsbrain
New diagnosis of primary CNS lymphoma.,cnsbrain
no brain metastases,cnsbrain
No CNS lymphoma or cerebrospinal fluid involvement with malignant lymphoma cells,cnsbrain
no cns metastases,cnsbrain
no evidence of new or enlarging CNS metastasis and,cnsbrain
"No evidence, suspicion and/or history of CNS involvement of lymphoma",cnsbrain
No known lymphomatous involvement of the central nervous system (CNS,cnsbrain
No known lymphomatous involvement of the central nervous system (CNS). A lumbar puncture or neuroimaging prior to study enrollment is not required in the absence of neurological signs or symptoms concerning for CNS involvement.,cnsbrain
No large ( >= 2 cm) hemorrhagic or symptomatic brain metastases until local treatment has been administered (radiation therapy or surgery). Treatment may begin >= 7 days after completion of local treatment. Patients with small ( < 2 cm) and asymptomatic brain metastases are allowed and may be treated with radiation therapy and/or surgery concurrently with Arm A or cycles 1 and 2 of Arm B if deemed medically indicated. Radiation therapy should not be given concurrently with high-dose carboplatin or etoposide.,cnsbrain
"No radiographic evidence, suspicion and/or history of central nervous system (CNS) involvement of lymphoma",cnsbrain
"Participants with active central nervous system (CNS) metastases causing clinical symptoms or metastases that require therapeutic intervention are excluded. Participants with a history of treated -CNS metastases (by surgery or radiation therapy) are not eligible unless they have fully recovered from treatment, demonstrated no progression for at least 2 months, and do not require continued steroid therapy.",cnsbrain
Participants with central nervous system (CNS) involvement by leukemia (CNS2 and CNS3) may be considered eligible after discussions with the study team.,cnsbrain
Participants with known brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events.,cnsbrain
Participants with symptomatic uncontrolled brain metastases. Baseline brain imaging by CT or MRI is required for all patients. Participants with brain metastases that have been treated with prior radiation therapy and are stable on a subsequent scan are allowed. Participants with untreated possible brain metastases that are new at the time of screening and are < 1 cm and asymptomatic are allowed. The participant can receive corticosteroids as long as these were started and at a stable dose at least 28 days prior to treatment.,cnsbrain
"Patient does not have any documented history of central nervous system (CNS) involvement by mantle cell lymphoma; this includes no evidence of parenchymal brain, spinal cord, or cerebrospinal fluid involvement; radiculopathy symptoms from nerve root compression by lymphoma do not constitute CNS involvement",cnsbrain
Patient does not have known brain metastases (testing optional),cnsbrain
Patient has known active or suspected disease involvement of the central nervous system (CNS),cnsbrain
Patient has leptomeningeal disease,cnsbrain
Patient may have CNS 2 status if other sites of leukemia or lymphoma involvement are present.,cnsbrain
"Patient with leukemia phase (peripheral blood involvement), CNS lymphoma [including cerebrospinal fluid (CSF)-only disease], non-measurable disease, gastrointestinal (GI) mantle cell lymphoma (MCL), or bone marrow (BM) MCL are also eligible; gastrointestinal or bone marrow or spleen only patients are allowable and will be analyzed separately",cnsbrain
Patient with untreated or inadequate controlled brain metastases. Brain metastases or lymphoma with CNS involvement previously treated by radiotherapy or other modality and stable for at least 3 months prior to screening without requirement of corticosteroids or anticonvulsants are permitted,cnsbrain
"Patients are ineligible if they have any currently active CNS metastases; patients who have treated brain metastases (with either surgical resection or stereotactic radiosurgery [SRS]) could be eligible to proceed; patients crossing over from dabrafenib/trametinib to nivolumab (nivo)/ipilimumab (ipi) must not have taken any steroids <= 10 days prior to registration for the purpose of managing their brain metastases; patients with only whole brain irradiation for treatment of CNS metastases are ineligible; patients with definitive CNS metastases treated with only WBRT are ineligible; patients with potential CNS metastases that are too small for treatment with either SRS or surgery (e.g. 1-2 mm) and/or are of uncertain etiology are potentially eligible, but need to be discussed with and approved by the study PI",cnsbrain
"Patients having undergone surgical resection of brain metastases will be eligible after they have healed and recovered from the surgical intervention sufficiently to start systemic treatment for NSCLC, as determined by a neurosurgeon.",cnsbrain
patients may have history of central nervous system (CNS) leukemic involvement if definitively treated with prior therapy and no evidence of active disease (defined as >= 2 consecutive spinal fluid assessments with no evidence of disease) at that time of registration,cnsbrain
Patients may not have current/active Central Nervous System (CNS) involvement with mantle cell lymphoma (patients with prior CNS involvement are eligible as long as they have had no evidence of active CNS disease for at least 6 months).,cnsbrain
"Patients must have 3 or fewer brain metastases, of size <= 4 cm",cnsbrain
"Patients must have histologically or cytologically confirmed secondary involvement of an aggressive B-cell lymphoma in the CNS (eye, CSF, and/or brain parenchyma).",cnsbrain
"Patients must not have active central nervous system (CNS) leukemia, as defined by unequivocal morphologic evidence of lymphoblasts in the cerebrospinal fluid (CSF), use of CNS-directed local treatment for active disease within the prior 28 days",cnsbrain
Patients must not have known central nervous system metastasis or a history of central nervous system (CNS) metastases; patients with leptomeningeal disease are not eligible,cnsbrain
Patients who have known central nervous system (CNS) lymphomatous involvement are not eligible,cnsbrain
"Patients who have undergone treatment for their brain metastases with whole brain radiotherapy, stereotactic radiosurgery, or surgical resection must be clinically stable and recovered from all procedures at the time of study enrollment.",cnsbrain
"Patients who have: any other histological type of lymphoma including, e.g., primary mediastinal (thymic) large B-cell lymphoma (PMBL) or Burkitt's lymphoma, primary refractory DLBCL, patients with known ""double/triple hit"" DLBCL genetics, CNS lymphoma involvement in present or past medical history",cnsbrain
Patients with a prior history of brain metastases are eligible provided:,cnsbrain
Patients with active and/or untreated CNS lymphoma will not be eligible.,cnsbrain
Patients with active brain metastases. A scan to confirm the absence of brain metastases is not required for asymptomatic patients.,cnsbrain
"Patients with active brain metastasis or leptomeningeal involvement with brain metastases who are asymptomatic, and whose lesions by imaging are at least stable and without interim development of new lesions for at least 4 weeks may be enrolled. Patients who require continued therapy with steroid medication for management for their brain metastases are eligible; dosing must be stable for at least 4 weeks prior to randomization.",cnsbrain
Patients with active central nervous system (CNS) involvement with lymphoma are not eligible,cnsbrain
"Patients with active central nervous system (CNS) metastasis and/or carcinomatous meningitis; however, patients with CNS metastasis (except leptomeningeal disease) who have completed a therapy and are clinically stable for 3 weeks as defined as:",cnsbrain
Patients with active known central nervous system (CNS) involvement of CLL or lymphoma; (patients with history of CNS CLL or lymphoma now in remission are eligible for the trial),cnsbrain
Patients with brain metastases (either remote or current) or presence of carcinomatous meningitis are not eligible.,cnsbrain
"Patients with brain metastases are eligible if metastases have been adequately treated and neurologically returned to baseline (except for residual signs or symptoms related to the CNS treatment) for at least two weeks prior to C1D1. In addition, must also be no requirement for immunosuppressive doses of systemic corticosteroids ( > 10 mg/day prednisone equivalents) for at least 2 weeks prior to study drug administration.",cnsbrain
Patients with brain metastases treated with whole brain radiation that have been stable for 2 months are eligible; patients with brain metastases treated with gamma knife or surgery are allowed to participate after 2 weeks have elapsed since their procedure. Subjects are excluded if they have leptomeningeal or metastases causing spinal cord compression that are symptomatic or untreated or not stable for >= 3 months (must be documented by imaging) or requiring corticosteroids. Subjects on a stable dose of corticosteroids > 1 month or who have been off of corticosteroids for at least 1 week can be enrolled with approval of the medical monitor,cnsbrain
"Patients with brain metastases. However, if radiation therapy and/or surgery has been completed and serial evaluation by CT (with contrast enhancement) or MRI over a minimum of one month demonstrates the disease to be stable and if the patient remains must have no need for treatment with steroids",cnsbrain
Patients with brain metastasis will be included as long as they are free of neurologic symptoms related to metastatic brain lesions and who do not require or receive systemic corticosteroid therapy in the 14 days prior to beginning MK-3475 therapy,cnsbrain
Patients with central nervous system (CNS) involvement refractory to intrathecal chemotherapy and/or standard cranial-spinal radiation,cnsbrain
"Patients with central nervous system (CNS) involvement, unless they meet ALL of the following criteria:",cnsbrain
Patients with CNS tumors or known CNS metastases will be excluded from this trial; patients with a history of CNS metastases that have been previously treated may enroll if sequential imaging shows not evidence for active disease; patients with extra axial disease (e.g. skull [bone] metastasis that do not invade the dura) may enroll if there is no evidence for CNS edema associated with the lesion,cnsbrain
Patients with CNS3 disease will be eligible if CNS disease is responsive to therapy,cnsbrain
Patients with current or prior central nervous system (CNS) involvement with lymphoma are not eligible,cnsbrain
"Patients with definitively treated brain metastases may be considered for Enrollment, and must be stable for >= 14 days prior to beginning the NMA LD preconditioning regimen",cnsbrain
patients with history of active CNS disease should have at least two negative spinal fluid evaluations before being considered eligible,cnsbrain
"Patients with history or evidence upon physical examination of central nervous system (CNS) disease, including primary brain tumor, seizures which are not controlled with non-enzyme inducing anticonvulsants, and/or epidural disease, or history of cerebrovascular accident (CVA, stroke), transient ischemic attack (TIA) or subarachnoid hemorrhage within six months prior to the first date of study treatment. Those with brain metastases are permitted as long as they have been treated with brain radiation therapy and have been documented stability 4 weeks following completion of brain radiation therapy.",cnsbrain
"Patients with history or evidence upon physical examination of CNS disease, including primary brain tumor, seizures which are not controlled, any brain metastases and/or epidural disease, or history of cerebrovascular accident (CVA, stroke) within six months prior to the first date of study treatment.",cnsbrain
Patients with known active central nervous system (CNS) disease,cnsbrain
Patients with known active central nervous system (CNS) disease; patients with history of active CNS disease should have at least two negative spinal fluid evaluations before being considered eligible,cnsbrain
"Patients with known active central nervous system (CNS) involvement by lymphoma, including leptomeningeal involvement",cnsbrain
Patients with known active CNS leukemia.,cnsbrain
Patients with known brain metastases,cnsbrain
Patients with known brain metastases should be excluded from this clinical trial,cnsbrain
Patients with known brain metastases should be excluded from this clinical trial because of their poor prognosis and because of the possible increased risk of bleeding if treatment with antiangiogenic agents is provided.,cnsbrain
Patients with known brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events,cnsbrain
Patients with known central nervous system (CNS) disease are allowed if there is no evidence of active CNS disease as documented by negative imaging or spinal fluid analysis carried out at least 2 weeks prior to study drug administration,cnsbrain
"Patients with known central nervous system (CNS) involvement may be excluded because of poor prognosis and concerns regarding progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events; however, if CNS disease is cleared before the treatment with nivolumab, patients could be allowed if no permanent CNS damage",cnsbrain
Patients with known leptomeningeal or brain metastases or spinal cord compression should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events,cnsbrain
Patients with known or suspected CNS involvement of lymphoma.,cnsbrain
Patients with leptomeningeal metastases.,cnsbrain
"Patients with previously treated brain metastases may participate provided they are stable (without evidence of progression by imaging for at least 3 months prior to the first dose of trial treatment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and are not using steroids for at least 7 days prior to trial treatment",cnsbrain
Patients with primary CNS lymphoma who develop systemic recurrence following standard therapy may be included as long as no active CNS disease is present at the time or enrollment,cnsbrain
"Patients with primary CNS lymphoma who develop systemic recurrence following standard therapy may be included as long as no active CNS disease is present at the time or enrollment; similarly, patients with secondary involvement of the CNS from a systemic lymphoma may be included as long as the CNS disease has been optimally treated and they demonstrate no evidence of active CNS disease",cnsbrain
"Patients with Richter's transformation, and Burkitt lymphoma, and primary DLBCL of CNS.",cnsbrain
"Patients with Richter's transformation, Burkitt's lymphoma, and primary DLBCL of the CNS.",cnsbrain
Patients with symptomatic CNS leukemia or patients with poorly controlled CNS leukemia,cnsbrain
"Patients with the following diagnoses: CNS 3 leukemia, CNS lymphoma, active GVHD, Downs Syndrome, CNS or testicular relapse, optic nerve or retinal involvement requiring radiation therapy",cnsbrain
"Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression, and they have been off steroids for at least 4 weeks prior to Step 1 registration and remain clinically stable.",cnsbrain
"Patients with untreated brain metastases, spinal cord compression, or evidence of symptomatic brain metastases or leptomeningeal disease as noted on computed tomography (CT) or magnetic resonance imaging (MRI) scans should be excluded from this clinical trial, since neurologic dysfunction may confound the evaluation of neurologic and other adverse events (AEs); screening brain MRI (or CT if MRI contraindicated) will be required for patients with recurrent NSCLC, TNBC, or SCLC; brain MRI (or CT if MRI contraindicated) is required for PDAC if clinically suspected by patient's symptoms or neurological exam; should patient found to have brain metastasis, treatment of brain metastasis must precede the participation in this study; for patients with known and treated brain metastases is allowed in this study if they fulfill the following criteria:",cnsbrain
Patients with untreated or symptomatic metastatic central nervous system (CNS) disease. However patients with CNS involvement may participate if:,cnsbrain
Phase 1 and Phase 2: confirmed diagnosis of previously treated relapsed and/or refractory lymphoma; patients with central nervous system (CNS) lymphoma are included,cnsbrain
Presence of brain metastases.,cnsbrain
Presence of brain metastasis.,cnsbrain
Presence of central nervous system (CNS) lymphoma,cnsbrain
Presence of central nervous system (CNS) lymphoma or leptomeningeal disease.,cnsbrain
"Presence of symptomatic central nervous system metastatic disease or disease that requires local therapy such as radiotherapy, surgery, or increasing dose of steroids within the prior 2 weeks",cnsbrain
"Presence of untreated or symptomatic central nervous system metastases, or central nervous system metastases that currently require local therapy (such as radiotherapy or surgery), or require doses of corticosteroids within the prior 4 weeks",cnsbrain
"Presence of, or history of, central nervous system (CNS) lymphoma, leptomeningeal disease or spinal cord compression.",cnsbrain
"Previously untreated brain metastases. Patients who have received radiation or surgery for brain metastases are eligible if therapy was completed at least 3 weeks previously and there is no evidence of central nervous system disease progression, mild neurologic symptoms, and no requirement for chronic corticosteroid therapy.",cnsbrain
Primary central nervous system (CNS) lymphoma,cnsbrain
Primary CNS lymphoma (PCNSL),cnsbrain
Primary CNS Lymphoma in high risk elderly patients,cnsbrain
"Relapsed or refractory primary central nervous system (CNS) diffuse large B cell lymphoma (PCNSDLBCL) with a brain lesion >= 1 cm, or with cerebrospinal fluid (CSF) relapse with positive CSF cytology, or with ocular relapse with positive ocular tissue biopsy",cnsbrain
Research participant with central nervous system (CNS) leukemic involvement that is refractory to intrathecal chemotherapy and/or cranio-spinal radiation but effectively treated to completion remission ( < 5 white blood cell[WBC]/mm^3 and no blast in cerebrospinal fluid [CSF]) is eligible to proceed with lymphodepletion,cnsbrain
Subject has a history of central nervous system involvement by their myeloma.,cnsbrain
Subject has clinically active central nervous system leukemia.,cnsbrain
Subject has known active central nervous system (CNS) metastases and/or carcinomatous meningitis.,cnsbrain
Subject has or is suspected of having central nervous system (CNS) leukemia,cnsbrain
Subject with known central nervous system (CNS) involvement with myeloma.,cnsbrain
Subject with primary CNS lymphoma (defined as isolated CNS lymphoma without systemic involvement) are excluded from study,cnsbrain
Subjects may have previously treated brain or Central Nervous System (CNS) metastasis with radiation completed at least 2 weeks prior to registration. Prior radiation to places other than CNS disease must be completed at least 14 days prior to registration. Any number of prior radiation therapy regimens is allowed provided all toxicity of prior therapy is resolved to grade 1 or less.,cnsbrain
Subjects must be <= 90 days from diagnosis of PCNSL in the brain or spine; time from pathologic diagnosis to initiation of treatment should be specified; subjects with history of only ocular lymphoma are eligible if < 90 days since documented brain parenchymal disease (by imaging or by biopsy),cnsbrain
Subjects who document stable and central nervous system metastases and are off steroids for more than 4 weeks may be enrolled in the study,cnsbrain
Subjects with <= 3 brain metastases and each <= 1 cm size that were treated with either surgical resection and/or radiation therapy are eligible for study participation provided,cnsbrain
Subjects with active central nervous system (CNS) metastases causing clinical symptoms or metastases that require therapeutic intervention are excluded,cnsbrain
Subjects with known central nervous system (CNS) disease,cnsbrain
Subjects with known symptomatic central nervous system tumors or known central nervous system metastases or leptomeningeal disease requiring steroids,cnsbrain
Subjects with prior CNS involvement by lymphoma must have a baseline magnetic resonance imaging (MRI) and lumbar puncture at screening that demonstrate no active lymphoma in the CNS,cnsbrain
Subjects with radiologically-detected CNS lymphoma or CNS 3 disease (presence of >= 5/µL WBCs in CSF and cytospin positive for blasts [in the absence of a traumatic lumbar puncture] and/or clinical signs of CNS leukemia).,cnsbrain
Subjects with radiologically-detected CNS lymphoma or CNS 3 disease (presence of greater than or equal to 5/micro L WBCs in CSF and cytospin positive for blasts [in the absence of a traumatic lumbar puncture] and/or clinical signs of CNS leukemia and/or radiographic signs of leptomeningeal disease),cnsbrain
"Subjects with symptomatic brain metastases will be excluded from trial secondary to poor prognosis; however, subjects who have had treatment for their brain metastasis and whose brain disease is stable without steroid therapy for at least 3 months may be enrolled.",cnsbrain
Subjects with untreated Central nervous system (CNS) metastases are excluded,cnsbrain
Symptomatic and/or untreated Brain Metastases,cnsbrain
Symptomatic brain metastases or brain metastases requiring chronic steroids to control symptoms.,cnsbrain
Symptomatic CNS metastases.,cnsbrain
Symptomatic or unstable brain metastases. (Note: Asymptomatic patients with metastatic brain disease who have been on a stable dose of corticosteroids for treatment of brain metastases for at least 14 days are eligible to participate in the study.) Patients with primary central nervous system tumors are eligible.,cnsbrain
Symptomatic or unstable brain metastases. (Note: Subjects with asymptomatic brain metastases are eligible to participate in the study.) Subjects with primary CNS tumors are eligible.,cnsbrain
"Symptomatic or untreated Central nervous system (CNS) disease, Subjects with a history of CNS disease (leukemia, lymphoma or myeloma) are permitted to enrol if they have previously received appropriate therapy and CNS remission has been documented. Subject with primary CNS lymphoma (defined as isolated CNS lymphoma without systemic involvement) are excluded from study.",cnsbrain
"Symptomatic uncontrolled brain or leptomeningeal metastases. (To be considered  controlled,  central nervous system [CNS] disease must have undergone treatment [eg, radiation or chemotherapy] at least 2 weeks prior to first IMP administration. The patient must not have any new or progressive signs or symptoms related to the CNS disease and must be taking < 10mg of prednisone or equivalent per day or no steroids). Patients who have untreated brain metastases and who are not symptomatic may enroll if the investigator feels that treatment of these metastases is not indicated. Patients with spinal cord compression may be considered for enrolment if they have received definitive treatment for this and evidence of clinically stable disease (SD) for 28 days.",cnsbrain
The brain metastases are stable on pre-registration imaging,cnsbrain
The brain metastases have been treated,cnsbrain
The patient is asymptomatic from the brain metastases at enrollment,cnsbrain
The patient may not have active brain metastases or epidural disease. Patients with brain metastases previously treated with whole brain radiation or radiosurgery or subjects with epidural disease previously treated with radiation or surgery who are asymptomatic and do not require steroid treatment for at least 2 weeks before starting study treatment are eligible. Neurosurgical resection of brain metastases or brain biopsy is permitted if completed at least 3 months before starting study treatment. Baseline brain imaging with contrast-enhanced computed tomography (CT) or magnetic resonance imaging (MRI) scans for subjects with known brain metastases is required to confirm eligibility.,cnsbrain
The subject has active brain metastases or epidural disease; subjects with brain metastases previously treated with whole brain radiation or radiosurgery or subjects with epidural disease previously treated with radiation or surgery who are asymptomatic and do not require steroid treatment for at least 2 weeks before starting study treatment are eligible; neurosurgical resection of brain metastases or brain biopsy is permitted if completed at least 3 months before starting study treatment; baseline brain imaging with contrast-enhanced CT or magnetic resonance imaging (MRI) scans for subjects with known brain metastases is required to confirm eligibility,cnsbrain
Those with leptomeningeal metastases as the only site of CNS disease,cnsbrain
To bone or brain metastasis within 14 days of the first dose of study treatment,cnsbrain
Uncontrolled brain metastases,cnsbrain
Uncontrolled central nervous system (CNS) metastases (previously treated with radiation and off steroids is acceptable).,cnsbrain
Uncontrolled CNS metastases,cnsbrain
"Uncontrolled metastatic disease to the central nervous system. To be eligible, CNS metastases should have been treated with surgery and/or radiotherapy and the patient should have been receiving a stable dose of steroids for at least 2 weeks prior to randomisation, with no deterioration in neurological symptoms during this time",cnsbrain
"Untreated brain metastases. Subjects must have completed treatment for brain metastasis, and be neurologically stable off steroids, for at least 28 days prior to first dose of study drug",cnsbrain
Untreated or symptomatic brain metastases or leptomeningeal disease,cnsbrain
Untreated or symptomatic brain metastases requiring corticosteroid therapy (no corticosteroid use for this purpose in the preceding 4 weeks),cnsbrain
With clinical signs of central nervous system (CNS) involvement of MM.,cnsbrain
Acceptable renal function with serum creatinine <= 1.5 x ULN or a calculated creatinine clearance >= 50 mL/min using the Cockcroft-Gault or Modification of Diet in Renal Disease formulas.,creatinine
Acceptable renal function with serum creatinine <= 1.5 x ULN or a calculated creatinine clearance >= 60 mL/min using the Cockcroft-Gault or Modification of Diet in Renal Disease formulas.,creatinine
"Acceptable renal function with serum creatinine <= 1.5 x ULN or a calculated creatinine clearance >= 60 mL/min using the Cockcroft-Gault, CKD-EPI or MDRD formulas.",creatinine
Actual lab serum creatinine value with a minimum of 0.8 mg/dL,creatinine
"Adequate Renal and Metabolic Function defined as creatinine clearance or radioisotope Glomerular filtration rate (GFR) >= 70 millilitre (mL)/ (min)/1.73 meter (m)^2 or A serum creatinine based on age/gender as follows, age 1 to < 2 years (male-0.6 milligrams (mg)/dL, female-0.6 mg/dL), age 2 to < 6 years (male-0.8 mg/dL, female-0.8 mg/dL), age 6 to < 10 years (male-1 mg/dL, female-1 mg/dL), age 10 to < 13 years (male-1.2 mg/dL, female-1.2 mg/dL), age 13 to < 16 years (male-1.5 mg/dL, female-1.4 mg/dL), age >= 16 years (male-1.7 mg/dL, female-1.4 mg/dL), urine creatinine ratio of < 1 or a urinalysis that is negative for protein; or, 24-hour urine protein level < 1000 mg/dL, adequate thyroid function ,no more than Grade 1 abnormalities of potassium, calcium (confirmed by ionized calcium), magnesium and phosphorous.",creatinine
Adequate renal function as demonstrated by serum creatinine <= 1.5 x ULN or creatinine clearance > 60 mL/min as calculated by the Cockcroft and Gault formula,creatinine
Adequate renal function defined by either creatinine <= 1.5 * ULN or an estimated creatinine clearance (CCr) > 40 milliliter (mL) per minute (min) according to the Cockcroft-Gault formula or by measure of CCr from 24-hour urine collection.,creatinine
Adequate renal function within 28 days before randomization defined as serum creatinine <= ULN for the lab and measured or calculated creatinine clearance > 60 mL/min (see Appendix D for instructions regarding calculation of creatinine clearance).,creatinine
"Adequate renal function, defined as estimated serum creatinine clearance > 30 mL/minute calculated using the Cockcroft-Gault equation (see Appendix E).",creatinine
"Adequate renal function, defined as serum creatinine <= 1.5 x upper limit of normal (ULN) or calculated CrCl (Cockcroft-Gault; see Appendix D) > 60 mL/min",creatinine
Adequate renal function: creatinine clearance >= 60 mL/min (Cockcroft and Gault),creatinine
"Adequate renal function: estimated creatinine clearance of >= 60 mL/min, calculated using the formula of Cockroft and Gault (140-Age) ?��?��????��?��???��?��????��?��??? Mass (kg)/(72 ?��?��????��?��???��?��????��?��??? creatinine mg/dL); multiply by 0.85 if female.",creatinine
"Adequate renal function: Serum Creatinine <~1.5 x normal, or Creatinine clearance of 70 mL/min/1.73 mE2 or an equivalent GFR as determined by the institutional normal range",creatinine
An estimated Glomerular Filtration Rate (eGFR) of at least 45 mL/min/1.73 m2,creatinine
Calc. Creatinine Clearance > 20 ml/min (using either CKD-EP1 equation or Cockroft-Gault formula).,creatinine
Calc. Creatinine Clearance >= 60 mL/min Calculated using the Cockcroft-Gault formula,creatinine
Calculated (calc.) creatinine clearance >= 50 mL/min by Cockcroft-Gault.,creatinine
Calculated creatinine clearance (CrCl) >= 30 mL/min (Cockroft & Gault formula or MDRD formula for patients aged >= 65 years).,creatinine
Calculated creatinine clearance (using Cockcroft-Gault equation below)* >= 30 mL/min,creatinine
Calculated creatinine clearance (using Cockcroft-Gault equation) >= 30 mL/min.,creatinine
Calculated creatinine clearance (using Cockcroft-Gault formula) >= 45 mL/min,creatinine
Calculated Creatinine Clearance < 30 mL/min (as calculated by Cockcroft-Gault formulaa or Modification of Diet in Renal Disease [MDRD] formulab),creatinine
Calculated creatinine clearance = (140 - age) x wt* (kg) x 0.85 (if female) 72 Creatinine** (mg/dl),creatinine
Calculated creatinine clearance >= 0 mL/min (see Section 9.4.15.1).,creatinine
Calculated creatinine clearance >= 30 mL/min,creatinine
Calculated creatinine clearance >= 40 mL/minute,creatinine
Calculated creatinine clearance >= 45 mL/min by Cockcroft-Gault equation,creatinine
Calculated creatinine clearance >= 45 ml/min using the Cockcroft-Gault formula,creatinine
Calculated creatinine clearance >= 45 ml/min using the Cockcroft-Gault formula below:,creatinine
Calculated creatinine clearance >= 50 mL/min,creatinine
calculated creatinine clearance >= 50 mL/min (MDRD formula),creatinine
Calculated creatinine clearance >= 50 mL/minute as determined by Cockcroft-Gault (using actual body weight) or 24-hour urine creatinine clearance,creatinine
Calculated creatinine clearance must be >= 30 ml/min using the Cockcroft-Gault formula,creatinine
Calculated creatinine clearance must be >= 45 ml/min using the Cockcroft-Gault formula below:,creatinine
Calculated creatinine clearance must be >= 50 ml/min using the Cockcroft-Gault formula below:,creatinine
Calculated creatinine clearance must be >= 50 ml/min using the Cockcroft-Gault formula.,creatinine
Calculated GFR >= 55 mL/min.,creatinine
Calculated glomerular filtration rate (GFR*) > 40 mL/min or Serum creatinine <= 1.5 x ULN,creatinine
Calculated or measured creatinine clearance (CrCl) of >= 30 mL/minute calculated using the formula of Cockcroft and Gault [(140 - Age) x Mass (kg) / (72 x serum creatinine mg/dL)]. Multiply result by 0.85 if female.,creatinine
Calculated or measured creatinine clearance >= 30 ml/min,creatinine
Calculated or measured creatinine clearance >= 30 ml/min (see Appendix II).,creatinine
calculated or measured creatinine clearance >= 30 mL/min using the Cockcroft-Gault equation OR via 24-hour urine collection with plasma and urine creatinine concentrations.,creatinine
"Calculated or measured creatinine clearance >= 30 ml/min, obtained <= 14 days prior to registration",creatinine
Calculated or measured creatinine clearance 1 >= 50 mL/min,creatinine
CCr = {((l40 &ndash; age) x actual body weight)/ (72 x SCr)} x 0.85 (if female).,creatinine
CrCl >= 30 mL/min as measured by 24-hour urine collection or estimated by the Cockcroft-Gault criteria,creatinine
Creatinine < 1.5 x institutional ULN,creatinine
creatinine < 1.5 x ULN OR,creatinine
Creatinine < 1.5 x upper limits of normal (ULN),creatinine
creatinine < institutional upper limit of normal (ULN) OR creatinine clearance >= 60 mL/min/1.73 m2 for patients with creatinine levels above institutional normal.,creatinine
Creatinine <= 1.0 mg/dL,creatinine
Creatinine <= 1.0 mg/dL or creatinine clearance >= 45 ml/min using the Cockcroft-Gault formula below: Cockcroft-Gault Equation:,creatinine
Creatinine <= 1.5 mg/dL and estimated glomerular filtration rate (eGFR) >= 60 mL/min/1.73m2 or measured creatinine clearance >= 60 mL/min,creatinine
"Creatinine <= 1.5 mg/dl OR creatinine > 1.5 mg/dl, estimated creatinine clearance must be >= 55 mL/minute by CockcroftGault formula: Cockcroft-Gault Equation:",creatinine
Creatinine <= 1.5 mg/dL OR creatinine clearance >= 45 mL/min,creatinine
Creatinine <= 1.5 x institutional upper limit of normal (ULN) or creatinine clearance (CrCl) >= 60 mL/min using Cockcroft-Gault formula within 14 days prior to registration.,creatinine
Creatinine <= 1.5 x institutional upper limit of normal OR creatinine clearance >= 60 mL/min/1.73 m2 for subjects with creatinine levels above institutional normal,creatinine
Creatinine <= 1.5 x ULN,creatinine
Creatinine <= 1.5 X ULN OR,creatinine
Creatinine <= 1.5 x ULN OR creatinine clearance > 50 ml/min as calculated by the CockcroftGault equation,creatinine
Creatinine <= 1.5 x ULN or creatinine clearance >= 30 mL/min (calculated using the Cockcroft-Gault formula),creatinine
Creatinine <= 1.5 x ULN OR creatinine clearance >= 60 mL/min/1.73 m^2 for patients with creatinine levels above institutional normal.,creatinine
Creatinine <= 1.5 x ULN.,creatinine
Creatinine <= 1.5 x ULN; OR,creatinine
Creatinine <= 1.5 x upper limit of normal (ULN) or,creatinine
Creatinine <= 1.5 x upper limit of normal (ULN) OR Measured or calculated creatinine clearance (GFR can also be used in place of creatinine or CrCl) >= 30 mL/min for subject with creatinine level > 1.5 x institutional ULN,creatinine
Creatinine <= 1.5 x upper limit of normal ULN,creatinine
Creatinine <= 2 mg/dL,creatinine
Creatinine <= 2 x ULN,creatinine
Creatinine <= 2.0 mg/dL,creatinine
Creatinine <= 2.0 mg/dL or creatinine clearance >= 50 mL/min,creatinine
Creatinine <= 2.0 mL/dL and creatinine clearance (CrCl) >= 30 mL/min (either calculated or per 24-hr urine collection).,creatinine
Creatinine <= 3 x upper limit of normal (ULN)or Creatinine Clearance >= 30 mL/min/1.73m,creatinine
Creatinine <= IULN OR creatinine clearance >= 60 mL/min/1.73 m^2 for patients with creatinine levels above institutional normal.,creatinine
creatinine <= the institutional upper limit of normal OR creatinine clearance >= 60 mL/min/1.73 m2 for patients with creatinine levels above institutional normal.,creatinine
Creatinine <= upper normal institutional limits,creatinine
Creatinine > 1.5 x institutional ULN OR,creatinine
Creatinine > 1.5 x ULN or creatinine clearance < 60 mL/min. Creatinine clearance can either be measured in a 24-hour urine collection or estimated by the Cockraft-Gault equation as follows: ClCr (mL/min) = [(140 - age) x (weight in kg) ÷ [72 x (serum creatinine in mg/dL)] [0.85 if female].,creatinine
Creatinine >= 51 mL/min estimated using the Cockcroft-Gault equation,creatinine
Creatinine 1.5 x ULN; OR,creatinine
Creatinine CL (mL/min) = Weight (kg) x (140 &ndash; Age),creatinine
Creatinine CL (mL/min) = Weight (kg) x (140 &ndash; Age) x 0.85,creatinine
Creatinine clearance (as estimated by Cockcroft Gault) >= 60 cc/min,creatinine
Creatinine clearance (calculated* or measured value**): >= 40 mL/min,creatinine
Creatinine clearance (Cockcroft-Gault),creatinine
Creatinine clearance [either directly measured or calculated by Cockcroft-Gault formula >= 50 mL/min. Refer to Appendix 6 for Cockcroft-Gault formula,creatinine
Creatinine clearance < 40 mL/min ( < 30 mL/min for MM) based on Cockroft-Gault formula or 24-hour urine analysis.,creatinine
Creatinine clearance < 50 mL/min ( < 30 mL/min for MM) based on Cockroft-Gault formula or 24-hour urine analysis.,creatinine
Creatinine clearance > 30 mL/min based on the Modification of Diet in Renal Disease (MDRD) glomerular filtration rate (GFR):,creatinine
Creatinine Clearance > 60 mL/min,creatinine
Creatinine clearance >= 30 ml/min,creatinine
Creatinine Clearance >= 30 mL/min by Cockroft Gault Equation.,creatinine
Creatinine clearance >= 30 mL/min/1.73 m^2 by Cockcroft-Gault.,creatinine
creatinine clearance >= 30 mL/min/1.73 m2 by Cockcroft-Gault: (140 - age) x (weight in kg) x (0.85 if female) / 72 x (serum creatinine in mg/dL),creatinine
"Creatinine clearance >= 40 mL/min (per 24-hour urine or calculated by the Cockcroft and Gault equation [Cockcroft and Gault, 1976; Section 10.5]).",creatinine
Creatinine clearance >= 45 mL/min (calculated using the Cockcroft-Gault formula) For patients intended to receive cisplatin: creatinine clearance >= 60 mL/min,creatinine
Creatinine clearance >= 50 mL/min,creatinine
"Creatinine clearance >= 50 mL/min by either measured (using the Cockcroft-Gault, Modification of Diet in Renal Disease [MDRD] or Chronic Kidney Disease Epidemiology [CKD-EPI] formula) or calculated clearance (i.e. glomerular filtration rate [GFR])",creatinine
Creatinine clearance >= 50 mL/min by either measured or calculated clearance,creatinine
"Creatinine clearance >= 50 mL/min calculated with the use of the 24-hour creatinine clearance or modified Cockcroft-Gault equation (i.e., estimation of creatinine clearance rate [eCCr]) with the use of ideal body mass (IBM) instead of mass):",creatinine
creatinine clearance >= 50 mL/min/1.73 m2 for patients with creatinine levels above institutional normal,creatinine
Creatinine Clearance >= 50 mL/min/1.73 m2 for patients with creatinine levels above institutional normal.,creatinine
Creatinine clearance >= 60 cc/min,creatinine
Creatinine clearance for females = (140 - age)(actual body weight in kg)(0.85) (72)(serum creatinine in mg/dL),creatinine
Creatinine clearance for females = (140 - age)(actual body weight in kg)(0.85)/(72)(serum creatinine in mg/dL).,creatinine
Creatinine clearance for females = (140 - age)(weight in kg)(0.85),creatinine
Creatinine clearance for females = (140 - age)(weight in kg)(0.85) - (72)(serum creatinine in mg/dL),creatinine
Creatinine clearance for females = (140 - age)(weight in kg)(0.85) (72)(serum creatinine in mg/dL),creatinine
Creatinine clearance for females = (140 - age)(weight in kg)(0.85) / (72)(serum creatinine in mg/dL),creatinine
Creatinine clearance for males = (140 - age)(actual body weight in kg) (72)(serum creatinine in mg/dL),creatinine
Creatinine clearance for males = (140 - age)(actual body weight in kg)/ (72)(serum creatinine in mg/dL),creatinine
Creatinine clearance for males = (140 - age)(weight in kg),creatinine
Creatinine clearance for males = (140 - age)(weight in kg) - (72)(serum creatinine in mg/dL),creatinine
Creatinine clearance for males = (140 - age)(weight in kg) (72)(serum creatinine in mg/dL),creatinine
Creatinine clearance for males = (140 - age)(weight in kg) (72)(serum creatinine in mg/dL) Creatinine clearance for females = (140 - age)(weight in kg)(0.85) (72)(serum creatinine in mg/dL),creatinine
Creatinine clearance for males = (140 - age)(weight in kg) / (72)(serum creatinine in mg/dL),creatinine
Creatinine clearance less than 60ml/min. GFR should be assessed by calculation from serum/plasma creatinine (Cockcroft-Gault formula),creatinine
Creatinine clearance of >= 60 mL/min as estimated by the Cockcroft-Gault equation,creatinine
Creatinine clearance or radioisotope glomerular filtration rate (GFR) >= 70 ml/min/1.73 m^2 or a serum creatinine based on age/gender as follows:,creatinine
Creatinine clearance or radioisotope glomerular filtration rate (GFR) 70ml/min/1.73 m^2 or,creatinine
Creatinine level <= 1.2 x ULN or creatinine clearance > 60 mL/min/1.73 m2 for patients with creatinine levels above or below the institutional normal (as determined by Cockroft-Gault equation*),creatinine
Creatinine OR Calculated creatinine clearance: <= 1.5 X upper limit of normal (ULN) OR >= 60 mL/min for subject with creatinine levels > 1.5 X institutional ULN,creatinine
Creatinine or Measured or calculated creatinine clearance (GFR can also be used in place of creatinine or CrCl) < 1.5 x ULN or > mL/min for participant with creatinine leves of > 1.5 x institutional ULN,creatinine
Creatinine or Measured or calculated creatinine clearance (GFR can also be used instead of CrCl) <= 1.5 x ULN or >= mL/min for participants with creatinine levels >= 1.5 x institutional ULN,creatinine
Creatinine within normal institutional limits for age OR Creatinine clearance >= 60 mL/min/1.73 m2 for patients with creatinine levels above ULN.,creatinine
Creatinine Within normal institutional limits OR,creatinine
creatinine within normal laboratory limits,creatinine
"eCCr = (140 - Age) x IBM (kg) x [0.85 for female] 72 x serum creatinine (mg/dL) Or, if serum creatinine is in µmol/L: eCCr = (140 - Age) x IBM (kg) x [1.04 for female] serum creatinine (µmol/L)",creatinine
eGFR (CKD-EPI) greater than or equal to 50 mL/min/1.73 m2,creatinine
"Either a serum creatinine <= ULN for age, or calculated or measured GFR >= 70 mL/min/1.73 m2",creatinine
Eligible for contrasted magnetic resonance imaging (MRI) on initial evaluation with glomerular filtration rate (GFR) >= 60 ml/min. A diagnostic MRI ordered within one month will be considered an acceptable alternative and will not be repeated.,creatinine
Estimated (Cockroft-Gault formula) or measured creatinine clearance < 40 mL/min.,creatinine
"estimated creatinine clearance (CrCl, by Cockcroft-Gault formula) or estimated glomerular filtration rate (eGFR) >= 30 mL/min/1.73 m2",creatinine
Estimated creatinine clearance < 50 mL/min calculated by the Cockroft Gault or Modification of Diet in Renal Disease formulas at screening.,creatinine
Estimated creatinine clearance >= 30 mL/min,creatinine
Estimated GFR > 50 mL/min,creatinine
Estimated GFR > 50mL/min,creatinine
Estimated glomerular filtration rate (GFR) > 30 ml/min,creatinine
GFR (mL/min/1.73 m2) = 175 x (serum creatinine)-1.154 x (Age)-0.203 x (0.742 if female) x (1.212 if African American),creatinine
"GFR > 30 mL/min calculated by the Cockcroft-Gault, MDRD study, or CKD-EPI creatinine equations, or equivalent",creatinine
GFR >= 40.,creatinine
Glomerular Filtration Rate (GFR) >= 60 ml/min/1.73m2,creatinine
"Glomerular filtration rate (GFR), calculated via I-125 iothalamate clearance, 24-hour creatinine clearance, or Schwartz formula*, >= 70 mL/min and >= 50 mL/min/1.73 m2 done within 4 weeks of study entry",creatinine
Have a serum creatinine level <= 1.8 mg/dL,creatinine
Inadequate renal function defined by creatinine clearance <= 5 mL/min using the Cockcroft-Gault formula.,creatinine
INCLUSION CRITERIA FOR STRATUM C: Serum creatinine based on age/gender as noted below; patients that do not meet the criteria below but have a 24 hour creatinine clearance or GFR (radioisotope or iothalamate) >= 70 ml/min/1.73 m^2 are eligible,creatinine
Male Ccr (mL/min) = Body weight (kg) x (140 - age)/[72 x serum creatinine (mg/dL)],creatinine
Measured or calculated creatinine clearance (glomerular filtration rate [GFR] can also be used in place of creatinine or creatinine clearance [CrCl]) <= 1.5 X upper limit of normal (ULN) OR,creatinine
"No findings consistent with renal failure, as determined by glomerular filtration rate (GFR) < 30 mL/min/1.73 m^2 based on a creatinine level obtained within 28 days prior to registration",creatinine
Normal Serum creatinine based on age or Creatinine clearance > 60 ml/min or > 60 ml/min/1.73 m2 or an equivalent radioisotope glomerular filtration rate (GFR) as determined by the institutional normal range.,creatinine
Obtained <= 14 days prior to registration: Calculated creatinine clearance must be >= 45 ml/min using the Cockcroft-Gault formula,creatinine
Obtained <= 14 days prior to registration: Creatinine <= 1.5 x ULN,creatinine
Obtained <= 14 days prior to registration: Creatinine <= 1.5 x ULN OR,creatinine
Obtained <= 14days prior to registration: Calculated creatinine clearance (using Cockcroft-Gault equation below) >= 30 mL/min,creatinine
"Patients must have adequate renal function as evidenced by calculated creatinine clearance >= 51 mL/min by Cockcroft-Gault equation, within 28 days prior to registration. Calculated creatinine clearance = (140 - age) x wt (kg) x 0.85 (if female) 72 x creatinine (mg/dl)",creatinine
"Patients must have Adequate Renal Function Defined as: Creatinine clearance or radioisotope GFR >= 70ml/min/1.73 m^2 or a serum creatinine based on age/gender less than listed value in the table below: 1 to < 2 years 0.6 mg/dL for both males and females, 2 to < 6 years 0.8 mg/dL for both males and females, 6 to < 10 years 1 mg/dL for both males and females, 10 to < 13 years 1.2 mg/dL for both males and females, 13 to < 16 years 1.5 mg/dL for males and 1.4 mg/dL for females, >= 16 years 1.7 for males and 1.4 for females",creatinine
"Patients must have adequate renal function: creatinine < 1.5 mg/dL is recommended; however, institutional norms are acceptable. Creatinine within institutional limits of normal or creatinine clearance (CrCl) > 50 mL/min calculated using the Cockcroft-Gault equation.",creatinine
Patients must have creatinine clearance <= 2.5 x IULN,creatinine
Patients must have serum creatinine <= 1.5 mg/dl within 14 days prior to registration.,creatinine
Pre-existing renal impairment (creatinine clearance < 60 mL/min),creatinine
Renal function: Serum creatinine <= 1.5 X upper normal limit of institution's normal range OR creatinine clearance >= 40 mL/min/1.73 m2 for subjects with creatinine levels above institutional normal.Creatinine clearance should be determined by the Cockcroft-Gault formula (below) or by 24-hour urine collection for determination of creatinine clearance:,creatinine
"Renal impairment defined as serum creatinine > 1.3 mg/dL ( > 115 µmol/L) or creatinine clearance < 70 mL/min, but still fulfilling criterion #7.",creatinine
Renal: Creatinine <= 2.0 mg/dl (adults) and estimated glomerular filtration rate (GFR) >= 40 mL/min (pediatrics). Adults with a creatinine > 1.2 mg/dl or a history of renal dysfunction must have estimated glomerular filtration rate (GFR) > 40 mL/min.,creatinine
"Renal: Creatinine clearance or GFR > 60 ml/min/1.73m2 (If a creatinine clearance is performed at end of induction and the result is < 100 ml/min/1.73m2, a GFR must be performed using a nuclear blood sampling method or iothalamate clearance method. Camera method is NOT allowed as measure of GFR prior to or during Consolidation therapy for patients with GFR or creatinine clearance of < 100 ml/min/1.73m2.)",creatinine
Renal: creatinine clearance or radioisotope GFR >= 70 mL/min/1.73 m2.,creatinine
Renal: GFR >= 50 ml/min/1.73m2,creatinine
Renal: GFR >= 50 ml/min/1.73m2 or serum creatinine <= 2.5 x ULN for age,creatinine
Renal: Serum creatinine <= 1.5 times ULN.,creatinine
"Serum creatinine (Scr) <= 1.5mg/dl; if the Scr > 1.5, patients may still be eligible if the calculated glomerular filtration rate (GFR) (Cockroft-Gault) is >= 40ml/minute",creatinine
Serum creatinine (serum or plasma) <= 1.5 x ULN or GFR > 50 mL/min,creatinine
Serum creatinine < 1.5 times upper limit of normal (ULN),creatinine
Serum creatinine < 1.5 x institutional upper limit of normal (ULN),creatinine
"Serum creatinine < 1.5 x ULN or if available, calculated or measured creatinine clearance > 50 mL/min/1.73 m2",creatinine
Serum creatinine < 1.5 x ULN; the values must be obtained within 48 hours prior to randomization,creatinine
Serum creatinine < 2 mg/dl,creatinine
Serum creatinine < 2.5 X institutional ULN OR measured or calculated* creatinine clearance (CrCl) (glomerular filtration rate [GFR] can also be used in place of creatinine or CrCl) >= 30 mL/min for subject with creatinine levels > 2.5 X institutional ULN,creatinine
Serum creatinine <= 1.5 mg/dL (or <= 114 _mol/L),creatinine
Serum creatinine <= 1.5 mg/dL or calculated creatinine clearance >= 40 mL/min by Cockcroft-Gault formula,creatinine
Serum creatinine <= 1.5 mg/dL or creatinine clearance >= 50 mL/min (calculated by Cockcroft Gault equation),creatinine
Serum creatinine <= 1.5 times the ULN,creatinine
Serum creatinine <= 1.5 X institutional ULN and creatinine clearance >= 60 ml/min,creatinine
Serum creatinine <= 1.5 x institutional ULN or an estimated glomerular filtration rate (eGFR) of > 50 ml/min as calculated by the Modification of Diet in Renal Disease (MDRD) equation.,creatinine
Serum creatinine <= 1.5 X ULN (NCI-CTCAE Grade 1 baseline),creatinine
Serum creatinine <= 1.5 x ULN OR calculated creatinine clearance (CrCl) or 24-hour urine CrCl >= 40 mL/minute,creatinine
Serum creatinine <= 1.5 x ULN or creatinine clearance >= 35 ml/min using Cockcroft-Fault formula.,creatinine
Serum creatinine <= 1.5 x ULN or creatinine clearance >= 50 mL/min according to institutional standards,creatinine
Serum creatinine <= 1.5 x ULN or creatinine clearance >= 50 mL/min.,creatinine
Serum creatinine <= 1.5 X ULN or measured or calculated creatinine clearance (CrCl) >= 60 mL/min for subject with creatinine levels > 1.5 X institutional ULN (glomerular filtration rate [GFR] can also be used in place of creatinine or CrCl); creatinine clearance should be calculated per institutional standard (within 10 days of treatment initiation),creatinine
Serum creatinine <= 1.5 x ULN.,creatinine
Serum creatinine <= 1.5 x upper limit of normal (ULN) (or glomerular filtration rate [GFR] >= 60 ml/min for patients with creatinine > 1.5 x ULN),creatinine
Serum creatinine <= 1.5 x upper limit of normal (ULN) or a calculated creatinine clearance > 60 mL/min,creatinine
Serum creatinine <= 1.5 x upper limit of normal (ULN) or calculated creatinine clearance >= 50 mL/min using Cockcroft-Gault equation,creatinine
Serum creatinine <= 1.5 X upper limit of normal (ULN) OR measured or calculated creatinine clearance (glomerular filtration rate [GFR] can also be used in place of creatinine or creatinine clearance rate [CrCl]) >= 35 mL/min for subject with creatinine levels > 1.5 X institutional ULN,creatinine
Serum creatinine <= 1.5 X upper limit of normal (ULN) OR measured or calculated* creatinine clearance >= 60 mL/min for subject with creatinine levels > 1.5 X institutional ULN; (glomerular filtration rate [GFR] can also be used in place of creatinine or creatinine clearance [CrCl]),creatinine
Serum creatinine <= 1.5x institutional ULN or creatinine clearance (CrCl) >= 40 mL/min (measured using the Cockcroft-Gault formula below):Female CrCl = (140 - age in years) x weight in kg x 0.85 72 x serum creatinine in mg/dL Male CrCl = (140 - age in years) x weight in kg x 1.00 72 x serum creatinine in mg/dL,creatinine
serum creatinine <= 1.5x ULN,creatinine
Serum creatinine <= 1.5x ULN or creatinine clearance (CrCl) >= 40 mL/min (measured using the Cockcroft-Gault formula below): Female CrCl = (140 - ) x _ x 0.85 72 x serum creatinine in mg/dL Male CrCl = (140 - ) x _ x 1.00 72 x serum creatinine in mg/dL,creatinine
Serum creatinine <= 1.5x upper limit of normal (ULN) or calculated creatinine clearance >= 50 mL/min using Cockcroft-Gault equation,creatinine
Serum creatinine <= 1.7 mg/dL or calculated creatinine clearance >= 50 mL/min per the Cockcroft and Gault formula,creatinine
Serum Creatinine <= 2 x ULN,creatinine
Serum creatinine <= 2 x ULN or 24 hour Cr clearance > 60ml/min.,creatinine
Serum creatinine <= 2 x ULN or glomerular filtration rate (GFR) >= 50,creatinine
"Serum creatinine <= 2 x ULN, or 24-hr urine creatinine clearance calculation >= 50 mL/min",creatinine
Serum creatinine <= 2.0 mg/dl,creatinine
Serum creatinine <= 2.0 x ULN or calculated creatinine clearance >= 30 mL/min ( >= 0.5 mL/sec) using the Cockcroft-Gault equation (see Table 5-2 for Cockcroft-Gault formula).,creatinine
Serum creatinine <= 2.0 x ULN or creatinine clearance >= 50 mL/min,creatinine
Serum creatinine <= 2.0 x upper limit of normal or calculated creatinine clearance:,creatinine
Serum creatinine <= 2.5 x ULN,creatinine
Serum creatinine <= 2x ULN,creatinine
serum creatinine <= IULN OR calculated creatinine clearance >= 60 mL/min.,creatinine
"Serum creatinine <= upper limit of normal, and calculated creatinine clearance (MDRD or CKDEPI) >= 60 mL/min/1.73 m2.",creatinine
Serum creatinine > 2.0 x ULN OR estimated creatinine clearance < 40 mL/min calculated by either the Cockroft Gault or Modification of Diet in Renal Disease (MDRD)1 formula at screening.,creatinine
Serum creatinine >= 2.5 or estimated creatinine clearance <= 30 mL/min and not dialysis dependent,creatinine
Serum creatinine based on age/gender as noted below; patients that do not meet the criteria below but have a 24 hour creatinine clearance or glomerular filtration rate (GFR) (radioisotope or iothalamate) >= 70 ml/min/1.73 m^2 are eligible,creatinine
Serum Creatinine Clearance (CrCl) < 45 mL/min,creatinine
Serum creatinine clearance CLcr > 30 mL/min).,creatinine
Serum creatinine must be <= 2 X ULN within 2 weeks prior to registration,creatinine
Serum creatinine must be <= 2 X upper limit of normal (ULN) within 2 weeks prior to registration,creatinine
Serum creatinine OR Measured or calculated creatinine CL (per CKD-EPI) <= 2.0 x ULN OR >= 40 mL/min for patients with creatinine levels > 2.0 x ULN,creatinine
Serum creatinine OR Measured or calculated creatinine clearance (GFR can also be used in place of creatinine or CrCl): <= 1.5 X upper limit of normal (ULN) OR >= 60 mL/min for subject with creatinine levels > 1.5 X institutional ULN,creatinine
Serum creatinine or measured or calculated creatinine clearance (glomerular filtration rate [GFR] can also be used in place of creatinine or creatinine clearance [CrCl]) <= 1.5 X upper limit of normal (ULN) or >= 60 mL/min for subject with creatinine levels > 1.5 X institutional ULN (creatinine clearance should be calculated per institutional standard) (performed within 10 days of treatment initiation),creatinine
"Serum creatinine OR Measured or calculateda creatinine clearance <= 1.5 X upper limit of normal (Institutional Upper Limit of Normal, IULN",creatinine
Serum Creatinine OR Measured or calculatedb creatinine clearance (GFR can also be used in place of creatinine or CrCl) <= 1.5 x ULN OR >= 60 mL/min for participant with creatinine levels > 1.5 x institutional ULN,creatinine
Serum creatinine within normal institutional limits or creatinine clearance >= 60 mL/min/1.73 m2 for patients with serum creatinine levels above institutional ULN.,creatinine
"serum creatinine within normal limits (WNL), defined as ±25% of the institution's stated reference range, or a calculated creatinine clearance > 45 mL/min for patients with abnormal, increased, creatinine levels (Cockcroft-Gault formula; Appendix I).",creatinine
"Serum creatinine within normal limits, OR calculated creatinine clearance >= 60 mL/min/1.73 m2 for patients with creatinine levels above institutional normal.",creatinine
"Serum creatinine within normal range for age, or if serum creatinine outside normal range for age, then renal function (creatinine clearance or glomerular filtration rate [GFR]) > 40 mL/min/1.73m^2",creatinine
"Serum creatinine within normal range, or if serum creatinine outside normal range, then GFR > 40 mL/min/1.73m 2 as calculated with the Cockcroft-Gault equation with adjustment if total body weight is >= 125% of ideal body weight.",creatinine
Serum creatinine: <= 1.5 x ULN,creatinine
Within 14 days prior to registration: Serum creatinine < 1.5 X institutional ULN mg/dL OR estimated glomerular filtration rate (eGFR) >= 50 mL/min,creatinine
Clinical history of Type I or Type II diabetes.,diabetes
Controlled Type 1 diabetes mellitus and on an insulin regimen,diabetes
"Diabetes mellitus with symptomatic end-organ damage (e.g., retinopathy, nephropathy, neuropathy, vasculopathy)",diabetes
Diabetes stable with current management,diabetes
Fasting or random blood glucose within the upper limits of normal for age.,diabetes
For Part G: Have type 1 diabetes mellitus or a history of gestational diabetes mellitus. Patients with type 2 diabetes mellitus are eligible if adequate control of blood glucose level is obtained with oral therapy as documented by HbA1c < 7%.,diabetes
"For patients with diabetes, hemoglobin A1C test must have been performed <= 90 days prior to registration.",diabetes
Hemoglobin A1c (HbA1c) > 8.0% (all subjects will have HbA1c tested at screening).,diabetes
History of uncontrolled diabetes mellitus (stable insulin dose and/or stable oral hypoglycemic agent permitted),diabetes
"If random blood glucose is above upper limits for age, a fasting blood glucose can be obtained and must be within normal limits for age",diabetes
No diabetes mellitus currently treated with insulin or sulfonylureas.,diabetes
Part 1 and Part 3 only: Type 1 diabetes or uncontrolled Type 2 diabetes.,diabetes
"Patient does not have uncontrolled diabetes mellitus (i.e., fasting blood glucose > 200 mg/dL).",diabetes
Patient has fasting plasma glucose (FPG) <= 140 mg/dL (7.7 mmol/L) and glycosylated hemoglobin (HbA1c) <= 6.4% (both criteria have to be met).,diabetes
Patient with an established diagnosis of diabetes mellitus type I or uncontrolled type II.,diabetes
"Patients with an established diagnosis of diabetes mellitus type I or uncontrolled type II (based on FPG and HbA1c, see inclusion criterion 12).",diabetes
Patients with controlled type 1 diabetes mellitus on a stable insulin regimen are eligible,diabetes
Patients with controlled type 1 diabetes mellitus on a stable insulin regimen may be eligible,diabetes
Patients with controlled Type 1 diabetes mellitus on a stable insulin regimen may be eligible.,diabetes
Patients with controlled Type 1 diabetes mellitus who are on a stable insulin regimen are eligible for the study.,diabetes
Patients with controlled Type 1 diabetes mellitus who are on an insulin regimen are eligible for the study,diabetes
Patients with Type 2 diabetes mellitus currently under treatment with DPP-4 inhibitors,diabetes
Patients with uncontrolled diabetes. Uncontrolled diabetes is defined as hemoglobin A1C (HbA1c) >= 8% or HbA1c 7-< 8% with associated diabetes symptoms (polyuria or polydipsia) that are not otherwise explained.,diabetes
Poorly controlled diabetes,diabetes
"Poorly controlled diabetes mellitus as evidenced by an HbA1c level >= 10%, or significant diabetes-related dietary or therapeutic regimen changes within 12 weeks of enrollment.",diabetes
Random or fasting glucose within the upper limits of normal for age. If the initial blood glucose is non-fasting and above normal limits a fasting glucose can be obtained and must be within the upper limits of normal for age.,diabetes
Subjects with controlled Type I diabetes mellitus on a stable dose of insulin regimen may be eligible for this trial,diabetes
Type 1 diabetes or uncontrolled Type 2 diabetes.,diabetes
Uncontrolled diabetes as defined by fasting serum glucose > 1.5 x ULN (NOTE: Optimal glycemic control should be achieved before starting trial therapy.),diabetes
Uncontrolled diabetes mellitus (despite therapeutic; compliance to,diabetes
uncontrolled diabetes.,diabetes
"5/6 or 6/6 (HLA-A, B, DR) matched related donor",donorsct
"A donor, who will donate peripheral stem cells by apheresis, must be willing and able to interrupt breast-feeding or substitute formula feeding for her infant during the period of filgrastim administration and for two days following the final dose. Filgrastim may be ailability from this source is not known. f) No mutation in GATA2, or in the case where the mutation in GATA2 has not been identified, but the recipient has the clinical syndrome of MonoMAC, the donor is required to have no clinical evidence of MonoMAC",donorsct
"a related donor mismatched at 1 HLA-A, B, C and DRB1 antigen",donorsct
"Absence of a suitable partially HLA-mismatched (haploidentical), first-degree related donor.",donorsct
Absence of donor (product)-specific anti-HLA antibodies,donorsct
Absence of donor-specific antibodies (DSA) to the mismatched HLA-locus,donorsct
Acceptable allogeneic stem cell donor with imminent plans to proceed with allo-SCT.,donorsct
Acceptable stem cell source identified,donorsct
"All candidates for this study must have a human leukocyte antigen (HLA) (A, B, C, DR) identical siblings who is willing to donate bone marrow or primed blood stem cells or a 10/10 allele matched unrelated donor; a single allele mismatch at A, B, C, DR or DQ and a killer immunoglobulin-like receptor (KIR) mismatch at C will be allowed; all ABO blood group combinations of the donor/recipient are acceptable",donorsct
"All candidates for this study must have a human leukocyte antigen (HLA) (A,B,C,DR) identical sibling who is willing to donate primed blood stem cells (preferred) or bone marrow, or have a 10/10 allele matched unrelated donor; all ABO blood group combinations of the donor/recipient are acceptable",donorsct
An acceptable source of stem cells according to current University of Minnesota Bone Marrow Transplant program guidelines. Acceptable stem cell sources include:,donorsct
"an HLA-A, B, DRB1 matched related donor (other than sibling)",donorsct
Anti-donor HLA antibodies with positive crossmatch and unsuccessful -,donorsct
Availability of a consenting human leukocyte antigens(HLA) -matched donor,donorsct
"Availability of a genetic child, genetic parent or sibling as a potential HLA haploidentical donor",donorsct
"Availability of an HLA identical or 9/10 HLA matched (HLA A, B, C, DR, and DQ loci) - relative to serve as a stem cell donor.",donorsct
"Availability of an HLA identical or 9/10 HLA matched (HLA A, B, C, DR, and DQ loci) -relative to serve as a stem cell donor.",donorsct
"Availability of at least one HLA- haploidentical (i.e. > 5/10 and less than or equal to 8/10 HLA match) related donor (HLA- A, B, C, DR, and DQ loci) who is available to donate stem cell graft (6-75 years old).",donorsct
Available HLA-haploidentical donor that meets the criteria in the protocol,donorsct
Available HLA-haploidentical donor that meets the following criteria:,donorsct
Available human leukocyte antigen (HLA)-haploidentical donor who meets the following criteria:,donorsct
Available original donor (same donor as used for the initial stem cell transplant) that is willing and eligible for non-mobilized collection,donorsct
Available original donor (same donor as used for the initial stem cell transplant) that is willing and eligible for non-mobilized collection.,donorsct
Available original stem cell donor.,donorsct
Available stem cell donor-derived CD19-CAR transduced multi-virus-specific cytotoxic T lymphocytes with 15% expression of CD19-CAR determined by flow-cytometry and < 10% cytotoxicity against patient or donor-derived (or other family member-derived) PHA blasts.,donorsct
Clinical justification of allogeneic stem cell transplantation where a suitable HLA matched sibling or unrelated donor is unavailable in a timely manner,donorsct
Donor evaluation and selection is by standard for normal clinical practice. No study procedures are to be performed on donors. All donors must be willing to donate peripheral blood stem cells and meet institutional or NMDP criteria for donation.,donorsct
Donor grafts must be G-CSF mobilized peripheral blood stem cells with dose and apheresis logistics at the discretion of institutional standard,donorsct
"Donor match at 10 of 10 loci for HLA-A, -B, -C, -DRB1 and DQB1, with each typed at high resolution by DNA-based methods.",donorsct
Donor must be willing to donate peripheral blood stem cells,donorsct
Donor must not be HLA identical to the recipient.,donorsct
Donor unable to donate peripheral stem cells,donorsct
"DONOR: Arm A: All candidates for this study must have an human leukocyte antigen (HLA) (A, B, C, and DR) identical sibling who is willing to donate primed blood stem cells (preferred) or bone marrow, or have a 10/10 (A, B, C, DR and DQ) allele matched unrelated donor; DQ or DP mismatch is allowed per discretion of the principal investigator",donorsct
"DONOR: Donor must be a human leukocyte antigen (HLA)-haploidentical relative selected for best NK alloreactivity, defined as having a KIR gene present on the donor NK cells for which the relevant HLA haplotype (KIR ligand) is absent in the recipient and present in the donor or selected on the basis of activating KIR gene content",donorsct
DONOR: Donor must be related to patient and be partially ( >= 3/6 antigen) HLA-matched,donorsct
DONOR: Donor must meet all Robert Wood Johnson (RWJ) Blood Services requirements for hematopoietic stem cell donation including:,donorsct
"DONOR: Donors must be haploidentical relatives of the patients. Donor-recipient compatibility will be tested through HLA typing at high resolution for the HLA loci (-A, -B, -C, -DRB1, -DQB1). Donor and recipient should share at least 5/10 HLA loci",donorsct
"DONOR: Donors who are HIV-positive and/or, medical conditions that would result in increased risk for G-CSF mobilization and harvest of peripheral blood stem cell (PBSC)",donorsct
"DONOR: If more than one potential volunteer unrelated donor is considered suitable, further selection of the most suitable donor will be prioritized as follows or will follow our institutional guideline from our stem cell transplant standard operating procedure (SOP):",donorsct
"DONOR: Must be matched to the subject at 8/8 HLA alleles (HLA-A, -B, -C, and -DRB1)",donorsct
"DONOR: Patients who are homozygous at the mismatched HLA class I or II locus, the donor is excluded if homozygous at the mismatched locus (i.e., patient is homozygous A *01:01 and donor is homozygous A *02:01); this type of mismatch is considered a two-antigen mismatch and is not allowed",donorsct
DONOR: Selection of a haploidentical donor will require absence of pre-existing donor-directed anti-HLA antibodies in the recipient,donorsct
"Donors for allogeneic (i.e. HLA matched or mismatched related or unrelated) stem cell transplants who have fulfilled eligibility for and consented to stem cell donation as per the stem cell transplant program's standard operating procedures. Subjects must be at least 12 kg or 24 pounds to be eligible for stem cell donation. The stem cell donor will have already been selected by the primary Bone Marrow Transplant attending according to CAGT SOPs for Donor Evaluation, Donor Selection, and Donor Deferral. If a donor has been chosen for the transplant based on urgent medical need, that same donor will also be used for T cell generation, provided that there are no new reasons for ineligibility since the stem cell collection. In this study, the subject's hematopoietic stem cell donor will also be the donor for the T cells.",donorsct
Donors greater than or equal to 18 years of age must be the same individual whose cells were used as the source for the patient s original stem cell transplant.,donorsct
Donor's high resolution HLA typing must be available for review,donorsct
"Donors must be 8/8 HLA-matched (at the allele level) as defined by matching at HLA-A, -B, -DR and -C who pass institutional standard to serve as a peripheral blood stem cell donor",donorsct
"Donors must be HLA-haploidentical relatives of the patient, defined as having a shared HLA haplotype between donor and patient at HLA-A, -B, -C, and -DRB1.",donorsct
"Eligible donors will include siblings age >= 18 matched with the recipient at HLA-A, B, C, and DRB1",donorsct
"ENROLLMENT: Confirmation that a cord blood donor which is matched with the recipient at a 4, 5, or 6/6 human leukocyte antigen (HLA) class I (serological) and HLA class II (molecular) antigens.",donorsct
"Family donor with patient-donor number of HLA mismatches >= 2 (full haploidentical), or family donors sharing one HLA-haplotype with the patient",donorsct
"Fulfillment of this criterion shall be considered sufficient evidence that the donor and recipient share one HLA haplotype, and typing of additional family members is not required",donorsct
Fully HLA-matched related donor.,donorsct
Haploidentical by HLA-typing,donorsct
"Have 8/8 allele-level, related or unrelated, medically cleared HSC donor matching at human leukocyte antigen (HLA)-A, HLA-B, HLA-C, and DRB-1",donorsct
"Have an available 6/6 related donor or an unrelated donor with a 10/10 match for HLA-A, B, C, DRB1 and DQ antigen who consents to provide a marrow or peripheral blood stem cell allograft. Typing is by DNA techniques: intermediate resolution for A, B and C, and high resolution for DRB1/DQ",donorsct
Have evidence of recipient donor specific anti-HLA antibodies.,donorsct
High titer of donor specific anti-HLA antibodies (MFI > 1000),donorsct
HLA identical or single HLA mismatched family donor,donorsct
HLA-haploidentical donor/recipient match by at least Class I serologic typing at the A&B locus.,donorsct
HLA-haploidentical or mismatched related donor (aged 12 to 70 years) with donor/recipient match based on a minimum of intermediate resolution DNA based Class I typing of the A and B locus (at least 2/4 class I allele) and absence of recipient anti HLA antibodies against selected donor,donorsct
HLA-identical sibling,donorsct
HLA-matched donor able to donate,donorsct
"HLA-matched or one of six HLA A, B, or DR antigen-mismatched related male or female donor 18-65 years of age.",donorsct
HLA-matched or single allele-mismatched donor able to donate,donorsct
HLA-matched related donors >= 18 years and capable and willing to donate PBSC (Arms A and B),donorsct
HLA-matched related or unrelated donor peripheral blood stem cells,donorsct
"HLA-matched stem cell donor, either related (6/6 or 5/6 loci matched) or unrelated (8/8 or 7/8 loci matched)",donorsct
"HLA-matched unrelated donors (HLA-A, B, C, and DRB1 matched based on high-resolution typing) capable and willing to donate PBSC (Arms C and D)",donorsct
HLA-MISMATCHED UNRELATED DONOR: Unrelated volunteer donors who are mismatched with the recipient within one of the following limitations:,donorsct
"Identification of at least one alternative donor (i.e. HLA- haploidentical related donor (i.e. greater than or equal to 5/10 HLA match: HLA-A, B, C, DR, and DQ loci) or greater than or equal to 9/10 HLA matched unrelated donor) who is available to serve as a stem cell donor for a salvage allogeneic transplant in the event that the CordIn unit has been rejected.",donorsct
"If more than one preferred donor is identified and there is no medical, HLA- or KIR ligand reason to prefer one of them, then the following guidelines are recommended:",donorsct
"If the donor-specific HLA antibodies (DSA) are positive, the patient must undergo a desensitization protocol resulting in undetectable DSA prior to day of transplant",donorsct
In the case of a related donor: The identified donor must be the original donor whose stem cells were used for the research participant's allogeneic stem cell transplantation (alloSCT),donorsct
"It is preferred that the haploidentical donor must be available to donate on day -1 and day 0, so that fresh product can be processed by the Stem Cell lab and administered to the patient on day 0. While less preferable, cryopreserved product may be utilized with this product.",donorsct
Lack of a suitable 8/8 HLA-matched sibling donor,donorsct
"Lack of recipient anti-donor HLA antibody. Note: In some instances, low level, non-cytotoxic HLA specific antibodies may be permissible if they are found to be at a level well below that detectable by flow cytometry. This will be decided on a case-by-case basis by the PI and one of the immunogenetics directors. Pheresis to reduce anti-HLA antibodies is permissible; however eligibility to proceed with the transplant regimen would be contingent upon the result.",donorsct
Must be 6/6 matched sibling donor as determined by HLA typing,donorsct
Must have a human leukocyte antigen (HLA)-matched or single allele-mismatched adult sibling serving as donor,donorsct
No available human leukocyte antigen (HLA)-matched related donor,donorsct
No eligible fully HLA-matched related donor,donorsct
Patient has donor-specific anti-HLA antibodies,donorsct
"Patient must have an identified HLA (A,B,C,DR) compatible related or unrelated donor who is age 16 years of age or older and weighs at least 110 pounds for the stem cell donation",donorsct
"Patients must have a related donor who is HLA mismatched at 2, 3, or 4 antigens at the HLA-A; B; C; DR loci in the GVHD direction. (Patients with related donors who are HLA identical or are a 1-antigen mismatch may be treated on this therapeutic approach, but will have their outcomes will not be part of the statistical aims of the study (see Summary section).",donorsct
"Patients must have a related donor who is HLA mismatched at 2, 3, or 4 antigens at the HLA-A; B; C; DR loci in the GVHD direction. (Patients with related donors who are HLA identical or are a 1-antigen mismatch may be treated on this therapeutic approach, but will have their outcomes will not be part of the statistical aims of the study (see Statistical Section). The HLA matched related category includes patients with a syngeneic donor.",donorsct
"Patients must have a related donor who is identical for one HLA haplotype and mismatched at the HLA-A, -B or DRB1 loci of the unshared haplotype with the exception of single HLA-A, -B or DRB1 mismatches.",donorsct
Patients must have a related or unrelated peripheral blood stem cell donor as follows:,donorsct
"Patients must have an HLA-matched related donor or an HLA-matched unrelated donor who meets standard Seattle Cancer Care Alliance (SCCA) and/or National Marrow Donor Program (NMDP) or other donor center criteria for peripheral blood stem cell (PBSC) or bone marrow donation, as follows:",donorsct
Patients must not have an HLA-matched related donor or an HLA-matched unrelated donor who meets standard Seattle Cancer Care Alliance (SCCA) or National Marrow Donor Program (NMDP) or other donor center criteria for peripheral blood stem cell (PBSC) or bone marrow donation.,donorsct
Patients must not have prior evidence of human leukocyte antigen (HLA) or non-HLA donor-specific antibodies (DSA). Patients with detectable DSA but negative dd-cfDNA may be eligible after consultation with the study PI,donorsct
Patients who lack a fully HLA matched sibling and who are candidates for allogeneic hematopoietic stem cell transplant (HSCT) but do not meet criteria for current open institutional protocols using ClinMACs device for CD3+/CD19+ depletion.,donorsct
Patients with HLA-matched related donors will be excluded if they weigh >= 100 kg.,donorsct
Positive anti-donor HLA antibodies against a mismatched allele in the selected donor,donorsct
Positive for anti-donor HLA antibodies against an allele in the selected donor,donorsct
Preference will be given to donors who demonstrate KIR incompatibility with recipient HLA class I ligands defined as the donor expressing a KIR gene for which the corresponding HLA class I ligand is not expressed by the recipient.,donorsct
Presence of donor-specific anti-HLA antibodies.,donorsct
"Recipient should not have HLA antibodies to potential donor; if the recipient does have HLA antibodies to the potential donor, an alternative donor is preferred; however, if there are no suitable alternative donors, the donor to whom the patient has HLA antibodies can be utilized as long as the antibody titer is less than 2000 median fluorescence intensity (MFI); if the titer is >= to 2000 MFI, the recipient must undergo successful antibody desensitization prior to enrollment on this study; any patients who have demonstrated donor specific antibodies will not be evaluated for the end points measured in this study but will be followed for treatment related toxicities",donorsct
RECIPIENT: Prophylactic therapy with CMV immunoglobulin or prophylactic antiviral CMV treatment (Letermovir is permitted). EXCEPT for low risk patients [8/8 high resolution HLA donor allele matching HCT]),donorsct
Related Donor approved for stem cell transplant,donorsct
"Related donor: related to the patient and genotypically or phenotypically identical for HLA-A, B, C, DRB1 and DQB1; phenotypic identity must be confirmed by high-resolution typing",donorsct
"Research participants must have a donor or stem cells source identified for allogeneic transplantation, either related (7/8 or 8/8 allele matched or haploidentical), unrelated 7/8 or 8/8 allele match) donor, or cord blood stem cell source (at lease 4/6 matched)",donorsct
"Sibling donor must be a 6/6 match for Human Leukocyte Antigen-A (HLA)-A and -B at intermediate (or higher) resolution, and -DRB1 at high resolution using DNA-based typing, and must be willing to donate peripheral blood stem cells and meet institutional criteria for donation.",donorsct
"Subject is scheduled as a recipient or respective donor for the following procedure at Levine Cancer Institute (LCI), and has been deemed a qualified candidate by his/her physician, per LCI medical standards: haplo-identical hematopoietic stem cell transplant (HCT) using a non-myeloablative regimen.",donorsct
"Subject must have a donor or stem cell source identified for allogeneic transplantation, either related (7/8 or 8/8 allele matched or haploidentical), unrelated (7/8 or 8/8 allele matched donor), or cord blood stem cell source (at least 4/6 matched).",donorsct
Subjects must have a suitable stem cell donor available who may donate cells in the event the subject needs to undergo an allogeneic HCT. Donor may be matched or mismatched and must be found to be suitable according to the institution's standard criteria; donors must be fully cleared to proceed as the donor.,donorsct
Subjects who have opted not to undergo allogeneic hematopoietic stem cell transplantation or for whom no donor is available and who are not deemed eligible for high intensity chemotherapy.,donorsct
"The donor and recipient must have an HLA-8/8 allelic match at the HLA-A, -B, -C, and -DRB1. High resolution typing is required for all alleles.",donorsct
"The donor will also be assessed by physician who will document behavioral risk for exposure to infectious agents and diseases.Testing will include the following: Human transmissible spongiform encephalopathy, including Creutzfeldt-Jakob disease, communicable disease risks associated with xenotransplantation, Chlamydia trachomatis and for Neisseria gonorrhea, Treponema pallidum (syphilis).This will exclude the donor.",donorsct
The patient does not have any HLA antibodies detectable against any of the mismatched HLA alleles expressed by the haplo-donor.,donorsct
The patient does not have donor specific anti-HLA antibodies,donorsct
The patient is deemed to be a candidate for a 10/10 HLA matched unrelated stem cell transplant (availability of a donor and resources required for such a transplant).,donorsct
"The recipient must have a related donor genotypically human leukocyte antigen (HLA)-A, B,C and DRB1 loci haploidentical to the recipient",donorsct
"Treating physician considers the potential HLA haploidentical donor to be ineligible to receive G-CSF, and/or concern on the part of the treating physician for risk of harm to the potential donor with administration of G-CSF, and/or refusal by the potential donor (or donor?s guardian) to receive G-CSF",donorsct
1. Patients who have previously received bortezomib or other proteasome inhibitors that did not have a response while receiving the inhibitor are not eligible. Patients that responded but had a subsequent relapse are eligible. 2. ,drug
"1. Prior exposure to MEK, RAS or RAF inhibitors.  ",drug
"1. Prior treatment with an anti-CD123-directed agent, with the exception of patients with relapsed disease after flotetuzumab treatment.",drug
1. Prior treatment with CD33 antibody.,drug
1st line combination of checkpoint inhibitor and chemotherapy,drug
"5-alpha reductase inhibitors (e.g., finasteride, dutasteride)",drug
"5-alpha-reductase inhibitors - patients already taking 5-alpha-reductase inhibitors prior to 28 days prior to registration may stay on these agents throughout the course of therapy, but these should not be started while patients are on study",drug
"A minimum washout period of at least 5 half-lives between the last dose of ALK or ROS inhibitor therapy and the first dose of study treatment is required. A shorter washout period may be considered in the event of disease flare, after discussion with the Sponsor.",drug
A strong P-glycoprotein (P-gp) inhibitor or inducer. Subjects who are taking such medications but who are otherwise eligible may be enrolled if they discontinue the medication >= 1 week before dosing,drug
Administration of strong/potent cytochrome P3A4 (CYP3A4) inhibitors or inducers within 14 days prior to the first dose of study treatment and while on treatment with alectinib,drug
Administration of strong/potent cytochrome P450 (CYP)3A inhibitors or inducers within 14 days,drug
All biologic agents including hematopoietic growth factors must have been stopped at least 1 week prior to Day 1 of treatment on the study.,drug
"All CYP2C8 inhibitors, inducers, and substrates should be discontinued >= 7 days prior to registration; systemic treatment with CYP2C8 inhibitors (anastrozole, montelukast, quercetin, trimethoprim, gemfibrozil, rosiglitazone, pioglitazone), inducers (carbamazepine, phenytoin, rifabutin, rifampin), or substrates (amiodarone, repaglinide, rosiglitazone, sorafenib, torsemide) should be discontinued >= 7 days prior to registration",drug
Angiotensin-converting enzyme (ACE) inhibitors: Patients who are currently receiving ACE inhibitors are not eligible due to the development of angioneurotic edema-type reactions in some subjects who received concurrent treatment with temsirolimus + ACE inhibitors. At least 3 half-lives must have elapsed after the last dose of ACE inhibitors.,drug
Anti-CD20 antibody treatment within 4 weeks of cell infusion.,drug
"Anti-leukemic agents given as post-transplant maintenance therapy (e.g., subcutaneous or oral 5-azacytidine or FLT3 inhibitors for maintenance)",drug
"Anti-retrovirals: delaviridine or protease inhibitors (ritonavir, indinavir, lopinavir/ritonavir, saquinavir, nelfinavir) or cobicistat-boosted antiretrovirals",drug
"Any hematopoietic growth factors (eg, filgrastim [granulocyte colony-stimulating factor; G-CSF], sargramostin [granulocyte-macrophage colony-stimulating factor; GM-CSF]) within 7 days of the first dose of study drug or pegylated G-CSF (pegfilgrastim) or darbepoetin within 14 days of the first dose of study drug.",drug
Any hormonal therapy directed at the malignant tumor must be discontinued at least one week prior to registration,drug
Any number and type of prior anticancer therapies are allowed except BRAF or MEK inhibitors .,drug
Any number of previous treatments with the exception of previous inhibitors of PD-1 or PD-L1.,drug
"Any number of previous treatments with the exception of previous inhibitors of PD-1, PD-L1, or PD-L2. Other prior systemic therapies must have been administered at least 2 weeks before administration of pembrolizumab; the exception to this is ipilimumab which must have been administered at least 4 weeks prior to the start of pembrolizumab. Patients are not required to have had prior systemic therapy.",drug
"Any other prior therapy directed at the malignant tumor, including chemotherapy and radiation therapy, must be discontinued at least 4 weeks prior to registration; any investigational agent must be discontinued at least 28 days prior to registration",drug
"Any other prior therapy directed at the malignant tumor, including immunologic agents, must be discontinued at least three weeks prior to registration",drug
Any P-glycoprotein (P-gp) inducers/inhibitors or strong cytochrome P4503A (CYP3A) inhibitors within 14 days prior to the first dose of study drug,drug
"Any previous treatment with a HDAC inhibitor, including Citarinostat.",drug
"Any previous treatment with a PARP inhibitor, including olaparib",drug
"Any previous treatment with a PD1 or PD-L1 inhibitor, including durvalumab",drug
"Any previous treatment with a programmed cell death protein 1 (PD1) or programmed cell death ligand 1 (PD-L1) inhibitor, including durvalumab",drug
"Any previous treatment with adoptive T cells therapy, a PD1 or PDL1 inhibitor, including durvalumab or any anti-CTLA4 therapy, including tremelimumab.",drug
"Any previous treatment with PARP inhibitor, including olaparib.",drug
"Any prior arterial liver-directed therapy, including chemoembolization, bland embolization, and 90Y radioembolization",drug
"Any prior therapy directed at the malignant tumor, including immunologic agents and chemotherapy, must be discontinued at least four weeks prior to registration (6 weeks for nitrosoureas or mitomycin C).",drug
"Any prior treatment with either a MEK, RAS, or RAF inhibitor for advanced or metastatic NSCLC.",drug
"At least 2 prior regimens, which must include at least 1 approved proteasome inhibitor (bortezomib, carfilzomib, or ixazomib) and at least 1 approved immunomodulatory agent (thalidomide, lenalidomide, or pomalidomide), with or without maintenance therapy, unless patients are intolerable to such agents or ineligible to receive such agents.",drug
"At least 21 days must have elapsed since the completion of the last dose of VEGF-Trap, and at least 7 days since a VEGF blocking tyrosine kinase inhibitor. Subjects must have recovered from any VEGF blocking drug-related toxicity (e.g., proteinuria).",drug
At least 3 half-lives must have elapsed from any prior systemic inhibitory/stimulatory immune checkpoint molecule therapy prior to enrollment,drug
"At least 3 prior lines of MM therapy, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 antibody (unless contraindicated), and refractory to the last treatment line.",drug
At least 4 weeks must have elapsed since completion of antibody-directed therapy,drug
At least 4 weeks since any prior systemic therapy (excluding corticosteroid therapy) to treat the underlying malignancy (standard or investigational). NOTE: subjects on FDA-approved tyrosine kinase inhibitors or other targeted therapies for RCC such as mTOR inhibitors that have evidence of disease progression on therapy may continue these medicines until the time of study enrollment (as accelerated disease progression following discontinuation of these drugs has been described).,drug
"At least 90 days post chemotherapy, biologic therapy, or radiation therapy treatment and/or breast surgery. Current use of hormonal therapy is permitted (e.g., tamoxifen and aromatase inhibitors).",drug
be treatment naive for 3rd generation EGFR-TKI (CO-1686 and osimertinib [AZD9291]) and mTOR inhibitors,drug
"be treatment naive to 3rd generation EGFR-TKI (rociletinib, EGFR inhibitor HM61713 [HM61713] and AZD9291) and EGFR monoclonal antibodies",drug
"be treatment naive to T790M-directed EGFR TKI (e.g. AZD9291, rociletinib, etc); T790M testing may be done locally or centrally on study, but if done locally, tissue must be available for central confirmation",drug
Biologic (anti-cancer agent): The last dose of all biologic agents for the treatment of the patient's cancer (such as retinoids or tyrosine kinase inhibitors) must be at least 7 days prior to study entry.,drug
"Chemo-, hormon-, radio-(except for brain and extremities) or immunotherapy or therapy with monoclonal antibodies or small tyrosine kinase inhibitors within the past 4 weeks prior to treatment with the trial drug",drug
"Chemotherapy, small molecule inhibitors, radiation, and/or other investigational anticancer agents (excluding investigational monoclonal antibodies): 2 weeks.",drug
"Chemotherapy, targeted therapy (such as a tyrosine kinase inhibitor) or therapeutic radiotherapy must have been completed at least 14 days prior to administration of T cells. Continuation of hormonal therapy (ie for breast cancer) is acceptable. Prior immunotherapy with checkpoint blockade (i.e. PD1 inhibitor, PDL1 inhibitor or CTL4-antagonist or similar agent) must have been completed more than 1 month1prior to the T cell infusion.",drug
"Chemotherapy, targeted therapy (such as a tyrosine kinase inhibitor), or radiotherapy must have been completed at least 14 days before administration of T-cells. Prior immunotherapy with checkpoint blockade (i.e., PD1 inhibitor, PDL1 inhibitor, or CTL4-antagonist or similar agent) must have been completed more than 1 month before the T-cell infusion.",drug
"Chemotherapy, Tyrosine Kinase Inhibitor therapy, radiation therapy or hormonal therapy within 2 weeks",drug
"Co-administration with strong inhibitors of CYP3A4 (e.g., ketoconazole, itraconazole, ritonavir) or P-glycoprotein (PgP) is prohibited. Co-administration with moderate CYP3A4 inhibitors (e.g., erythromycin, fluconazole) or PgP inhibitors may be used with caution and everolimus dosing must be discussed with PI at the time of enrollment. For a current table of Substrates, Inhibitors and Inducers please access the following website:http://www.fda.gov/Drugs/DevelopmentApprovalProcess/ ",drug
"Concomitant therapy with bisphosphonates, RANKL inhibitors or growth-colony-stimulating factor (G-CSF) is allowed as per physician decision.",drug
"Concomitant therapy with potent inhibitors of CYP450 3A4 (e.g. ketoconazole, verapamil etc) or with potent CYP450 1A2 inhibitors (fluoroquinolone antibiotics including ciprofloxacin, levofloxacin, and norfloxacin; ticlodipine, cimetidine, amiodarone,etc. see Appendix C)",drug
Concomitant treatment with strong inhibitor of P-gp,drug
"Concomitant treatment with strong inhibitors or inducers of CYP3A4, CYP2C9 and CYP2C19 within 14 days prior to enrollment and during the study unless there is an emergent or life-threatening medical condition that required it.",drug
"Concomitant use of a strong CYP3A inhibitors (e.g., itraconazole, telithromycin, clarithromycin, ketoconazole, voriconazole, nefazodone, posaconazole, ritonavir, lopinavir/ritonavir, indinavir, saquinavir, nelfinavir, boceprevir, telaprevir) and moderate CYP3A inhibitors (e.g., amprenavir, aprepitant, atazanavir, ciprofloxacin, crizotinib, darunavir/ritonavir, diltiazem, erythromycin, fluconazole. Fosamprenavir, imatinib, verapamil)",drug
Concomitant use of bisphosphonates or RANK-ligand inhibitors is allowed,drug
Concomitant use of CYP3A4 inhibitors,drug
Concomitant use of CYP3A4 inhibitors where the interaction is thought too great to proceed with romidepsin.,drug
"Concomitant use of cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4) inhibitors",drug
Concomitant use of known potent cytochrome P450 isoform 3A4 (CYP3A4) inhibitors,drug
"Concomitant use of known strong CYP3A inhibitors (e.g. itraconazole, telithromycin, clarithromycin, protease inhibitors boosted with ritonavir or cobicistat, indinavir, saquinavir, nelfinavir, boceprevir, telaprevir) or moderate CYP3A inhibitors (e.g. ciprofloxacin, erythromycin, diltiazem, fluconazole, verapamil); the required washout p",drug
Concomitant use of known strong CYP3A inhibitors or moderate CYP3A inhibitors,drug
Concomitant use of known strong cytochrome P450 (CYP) 3A (CYP3A) inhibitors or moderate CYP3A inhibitors. Concomitant use of known strong or moderate CYP3A inducers.,drug
Concomitant use of other histone deacetylase (HDAC) inhibitors,drug
Concomitant use of strong CYP3A4 inhibitors and inducers,drug
Concurrent administration of strong inducers and inhibitors of CYP3A enzyme or CYP3A substrates with narrow therapeutic window,drug
Concurrent administration of strong inhibitors or moderate inducers of CYP1A2 is not permitted; administration must be discontinued at least 7 days prior to initiating study drug administration.,drug
Concurrent brain directed therapy (beyond SRS and NovoTTF-100M as per protocol),drug
"Concurrent or planned systemic chemotherapy, radiotherapy, new hormonal or anti-HER2 directed therapy directed at management of breast cancer (existing anti-HER2 therapy can be continued as recently recommended in the National Consensus Guidelines",drug
"Concurrent or planned treatment with strong inhibitors or strong inducers of cytochrome P450 family 3, subfamily A, polypeptide 4/5 (3A4/5); (a one-week wash-out period is necessary for patients who are already on these treatments)",drug
"Concurrent therapy with strong inhibitors or inducers of cytochrome P450 family 3, subfamily A, polypeptide 4 (CYP3A4) or cytochrome P450 family 2, subfamily C, polypeptide 8 (CYP2C8) due to concerning possible drug-drug interactions",drug
Concurrent treatment with strong CYP3A4 inhibitors or inducers.,drug
"Concurrent use of a strong CYP3A4 inhibitor or inducer (refer to Section 7). These medications should be discontinued or switched to a different medication with a weaker CYP3A4 interaction prior to enrollment into the study. If patients need to continue the same medication(s), they are excluded from the study.",drug
"Concurrent use of drugs that are known to be moderate or strong cytochrome P450, family 3, subfamily A (CYP3A) inhibitors or inducers or drugs that are known to prolong the QT interval",drug
"Concurrent use of inhibitors or inducers of CYP3A4, or medications which prolong the QTc interval",drug
"Concurrent use of other antiandrogens, estrogen-like agents, or 5a-reductase inhibitors.",drug
Concurrent use of potent cytochrome P450 (CYP)3A4 inhibitors,drug
Concurrent use of selective serotonin reuptake inhibitors or aromatase inhibitors.,drug
Concurrent use of systemic immune suppressive other than calcineurin inhibitors and sirolimus,drug
Condition requiring treatment with strong inhibitors/inducers of cytochrome (CYP) p450 3A4 within 7 days prior to first dose of chemotherapy (requirement applies to subjects enrolled to Part 2 chemotherapy combination with docetaxel).,drug
Contraindication to the use of etoposide or cisplatin,drug
"Current HRT, SERM or Aromatase Inhibitor (AI) use. If yes, the wash-out period is 30 days before diagnostic core needle biopsy.",drug
"Current or previous use of 5α-reductase inhibitors, antiandrogen drugs, metformin, oral or injectable diabetes drug",drug
"Current or prior androgen deprivation therapy. A history of use of a 5-α reductase inhibitor is allowed, provided it was discontinued at least one month prior to study entry.",drug
"Current systemic use of medications known to interact with statins and potentially increase toxicity, including gemfibrozil, cyclosporine, danazol, lomitapide, verapamil, diltiazem, dronedarone, amiodarone, amlodipine, ranolazine, strong CYP3A4 inhibitors (e.g., itraconazole, ketoconazole, posaconazole, voriconazole, human immunodeficiency virus [HIV] protease inhibitors, boceprevir, telaprevir, erythromycin, clarithromycin, telithromycin, nefazodone, or cobicistat-containing products), or strong CYP3A4 inducers (e.g., carbamazepine, phenytoin, rifampin, St. John's wort, bosentan, efavirenz, etravirine, modafinil, nafcillin)",drug
Current treatment with tamoxifen or aromatase inhibitors,drug
Current treatment with tyrosine kinase inhibitors,drug
"Current use of (other N-methyl D-aspartate [NMDA] antagonists) amantadine, ketamine, or dextromethorphan",drug
"Current use or anticipated need for food or drugs that are known strong CYP3A4 inhibitors (i.e., grapefruit juice, verapamil, ketoconazole, miconazole, itraconazole, posaconazole, erythromycin, clarithromycin, telithromycin, indinavir, saquinavir, ritonavir, nelfinavir, lopinavir, atazanavir, amprenavir, fosamprenavir, nefazodone, diltiazem, and delavirdine) or inducers (i.e. dexamethasone, glucocorticoids, progesterone, rifampin, phenobarbital, St. John's wort).",drug
"Currently on no active treatment for breast cancer and at least 3 months post all the treatments, with the exception of aromatase inhibitors (exemestane, anastrozole, letrozole)",drug
"Currently receiving treatment, including medications and herbal preparations, with known strong inducers or inhibitors of cytochrome p450 enzymes CYP3A4/5 medications that have a narrow therapeutic window and are predominately metabolized through CYP3A4/5 or herbal preparations/medications, dietary supplements, which cannot be discontinued at least one week prior to receiving investigational drug. Anti-retrovirals, anti-microbials, and anti-arrhythmics are the most common medications that interact with these enzymes. Section 5: Pharmaceutical Information and Appendix B for more information and a list of drugs that should not be used concurrently with ribociclib. An additional reference can be the CT scholar tool designed for Novartis Oncology",drug
Currently using concomitant medications that are strong inhibitors or inducers of CYP3A4.,drug
"CYP3A4 inducers: patients chronically receiving drugs that are known potent CYP3A4 inducers within 12 days prior to study enrollment, including but not limited to carbamazepine, phenobarbital, phenytoin, rifabutin, rifampin, ritonavir, and St. John's wort are not eligible; the topical use of these medications (if applicable) is allowed",drug
Cytochrome (CYP) -17 inhibitors (e.g. ketoconazole),drug
"Cytochrome P450 (CYP)-17 inhibitors (e.g. abiraterone, ketoconazole)",drug
"Documented history of prior tamoxifen, aromatase inhibitor, or raloxifene in last 6 months",drug
"Drugs that affect the cytochrome P450 family 3 subfamily A polypeptide 4 (CYP3A4) system (inducers/inhibitors/substrates) are allowed but should be used with caution depending on specific kinase inhibitor used; dietary supplements will be discouraged; however, their use may be allowed on a case by case basis per the discretion of the investigator after consultation with an oncology pharmacist",drug
"Drugs that affect the cytochrome P450 family 3, subfamily A, polypeptide 4 (CYP3A4) systems are allowed but should be used with caution depending on specific kinase inhibitor used",drug
"Drugs with potent cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4) inhibitors and inducers should be avoided during the course of treatment",drug
"Endocrine therapy and other prior HER2-directed therapy, including pertuzumab, TDM-1 is permitted",drug
"For cohort 2, received > 30 days of prior treatment with endocrine therapy +/- CDK4/6 inhibitors before screening (letrozole is allowed for prior adjuvant endocrine therapy)",drug
For Cohort A: Is currently receiving strong or moderate inhibitors of CYP3A4 including azole antifungals; macrolide antibiotics; or protease inhibitors,drug
For Cohort B: Is currently receiving any of the following classes of inhibitors of CYP3A4: azole antifungals; macrolide antibiotics; or protease inhibitors,drug
"For Cohort C: Has received treatment with 5-α reductase inhibitors (e.g., finasteride, dutasteride), estrogens, and/or cytproterone within 4 weeks prior to Cycle 1",drug
"For Part D (LY2835219 + exemestane): The participant must have received prior systemic endocrine therapy with at least one nonsteroidal aromatase inhibitor (anastrozole, letrozole) for metastatic disease and may be receiving ongoing therapy with exemestane.",drug
"For Part E (LY2835219 + exemestane + everolimus): The participant must have received prior systemic endocrine therapy with at least one nonsteroidal aromatase inhibitor (anastrozole, letrozole) for metastatic disease and may be receiving ongoing therapy with either exemestane or exemestane + everolimus.",drug
"For Part G (abemaciclib + LY3023414 + fulvestrant): The participant may have received prior systemic endocrine therapy with at least one nonsteroidal aromatase inhibitor (anastrozole, letrozole) for metastatic disease.",drug
"For Parts A, B, C, D, E, F, H: Have received prior therapy with a CDK4/6 inhibitor, Part G: Have received prior therapy with fulvestrant or any PI3K and/or mTOR inhibitor (including LY3023414); Part I: Have received prior treatment with abemaciclib in any setting.",drug
"For two weeks prior to first day of study drug treatment, administration of any of the following cytochrome P450 3A (CYP3A) inducers: phenytoin, phenobarbital, carbamazepine, rifampin, rifabutin, St. John's Wort; or CYP3A inhibitors: ketoconazole, itraconazole, nefazodone, ritonavir, nelfinavir, indinavir, atazanavir amprenavir, fosamprenavir, boceprevir, clarithromycin, conivaptan, lopinavir, posaconazole, saquinavir, telaprevir, telithromycin, or voriconazole",drug
"For UC cohort 5: Minimum of 1 and maximum of 2 prior regimens, one of which must have included a checkpoint inhibitor.",drug
Has had prior exposure to tazemetostat or other inhibitor(s) of enhancer of zeste homologue-2 (EZH2),drug
Has had prior exposure to tazemetostat or other inhibitor(s) of EZH2,drug
Has had prior systemic cancer therapy within the past four weeks or v-raf murine sarcoma viral oncogene homolog B (B-RAF) or mitogen-activated protein kinase (MEK) inhibitors within 7 days at the time of the start of the lymphodepletion regimen (Turnstile II),drug
"Has received hematopoietic colony-stimulating growth factors (eg, granulocyte-colony stimulating factor, granulocyte-macrophage-colony stimulating factor, macrophage colony stimulating factor) within 2 weeks prior to the first dose of study intervention.",drug
Has received previous treatment with another agent targeting the T cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif (TIGIT) receptor,drug
"Has received prior immunotherapy including anti-PD-1, anti-PD-L1, or anti-PD-L2 agents, or with an agent directed to another stimulatory or co-inhibitory T cell receptor (eg, CTLA-4, OX-40, CD137), or has previously participated in Merck pembrolizumab or PEGPH20 clinical trials",drug
"Has received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2 agent, anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell costimulation or immune checkpoint pathways.",drug
"Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti PD L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g., CTLA-4, OX 40, CD137), interferon, high dose IL-2 or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways.",drug
"Has received prior therapy with an anti-Programmed Death 1 (PD-1), anti-Programmed Death Ligand 1 (PD-L1), or anti-PD-L2 agent.",drug
Has received prior therapy with any immune checkpoint inhibitor,drug
Has received therapy with hematopoietic growth factor such as granulocyte-colony stimulating factor (G-CSF) or granulocyte-monocyte-colony stimulating factor(GM-CSF) in 14 days prior to randomization.,drug
"have been treated with a third generation TKI (eg, osimertinib) in either the front line or second-line setting, and are not eligible for enrollment in either Cohort C or MET-1 For Part 2 only: Participants must also have disease with a previously diagnosed activating epidermal growth factor receptor (EGFR) mutation (includes both inhibitor sensitive primary mutations such as Exon 19 deletion and L858R [Cohort C, E, and MET-1], as well as marketed tyrosine kinase inhibitor [TKI] -resistant mutations such as Exon 20 insertion [Cohort C, D and MET-1] or activating cMet Exon 14 skipping mutation [Cohort MET-2]). Documentation of primary activating EGFR or cMet mutation eligibility by CLIA-certified laboratory (or equivalent) testing is required",drug
Have received at least 2 doses of an approved PD-1/L1 inhibitor (by any regulatory authority),drug
"Have received at least 2 prior lines of anti-HER2 directed therapy in the metastatic setting, or in case of having received (neo)adjuvant pertuzumab, at least 1 prior line of anti-HER2 directed therapy in the metastatic setting. In either case, patients must have received prior treatment with pertuzumab, in the (neo)adjuvant or metastatic setting. Prior radiotherapy, hormonal therapies, and other anti-HER2 therapies are allowed.",drug
"Have received at least 3 prior lines of therapy, including a proteasome inhibitor [PI] and an immunomodulatory agent [IMiD] OR have disease that is double refractory to a PI and IMiD",drug
Have received at least one prior course of treatment for ccRCC. Part C only: Prior treatment must include at least 1 course of VEGF-directed therapy.,drug
"Have received prior treatment with chemotherapy (except for neoadjuvant/ adjuvant chemotherapy), fulvestrant, everolimus, or any CDK4/6 inhibitor. For the endocrine naïve cohort: In addition, have received treatment with any prior endocrine therapy",drug
"Have received treatment with any form of therapy with CYP17 inhibitory activity such as ketoconazole, aminoglutethimide, or an antiandrogen such as bicalutamide within 6 months of study treatment initiation.",drug
"Have used a strong CYP3A4 or CYP2C8 inhibitor within 5 half-lives of the inhibitor, or a strong CYP3A4 or CYP2C8 inducer within 5 days prior to first dose of study treatment",drug
"Having gotten prior programmed cell death protein 1 (PD1) therapy is allowed for, especially if they have previously progressed on it; progression may include extra-cranial as well as intra-cranial progression; after progressing on PD1 therapy, intervening chemotherapy and/or targeted therapy (BRAF inhibitors [BRAFi], etc) is allowed; if they are on intervening chemotherapy and/or targeted therapy (BRAFi, etc), they have to have progression intra-cranially and/or extra-cranially and must be off intervening therapy for at least 2 weeks",drug
Hematopoietic growth factor (>= 14 days from last dose of hematopoietic growth factor prior to first dose of tazemetostat),drug
Hematopoietic growth factor (At least 14 days from last dose of hematopoietic growth factor prior to first dose of tazemetostat),drug
Hematopoietic growth factors- At least 7 days must have elapsed since the last dose of G-CSF or GM-CSF. At least 14 days must have elapsed since last dose of pegfilgrastim (Neulasta®).,drug
Hematopoietic growth factors.,drug
"Hematopoietic growth factors: >= 14 days after the last dose of a long-acting growth factor (e.g. Neulasta) or 7 days for short-acting growth factor; for agents that have known adverse events occurring beyond 7 days after administration, this period must be extended beyond the time during which adverse events are known to occur; the duration of this interval must be discussed with the study chair and the study-assigned research coordinator",drug
"Hematopoietic growth factors: >= 14 days after the last dose of a long-acting growth factor (e.g. Peg-Filgrastim) or 7 days for short-acting growth factor. For agents that have known adverse events occurring beyond 7 days after administration, this period must be extended beyond the time during which adverse events are known to occur. The duration of this interval must be discussed with the study chair and the study-assigned Research Coordinator.",drug
"Hematopoietic growth factors: >= 14 days after the last dose of a long-acting growth factor (e.g. pegfilgrastim) or 7 days for short-acting growth factor. For growth factors that have known adverse events occurring beyond 7 days after administration, this period must be extended beyond the time during which adverse events are known to occur. The duration of this interval must be discussed with the study chair and the study-assigned research coordinator.",drug
"Hematopoietic growth factors: >= 14 days after the last dose of a long-acting growth factor (e.g. pegfilgrastim) or 7 days for short-acting growth factor; for growth factors that have known adverse events occurring beyond 7 days after administration, this period must be extended beyond the time during which adverse events are known to occur; the duration of this interval must be discussed with the study chair and the study-assigned research coordinator",drug
Hematopoietic growth factors: At least 14 days after the last dose of a long-acting growth factor (e.g. Neulasta) or 7 days for short-acting growth factor.,drug
"Hematopoietic growth factors: At least 14 days after the last dose of a long-acting growth factor (e.g. Pegfilgrastim) or 7 days for short acting growth factor. For agents that have known adverse events occurring beyond 7 days after administration, this period must be extended beyond the time during which adverse events are known to occur. The duration of this interval must be discussed with the study chair.",drug
"Hematopoietic growth factors: At least 14 days after the last dose of a long-acting growth factor (e.g. pegfilgrastim) or 7 days for short-acting growth factor; for agents that have known adverse events occurring beyond 7 days after administration, this period must be extended beyond the time during which adverse events are known to occur; the duration of this interval must be discussed with the study chair",drug
"Hematopoietic growth factors: at least 14 days after the last dose of a long-acting growth factor (e.g., pegfilgrastim) or 7 days for short-acting growth factor; for agents that have known adverse events occurring beyond 7 days after administration, this period must be extended beyond the time during which adverse events are known to occur",drug
Hematopoietic growth factors: At least 14 days after the last dose of long acting hematopoietic growth factor (e.g. Neulasta) or 7 days for short acting growth factor (e.g. Neupogen),drug
Hematopoietic growth factors: At least 7 days must have elapsed since the completion of therapy with a growth factor,drug
Hematopoietic growth factors: At least 7 days must have elapsed since the completion of therapy with a growth factor. At least 14 days must have elapsed after receiving pegfilgrastim.,drug
Hematopoietic growth factors: At least 7 days must have elapsed since the completion of therapy with a growth factor. At least 14 days must have elapsed since receiving pegfilgrastim.,drug
Hematopoietic growth factors: At least 7 days must have elapsed since the completion of therapy with granulocyte colony-stimulating factor (G-CSF) or other growth factor at the time of enrollment. At least 14 days must have elapsed since the completion of therapy with pegfilgrastim.,drug
Hematopoietic Growth Factors: At least 7 days since the completion of therapy with short-acting hematopoietic growth factors and 14 days with long-acting growth factors.,drug
Hematopoietic growth factors: It must have been at least 7 days since the completion of therapy with G-CSF or other growth factors at the time of enrollment. It must have been at least 14 days since the completion of therapy with pegfilgrastim (Neulasta®).,drug
Hematopoietic growth factors: It must have been at least 7 days since the completion of therapy with GCSF or other growth factors at the time of enrollment. It must have been at least 14 days since the completion of therapy with pegfilgrastim (Neulasta®).,drug
Hematopoietic growth factors: It must have been at least seven days since the completion of therapy with granulocyte colony-stimulating factor (GCSF) or other growth factors at the time of enrollment. It must have been at least 14 days since the completion of therapy with pegfilgrastim (Neulasta®).,drug
"History of discontinuation of any previous treatment with PARP inhibitors, including olaparib, or a PD-1 or PD-L1 inhibitor, including durvalumab or anti-CTLA4 antibody, including tremelimumab due to toxicity.",drug
History of exposure to alvocidib or any other cyclin-dependent kinase 9 (CDK9) inhibitor.,drug
"Immune-checkpoint inhibitors (e.g., anti-PD-1, anti-PD-L1, or anti-CTLA-4), monoclonal antibodies, antibody-drug conjugates, radioimmunoconjugates, or T-cell or other cell-based therapies: 4 weeks (2 weeks with documented disease progression).",drug
"Interleukins, interferons and cytokines (other than hematopoietic growth factors): >= 21 days after the completion of interleukins, interferon or cytokines (other than hematopoietic growth factors )",drug
"Interleukins, Interferons and Cytokines (other than hematopoietic growth factors): >= 21 days after the completion of interleukins, interferon or cytokines (other than hematopoietic growth factors).",drug
"Interleukins, Interferons and Cytokines (other than Hematopoietic Growth Factors): >= 21 days after the completion of interleukins, interferon or cytokines (other than Hematopoietic Growth Factors)Stem cell Infusions (with or without TBI).",drug
is currently taking strong CYP3A4 inhibitor or concomitant meds.,drug
Is receiving concomitant treatment with a strong inhibitor or inducer of cytochrome P450 3A4/5.,drug
Is receiving treatment with medication(s) that are known to be strong inhibitors or inducers of CYP3A4/5.,drug
"It is recommended to utilize a regimen of the integrase inhibitor, dolutegravir, combined with either disoproxil fumarate/emtricitabine or dolutegravir combined with tenofovir alafenamide/emtricitabine",drug
Known strong inducers or inhibitors of CYP2D6.,drug
"Medications known to be strong inhibitors (gemfibrozil) or inducers (rifampin) of cytochrome P450 (CYP) 2C8 or medications known to be strong CYP3A4 inhibitors (eg, ketoconazole) or inducers (eg, rifampin or St. John's Wort). Subjects who are currently taking such medications but who are otherwise eligible may be enrolled if they discontinue the medication 1 week before dosing and remain off that medication during treatment with Oraxol.",drug
MEK inhibitor,drug
Module 2 Part B All - No previous treatment with PARP inhibitor.,drug
Monoamine oxidase inhibitors.,drug
"Monotherapy Arm (Arm 1): Previously treated with a JAK inhibitor and be intolerant, resistant, refractory or lost response to the JAK inhibitor",drug
"More than one prior line of chemotherapy in the metastatic setting 2. Washout of 2 weeks is required for aromatase inhibitors; washout of 4 weeks is required for, everolimus or other biological agents.",drug
"Must have appropriate wash out ( > 6 half-lives) of androgen receptor antagonists, 5 alpha reductase inhibitors or ketoconazole prior to the start of cycle 1; if the agent is not in the table below, the washout should be 2 weeks",drug
Must have completed at least 4 cycles of adjuvant/neo-adjuvant cytotoxic chemotherapy between 1 and 5 years prior to registration (Ongoing herceptin or other chronic HER 2 directed therapies are allowed).,drug
"Must have received at least 2 prior therapies approved for CRPC; including a prior AR inhibitor (e.g., enzalutamide or apalutamide). (Part 1 only)",drug
"No  prior treatment with a CDK4/6 inhibitor (Ribociclib, Palbociclib, Abemaciclib).",drug
"No current history of receiving hormonal therapy, tamoxifen, and or aromatase inhibitors for therapeutic measures",drug
"No more than 3 prior treatment regimens (including primary therapy; no more than 1 prior non-platinum based therapy in the platinum-resistant/-refractory setting); hormonal therapies used as single agents (i.e. tamoxifen, aromatase inhibitors) will not count towards this line limit",drug
"No prior chemotherapy in the recurrent setting. Prior hormonal therapy is permitted. Concomitant anti-neoplastic anti-hormonal therapy (including tamoxifen, aromatase inhibitors etc.) is not allowed for patients participating in study treatment. Low-dose (physiologic) estrogen hormone-replacement therapy (HRT) may be given.",drug
"No prior cisplatin, oxaliplatin, nitrosoureas, or mitomycin",drug
No prior EGFR tyrosine kinase inhibitor (TKI) therapy (Cohort 1),drug
"No prior immune checkpoint inhibitors (e.g., anti-CTLA4, anti-PD-1 or anti-PDL1) are allowed.",drug
No prior systemic anticancer therapy (including EGFR and ALK inhibitors),drug
No prior systemic anti-cancer therapy for advanced HR+ disease. NOTE: Subjects receiving adjuvant treatment with aromatase inhibitors at time of recurrence are allowed to participate. There is no AI washout period required.,drug
"No prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent (programmed cell death protein 1 [PD-1] and its ligands, programmed cell death ligand 1 (PD-L1) and programmed cell death ligand 2 [PD-L2]) or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, CTLA-4, OX-40, CD137).",drug
No prior treatment with a VEGF inhibitor,drug
No prior treatment with an aurora Kinase inhibitor (either an aurora A or pan-aurora kinase inhibitor),drug
"No prior treatment with an immune checkpoint inhibitor (anti-programmed cell death [PD]-1, anti-PD-L1, anti-cytotoxic T-lymphocyte-associated protein 4 [CTLA4] monoclonal antibody)",drug
No prior treatment with CB-839 or palbociclib,drug
No prior treatment with crizotinib or another ALK inhibitor,drug
"no prior treatment with fulvestrant, everolimus",drug
No prior treatment with T-DM1 is allowed,drug
No strong inducers of cytochrome P450 (CYP) 3A4 or CYP1A2 or strong inhibitors of CYP3A4 or CYP1A2 within 14 days prior to registration,drug
"Not previously received XL184 or another MET/HGF inhibitor (tivantinib or crizotinib); there are no limits on number of prior therapeutic regimens; patients who have been treated with prior VEGF pathway, or RET inhibitors (except XL184) may be eligible",drug
"Novel androgen-directed therapies (e.g., abiraterone, enzalutamide)",drug
Off biologic therapies including hematopoietic growth factors >= 1 week,drug
"Ongoing therapy with a P-gp inhibitor (e.g., nelfinavir, indinavir, or saquinavir-protease inhibitors for HIV) as these drugs interact with the factor Xa inhibitors",drug
Only granulocyte colony-stimulating factor (G-CSF) mobilized peripheral blood stem cell (PBSC) will be permitted as a hematopoietic stem cell (HSC) source on this protocol,drug
"Other monoclonal antibodies, antibody-drug conjugates, radioimmunoconjugates, or experimental therapies: <= 4 weeks ( <= 3 weeks with documented disease progression).",drug
"Other RBC hematopoietic growth factors (eg, Interleukin-3)",drug
"Other targeted anti-cancer therapy (chemotherapy, molecular targeted therapy, steroids) within 14 days or 5 half lives (which ever is longer) prior to first dose of AMG 562. Patients requiring continued treatment due to aggressive disease may only be included if there is agreement by both the investigator and the Amgen Medical Monitor.",drug
"Others: greater than or equal to 7 days from last dose of short active hematopoietic growth factors, i.e. filgrastim, greater than or equal to 14 days for long-acting, i.e. pegfilgrastim.",drug
Patient is receiving any azole.,drug
Patients may not have previously received a PARP-inhibitor,drug
Patients may not have received prior HER2 directed therapies,drug
"Patients may not have received prior MEK, v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS), or v-raf murine sarcoma viral oncogene homolog B1 (BRAF) inhibitor therapy",drug
"Patients may not receive strong cytochrome P450, family 2, subfamily C, polypeptide 8 (CYP2C8) inhibitors, CYP2C8 inducers, or cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4) inducers; in addition, patients should not receive drugs that are metabolized by CYP3A4 or cytochrome P450, family 2, subfamily C, polypeptide 9 (CYP2C9)",drug
"Patients must be at least 2 weeks from last treatment with a proteasome inhibitor (e.g., bortezomib, carfilzomib) at time of treatment on this protocol.",drug
"Patients must have previously received an aromatase inhibitor in the adjuvant, neo-adjuvant or metastatic setting.",drug
"Patients must have received a biologic therapy (e.g. interleukin 2) and a BRAF and/or MEK inhibitor (if tumor contains the V600E or V600K mutation) for 628 metastatic disease. If patient did not receive such agents, rationale for not treating the patients with the 629 agent must be cleared with the study PI (ie no V600e/k BRAF mutation or patient with autoimmunity, thus 630 not eligible for biologic therapy).",drug
"Patients must have received at least three prior lines of therapy, including an immunomodulatory drug (e.g. lenalidomide, pomalidomide), a proteasome inhibitor (e.g. bortezomib, carfilzomib), and anti-CD38 monoclonal antibody (e.g. daratumumab)",drug
"Patients must not be receiving any of the following potent CYP3A4 inducers or inhibitors: erythromycin, clarithromycin, ketoconazole, azithromycin, itraconazole, grapefruit juice or St. John's wort",drug
"Patients must NOT be receiving valproic acid, an histone deacetylase (HDAC) inhibitor, and may not have previously received any HDAC inhibitor prior to enrollment (e.g. valproic acid, entinostat, vorinostat) unless discussed with the study chair; patients must not have received prior HDAC therapy for the treatment of their malignancy",drug
"Patients must not be taking, nor plan to take while on protocol treatment, strong CYP3A4 inhibitors (e.g. boceprevir, cobicistat, danoprevir, elvitegravir/RIT, fluvoxamine, indinavir, itraconazole, ketoconazole, lopinavir/RIT, nefazodone, nelfinavir, posaconazole, ritonavir, telaprevir, telithromycin, tipravavir/RIT, or voriconazole); strong CYP3A4 inducers (e.g. avasimibe, phenytoin, rifampin, rifabutin); potent inhibitors of CYP1A2 (e.g. ciprofloxacin); and/or drugs known to be CYP3A4 substrates with a narrow therapeutic range (e.g., diergotamine, ergotamine) within 14 days prior to randomization; moderate inhibitors or inducers of isoenzyme CYP3A4 should be avoided, but if necessary can be used with caution",drug
"Patients must not currently be receiving any other investigational agents or any other systemic anti-cancer therapy (including radiation, excluding RANKL inhibitors and bisphosphonates); in event patient recently received any other systemic anti-cancer therapy, patient must be off therapy at least 7 days prior to registration and any therapy-induced toxicity must have recovered to <= grade 1, except alopecia and <= grade 2 neuropathy which are allowed; any planned radiation therapy must be completed before registration to S1609",drug
Patients must not have been treated with CHK1/2 inhibitors,drug
"Patients must not have had any systemic therapy (chemotherapy or combination regimens) in the 180 days just prior to registration. Prior biologic therapy, immunotherapy, tyrosine kinase inhibitors, and hormonal therapy are allowed.",drug
Patients must not have had prior treatment with nivolumab or any other PDL1 or PD-1 antagonists,drug
"Patients must not have prior exposure to mTOR inhibitors (rapamycin, everolimus, temsirolimus, deforolimus)",drug
Patients must not have received a prior BRAF or mitogen-activated protein kinase kinase (MEK) inhibitor,drug
"Patients must not have received any prior immune-oncology regimens, including but not limited to checkpoint inhibitors such as anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T cell co-stimulation or checkpoint pathways, indoleamine 2,3-dioxygenase pathway inhibitors, cancer vaccines, adoptive cell therapies, or other cytokine therapies.",drug
"Patients receiving CYP3A substrates with narrow therapeutic indices, strong CYP3A inhibitors, and strong CYP3A inducers.",drug
Patients receiving strong inducers or inhibitors of cytochrome P450 3A4 (CYP3A4),drug
Patients receiving treatment with azoles such as fluconazole or voriconazole which are potent inhibitors of temsirolimus metabolism. At least 3 half-lives must have elapsed after the last dose of azoles.,drug
Patients requiring a strong inhibitor or inducer of CYP3A4,drug
Patients requiring medications that are strong inducers or strong inhibitors of CYP3A4,drug
"Patients requiring strong cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4) inhibitors",drug
Patients requiring treatment with a RANKL inhibitor (e.g. denosumab) who cannot discontinue it before treatment with atezolizumab,drug
Patients requiring treatment with a strong CYP3A4 inhibitor or inducer,drug
Patients requiring treatment with moderate CYP3A4 inhibitors,drug
Patients requiring treatment with strong CYP2C8 inhibitors,drug
Patients should be proteasome inhibitor naïve (including bortezomib and carfilzomib) OR have received less than 6 cycles of therapy with a bortezomib or carfilzomib containing regimen and were not refractory to the bortezomib or carfilzomib based regimen (less than a PR or progression on or within 60 days of discontinuation),drug
"Patients should have been off conventional therapy for at least 48 hours prior to entry in this study (except for lenalidomide, thalidomide, pomalidomide or immune checkpoint inhibitors such as CTLA4 and/or PD-1/PD-L1 inhibitors)",drug
"Patients taking 5-alpha-reductase inhibitors (e.g. finasteride, dutasteride)",drug
"Patients taking anti-arythmic agents such as amiodarone, quinidine, rifampin, ergot derivatives such as ergotamine, St John's Wort, HMG-CoA reductase inhibitors such as lovastatin, neuroleptic such as pimozide, sedatives such as midazolam and triazolam among other CYP3A4 and CYP2C19 substrates.",drug
Patients taking any medications or substances that are strong inhibitors or inducers of CYP3A or CYP2C8 are ineligible,drug
"Patients taking substrates, inhibitors, or inducers of cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4) should be encouraged to switch to alternative drugs whenever possible, given the potential for drug-drug interactions with irinotecan",drug
"Patients that are taking cytochrome P450 family 3, subfamily A, polypeptide 4 (CYP3A4) inducers and/or inhibitors; if a patient has a history of taking CYP3A4 inducers and/or inhibitors prior to enrollment on the protocol, it is strongly recommended that the patient stops the drug and waits at least 5 half-lives of said drug before initiating therapy on protocol",drug
"Patients that have previously been treated with ixazomib, or participated in a study with ixazomib whether treated with ixazomib or not",drug
"Patients that have previously been treated with ixazomib, or who participated in a blinded study with ixazomib (whether treated with ixazomib or not)",drug
Patients who have been previously treated with MET or vascular endothelial growth factor receptor (VEGFR) inhibitors (except for patients on renal cell cancer [RCC] cohort) are not eligible for the expansion cohorts but can enroll in the phase I portion,drug
"Patients who have been treated with any hematopoietic colony-stimulating growth factors (e.g., G-CSF, GM-CSF) <= 2 weeks prior to starting study drug. Erythropoietin or darbepoetin therapy, if initiated before enrollment, may be continued",drug
Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier. Patients who have had prior treatment with any PARP inhibitors are ineligible.,drug
"Patients who have had prior immune checkpoint inhibitors, such as MEDI4736 or other PD1 or PD-L1 inhibitors or an anti-CTLA4 therapy are not eligible.",drug
Patients who have had prior treatment with any PARP inhibitors are ineligible.,drug
Patients who have had prior treatment with LY2606368 or other Chk inhibitors,drug
Patients who have previously received anti-CTLA-4 antibody therapy,drug
Patients who have previously received palbociclib or other CDK4/6 inhibitors are not eligible.,drug
Patients who have prior therapy with everolimus or any other mammalian target of rapamycin (mTOR) inhibitor,drug
Patients who have received a prior PARP inhibitor are not allowed to enroll to Cohort 2 of the trial,drug
Patients who have received adequate prior treatment with a highly selective FGFR inhibitor,drug
"Patients who have received any checkpoint inhibitor, including ipilimumab, nivolumab, pembrolizumab or others.",drug
"Patients who have received any targeted therapy (including but not limited to vaccines, antibodies, tyrosine kinase inhibitors) or hormonal therapy for management of their epithelial ovarian, fallopian tube or peritoneal primary cancer",drug
Patients who have received prior anti-PD1 directed therapy (monoclonal antibody [mAb] or small molecule) are not eligible,drug
"Patients who have received prior epigenetic (e.g., histone deacetylase [HDAC] inhibitors such as entinostat, panobinostat, vorinostat, romidepsin or demethylating agents such as 5-azacitidine or decitabine) immunomodulatory or other checkpoint inhibitors should only be considered after discussion with the protocol chair",drug
"Patients who have received prior inhibitor of VEGF signaling and a poly (ADP-ribose) polymerases (PARP) inhibitor administered in combination; unless administered in combination, patients who received a prior PARP inhibitor or a prior VEGF-signaling inhibitor agent are allowed after discussing with the PI",drug
Patients who have received prior PARPi or immune checkpoint inhibitors are ineligible.,drug
"Patients who have received prior therapy with immune checkpoint inhibitors (e.g. anti-PD-1, anti-PD-L1, anti-LAG3, anti-CTLA-4) or immune costimulatory molecules (e.g. anti-CD137, anti-OX40, anti-GITR) directed agents.",drug
Patients who have received prior therapy with Taselisib (GDC-0032) or BYL-719 are excluded.,drug
Patients who have received prior treatment with a selective CDK4/6 inhibitor,drug
"Patients who have received prior treatment with an mTOR inhibitor (sirolimus, temsirolimus, everolimus).",drug
Patients who previously received daratumumab or other anti-CD38 therapies must have at least 6 months washout,drug
Patients who received daratumumab or other anti-CD38 therapies previously must have 6 months washout,drug
Patients who require medications that are strong CYP3A4 inhibitors or inducers.,drug
Patients who require the following treatments moderate to strong CYP3A4 inhibitors; any substrates of CYP3A4/5 with a narrow therapeutic index,drug
Patients whose tumors harbor an anaplastic lymphoma kinase (ALK) translocation must have progressed on or had intolerance to an ALK inhibitor,drug
Patients with a history of tamoxifen and/or aromatase inhibitor use for treatment or prevention are eligible but should discontinue these medications at least 2 weeks prior to starting this trial,drug
"Previous therapy with histone deacetylase (HDAC) inhibitor and/or anti PD 1, anti PD L1, or anti CTLA4 immunotherapy.",drug
Previous therapy with T-DM1 or any HER2 tyrosine kinase inhibitor (TKI) including neratinib for any malignancy.,drug
Previous treatment with a CDK 4/6 inhibitor or an mTOR inhibitor,drug
Previous treatment with a c-MET inhibitor or HGF-targeting therapy (applies only to Group 2),drug
"Previous treatment with a PARP inhibitor, or any other targeted therapy directed against the homologous recombination pathway.",drug
Previous treatment with alectinib or any other ALK inhibitor,drug
Previous treatment with an histone deacetylase inhibitor or an epidermal growth factor receptor inhibitor within at least 4 weeks of the date of first administration of study drug,drug
"Previous treatment with anti_PD-1, or anti_PD-L1 therapeutic antibody or any immune directed anti-cancer therapy.",drug
Previous treatment with anti-CD123 CAR-T treatment.,drug
Previous treatment with any anti-CD22 directed therapy,drug
Previous treatment with any MEK inhibitor,drug
Previous treatment with any prior BET inhibitor therapy,drug
Previous treatment with atezolizumab or another programmed death-1 (PD-1)/PD-L1 inhibitor,drug
Previous treatment with cobimetinib or any other mitogen-activated protein/extracellular signal-regulated kinase (MEK) inhibitor,drug
Previous treatment with docetaxel or an Axl inhibitor,drug
Previous treatment with erlotinib or any other EGFR inhibitor,drug
Previous treatment with non-CAR-T anti-CD123 agents is allowed e.g. SL-401.,drug
"Previous treatment with phosphoinositide 3-kinase (PI3K), serine/threonine-specific protein kinase (AKT), dual PI3K/ mammalian (or mechanistic) target of rapamycin (mTOR) inhibitors, target of rapamycin complex 1/2 (TORC1/2) inhibitors or TORC1 inhibitors.",drug
"Previous treatment with tocilizumab or other cytokine-targeted biologic disease modifying antirheumatic drugs (including adalimumab, certolizumab, etanercept, golimumab, infliximab, anakinra) within 3 months of enrollment",drug
Previous treatment with vemurafenib or any other BRAF inhibitor (prior sorafenib is allowed),drug
Previous treatment with vismodegib or any other hedgehog pathway inhibitor,drug
"Previous treatment with XL184 (cabozantinib) or another MET/HGF inhibitor (tivantinib, crizotinib)",drug
"Prior exposure to a combination of IRX-2 regimen, PD-1/PD-L1 inhibitors and CTLA-4 inhibitors are excluded",drug
Prior exposure to abiraterone acetate or other specific CYP-17 inhibitors. Abiraterone acetate given in the castration-sensitive setting is permissible if stopped at least 6 months prior to initial protocol treatment.,drug
"Prior exposure to abiraterone acetate, ketoconazole or other specific CYP-17 inhibitors",drug
Prior exposure to agents specifically targeting both mTOR complexes (dual TORC1+TORC2 inhibitors) and/or PI3K/AKT pathways,drug
Prior exposure to an ATR inhibitor,drug
Prior exposure to any anti-PD-1 or anti-PD-L1 antibody.,drug
"Prior exposure to apalutamide. Prior exposure to abiraterone acetate and/or other CYP17 inhibitors, enzalutamide is allowed (but not preferred) only during the dose escalation period.",drug
"Prior exposure to Bcl-2 inhibitors, murine double minute 2 (MDM2) antagonists or prior exposure to experimental treatment targeting Raf, mitogen-activated protein kinase (MEK), or the mitogen-activated protein kinase (MAPK) RAS/RAF/MEK/ERK MAPK pathway",drug
Prior exposure to BTK inhibitors,drug
Prior exposure to enzalutamide or other investigational AR directed therapy,drug
"Prior exposure to enzalutamide, ARN-509, or other investigational AR-directed therapy",drug
Prior exposure to lenvatinib or mammalian target of rapamycin (mTOR) inhibitor,drug
Prior exposure to PD-1 / PD-L1 inhibitors,drug
"Prior exposure to T cell checkpoint inhibitor therapies, including durvalumab and tremelimumab",drug
"Prior history of treatment with anti-CTLA-4 or anti-PD-1 pathway therapy, or CD137 agonist therapy for post-transplant relapse.",drug
"Prior immune checkpoint therapy including, but not limited to, an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody, or any other prior immune-modulating agent administered with antineoplastic intent (monoclonal antibodies used against VEGF are permitted)",drug
"prior immunotherapy including anti-PD/L1, CTLA4 or Sipuleucel-T",drug
"Prior immunotherapy is allowed (previous immune checkpoint inhibitors; anti-CTLA-4, anti-PD-1, anti-PD-L1 and/or combinations), except for the patients enrolled to the immunotherapy naïve group of the phase IB dose expansion.",drug
"Prior immunotherapy with IL-2, IFN-α, or anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-cytotoxic T lymphocyte associated antigen 4 (anti-CTLA-4) antibody (including Ipilimumab), or any other antibody or drug specifically targeting T cell co-stimulation or immune checkpoint pathways",drug
Prior investigational ccRCC-directed cancer vaccine therapy.,drug
"Prior navitoclax, BRAF inhibitor, and MEK inhibitor is prohibited; (exceptions for Phase I are described above)",drug
"Prior or current treatment with a JAK inhibitor, for any indication.",drug
"Prior or current treatment with a MEK inhibitor (all cohorts), BGJ398/infigratinib (all cohorts), or selective FGFR inhibitor (Cohorts 1 and 2 only).",drug
"Prior PD-1 or PD-L1 inhibitor therapy, or prior therapy with anti-PD-L2 or anti-CTLA-4 inhibitor, or any other drug specifically targeting T-cell co-stimulation or immune checkpoint pathways.",drug
Prior PD-1- or PD-L1-directed therapy.,drug
Prior receipt of a PIM inhibitor,drug
Prior receipt of a selective FGFR inhibitor.,drug
"Prior receipt of any immune-mediated therapy including, but not limited to, other anti-CTLA-4, anti-PD-1, and anti-PD-L1 antibodies and agents targeting CD73, CD39, or adenosine receptors, excluding therapeutic anticancer vaccines.",drug
"Prior receipt of survivin based vaccines or immune checkpoint inhibitors (e.g. anti-CTLA-4, anti-PD-1, anti-PD-L1, ",drug
"Prior receipt of survivin based vaccines or immune checkpoint inhibitors (e.g. anti-CTLA-4, anti-PD-1, anti-PD-L1, or any other antibody or drug specifically targeting T cell co-stimulation) or an IDO inhibitor",drug
Prior therapy with a MEK inhibitor.,drug
Prior therapy with an angiogenesis inhibitor,drug
"Prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways) is not allowed.",drug
"Prior therapy with an anti-PD-1, anti-PD-L1, anti-PDL-2, or anti-CTLA-4 antibody (or any other antibody targeting T cell co-regulatory pathways).",drug
"Prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, or anti-CTLA-4 antibody (or any other antibody targeting T cell co-stimulation pathways)",drug
"Prior therapy with an anti-programmed cell death (PD)-1, anti-PD-ligand 1 (anti-PD-L1), anti-PD-L2 agent, or any agent directed to another stimulatory or inhibitory T-cell receptor (eg, cytotoxic lymphocyte associated protein-4 [CTLA-4], OX-40, CD137)",drug
Prior therapy with antibody to hepatocyte growth factor (HGF).,drug
"Prior therapy with any agent targeting the vascular endothelial growth factor receptor (VEGFR) pathway to include bevacizumab, pazopanib, and other anti-angiogenesis inhibitors",drug
"Prior therapy with any Bromodomain and extra-terminal (BET) inhibitor, any selective estrogen receptor degrader (SERD) including fulvestrant, or inhibitors of the Phosphoinositide-3-kinase (PI3K)/ serine/threonine-specific protein kinase (AKT)/Mammalian Target of Rapamycin (mTOR) pathway.",drug
Prior therapy with any CDK 4/6 inhibitor.,drug
Prior therapy with any CDK inhibitor.,drug
Prior therapy with any Cdk4 inhibitor,drug
Prior therapy with any proteasome inhibitor other than bortezomib or carfilzomib,drug
"Prior therapy with CD123- or IL-3R-directed immunotherapies, including monospecific and bsAbs, immunoconjugates, or chimeric antigen receptor- modified T-cell therapy",drug
Prior therapy with DNA methyltransferase therapy or HDAC inhibitor therapy.,drug
"Prior therapy with hydroxyurea, chemotherapy, biological or targeted therapy (e.g. FLT3 inhibitors, other kinase inhibitors), or hematopoietic growth factors is allowed",drug
Prior therapy with inhibitors of IGF-1,drug
Prior therapy with PD-1/PDL-1 inhibitors is allowed provided any toxicity attributed to prior PD-1- or PD-L1-directed therapy did not lead to discontinuation of therapy.,drug
Prior treatment (at least 1 full treatment cycle) with a farnesyltransferase inhibitor.,drug
Prior treatment with a BET inhibitor.,drug
Prior treatment with a BRAF inhibitor,drug
Prior treatment with a Bruton's tyrosine kinase (BTK) inhibitor,drug
"Prior treatment with a drug of the FAK inhibitor class or with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-cytotoxic T-lymphocyte associated antigen 4 (CTLA-4) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways).",drug
"Prior treatment with a FLT3 targeted therapy including sorafenib or investigational FLT3 inhibitors (not including the multi-kinase inhibitor, midostaurin).  ",drug
Prior treatment with a mechanistic target of rapamycin (mTOR) inhibitor or phosphoinositide 3-kinase (PI3K) inhibitor.,drug
"Prior treatment with a MEK, Ras or Raf inhibitor",drug
"Prior treatment with a PARP inhibitor (such as rucaparib, olaparib, niraparib, talozaparib, etc.) or a targeted DNA damage response inhibitor (such as ATM or ataxia telangiectasia and Rad3-related protein [ATR] inhibitor). (sub protocol C)",drug
Prior treatment with a PARP inhibitor or CDK4/6 inhibitor,drug
Prior treatment with a PARP inhibitor or topotecan,drug
Prior treatment with a poly (adenosine diphosphate [ADP] ribose) polymerase (PARP) inhibitor,drug
Prior treatment with a RAF inhibitor,drug
Prior treatment with a small molecule inhibitor of c-MET or monoclonal antibody against c-MET or HGF,drug
Prior treatment with a smoothened inhibitor (SMOi) and/or hypomethylating agent.,drug
Prior treatment with a taxane at any dose. ,drug
Prior treatment with a Wee1 inhibitor or any irinotecan containing regimen,drug
Prior treatment with an ALK inhibitor other than crizotinib.,drug
"Prior treatment with an antibody-drug conjugate (ADC) which consists of an exatecan derivative that is a topoisomerase I inhibitor (eg, DS-8201)",drug
"Prior treatment with an anti-CD123-directed agent, with the exception of patients with relapsed disease after flotetuzumab treatment",drug
Prior treatment with an anti-ErbB3 antibody,drug
"Prior treatment with an anti-PD-1, anti-PD-L1 or anti-CTLA-4 antibody",drug
"Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, anti-CTLA-4 antibody, or agents that target IL-2 pathways, T-cell stimulators, or checkpoint pathways",drug
"Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways",drug
"Prior treatment with an anti-PD1, anti-PDL1, or anti PD L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, CTLA-4, OX 40, CD137).",drug
"Prior treatment with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent, or with any agent directed to another T-cell stimulatory or inhibitory receptor (e.g. CTLA-4, OX-40, CD137).",drug
"Prior treatment with an anti-programmed death (PD)-1, anti-programmed death ligand 1 (PD-L1), anti-programmed death ligand 2 (PD-L2), anti-Cluster of differentiation (CD137), or anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways",drug
"Prior treatment with an immunotherapy agent including high dose IL-2, anti-CTLA-4, anti-PD1, and anti-PD-L1 agents",drug
Prior treatment with an MDM2 inhibitor.,drug
"Prior treatment with an mTOR, AKT, or PI3K inhibitor.",drug
"Prior treatment with anti-PD-1, anti-CTLA-4 (cytotoxic T lymphocyte-associated antigen (CTLA-4)), or anti-PD-L1 therapeutic antibody or pathway-targeting agents",drug
"Prior treatment with any anti-PD-1 blocking therapies or histone deacetylase inhibitors (HDACi), or anti-CTLA-4 antibody, CD137 agonist or other immune activating therapy such as anti-CD 40 antibody within the last 3 months of enrollment in the study",drug
"Prior treatment with any anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways.",drug
Prior treatment with any CDK 4/6 inhibitor.,drug
Prior treatment with any CDK inhibitor .,drug
Prior treatment with any drug that targets T cell co-stimulation pathways (such as checkpoint inhibitors),drug
"Prior treatment with any pan-HER tyrosine kinase inhibitor (eg, lapatinib, afatinib, dacomitinib, neratinib).",drug
Prior treatment with any PARP inhibitor or any anti-PD-1/anti-PD-L1 antibody,drug
"Prior treatment with any PARP inhibitor, mitoxantrone, cyclophosphamide or any platinum-based chemotherapy",drug
Prior treatment with any therapy on the programmed cell death 1 (PD-1)/PD-L1 axis or anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitors unless enrolling the urothelial carcinoma with previous checkpoint inhibition therapy expansion cohort,drug
"Prior treatment with approved or investigational TRK, ROS1, or ALK inhibitors",drug
"Prior treatment with approved or investigational Trk, ROS1, or ALK inhibitors in patients who have tumors that harbor those respective gene rearrangements",drug
Prior treatment with arfolitixorin.,drug
"Prior treatment with ATR or PARP inhibitor (e.g. olaparib, rucaparib, niraparib).",drug
Prior treatment with cabozantinib (or other MET inhibitor) or CB-839,drug
Prior treatment with cabozantinib or other c-MET directed therapy.,drug
Prior treatment with capecitabine at any dose,drug
"Prior treatment with CD137 agonists or immune checkpoint blockade therapies, anti_PD1, or anti_PDL1 therapeutic antibodies or anti-CTLA4 .",drug
Prior treatment with CD33 antibody.,drug
Prior treatment with CD47 or signal regulatory protein alpha (SIRP_) targeting agents.,drug
"Prior treatment with crizotinib, or any other cMET or HGF inhibitor",drug
prior treatment with DAC inhibitors,drug
Prior treatment with EGFR inhibitors or ALK inhibitors,drug
Prior treatment with EGFR-targeting therapies,drug
"Prior treatment with either ET or CDK4/6 inhibitors for Breast Cancer or an anti-PD-1, anti-PD-L1, anti-PD-L2, or anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways, or history of allergy, or hypersensitivity to study drug components",drug
Prior treatment with ERK inhibitors.,drug
"Prior treatment with fulvestrant or other selective estrogen receptor degraders (SERDs), venetoclax, or any agent whose mechanism of action is to inhibit BCL-2",drug
"Prior treatment with histone deacetylase (HDAC) inhibitors (e.g. valproic acid, Zolinza?��?��????��?��???��?��????��?��??? (SAHA), romidepsin (Istodax?��?��????��?��???��?��????��?��???).",drug
"Prior treatment with immune checkpoint inhibitor, including (but not limited to) those targeting PD-1, PD-L1, PD-L2, CTLA-4, CD137, GITR, TIM3, LAG3, or OX40",drug
"Prior treatment with immune checkpoint inhibitors (eg, anti-CTLA-4, anti-PD-1, anti-PD-L1, and any other antibody or drug specifically targeting T-cell co-stimulation) or an IDO inhibitor (exception is tumor types in which a PD-1 pathway targeted agent is approved, e.g. melanoma, non-small cell lung cancer.)",drug
"Prior treatment with immune therapy (including but not limited to cluster of differentiation [CD]137, OX40, programmed death [PD]-1, PD-L1 or cytotoxic T-lymphocyte antigen 4 [CTLA4] inhibitors)",drug
"Prior treatment with less than or equal to ( >= ) 2 treatment lines of anti-myeloma therapy. Prior lines of therapy must include a proteasome inhibitor (PI) (eg, bortezomib, carfilzomib) and an immunomodulatory drug (IMiD) (example, thalidomide, lenalidomide, pomalidomide) in any order during the course of treatment. Each prior line of therapy may consist of one or more agents and may include induction, hematopoietic stem cell transplantation, and/or maintenance therapy. Radiotherapy, bisphosphonates, or a single short course of steroids is not considered a prior line of therapy",drug
"Prior treatment with MDM2 inhibitor, with protocol specified exceptions",drug
"Prior treatment with MET or VEGFR inhibitors is allowed. However, prior cabozantinib will not be allowed. Also, patients that have received both prior MET or VEGF and prior PD-1/PD-L1/CTLA-4 (sequentially or in combination) are also not allowed",drug
"Prior treatment with MET or VEGFR inhibitors is allowed. However, prior cabozantinib will not be allowed.?��?��????��?��???��?��????��?��???Prior treatment with any therapy on the PD-1/PD-L1 axis or anti- CTLA-4/CTLA-4 inhibitors is allowed, either in the perioperative or in the metastatic setting.",drug
Prior treatment with nintedanib or any other VEGFR inhibitor,drug
Prior treatment with or intolerance to proteasome inhibitor and immunomodulator,drug
Prior treatment with PD-1 and programmed death ligand (PD-L)1 inhibitors,drug
Prior treatment with platinum based doublet and checkpoint inhibitor,drug
"Prior treatment with PV-10 or any checkpoint inhibitor; however, subjects",drug
Prior treatment with quizartinib or other FLT3-ITD inhibitors,drug
"Prior treatment with tucatinib, lapatinib, neratinib, afatinib, trastuzumab deruxtecan (DS-8201a), or any other investigational anti-HER2, anti-EGFR, or HER2 TKI agent; Prior treatment with T-DM1",drug
Prior treatment with VEGFR tyrosine kinase inhibitors.,drug
"Prior treatment with: LHRH agonist/antagonists; second generation androgen receptor (AR) inhibitors such as enzalutamide, ARN-509, darolutamide (ODM-201); other investigational AR inhibitors; CYP17 enzyme inhibitor such as abiraterone acetate or oral ketoconazole as antineoplastic treatment for prostate cancer, chemotherapy or immunotherapy for prostate cancer prior to randomization.",drug
"Prior treatments with Cyp 17 inhibitors like TAK-700/Orteronel, ketoconazole, radium 223 or docetaxel (up to 6 cycles of docetaxel given in the non CRPC setting is allowed). Prior treatment with Sipuleucel-T is allowed.",drug
Prior use of PARP-inhibitors,drug
Prior use of trametinib or other mitogen activated protein kinase (MAPK) inhibitor in any context,drug
Prophylactic use of hematopoietic growth factors within 1 week prior to first study drug administration and during Cycle 1 of study; thereafter prophylactic use of growth factors is allowed as clinically indicated,drug
Receipt of any type of small molecule kinase inhibitor (including investigational kinase inhibitor) within 14 days before the first dose of study treatment,drug
Receipt of monoamine oxidase inhibitors (MAOIs) or UGT1A9 inhibitors,drug
Received a moderate or strong CYP4503A inhibitor or moderate or strong CYP3A inducer within 10 days prior to first dose of TAK-788.,drug
Received a prior CDK4/6 inhibitor,drug
Received any previous treatment with alvocidib or any other CDK inhibitor,drug
Received prior ALK TKI therapy within 7 days prior to D1 of treatment under study drug. 7 day wash out period is required after prior ALK inhibitor treatment.,drug
"Received strong cytochrome (CYP) 3A inhibitors, moderate CYP3A inhibitors, strong CYP3A inducers and moderate CYP3A inducers within 7 days prior to initiation of study treatment",drug
Receiving any medications or substances that are inhibitors of CYP3A4.,drug
Receiving hematopoietic growth factors,drug
Regimen B (FT516 + rituximab or obinutuzumab):,drug
Research participants who received memory-enriched CD19R(EQ):CD28:zeta/EGFRt+ on IRB#13277,drug
"Small molecule kinase inhibitors, such as pazopanib",drug
Steroids and tyrosine kinase inhibitors are allowed up to 7 days prior to leukapheresis,drug
Strong and moderate inhibitors of CYP3A4,drug
Strong CYP2C8 inhibitors or CYP2C8 substrates,drug
"Strong Cytochrome P450 3A4 (abbreviated CYP3A4) (e.g., clarithromycin, HIV protease inhibitors, and itraconazole), given potential interactions with atorvastatin",drug
"Strong inhibitors (eg, ketoconazole) or inducers (eg, rifampicin or St. John's Wort) of CYP3A4 (within 2 weeks prior to the start of dosing in the study)",drug
Strong inhibitors and inducers of UGT/PgP should be used with caution,drug
Strong inhibitors and strong inducers of CYP3A4 should not be used concomitantly.,drug
Strong inhibitors of CYP3A or CYP2C8,drug
"Strong inhibitors of cytochrome P450, family 1, subfamily A, polypeptide 2 (CYP1A2)",drug
"Strong inhibitors of family cytochrome P450 family 3, subfamily A (3A)",drug
"Strong inhibitors or inducers of CYP3A4, including grapefruit products and herbal supplements",drug
"Strong inhibitors or strong inducers of cytochrome P450, family 3, subfamily A, polypeptide 4/cytochrome P450, family 3, subfamily A, polypeptide 5 (CYP3A4/5)",drug
Strong P-gp inhibitors or inducers. Subjects who are taking such medications but who are otherwise eligible may be enrolled if they discontinue the medication >= 1 week before dosing and remain off that medication through the end of PK sampling after the administration of the second study treatment,drug
"Subject has previously been treated with a Histone deacetylases (HDAC) inhibitor, PD-1 inhibitor, PD-L1 inhibitor, PD-L2 inhibitor, CTLA-4 inhibitor, or any other antibody or drug specifically targeting T-cell costimulation or immune checkpoint pathways",drug
Subject use of hydroxyurea or other drugs with potential effects on hematopoiesis or ongoing adverse events from previous treatment <= 112 days immediately up to the enrollment date.,drug
"Subjects who could not tolerate a PI, IMiDs, or a CD38-directed cytolytic antibody are eligible to enroll in the study.",drug
"Treatment with hematopoietic colony stimulating factors (e.g., filgrastim, sargramostim) within 7 days of the first dose of study drug, or pegfilgrastim or darbepoetin within 14 days of the first dose of study drug",drug
"Treatment with hematopoietic growth factors including: erythropoietin, granulocyte colony stimulating factor (G-CSF), and granulocyte macrophage colony stimulating factor (GM-CSF), or thrombopoietin receptor agonists within 3 weeks prior to study entry.",drug
Use of hematopoietic colony stimulating growth factors <= 3 weeks prior to first dose,drug
"Use of hematopoietic colony-stimulating growth factors (e.g. G-CSF, GMCSF, M-CSF) <= 2 weeks prior start of study drug. An erythroid stimulating agent is allowed as long as it was initiated at least 2 weeks prior to the first dose of study treatment.",drug
"Use of hematopoietic colony-stimulating growth factors (eg, G-CSF, GM-CSF, M-CSF) <= 2 weeks prior to start of study drug",drug
Use of hematopoietic growth factors within 2 weeks prior to C1/D1.,drug
2A : TNBC ABBV-368 monotherapy cohorts: Subjects with locally advanced or metastatic TNBC that have exhausted standard treatment for their incurable disease.,exhaust
3A: Participants with locally advanced or metastatic TNBC that have exhausted standard treatment for their incurable disease and are treatment naïve to a PD-1/PD-L1 targeting agent.,exhaust
A diagnosis of acute myeloid leukemia (AML) according to the World Health Organization 2008 criteria with relapsed or refractory disease and ineligible for or have exhausted standard therapeutic options,exhaust
Acute Myeloid Leukemia (AML) according to the World Health Organization 2008 criteria with relapsed or refractory disease and ineligible for or have exhausted standard therapeutic options,exhaust
All subjects' cancer must have progressed after treatment with standard therapies or have no appropriate available therapies.,exhaust
All subjects' cancer must have progressed after treatment with standard/approved therapies or have no appropriate available therapies.,exhaust
AML patients who have relapsed or are refractory to standard therapies.,exhaust
"CML-AP Ph+, CML-BC Ph+, Ph- ALL, and Ph+ ALL patients with relapsed and refractory disease who have exhausted all available therapy.",exhaust
"CMML (with >= 5% blasts in bone marrow) as defined by WHO that is relapsed and/or refractory and that, in the opinion of the Investigator, requires treatment or that has exhausted treatment options that would be considered standard of care.",exhaust
"Cohort A. Unresectable, recurrent, locally advanced, or metastatic Pheochromocytoma-paraganglioma (PC-PG) who have failed or are refractory to available therapies. N = 12.",exhaust
"Cohort B will include only patients with unresectable, locally advanced or metastatic tumors who have failed or are refractory to available therapyOther neuroendocrine cancer varieties as characterized by expression of neuroendocrine markers on tumor tissue including CD56, synaptophysin, , chromogranin and/or presence of a detectable serum or urine biomarker (3-methoxytyramine, normetanephrine, metanephrines, homovanillic acid (HVA), vanillylmandelic acid (VMA), and dopamine, Varieties will include neuroblastoma, Ewing sarcoma, neuroectodermal tumor, clear call sarcoma, myoepithelial tumor, primitive neuroectodermal tumor (PNET), desmoplastic small round cell tumor, round cell sarcoma, and unresectable, metastatic or locally advanced , well-differentiated neuroendocrine tumors who have relapsed or are refractory to at least 2 systemic therapies (e.g. lanreotide, sunitinib, or everolimus). Patients with small cell carcinomas will not be included in this clinical trial.N = 12",exhaust
Confirmed relapsed/refractory diagnosis of select hematologic malignancies for which no standard/salvage therapies are available.,exhaust
"CRC for Arm 1 and Arm 2: CRC originating in either the colon or rectum that is locally advanced unresectable or metastatic (i.e., Stage IV) and that has received, and progressed on, all available standard-of-care therapies including fluoropyrimidine, oxaliplatin, and irinotecan but has not been treated with prior anti-PD-1/PD-L1 therapy.",exhaust
"Dose escalation: subjects with advanced and unresectable solid tumor who progressed on at least one line of systemic therapy, and no approved therapy or standard therapy with demonstrated clinical benefit exists; and all subjects with T790M mutation positive NSCLC have progressed on osimertinib.",exhaust
Failure to respond or intolerance to standard therapy or for whom no appropriate therapies are known to provide clinical benefit (per the judgement of the Investigator).,exhaust
"Failure to respond to standard therapy, or for whom no appropriate therapies are available (based on the judgement of the Investigator)",exhaust
"For Phase 1, histologically and / or cytological confirmed locally advanced, recurrent or relapsed or metastatic incurable solid malignancy",exhaust
"Histologically / cytologically confirmed advanced/unresectable or metastatic SCLC, CRPC, DLBCL and FL that is refractory to or intolerable of standard treatment, or for which no curative treatment is available. Note for FL (Parts 1A and 1B) during the dose finding phase of study, follicular lymphoma patients must have exhausted all standard of care therapies.",exhaust
Histologically confirmed FL patients that have exhausted all curative therapies and have relapsed or refractory disease.,exhaust
"Histologically or cytologically confirmed, locally advanced or metastatic solid malignancy and has exhausted all the available standard therapy or is not a candidate for the available standard therapy.",exhaust
Males or females with multiple myeloma who have exhausted available standard therapies.,exhaust
"Metastatic or unresectable solid malignancy that is histologically or cytologically confirmed to be one of the tumor types listed below. Participants must have relapsed, refractory, or progressive disease (PD) and should have no appropriate standard therapy available.",exhaust
Participant must have relapsed/refractory AML and exhausted standard available therapies known to provide clinical benefit.,exhaust
Patient with relapsed or refractory CD19-positive B-acute lymphoblastic leukaemia (B-ALL) who have exhausted alternative treatment options.,exhaust
"Patients 18 years of age or older, with relapsed/refractory AML by World Health Organization classification who have exhausted available therapy.",exhaust
Patients refractory to all approved therapies or for which no approved or conventional therapies are available,exhaust
"Patients who are ineligible for chemotherapy, and have exhausted any approved and available treatment options",exhaust
Patients who have exhausted targeting therapy options.,exhaust
"Patients whose malignancy is either refractory to standard therapy, or for which no standard therapy is available",exhaust
"Patients with a malignancy that is either refractory to standard therapy, or for which no standard therapy is available",exhaust
"Patients with advanced malignant epithelioid mesothelioma or advanced recurrent serous ovarian cancer, who have exhausted available therapeutic options; in addition, in the dose expansion part of the study, patients with metastatic pancreatic adenocarcinoma, who have exhausted available therapeutic options",exhaust
"Patients with MM who have exhausted all therapeutic options known to provide clinical benefit, either through disease relapse or intolerance or refusal of the therapy and including either:",exhaust
"Phase 1 and Phase 2 participants with advanced/metastatic malignancies who have measurable disease (non-measurable disease is allowed only in Phase 1) as determined by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) will be eligible if, according to the National Comprehensive Cancer Network (NCCN) guidelines, there are no available therapies known to confer a clinical benefit for their disease, or they have exhausted all such available options. Additionally, the following specific tumor indications will be enrolled:",exhaust
Prior treatment with standard systemic therapy (must have exhausted or declined all known effective therapies),exhaust
Recurrent or persistent progressive disease which is refractory to curative therapy or established treatments and cannot be treated with surgery or radiotherapy,exhaust
Refractory to or intolerant of existing therapy(ies) known to provide clinical benefit.,exhaust
Relapsed or refractory disease for which patients are ineligible for or have exhausted standard therapeutic options that would be considered standard of care,exhaust
"Relapsed, refractory, or progressive disease with no appropriate standard therapy available at the time of enrollment",exhaust
"Subject has a locally advanced unresectable or metastatic, relapsed and/or refractory, non-hematological malignancy for which treatment with an approved agent that is considered standard of care in the indication either does not exist or has proven ineffective.",exhaust
"Subject has a locally advanced unresectable or metastatic, relapsed and/or refractory, non-hematological malignancy for which treatment with an approved agent that is considered standard of care in the indication either does not exist or has proven ineffective. Amendment 4, 11 June 2018",exhaust
"Subject must have received, been intolerant to, or is ineligible for standard therapy (per local guidelines and approvals) or have a malignancy for which there is no approved therapy considered standard of care.",exhaust
"Subjects must be refractory to, or intolerant of, established therapy known to provide clinical benefit for their conditions, or where subjects refuse existing therapies.",exhaust
"Subjects must have a confirmed diagnosis of relapsed/refractory MM as per IMWG criteria (Rajkumar et al, 2014) and have exhausted standard of care regimens with proven clinical benefit, which include agents from the following anti myeloma therapies: PIs, IMIDs, and mAbs and have measurable disease with at least one of the following criteria:",exhaust
"Subjects must have primary or metastatic liver malignancies which are surgically unresectable, and exhausted all standard therapeutic options",exhaust
achieving a plateau in oxygen consumption concurrent an with increase in power output,fev1-dlco-copd-oxygen
Adequate pulmonary function as assessed by >= 92% oxygen saturation on room air by pulse oximetry,fev1-dlco-copd-oxygen
Adequate pulmonary function as assessed by oxygen saturation >= 90% when ambulating and not requiring supplemental oxygen,fev1-dlco-copd-oxygen
Adequate pulmonary function defined as absence of oxygen (O2) requirements and one of the following:,fev1-dlco-copd-oxygen
"Adequate pulmonary function, defined as <= Grade 1 dyspnea according to Common Terminology Criteria for Adverse Events (CTCAE) and oxygen saturation (SaO2) >= 92% on room air and FEV1 >= 50%",fev1-dlco-copd-oxygen
"Adequate pulmonary function, defined per protocol and oxygen saturation > 92% on room air.",fev1-dlco-copd-oxygen
Any patient requiring supplemental oxygen therapy,fev1-dlco-copd-oxygen
Any patients requiring oxygen at baseline,fev1-dlco-copd-oxygen
Baseline oxygen saturation > 92% on room air,fev1-dlco-copd-oxygen
Baseline oxygen saturation > 92% on room air at rest,fev1-dlco-copd-oxygen
Baseline oxygen saturation levels that do not show abnormalities according to the protocol,fev1-dlco-copd-oxygen
blood saturation oxygen level (SpO2) < 90% at rest on room air,fev1-dlco-copd-oxygen
Cardiovascular disease-related requirement for daily supplemental oxygen,fev1-dlco-copd-oxygen
Cardiovascular disease-related requirement for daily supplemental oxygen therapy.,fev1-dlco-copd-oxygen
"Cardiovascular, respiratory or musculoskeletal disease or joint problems that preclude moderate physical activity. Examples would include unstable angina, recent myocardial infarction, oxygen-dependent pulmonary disease, and osteoarthritis requiring imminent joint replacement. Moderate arthritis that does not preclude physical activity is not a reason for ineligibility.",fev1-dlco-copd-oxygen
Chronic obstructive pulmonary disease with a forced expiratory volume in 1 second (FEV1) is less than ( < ) 50 % of predicted normal,fev1-dlco-copd-oxygen
Chronic obstructive pulmonary disease with a forced expiratory volume in 1 second (FEV1) is less than ( < ) 50 % of predicted normal; or,fev1-dlco-copd-oxygen
Chronic respiratory disease that requires continuous oxygen use.,fev1-dlco-copd-oxygen
"Clinically significant pulmonary compromise, including a requirement for supplemental oxygen use to maintain adequate oxygenation.",fev1-dlco-copd-oxygen
Continuous oxygen use,fev1-dlco-copd-oxygen
Corrected diffusing capacity of the lungs for carbon monoxide (DLCO) < 35% or receiving supplemental continuous oxygen,fev1-dlco-copd-oxygen
Corrected diffusion capacity of the lung for carbon monoxide (DLCO) < 35% or receiving supplemental continuous oxygen.,fev1-dlco-copd-oxygen
"Current dyspnea at rest of any origin, or other diseases requiring continuous oxygen therapy.",fev1-dlco-copd-oxygen
"Currently requiring supplemental oxygen, mechanical ventilation, vasopressors, and/or hemodialysis (life-support).",fev1-dlco-copd-oxygen
Decreased oxygen in the tissues or blood,fev1-dlco-copd-oxygen
Dependence on continuous supplemental oxygen use,fev1-dlco-copd-oxygen
Dependent on continuous supplemental oxygen,fev1-dlco-copd-oxygen
Diffusing capacity of the lung for carbon monoxide (DLCO) (adjusted for hemoglobin) >= 50%,fev1-dlco-copd-oxygen
"Diffusing capacity of the lung for carbon monoxide (DLCO) corrected < 60%; patients who are unable to perform pulmonary function tests (for example, due to young age and/or developmental status) will be excluded if the oxygen (O2) saturation is < 92% on room air",fev1-dlco-copd-oxygen
"Diffusing capacity of the lung for carbon monoxide (DLCO) equal or greater than 50% predicted corrected for hemoglobin; for children <= 7 years of age who are unable to perform pulmonary function tests (PFT), oxygen saturation >= 92% on room air by pulse oximetry",fev1-dlco-copd-oxygen
"Diffusion capacity corrected (DLCOcorr) > 40% predicted, and absence of O2 requirements",fev1-dlco-copd-oxygen
Diffusion capacity of the lung for carbon monoxide (DLCO) >= 40% (adjusted for hemoglobin),fev1-dlco-copd-oxygen
Diffusion Lung Capacity of Oxygen (DLCO) > 50% of predicted corrected for hemoglobin,fev1-dlco-copd-oxygen
DLCO > 50% of the expected value (using USA-ITS-NIH equation) when corrected for Hgb (DLCO Adj.),fev1-dlco-copd-oxygen
"DLCO corrected < 50%; patients who are unable to perform pulmonary function tests (for example, due to young age and/or developmental status) will be excluded if the O2 saturation is < 92% on room air; patients with a DLCO 50-60% must also have a partial pressure of oxygen (pO2) of > 80 mmHg",fev1-dlco-copd-oxygen
DLCO corrected between 50% - 59% mm Hg and pO2 >= 80 mm Hg Pediatric patients unable to perform pulmonary function tests must have O2 saturation >= 92% on room air. May not be on supplemental oxygen,fev1-dlco-copd-oxygen
DLCO corrected between 60% - 69% mm Hg and partial pressure of oxygen (pO2) >= 70 mm Hg,fev1-dlco-copd-oxygen
dyspnea at rest or required supplemental oxygen within 2 weeks of study enrollment.,fev1-dlco-copd-oxygen
"Eastern Cooperative Oncology Group performance status of >= 2 or oxygen dependence (e.g., advanced chronic obstructive pulmonary disease).",fev1-dlco-copd-oxygen
Evidence of dyspnea at rest or oxygen saturation ( <= ) 94 percent (%).,fev1-dlco-copd-oxygen
Exercise oxygen consumption > 50% predicted,fev1-dlco-copd-oxygen
FEV1 is required for patients suspected of having chronic obstructive pulmonary disease and are not eligible if FEV1 is < 50% of predicted normal,fev1-dlco-copd-oxygen
"For pediatric patients unable to perform pulmonary function tests, oxygen (O2) saturation > 92% on room air",fev1-dlco-copd-oxygen
Forced expiratory volume in 1 s (FEV1) >= 50% and/or carbon monoxide diffusion test (DLCO) >= 50% of predicted level.,fev1-dlco-copd-oxygen
forced expiratory volume in 1 second (FEV1) < 60%,fev1-dlco-copd-oxygen
Forced Expiratory volume in 1 second (FEV1) > 1.0 L,fev1-dlco-copd-oxygen
Forced expiratory volume in 1 second (FEV1) >= 40% of predicted (corrected for hemoglobin).,fev1-dlco-copd-oxygen
Has a pre-treatment PFT showing an DLCO adjusted for hemoglobin of less than 60%,fev1-dlco-copd-oxygen
Has a pulse oximetry of < 92% on room air or is on supplemental home oxygen.,fev1-dlco-copd-oxygen
Has oxygen saturation >= 92% on room air.,fev1-dlco-copd-oxygen
Hemoglobin-adjusted diffusing capacity of carbon monoxide (DLCO) of >= 45%,fev1-dlco-copd-oxygen
"History of uncontrolled sleep apnea syndrome and other conditions that could result in excessive daytime sleepiness, such as severe chronic obstructive pulmonary disease requiring supplemental oxygen.",fev1-dlco-copd-oxygen
Hypoxemia (less than 90% saturation with supplemental oxygen),fev1-dlco-copd-oxygen
Hypoxemia (less than 90% saturation with supplemental oxygen) prior to bronchoscopy.,fev1-dlco-copd-oxygen
Hypoxemia (less than 90% saturation with supplemental oxygen).,fev1-dlco-copd-oxygen
Hypoxemia requiring oxygen therapy,fev1-dlco-copd-oxygen
"if unable to perform pulmonary function tests, then oxygen saturation >= 92% on room air",fev1-dlco-copd-oxygen
"Impairment of lung function (COPD > grade 2, lung conditions requiring oxygen therapy)",fev1-dlco-copd-oxygen
Inability to adequately oxygenate subject during procedure per physicians discretion (i.e. unable to achieve S02 > 92% or requiring > 4L of oxygen via nasal cannula),fev1-dlco-copd-oxygen
Inadequate pulmonary function defined as oxygen saturation < 92 % on room air,fev1-dlco-copd-oxygen
Known chronic obstructive pulmonary disease with a forced expiratory volume in 1second (FEV1) < 50% of predicted normal.,fev1-dlco-copd-oxygen
"Known history of uncontrolled sleep apnea syndrome and other conditions that could result in excessive daytime sleepiness, such as severe chronic obstructive pulmonary disease; requirement for supplemental oxygen.",fev1-dlco-copd-oxygen
Known pulmonary disease with decreased diffusion capacity of lung for carbon monoxide (DLCO) and/or requiring oxygen <= 2 liters per minute; Prior or current malignancy that does not require concurrent treatment; Subject has received a cumulative anthracycline dose above 400 mg/m2 of doxorubicin (or cumulative maximum dose of another anthracycline). Any other comorbidity incompatible with intensive chemotherapy must be reviewed and approved by the Medical Monitor during screening and before randomization.,fev1-dlco-copd-oxygen
Known severe chronic obstructive pulmonary disease or asthma defined as forced expiratory volume (FEV1) in 1 second < 60% of expected.,fev1-dlco-copd-oxygen
Known severe chronic obstructive pulmonary disease or asthma defined as forced expiratory volume (FEV1) in 1 second less than < 60% of expected.,fev1-dlco-copd-oxygen
Known severely impaired lung function (spirometry and carbon monoxide diffusing capacity [DLCO] 50% or less of normal and oxygen [O2] saturation 88% or less at rest on room air),fev1-dlco-copd-oxygen
known severely impaired lung function (spirometry and diffusing capacity of the lung for carbon monoxide [DLCO] 50% or less of normal and oxygen [O2] saturation 88% or less at rest on room air),fev1-dlco-copd-oxygen
known severely impaired lung function (spirometry and Diffusing capacity of the lungs for carbon monoxide [DLCO] 50% or less of normal and oxygen (O2) saturation 88% or less at rest on room air),fev1-dlco-copd-oxygen
May not be on supplemental oxygen,fev1-dlco-copd-oxygen
"Must have a minimum level of pulmonary reserve defined as <= Grade 1 dyspnea, pulse oxygen > 92% on room air; DLCO > 40% (corrected for anemia) if PFTs are clinically appropriate as determined by the treating investigator",fev1-dlco-copd-oxygen
Must have an ambulatory oxygen saturation of > 88% on room air,fev1-dlco-copd-oxygen
Need for supplemental oxygen,fev1-dlco-copd-oxygen
"No clinically significant abnormalities in core vital signs like heart rate, blood pressure or oxygenation which require inpatient evaluation or monitoring.",fev1-dlco-copd-oxygen
No supplemental oxygen requirement,fev1-dlco-copd-oxygen
"Normal lung oxygen saturation by pulse oximeter, as determined by the Principal Investigator based on patient history and status.",fev1-dlco-copd-oxygen
Normal oxygen saturation at baseline ABG (arterial blood gas) testing,fev1-dlco-copd-oxygen
"Normal pulmonary function tests (including diffusion capacity of the lung for carbon monoxide [DLCO]) if there is clinical indication for determination (e.g. dyspnea at rest, known requirement for supplemental oxygen) (for patients receiving chemotherapy [Groups A2, B, C, D, E2, F]); for patients who do not have respiratory symptoms or requirement for supplemental oxygen, pulmonary function tests (PFTs) are NOT required",fev1-dlco-copd-oxygen
"Not requiring supplemental oxygen or mechanical ventilation, oxygen saturation 90% or higher on room air",fev1-dlco-copd-oxygen
Oxygen (O2) saturation >= 92%.,fev1-dlco-copd-oxygen
Oxygen dependence of > 2 L/min continuously throughout the day at baseline,fev1-dlco-copd-oxygen
Oxygen dependent obstructive pulmonary disease.,fev1-dlco-copd-oxygen
Oxygen dependent pulmonary disease. To be documented by physician,fev1-dlco-copd-oxygen
Oxygen requirement attributable to pleural effusion or other malignant process,fev1-dlco-copd-oxygen
Oxygen Saturation (O2 Sat.) >= 92% on ambient air Hepatitis B status HBV Surface Antigen Negative HBV Surface Antibody Positive or Negative HBV Core Antibody Negative Hepatitis C status Anti-HCV Total Antibody Negative HCV RNA analysis Negative HIV status Rapid HIV 1/2 Antibodies Negative *Creatinine Clearance Calculated using the Cockcroft-Gault formula,fev1-dlco-copd-oxygen
Oxygen saturation (Sp02) of less than 95% on room air.,fev1-dlco-copd-oxygen
"Oxygen saturation < 85% on room air, or",fev1-dlco-copd-oxygen
Oxygen saturation < 88% despite supplemental oxygen,fev1-dlco-copd-oxygen
Oxygen saturation < 92% on room air,fev1-dlco-copd-oxygen
Oxygen saturation >= 90% on room air,fev1-dlco-copd-oxygen
Oxygen saturation >= 92% on room air for all indications; oxygen saturation >= 90% on room air for lung cancer considered to be due to lung metastasis.,fev1-dlco-copd-oxygen
oxygen saturation of > 90% on room air F. Adequate cardiac function defined as LVSF >= 28% confirmed by echocardiogram or LVEF >= 45% confirmed by echocardiogram or MUGA within 6 weeks of screening,fev1-dlco-copd-oxygen
Oxygen saturation: >= 92% on room air,fev1-dlco-copd-oxygen
Oxygen-dependent chronic obstructive pulmonary disease (NSCLC cohort only).,fev1-dlco-copd-oxygen
Participant does not require supplemental oxygen or mechanical ventilation AND has an oxygen saturation by pulse oximetry of >= 92% or higher on room air.,fev1-dlco-copd-oxygen
Participant has a need for supplemental oxygen with the exception of using previously existing non-invasive continuous positive airway pressure (CPAP) at night.,fev1-dlco-copd-oxygen
Participant has diffusing capacity of the lung for carbon monoxide (DLCO) (corrected for hemoglobin) >= 50% predicted and/or forced expiratory volume in 1 second (FEV1) >= 50% predicted.,fev1-dlco-copd-oxygen
"Participants must have adequate pulmonary function defined as a forced expiratory volume in 1 second (FEV1) >= 1.2 liters or >= 50% of predicted normal volume measured within 3 weeks prior to randomization. If participants do not meet the above criteria, treatment with inhaled steroids and bronchodilators can be initiated if clinically indicated and eligibility can be reassessed after 1-2 weeks.",fev1-dlco-copd-oxygen
Participants requiring any daily supplemental oxygen,fev1-dlco-copd-oxygen
Patient has dyspnea at rest (CTCAE >= Grade 3) or has required supplemental oxygen within 2 weeks of study enrollment.,fev1-dlco-copd-oxygen
Patient is known to have chronic obstructive pulmonary disease with a forced expiratory volume in 1 second (FEV1) < 50% of predicted normal.,fev1-dlco-copd-oxygen
Patient is on supplemental home oxygen.,fev1-dlco-copd-oxygen
Patient is oxygen-dependent.,fev1-dlco-copd-oxygen
Patient requires treatment with supplemental oxygen not including usage of non-invasive CPAP (continuous positive airways pressure) at night.,fev1-dlco-copd-oxygen
"Patients must have FEV1/FVC > 60% by pulmonary function test (PFT), unless due to large mediastinal mass from HL. Carbon monoxide diffusion capacity (DLCO), FEV1, and FVC all > 50% predicted value. ",fev1-dlco-copd-oxygen
"Patients must have FEV1/FVC > 60% by pulmonary function test (PFT), unless due to large mediastinal mass from HL. Carbon monoxide diffusion capacity (DLCO), FEV1, and FVC all > 50% predicted value. All pulmonary function tests must be obtained within one month prior to registration.",fev1-dlco-copd-oxygen
Patients must not have chronic obstructive pulmonary disease with a forced expiratory volume in 1 second (FEV1) < 50% of predicted normal,fev1-dlco-copd-oxygen
Patients must not have chronic obstructive pulmonary disease with a forced expiratory volume in 1 second (FEV1) < 50% of predicted normal. FEV1 is required for patients suspected of having chronic obstructive pulmonary disease and are not eligible if FEV1 is < 50% of predicted normal.,fev1-dlco-copd-oxygen
Patients must not have required supplemental oxygen within the past month unless it was for a resolved infection.,fev1-dlco-copd-oxygen
Patients on home oxygen,fev1-dlco-copd-oxygen
Patients on supplemental home oxygen.,fev1-dlco-copd-oxygen
patients requiring continuous supplemental oxygen are excluded to avoid possible complications from pneumonitis,fev1-dlco-copd-oxygen
Patients requiring supplemental oxygen or mechanical ventilation or oxygen saturation < 92% on room air.,fev1-dlco-copd-oxygen
Patients requiring supplemental oxygen therapy.,fev1-dlco-copd-oxygen
Patients that require supplemental oxygen are excluded.,fev1-dlco-copd-oxygen
"Patients where the burden of pulmonary metastasis, location, or bulkiness of disease may cause high morbidity if localized swelling such as causing uncontrolled symptoms, oxygen dependence, or location near a major bronchi as determined by investigator.",fev1-dlco-copd-oxygen
Patients who are on continuous supplemental oxygen.,fev1-dlco-copd-oxygen
Patients who are unable to perform PFTs (age < 6 years or considered developmentally incapable of PFTs): oxygen saturation (by oximetry) must be >= 92% on room air.,fev1-dlco-copd-oxygen
"Patients who meet the criterion above without oxygen (O2), but who need acute (started within 10 days prior to registration) supplemental oxygen due to tumor-caused obstruction/hypoxia are eligible, provided the amount of the O2 needed has been stable",fev1-dlco-copd-oxygen
Patients with oxygen saturation of < 92% on room air by pulse oximetry,fev1-dlco-copd-oxygen
Patients with respiratory symptoms must have a DLCO/adjusted > 45%. For children who are unable to cooperate for PFTs they must not have dyspnea at rest or known requirement for supplemental oxygen.,fev1-dlco-copd-oxygen
Patients/subjects who need daily oxygen therapy,fev1-dlco-copd-oxygen
Postoperative percent predicted forced expiratory volume in 1 second (FEV1) and diffusion capacity must be >= 40% and/or maximal oxygen consumption (VO2max) should be > 10 mL/kg/min.,fev1-dlco-copd-oxygen
"Pre-treatment PFTs, collected <= 90 days prior to enrollment, must show FEV1 > 60% of predicted.",fev1-dlco-copd-oxygen
"Pulmonary criteria: not requiring supplemental oxygen or mechanical ventilation, oxygen saturation 90% or higher on room air",fev1-dlco-copd-oxygen
Pulmonary function: baseline oxygen saturation > 92% on room air at rest,fev1-dlco-copd-oxygen
Pulmonary function: oxygen saturation > 92%,fev1-dlco-copd-oxygen
Pulmonary Function: oxygen saturation >= 90% on room air,fev1-dlco-copd-oxygen
Pulmonary: Diffusing Capacity (DLCO) > 50% predicted in patients old enough to comply with pulmonary function testing (PFTs) or no baseline oxygen requirement for younger patients.,fev1-dlco-copd-oxygen
"Pulmonary: Diffusion capacity of oxygen, corrected for hemoglobin, > 50% of predicted",fev1-dlco-copd-oxygen
Pulmonary: normal lung function as manifested by no dyspnea and/or oxygen saturation >= 88% on room air.,fev1-dlco-copd-oxygen
Pulmonary: normal lung function as manifested by no dyspnea and/or oxygen saturation >= 94% on room air.,fev1-dlco-copd-oxygen
"Pulmonary: not requiring supplemental oxygen or mechanical ventilation, oxygen saturation 90% or higher on room air",fev1-dlco-copd-oxygen
Pulmonary: oxygen saturation > 92% at rest (on room air),fev1-dlco-copd-oxygen
Pulse Oximetry measurement >= 95% saturation without supplemental oxygen,fev1-dlco-copd-oxygen
Pulse oximetry of < 92% on room air or the need for supplemental home oxygen,fev1-dlco-copd-oxygen
Receiving supplementary continuous oxygen,fev1-dlco-copd-oxygen
Require supplemental oxygen for daily activities.,fev1-dlco-copd-oxygen
Requirement for oxygen therapy,fev1-dlco-copd-oxygen
Requirement for supplemental oxygen,fev1-dlco-copd-oxygen
Requirement for supplemental oxygen therapy,fev1-dlco-copd-oxygen
Requires daily supplemental oxygen.,fev1-dlco-copd-oxygen
Requires the use of home oxygen.,fev1-dlco-copd-oxygen
Respiratory condition that required any oxygen supplementation <= 6 months prior to registration,fev1-dlco-copd-oxygen
Room air oxygen saturation of 92% or greater,fev1-dlco-copd-oxygen
"Severe chronic obstructive or other pulmonary disease with hypoxemia (requires supplementary oxygen, symptoms due to hypoxemia or oxygen saturation < 90% by pulse oximetry after a 2 minute walk) or in the opinion of the investigator any physiological state likely to cause systemic or regional hypoxemia",fev1-dlco-copd-oxygen
Severe chronic obstructive pulmonary disease requiring oxygen supplementation,fev1-dlco-copd-oxygen
Severe dyspnea at rest or requiring supplementary oxygen therapy.,fev1-dlco-copd-oxygen
Severe dyspnea or requiring supplemental oxygen therapy at rest,fev1-dlco-copd-oxygen
Severely impaired lung function as defined as oxygen (O2) saturation that is 92% or less at rest on room air,fev1-dlco-copd-oxygen
Shortness of breath requiring continuous oxygen treatment for at least 15 hours per day in chronically hypoxemic patients,fev1-dlco-copd-oxygen
Spirometry and diffusion capacity of the lung for carbon monoxide (DLCO) 50% or greater of normal and oxygen (O2) saturation 88% or greater at rest on room air. Baseline testing is not required unless known severely impaired lung function.,fev1-dlco-copd-oxygen
"Subject does not require supplemental oxygen or mechanical ventilation, and oxygen saturation by pulse oximetry is 94% or higher on room air.",fev1-dlco-copd-oxygen
Subject has a chronic respiratory disease that requires continuous oxygen use.,fev1-dlco-copd-oxygen
Subject has chronic respiratory disease that requires continuous oxygen use.,fev1-dlco-copd-oxygen
"Subject has chronic respiratory disease that requires continuous oxygen, or significant history of renal, neurologic, psychiatric, endocrinologic, metabolic, immunologic, hepatic, cardiovascular disease, or any other medical condition that in the opinion of the investigator would adversely affect his/her participating in this study.",fev1-dlco-copd-oxygen
Subject has inadequate pulmonary function defined as oxygen saturation (SaO2) < 92% on room air.,fev1-dlco-copd-oxygen
Subject has known chronic obstructive pulmonary disease (COPD) with a forced expiratory volume in 1 second (FEV1) 50% of predicted normal.,fev1-dlco-copd-oxygen
Subject requires continuous supplemental oxygen for any reason.,fev1-dlco-copd-oxygen
"Subjects must have a baseline O2 saturation by pulse oximetry that is >= 92% both at rest and while walking, off supplemental oxygen",fev1-dlco-copd-oxygen
Subjects requiring supplemental oxygen therapy.,fev1-dlco-copd-oxygen
Subjects who need daily oxygen therapy,fev1-dlco-copd-oxygen
Supplemental oxygen dependency,fev1-dlco-copd-oxygen
Supplemental oxygen dependency or clinically significant interstitial lung disease.,fev1-dlco-copd-oxygen
Supplemental oxygen utilization at baseline,fev1-dlco-copd-oxygen
"Symptomatic active lung disease, or requiring daily supplemental oxygen",fev1-dlco-copd-oxygen
The patient has oxygen-support requirements.,fev1-dlco-copd-oxygen
The patient is oxygen-dependent.,fev1-dlco-copd-oxygen
The use of supplemental oxygen.,fev1-dlco-copd-oxygen
Uncontrolled asthma or oxygen (O2) saturation < 90% by ABG (arterial blood gas) analysis or pulse oximetry on room air,fev1-dlco-copd-oxygen
Uncontrolled asthma or oxygen (O2) saturation < 90% by arterial blood gas analysis or pulse oximetry on room air,fev1-dlco-copd-oxygen
Uncontrolled asthma or oxygen (O2) saturation < 90% by pulse oximetry on room air,fev1-dlco-copd-oxygen
Uncontrolled asthma or oxygen saturation < 90% by arterial blood gas analysis or pulse oximetry on room air.,fev1-dlco-copd-oxygen
Use of continuous oxygen,fev1-dlco-copd-oxygen
Female CrCl = (140 - age in years) x weight in kg x 0.85,fmcrcl
Female CrCl = (140 - age in years) x weight in kg x 0.85 72 x serum creatinine in mg/dL,fmcrcl
Female CrCl = (140- age in years) x weight in kg x 0.85 72 x serum creatinine in mg/dL,fmcrcl
Female CrCl = (140-age in years) x weight in kg x 0.85 72 x serum creatinine in mg/dL,fmcrcl
Female: Multiply above result by 0.85,fmcrcl
Female: Multiply above result by 0.85 <= 1.5 x ULN,fmcrcl
Male CrCl = (140 - age in years) x weight in kg x 1.00,fmcrcl
Male CrCl = (140 - age in years) x weight in kg x 1.00 72 serum creatinine in mg/dL,fmcrcl
Male CrCl = (140 - age in years) x weight in kg x 1.00 72 x serum creatinine in mg/dL,fmcrcl
Male CrCl = (140 - age in years) x weight in kg x 1.00/ 72 x serum creatinine in mg/dL,fmcrcl
Male CrCl = (140- age in years) x weight in kg x 1.00 72 x serum creatinine in mg/dL,fmcrcl
Male: CrCl (mL/min) = (140 - age) x wt (kg) / (serum creatinine x 72),fmcrcl
> 16 years (male) 1.7 (Female) 1.4,fmlabs
> 16 years: 1.7 (male) 1.4 (female).,fmlabs
>= 16 years | Male 1.7 | Female 1.4,fmlabs
>= 16 years: <= 1.7 mg/dL (males) and <= 1.4 mg/dL (females),fmlabs
1 to < 2 years: 0.6 (male) 0.6 (female),fmlabs
1 to < 6 months: 0.4 (male) 0.4 (female),fmlabs
10 to < 13 years | Male 1.2 | Female 1.2,fmlabs
10 to < 13 years: 1.2 (male) 1.2 (female),fmlabs
13 to < 16 years (Male)1.5 (Female) 1.4,fmlabs
13 to < 16 years | Male 1.5 | Female 1.4,fmlabs
13 to < 16 years: <= 1.5 mg/dL (males) and <= 1.4 mg/dL (females),fmlabs
13 to < 16 years: 1.5 (male) 1.4 (female),fmlabs
2 < 6 years: 0.8 (male) 0.8 (female),fmlabs
2 to < 6 years | Male 0.8 | Female 0.8,fmlabs
6 months to < 1 year: 0.5 (male) 0.5 (female),fmlabs
6 to < 10 years | Male 1.0 | Female 1.0,fmlabs
6 to < 10 years: 1.0 (male) 1.0 (female),fmlabs
Age | Maximum Serum Creatinine (mg/dL) | Male | Female,fmlabs
"If female, x 0.85",fmlabs
25% increase in serum FLC level from the lowest response value during (or after) last therapy; the absolute increase must be > 10 mg/dL,free-light-chain
Abnormal serum free light chain ratio ( <= 0.125 or >= 8.0 and involved chain < 100 mg/L) by serum free light chain (FLC) assay,free-light-chain
Clonality as evidenced by (kappa) or (lambda) light chain expression (typically dim immunoglobulin expression) or other genetic method (e.g. IGHV analysis),free-light-chain
Clonality as evidenced by kappa (&kappa;) or lambda (&lambda;) light chain expression or other genetic method,free-light-chain
Clonality as evidenced by kappa or lambda light chain restriction (typically dim immunoglobulin expression).,free-light-chain
FLC ratio ( < 0.26 or > 1.65).,free-light-chain
"in subjects who do not meet these criteria, serum free light chains (FLC) > 100 mg/L (involved light chain) and abnormal ratio (FLC kappa/FLC lambda)",free-light-chain
Involved free light chain >= 10 mg/dL AND abnormal serum immunoglobulin kappa to lambda free light chain ratio ( < 0.26 or > 1.65),free-light-chain
Involved free light chain >= 10 mg/dL AND abnormal serum immunoglobulin kappa to lambda free light chain ratio ( < 0.26 or > 1.65).,free-light-chain
Involved serum free light chain (sFLC) level >= 10 mg/dL with abnormal Kappa/Lambda ratio (light chain disease is acceptable only for subjects without measurable disease in the serum or urine),free-light-chain
Involved serum free light chain > 100 mg/dL (1000 mg/L) in the setting of prior diagnosis of cast nephropathy,free-light-chain
"involved serum free light chain >= 10 mg/dL, with an abnormal free light chain ratio.",free-light-chain
Restricted surface kappa or lambda light chain expression,free-light-chain
"Serum FLC assay result with an involved FLC level >= 10 mg/d ( >= 100 mg/L), provided the serum FLC ratio is abnormal",free-light-chain
"Serum FLC assay result with an involved FLC level >= 10 mg/dL ( >= 100 milligram per liter [mg/L]), provided the serum FLC ratio is abnormal.",free-light-chain
Serum FLC assay: Involved FLC assay >= 10 mg/dL ( >= 100 mg/L) and an abnormal serum,free-light-chain
Serum FLC assay: Involved FLC level >= 10 mg/dL provided serum FLC ratio is abnormal.,free-light-chain
Serum free light chain (FLC) assay: involved FLC level > or equal to 10 mg/dL provided serum FLC ratio is abnormal,free-light-chain
Serum free light chain (FLC) assay: involved FLC level > or equal to 10 mg/dL provided serum FLC ratio is abnormal; subjects who are non-secretors will be considered on a case-by-case basis,free-light-chain
Serum free light chain (FLC) assay: Involved FLC level >= 10 mg/dl ( >= 100 mg/L) and an abnormal serum FLC ratio ( < 0.26 or > 1.65).,free-light-chain
Serum free light chain (FLC) assay: involved FLC level >= 10 mg/dL provided serum FLC ratio is abnormal.,free-light-chain
Serum free light chain (FLC) assay: involved FLC level greater or equal to 10 mg/dL (100 mg/L) provided serum FLC ratio is abnormal.,free-light-chain
Serum free light chain (FLC) assay; involved FLC level greater than or equal to 10 mg/dL provided the serum FLC ratio is abnormal,free-light-chain
Serum free light chain (FLC) assay; involved FLC level greater than or equal to 10 mg/dL provided the serum FLC ratio is abnormal; OR,free-light-chain
Serum free light chain (FLC): involved FLC level >= 10 mg/dL (100 mg/L) provided serum FLC ratio is abnormal.,free-light-chain
Serum Free Light Chain (sFLC) >= 10 mg/dL ( >= 100 mg/L) AND an abnormal sFLC ratio ( < 0.26 or > 1.65) as per the IMWG response criteria,free-light-chain
Serum free light chain (SFLC) assay: Involved SFLCs >= 10 mg/dL ( >= 100 mg/L) and an abnormal SFLC ratio ( < 0.26 or > 1.65).,free-light-chain
Serum free light chain assay.,free-light-chain
Serum free light chain assay:,free-light-chain
Serum free light chain level >= 10 mg/dL with an abnormal free light chain ratio,free-light-chain
Serum immunoglobulin FLC >= 10 mg/dL AND abnormal serum immunoglobulin kappa to lambda FLC ratio,free-light-chain
"Serum immunoglobulin free light chain (FLC) >= 10 mg/dL (100 mg/L), provided serum FLC ratio is abnormal.",free-light-chain
Serum immunoglobulin free light chain >= 10 mg/dL AND abnormal serum immunoglobulin kappa to lambda free light chain ratio,free-light-chain
Serum immunoglobulin free light chain >= 10 mg/dL AND abnormal serum immunoglobulin kappa to lambda free light chain ratio The following laboratory values obtained <= 14 days prior to registration,free-light-chain
Serum immunoglobulin free light chain >= 10 mg/dL AND abnormal serum immunoglobulin kappa to lambda free light chain ratio.,free-light-chain
"(For expansion cohort only): Tissue must be available to confirm positive expression of AG7 antigen, defined as proportional score >= 2, via slides or tumor block from either original diagnostic biopsy material or biopsy of relapsed disease",gene
5q33 translocation (PDGFRB fusion gene (gene-rearrangement),gene
A CD4 count above 250 cells/mcL and an undetectable HIV viral load on standard PCR-based test,gene
A CD4 count above 250 cells/mcL and an undetectable HIV viral load on standard PCR-based tests,gene
"A CD4 count above 250 cells/mcL, and an undetectable HIV viral load on standard PCR-based tests",gene
A leukemia-specific phenotype (e.g. expression of markers including CD13 and/or CD33 and/or CD117 and/or HLA-DR+) post-transplant at a level of >= 0.01%.,gene
"Absence of 5q33 translocation on cytogenetic analysis of BM aspirate/biopsy (i.e., PDGFRB rearrangement).",gene
Absence of inactivating TP53 alteration by Next Generation Sequencing assay or PCR-based assay in a laboratory certified to return results for clinical purposes.,gene
Acute promyelocytic leukemia or Bcr-Abl positive leukemia (chronic myelogenous leukemia in blast crisis),gene
Adenocarcinoma of the breast - triple negative (TNBC),gene
"ALK genetic alterations (gene rearrangements, putative activating non-synonymous ALK mutations, ALK copy number gain) and selected alterations in ALK expression (see Appendix 5 and Appendix 10 for specific requirements)",gene
ALK rearrangement identified by Next Generation (NextGen) sequencing. This must have been performed:,gene
"ALK-positive NSCLC, neuroblastoma, and childhood tumors",gene
All cohorts: Patient has EGFR T790M mutation,gene
"All patients must have a deleterious gene mutation in BRCA1/BRCA2 or ATM. Mutations may be identified by local testing or through central testing by the sponsor of plasma or tumor tissue. For local test results, the classification of the mutation as deleterious must be documented in the patient's medical record.",gene
"Anaplastic large cell lymphoma (ALCL), ALK positive",gene
"AND ALK-negative rearrangement. This should have been assessed as part of the patient standard of care by a validated test. The ALK rearrangement negative status must be documented in the patient source documents before the patient can be consented for pre-screening for cMET amplification and cMET mutation status, except for patients who are treatment-naïve potentially eligible for Sub-Cohort 5a and 5b; if local ALK testing is not available, patient status will be determined centrally along with the cMET status. Patients with NSCLC of pure squamous cell histology can enter pre-screening without ALK testing or result, however patients with pure squamous cell histology that are known to have ALK rearrangement will be excluded.",gene
Anti-CD20 mAb unless investigator determines that tumor is CD20-negative,gene
Anti-CD20 monoclonal antibody unless investigator determines that tumor is CD20 negative; and,gene
Anti-CD20 monoclonal antibody unless tumor is CD20 negative; and,gene
"At least one or more of the following point ESR1 mutations as assessed in cell-free circulating tumor DNA (ctDNA) obtained from a blood (plasma) or tissue sample: Y537S, Y537C, D538G, E380Q, S463P, V534E, P535H, L536H, L536P, L536R, L536Q, or Y537N. The ctDNA sample collection must be obtained within 30 days prior to randomization to determine eligibility and baseline. A pre-study assessment, however, may be used to determine eligibility if done within 30 days prior to Screening but a screening sample will be collected to confirm eligibility.",gene
"BCR-ABL mutations (t[9,22]/Philadelphia chromosome).",gene
Be HLA-A*02+ as determined by Central Laboratory,gene
Breast cancer in BRCA1 or BRCA2 positive ovarian cancer patients.,gene
"CD19 expression CD19 expression is required at any time since diagnosis. If patient has received anti-CD19 targeted therapy (i.e. Blinatumomab), then CD19 expression must be subsequently demonstrated. CD19 expression. must be detected on greater than 50% of the malignant cells by immunohistochemistry or >= 90% by flow cytometry. The choice of whether to use flow cytometry or immunohistochemistry will be determined by what is the most easily available tissue sample in each subject. In general, immunohistochemistry will be used for lymph node biopsies, flow cytometry will be used for peripheral blood and bone marrow samples.",gene
"CD19 expression is required and must be detected on greater than 50% of the malignant cells by immunohistochemistry or >= 90% by flow cytometry; the choice of whether to use flow cytometry or immunohistochemistry will be determined by what is the most easily available tissue sample in each subject; in general, immunohistochemistry will be used for lymph node biopsies, flow cytometry will be used for peripheral blood and bone marrow samples",gene
"CD19 expression must be detected on the majority of the malignant cells by immunohistochemistry or by flow cytometry in the Laboratory of Pathology, CCR, NCI, NIH. Definition of which cells are malignant must be determined for each patient by the Laboratory of Pathology using techniques to demonstrate monoclonality such as kappa/lambda restriction (other techniques can be used to determine monoclonality at the discretion of the Laboratory of Pathology). The choice of whether to use flow cytometry or immuohistochemistry will be determined by what is the most easily available tissue sample in each patient. Immunohistochemistry will be used for lymph node biopsies and bone marrow biopsies. Flow cytometry will be used for peripheral blood, fine needle aspirate, and bone marrow aspirate samples.",gene
CD20-positive disease,gene
"CD22 expression must be detected on greater than 15% of the malignant cells by immunohistochemistry or greater than 80% by flow cytometry. The choice of whether to use flow cytometry or immunohistochemistry will be determined by what is the most easily available tissue sample in each patent. In general, immunohistochemistry will be used for lymph node biopsies, flow cytometry will be used for peripheral blood and bone marrow samples and CSF when feasible.",gene
"CD30 expression determined by flow cytometry or IHC. NOTE: If CD30 testing was previously done on the biopsy sample from diagnosis, this information will be collected. If CD30 testing was not done, an archival sample from the biopsy used for diagnosis will be requested and tested for CD30. CD30 testing will also be done on the bone marrow tissue collected from the bone marrow exam. If we are unable to obtain an archival sample or if the bone marrow exam is negative, a new biopsy will be performed to confirm the diagnosis and test for CD30.",gene
CD4 cells > 350 cells/mm3,gene
CD4 count above 250 cells/mcL and an undetectable HIV viral load on standard PCR-based test,gene
c-Met amplification,gene
c-Met overexpression,gene
"Co-expression of CD5, CD19, CD20, and CD23. CD23 negative cases may be included if there is an absence of t(11;14).",gene
"Cohort 2, Ph+ and Ph-like DSMKF Patients Only:",gene
"Cohort 2, Ph-positive and Ph-like DSMKF patients only:",gene
"Cohort 4 (closed): Pre-treated patients with cMET mutations regardless of cMET GCN, or",gene
Cohort 5: Documented EGFR or HER2 exon 20 insertion mutations using tissue samples using the criteria described for Cohorts 1 to 4,gene
"Cohort 6(Closed): Pre-treated patients with either cMET GCN >= 10 without cMET mutations or cMET mutations regardless of cMET GCN cMET (and ALK, if applicable) testing may be performed while patient is still receiving anti-cancer therapy. However, the patient can only be screened for the main study once the patient has discontinued the last prior systemic treatment due to either disease progression or intolerance.",gene
Cohort 6: Documented acquired EGFR mutation who have progressed while on firstline osimertinib treatment using tissue tested with a next-generation sequencing assay,gene
Cohort 6: Patients with EGFR mutation-positive NSCLC who progressed while on treatment with first-line osimertinib.,gene
Cohort 7: Documented EGFR or HER2 activating mutations using tissue tested with a next-generation sequencing assay or plasma tested with a Guardant assay,gene
"Cohort 7: EGFR Exon 19 deletion and L858R or HER2 T798I mutations, EGFR and HER2 Exon 20 insertion mutation",gene
"Cohorts 1 and 3: Documented EGFR exon 20 insertion mutation (including duplication mutations) using a next generation sequencing diagnostic test, such as OncoMine Comprehensive Assay (OCA) or FoundationOne Assay, or by an FDA approved test (eg, cobas® EGFR mutation test v2 or therascreen EGFR RGQ PCR kit) performed by a US CLIA certified and locally licensed clinical laboratory or similarly accredited lab for ex-US sites using tissue samples.",gene
Cohorts 1 to 5: EGFR exon 20 point mutation,gene
"Cohorts 2 and 4: Documented HER2 exon 20 insertion mutation (including duplication mutations) using a next generation sequencing diagnostic test, such as OncoMine Comprehensive Assay (OCA) or FoundationOne Assay, performed by a US CLIA certified and locally licensed clinical laboratory or similarly accredited lab for ex-US sites using tissue samples.",gene
Concomitant Kras and BRAF-V600 mutations or MSI-H/dMMR (Microsatellite Instability High/Deficient Mismatch Repair).,gene
Confirmation of NAPRT1 expression and IDH1 mutation based on evaluation of a fresh tumor biopsy or archival tumor biopsy taken <= 6 months of screening tests as follows:,gene
Confirmed kappa-positive expression on lymphoma tissue sample (archival or fresh) as confirmed by pathology.,gene
"Criteria for DHL are concurrent MYC translocation+ and BCL2 translocation+ by fluorescence in situ hybridization (FISH) (same criteria for THL, which also includes BCL6 translocation+ by FISH",gene
Cytogenetics or fluorescent in situ hybridization (FISH) del17p,gene
Disease must be anaplastic lymphoma kinase (ALK) positive (defined by local institutional standards),gene
Disease must be cluster of differentiation (CD)30 positive,gene
Documentation of an FGFR1-3 gene mutation or translocation (Section 8.5.1 and Appendix C). Participants will be assigned to 1 of 3 cohorts:,gene
"Documentation of ER-positive and/or PR-positive tumor ( >= 1% positive stained tumor cell nuclei) based on local testing of the most recent tumor biopsy, using an assay consistent with local standards",gene
"Documentation of HER2- tumor with an IHC result of 0 or 1+ for cellular membrane protein expression or an in situ hybridization negative result as defined in the 2013 or 2018 ASCO recommendations for HER2 testing (Wolff, 2013; Wolff, 2018)",gene
"Documentation of HER2-negative tumor based on local testing of the most recent tumor biopsy, as per most recent American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines [Wolff, 2013]. At the time of writing, HER2-negative tumor is defined as immunohistochemistry (IHC) score of 0 or 1+, or negative by in situ hybridization defined as a HER2/CEP17 ratio < 2 or for single probe assessment of an average HER2 copy number < 4",gene
"Documented EGFR and ALK status (local testing is preferred; if not feasible, central testing will be performed). If the local laboratory will perform the test, a well-validated, local regulatory-approved kit must be used. EGFR/ALK status should be available prior to randomization. If the number of patients with EGFR or ALK mutations (ie, the total number of patients summed across both types of mutations) reaches approximately 20% of the total randomization target patient number, the incoming patients with EGFR/ALK mutations will not be randomized.",gene
Documented HER2-negative per ASCO/CAP criteria (Wolff et al. 2013). Patients who were originally diagnosed with HER2-positive breast cancer that converted to HER2-negative MBC are NOT eligible to take part in this study.,gene
"Documented mutation in KRAS or NRAS (codon 12, 13, 59, 61, 117, or 146) in tumor tissue from primary or metastatic site, tested by a Clinical Laboratory Improvement Act (CLIA)-certified laboratory.",gene
Dose Escalation Phase: Patients will be enrolled according to their NAPRT1 status at a ratio of 2:1 (NAPRT1 negative:NAPRT1 positive). The NAPRT1 status must be determined prior to enrollment based on evaluation of a fresh tumor biopsy or archival tissue prior to screening.,gene
"EGFR exon 18 mutation in lung cancer, or",gene
EGFR status: GBM/AA must have been previously demonstrated to have EGFR amplification and/or EGFRvIII mutation based on any prior resection.,gene
EGFR status: GBM/AA must have EGFR amplification and/or EGFRvIII mutation.,gene
"EGFR status: NSCLC must have confirmed activating EGFR mutation (including Del19, L858R, EGFRvIII, G719A).",gene
"EGFR wt. This should have been assessed as part of the patient standard of care by a validated test for EGFR mutations, as per the Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors from College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology (Lindeman et al 2013). The EGFR wt status (for exon 19 deletions and exon 21 L858R substitution mutations) must be documented in the patient source documents before the patient can be consented for pre-screening for cMET amplification and cMET mutation status (except for patients who are treatment-naïve potentially eligible for Sub-Cohort 5a and 5b or if molecular pre-screening will be performed by NGS and local status is not available). Patients with NSCLC of pure squamous cell histology can enter pre-screening without EGFR mutation testing or result, however patients with pure squamous cell histology and are known to have EGFR mutations in exons 19 or 21 will be excluded",gene
"ER and PR <= 10% by immunohistochemistry, and HER2-negative (as per ASCO/CAP guidelines, defined as IHC 0 or 1+, or FISH ratio < 2.0 or HER2 copy number < 6.0).",gene
"ER negative and PR negative (defined as < 1% staining for ER and PR by IHC): T2 or T3 N0, T0-3, N1-3.",gene
"ER, PR and HER2 measurements should be performed according to institutional guidelines, in a CLIA-approved setting in the US or certified laboratories for Non-US regions. Cut-off values for positive/negative staining should be in accordance with current ASCO/CAP (American Society of Clinical Oncology/College of American Pathologist) guidelines.",gene
"ERBB2 mutation in breast, bladder/urinary tract, biliary tract, colorectal, endometrial, cervical, gastroesophageal, lung, ovarian, and any other cancers, or",gene
"ERBB3 mutation in any cancer (Note: ERBB3 solid tumor NOS cohort closed per Amendment 4), or",gene
ERBB4 mutation in any cancer,gene
Estrogen receptor (ER) and progesterone receptor (PR) negative; defined as ER <= 10% and PR <= 10% staining by immunohistochemistry (IHC).,gene
"Evidence of an activating RET gene alteration in tumor tissue from a laboratory with CLIA, International Organization for Standardization (ISO)/IEC, College of American Pathologists (CAP), or other similar certification (examples of RET activating mutations provided in Appendix B). A positive germline test for a RET mutation is acceptable for patients with MTC. In all cases, an anonymized/redacted Molecular Pathology Report or other report(s) describing tumor RET (and other) alteration analysis should be submitted to Sponsor or designee during/prior to eligibility. Patients identified as having a RET gene alteration of unknown significance or other evidence of RET activation (e.g., increased expression) may be considered for enrolment by the Sponsor if sufficient clinical rationale is provided and agreed upon. The Sponsor has final determination regarding eligibility based upon genomic findings. Blood-based testing which reveals an activating RET mutation should (whenever possible) be confirmed with tissue testing. If tumor tissue is unavailable for confirmatory testing, blood-based testing may be utilized for enrollment with Sponsor permission.",gene
Evidence of CD20 expression by immunohistochemistry or flow cytometry on the tumor specimen obtained with the biopsy performed with screening,gene
Evidence of CD37 expression on tumor cells as demonstrated by flow cytometry and/or IHC on fresh biopsy or historic samples.,gene
"Excluded are subjects who have been diagnosed with an EGFR sensitizing mutation, ALK rearrangement, ROS1 rearrangement, or BRAF V600E mutation.",gene
Expansion cohort only: Plasma cell fluorescence in situ hybridization (FISH) test demonstrating presence of t(11;14),gene
Expression of HLA-A*0201 as determined by high resolution sequence-based typing method (eg. TruSight HLA v2 Sequence Panel),gene
Expression of HLA-A*0201.,gene
Expression of human leukocyte antigen (HLA)-A:0201 or HLA-A:2402.,gene
"Expression of one or more of the following HLA class I alleles: HLA-A02, HLA-A03, HLA-A11, HLA-B07 and HLA-C08.",gene
"Fluorescence in situ hybridization showing t(4:14), t(14:16)t (14:20 deletion (Del) 17/17p or gain (amp) 1q",gene
"Fluorescence in situ hybridization showing t(4;14), t(14;16), t(14;20), deletion (Del) 17/17p or gain (amp) 1q",gene
Fluorescent in situ hybridization (FISH) or conventional cytogenetics positive for t(11;14),gene
Fluorescent in situ hybridization (FISH) translocation 4:14,gene
"For Part A (Dose Escalation) only: Evidence of cell membrane BCMA expression detected on >= 50% of malignant plasma cells from either a bone marrow biopsy or plasmacytoma determined by a validated IHC of formalin-fixed, paraffin-embedded (FFPE) tumor tissue.",gene
"For Parts A, B, C, D, E, G, and I: Have a diagnosis of HR+, HER2 negative mBC. To fulfill the requirement for HR+ disease, a breast cancer must express, by immunohistochemistry (IHC), at least one of the hormone receptors (ER, PR). To fulfill the requirement for HER2 negative disease, a breast cancer must not demonstrate over-expression of HER2 by either IHC or fluorescence in-situ hybridization (FISH).",gene
GBM/AA must have EGFR amplification and/or EGFRvIII mutation,gene
GIST patients must have a KIT or PDGFRA mutation and must have progressed on or had an intolerability to at least 1 line of systemic anticancer therapy:,gene
"Has ER-, progesterone receptor positive breast cancer.",gene
Have acute promyelocytic leukemia and the associated cytogenetic translocation t(15;17).,gene
Having at least one TP53 mutation which is not benign or likely benign.,gene
"HER2 negative status should be determined based on the American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines (22, 23). ER expression must be less than 10% nuclei positive based on immunohistochemistry analysis.",gene
HER2 negative subjects (defined by HER2 <= 2+ by IHC) by medical history.,gene
"Her-2 negative, defined as:",gene
"HER2 positive (IHC 3+ and or FISH amplified) or triple receptor negative (TN, ER/PR < 10% HER2 negative (IHC 1+ or 2+ FISH non-amplified) receiving any standard routine clinical NST regimen.",gene
"HER2-negative status is defined as immunohistochemistry score of 0-1+, or with a FISH ratio of < 2 if IHC is 2+ or if IHC has not been done (as per ASCO/CAP definitions). In cases of borderline or equivocal HER2 status, eligibility will be determined by the PI.",gene
HER2-positive breast cancer:,gene
"High grade B-cell lymphoma with translocations of MYC and BCL2 (double hit lymphoma, DHL), or DLBCL or high grade B-cell lymphoma not otherwise specified (NOS) with protein expression by immunohistochemistry (IHC) of both MYC ( >= 40%) and BCL2 ( >= 50%) in the absence of dual translocations (double expressing lymphoma, DEL). Local determination of fluorescence in situ hybridization (FISH) and IHC will be performed per standardized guidelines and will be acceptable for study entry.",gene
"High risk factors defined by the presence of any one of the following detected at any time prior to enrollment: deletion of chromosome 13 by conventional cytogenetics, hypodiploidy, abnormality in chromosome 1 (1q amplification or 1p deletion), t(4;14), t(14;16), t(14;20) or deletion of 17p by fluorescence in situ hybridization (FISH) or conventional karyotyping; high risk criteria based on commercially available gene expression profiling; OR",gene
"Histologic confirmation from local lab that tumor is ERα negative ( < 1% nuclear staining), and HER2 negative (see prior note in Section 4.1.2).",gene
Histologic documentation of node positivity is required for ER/PR positive tumors.,gene
Histologic documentation of women or men with HER2 negative breast carcinoma and no recurrence.,gene
Histological confirmation of expressing cluster of differentiation 20 antigen as determined by pathology at the respective institution and central pathology review at Mayo Clinic Rochester,gene
Histological confirmation of HER2-positive advanced breast cancer; HER2+ is defined by 2013 American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines,gene
"Histological confirmation of triple negative invasive breast cancer (defined as ER <= 10%, PR <= 10% and HER2 not amplified by ISH or IHC 0/1) at diagnosis.",gene
Histologically confirmed diagnosis of CD20 positive iNHL with histological subtype limited to:,gene
"HLA A*0201 High resolution, 4-digit typing is required at HLA-A2 to ensure A*0201 status.",gene
HLA A2+ by deoxyribonucleic acid (DNA) sequence analysis (by history with documentation or as part of this study).,gene
HLA phenotype positive NOTE: Patients who were previously HLA-typed for participation in other Immatics' sponsored clinical trials and were HLA phenotype positive may enter IMA201-101 main screening,gene
HLA-A*02:01,gene
HLA-A*02:06,gene
HLA-A*0201 negative,gene
HLA-A*0201 positive and HA-1(H) negative (RS_1801284: G/G) or,gene
HLA-A*0201 positive by Central Assay,gene
HLA-A*0201 positive.,gene
HLA-A*24:02,gene
IDH1 mutation status for expansion cohort IV,gene
"If ER positive and/or PR positive, tumor must be node positive and within 10 years of diagnosis. pN1mic is eligible.",gene
"If positive,the CD4 count must be > 400.",gene
"If possible, a biopsy of metastatic breast cancer tissue will be obtained to provide histological or cytological confirmation of ER+/HER2- disease as assessed by a local laboratory, according to ASCO/CAP guidelines, using slides, paraffin blocks, or paraffin samples. If a biopsy is not possible, the ER and HER2 status from the tissue obtained at the time of the original diagnosis must confirm that the subject is ER+ and HER2-.",gene
"If test at CLIA-certified lab used a non-Food and Drug Administration (FDA) approved method, information about the assay must be provided; (FDA approved tests for BRAF V600 mutations in melanoma include: THxID BRAF Detection Kit and Cobas 4800 BRAF V600 Mutation Test)",gene
Indeterminate or negative HER2 status.,gene
Kappa-positive expression on lymphoma tissue sample or kappa restriction on flow cytometry (archival or fresh) as confirmed by institutional hematopathology standard (result must be confirmed at the time of cell procurement).,gene
Known CD19 negative or CD20 negative tumor.,gene
"Malignancy of non-squamous histology that carries a BRAF, KRAS, NRAS or Harvey rat sarcoma viral oncogene homolog (HRAS) mutation(s).",gene
"Malignant glioma patients with genomic alterations potentially conferring sensitivity to DCC-2618 including, but not limited to, amplification and/or mutations of PDGFRA and/or KIT.",gene
MammaPrint low and ER-,gene
"MammaPrint Low, ER+, HER2/neu positive by any one of the three methods used (IHC, FISH/alternative probe,). See Section 3, Table of Eligibility",gene
"Melanoma patients with mutations and/or amplification potentially conferring sensitivity to DCC-2618 including KIT, PDGFR (A or B), TIE2, CSF1R, and VEGFR2 (KDR). Gene amplification must be confirmed by fluorescence in situ hybridization (FISH).",gene
Must have determination of biomarker (BM) status for DNA-repair gene defects (DRD) (either BM positive [+] or BM negative [-]) by the sponsor's blood or tissue assay,gene
MYC gene rearrangement (by [fluorescent in situ hybridization] FISH),gene
NAPRT1 positive for expansion cohort I or III ii NAPRT1 negative for expansion cohort II or III,gene
Negative HAMA test at screening.,gene
Negative human anti-murine antibody (HAMA) test.,gene
"Negativity for the Philadelphia chromosome must be established by conventional cytogenetics, fluorescence in situ hybridization (FISH) and/or polymerase chain reaction (PCR",gene
"Neoplasia harbours RAS mutation (NRAS mutant, KRAS mutant or double mutant)",gene
"Newly diagnosed de novo ALL (B-ALL or T-ALL) with definitive evidence of BCR-ABL1 fusion by karyotype, fluorescence in situ hybridization (FISH) and/or reverse transcriptase (RT)-PCR",gene
Newly diagnosed patients with CD-22 positive B-cell acute lymphoblastic leukemia (WHO criteria) are eligible.,gene
No activating mutation in the Fms-like tyrosine kinase-3 (FLT3) defined as a ratio of mutant to wild-type allele >= 0.05 by capillary electrophoresis or a variant allele fraction of >= 5% by next generation sequencing from either bone marrow or peripheral blood.,gene
No evidence of t(14;16) by fluorescence in situ hybridization (FISH) testing on bone marrow or not available,gene
No known presence of known EGFR or EML4-ALK driver mutations in the tumor.,gene
"Once a safe dose level is achieved that is consistent with inhibiting RET, patients must have advanced NSCLC, MTC or other advanced solid tumor with evidence of RET alteration or other evidence of increased RET activity in tumor tissue and/or blood.",gene
One of the following Ph-like ALL genetic lesions must be present in the diagnostic bone marrow or peripheral blood sample:,gene
or c-Met amplification,gene
Participants with any programmed death-ligand 1 (PD-L1) test result by immunohistochemistry (IHC) are eligible for the study,gene
Patient has a pathology report confirming PIK3CA mutant status by a certified laboratory using a validated PIK3CA mutation assay (either from tissue or blood). It is also mandatory to provide a tumor sample (either archival or newly obtained) for PIK3CA mutation confirmation by a Novartis designated laboratory. It is recommended the tumor sample is collected after the most recent progression or recurrence.,gene
"Patient has PIK3CA mutation confirmed by a Novartis designated laboratory, in which adequate formalin-fixed paraffin-embedded tissue sections with > 10% tumor tissue must be provided. It is recommended to provide a tumor sample collected after the most recent progression or recurrence OR",gene
Patient is HLA-A2+,gene
Patient is MammaPrint low and ER+ and HER2+,gene
Patient is positive for EGFR or HER2 exon 20 mutations based on tissue testing:,gene
Patients confirmed to have a cis double mutation (Del19/T790M or L858R/T790M) or cis triple mutation (Del19/T790m/C797S or L858R/T790M/C797S).,gene
Patients must be ER >= 1% and HER2 negative on local testing.,gene
Patients must be HLA-A 11:01 positive (confirmed by HLA typing at the NIH DTM),gene
Patients must be HLA-A*11:01 positive as confirmed by the NIH ,gene
Patients must be HLA-A*11:01 positive as confirmed by the NIH Department of Transfusion Medicine.,gene
Patients must be HLA-A2 for cohort A. (Turnstile II-Chemotherapy/Cell Infusion-Inclusion Criteria),gene
Patients must be HLA-DP4 positive.,gene
Patients must be positive for at least 1 of the following human leukocyte antigens (HLA):,gene
"Patients must be PPD negative within 90 days prior to registration; PPD negativity is defined as < 10 mm diameter induration (palpable, raised hardened area) in the volar forearm at 48-72 hours following injection with standard tuberculin dose (5 units, 0.1 ml)",gene
Patients must express HLA-A*0201,gene
"Patients must have a diagnosis of Philadelphia chromosome negative ALL or Ph chromosome positive ALL by cytogenetics, FISH or polymerase chain reaction (PCR). Patients will be registered to receive treatment in either Cohort 1 (Ph-) or Cohort 2 (Ph+ or Ph-like DSMKF) based on these results. Diagnostic specimens must be submitted to the site's local CLIA-approved cytogenetics laboratory and results of tests (cytogenetics, FISH or PCR) must confirm Ph status prior to registration. If not already known, BCR-ABL status (p190 or p210) must be evaluated in Ph-positive patients by PCR.",gene
"Patients must have known ER, PR, and HER2 status defined as triple-negative breast cancer (TNBC), defined as:",gene
"Patients must have RPA (including KRAS, NRAS, NF1, HRAS, and BRAF)",gene
Patient's tumor must be HR+: expression of the estrogen receptor (ER) or progesterone receptor (PR) is > 1% by immunohistochemistry (IHC); and HER2-: either 0 to 1+ by IHC or 2+ by fluorescence in situ hybridization (FISH) negative (not amplified).,gene
Patients who are CMV PCR positive at baseline will not be eligible,gene
Patients who are human leukocyte antigen (HLA)-A2 positive.,gene
"Patients who are known to have Lynch syndrome and have been found to carry a specific germline mutation in an MMR gene (MLH1, MSH2, MSH6, PMS2) are eligible to participate",gene
Patients with a known BRAF V600E mutation or patients with peritoneal carcinomatosis.,gene
"Patients with a pre-existing resistance mutation to an approved line of therapy are eligible. For example, imatinib resistant mutations including KIT Exon 17 and PDGFRA D842V.",gene
Patients with characterized ALK-positive rearrangement.,gene
"Patients with characterized EGFR mutations that predict sensitivity to EGFR therapy, including, but not limited to exon 19 deletions and exon 21 mutations.",gene
Patients with elevated tissue tumor mutational burden (tTMB) ( >= 10 mutations/Mb as determined using any CLIA validated assay; see Appendix 5 for details). For tissue requirements; refer to A11-4.5.1.2.1,gene
"Patients with hematologic malignancies featuring clonal expansion of eosinophils driven by genomic alterations of KIT or PDGFR (eg, HES or CEL) must have a diagnosis confirmed by a central independent pathologist and are eligible if they have progressed on or are intolerant of imatinib therapy. Patients with de novo imatinib resistant mutations, such as but not limited to KIT D816V or PDGFRA D842V, are eligible without prior imatinib therapy.",gene
Patients with known resistant mutations in the EGFR TK domain (T790M) are not eligible.,gene
Positive for any of the HLA-A*02 allele other than HLA-A*02:01 or HLA-A*02:642 (except null alleles or HLA-A*02:03) or the following alleles: HLA-C*04:04 or HLA-B*51:03.,gene
Positive for either CD19 or CD 20 together with CD23 and CD5.,gene
Positive for HLA-A*02:01or HLA-A*02:642 allele.,gene
Positive for HLA-A*02:05 or HLA-A*02 allele other than A*02:07 or A*02 null allele,gene
Positive serology for HTLV 1 or 2.,gene
Presence of t(4;14) or del 17p or 1q gain by conventional cytogenetics or fluorescence in situ hybridization (FISH) studies.,gene
"Pretreatment cytogenetics must be performed on all patients; collection of pretreatment specimens must be completed within 28 days prior to registration to S1318; specimens must be submitted to the site's preferred CLIA-approved cytogenetics laboratory; BCR-ABL status must be verified in Ph-positive patients by FISH, cytogenetics, and/or PCR prior to enrollment; if a patient is Ph-positive, PCR for both p190 and p210 must be sent",gene
"Previously registered to A151216, with the result of lung cancer harboring an EGFR exon 19 deletion or L858R mutation. The testing must have been performed by one of the following criteria:",gene
"Primary eosinophilia associated with 8p11 translocation FGFR1 fusion gene, defined by the presence of the 8p11 translocation (cytogenetic analysis) and/or evidence of the FGFR1 fusion gene on FISH or RT-PCR).",gene
q32) and/or overexpress cyclin D1 in tissue biopsy,gene
RAS (KRAS and NRAS) wild-type in primary or metastatic tumor tissue.,gene
RET Fusion-Positive Solid Tumor,gene
ROS proto-oncogene 1 negative or unknown,gene
"Screen-detected, ER positive DCIS of the breast proven on core needle biopsy, defined as 10% ER positive cells. The presence of a focus suspicious for microinvasion will be allowed. The size of the DCIS in the core biopsy sample must be at least 4mm for a single core or total at least 5 mm if multiple cores are summed and must be estimated on the deepest step section (if step sections are taken).",gene
Subject is HLA-A*02 positive and subject's tumor shows expression of the MAGE-A4 RNA or protein.,gene
"Subject is HLA-A*02:01, HLA-A*02:05, and/or HLA-A*02:06 positive as determined by a central laboratory. (This determination will be made under a pre enrollment screening informed consent form [ICF]. There are no restrictions on the timing of HLA typing for screening and data can be taken from subjects' records).",gene
"Subject is HLA-A*02:05 positive in either allele; Subject has HLA-A*02:07 as the sole HLA-A*02 allele (e.g., a subject with HLA alleles A*02:04 and A*02:07 is eligible); or Subject has any A*02 null allele (designated with an  N , e.g., A*02:32N) as the sole HLA-A*02 allele",gene
Subjects must express HLA-A2 phenotype as assessed serologically.,gene
"Substudy 2 FGFR2 mutation status based on NGS testing performed or commissioned by the respective study site using a validated test listed in Section 6.7. For NGS testing, no central laboratory will be established for the purpose of Substudy 2.",gene
"t(11;14) detected by fluorescence in situ hybridization (FISH), conventional cytogenetics, or other molecular evaluation",gene
"The absence of 5q33 translocation on cytogenetic analysis of BM aspirate/biopsy (i.e., PDGFRB rearrangement)",gene
"The predominant population of lymphocytes share both B-cell antigens (CD19, CD20, or CD23) as well as CD5 in the absence of other pan-T-cell markers (CD3, CD2, etc.)",gene
"Y537S, Y537C, D538G, E380Q, S463P, V534E, P535H, L536H, L536P, L536R, L536Q, or Y537N. The ctDNA sample collection must be obtained within 90 days prior to randomization to determine eligibility and baseline.",gene
"Abdominal fistula, gastrointestinal perforation, bowel obstruction, or intraabdominal abscess within 12 weeks before enrollment. NOTE: Complete healing of an intra-abdominal abscess must be confirmed before enrollment.",gi-disorders
"Abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 6 months.",gi-disorders
Active diarrhea or inflammatory bowel disease,gi-disorders
"Active diverticulitis, intra-abdominal abscess, gastrointestinal obstruction, abdominal carcinomatosis or other known risk factors for bowel perforation.",gi-disorders
"Active gastrointestinal (GI) disorders including those associated with a high risk of perforation or fistula formation. Subjects with enteric stomata (such as ileostomy, colostomy) are also excluded:",gi-disorders
Active gastrointestinal (GI) ulceration or hemorrhage,gi-disorders
Active inflammatory gastrointestinal disease or previous gastric resection or lap band.,gi-disorders
"Active inflammatory gastrointestinal disease, chronic diarrhea (unless related to underlying malignancy or prior related treatment) or history of abdominal fistula, gastrointestinal perforation, peptic ulcer disease, or intra-abdominal abscess within 6 months prior to study enrollment. Gastroesophageal reflux disease under treatment with proton pump inhibitors is allowed.",gi-disorders
"Active or history of inflammatory bowel disease (colitis, Crohn s), irritable bowel disease, celiac disease, or other serious, chronic, gastrointestinal conditions associated with diarrhea. Active or history of systemic lupus erythematosus or Wegener s granulomatosis.",gi-disorders
"Active or history of inflammatory bowel disease (colitis, Crohn s), irritable bowel disease, celiac disease, or other serious, chronic, gastrointestinal conditions associated with diarrhea. Active or history of systemic lupus erythematosus or Wegener s granulomatosis. Currently receiving immunosuppressive doses of steroids or other immunosuppressive medications (inhaled and topical steroids are permitted)",gi-disorders
"Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease [e.g., ulcerative colitis, Crohn's disease], celiac disease, or other serious chronic gastrointestinal conditions associated with diarrhea",gi-disorders
Any known gastrointestinal disorders which would preclude oral administration of 5-azacitidine.,gi-disorders
"any of the following within 6 months before the first dose of study treatment: abdominal fistula, gastrointestinal perforation, bowel obstruction or gastric outlet obstruction, or intra-abdominal abscess (complete resolution of an intra-abdominal abscess must be confirmed prior to initiating treatment with cabozantinib even if the abscess occurred more than 6 months before the first dose of study treatment)",gi-disorders
"Clinical signs or symptoms of gastrointestinal obstruction or requirement for routine parenteral hydration, parenteral nutrition, or tube feeding",gi-disorders
"Clinically active diverticulitis, intra-abdominal abscess, gastrointestinal (GI) obstruction, or abdominal carcinomatosis (known risks factors for bowel perforation)",gi-disorders
"Clinically significant gastrointestinal (GI) disorders, including history of small bowel obstruction unless the obstruction was a surgically treated remote episode",gi-disorders
"Clinically significant gastrointestinal (GI) disorders, including history of small bowel obstruction unless the obstruction was a surgically treated remote episode.",gi-disorders
"Evidence of >= Grade 2 gastrointestinal toxicity (including, but not limited to: nausea, vomiting, anorexia, gastrointestinal pain)",gi-disorders
"Evidence of gastric ulcers, gastrointestinal fistulas, and gastrointestinal perforations.",gi-disorders
"Gastrointestinal (GI) disorders associated with a high risk of perforation or fistula formation such as tumors invading the GI tract, active peptic ulcer disease, inflammatory bowel disease, diverticulitis, cholecystitis, symptomatic cholangitis or appendicitis, acute pancreatitis or acute obstruction of the pancreatic or biliary duct, or gastric outlet obstruction, abdominal fistula, gastrointestinal perforation, bowel obstruction, or intraabdominal abscess, within 1 month before start of study treatment, or incompletely healed intra-abdominal abscess during the screening",gi-disorders
Gastrointestinal (GI) disorders including those associated with a high risk of perforation or fistula formation:,gi-disorders
"Gastrointestinal (GI): cimetidine, aprepitant",gi-disorders
"Gastrointestinal diseases including ulcerative colitis, Crohn's disease, or hemorrhagic coloproctitis.",gi-disorders
Gastrointestinal disorders particularly those associated with a high risk of perforation or fistula formation including:,gi-disorders
"Gastrointestinal disorders, particularly those associated with a high risk of perforation or fistula formation, including:",gi-disorders
Gastrointestinal hemorrhage,gi-disorders
Gastrointestinal perforation,gi-disorders
Gastrointestinal perforation or fistulae within 6 months prior to randomization.,gi-disorders
Gastrointestinal tract disease or defect or previous history of colitis.,gi-disorders
"GI Disorders: (including inflammatory bowel disease [eg, ulcerative colitis, Crohn's disease], diverticulitis (with the exception of a prior episode that has resolved), celiac disease, or other serious gastrointestinal chronic conditions associated with diarrhea.",gi-disorders
Grade > 1 gastrointestinal toxicity that cannot be managed with supportive care measures.,gi-disorders
Has a history of inflammatory bowel disease or history of scleroderma.,gi-disorders
Has any history of inflammatory bowel disease or scleroderma.,gi-disorders
History of a gastrointestinal perforation,gi-disorders
"History of abdominal fistula or gastrointestinal perforation <= 6 months before Cycle 1, Day 1. Serious non-healing wound, active ulcer, or untreated bone fracture (adjuvant trials: bone fractures must be healed)",gi-disorders
History of abdominal fistula or gastrointestinal perforation within 6 months prior to Day 1 of FOLFIRI + bevacizumab initiation,gi-disorders
"History of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess within 6 months prior to day 1",gi-disorders
"History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess <= 28 days prior to randomization",gi-disorders
"History of abdominal or tracheoesophageal fistula or gastrointestinal perforation within 6 months prior to Cycle 1, Day 1",gi-disorders
"History of abdominal or tracheoesophageal fistula, gastrointestinal (GI) perforation, or intra-abdominal abscess within 6 months prior to Day 1",gi-disorders
"History of acute diverticulitis, intra-abdominal abscess, gastrointestinal (GI) obstruction, abdominal carcinomatosis or other known risk factors for bowel perforation.",gi-disorders
"History of gastrointestinal or urinary fistulae, non-healed or chronic wound, or other conditions that, in the investigator's view, would contraindicate or significantly increase the risks of bevacizumab therapy.",gi-disorders
"History of gastrointestinal perforation; patients with a history of abdominal fistula will be considered eligible if the fistula was surgically repaired or has healed, there has been no evidence of fistula for at least 6 months, and patient is deemed to be at low risk of recurrent fistula",gi-disorders
"History of hemorrhagic diarrhea, inflammatory bowel disease or active uncontrolled peptic ulcer disease. (Concomitant therapy with ranitidine or its equivalent and/or omeprazole or its equivalent is acceptable.) History of ileus or other significant gastrointestinal disorder known to predispose to ileus or chronic bowel hypomotility.",gi-disorders
History of ileus or other significant gastrointestinal disorder known to predispose to ileus or chronic bowel hypomotility.,gi-disorders
History of inflammatory bowel disease,gi-disorders
History of inflammatory bowel disease requiring ongoing therapy,gi-disorders
History of inflammatory bowel disease.,gi-disorders
"History of known hemoptysis, gastrointestinal or intracerebral hemorrhage.",gi-disorders
Impairment of gastrointestinal (GI) function,gi-disorders
inflammatory bowel disease,gi-disorders
Inflammatory bowel disease (IBD),gi-disorders
Inflammatory conditions such as lupus or inflammatory bowel disease,gi-disorders
"No acute gastrointestinal conditions, such as: obstruction, fecal impaction, obstipation, acute surgical abdomen, ongoing need for manual maneuvers to induce bowel movements (such as digital evacuation)",gi-disorders
"No acute gastrointestinal conditions, such as: obstruction, fecal impaction, obstipation, acute surgical abdomen, ongoing need for manual maneuvers to induce bowel movements (such as digital evacuation).",gi-disorders
No diagnosis of inflammatory bowel disease,gi-disorders
"No history of gastrointestinal obstruction, or conditions that increase the risk of gastrointestinal obstruction, perforation, bleeding or impairment of the gastrointestinal wall. No abdominal surgery within 60 days of registration.",gi-disorders
No significant gastrointestinal disorders particularly those associated with a high risk of perforation or fistula formation including:,gi-disorders
Partial or complete gastrointestinal obstruction,gi-disorders
"Participants may not have evidence of a bowel obstruction, abdominal fistula, or intra-abdominal abscess within 6 months of study entry. Participants with current signs or symptoms suggestive of bowel obstruction including early or partial obstruction are ineligible. Participants with a history of gastrointestinal perforation at any time point are ineligible.",gi-disorders
"Patients who have evidence of active or acute diverticulitis, intra-abdominal abscess, and gastrointestinal (GI) obstruction, within 12 months are not eligible.",gi-disorders
"Patients who have had evidence of active or acute diverticulitis, intra-abdominal abscess, abdominal/pelvic fistula, gastrointestinal perforation, gastrointestinal (GI) obstruction and/or who require parenteral hydration and/or nutrition.",gi-disorders
"Patients who have had evidence of active or acute diverticulitis, intra-abdominal abscess, abdominal/pelvic fistula, gastrointestinal perforation, GI obstruction and/or who require parenteral hydration and/or nutrition.",gi-disorders
"Patients who have had evidence of active or acute diverticulitis, intra-abdominal abscess, and gastrointestinal (GI) obstruction which are known risk factors for bowel perforation should be evaluated for the potential need for additional treatment before coming on study.",gi-disorders
"Patients who have had evidence of active or acute diverticulitis, intra-abdominal abscess, gastrointestinal (GI) obstruction and abdominal carcinomatosis should be evaluated for the potential need for additional treatment before coming on study",gi-disorders
"Patients who have had evidence of active or acute diverticulitis, intra-abdominal abscess, gastrointestinal (GI) obstruction and abdominal carcinomatosis which are known risk factors for bowel perforation should be evaluated for the potential need for additional treatment before coming on study.",gi-disorders
Patients with active inflammatory bowel disease,gi-disorders
Patients with inflammatory bowel disease,gi-disorders
"Patients with irritable bowel syndrome, Crohn's disease, or other clinically significant gastrointestinal (GI) related condition that might confound the VEGF-TKI-related-diarrhea endpoint",gi-disorders
Patients with significant gastrointestinal (GI) abnormalities,gi-disorders
Poorly controlled inflammatory bowel disease,gi-disorders
"Previous history of abdominal fistula, tracheoesophageal fistula or other fistula with grade 4 severity, gastrointestinal perforation or intra-abdominal abscess within 6 months prior to enrolment.",gi-disorders
Prior  inflammatory bowel disease,gi-disorders
Prior surgery or gastrointestinal perforation within 28 days of enrollment.,gi-disorders
"Recent history (within the past 6 months) of acute diverticulitis, inflammatory bowel disease, intra-abdominal abscess, or gastrointestinal obstruction.",gi-disorders
"Risk of, or active hemorrhage: history or presence of active gastric/duodenal ulcer or ulcerative colitis, active hemorrhage of an unresected gastrointestinal tumor, history of perforation of fistulas; or any other condition that could possibly result in gastrointestinal tract hemorrhage or perforation within 6 months prior to screening",gi-disorders
"Severe gastrointestinal conditions such as clinical or radiological evidence of bowel obstruction within 4 weeks prior to study entry, uncontrolled diarrhea in the last 4 weeks prior to enrollment, or history of inflammatory bowel disease.",gi-disorders
Significant or recent gastrointestinal disorders with diarrhea as a major symptom,gi-disorders
Subjects with clinical symptoms or signs of gastrointestinal obstruction and/or who require drainage gastrostomy tube and/or parenteral hydration or nutrition.,gi-disorders
"The patient has clinically active diverticulitis, intra-abdominal abscess, gastrointestinal obstruction, peritoneal carcinomatosis",gi-disorders
"The subject has evidence of tumor invading the GI tract, active peptic ulcer disease, inflammatory bowel disease (e.g., Crohn's disease), diverticulitis, cholecystitis, symptomatic cholangitis or appendicitis, acute pancreatitis, acute obstruction of the pancreatic duct or common bile duct, or gastric outlet obstruction. Abdominal fistula, GI perforation, bowel obstruction, or intra-abdominal abscess within 6 months before first dose.",gi-disorders
"This includes uncontrolled diarrhea ( > 1 watery stool/day), major abdominal surgery, significant bowel obstruction and/or gastrointestinal diseases that could alter the assessment of PK or safety, including but not limited to: irritable bowel syndrome, ulcerative colitis, Crohn&rsquo",gi-disorders
"To be eligible to participate in the food effect assessment, patients must not have a history or presence of any clinically significant abnormality involving the gastrointestinal tract and an inability to fast for a minimum of 8 hours",gi-disorders
"Tumors invading the GI-tract, active peptic ulcer disease, inflammatory bowel disease, diverticulitis, cholecystitis, symptomatic cholangitis or appendicitis, acute pancreatitis or acute obstruction of the pancreatic or biliary duct, or gastric outlet obstruction. Presence of primary GI tumor is not excluded.",gi-disorders
Absence of PSA and total testosterone tests within 30 days.,gleason-psa
Any combination of Gleason Score 4+3 ( = GG 3) and Gleason Score 8 (4+4 or 5+3) from >= 3 systematic cores and PSA >= 20 ng/mL,gleason-psa
Any combination of Gleason Score 4+3 ( = Grade Group [GG] 3) and Gleason Score 8 (4+4 or 5+3) from >= 6 systematic cores,gleason-psa
"At least 2 systematic or targeted cores with continuous Gleason Score >= 8 ( = GG 4), each with >= 80% involvement",gleason-psa
"Calculation of PSA doubling time should include the use of all available PSA values obtained within past 12 months prior to randomization, with a minimum of 3 values separated by at least 2 weeks apart.",gleason-psa
Gleason score <= 7 (International Society of Urological Pathologists grades 1-3).,gleason-psa
Gleason Score >= 9 ( = GG 5) in at least 1 systematic or targeted core; or,gleason-psa
Gleason Score 7,gleason-psa
Gleason score 7-10 (ISUP grade group 2 to 5),gleason-psa
Gleason score must be in the range of 2-6,gleason-psa
Gleason score must be in the range of 2-7. > 6 cores are strongly recommended.,gleason-psa
"Gleason score, obtained at biopsy, < 6, 3+4 = 7, or 4+3 = 7",gleason-psa
Grade Group 1 = Gleason score <= 6,gleason-psa
Grade Group 2 = Gleason score 3 + 4 = 7,gleason-psa
Grade Group 3 = Gleason score 4 + 3 = 7,gleason-psa
Grade Group 4 = Gleason score 8,gleason-psa
Grade Group 5 = Gleason scores 9 and 10.,gleason-psa
"In patients post-ablation for primary prostate cancer treatment, PSA greater than or equal to 0.2 ng/mL measured more than 6 weeks after ablation.",gleason-psa
Patients must have a PSA documented prior to initiation of SST and within 28 days prior to registration. Any additional PSAs measured while receiving SST should be recorded.,gleason-psa
Persistent elevation of PSA after prostatectomy measured within 90 days after surgery (PSA never became undetectable) of > 0.04 but < 0.2 ng/mL (PSA nadir),gleason-psa
"Post-prostatectomy patients with a detectable serum PSA ( >= 0.1, but <= 1.0 ng/mL) at study entry (within 90 days of Step 1 registration) and at least one of the following:",gleason-psa
Prostate cancer Gleason grade 6 or lower AND with stable Prostate Specific Antigen (PSA) levels not receiving any current therapy,gleason-psa
Prostate cancer Gleason grade 6 or lower AND with stable Prostate Specific Antigen (PSA) levels off treatment,gleason-psa
Prostate cancer Gleason grade 6 or lower AND with stable Prostate Specific Antigen (PSA) levels off treatment; or,gleason-psa
Prostate cancer with a current PSA level < 0.1 ng/mL.,gleason-psa
Prostate cancer with a Gleason score < 6 with undetectable prostate specific antigen (PSA) over 12 months,gleason-psa
PSA < 20 within 6 months of study entry.,gleason-psa
PSA > = 10 and < = 20,gleason-psa
PSA doubling time to be estimated using Memorial Sloan Kettering Cancer Center online calculator,gleason-psa
PSA greater than or equal to 0.2 ng/mL measured more than 6 weeks after RP.,gleason-psa
PSA values < 10 ng/ml within 90 days prior to randomization,gleason-psa
PSA values < 2 ng/ml within 90 days prior to enrollment. Obtained at least 6 weeks after surgery,gleason-psa
PSA values obtained prior to therapeutic interventions (e.g. salvage radiation) will be excluded from the determination of PSA doubling time.,gleason-psa
"Rise in PSA: a minimum of two consecutive rising levels, with an interval of >= 1 week between each determination. The most recent screening measurement must have been >= 2 ng/mL",gleason-psa
Screening PSA > 0.5 ng/mL,gleason-psa
"Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (e.g., FluMist&reg;) are live attenuated vaccines and are not allowed.",vaccine-live
Sequence of at least 2 rising PSA values at a minimum of 1-week intervals with the last result being at least 1.0 ng/mL if confirmed PSA rise is the only indication of progression. Patients who received an anti-androgen must have PSA progression after withdrawal ( >= 4 weeks since last flutamide or >= 6 weeks since last bicalutamide or nilutamide).,gleason-psa
"The PSA values used to calculate the PSA doubling time must all be >= 0.1 ng/mL, and should be measured in the same laboratory whenever feasible.",gleason-psa
>= Grade II aGVHD,gvhd
Active acute or chronic graft versus host disease (GVHD),gvhd
Active acute or chronic graft-versus-host disease (GVHD) of the liver,gvhd
Active acute or chronic graft-versus-host disease (GVHD) requiring systemic therapy.,gvhd
Active acute or chronic graft-versus-host-disease (GvHD) or receiving immunosuppressive therapy as treatment for GvHD,gvhd
Active graft versus (vs.) host disease (gvhd),gvhd
Active graft versus host disease (GVHD) or on immunosuppressive medication of GVHD,gvhd
Active graft versus host disease (GVHD) or ongoing immunosuppression for GVHD,gvhd
Active graft versus host disease (GVHD) within 90 days prior to cycle 1 day 1,gvhd
Active graft-versus-host disease (GVHD) or severe/extensive chronic GVHD,gvhd
"Active graft-versus-host disease (GVHD), except for non-neurologic symptoms as a manifestation of mild ( <= Grade 1) chronic GVHD.",gvhd
Active GVHD or on immunosuppressive medication for GVHD (applies to cohort #2),gvhd
Active GVHD or recent GVHD and still on > 10 mg prednisone (or equivalent),gvhd
Active GvHD symptoms.,gvhd
Active hepatic graft-versus-host disease,gvhd
Acute GVHD grade II-IV by Glucksberg criteria or severity B-D by IBMTR index,gvhd
Acute GVHD grade II-IV by Glucksberg criteria or severity B-D by IBMTR index.,gvhd
Acute GVHD grade II-IV by Glucksberg criteria or severity B-D by IBMTR index; acute or chronic GVHD requiring systemic treatment within 4 weeks prior to enrollment,gvhd
Acute or chronic graft-versus-host-disease (GvHD) or receiving immunosuppressive therapy as treatment for or prophylaxis agent against GvHD,gvhd
acute or chronic GVHD requiring systemic treatment within 4 weeks prior to enrollment,gvhd
"Any active acute graft versus host disease (GvHD), grade 2- 4, according to the Glucksberg criteria or active chronic GvHD requiring systemic treatment",gvhd
Any drug used for graft-versus-host disease (GVHD) within 4 weeks prior to enrollment,gvhd
Any drug used for GVHD within 4 weeks prior to enrollment,gvhd
Any planned conditioning regimen and GVHD prophylaxis approach is eligible.,gvhd
Any systemic therapy against GvHD < 2 weeks prior to study Day 1.,gvhd
Chronic graft versus host disease (GVHD) or on immunosuppressive therapy for the control of GVHD,gvhd
"Either no evidence of GVHD or minimal clinical evidence of acute GVHD and chronic GVHD while off of systemic immunosuppressive therapy for at least 28 days. Minimal clinical evidence of acute GVHD is defined as grade 0 to I acute GVHD. Minimal evidence of chronic GVHD is defined as mild global score chronic GVHD (as defined by the 2005 NIH consensus project) or no chronic GVHD. Subjects with disease that is controlled to stage I acute GVHD or to mild global score chronic GVHD with local therapy only, e.g., topical cutaneous steroids or oral budesonide, will be eligible for enrollment.",gvhd
"Evidence of graft-versus-host disease (GVHD) with Grade >= 2 serum bilirubin, Grade >= 3 skin involvement, or Grade >= 3 diarrhea.",gvhd
Evidence of GVHD > grade II.,gvhd
Evidence of GVHD greater than Grade II.,gvhd
GVHD grade III or IV.,gvhd
"GVHD therapies within 4 weeks prior to leukapheresis (e.g., calcineurin inhibitors, methotrexate or other chemotherapeutics, mycophenolate, rapamycin, thalidomide, immunosuppressive antibodies such as anti-TNF, anti-IL-6, or anti-IL-6R)",gvhd
"Must be able to receive GVHD prophylaxis with tacrolimus, mycophenolate mofetil, and cyclophosphamide",gvhd
No active graft-versus-host disease (GVHD) or on immunosuppressive medication for GVHD,gvhd
Patient has evidence of active graft versus host disease (GVHD),gvhd
Patient must have had no more than one previous HSCT and currently have no evidence of active graft vs. host disease (GVHD),gvhd
Patients requiring calcineurin inhibitors (i.e. tacrolimus or sirolimus) or other systemic immunosuppressants (cyclosporine (CNI); methotrexate or similar) for GVHD prophylaxis or treatment within 2 weeks prior to study enrollment.,gvhd
"Patients who have active acute graft versus host disease (GvHD) or chronic GvHD, or patients who had previous Grade 2 or higher GvHD.",gvhd
Patients who required steroids for the treatment of GVHD will need to be off steroids for at least 2 weeks before enrollment,gvhd
patients with a history of acute GVHD overall grade II based on skin only involvement or upper gastrointestinal (GI) tract involvement only will be eligible,gvhd
patients with a history of liver or lower GI tract GVHD will not be eligible,gvhd
"Patients with active (grade 2-4) acute graft versus host disease (GVHD), chronic GVHD or an overt autoimmune disease (e.g. hemolytic anemia) requiring glucocorticosteroid treatment ( > 0.5 mg/kg/day prednisone or its equivalent) as treatment",gvhd
Patients with active acute GVHD (grade 2-4) and active moderate or severe chronic GVHD with GVHD therapy initiation or escalation within 28 days,gvhd
Patients with active acute GVHD (grade 2-4) and active moderate or severe chronic GVHD with GVHD therapy initiation or escalation within 28 days. Patients who required steroids for the treatment of GVHD will need to be off steroids for at least 2 weeks before enrollment. (Topical steroids or physiologic adrenal replacement steroid doses are allowed).,gvhd
Patients with GVHD > Grade II,gvhd
Patients with GVHD requiring systemic immunosuppressive therapy,gvhd
Patients with GVHD requiring systemic immunosuppressive therapy.,gvhd
Presence of active acute or chronic graft versus host disease (GVHD),gvhd
Presence of active acute or chronic GVHD,gvhd
"Presence of active GVHD, or receiving immunosuppressive therapy for treatment or prevention of GVHD within 4 weeks prior to enrollment",gvhd
Presence of acute or chronic graft-versus-host disease (GVHD),gvhd
Presence of acute or extensive chronic graft versus host disease (GVHD),gvhd
Presence of acute or extensive chronic graft versus host disease (GVHD).,gvhd
Presence of graft-vs-host disease (GVHD),gvhd
"Subject is on chronic systemic immunosuppressive therapy or corticosteroids (eg, prednisone or equivalent not to exceed 10 mg per day within the last 14 days) or subjects with clinically significant graft-versus-host disease (GVHD).",gvhd
Subjects must not have a history of chronic GVHD (whether limited or extensive stage,gvhd
"Subjects must not have a history of severe (grade 3-4) acute GVHD, and/or current > grade 1 acute GHVD. Subjects must not have a history of chronic GVHD (whether limited or extensive stage).",gvhd
Subjects who are enrolled on another GVHD treatment or prevention trial.,gvhd
Subjects with acute or chronic graft-versus-host-disease (GvHD) or receiving immunosuppressive therapy as treatment or as prophylaxis against GvHD,gvhd
"Systemic treatment for graft versus host disease (GVHD), including but not limited to oral or parenteral corticosteroids, ibrutinib, and extracorporeal phototherapy, within the last 12 weeks",gvhd
The patient must not have >= grade 2 acute graft versus host disease (GvHD) or either moderate or severe limited chronic GvHD within 14 days prior to registration,gvhd
"Active, clinically significant hepatic impairment Child-Pugh class B or C according to the Child Pugh classification.",hepatic
Adequate hepatic profile,hepatic
Adequate hepatic profile:,hepatic
Baseline moderate or severe hepatic impairment (Child-Pugh class B or C),hepatic
Borderline Child-Pugh class A6,hepatic
Child-Pugh A or B (up to 2 lesions < 5cm in size),hepatic
Child-Pugh class A or B7 without ascites,hepatic
Child-Pugh class A5,hepatic
Child-Pugh class B,hepatic
Child-Pugh Class B or C cirrhosis of the liver or cirrhosis (any degree) and a history of hepatic encephalopathy or a history of ascites resulting from cirrhosis requiring diuretics or paracentesis,hepatic
Child-Pugh score < 7 (Child-Pugh Class A).,hepatic
Child-Pugh score A,hepatic
Child-Pugh Score A or B7,hepatic
Child-Pugh score A within 14 days prior to study entry,hepatic
Child-Pugh Score of up to B7,hepatic
Child-Pugh-Turcotte score < 7,hepatic
Child-Pugh-Turcotte score < 8,hepatic
Child's Pugh score of A (see Appendix F),hepatic
Chronic liver disease as indicated by Child-Pugh score A (6) or greater,hepatic
Chronic liver dysfunction prior to development of liver metastases (Child-Pugh C or greater).,hepatic
Cirrhosis at a level of Child-Pugh B (or worse) or,hepatic
Cirrhosis with Child-Pugh score of B or C,hepatic
Cirrhotic status of Child-Pugh class A or B,hepatic
"CRITERIA SPECIFIC FOR COHORT #2 (MCL): Currently active, clinically significant hepatic impairment Child-Pugh class B or C according to the Child Pugh classification",hepatic
Current active hepatic or biliary disease (with exception of Gilbert's syndrome).,hepatic
"Currently active, clinically significant hepatic impairment (Child-Pugh class B or C according to the Child Pugh classification",hepatic
"Currently active, clinically significant hepatic impairment (greater than or equal moderate hepatic impairment according to the Child Pugh classification (see Appendix IX)",hepatic
"Currently active, clinically significant hepatic impairment (greater than or equal to moderate hepatic impairment according to the NCI/Child Pugh classification.",hepatic
"Currently active, clinically significant hepatic impairment Child-Pugh class B or C according to the Child Pugh classification",hepatic
"Currently active, clinically significant hepatic impairment Child-Pugh class B or C according to the Child Pugh classification (see Appendix L)",hepatic
"Currently active, clinically significant hepatic impairment Child-Pugh class B or C according to the Child Pugh classification.",hepatic
"Hepatic dysfunction attributed to lymphoma, KSHV-MCD, or KICS",hepatic
Hepatic encephalopathy,hepatic
Hepatic impairment which is moderate (Child-Pugh B) or severe (Child-Pugh C),hepatic
Hepatic:,hepatic
"hepatic: no clinical evidence of hepatic failure (e.g., coagulopathy, ascites)",hepatic
Hepatic: no history of severe prior or ongoing chronic liver disease,hepatic
"If liver cirrhosis is present, patient must have a Child-Pugh A/B7 classification",hepatic
Known hepatic cirrhosis or severe pre-existing hepatic impairment,hepatic
Liver function tests may be mildly abnormal but within the parameters. Child Pugh score must be A to B7.,hepatic
Moderate or severe hepatic impairment (Child-Pugh B or C),hepatic
Moderate or severe hepatic impairment defined as Child-Pugh Class B or C.,hepatic
"Moderate or severe hepatic impairment, i.e. Child-Pugh class B or C",hepatic
"Must have Child-Pugh A only. Participants may have any viral status (hepatitis B, hepatitis C, or none).",hepatic
Patient with a Child-Pugh score B or C.,hepatic
Patients must NOT have liver disease such as cirrhosis or sever hepatic impairment as defined by Child-Pugh Class B or C,hepatic
Patients w/ severe hepatic impairment (Child-Pugh Class C) are not permitted to enroll in the mCRPC plus hormone arms containing abiraterone acetate.,hepatic
Patients with a Child-Pugh score less than 6 or greater than 9 for radiation naive patients with cirrhosis (cohort 1),hepatic
Patients with baseline severe hepatic impairment (Child Pugh Class C),hepatic
Patients with Child-Pugh Class B or C,hepatic
Patients with chronic liver disease with a Child-Pugh score B or C.,hepatic
Patients with known hepatic cirrhosis or severe pre-existing hepatic impairment are not eligible,hepatic
"Patients with liver disease classified as Child Pugh class A or B, with score <= 9 ((within 4 weeks of treatment)",hepatic
Patients with severe hepatic dysfunction (Child Pugh Class C).,hepatic
"Several hepatic impairments, define as Child-Pugh Class C or worse",hepatic
"Severe hepatic disease, defined as a diagnosis of Child-Pugh class B or C liver disease",hepatic
Severe liver dysfunction defined as Child-Turcotte-Pugh class B & C (significant functional compromise - decompensated disease),hepatic
Subject has hepatic decompensation (Child-Pugh score > 6 [class B and C]).,hepatic
Subject is classified into Child-Pugh Class C,hepatic
"Subjects who have currently active hepatic or biliary disease (with exception of patients with Gilbert's syndrome, asymptomatic gallstones, liver involvement with NHL or stable chronic liver disease per investigator assessment).",hepatic
Subjects with chronic liver disease and hepatic impairment meeting Child-Pugh class C,hepatic
Subjects with severe hepatic insufficiency Child-Pugh Score > 6,hepatic
System: Hepatic - Bilirubin,hepatic
Uncorrectable hepatic synthetic dysfunction evidenced by prolongation of the prothrombin time,hepatic
Underlying hepatic cirrhosis with Child-Pugh class B9 or C,hepatic
"Active HCV infection, defined as having a positive HCV antibody test at screening Patients who have a positive HCV antibody test are eligible for the study if a PCR assay is negative for HCV RNA.",hepatitis
Active hepatitis B (defined as having a positive hepatitis B surface antigen [HBsAg] test at screening):,hepatitis
"Active Hepatitis B (HBV) or C (HCV) infection. All patients must be screened for hepatitis B and C up to 28 days prior to study drug start using the routine hepatitis virus laboratory panel (HBsAg, HBcAb and anti-HCV). Patients positive for hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) will be eligible if they are negative for HBV-DNA. These patients should receive a prophylactic antiviral therapy that is not prohibited by the study. Patients positive for anti-HCV antibody (HCV IgG) will be eligible if they are negative for HCVRNA.",hepatitis
Active hepatitis B (hepatitis B surface antigen reactive) or active hepatitis C (HCV qualitative RNA detected); testing is recommended per investigator's clinical suspicion,hepatitis
Active hepatitis B and C based on the following results:,hepatitis
Active hepatitis B can be defined as:,hepatitis
"Active hepatitis B or C. HBV carriers without active disease (HBV DNA titer < 1000 cps/mL or 200 IU/mL), or cured Hepatitis C (negative HCV RNA test) may be enrolled.",hepatitis
Active hepatitis B or hepatitis C with abnormal liver function tests (Cohorts 4A-4C),hepatitis
"Active hepatitis B virus (HBV) infection (chronic or acute), defined as having a positive hepatitis B surface antigen (HBsAg) test at screening",hepatitis
Active hepatitis C can be defined as:,hepatitis
"Active hepatitis C virus (HCV) infection, defined as having a positive HCV antibody test followed by a positive HCV RNA test at screening",hepatitis
Active hepatitis C.,hepatitis
Active hepatitis viral infections.,hepatitis
Active viral hepatitis.,hepatitis
Acute hepatitis B or acute HCV. Patients with chronic hepatitis B or HCV may be enrolled provided their liver function is adequate as per Inclusion Criteria.,hepatitis
Acute or chronic HCV infection:,hepatitis
Clinically active infection with a hepatitis virus.,hepatitis
Evidence of hepatitis B virus (HBV) or hepatitis C virus (HCV) infection.,hepatitis
"EXCEPTION: subjects with serologic findings suggestive of HBV vaccination (anti-HBs positivity as the only serologic marker) AND a known history of prior HBV vaccination, do not need to be tested for HBV DNA by PCR.",hepatitis
"For patients with positive HBV-DNA and/or positive HBsAg results, they must be treated with antivirals, as prophylaxis starting at least 1-2 weeks prior to receiving study drug",hepatitis
Has a known history of hepatitis B (defined as hepatitis B surface antigen [HBsAg] reactive) or known active hepatitis C virus (defined as HCV RNA [qualitative] is detected) infection.,hepatitis
Has a known history of Hepatitis B or Hepatitis C.,hepatitis
Has a known history of hepatitis B or known active hepatitis C virus infection.,hepatitis
"Has known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA [qualitative] is detected).",hepatitis
"Has known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA [qualitative] is detected). In patients without a known history of hepatitis B or C, serologies should be obtained at screening.",hepatitis
"Has known active hepatitis B (e.g., hepatitis B surface antigen [HBsAg] reactive) or hepatitis C (e.g., hepatitis C virus [HCV] ribonucleic acid [RNA] [qualitative] is detected)",hepatitis
"HBsAg negative, anti-HBs positive and/or anti-HBc positive and detectable viral DNA",hepatitis
HBsAg positive,hepatitis
HBsAg+ or,hepatitis
Hepatitis B - antigen positive,hepatitis
Hepatitis B surface antigen,hepatitis
Hepatitis B virus (HBV) deoxyribonucleic acid (DNA) positive participants must be treated and on a stable dose of antivirals.,hepatitis
hepatitis B virus (HBV) or hepatitis C virus (HCV) infection at screening (positive HBV surface antigen or HCV RNA if anti-HCV antibody screening test is positive),hepatitis
Hepatitis B virus surface antigen (HBsAg) detectable for > 6 months,hepatitis
Hepatitis C antibody,hepatitis
Hepatitis C antibody (AB) positive AND,hepatitis
"History of active hepatitis B or C; blood tests are not required to determine if the patient has had hepatitis B or C, unless the patient reports a history of hepatitis.",hepatitis
History of any chronic hepatitis as evidenced by the following:,hepatitis
History of chronic hepatitis B or C,hepatitis
History of chronic hepatitis B or C.,hepatitis
History of hepatitis B or C or chronic hepatitis.,hepatitis
"If a patient has a negative HBsAg test and a positive total hepatitis B core antibody (HBcAb) test at screening, an HBV DNA test must also be performed to determine if the patient has an HBV infection",hepatitis
"Known active hepatic disease (ie, Hepatitis B or C)",hepatitis
Known active hepatitis B or C. HBV and HCV tests are required prior to Day 1.,hepatitis
"Known hepatitis A virus (HAV), hepatitis B virus (HBV) or hepatitis C virus (HCV) positivity with evidence of ongoing infection. Note that subjects with positive anti-HAV IgM are not eligible; subjects with positive anti-HAV IgG are eligible. Subjects who have been vaccinated against hepatitis B [positive for hepatitis B surface antibody (HBsAb)] who are negative for other markers of prior hepatitis B infection [e.g., negative for hepatitis B core antibody (HBcAb)] are eligible. Subjects with past exposure to HBV [HBc Ab positive and/or HBe Ab positive] are also eligible for the study provided they have received an antiviral treatment, and are negative by assessment for HBV DNA for 6 months prior to treatment. Subjects with known HBV infection should have undetectable HBV viral load and be maintained on antiviral therapy to prevent HBV re-activation. Also note that subjects who are positive for anti-hepatitis C antibody are eligible as long as they have a negative HCV viral load.",hepatitis
Known hepatitis B or C infection.,hepatitis
Known hepatitis B or hepatitis C infection.,hepatitis
"Known hepatitis B or hepatitis C infection; EXCEPTION: if viral load < 800,000 IU/L",hepatitis
"Known hepatitis B surface antigen-positive status, or known or suspected active hepatitis C infection.",hepatitis
Known history of hepatitis B (defined as hepatitis B surface antigen [HBsAg] reactive) or known active hepatitis C virus (defined as HCV RNA [qualitative] is detected).,hepatitis
Known or suspected active hepatitis C infection.,hepatitis
"Known, active hepatitis A, B, or C infection; or known to be positive for HCV RNA or HBsAg (HBV surface antigen).",hepatitis
Liver biopsy showing chronic hepatitis with moderate or severe necroinflammation,hepatitis
Negative HBsAg and positive for hepatitis B core antibody: hepatitis B virus DNA by polymerase chain reaction (PCR) is necessary. Detectable hepatitis B virus DNA suggests occult hepatitis B.,hepatitis
Negative hepatitis B surface antigen (HBsAg) test at screening,hepatitis
"Negative hepatitis B test (defined by a negative test for hepatitis B surface antigen [HBsAg], or antibodies to hepatitis B surface and/or core antigens [antiHBs or antiHBc) (added as of addendum 9)",hepatitis
"Negative hepatitis C virus (HCV) antibody test at screening, or positive HCV antibody test followed by a negative HCV RNA test at screening The HCV RNA test will be performed only for patients who have a positive HCV antibody test.",hepatitis
Negative HepBsAg and positive for hepatitis B core antibody: hepatitis B virus DNA by polymerase chain reaction (PCR) is necessary. Detectable hepatitis B virus DNA suggests occult hepatitis B,hepatitis
Negative test for antibodies to hepatitis B surface antigens (anti-HBs),hepatitis
"Negative total hepatitis B core antibody (HBcAb) test at screening, or a positive total HBcAb test followed by a negative hepatitis B virus (HBV) DNA test at screening The HBV DNA test will be performed only for patients who have a positive total HBcAb test.",hepatitis
"No known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA [qualitative] is detected).",hepatitis
No known active hepatitis B or C,hepatitis
Participant has active hepatitis B infection as determined by nucleic acid amplification test (NAAT) or surface antigen assay. Participants who have acquired immunity from past exposure (HBcAb positive/HBsAb positive/HBsAg negative) are eligible.,hepatitis
"Participants must not have any positive test result for hepatitis B virus or hepatitis C virus (HCV) indicating presence of virus, for example,hepatitis B surface antigen (Australia antigen) positive or hepatitis C antibody (anti-HCV) positive (except if HCV-ribonucleic acid [RNA] negative).",hepatitis
Participants with a history of resolved hepatitis A virus infection are eligible.,hepatitis
Patient has evidence of active or chronic Hepatitis B or Hepatitis C infection.,hepatitis
"Patient has known active hepatitis B (e.g., hepatitis B surface antigen reactive) or hepatitis C (e.g., hepatitis C virus ribonucleic acid [qualitative] is detected).",hepatitis
"Patient previously treated with IFNs (e.g., for chronic active hepatitis).",hepatitis
"Patients co-infected with HBV and HCV, or co-infected with HBV and hepatitis D virus (HDV). HBV positive [presence of hepatitis B surface antigen (HBsAg) and/or hepatitis B core antibodies (anti-HBcAb) with detectable HBV DNA ( >= 10IU/ml)]; HCV positive (presence of anti-HCV antibodies); HDV positive (presence of anti-HDV antibodies).",hepatitis
Patients positive for hepatitis C virus (HCV) antibody are eligible only if PCR is negative for HCV RNA.,hepatitis
Patients positive for hepatitis C virus (HCV) antibody are eligible only if polymerase chain reaction (PCR) is negative for HCV ribonucleic acid (RNA),hepatitis
Patients positive for hepatitis C virus (HCV) antibody are eligible only if polymerase chain reaction (PCR) is negative for HCV ribonucleic acid (RNA).,hepatitis
Patients positive for hepatitis C virus (HCV) antibody are eligible only if polymerase chain reaction (PCR) is negative for HCV RNA.,hepatitis
Patients who are positive for HCV antibody must be negative for HCV by PCR to be eligible for study participation.,hepatitis
Patients whose HBV infection status cannot be determined by serologic test results (www.cdc.gov/hepatitis/hbv/pdfs/serologicchartv8.pdf) must be negative for HBV by PCR to be eligible for study participation.,hepatitis
"Patients with a past or resolved HBV infection, defined as having a negative HBsAg test and a positive total hepatitis B core antibody (HBcAb) test at screening are eligible for the study if HBV DNA is negative or undetectable.",hepatitis
Patients with a past or resolved hepatitis B virus (HBV) infection (defined as having a positive total HBcAb and negative hepatitis B surface antigen [HbsAg]) may be included if HBV DNA is undetectable. These patients must be willing to undergo monthly DNA testing.,hepatitis
Patients with a positive hepatitis B surface antigen and/or antihepatitis B core antibody. Patients with a negative polymerase chain reaction (PCR) assay are permitted with appropriate antiviral prophylaxis.,hepatitis
"Patients with HBV infection [as characterized by positive hepatitis B surface antigen (HBsAg) and/or hepatitis B core antibodies (anti-HBcAb) with detectable HBV DNA ( >= 10 IU/ml)] must be treated with antiviral therapy, as per institutional practice, to ensure adequate viral suppression (HBV DNA <= 2000 IU/mL) prior to enrollment. Patients must remain on antiviral therapy for the study duration and for 6 months after the last dose of study medication. Patients who test positive for antiHBc with undetectable HBV DNA ( < 10 IU/ml) do not require anti-viral therapy prior to enrollment. These subjects will be tested at every cycle to monitor HBV DNA levels and initiate antiviral therapy if HBV DNA is detected ( >= 10 IU/ml). HBV DNA detectable subjects must initiate and remain on antiviral therapy for the study duration and for 6 months after the last dose of study medication.",hepatitis
Patients with HCV infection must have confirmed diagnosis of HCV characterized by the presence of detectable HCV RNA or anti-HCV antibody upon enrollment (management of this disease is per local institutional practice).,hepatitis
Patients with known active Hepatitis B or Hepatitis C.,hepatitis
Patients with occult or prior HBV infection (defined as positive total hepatitis B core antibody [HBcAb] and negative HBsAg) may be included if HBV DNA is undetectable. These patients must be willing to undergo monthly DNA testing during treatment and for at least 12 months after completion of study therapy.,hepatitis
Patients with past or resolved hepatitis B infection (defined as having a negative HBsAg test and a positive IgG antibody to hepatitis B core antigen [anti-HBc] OR negative HBV viral load by PCR) are eligible.,hepatitis
Patients with past or resolved hepatitis B infection (defined as having a negative hepatitis B surface antigen [HBsAg] test and a positive anti-HBc [antibody to hepatitis B core antigen] antibody test) are eligible,hepatitis
Patients with past or resolved hepatitis B infection (defined as having a negative hepatitis B surface antigen [HBsAg] test and a positive anti-HBc [antibody to hepatitis B core antigen] antibody test) are eligible.,hepatitis
"Patients with treated hepatitis viral infections (hepatitis B and C) are eligible if they have completed definitive treatment at least 6 months prior, have no detectable viral load on quantitative PCR, and liver function tests (LFTs) meet eligibility requirements.",hepatitis
"Positive for HBsAg, but for > 6 months have had normal transaminases and HBV DNA levels between 0-2000 IU/ml (inactive carrier state) and willing to start and maintain antiviral treatment for at least the duration of the study OR",hepatitis
Positive for hepatitis B surface antigen (HBsAg) (indicative of chronic hepatitis B or recent acute hepatitis B).,hepatitis
Positive for hepatitis B surface antigen (HepBsAg) (indicative of chronic hepatitis B or recent acute hepatitis B),hepatitis
"Positive HCV antibody followed by positive confirmatory test (eg, quantitative HCV RNA test)",hepatitis
Positive Hepatitis B (Hepatitis B surface antigen and antibody) and/or Hepatitis C (Hepatitis C antibody test) as indicated by serologies conducted <= 3 months prior to registration if liver function tests are outside of the normal institutional range.,hepatitis
Positive hepatitis B surface antigen (HBsAg) or positive hepatitis B core (HBc) antibody,hepatitis
Positive Hepatitis C virus antibody (HCVAb): hepatitis C virus RNA by PCR is necessary. Detectable hepatitis C virus RNA suggests chronic hepatitis C,hepatitis
Positive Hepatitis C virus antibody (HepCAb): hepatitis C virus RNA by PCR is necessary. Detectable hepatitis C virus RNA suggests chronic hepatitis C.,hepatitis
Positive serologic or PCR test results for acute or chronic HBV infection:,hepatitis
Positive test for HBsAg or HBcAb (a subject whose HBsAg is negative and HBcAb is positive may be enrolled if an HBV DNA test is negative and either the subject is treated with potent anti-viral therapy or is re-tested for HBsAg and HBV DNA every month).,hepatitis
Positive test for hepatitis B surface antigen,hepatitis
Positive test for hepatitis B surface antigen (HBsAg) and,hepatitis
Positive test for qualitative hepatitis C viral load (by polymerase chain reaction [PCR]),hepatitis
Positive test results for hepatitis B core antibody (HBcAb) or hepatitis C virus (HCV) antibody at screening,hepatitis
Presence of hepatitis B surface antigen (HBsAg) or positive hepatitis C antibody test result at screening.,hepatitis
Presence of hepatitis C virus (HCV) RNA,hepatitis
"Seropositive for hepatitis B (defined by a positive test for hepatitis B surface antigen [HBsAg]). Subjects with resolved infection (ie., subjects who are HBsAg negative but positive for antibodies to hepatitis B core antigen [anti-HBc] and/or antibodies to hepatitis B surface antigen [anti-HBs]) must be screened using real-time polymerase chain reaction (PCR) measurement of hepatitis B virus (HBV) DNA levels. Those who are PCR positive will be excluded.",hepatitis
"Serum hepatitis B virus (HBV) DNA 20,000 IU/ml (105 copies/ml); lower values 2,000-20,000 IU/ml (104-105 copies/ml) are often seen in hepatitis B virus e antigen (HBeAg)-negative chronic hepatitis B",hepatitis
"Subject has a history of hepatitis B surface antigen (HBsAg) or hepatitis C antibody (anti-HCV) positive, or other clinically active infectious liver disease, or tests positive for HBsAg or anti-HCV at Screening.",hepatitis
"Subject has a known history of a positive test for human immunodeficiency virus infection or known active Hepatitis B (positive HBs antigen [Ag]) or Hepatitis C infection. For subjects who are negative for HBs Ag, but Hepatitis B core antibody positive, a Hepatitis B virus DNA test will be performed and if positive, the subject will be excluded. Subjects with positive serology but negative Hepatitis C virus RNA test results are eligible.",hepatitis
Subjects positive for hepatitis B surface antigen not on antiviraltreatment/prophylaxis or subjects with detectable hepatitis B DNA.,hepatitis
"Subjects who are HBsAg negative, anti-HBs positive, and/or anti-HBc positive, viral DNA negative are eligible. For these subjects, DNA monitoring and prophylactic medication for HBV reactivation are recommended per local practice.",hepatitis
Subjects with active hepatitis B virus (HBV) infection (defined by HBsAg positive) must be on standard of care antiviral therapy and have HBV DNA < 500 IU/mL.,hepatitis
"Subjects with evidence of hepatitis B or C virus infection, unless their hepatitis is considered to have been cured. (Note that subjects with prior hepatitis B virus (HBV) infection must have HBV viral load (VL) < 100 IU/mL before study enrollment, and must be treated according to local standards; hepatitis C virus (HCV) infection must have, before study enrollment, no detectable viral load and must be treated according to local",hepatitis
Subjects with hepatitis C allowed provided they meet all othereligibility criteria.,hepatitis
"Subjects with resolved (surface antigen negative, core antibodypositive) or chronic stable (surface antigen positive) hepatitis Bon antiviral treatment/prophylaxis with DNA levels of <= 100IU/mL are allowed with HBV DNA monitoring after treatment",hepatitis
"Active hepatitis A, B or C viral infection or known HIV infection.",heporhiv
"Active hepatitis A, B or C virus infection, or known human immunodeficiency virus (HIV) positive",heporhiv
Active hepatitis B or C or a history of HIV infection,heporhiv
"Active hepatitis B, active hepatitis C, or any human immunodeficiency virus (HIV) infection at the time of Screening",heporhiv
Active hepatitis C infection or known human immunodeficiency virus (HIV) infection. Patients who have been treated for hepatitis C infection are permitted if they have documented sustained virologic response of >= 12 weeks.,heporhiv
"Active uncontrolled infection (eg, human immunodeficiency virus [HIV] or viral hepatitis)",heporhiv
"Detectable viral infections (e.g. known HIV, known active hepatitis B or C)",heporhiv
"Has a known history of or screens positive for Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies), or an active chronic or acute Hepatitis B (i.e., hepatitis B surface antigen [HBsAg] reactive) or Hepatitis C infection (i.e., hepatitis C virus [HCV] RNA [qualitative] is detected).",heporhiv
"Have known infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C. Patients with history of chronic hepatitis that is currently not active are eligible.",heporhiv
"History of active tuberculosis (TB), human immunodeficiency virus (HIV), active hepatitis B (e.g., hepatitis B surface antigen [HBsAg] reactive) and/or active hepatitis C infection (e.g. hepatitis C virus [HCV] ribonucleic acid [RNA] qualitative is detected).",heporhiv
HIV or Hepatitis C - presence of viral load,heporhiv
Human immunodeficiency virus (HIV) infection or an active and uncontrolled infection with hepatitis C virus (HCV) or hepatitis B virus (HBV),heporhiv
"Known active HIV, hepatitis B or hepatitis C, where active is defined as follows:",heporhiv
"Known active human immunodeficiency virus (HIV), acquired immunodeficiency syndrome (AIDS) related illness, or hepatitis B or C infection.",heporhiv
Known active infection with HIV or Hepatitis B or C virus.,heporhiv
"Known active infection with HIV, hepatitis B, hepatitis C.",heporhiv
"Known active infection with Human Immunodeficiency Virus (HIV), with measurable viral titer, and/or active infection with hepatitis B or C (patients who have had a hepatitis B virus [HBV] immunization are eligible).",heporhiv
"Known history of HIV, HBV or HCV infection.",heporhiv
"Known history of HIV, hepatitis C or hepatitis B infection",heporhiv
Known history of human immunodeficiency virus (HIV) or active hepatitis B virus (HBV) or hepatitis C virus (HCV) infections at the time of screening which are defined as:,heporhiv
"Known history of human immunodeficiency virus (HIV), or active Hepatitis B or C.",heporhiv
"Known history of human immunodeficiency virus (HIV), or historical seropositive results consistent with active infection for hepatitis C virus (HCV) or hepatitis B virus (HBV) with high viral loads not actively managed with antiviral therapy. If history is unclear, a test at Screening will be required.",heporhiv
"Known history of human immunodeficiency virus (HIV), or known active hepatitis A, B, or C infection (hepatitis B carriers with normal LFTs and undetectable viral loads are allowed); VICC HEM 1538",heporhiv
"Known history of human immunodeficiency virus, hepatitis C, or hepatitis B infection",heporhiv
Known HIV infection or known positivity for active Hepatitis B (HBsAg reactive) or Hepatitis C (HCV RNA [qualitative] is detected).,heporhiv
"Known HIV or acquired immunodeficiency syndrome-related illness, acute or history of chronic hepatitis B or C.",heporhiv
"Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness, or hepatitis B or C",heporhiv
"Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness, or history of chronic hepatitis B or C, with the exception of patients with sustained virologic response after completion of treatment for hepatitis C",heporhiv
"Known human immunodeficiency virus or hepatitis C infection only if the patient is taking medications that are described in Section 5.8.2.2, active hepatitis B, or active hepatitis C infection.",heporhiv
"Known infection with HIV, hepatitis B (HBsAg positive) or hepatitis C virus (anti-HCV positive)",heporhiv
"Known infection with HIV, hepatitis B or hepatitis C virus. A history of hepatitis B or hepatitis C is permitted if the viral load is undetectable per quantitative PCR and/or nucleic acid testing.",heporhiv
"Known infection with HIV, hepatitis B, or hepatitis C",heporhiv
"Known or suspected diagnosis of human immunodeficiency virus (HIV) or chronic active Hepatitis B or C, or cirrhosis.",heporhiv
"No known clinical finding or suspicion of human immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis C.",heporhiv
"Patients must not have a known history of HIV, hepatitis B, or hepatitis C infection that is untreated and/or with a detectable viral load.",heporhiv
"Patients with known HIV, hepatitis B or C infections. Testing to prove negative status is not required for enrollment unless it is deemed necessary for usual medical care of the patient.",heporhiv
"Positive for hepatitis B by surface antigen expression, active hepatitis C infection (positive by polymerase chain reaction (PCR) or on antiviral therapy for hepatitis C within the last 6 months), or a known history of being seropositive for HIV.",heporhiv
"Positive test for hepatitis B virus surface antigen (HBV sAg) or hepatitis C virus ribonucleic acid (HCV RNA), or human immunodeficiency virus (HIV1 or 2) indicating acute or chronic infection.",heporhiv
Positive test for HIV or hepatitis C antibodies.,heporhiv
"Positive test for human immunodeficiency virus (HIV) -I or -II antibodies, hepatitis B surface antigen (HBsAg), hepatitis B core antibody (HBcAb), or hepatitis C virus (HCV) antibody (unless HCV viral load test by PCR is negative). HBcAb positivity will be allowed if one or more of the following is true:HBsAb is present; or hepatitis B DNA testing is negative and the patient is receiving hepatitis B reactivation prophylaxis with entecavir, tenofovir, or lamivudine.",heporhiv
"Serologic positivity for HIV, HCV, or HbsAg positivity",heporhiv
"Significant acute or chronic infection including, among others: Known history of human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome. Hepatitis B virus (HBV) or hepatitis C virus (HCV) infection (defined as, HBV surface antigen positive and HBV core antibody positive with reflex to positive HBV DNA or HBV core antibody positive alone with reflex to positive HBV DNA or positive HCV antibody with reflex to positive HCV RNA).",heporhiv
"Subject does not have any significant medical condition that in the opinion of the investigator would adversely affect his/her participation in the study, including no known active infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C. Note: HIV and hepatitis B or C testing is not required and subjects with serologic evidence of prior vaccination to hepatitis B virus (i.e., hepatitis B surface antigen [HBsAg] negative, anti-hepatitis B surface [HBs] positive, and anti-hepatitis B core [HBc] negative) may participate.",heporhiv
"Subject is positive for human immunodeficiency virus (HIV-1), chronic or active hepatitis B or active hepatitis A or C.",heporhiv
"Subject known to test positive for human immunodeficiency virus (HIV), chronic or active hepatitis B, or active hepatitis A or C.",heporhiv
"Subject with human immunodeficiency virus (HIV), evidence of active infectious Hepatitis B (HepB), and/or evidence of active Hepatitis C (HepC).",heporhiv
"100,000/ mcL Hemoglobin",hgb
Glycated hemoglobin (HbA1c < 6.4%,hgb
Glycosylated hemoglobin (Hb A1c) <= 7.0%,hgb
Glycosylated hemoglobin (HbA1c) < 7%.,hgb
Glycosylated hemoglobin measurement (HbA1c) < 7.0%,hgb
Hemoglobin,hgb
Hemoglobin (Hb) < 10 g/dL,hgb
hemoglobin (Hb) >= 8 g/dL,hgb
"Hemoglobin (Hb) at least 9 g/dL (or 5.69 mmol/L) at baseline (blood transfusions, hematopoietic growth factors and hematinics are not allowed during the 7 days prior to screening to correct Hb values less than 9 g/dL)",hgb
Hemoglobin (HgB) > 9.0 g/dL,hgb
Hemoglobin (Hgb) >= 8 g/dL (may be achieved with erythropoietin agents or transfusions),hgb
Hemoglobin (Hgb) >= 8.0 g/dL within 14 days prior to registration.,hgb
Hemoglobin (Hgb) >= 8.5 g/dL without transfusion or EPO dependency ( <= 7 days prior to assessment),hgb
Hemoglobin (Hgb) >= 9 g/dL (may be achieved with erythropoietin agents or transfusions),hgb
Hemoglobin (Hgb) >= 9 g/dl without transfusion or epoetin dependency ( <= 7 days prior to assessment),hgb
hemoglobin (Hgb) >= 9 grams/decilitre,hgb
Hemoglobin (Hgb) >= 9.0 g/dL,hgb
Hemoglobin _ 8.0 g/dL within first 2 weeks prior to first dose of TAB001,hgb
Hemoglobin < 8 g/dL (transfusion allowed to treat low hemoglobin),hgb
Hemoglobin < 8.0 g/dcl,hgb
Hemoglobin < 90 g/L,hgb
Hemoglobin <= 8.0 g/dL,hgb
Hemoglobin > 100 g/L,hgb
Hemoglobin > 7.0 (can be a transfused value),hgb
Hemoglobin > 9.0 g/dL,hgb
Hemoglobin > 9.0 g/dL or > 5.6 mmol/L,hgb
Hemoglobin > 9g/dLb (For group 1 only. There is no hemoglobin cut-off level for groups 2-4).,hgb
Hemoglobin >= 10 g/dL,hgb
Hemoglobin >= 10 g/dL without need for hematopoietic growth factor or transfusion support,hgb
Hemoglobin >= 10 g/dL.,hgb
Hemoglobin >= 10.0 g/dl (Note: The use of transfusion or other intervention to achieve Hgb >= 10.0 g/dl is NOT allowed),hgb
Hemoglobin >= 10g/dL,hgb
Hemoglobin >= 5.6 mmol/L (~ 9 g/dL).,hgb
hemoglobin >= 7 g/L,hgb
Hemoglobin >= 8 g/dL,hgb
"Hemoglobin >= 8 g/dL, and",hgb
Hemoglobin >= 8.0 g/dL,hgb
Hemoglobin >= 8.0 g/dl (Note: The use of transfusion or other intervention to achieve Hgb >= 8.0 g/dl is acceptable),hgb
Hemoglobin >= 8.0 g/dL.,hgb
Hemoglobin >= 9 g/deciliter,hgb
Hemoglobin >= 9 g/dL,hgb
Hemoglobin >= 9 g/dL (9 g/dL is equivalent to 90 g/L and 5.59 mmol/L).,hgb
Hemoglobin >= 9 g/dl (no transfusion within 14 days of start of study treatment),hgb
Hemoglobin >= 9 g/dL (subjects that required transfusion or growth factor need to demonstrate stable hemoglobin for 7 days of 9 g/dL),hgb
hemoglobin >= 9 g/dL or >= 5.6 mmol/L,hgb
Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or,hgb
Hemoglobin >= 9 g/dL or >= 5.6 mmol/L.,hgb
Hemoglobin >= 9 g/dL or >= 90 g/L).,hgb
Hemoglobin >= 9 g/dL.,hgb
Hemoglobin >= 9.0 g/dL,hgb
Hemoglobin >= 9.0 g/dL (after transfusion if required),hgb
Hemoglobin >= 9.0 g/dL (patients may be transfused to meet Hgb requirement),hgb
Hemoglobin >= 9.0 g/dL (without need for hematopoietic growth factor or transfusion support) (obtained <= 14 days prior to registration),hgb
Hemoglobin >= 9.0 g/dL or >= 5.6 mmol/La,hgb
Hemoglobin >= 9.0 g/dL.,hgb
Hemoglobin >= 9.0 g/ul,hgb
Hemoglobin >= 9.0 mg/dL,hgb
Hemoglobin >= 90 g/L,hgb
Hemoglobin >= 90.0 g/L (9.0 g/dL),hgb
Hemoglobin 9 g/dL,hgb
Hemoglobin concentrations within the normal ranges.,hgb
Hemoglobin must be >= 10 g/dL.,hgb
hemoglobin/hematocrit,hgb
Hemoglobin-adjusted diffusing capacity for carbon monoxide >= 50%,hgb
HgB > 9.0 g/dL,hgb
Hgb >= 8 g/dl,hgb
HGB >= 9.0 g/dL,hgb
Hgb >= 9.0 g/dL NOTE: Subjects may not have had a transfusion <= 7 days of randomization,hgb
Hgb >= 9.0 g/dL.,hgb
Hgb >= 9g/dl,hgb
"Obtain >= 3 Hemoglobin (Hgb) levels of <= 9.5 g/dL recorded on >= 3 different days, including the day of dosing, in the 84-day period immediately up to the C1D1 date. There must be >= 14 days in between each Hgb measurement. No subjects with an interval >= 42 days between hemoglobin measurements will be enrolled",hgb
Obtained <= 14 days prior to registration: Hemoglobin (Hgb) >= 9 g/dL,hgb
Obtained <= 14 days prior to registration: Hemoglobin >= 8.0 g/dL,hgb
Obtained <= 14 days prior to registration: Hemoglobin >= 9.0 g/dL,hgb
Paroxysmal Nocturnal Hemoglobinuria,hgb
Paroxysmal nocturnal hemoglobinuria (PNH),hgb
Patients must have hemoglobin levels of > 10g/dL within 2 weeks prior to registration,hgb
Severe anemia with hemoglobin < 10,hgb
Subjects must have a Hgb value of < 13 g/dL on C1D1 prior to luspatercept administration,hgb
Total hemoglobin >= 8 g/dL,hgb
"Has a congenital or acquired immunodeficiency, including patients with known history of infection with human immunodeficiency virus.",hiv
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies),hiv
Has a known history of human immunodeficiency virus (HIV) infection.,hiv
Has a known history of human immunodeficiency virus (HIV) infection. No HIV testing is required unless mandated by local health authority.,hiv
"Has an active, known, or suspected autoimmune disease. Subjects are permitted to enroll if they have vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger",hiv
"History of HIV (If the investigator suspects a clinical evidence of HIV, an HIV antibody test should be performed to exclude this possibility)",hiv
History of human immunodeficiency virus (HIV) infection or a positive HIV test.,hiv
History of known HIV infection.,hiv
history of testing positive to human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome,hiv
history of testing positive to human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome.,hiv
HIV negative,hiv
HIV negative patients,hiv
HIV positive,hiv
HIV positive patients,hiv
HIV positive test result or other immunodeficiency or immunosuppression.,hiv
HIV-positive individuals on combination antiretroviral therapy are eligible for enrollment and will be monitored closely for potential pharmacokinetic interactions with neratinib.,hiv
"HIV-positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with olaparib or AT13387. In addition, these patients are at increased risk of lethal infections when treated with marrow-suppressive therapy. Appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated.",hiv
"HIV-positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with VX-970 and the uncertainties of any impact thereof on the radiation toxicities. In addition, these patients are at increased risk of lethal infections when treated with marrow-suppressive therapy. Appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated.",hiv
Human immunodeficiency virus (HIV) protease inhibitors can affect the unfolded protein response in myeloma cells as well as the activity of PIs.,hiv
Human Immunodeficiency Virus (HIV) type 1 and 2,hiv
Human immunodeficiency virus (HIV)+ patients with CD4 > 200 and serum HIV viral load of < 200 copies/mm^3 are permitted,hiv
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated.,hiv
Human immunodeficiency virus (HIV)-positive patients on highly active antiretroviral therapy (HAART) are excluded,hiv
Human immunodeficiency virus (HIV)-positive test result or history of other immunodeficiency.,hiv
"Human immunodeficiency virus (HIV)-positive test result, or history of other immunodeficiency",hiv
Immunocompromised due to HIV positive state.,hiv
Immunocompromised patients (other than that related to the use of corticosteroids) including patients known to be HIV positive.,hiv
Immunocompromised patients and patients known to be HIV positive and currently receiving antiretroviral therapy.,hiv
"Immuno-compromised patients and patients known to be HIV positive and currently receiving antiretroviral therapy. NOTE: Patients known to be HIV positive, but without clinical evidence of an immunocompromised state, are eligible for this trial",hiv
Immunocompromised patients and patients known to be HIV positive and not currently receiving antiretroviral therapy.,hiv
Immunocompromised patients and patients known to be HIV positive.,hiv
Immunocompromised patients and patients known to be human immunodeficiency virus (HIV) positive and currently receiving antiretroviral therapy,hiv
"Immunocompromised patients and patients known to be human immunodeficiency virus (HIV) positive and currently receiving antiretroviral therapy; Note: patients known to be HIV positive, but without clinical evidence of an immunocompromised state, are eligible for this trial",hiv
Immunocompromised patients including patients known to be HIV positive or those on chronic steroids.,hiv
Immunocompromised patients including patients known to be HIV positive.,hiv
"In order for patients with human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS) to be eligible, they must be on a stable highly active antiretroviral therapy (HAART) regimen with no drug-drug interaction with UGT1A9, have CD4+ counts > 350, with no detectable viral load on quantitative polymerase chain reaction (PCR), and no opportunistic infection.",hiv
Individuals who are known to have AIDS (CD4 < 200 or an AIDS-defining illness) or are known to be HIV positive and not on HAART therapy are ineligible,hiv
Know to be HIV positive.,hiv
Known history of HIV seropositivity.,hiv
Known history of human immunodeficiency virus (HIV) infection.,hiv
"Known history of positive test for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (no testing at Screening required). If an Investigator has a strong suspicion of HIV infection without known history for a participant in Screening, and the participant refuses testing, discuss with the Medical Monitor to assess eligibility. (Note: HIV testing is not mandated for study inclusion; however, if it is performed at any point in Screening or while on study, a site must consent the participant for HIV testing as per local standard guidance.)",hiv
Known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (Testing for HIV must be performed at sites mandated by local requirements),hiv
Known HIV infection.,hiv
"Known HIV positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with tazemetostat. In addition, treatments involved in this protocol may be immunosuppressive, increasing the risk of lethal infections in this patient population.",hiv
Known HIV-positive individuals on combination antiretroviral therapy are eligible so long as they meet all other criteria. Known HIV-positive individuals who are not on combination antiretroviral therapy are not eligible because these individuals are at increased risk of lethal infections when treated with marrow-suppressive therapy. Appropriate studies will be undertaken in participants receiving combination antiretroviral therapy when indicated.,hiv
Known HIV-positive on combination antiretroviral therapy.,hiv
"Known HIV-positivity on combination antiretroviral therapy because of the potential for pharmacokinetic interactions with pembrolizumab and/or defactinib. In addition, these patients are at increased risk of lethal infections when treated with marrow-suppressive therapy. Appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated.",hiv
Known human immunodeficiency virus (HIV) infection,hiv
Known human immunodeficiency virus (HIV) infection or a known HIV-related malignancy. Note: HIV testing is not required unless there is any clinical suspicion that the patient might be HIV positive.,hiv
Known human immunodeficiency virus (HIV) patients with active and untreated disease,hiv
Known human immunodeficiency virus (HIV) positive (+) patients; EXCEPTION: if they meet the following additional criteria <= 28 days prior to registration:,hiv
Known human immunodeficiency virus (HIV) positivity.,hiv
Known human immunodeficiency virus positive (HIV+) patients.,hiv
Known human immunodeficiency virus seropositivity.,hiv
Known infection with human immunodeficiency virus.,hiv
Known positive results for human immunodeficiency virus (HIV),hiv
Known uncontrolled human immunodeficiency virus (HIV) infection,hiv
Participant has a known infection with human immunodeficiency virus (HIV).,hiv
Participants must not have a known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome.,hiv
"Participants MUST receive appropriate care and treatment for HIV infection, including antiretroviral medications when clinically indicated, and should be under the care of a physician experienced in HIV management; participants will be eligible regardless of antiretroviral medication (including no antiretroviral medication) provided there is no intention to initiate therapy or the regimen has been stable for at least 4 weeks with no intention to change the regimen within 12 weeks following enrollment",hiv
"Patient does not have known human immunodeficiency virus syndrome (HIV, testing optional). Known HIV-positive patients receiving combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with triapine.",hiv
Patient has known human immunodeficiency virus (HIV).,hiv
Patient must be on combination antiretroviral therapy with minimal pharmacokinetic interactions with study therapy and minimal overlapping clinical toxicity with protocol therapy,hiv
"Patients known to be positive for HIV (the human immunodeficiency virus) may be eligible, providing they meet the following additional criteria within 28 days prior to registration:",hiv
"Patients on combination antiretroviral therapy, i.e. those who are HIV-positive, are ineligible because of the potential for pharmacokinetic interactions or increased immunosuppression with palbociclib.",hiv
Patients positive for human immunodeficiency virus (HIV) are eligible only if they meet all of the following:,hiv
"Patients positive for human immunodeficiency virus (HIV) are NOT excluded from this study, but HIV-positive patients must have:",hiv
Patients who are HIV-positive on combination antiretroviral therapy because of the potential for pharmacokinetic interactions with olaparib. In addition these patients are at increased risk of lethal infections when treated with marrow suppressive therapy.,hiv
"Patients who are known to have HIV or are on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with cisplatin, carboplatin, etoposide, temozolomide, and/or capecitabine. In addition, these patients are at increased risk of lethal infections when treated with marrowsuppressive therapy. Appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated.",hiv
Patients with a known history of Human Immunodeficiency Virus (HIV); HIV testing is not required as part of this study.,hiv
Patients with acquired immunodeficiency syndrome (AIDS-related illnesses) or known human immunodeficiency virus (HIV) disease must:,hiv
Patients with known HIV infection.,hiv
Patients with known human immunodeficiency virus (HIV) infection,hiv
Patients with known human immunodeficiency virus (HIV) infection are eligible if they meet all of the following criteria:,hiv
Positive results for human immunodeficiency virus (HIV).,hiv
Positive test for HIV infection.,hiv
"Subject has a history of human immunodeficiency virus (HIV) antibody positive, or tests positive for HIV at Screening.",hiv
Subjects who are known to be human immunodeficiency virus (HIV) positive.,hiv
"A blood pressure (BP) <= the 95th percentile for age, height, and gender for pediatric patients < 18 years old (Appendix V) and <= 140/90 mmHg for patients >= 18 years old. BP should be measured as described in Section 5.5, and patients should not be receiving medication for treatment of hypertension (except patients with Wilms tumor and RCC who may be eligible if on stable doses of no more than one anti-hypertensive medication with a baseline BP <= ULN for pediatric patients and <= 140/90 for adult patients). Please note that 3 serial blood pressures should be obtained and averaged to determine baseline BP.",hypertension-blood-pressure
Adequate Blood Pressure Control defined as:,hypertension-blood-pressure
Blood pressure < 160/100 mmHg.,hypertension-blood-pressure
"Concurrent uncontrolled hypertension defined as sustained blood pressure (BP) > 150 mm Hg systolic, or > 90 mm Hg diastolic despite optimal antihypertensive treatment within 7 days of the first dose of study treatment",hypertension-blood-pressure
"Concurrent uncontrolled hypertension defined as sustained BP > 140 mm Hg systolic, or > 90 mm Hg diastolic despite optimal antihypertensive treatment within 7 days of the first dose of study treatment",hypertension-blood-pressure
Current uncontrolled hypertension (systolic blood pressure [BP] > 150 mmHg or diastolic pressure > 90 mmHg despite optimal medical management) and prior history of hypertensive crisis or hypertensive encephalopathy.,hypertension-blood-pressure
"despite adequate therapy, will be defined as uncontrolled hypertension.",hypertension-blood-pressure
diastolic blood pressure (DBP) > 60 and baseline heart rate > 60 (to be performed within 10 business days prior to day 1,hypertension-blood-pressure
Grade >= 2 uncontrolled hypertension (patients with a history of hypertension controlled with anti-hypertensive medication to Grade <= 1 are eligible),hypertension-blood-pressure
Has hypotension as indicated by systolic blood pressure < 86 millimeters of mercury (mmHg) at the Screening visit.,hypertension-blood-pressure
Has uncontrolled hypertension (systolic BP >= 160 mm Hg or diastolic BP >= 95 mm Hg). Patients with a history of hypertension are allowed provided blood pressure is controlled by anti-hypertensive treatment.,hypertension-blood-pressure
Has uncontrolled hypertension as indicated by systolic blood pressure > 170 mmHg or diastolic blood pressure > 105 mmHg at the Screening visit.,hypertension-blood-pressure
History of poorly controlled hypertension (defined as systolic blood pressure > 150 mmHg),hypertension-blood-pressure
"Hypertension (TAs > 130, TAd > 80mmHg or under antihypertensive treatment).",hypertension-blood-pressure
hypertension uncontrolled by standard therapies.,hypertension-blood-pressure
"Hypertension, labile hypertension, or history of poor compliance with antihypertensive medication",hypertension-blood-pressure
"In patients who are to receive VRP, base systolic blood pressure (SBP) > 110",hypertension-blood-pressure
"In patients who are to receive VRP, base systolic blood pressure (SBP) > 110; diastolic blood pressure (DBP) > 60 and baseline heart rate > 60 (to be performed within 10 business days prior to day 1)",hypertension-blood-pressure
"Inadequately controlled hypertension (i.e., systolic blood pressure [SBP] > 180 mmHg or diastolic blood pressure (DBP) > 100 mmHg) (patients with values above these levels must have their blood pressure (BP) controlled with medication prior to starting treatment).",hypertension-blood-pressure
Inadequately controlled hypertension (systolic blood pressure of > 150 mmHg or diastolic pressure > 90 mmHg on anti-hypertensive medications),hypertension-blood-pressure
Known history or current evidence of uncontrolled hypertension defined as systolic blood pressure >= 150 mmHg or diastolic blood pressure >= 90 mmHg at screening despite optimal medical management. Patients with a history of mild to moderate hypertension are eligible at the investigator's discretion if the hypertension is adequately controlled by antihypertensive treatment used at a stable dose for at least 14 days before the start of study treatment.,hypertension-blood-pressure
Known portal hypertension or history of variceal bleeding,hypertension-blood-pressure
Medically uncontrolled hypertension,hypertension-blood-pressure
"No history of grade 4 hypertension, defined as hypertension resulting in life-threatening consequences (e.g., malignant hypertension, transient or permanent neurologic deficit, hypertensive crisis).",hypertension-blood-pressure
No uncontrolled hypertension within 14 days of registration (defined as systolic blood pressure [SBP] >= 150 mmHg and/or diastolic blood pressure [DBP] >= 90 mmHg despite optimal medical management),hypertension-blood-pressure
or uncontrolled Grade >= 3 hypertension (diastolic blood pressure >= 100 mmHg or systolic blood pressure >= 160 mmHg) despite antihypertensive therapy,hypertension-blood-pressure
"Participants must have adequately controlled blood pressure (BP) with or without antihypertensive medications, defined as BP <= 150/90 mm Hg at Screening and no change in antihypertensive medications within 1 week before Cycle 1/Day 1.",hypertension-blood-pressure
Patients who have uncontrolled hypertension (defined as sustained systolic blood pressure >= 160 mmHg or diastolic >= 100 mmHg),hypertension-blood-pressure
Patients with a history of hypertension are allowed provided blood pressure is controlled by anti-hypertensive treatment,hypertension-blood-pressure
patients with hypertension should be under treatment on study entry to effect blood pressure control,hypertension-blood-pressure
Patients with persistently uncontrolled hypertension (systolic blood pressure [BP] > 160 mm Hg or diastolic BP > 100 mm Hg) despite optimal medical therapy,hypertension-blood-pressure
Patients with systolic blood pressure < 90 mm Hg.,hypertension-blood-pressure
"Patients with uncontrolled high blood pressure (i.e., systolic/diastolic blood pressure > 99th percentile) are not eligible",hypertension-blood-pressure
Patients with uncontrolled hypertension.,hypertension-blood-pressure
"Relative hypotension ( < 90/60 mm Hg) or clinically relevant orthostatic hypotension, including a fall in blood pressure of > 20 mm Hg.",hypertension-blood-pressure
Severe hypertension is defined as a systolic or diastolic blood pressure (BP) > 5 mm Hg above the 95th percentile as defined by the National High Blood Pressure Education Program Working Group (NHBPEP) established guidelines for the definition of normal and elevated blood pressure in children,hypertension-blood-pressure
Subject with diastolic blood pressure >= 90 mmHg or systolic blood pressure >= 140 mmHg measured during the Screening Period despite appropriate treatment.,hypertension-blood-pressure
"Subjects who, at screening, have abnormal vital signs and/or physical exam, including a temperature >= 38.0 C, systolic blood pressure <= 90 or > 180 mmHg, pulse <= 60 or > 130 beats per minute, new rash, signs of infection",hypertension-blood-pressure
Systolic blood pressure (SBP) > 160 mmHg or < 90 mmHg at screening.,hypertension-blood-pressure
Systolic blood pressure < 90 mmHg at screening (average of 3 most recent readings).,hypertension-blood-pressure
Systolic blood pressure > 160 mmHg or < 90 mmHg,hypertension-blood-pressure
Systolic blood pressure higher than 150 mmHg or diastolic blood pressure,hypertension-blood-pressure
Treatment refractory hypertension defined as a blood pressure of systolic > 140 mmHg and/or diastolic > 90 mm Hg which cannot be controlled by anti-hypertensive therapy,hypertension-blood-pressure
Treatment-refractory hypertension defined as a blood pressure of systolic > 140 mmHg and/or diastolic > 90 mmHg which cannot be controlled by anti-hypertensive therapy,hypertension-blood-pressure
Uncontrolled (persistent) hypertension: systolic blood pressure > 180 mmHg; diastolic blood pressure > 100 mmHg,hypertension-blood-pressure
Uncontrolled arterial hypertension >= 150/ >= 90 mmHg despite standard medical management,hypertension-blood-pressure
Uncontrolled arterial hypertension defined as persistent elevation of systolic blood pressure >= 150 mmHg or diastolic blood pressure >= 100 mmHg despite medical treatment.,hypertension-blood-pressure
Uncontrolled arterial hypertension defined by a systolic pressure >= 150 mm Hg or diastolic pressure >= 90 mm Hg despite standard medical management.,hypertension-blood-pressure
"uncontrolled blood pressure as defined as systolic > 160 mmHg, diastolic > 100 mmHg",hypertension-blood-pressure
uncontrolled Grade >= 3 hypertension (diastolic blood pressure >= 100 mmHg or systolic blood pressure >= 160 mmHg) despite antihypertensive therapy,hypertension-blood-pressure
"Uncontrolled high blood pressure (ie, systolic blood pressure > 180 mmHg, diastolic blood pressure > 95 mm Hg )",hypertension-blood-pressure
Uncontrolled hypertension,hypertension-blood-pressure
Uncontrolled hypertension (defined as blood pressure > 160/90),hypertension-blood-pressure
uncontrolled hypertension (defined as blood pressure > 160/90).,hypertension-blood-pressure
Uncontrolled hypertension (defined as systolic BP >= 160 mmHg or diastolic BP >= 95mmHg). Note - Patients with a history of hypertension are allowed provided blood pressure is controlled by anti-hypertensive treatment,hypertension-blood-pressure
Uncontrolled hypertension (diastolic blood pressure > 90 mmHg,hypertension-blood-pressure
Uncontrolled hypertension (diastolic blood pressure > 90 mmHg; systolic > 140 mmHg); patients with hypertension should be under treatment on study entry to effect blood pressure control,hypertension-blood-pressure
Uncontrolled hypertension (systolic blood pressure [BP] >= 160 mmHg or diastolic BP >= 95 mmHg). Patients with a history of hypertension are allowed provided BP is controlled by anti-hypertensive treatment.,hypertension-blood-pressure
Uncontrolled hypertension (systolic blood pressure > 180 mmHg and/or diastolic blood pressure > 100 mmHg),hypertension-blood-pressure
Uncontrolled hypertension (systolic blood pressure > 190 mm Hg or diastolic blood pressure > 100 mm Hg),hypertension-blood-pressure
Uncontrolled hypertension [defined as systolic blood pressure (SBP) of >= 160 mmHg or diastolic blood pressure (DBP) of >= 100mmHg],hypertension-blood-pressure
Uncontrolled hypertension as defined by SBP > 160 and/or DBP > 100. Patient's blood pressure may be controlled on appropriate antihypertensive regimen and rescreening is permitted.,hypertension-blood-pressure
Uncontrolled hypertension defined as sitting systolic pressure > 160 mm Hg or diastolic pressure > 100 mm Hg at Screening.,hypertension-blood-pressure
Uncontrolled hypertension defined as sustained blood pressure (BP) > 140 mm Hg systolic or > 90 mm Hg diastolic despite optimal antihypertensive treatment.,hypertension-blood-pressure
Uncontrolled hypertension defined as sustained blood pressure (BP) > 150 mm Hg systolic or > 100 mm Hg diastolic despite optimal antihypertensive treatment,hypertension-blood-pressure
Uncontrolled hypertension defined as sustained blood pressure (BP) > 150 mm Hg systolic or > 100 mm Hg diastolic despite optimal antihypertensive treatment.,hypertension-blood-pressure
Uncontrolled hypertension defined as sustained BP > 150 mm Hg systolic or > 100 mm Hg diastolic despite optimal antihypertensive treatment.,hypertension-blood-pressure
Uncontrolled hypertension defined as sustained systolic blood pressure (BP) > 150 mmHg or diastolic BP > 90 mmHg; (patients with initial BP elevations are eligible if initiation or adjustment of BP medication lowers pressure to meet entry criteria).,hypertension-blood-pressure
"Uncontrolled hypertension defined as systolic blood pressure >= 160 mmHg and/or diastolic blood pressure >= 100 mmHg, despite optimal medical management.",hypertension-blood-pressure
"Uncontrolled hypertension defined by a Systolic Blood Pressure (SBP) >= 160 mm Hg and/or Diastolic Blood Pressure (DBP) >= 100 mm Hg, with or without antihypertensive medication. Initiation or adjustment of antihypertensive medication(s) is allowed prior to screening",hypertension-blood-pressure
"Uncontrolled hypertension defined by a Systolic Blood Pressure (SBP) >= 160 mmHg and/or Diastolic Blood Pressure (DBP) >= 100 mm Hg, with or without antihypertensive medication. Initiation or adjustment of antihypertensive medication(s) is allowed prior to screening.",hypertension-blood-pressure
Uncontrolled hypertension despite optimal medical management (per investigator&rsquo,hypertension-blood-pressure
Uncontrolled hypertension despite optimal medical management (per investigator&rsquo;s assessment).,hypertension-blood-pressure
Uncontrolled hypertension with systolic blood pressure >= 160 mm Hg or diastolic blood pressure >= 100 mm Hg,hypertension-blood-pressure
"Uncontrolled hypertension, defined as blood pressure (BP) of >= 160/95",hypertension-blood-pressure
"Uncontrolled hypertension, defined as blood pressure (BP) of >= 160/95; patients who have a history of hypertension controlled by medication must be on a stable dose (for at least one month) and meet all other inclusion criteria",hypertension-blood-pressure
"Uncontrolled hypertension, defined as persistent elevation of systolic blood pressure >= 150 mmHg or diastolic blood pressure >= 100mmHg despite current therapy",hypertension-blood-pressure
"Uncontrolled hypertension, defined as persistent elevation of systolic blood pressure.",hypertension-blood-pressure
"Uncontrolled hypertension, defined as: systolic blood pressure >= 140 mmHg and/or diastolic blood pressure >= 90 mmHg",hypertension-blood-pressure
"Uncontrolled hypertension, i.e., blood pressure (BP) of >= 160/95",hypertension-blood-pressure
"Uncontrolled hypertension, i.e., blood pressure (BP) of >= 160/95; patients who have a history of hypertension controlled by medication must be on a stable dose (for at least one month) and meet all other inclusion criteria; or",hypertension-blood-pressure
"Uncontrolled hypertension, i.e., blood pressure (BP) of >= 160/95; patients who have a history of hypertension controlled by medication must be on a stable dose and meet all other inclusion criteria; or",hypertension-blood-pressure
"Uncontrolled hypertension, i.e., blood pressure (BP) of >= 170/95",hypertension-blood-pressure
"Uncontrolled hypertension, i.e., blood pressure (BP) of >= 170/95; patients who have a history of hypertension controlled by medication must be on a stable dose (for at least one month prior to study registration) and meet all other inclusion criteria.",hypertension-blood-pressure
"Uncontrolled hypertension, uncontrolled pulmonary hypertension or uncontrolled diabetes within 14 days prior to enrollment",hypertension-blood-pressure
Uncontrolled or poorly controlled hypertension requiring 3 or more anti-hypertensive drugs.,hypertension-blood-pressure
Uncontrolled severe hypertension at enrollment. Severe hypertension is defined as a systolic or diastolic blood pressure (BP) > 5 mm Hg above the 95th percentile as defined by the National High Blood Pressure Education Program Working Group (NHBPEP) established guidelines for the definition of normal and elevated blood pressure in children,hypertension-blood-pressure
A history of autoimmune-related hypothyroidism and on thyroid replacement hormone,hypothyroidism
"Hypothyroidism (eg, following Hashimoto syndrome) stable on hormone replacement",hypothyroidism
Hypothyroidism stable on hormone replacement,hypothyroidism
Patients with a history of autoimmune hypothyroidism on a stable dose of thyroid replacement hormone are eligible,hypothyroidism
Patients with a history of autoimmune hypothyroidism on a stable dose of thyroid replacement hormone may be eligible,hypothyroidism
Patients with a history of autoimmune hypothyroidism on a stable dose of thyroid replacement hormone may be eligible.,hypothyroidism
Patients with a history of autoimmune-related hypothyroidism on a stable dose of thyroid replacement hormone may be eligible for this study.,hypothyroidism
Patients with a history of autoimmune-related hypothyroidism who are on thyroid-replacement hormone are eligible for the study,hypothyroidism
Patients with a history of autoimmune-related hypothyroidism who are on thyroid-replacement hormone are eligible for the study.,hypothyroidism
"Patients with hypothyroidism (eg, following Hashimoto syndrome) stable on hormone replacement",hypothyroidism
"Patients with hypothyroidism (eg, following Hashimoto syndrome), stable on hormone replacement",hypothyroidism
Subjects with history of autoimmune-related hypothyroidism on a stable dose of thyroid replacement hormone may be eligible for this trial,hypothyroidism
"Subjects with hypothyroidism (eg, following Hashimoto syndrome) stable on hormone replacement",hypothyroidism
"Subjects with hypothyroidism stable on hormone replacement, diabetes or Sjogren's syndrome are permitted for the study",hypothyroidism
"Intercurrent illness that is not controlled such as active infection, psychiatric illness/social situations that would limit compliance with study requirements",illness
"No uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements",illness
"No uncontrolled intercurrent illness including, but not limited to:",illness
"Patient has uncontrolled intercurrent illness including, but not limited to, symptomatic congestive heart failure, unstable angina pectoris, myocardial infarction within six months of protocol initiation, cardiac arrhythmia within six months of protocol initiation; known inadequately controlled hypertension; clinically significant pulmonary disease including dyspnea at rest, or patients requiring supplemental oxygen, or poor pulmonary reserve; proteinuria or clinically significant renal function impairment (baseline serum creatinine > 2mg/dL); or psychiatric illness/social situations that would limit compliance with study requirements.",illness
"Patient has uncontrolled intercurrent illness including, but not limited to, uncontrolled infection, disseminated intravascular coagulation, or psychiatric illness that would limit compliance with study requirements.",illness
"Patients must NOT have active or uncontrolled infection, symptomatic heart failure, unstable angina pectoris, cardiac arrhythmia or a serious psychiatric illness/social situation that would limit compliance with study requirements.",illness
"Patients must NOT have uncontrolled intercurrent illness including, but not limited to, serious ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, uncontrolled cardiac arrhythmia, or psychiatric illness/social situation that would limit compliance with study requirements.",illness
"Patients must NOT have uncontrolled intercurrent illness including, but not limited to, serious ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, uncontrolled cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.",illness
"Patients with uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure and unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.",illness
Patients with uncontrolled intercurrent illness.,illness
"Subject has uncontrolled inter-current illness, including but not limited to poorly controlled hypertension or diabetes, ongoing or active infection, or psychiatric illness/social situation that would limit compliance with study requirements.",illness
"Uncontrolled concurrent illness, including but not limited to ongoing or active serious infection requiring systemic antimicrobials (within 14 days prior to first dose of Oraxol), arterial hypertension ( > 160/100 mm/Hg on antihypertensive medications), uncontrolled endocrine diseases, altered mental status or psychiatric illness/social situations that would limit compliance with protocol requirements and/or obscure study results.",illness
"Uncontrolled current illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, diabetes, or psychiatric illness/social situations that would limit compliance with study requirements. Ability to comply with study requirements is to be assessed by each investigator at the time of screening for study participation.",illness
"Uncontrolled current illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.",illness
"Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements",illness
"Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.",illness
"Uncontrolled intercurrent illness including, but not limited to, active uncontrolled infection, known positive for active infectious hepatitis, type A, B or C (past infection allowed), or psychiatric illness/social situations that would limit compliance with study requirements.",illness
"Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection or psychiatric illness/social situations that would limit compliance with study requirements.",illness
"Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, clinically significant non-healing or healing wounds, symptomatic congestive heart failure (CHF) Class II or higher according to the New York Heart Association (NYHA) Functional Classification), unstable angina pectoris, clinically significant cardiac arrhythmia, significant pulmonary disease (shortness of breath at rest or mild exertion), uncontrolled infection or psychiatric illness/social situations that would limit compliance with study requirements.",illness
"Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, immunosuppression, autoimmune conditions, underlying pulmonary disease, or psychiatric illness/social situations that would limit compliance with study requirements.",illness
"Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, including localized infections, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia or psychiatric illness/social situations that would limit compliance with study requirements",illness
"Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure according to NYHA Functional Classification >= 3, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, active peptic ulcer disease or gastritis, or psychiatric illness/social situations that would limit compliance with study requirements, substantially increase risk of incurring adverse events from TAB001, or compromise the ability of the subject to give written informed consent",illness
"Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, clinically significant myocardial infarction within the last 6 months, unstable angina pectoris, clinically significant cardiac arrhythmia, bleeding disorder, chronic pulmonary disease requiring oxygen, or psychiatric illness/social situations that would limit compliance with study requirements",illness
"Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, lupus, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.",illness
"Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, active peptic ulcer disease or gastritis, or psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring AEs from MEDI4736 or tremelimumab, or compromise the ability of the subject to give written informed consent.",illness
"Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia (including symptomatic sinus bradycardia), or psychiatric illness/social situations that would limit compliance with study requirements.",illness
"Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, depression, or psychiatric illness/social situations within the last 12 months.",illness
"Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements",illness
"Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.",illness
"Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements or providing informed consent.",illness
"Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. NOTE: Any electrocardiogram (ECG) abnormality at screening must be documented by the investigator as not medically relevant",illness
"Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia.",illness
"Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.",illness
"Uncontrolled intercurrent illness including, but not limited to, ongoing or active major infection, unstable angina pectoris, or psychiatric illness/social situations that would limit compliance with study requirements.",illness
"Uncontrolled intercurrent illness including, but not limited to, symptomatic congestive heart failure or unstable angina pectoris",illness
"Uncontrolled intercurrent illness including, but not limited to, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.",illness
"Uncontrolled intercurrent illness including, but not limited to, uncontrolled infection, disseminated intravascular coagulation, or psychiatric illness/social situations that would limit adherence to study requirements.",illness
"Uncontrolled intercurrent illness including, but not limited to:",illness
"Uncontrolled intercurrent illness including, but not limited to:ongoing or active infection symptomatic congestive heart failure unstable angina pectoris cardiac arrhythmia or psychiatric illness/social situations that would limit compliance with study requirements.",illness
"Uncontrolled intercurrent illness Patient has an uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, known HIV infection, active Hepatitis B or Hepatitis C infection, active TB infection, chronic liver disease, chronic renal disease, pancreatitis, chronic pulmonary disease, active cardiac disease or cardiac dysfunction, interstitial lung disease, active autoimmune disease, uncontrolled diabetes, neuropsychiatric or social situations that would limit compliance with the study requirements.",illness
"Uncontrolled intercurrent illness that would increase the risk of toxicity or limit compliance with study requirements. This includes but is not limited to, ongoing uncontrolled serious infection requiring i.v. antibiotics at the time of registration, symptomatic congestive heart failure, unstable angina pectoris, symptomatic/uncontrolled cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.",illness
"Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, interstitial lung disease, serious chronic gastrointestinal conditions associated with diarrhea, or psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring AEs or compromise the ability of the patient to give written informed consent",illness
"Uncontrolled intercurrent illness, including, but not limited to:",illness
"Uncontrolled intercurrent non-cardiac illness including, but not limited to",illness
"Congenital primary immunodeficiencies (including but not limited to severe combined immunodeficiency syndrome, Wiskott-Aldrich syndrome, CD40 ligand deficiency, T-cell deficiencies)",immunodeficiency
Diagnosis of immunodeficiency.,immunodeficiency
"Immunodeficiency disorders (e.g. Severe Combined Immunodeficiency, Wiskott-Aldrich Syndrome)",immunodeficiency
Patients must not have had a diagnosis of inherited or acquired immunodeficiency.,immunodeficiency
Primary immunodeficiency.,immunodeficiency
Subject has history of primary immunodeficiency.,immunodeficiency
A positive fungal culture within 30 days of study enrollment or active therapy for presumed invasive fungal infection.,infection
"Absence of uncontrolled intercurrent illnesses, including uncontrolled infections, cardiac conditions, or other organ dysfunctions.",infection
"Active and uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy. Known infection with human immunodeficiency virus (HIV), or an active infection with hepatitis B or hepatitis C.",infection
"Active and uncontrolled infectious disease requiring systemic antibiotic, antifungal, or antiviral treatment.",infection
Active bacterial infection requiring intravenous antibiotics,infection
"Active bacterial or fungal infection requiring IV systemic therapy (except as indicated, discuss alternative scenarios with the Medical Monitor).",infection
"Active bacterial, viral or fungal infections.",infection
Active fungal infection (requiring intravenous or oral antifungal treatment),infection
Active infection (any grade) <= 5 days prior to study day 1.,infection
Active infection <= 5 days prior to registration,infection
Active infection <= 5 days prior to registration.,infection
Active infection <= 7 days prior to study entry,infection
Active infection not adequately responding to appropriate therapy,infection
Active infection or unexplained fever > 38.5°C (101.3°F).,infection
Active infection requiring antibiotics,infection
Active infection requiring parenteral antibiotics,infection
active infection requiring systemic therapy,infection
Active infection requiring systemic therapy.,infection
active infection requiring systemic treatment within 28 days before the first dose of study treatment,infection
"Active infection with completion of therapeutic antibiotics, antivirals, or antifungals within one week prior to C1D1. Prophylactic antibiotics, antivirals or antifungals are permitted.",infection
"Active infection, including any active viral infection, <= 5 days prior to registration.",infection
Active infection.,infection
Active or chronic infection requiring systemic therapy.,infection
"Active symptomatic fungal, bacterial and/or viral infection including HIV or viral (A, B or C) hepatitis which would not permit the patient to be managed according to the protocol.",infection
Active uncontrolled infection,infection
Active uncontrolled infection or severe systemic infection (enrollment is possible after control of infection).,infection
Active viral or protozoal infection requiring IV treatment.,infection
"Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy",infection
"Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy.",infection
"Active, uncontrolled, systemic bacterial, viral, or fungal infection within 72 hours of lymphodepletion,or infection requiring intravenous (IV) antimicrobials for management. Subjects with ongoing use of prophylactic antibiotics, antifungals, or antivirals are eligible as long as there is no evidence of active infection.",infection
Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration,infection
Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration.,infection
Acute bacterial or fungal infection requiring intravenous antibiotics at the time of Step 1 registration,infection
"Acute bacterial, viral, or fungal infection requiring treatment at the time of registration.",infection
"Acute or chronic infections requiring systemic therapy, including, among others:",infection
Bacterial or opportunistic infection within 3 months of treatment (upperrespiratory infection and uncomplicated urinary tract infection allowed).,infection
Chronic ongoing or active infection,infection
"Chronic or ongoing active infections requiring systemic treatment such as, but not restricted to, tuberculosis, chronic lung infection/bronchiectasis, or chronic renal infection.",infection
Clinically significant active infection requiring intravenous antibiotics ( <= 14 days prior to registration).,infection
Clinically significant active infection requiring intravenous antibiotics <= 14 days prior to registration,infection
"Clinically significant active viral, bacterial or fungal infection requiring:",infection
"Currently receiving systemic antimicrobial treatment for active infection (viral, bacterial, or fungal) at the time of first dose of enfortumab vedotin. Routine antimicrobial prophylaxis is permitted.",infection
"Evidence of active infection, or serious infection within the past 30 days.",infection
"Evidence of any active, uncontrolled bacterial, viral, parasitic or systemic fungal infections within 1 week of first dose of study drug.",infection
Evidence of ongoing or active infection requiring intravenous antibiotics,infection
"Evidence of uncontrolled, active infection, requiring parenteral anti-bacterial, anti-viral or anti-fungal therapy <= 7 days prior to administration of study medication.",infection
Has an active infection requiring systemic therapy,infection
Has an active infection requiring systemic therapy.,infection
Has an active infection requiring therapy.,infection
Has an active serious infection requiring systemic therapy.,infection
"Have active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy",infection
"Have an active, uncontrolled infection",infection
Infection requiring systemic antibiotic therapy or other serious infection within 14 days of enrolment (fist treatment).,infection
Infection requiring systemic antibiotic therapy or other serious infection within 14 days prior to start of study treatment,infection
"Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of nail beds) at study enrollment, or any major episode of infection requiring treatment with IV antibiotics or hospitalization (relating to the completion of the course of antibiotics) within 4 weeks prior to Cycle 1 Day 1",infection
"Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of nail beds) at study enrollment, or any major episode of infection requiring treatment with IV antibiotics within 4 weeks prior to first BFCR4350A infusion.",infection
Known acute systemic infection.,infection
Localized infection at the potential site of injection.,infection
No evidence of active infection and no serious infection within the past 30 days.,infection
ongoing or active infection,infection
"Participants must not have evidence of active infection requiring antibacterial, antifungal, or antiviral treatment <= 7 days prior to initiation of study treatment.",infection
"Patient has an active uncontrolled infection, underlying medical condition, or other serious illness that would not be appropriate for this study.",infection
Patient must not have an active uncontrolled infection,infection
"Patients considered a poor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disease or active, uncontrolled infection. Examples include, but are not limited to, uncontrolled ventricular arrhythmia, recent (within 3 months) myocardial infarction, unstable spinal cord compression (untreated or unstable within at least 28 days prior to registration), superior vena cava syndrome, and extensive bilateral lung disease on HRCT scan or any psychiatric disorder that prohibits obtaining informed consent.",infection
"Patients may be receiving IV or oral antibiotics to complete a course of therapy for a prior documented infection as long as cultures have been negative for at least 48 hours and signs or symptoms of active infection have resolved. For patients with c. difficile diarrhea, at least 72 hours of antibacterial therapy must have elapsed and stools must have normalized to baseline.",infection
Patients must not have an active infection requiring systemic therapy.,infection
"Patients must not have systemic fungal, bacterial, viral or other infection that is not controlled (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antibiotics or other treatment).",infection
Patients who develop clinically significant systemic infections requiring active use of IV antibiotics any time prior to randomization.,infection
Patients who have an active uncontrolled infection defined as:,infection
Patients who have an uncontrolled infection are not eligible.,infection
"Patients with active infections requiring intravenous (IV) antibiotic/antiviral therapy are not eligible for entry onto the study until resolution of the infection; patients on prophylactic antibiotics, antifungals or antivirals are acceptable",infection
"Patients with an active infection that require systemic antibiotics, antiviral, or antifungal treatments",infection
Persisting fever without other signs or symptoms will not be interpreted as progressing infection,infection
Persisting fever without other signs or symptoms will not be interpreted as progressing infection. Waivers to the exclusion criteria will NOT be allowed.,infection
"Poor medical risk because of systemic diseases (e.g., active uncontrolled infections) in addition to the advanced malignancy under study.",infection
"Poor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disease or active, uncontrolled infection. Examples include, but are not limited to, uncontrolled ventricular arrhythmia, recent (within 90 days) myocardial infarction, uncontrolled major seizure disorder, unstable spinal cord compression, superior vena cava syndrome, uncontrolled hypertension, active uncontrolled coagulopathy, bleeding disorder, or any psychiatric disorder that prohibits obtaining informed consent",infection
"Presence of fungal, bacterial, viral, or other infection that is uncontrolled or requiring antimicrobials for management. Simple UTI and uncomplicated bacterial pharyngitis are permitted if responding to active treatment and after consultation with the Kite Medical Monitor",infection
"Presence of fungal, bacterial, viral, or other infection that is uncontrolled or requiring IV antimicrobials for management.",infection
"Recent or ongoing serious infection, including:",infection
"REGISTRATION STEP 2-RANDOMIZATION: Patients must not have active infection (systemic bacterial, fungal, or viral infection) that is not controlled (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement despite appropriate antibiotics or other treatment)",infection
Serious infection requiring parenteral antibiotic therapy or any other serious infection within 14 days before randomization.,infection
"Serious, uncontrolled, concurrent infection(s) requiring antibiotics.",infection
"Severe infection within 4 weeks prior to initiation of study treatment, including, but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia",infection
"Severe infections <= 4 weeks prior to registration, including, but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia",infection
"Severe infections within 4 weeks prior to cycle 1, day 1, including, but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia.",infection
"Severe infections within 4 weeks prior to enrollment, including, but not limited to, hospitalization for complications of infection, bacteremia, or the presence of any active infection requiring systemic therapy",infection
"Severe infections within 4 weeks prior to Week 1, Day 1, including but not limited to hospitalization for complications of infection, bacteremia, or severe pneumonia.",infection
"Signs or symptoms of infection <= 2 weeks prior to Cycle 1, Day 1",infection
"Signs or symptoms of infection within 2 weeks prior to cycle 1, day 1.",infection
"Signs or symptoms of infection within 2 weeks prior to Cycle 1, Day 1. Abnormal urinalysis does not constitute signs/symptoms of infection unless urine culture obtained at screening grows >= 100,000 colonies of bacteria. Patients with an ileal conduit and a urinalysis and/or culture that are abnormal are eligible unless they have peripheral blood WBC > ULN, fever, or other symptoms suggestive of a urinary tract infection",infection
"Signs or symptoms of infection within 2 weeks prior to Week 1, Day 1.",infection
Subject has active infection requiring systemic therapy that has not completely resolved within 14 days prior to first dose of study treatment.,infection
"Subject has any condition including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study. This includes systemic fungal, bacterial, viral, or other infection that is uncontrolled (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antimicrobial treatment) or requiring IV antimicrobials for management.",infection
"Subject has uncontrolled systemic fungal, bacterial, viral or other infection (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antimicrobial treatment) or requiring IV antimicrobials for management.",infection
"Subject has uncontrolled systemic fungal, bacterial, viral or other infection (including tuberculosis) despite appropriate antibiotics or other treatment.",infection
"Subject with uncontrolled systemic fungal, bacterial, or viral infection (defined as ongoing signs/symptoms related to the infection without improvement despite appropriate antibiotics, antiviral therapy, and/or other treatment).",infection
Systemic infection requiring IV antibiotic therapy <= 14 days prior to registration.,infection
Systemic rheumatic or autoimmune diseases or acute or chronic infections .,infection
"Treatment for any serious bacterial, viral, parasitic, or systemic fungal infections within the 30 days prior to study entry.",infection
Uncontrolled active infection requiring intravenous anti-infective treatments within 1 week of study day 1,infection
Uncontrolled infection requiring systemic antibiotics/antivirals/antifungals,infection
Uncontrolled infection.,infection
Uncontrolled infections,infection
"Uncontrolled systemic fungal, bacterial or viral infection at time of enrollment in Part A or randomization in Part B (defined as ongoing signs/symptoms related the infection without improvement despite appropriate antibiotics, antiviral therapy and/or other treatment).",infection
"Untreated or active infection at the time of initial Screening, at the time of leukapheresis, or within 72 hours before lymphodepletion. Subjects with ongoing use of prophylactic antibiotics, antifungals, or antivirals are eligible if no evidence of active infection.",infection
Any anti-cancer therapy or investigational agents <= 4 weeks prior to registration.,investigational
"Any investigational agent received within 5 half-lives of the drug or 4 weeks, whichever is shorter. Concurrent participation in an observational study may be allowed after review by the Sponsor's Medical Monitor.",investigational
Any investigational agents within 28 days prior to day of randomization.,investigational
Any investigational drug being administered during the study,investigational
Are currently receiving any other investigational agent,investigational
"Chemotherapy, small molecule inhibitors, radiation, IR procedure, and/or other investigational agent: <= 3 weeks or 5 half-lives, whichever is shorter.",investigational
Concurrent use of any other investigational agents.,investigational
Currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigation device within 4 weeks prior to enrollment in Part A or randomization in Part B.,investigational
Currently participating and receiving trial therapy or has participated in a trial of an investigational agent and/or has used an investigational device within 28 days prior to Day 0,investigational
Currently receiving any other investigational agent which would be considered as a treatment for the primary neoplasm.,investigational
Currently receiving any other investigational agents or received any within the past 28 days.,investigational
Currently receiving any other investigational agents or systemic cancer therapy.,investigational
"Currently receiving treatment in another investigational device or drug study, or less than 30 days since ending treatment on another investigational device or drug study. Other investigational procedures while participating in this study are excluded.",investigational
Has participated in a study with an investigational agent or device within 30 days of enrollment.,investigational
Has received an investigational anti-cancer drug in the 21-day period before the first dose of study drug (or within 5 half-lives if longer) or is currently participating in another interventional clinical trial,investigational
Has received other investigational agents within 4 weeks or 5 half-lives of planned first dose of study agents.,investigational
Has received prior anticancer therapy including investigational agents within 4 weeks prior to randomization.,investigational
Investigational Drugs: Patients who are currently receiving another investigational drug are not eligible.,investigational
Investigational Drugs: Patients who are currently receiving another investigational drug.,investigational
Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment.,investigational
Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study treatment.,investigational
Is currently participating in or has participated in a study of an investigational agent or using an investigational device within 4 weeks of the first dose of trial treatment.,investigational
Is currently participating in or has participated in a trial of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of trial treatment.,investigational
"Is/was enrolled in a study of an investigational agent and received study therapy, or used an investigational device within 4 weeks (12 months for an investigational agent or device with anticancer or antiproliferative properties) prior to the first dose of study treatment.",investigational
Must not be receiving any other investigational medicinal product,investigational
No treatment with any other type of investigational agent <= 4 weeks before preregistration.,investigational
"Other concurrent chemotherapy, immunotherapy, radiotherapy, any ancillary therapy considered investigational (utilized for a non-Food and Drug Administration [FDA]-approved indication and in the context of a research investigation) or receiving any other investigational agent which would be considered as a treatment for the primary neoplasm",investigational
"Other concurrent chemotherapy, or any ancillary therapy considered investigational <= 14 days prior to study registration; NOTE: Bisphosphonates are considered to be supportive care rather than therapy, and are thus allowed while on protocol treatment",investigational
"Other concurrent chemotherapy, or any ancillary therapy considered investigational.",investigational
"Other concurrent chemotherapy, or any ancillary therapy considered investigational; NOTE: bisphosphonates are considered to be supportive care rather than therapy, and are thus allowed while on protocol treatment",investigational
"Other concurrent chemotherapy, radiotherapy, or any ancillary therapy considered investigational",investigational
"Other concurrent chemotherapy, radiotherapy, or any ancillary therapy considered investigational. NOTE: Bisphosphonates are considered to be supportive care rather than therapy, and are thus allowed while on protocol treatment.",investigational
Other investigational agents <= 21 days,investigational
"Other planned concurrent investigational agents or other tumor directed therapies (chemotherapy, radiation) are not allowed while on this study",investigational
Participant has used investigational agents within 4 weeks of randomization.,investigational
Participants may not be receiving any other investigational agents within 30 days of enrollment or during this study.,investigational
Participants may not be receiving any other investigational agents.,investigational
Participants who are currently receiving any other investigational agents,investigational
Participation in any interventional study within 4 weeks of Cycle 1 Day 1 or 5 half-lives of the investigational agent(s) used in the interventional study prior to Cycle 1 Day 1 (whichever is shorter).,investigational
Participation in any other clinical trials with other investigational agents not included in this trial <= 21 days prior to registration,investigational
"Participation in clinical trials with other investigational agents not included in this trial, <= 21 days prior to registration",investigational
"Participation in other clinical trials, including those with other investigational agents not included in this trial, within 30 days prior to start of study treatment and throughout the duration of this trial",investigational
Patient has received treatment with another investigational agent within 14 days of study entry or concurrent treatment with another investigational agent.,investigational
Patient is currently participating in a treatment study or has participated in a study of an investigational agent within 4 weeks of the first dose of treatment.,investigational
Patient is receiving another investigational agent for the treatment of cancer.,investigational
Patient is receiving or plans to receive other investigational therapy.,investigational
Patient is using or plans to use an investigational agent for the prevention of GvHD.,investigational
Patients concurrently receiving any other investigational agents.,investigational
Patients may not be receiving any other investigational agents while on study treatment.,investigational
Patients may not be receiving any other investigational agents while on study.,investigational
Patients must not be participating in any other clinical trial or taking any other experimental medications within 21 days prior to registration.,investigational
"Patients must not be planning to receive any other investigational agents during radiation therapy. Prior therapy, including prior treatment with olaparib or other PARP inhibitor, is allowed.",investigational
Patients must not be receiving any other investigational anti-cancer agents while on study.,investigational
Patients receiving any other investigational agents. Any prior investigational agents must be stopped at least 14 days (2 week washout) prior to registration.,investigational
"Patients receiving any other standard or investigational treatment for their cancer, or any other investigational agent for any indication within the past 2 weeks prior to initiation of CPI-613 treatment.",investigational
Patients who are concurrently receiving any other investigational agents.,investigational
Patients who are currently receiving any other investigational agent,investigational
Patients who are currently receiving any other investigational agent.,investigational
Patients who are receiving any other investigational agents.,investigational
Patients who were currently receiving any other investigational agent.,investigational
"Received investigational agents within 14 days or 5 half-lives prior to the first study dosing day, whichever is longer",investigational
Receiving any investigational agent concurrent with CRT which would be considered as a treatment for the primary neoplasm.,investigational
Receiving any investigational agent which would be considered as a treatment for the primary neoplasm.,investigational
"Receiving any investigational agent, that would be considered as a treatment for the primary neoplasm.",investigational
Receiving any other investigational agent that would be considered a treatment for the primary neoplasm.,investigational
Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm,investigational
Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm <= 14 days prior to registration.,investigational
"Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm OR participated in a study of an investigational agent, received study therapy or used an investigational device <= 4 weeks prior to registration.",investigational
Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm.,investigational
Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm; NOTE: Bisphosphonates are considered to be supportive care rather than therapy and are allowed while on protocol treatment,investigational
Receiving any other investigational agent.,investigational
Receiving any other investigational agents <= 28 days prior to registration,investigational
Receiving any other investigational agents.,investigational
"Subject has been treated with an investigational agent (ie, an agent not commercially available) within 28 days or 5 half-lives (whichever is longer) of initiating IP.",investigational
"Subject has received an investigational drug (including investigational vaccines, but not including anticancer therapy [refer to Exclusion Criterion #2]) or used an invasive investigational medical device within 6 weeks before the planned first dose of study drug.",investigational
Subject has received other investigational treatment within 28 days prior to screening.,investigational
Subject used any investigational agents within 14 days of leukapheresis.,investigational
"Treatment with any other investigational agent or investigational device within 4 weeks prior to registration (or within five half-lives of the investigational product, whichever is longer); patients must be >= 2 weeks since any investigational agent administered as part of a phase 0 study (also referred to as an early phase I study or pre phase I study where a sub- therapeutic dose of drug is administered) at the coordinating center principal investigator (PI)?s discretion, and should have recovered to eligibility levels from any toxicities",investigational
"Treatment with any other investigational agent within 4 weeks prior to cycle 1, day 1.",investigational
"Use of an investigational drug within 21 days or 5 half-lives (whichever is shorter) prior to the first dose of TGR-1202. For investigational drugs for which 5 half-lives is less than 21 days, a minimum of 10 days between termination of the investigational drug and administration of TGR-1202 is required.",investigational
Use of any other investigational agents within 30 days of starting study treatment.,investigational
Use of investigational agent within 28 days prior to randomization,investigational
Use of investigational cancer agents within 6 weeks prior to diagnosis,investigational
"Ability to comply with the study protocol, in the investigator's judgment",invjudge
Active infection or other serious underlying medical condition which would impair the ability of the patient to receive the planned treatment.,invjudge
"Active inflammatory bowel disease (i.e., patients requiring current medical interventions or who are symptomatic) or have a history of abdominal surgery or other medical condition that may, in the opinion of the treating physician, interfere with gastrointestinal motility or absorption.",invjudge
"Any clinically significant condition or situation, other than the condition being studied that, in the opinion of the investigator, would impair with their ability to receive or tolerate the planned treatment, or interfere with the study evaluations or optimal participation in the study.",invjudge
"Any condition (e.g., psychological, geographical, etc.) that does not permit compliance with the protocol.",invjudge
"Any condition in the investigator's judgment that would interfere with full participation in the study, including administration of study drug and attending required study visits; pose a significant risk to the subject; or interfere with interpretation of study data.",invjudge
"Any condition that, in the opinion of the investigator or sponsor, would interfere with evaluation of the investigational products or interpretation of subject safety or study results.",invjudge
"Any condition, which in the opinion of the patient's treating oncologist, or the provider performing the biopsy procedure, would make participation in this protocol unreasonably hazardous for the patient (including a history of a serious or life-threatening allergic reaction to such local anesthetics as lidocaine or xylocaine)",invjudge
"Any disease(s), psychiatric condition, metabolic dysfunction, or findings from a physical examination or clinical laboratory test result that would cause reasonable suspicion of a disease or condition, that contraindicates the use of pracinostat and/or AZA, that may increase the risk associated with study participation, that may affect the interpretation of the results, or that would make the patient inappropriate for this study",invjudge
Any illness or medical condition that is considered unstable or might jeopardize the safety of the patient and / or influence the patient's compliance in the study.,invjudge
Any illness that in the opinion of the investigator would compromise the ability of the patient to participate safely in the clinical trial.,invjudge
"Any major medical, addictive or psychiatric illnesses which would affect the consent process, the completion of treatment and/or interfere with follow-up",invjudge
"Any medical condition or abnormality in clinical laboratory tests that, in the investigator's or Medical Monitor's judgment, precludes the patient's safe participation in and completion of the study, or which could affect compliance with the protocol or interpretation of results.",invjudge
"Any medical or psychiatric illness that could, in the investigator&rsquo;s opinion, potentially interfere with the completion of treatment according to this protocol.",invjudge
"Any other clinically significant comorbidities, such as uncontrolled pulmonary disease, active infection, or any other condition, which in the judgment of the Investigator, could compromise compliance with the protocol, interfere with the interpretation of study results, or predispose the patient to safety risks.",invjudge
Any other concomitant serious illness or organ system dysfunction in opinion of Investigator would either compromise subject safety or interfere with test drug safety evaluation,invjudge
"Any other concurrent severe and/or uncontrolled medical condition that would, in the investigator?s judgment, cause unacceptable safety risks, contraindicate patient participation in the clinical study or compromise compliance with the protocol (e.g., chronic pancreatitis, chronic active hepatitis, active untreated or uncontrolled fungal, bacterial or viral infections etc.)",invjudge
"Any other condition that would, in the Investigator's judgment, contraindicate patient's participation in the clinical study due to safety concerns or compliance with clinical study procedures, e.g., infection (including active hepatitis B and C), inflammation, intestinal obstruction, unable to swallow medication, social/ psychological issues, etc.",invjudge
"Any other condition that would, in the investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns or compliance with clinical study procedures, e.g., infection/inflammation, intestinal obstruction, unable to swallow medication, social/psychological issues, etc.",invjudge
Any other condition which the Investigator believes would make participation in the study not acceptable,invjudge
"Any other condition, which in the opinion of the patient&rsquo;s treating oncologist, or the physician performing the biopsy procedure, would make participation in this protocol unreasonably hazardous for the patient.",invjudge
"Any other major illness that, in the Investigator&rsquo;s judgment, may substantially increase the risk associated with the patient&rsquo;s participation in this study.",invjudge
Any other pathology or condition where the principle investigator may deem to negatively impact treatment safety.,invjudge
Any other pathology or condition which the principal investigator may deem to negatively impact treatment safety,invjudge
any other serious uncontrolled medical disorders in the opinion of the investigator.,invjudge
Any other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or may interfere with the interpretation of study results,invjudge
"Any other significant medical condition, including psychiatric illness or laboratory abnormality, that would preclude the patient participating in the trial or would confound the interpretation of the results of the trial",invjudge
"Any serious and/or unstable pre-existing medical, psychiatric, or other existing condition that would prevent compliance with the trial or consent process",invjudge
"Any serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of treatment according to this protocol, such as life-threatening illness unrelated to cancer.",invjudge
"Any serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of treatment according to this protocol.",invjudge
"Any serious, unstable medical or psychiatric condition that would prevent, (as judged by the Investigator) the subject properly providing informed consent or any condition which would jeopardize compliance with the protocol",invjudge
"Bleeding from a site which, in the investigator's opinion, constitutes a potential life-threatening source (eg, pulmonary hemorrhage or CNS bleeding), irrespective of amount of blood loss.",invjudge
"Chronic nausea, vomiting, or diarrhea considered to be clinically significant in the opinion of the investigator.",invjudge
Cognitive or psychiatric conditions as determined by the treating oncologist to prohibit study consent or participation,invjudge
"Co-morbid illnesses or other concurrent disease that, in the judgement of the clinician obtaining informed consent, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens or prevent required follow-up.",invjudge
"Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens",invjudge
"Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens.",invjudge
"Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens; NOTE: this includes uncompensated heart or lung disease",invjudge
"Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the local investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens",invjudge
"Co-morbid systemic or psychiatric illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens.",invjudge
"Concomitant disease or condition that could interfere with the conduct of the study, or that would, in the opinion of the Investigator, pose an unacceptable risk to the subject in this study.",invjudge
"Concomitant disease or condition that could interfere with the conduct of the study, or that would, in the opinion of the Investigator, pose an unacceptable risk to the subject in this study. Amendment 4, 11 June 2018",invjudge
Concurrent condition that in the investigator's opinion would jeopardize compliance with the protocol.,invjudge
Currently uncontrolled hyper/hypothyroidism or hyper/hypocortism if in the opinion of the investigator they pose unacceptably high risk when combined with study treatment,invjudge
"Evidence of severe or uncontrolled systemic diseases (e.g., unstable or uncompensated respiratory, hepatic, renal, cardiac disease, or clinically significant bleeding episodes). Any serious and/or unstable pre-existing medical (aside from malignancy), psychiatric disorder, or other conditions that could interfere with subject's safety, obtaining informed consent or compliance to the study procedures, in the opinion of the Investigator.",invjudge
"Evidence of significant medical illness, abnormal laboratory finding, or psychiatric illness/social situations that could, in the Investigator's judgment, make the patient inappropriate for this study.",invjudge
"For patients in whom planned RT fields during the study will include the chest, any of the following, if in the opinion of the site investigator they pose unacceptably high risk when combined with study treatment:",invjudge
"For patients in whom planned RT fields will include the heart, any of the following heart conditions, if in the opinion of the investigator they pose unacceptably high risk when combined with study treatment:",invjudge
"Has a history of current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator",invjudge
"Has a history or current evidence of any condition (eg, transfusion-dependent anemia or thrombocytopenia), therapy or laboratory abnormality that is specifically contraindicated per the current locally-approved labeling, that might confound the results of the trial, interfere with the participant's involvement for the full duration of the trial, or is not in the best interest of the participat to be involved, in the opinion of the treating investigator.",invjudge
"Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the participant's participation for the full duration of the study, or is not in the best interest of the participant to participate, in the opinion of the treating investigator.",invjudge
"Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the subject's participation for the full duration of the study, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.",invjudge
"Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the participant's participation for the full duration of the trial, or is not in the best interest of the participant to participate.",invjudge
"Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.",invjudge
Has known phychiatric or sbstance abuse disorders that would may interfere with cooperation with the requirements of the trial,invjudge
Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.,invjudge
"Have a serious nonmalignant disease (eg, hydronephrosis, liver failure, or other conditions) that could compromise protocol objectives in the opinion of the investigator and/or the sponsor",invjudge
"History or current evidence of any condition, therapy or laboratory abnormality (e.g. chronic renal failure; angina, myocardial ischemia or infarction, class 3 or higher congestive heart failure, cardiomyopathy, or clinically significant arrhythmias) that in the opinion of the treating investigator might confound the results of the trial or interfere with the subject's participation for the full duration of the trial",invjudge
"History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the patient's participation for the full duration of the study drug, or is not in the best interest of the patient to participate",invjudge
"History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating Investigator. Is or has an immediate family member (e.g. spouse, parent/legal guardian, sibling or child) who is investigational site or sponsor staff directly involved with this trial, unless prospective IRB approval (by chair or designee) is given allowing exception to this criterion for a specific subject.",invjudge
"History or current evidence of any condition, therapy, or laboratory abnormality that might interfere with subject's participation for the full duration of the trial or is not in the best interest of the subject to participate, in the opinion of the treating investigator.",invjudge
"History or evidence of a clinically unstable/uncontrolled disorder, condition or disease (including but not limited to cardiopulmonary, renal, metabolic, hematologic or neurologic) other than their primary malignancy, that in the opinion of the Investigator would pose a risk to patient safety or interfere with the study evaluation, procedures or completion.",invjudge
"History or evidence of any other clinically unstable/uncontrolled disorder, condition, or disease (including, but not limited to, cardiopulmonary, renal, metabolic, hematologic or psychiatric) other than their primary malignancy that in the opinion of the Investigator would pose a risk to subject safety or interfere with the study evaluation, procedures or completion.",invjudge
"Illness or condition that may interfere with a patient's capacity to understand, follow, and/or comply with study procedures",invjudge
"In the investigators judgment, the subject is unlikely to complete all protocol-required study visits or procedures, including follow-up visits, or comply with the study requirements for participation",invjudge
Individuals with major medical or psychiatric illness which would prevent the completion of study treatment and/or interfere with follow up are excluded from this study.,invjudge
"Known previous or ongoing, active psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial",invjudge
Known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.,invjudge
"Known significant mental illness or other conditions such as active alcohol or other substance abuse that, in the opinion of the investigator, predisposes the subject to high risk of noncompliance with the protocol treatment or assessments.",invjudge
Legal incapacity or limited legal capacity or any psychiatric condition that would prohibit the understanding or rendering or informed consent or that might limit compliance with study requirements Any waiver of these exclusion criteria should be exceptional and justified and must be approved by the Investigator and the Sponsor on a case-by-case basis prior to enrolling the patient. Such waivers must be documented by both the Investigator and Sponsor.,invjudge
"Life-threatening illness, significant organ system dysfunction, or other reasons that, in the investigator's opinion, could compromise the subject's safety or the integrity of the study outcomes, or interfere with the absorption or metabolism of CBT-101.",invjudge
"Life-threatening illnesses other than AML, uncontrolled medical conditions or organ system dysfunction that, in the Investigator's opinion, could compromise the patient's safety or put the study outcomes at risk",invjudge
"Major medical, addictive or psychiatric illness which in the investigator?s opinion, will prevent the consent process, completion of the treatment and/or interfere with follow-up. (Consent by legal authorized representative is not permitted for this study)",invjudge
"Major medical, addictive or psychiatric illness which in the investigator's opinion, will prevent the consent process, completion of the treatment and/or interfere with follow-up. (Consent by legal authorized representative is not permitted for this study).",invjudge
"Major surgery to the upper gastrointestinal (GI) tract, or have a history of GI disease or other medical condition that, in the opinion of the Investigator, may interfere with oral drug absorption",invjudge
Medical or psychiatric conditions that preclude informed decision-making or adherence.,invjudge
Medical or psychological conditions that in the opinion of the investigator would not allow follow-up,invjudge
"No co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens.",invjudge
"No other condition which, in the opinion of the Investigator, would preclude participation in this trial.",invjudge
Or any other conditions that would limit compliance with study requirements,invjudge
"Other acute or chronic medical or psychiatric condition including recent (within the past year) or active suicidal ideation or behavior or laboratory abnormality that may increase the risk of study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgement of the Investigator, would make the patient inappropriate for entry into the study.",invjudge
"Other cardiac or pulmonary disease that, at the investigator's discretion, can impair treatment safety",invjudge
"Other cardiac or pulmonary disease that, at the investigators discretion, can impair treatment safety.",invjudge
"Other co-morbidity, which would interfere with patient's ability to participate in trial or that confounds the ability to interpret data from the study.",invjudge
"Other medical or psychiatric conditions that, in the opinion of the investigatory, may interfere with the patient's participation in the study",invjudge
Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that in the judgment of the investigator would make the patient inappropriate for entry into this study.,invjudge
"Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration or may interfere with the interpretation of study results and, in the judgment of the Investigator, would make the patient inappropriate for Entrectinib-F. Hoffmann-La Roche Ltd entry into this study or could compromise protocol objectives in the opinion of the Investigator and/or the Sponsor. Entrectinib-F. Hoffmann-La Roche Ltd",invjudge
"Other severe acute or chronic medical or psychiatric conditions, or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for enrollment in this study.",invjudge
"Other severe, acute, or chronic medical or psychotic conditions or laboratory abnormalities that in the opinion of the investigator may increase the risk associated with study participation, or that may interfere with the interpretation of study results",invjudge
Other significant medical condition unrelated to the primary malignancy that would compromise subject's safety or ability to comply with protocol requirements,invjudge
"Other underlying medical condition that, in the opinion of the investigator, would impair the ability of the patient to receive or tolerate the planned treatment and follow-up.",invjudge
Part 1 and Part 3: Current diagnosis of any chronic or acute respiratory condition or ongoing sequelae from any previously diagnosed respiratory condition that is significant in the judgment of the investigator or the sponsor's medical monitor.,invjudge
Participant has a serious medical or psychiatric illness likely to interfere with participation in this clinical study.,invjudge
"Participants must not have a known or underlying serious or uncontrolled medical condition that, in the opinion of the investigator or Sponsor, could make the administration of study treatment hazardous to the participants or could adversely affect the ability of the participant to comply with or tolerate the study.",invjudge
"Patient has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, might interfere with the patient's participation for the full duration of the study treatment, or is not in the best interest of the patient to participate.",invjudge
Patient has any medical condition that in the Investigator's opinion place the patient at an unacceptably high risk for toxicities.,invjudge
"Patient has uncontrolled, clinically significant pulmonary disease (e.g., chronic obstructive pulmonary disease, pulmonary hypertension) that, in the Investigator's opinion, would put the patient at significant risk for pulmonary complications during the study.",invjudge
Patient is judged by the Investigator to have the initiative and means to be compliant with the protocol and be within geographical proximity to make the required study visits,invjudge
"Patients who, in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study are not eligible.",invjudge
Patients with active keratitis or corneal ulcerations. Patients with superficial punctate keratitis are allowed if the disorder is being adequately treated in the opinion of the investigator.,invjudge
Patients with serious unstable medical illness,invjudge
"Patients with substance abuse or other medical or psychiatric conditions that, in the opinion of the investigator, would confound study interpretation or affect the patient's ability to tolerate or complete the study.",invjudge
platelet count between 25 and 50x10^9/L at time of enrollment requires agreement by both the Investigator and Amgen Medical Monitor of acceptability before enrollment can be approved,invjudge
"Pre-existing duodenal stent and/or any gastrointestinal disorder or defect that would, in the opinion of the investigator, interfere with absorption of study drug",invjudge
"Presence of any other condition that may increase the risk associated with study participation or may interfere with the interpretation of study results, and, in the opinion of the investigator, would make the patient inappropriate for entry into the study",invjudge
"Prior radiation to an area of the body which, if included in the current radiation field, poses an unacceptably high risk of toxicity in the opinion of the investigator. NOTE: A prior field that overlaps with the current field, by itself, does not exclude the patient.",invjudge
"Psychiatric or addictive disorders or other conditions that, in the opinion of the investigator, would preclude the patient from meeting the study requirements or interfere with interpretation of study results",invjudge
"Psychiatric or addictive disorders or other conditions that, in the opinion of the investigator, would preclude the patient from meeting the study requirements.",invjudge
"Psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol",invjudge
"Psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol.",invjudge
"Serious nonmalignant disease (e.g., hydronephrosis, liver failure, or other conditions) that could compromise protocol objectives in the opinion of the investigator and/or the sponsor",invjudge
"Serious nonmalignant disease (e.g., hydronephrosis, liver failure, or other conditions) that could compromise protocol objectives in the opinion of the investigator and/or the sponsor.",invjudge
"Serious pre-existing medical conditions that would preclude participation in this study (for example, interstitial lung disease, severe dyspnea at rest or requiring oxygen therapy, history of major surgical resection involving the stomach or small bowel, or preexisting Crohn's disease or ulcerative colitis or a preexisting chronic condition resulting in baseline Grade 2 or higher diarrhea).",invjudge
"Serious psychiatric or medical conditions that, in the opinion of the Investigator, could interfere with treatment, compliance, or the ability to give consent.",invjudge
"Severe active co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens.",invjudge
"Significant co-morbid condition or disease which in the judgment of the Investigator would place the subject at undue risk or interfere with the study; examples include, but are not limited to, cirrhotic liver disease, sepsis, recent significant traumatic injury, and other conditions.",invjudge
"Significant gastrointestinal disorder(s) that could, in the opinion of the Investigator, interfere with the absorption, metabolism, or excretion of ARQ 087 (e.g., Crohn's disease, ulcerative colitis, extensive gastric resection)",invjudge
"Subject has any condition including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study.",invjudge
Subject has any condition that confounds the ability to interpret data from the study.,invjudge
"Subject has any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject form participating in the study.",invjudge
"Subject has any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study.",invjudge
"Subject with any condition including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study.",invjudge
Subject with any condition or concomitant medication that confounds the ability to interpret data from the study.,invjudge
"Subject with any significant medical condition, laboratory abnormality, psychiatric illness, or is considered vulnerable by local regulations (e.g., imprisoned or institutionalized) that would prevent the subject from participating in the study.",invjudge
"Subject with any significant medical condition, laboratory abnormality, psychiatric illness, or is considered vulnerable by local regulations (eg, imprisoned or institutionalized) that would prevent the subject from participating in the study.",invjudge
"Subjects who, in the opinion of the investigator, are unable or unlikely to comply with the dose regimen and study evaluations.",invjudge
"Substance abuse, medical, psychological or social conditions that may interfere with the patient's participation in the trial or evaluation of the trial result",invjudge
"Substance abuse, psychological, or social conditions that may interfere with the patient's participation in the study or evaluation of the study results",invjudge
"Substance abuse, psychological, or social conditions that may interfere with the patient's participation in the study or evaluation of the study results.",invjudge
"Uncontrolled intercurrent illness including, but not limited to, psychiatric illness/social situations, or other co-morbid systemic illnesses or severe concurrent diseases which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens.",invjudge
"Uncontrolled intercurrent illness which in the opinion of the investigator poses unacceptably high risk when combined with study treatment, including but not limited to the following:",invjudge
"Uncontrolled medical, psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol, as judged by the Investigator; medical conditions or laboratory abnormalities that could jeopardize subject safety, as judged by the Investigator or Sponsor Medical Monitor; or unwillingness or inability to follow the procedures required in the protocol",invjudge
"Uncontrolled severe illness or medical condition (including uncontrolled diabetes), which in the judgment of the treating physician would make the administration of chemotherapy inadvisable",invjudge
"Uncontrolled, clinically significant pulmonary disease (e.g., COPD, pulmonary hypertension, continuous dependency on supplemental oxygen) that in the opinion of the Investigator would put the subject at significant risk for pulmonary complications during the study.",invjudge
Ability to communicate in English,language
Ability to complete English language questionnaires by themselves or with assistance,language
Ability to complete evaluation surveys in English,language
Ability to complete questionnaire(s) in English by themselves or with assistance,language
ability to complete the intervention and assessments in English; and,language
Ability to comprehend and speak English.,language
Ability to read and write English,language
Ability to read and write in English,language
Ability to understand and the willingness to sign a written informed consent document written in English that is approved by an institutional review board.,language
ability to understand English,language
Ability to understand English and the willingness to sign a written informed consent document.,language
Able to communicate in English or Spanish.,language
able to communicate with ease in English,language
"Able to complete forms, understand instructions and read intervention book in English",language
"Able to converse, write and read in English. The questionnaires were designed and validated in English and are not currently available in other languages. Translation of questionnaires into other languages would require a very lengthy process of reestablishing the reliability and validity and the establishment of norms for these measures. Therefore, participants must be able to communicate in English to complete the questionnaires.",language
Able to fluently speak and read English,language
Able to follow verbal and written instructions in English and complete all aspects of the study.,language
Able to read and comprehend English and Spanish.,language
Able to read and comprehend English. Eligibility is restricted to individuals who can comprehend and read English given that participation in the study will require the ability to read lifestyle intervention materials and communicate with a coach through 42 phone calls over 2 years. The study team plans to make the intervention available in Spanish in the future.,language
"Able to read and comprehend English. Eligibility is restricted to individuals who can comprehend and read English or Spanish given that participation in the study will require the ability to read lifestyle intervention materials and communicate with a coach through 42 phone calls over 2 years. Given the logistical and financial difficulties of supporting the intervention in multiple languages, participation will be limited to individuals speaking English at this time. The study team plans to make the intervention available in additional languages sometime after study activation. This eligibility criterion will be modified with an amendment at that time.",language
able to read and speak English,language
Able to read and write English well enough to understand and sign consent forms and respond to questionnaires,language
Able to read and write in English,language
"Able to read and write in one of the following languages, in which the PROCTCAE tool is available: English, Danish, German, Italian, Japanese, Korean, Spanish",language
able to read English at least at eighth-grade level,language
"Able to read, speak and consent in English.",language
"Able to read, speak, and write English or Spanish",language
"Able to read, write, and speak English",language
Able to speak and read English,language
Able to speak and read English (to allow for participation in study intervention sessions),language
Able to speak and read English fluently.,language
Able to speak and read English or Spanish,language
Able to speak English,language
Able to speak read or write English,language
"Able to speak, read and write in English.",language
Able to speak/read English,language
Able to understand English.,language
All participants must be able to understand English.,language
"ALL PHASES, PATIENTS AND PARTNERS: Able to read and speak English",language
Any patient who cannot understand written or spoken English.,language
Are able to speak or read English,language
"Are English-speaking and able to provide voluntary, written consent",language
are unable to read/speak English; or,language
Be able to communicate in English; and be competent to consent,language
Be able to read English,language
"Be able to read, write, and speak English",language
Be English-speaking due to objective speech perception tasks. Non-English speakers may show a reduced speech perception score due to language differences,language
"can read and write English, Mandarin Chinese, Korean or Japanese",language
Cannot participate in or understand English,language
Capable of speaking and reading English,language
CAREGIVER: English-speaking,language
CHILD: Child understands English and is enrolled in school (but can be bilingual),language
Cognition and English language skills must be sufficient for completion of consent and questionnaires.,language
Cohort 1: Patients must be able to speak and understand English,language
Cohort 2: Patients must be able to speak and understand English,language
Does not speak English,language
DONOR: Non-English speaking person,language
English 12+ months since,language
"English and Spanish speaking adult patients, 18 years of age and older who:",language
English language proficiency,language
English language proficient,language
English language proficient and ability to provide informed consent,language
English or Spanish speaker,language
English or Spanish speaking,language
English or Spanish speaking with ability to respond to the QoL questionnaires,language
English- or Spanish-speaking,language
English proficiency,language
English speaker.,language
English speakers,language
English speaking,language
English speaking and able to read English,language
English speaking as per EMR,language
English speaking patients,language
English speaking.,language
English speaking/reading patients willing and able to provide written informed consent for study participation,language
English-proficiency,language
English-speaking,language
English-speaking (6th grade reading level) as required to complete assessments,language
English-speaking or Spanish-speaking,language
English-speaking patients must be willing to participate in the BAHO substudy,language
English-speaking.,language
"FAMILY. Eligible family subjects18 years of age or older, English-speaking, and identified as someone involved in patient's medical care or decision-making. Eligible family may include any of the following: legal guardians, durable power of attorney for healthcare, spouses, adult children, parents, siblings, domestic partners, other relatives, and friends.",language
Fluent in English,language
Fluent in English (because not all components of the GA have been validated in other languages),language
Fluent in English as self-reported by a fluency of  Very well ,language
Fluent in English or Spanish,language
Fluent in speaking and understanding English,language
"For participation in the patient-reported outcomes and qualitative interviews, subjects must be fluent in English",language
"For the cognitive assessment and patient-reported QOL exploratory correlative portion of the study, subjects must speak, read and understand English. Subjects who do not speak, read and understand English but satisfy all other inclusion criteria may still participate in the study but will not complete the cognitive and QOL portions.",language
For the first 736 eligible English or French-speaking subjects who have agreed to optional questionnaire completion:,language
"In order to complete the mandatory patient-completed measures, participants must be able to speak and/or read English.",language
inability to converse in English,language
Inability to read or speak English,language
Inability to speak and read English proficiently,language
Inability to speak English,language
Inability to understand English as study instruments have not been validated in other languages,language
"Is capable of completing and fully understanding the informed consent process, study procedures, and study assessments in English",language
Must be able to read and understand English,language
Must be able to read and understand English to complete the required questionnaires,language
Must be able to read and understand English to complete the required questionnaires Must be able to read and understand protocol consent,language
"Must be able to read, write, speak and understand English",language
Must be able to read/understand English,language
Must be able to speak English.,language
Must be English speaking due to the study materials being available in English only and limited available resources for translation.,language
Non English speaking,language
Non English speaking individual,language
Non English speaking person,language
Non English-speaking,language
Non-English or Non-Spanish Speaking patients.,language
Non-English proficiency (plans to expand to Spanish by year 2),language
Non-English speakers,language
Non-English speakers and illiterate subjects will be excluded.,language
Non-English speakers will be excluded from participating in the patient-reported outcomes component of the study.,language
Non-English speakers without adequate interpreter assistance,language
Non-English Speaking,language
Non-English speaking individuals will be excluded from the study,language
Non-English speaking participants.,language
Non-English speaking person,language
Non-English-speaking,language
Non-English-speaking or reading,language
Non-English-speaking patients,language
Non-English-speaking patients who require an interpreter to give consent,language
Non-fluent in English speaking and understanding,language
Not able to read and write English well enough to understand and sign consent forms and respond to questionnaires,language
Not an English or Spanish speaker,language
Not English-speaking,language
"Not English-speaking Since not all outcome measures have been validated in Spanish and other languages, only English-speaking patients will be included.",language
"Only English, Spanish, and French-speaking patients are eligible to participate",language
Parent is fluent in English,language
Parent/legal guardian/caregiver that speaks English available to assist in participant's training,language
Participants must be able to read and write in English to participate.,language
Patient and at least one parent/guardian are able to read and write English; at least 1 parent/guardian must be able to read and write English in order to assist the patient with using their Sqord account,language
"Patient and/or Legally Authorized Representative must have the ability to read, write, speak and understand English. Note: If patient does not have the capability to read or write in English, the patient‟s preferred language should be English and the LAR will be responsible for completing all study forms on the patient's behalf.",language
Patient does not understand English,language
"Patient is able (i.e., sufficiently fluent) and willing to complete the quality of life, health utilities and lost productivity questionnaires in either English or French",language
Patient must be English-speaking [MD Anderson Symptom Inventory (MDASI) completion only],language
PATIENT: English-speaking,language
Patients must be able to follow directions and complete questionnaires and exercise diaries in English.,language
"Patients must be able to read and comprehend English, in order to be able to complete study questionnaires. However, patients participating through CCTG institutions who can read and comprehend French are eligible.",language
"Patients must be able to read and comprehend English, in order to be able to complete study questionnaires; however, patients participating through Canadian Cancer Trials Group (CCTG) institutions who can read and comprehend French are eligible",language
Patients must be able to read and write English to comply with the questionnaire portions of the protocol.,language
Patients must be able to read or speak English,language
Patients must be able to understand and provide information for the patient-completed study forms in either English or Spanish,language
Patients must be English speaking and sign an approved informed consent form (ICF) and HIPAA.,language
"Patients must be English-, French- or Spanish-speaking (languages in which the assessment is available)",language
Patients must be fluent in speaking English or Spanish.,language
Patients that are not able to read or understand English,language
"Patients unable to speak or understand English, since they cannot complete neurocognitive evaluation.",language
Patients who are non-English speaking,language
Patients who are primary English or French speakers are eligible,language
Patients who can complete Patient Reported Outcomes (PRO) forms in English are required to complete a pre-study S1400I Patient Reported Outcomes (PRO) Questionnaire and a pre-study S1400I European Quality of Life Five Dimension (EQ-5D) Questionnaire within 14 days prior to registration; NOTE: Patients enrolled to S1400I prior to 9/1/2016 are not eligible for the PRO study,language
"Patients who can complete Patient-Reported Outcome instruments in English or Spanish must agree to complete the EORTC QLQ-C30, the EORTC QLQ-BLM30, the EPIC-26 (bowel domain only), and the EQ-5D-5L per protocol schedule of assessment.",language
"Patients who can complete Patient-Reported Outcome instruments in English, Spanish or French, must participate in the quality of life studies.",language
"Patients who can complete patient-reported outcome instruments in English, Spanish, or French must complete the PROMIS Fatigue, the FACT/GOG-Ntx, and the PROMIS Global prior to registration and must agree to complete these instruments and the PRO-CTCAE or Pediatric PRO-CTCAE at the scheduled on-study assessment timepoints.",language
Patients who cannot read or speak English,language
Patients who speak English,language
"PATIENTS. Eligible patients 18 years of age or older, English-speaking, with a chronic life-limiting illness suggesting a median survival of approximately 2 years or a severe acute illness with a risk of hospital mortality of at least 15%. Chronic life-limiting illnesses include: cancer with a poor prognosis (e.g. metastatic cancer); chronic pulmonary disease (e.g. COPD, restrictive lung disease); coronary artery disease (CAD); congestive heart failure (CHF); peripheral vascular disease (PVD); severe liver disease (e.g. cirrhosis); diabetes with end-organ damage; renal failure (e.g. ESRD); and dementia. Acute illness criteria include a SOFA, APACHE or trauma severity score predicting a 15% or greater risk of hospital mortality. Acute illnesses and conditions also include: age >= 80 years; acute respiratory distress syndrome (ARDS) with P/F ratio <= 300; subarachnoid hemorrhage (SAH) Fisher grade 3/4 with Glasgow coma score (GCS) <= 12; spontaneous hemorrhage (ICH, IPH, EDH, SDH) with GCS <= 12; stroke or cardiovascular accident (CVA) with GCS <= 12; decompressive/crash craniotomy (bone flap) with GCS <= 12; traumatic brain injury (TBI) or diffuse axonal injury (DAI) based on MRI ~day 10; or anoxic brain injury due to cardiac arrest > 48 hours. All potential participants screened for facility with English and absence of significant cognitive impairment (prior to their current hospitalization) that would limit their ability to complete survey instruments.",language
PATIENTS: English-speaking,language
persons who cannot read or understand spoken English,language
Primary language is English,language
Proficient in English (due to number of questionnaires not validated in other languages),language
Proficient in English or Spanish,language
Proficient in English.,language
Proficient in the English language and self-reports as literate,language
Pts who are non-English speaking and English illiterate,language
read and speak English,language
Reads and speaks Spanish or English,language
"Reads and speaks Spanish or English, or availability of an appropriate professional interpreter at enrollment",language
Subject must be able to speak and read English,language
"Subjects must have the ability to read and speak English and Spanish at the 8th grade level or above, and survivors with mild depression, anxiety, or other psychiatric conditions will be eligible.",language
Subjects who cannot read or understand English,language
"SURROGATE/FAMILY. Eligible surrogate/family subjects will be those who are 18 years of age or older, English-speaking, involved in the patient's medical care or decision-making.",language
The ability to comprehend English or complete questionnaires with minimal assistance of an interpreter,language
The ability to read and respond to questions English,language
The ability to read and respond to questions in English or Spanish,language
The parent is not English speaking,language
The participant understands and is willing to provide informed consent in English or Spanish,language
The patient cannot speak / understand English or Spanish.,language
to be able to read and speak English,language
Unable to read and respond to questions in English,language
Unable to read and write in English,language
unable to read English at least at eighth-grade level,language
"Unable to read, speak, and understand English",language
Unable to undergo the informed consent process and the study interview in English per the judgment of the primary urologist or urological provider,language
Understands as is willing to provide informed consent in English or in Spanish,language
Understands English and is interested in participating,language
Verbal fluency in English,language
Willing and able to complete survey questionnaires in English without assistance through the duration of the study. This stipulation is in place because not all of the proposed quality of life or cognitive tests are available or validated in other languages.,language
A life expectancy >= 16 weeks at time of enrollment,lifeexpectancy
A life expectancy of at least 6 months with a Karnofsky performance status of at least 70,lifeexpectancy
Able to adhere to study visit schedule and other protocol requirements including follow-up for survival assessment,lifeexpectancy
"Active infection or other active medical condition that could be eminently life-threatening, including active blood clotting or bleeding diathesis.",lifeexpectancy
Another cancer with expected survival of < 2 years,lifeexpectancy
"Any life-threatening illness, medical condition or organ system dysfunction which, in the investigator's opinion, could compromise the subject's safety, or put the study outcomes at undue risk",lifeexpectancy
At least 12 month life expectancy,lifeexpectancy
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 and minimum life expectancy of >= 3 months,lifeexpectancy
"ECOG performance status 0, 1 or 2 and life expectancy of greater than 12 weeks based on the investigator's clinical judgment.",lifeexpectancy
Estimated life expectancy of greater than 6 months,lifeexpectancy
Estimated life expectancy of more than 6 months,lifeexpectancy
"Estimated life expectancy, in the judgment of the investigator, which will permit receipt of treatment of 12 weeks or more",lifeexpectancy
Expected survival > 3 months,lifeexpectancy
Expected survival > 3 months from study enrollment,lifeexpectancy
Expected survival > 3 months.,lifeexpectancy
Expected survival >= 3 months,lifeexpectancy
Expected survival >= 3 months after consenting.,lifeexpectancy
Expected survival >= 3 months in the view of the PI or investigators.,lifeexpectancy
Expected survival >= 8 months,lifeexpectancy
Expected survival greater than 3 months.,lifeexpectancy
Expected survival is > 100 days,lifeexpectancy
Expected survival is greater than 100 days,lifeexpectancy
Expected survival less than 6 months,lifeexpectancy
Expected survival must be greater than 3 months,lifeexpectancy
Expected survival must be greater than three months.,lifeexpectancy
Expected survival of at least 3 months.,lifeexpectancy
Expected survival of at least 3 years,lifeexpectancy
Expected survival of greater than 16 weeks.,lifeexpectancy
Expected survival of more than 12 weeks,lifeexpectancy
Expected survival of more than 6 months,lifeexpectancy
Greater than 5 year life expectancy,lifeexpectancy
Has a life expectancy of at least 3 months.,lifeexpectancy
have a life expectancy of > 12 weeks,lifeexpectancy
Have a performance status of at least 1 on the Eastern Cooperative Oncology Group (ECOG) scale and life expectancy > 6 months,lifeexpectancy
Have an estimated life expectancy > 4 months,lifeexpectancy
Have an estimated life expectancy of greater than 3 months,lifeexpectancy
Have an expected survival of > 60 day.,lifeexpectancy
Have an expected survival of > 60 days,lifeexpectancy
Have expected survival of at least 4 months,lifeexpectancy
Have other life-threatening illness,lifeexpectancy
Life expectancy < 12 months,lifeexpectancy
Life expectancy < 3 months,lifeexpectancy
Life expectancy < 6 months,lifeexpectancy
Life expectancy > 12 weeks,lifeexpectancy
Life expectancy > 2 months,lifeexpectancy
Life expectancy > 3 months,lifeexpectancy
Life expectancy > 4 months,lifeexpectancy
Life expectancy > 6 months,lifeexpectancy
Life expectancy > 6 months per investigator,lifeexpectancy
Life expectancy >= 12 weeks as judged by the Investigator,lifeexpectancy
Life expectancy >= 12 weeks.,lifeexpectancy
Life expectancy >= 16 weeks at time of enrollment,lifeexpectancy
Life expectancy >= 16 weeks.,lifeexpectancy
Life expectancy >= 52 weeks excluding their diagnosis of breast cancer,lifeexpectancy
Life expectancy >= 6 weeks,lifeexpectancy
Life expectancy >= 6 weeks.,lifeexpectancy
Life expectancy >= 90 days (3 months),lifeexpectancy
Life expectancy greater than 18 months,lifeexpectancy
Life expectancy greater than 3 months,lifeexpectancy
Life expectancy greater than 6 months,lifeexpectancy
Life expectancy greater than or equal to ( >= ) 12 weeks,lifeexpectancy
Life expectancy greater than or equal to 6 weeks.,lifeexpectancy
Life expectancy greater than six months.,lifeexpectancy
Life expectancy is not severely limited by concomitant illness,lifeexpectancy
Life expectancy is severely limited by concomitant illness or uncontrolled infection,lifeexpectancy
Life expectancy less than 3 months.,lifeexpectancy
Life expectancy less than 4 months,lifeexpectancy
Life expectancy less than 6 months,lifeexpectancy
Life expectancy limited by another co-morbid illness,lifeexpectancy
Life expectancy limited by other co-morbid illnesses,lifeexpectancy
Life expectancy must be estimated by patient's physician at > 6 months,lifeexpectancy
Life expectancy of < 12 weeks,lifeexpectancy
Life expectancy of < 3 months,lifeexpectancy
Life expectancy of > 3 months,lifeexpectancy
Life expectancy of >= 12 weeks.,lifeexpectancy
Life expectancy of >= 3 months,lifeexpectancy
Life expectancy of >= 4 months,lifeexpectancy
Life expectancy of 12 months or greater,lifeexpectancy
life expectancy of 3 years,lifeexpectancy
Life expectancy of at least 12 weeks,lifeexpectancy
Life expectancy of at least 12 weeks (3 months),lifeexpectancy
Life expectancy of at least 12 weeks in the opinion of investigator,lifeexpectancy
Life expectancy of at least 6 months,lifeexpectancy
Life expectancy of at least 9 months,lifeexpectancy
Life expectancy of at least 90 days,lifeexpectancy
Life expectancy of at least three months.,lifeexpectancy
Life expectancy of greater 3 months,lifeexpectancy
Life expectancy of greater than 4 months,lifeexpectancy
Life expectancy of greater than 4 months.,lifeexpectancy
Life expectancy of greater than 5 years,lifeexpectancy
Life expectancy of greater than 6 months,lifeexpectancy
Life expectancy of greater than 6 months.,lifeexpectancy
Life expectancy of greater than 60 months,lifeexpectancy
Life expectancy of greater than three months,lifeexpectancy
Life expectancy of more than 3 months,lifeexpectancy
Life expectancy with treatment should be >= 6 months in the estimation of the treating physicians.,lifeexpectancy
Life expectancy: >= at least 8 weeks,lifeexpectancy
Life expectancy: Greater than 8 weeks.,lifeexpectancy
Long term survival expected were it not for the cHL,lifeexpectancy
Minimum life expectancy of eight weeks,lifeexpectancy
Minimum life expectancy of eight weeks.,lifeexpectancy
Must have a life expectancy of at least 5 years based on age and co-morbidities.,lifeexpectancy
No co-existing medical condition that would limit life expectancy to < 2 years,lifeexpectancy
Other serious or life-threatening conditions deemed unacceptable by the principal investigator,lifeexpectancy
Participant must have a life expectancy >= 16 weeks.,lifeexpectancy
Participants must have a life expectancy of 2 years or more,lifeexpectancy
Patient has a life expectancy of greater than 20 weeks,lifeexpectancy
Patient must have a life expectancy > 3 months.,lifeexpectancy
Patient must have performance status of 0-1 on the ECOG Performance Scale and life expectancy > 3 months,lifeexpectancy
Patient must have performance status of 0-2 on the ECOG Performance Scale and life expectancy > 3 months.,lifeexpectancy
Patients must have a life expectancy >= 12 weeks,lifeexpectancy
Patients must have a life expectancy of > 3 months,lifeexpectancy
Patients must have a life expectancy of 100 days,lifeexpectancy
Patients must have a life expectancy of at least 12 weeks.,lifeexpectancy
Patients must have a minimum expected duration of survival of 8 weeks as determined and documented by the attending surgeon or medical oncologist.,lifeexpectancy
Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 and an estimated life expectancy of >= 3 months,lifeexpectancy
Patients must have an estimated survival greater or equal to 3 months,lifeexpectancy
Patients must have Eastern Cooperative Oncology Group (ECOG) performance status <= 1 and a life expectancy of at least 3 months,lifeexpectancy
"Patients must have Eastern Cooperative Oncology Group (ECOG)performance status of 0-1, and life expectancy greater 3 years.",lifeexpectancy
"Patients must not be at short term risk for life threatening complications (such as airway compromise or bleeding from locoregional or metastatic disease,).",lifeexpectancy
Patients with a life expectancy ( < / = 6 weeks) limited by diseases other than leukemia,lifeexpectancy
Patients with a life expectancy < 10 years,lifeexpectancy
Patients with a life expectancy < 3 months from co-existing disease other than the leukemia or RAEB,lifeexpectancy
Patients with a life expectancy of less than one year,lifeexpectancy
Patients with any severe concomitant disease that may limit their life expectancy,lifeexpectancy
Patients with life expectancy < 3-Months,lifeexpectancy
Patients with life expectancy greater than or equal to 6 weeks.,lifeexpectancy
Patients with life expectancy of < 6 months for reasons other than their underlying hematologic/oncologic disorder,lifeexpectancy
Patients with life expectancy of at least 12 months,lifeexpectancy
Patients with life-threatening condition or complication other than their basic condition,lifeexpectancy
PHASE I AIM 1: Life expectancy of at least six months,lifeexpectancy
PHASE I AIM 3.1: Life expectancy of at least six months,lifeexpectancy
PHASE I: Life expectancy >= 12 weeks,lifeexpectancy
PHASE II AIM 2: Life expectancy of at least six months,lifeexpectancy
Stable clinical conditions and life expectancy > 3 months,lifeexpectancy
Subject has a life expectancy >= 3 months,lifeexpectancy
Adequate cardiac function ( <= NYHA Class II) or normal cardiac function with left ventricular ejection fraction (LVEF) >= 50% at screening.,lvef
"Adequate cardiac function, defined as left ventricular ejection fraction (LVEF) >= 40% as assessed by echocardiogram (ECHO) or multiple uptake gated acquisition (MUGA) scan performed within 8 weeks prior to initial Screening",lvef
Baseline ejection fraction >= 50% by MUGA scan or echocardiogram performed <= 60 days prior to registration.,lvef
Cardiac ejection fraction (left ventricular ejection fraction [LVEF]) >= 50% by echocardiogram <= 30 days of registration,lvef
Cardiac ejection fraction >= 50% and no evidence of pericardial effusion as determined by an ECHO or MUGA,lvef
Echocardiogram (ECHO) or multigated acquisition (MUGA) with left ventricular ejection fraction (LVEF) < 45%.,lvef
Echocardiogram (ECHO) or multi-gated acquisition (MUGA) with left ventricular ejection fraction < 45%.,lvef
Echocardiogram with left ventricular ejection fraction < 45%.,lvef
Ejection fraction >= LLN by echocardiogram or MUGA scan,lvef
Ejection fraction of >= 50% by radionuclide angiogram,lvef
"For pediatric patients (age 12-17), the ECHO, MUGA, or functional cardiac imaging scan must be performed within 14 days prior to registration.",lvef
"Has left ventricular ejection fraction (LVEF) of < 50% or below the institution limit of normal, as assessed by echocardiogram (ECHO) or multigated acquisition (MUGA) scan performed at screening.",lvef
Have a left ventricular ejection fraction (LVEF) > 45% by echocardiogram (ECHO) or multigated acquisition (MUGA) scan,lvef
"If the patient received prior anthracycline therapy, the left ventricular ejection fraction (LVEF) must be within the institution's normal limits. An echocardiogram scan or multigated acquisition scan (MUGA) must be performed at the Screening visit (or within 28 days before IP infusion).",lvef
Impaired cardiac function (left ventricular ejection fraction [LVEF] less than [<]45%) as assessed by echocardiogram or multiple-gated acquisition (MUGA) scan (performed 8 weeks of apheresis).,lvef
Left ventricular ejection fraction (LVEF) < 50% as determined by echocardiogram (ECHO),lvef
"Left ventricular ejection fraction (LVEF) <= 50% measured within 3 months prior to Day 1, confirmed by ECHO/MUGA",lvef
"Left ventricular ejection fraction (LVEF) > 50% or above the lower limit of the institutional normal range, whichever is lower",lvef
Left ventricular ejection fraction (LVEF) >= 50% as assessed by echocardiogram (ECHO) or multiple-gated acquisition scan (MUGA) documented <= 28 days prior to registration.,lvef
Left ventricular ejection fraction (LVEF) >= 50% as determined by multigated acquisition (MUGA) scan or echocardiogram (echo),lvef
Left ventricular ejection fraction (LVEF) >= 50% at baseline as determined by either ECHO or MUGA,lvef
Left ventricular ejection fraction (LVEF) >= 50% by transthoracic echocardiogram or multigated acquisition scan (MUGA).,lvef
Left ventricular ejection fraction (LVEF) >= 50% measured by multiple-gated acquisition scan (MUGA) or echocardiogram (ECHO).,lvef
Left ventricular ejection fraction (LVEF) >= 50% or the lower limit of normal (LLN) according to local institution ranges of normality.,lvef
"Left ventricular ejection fraction (LVEF) >= 50%, no evidence of pericardial effusion as determined by an ECHO, no NYHA class III or class IV functional classification, and no clinically significant arrhythmias",lvef
Left ventricular ejection fraction (LVEF) >= institutional lower limit of normal as measured by multigated acquisition scan or 2-dimensional (2-D) echocardiogram (ECHO) within 28 days prior to start of therapy and no clinically significant abnormalities on a 12-lead electrocardiogram (ECG).,lvef
"Left ventricular ejection fraction (LVEF) below institutional lower level of normal (LLN) or below 50%, whichever is lower",lvef
"Left ventricular ejection fraction (LVEF) below institutional lower limit of normal or below 50%, whichever is lower",lvef
Left ventricular ejection fraction (LVEF) by ECHO or MUGA >= 50%,lvef
Left ventricular ejection fraction (LVEF) less than 40%.,lvef
Left ventricular ejection fraction > 50%.,lvef
"Left ventricular ejection fraction >= 50%, as determined by RVG (MUGA) or echocardiogram within 60 days prior to initiation of extension phase therapy (all cohorts)",lvef
"Left ventricular ejection fraction >= 50%, as determined by RVG (MUGA) or echocardiogram within 60 days prior to initiation of protocol therapy",lvef
Left ventricular ejection fraction LVEF < 50% or below the lower limit of normal (whichever is higher).,lvef
LVEF < 45% by MUGA or ECHO,lvef
LVEF > 40% as measured by echocardiography or MUGA,lvef
LVEF >= 50% calculated by echocardiogram (ECHO) or MUGA,lvef
Normal cardiac function as defined by a normal ejection fraction by MUGA or echocardiogram.,lvef
"Normal cardiac function, as determined by left ventricular ejection fraction (LVEF) >= institutional lower limit of normal on echocardiogram or multi-gated acquisition scan (MUGA) within 1 month of registration",lvef
Part B only: Left ventricular ejection fraction (LVEF) >= 50% as determined by echocardiogram or multigated acquisition (MUGA) scan.,lvef
Participant has left ventricular ejection fraction (LVEF) at rest >= 40%.,lvef
"Patient has a high risk of cardiac disease, as determined by the Investigator, may undergo either echocardiogram (ECHO) or multi-gated acquisition (MUGA) during Screening and has a cardiac ejection fraction < 50%.",lvef
"Patient must have a normal cardiac ejection fraction by pretreatment multigated acquisition scan (MUGA) or echocardiogram within 4 weeks prior to registration (resting ejection fraction >= 40% or >= 5% increase with exercise), shortening fraction by echocardiogram >= 24%, or to within the normal range of values for the institution",lvef
Patients known to have impaired left ventricular ejection fraction per institutional standards and of clinical significance as per Investigator review.,lvef
Patients must have ejection fraction >= 45% based on echocardiogram performed within 28 days prior to registration.,lvef
"Shortening fraction >= 27% by echocardiogram, or ejection fraction >= 50% by gated radionuclide study:",lvef
Subject with inadequately controlled heart disease and/or have a known left ventricular ejection fraction < 35%.,lvef
Any major surgery within 28 days of the first dose of study drug or anticipation of the need for major surgery during the course of study treatment,majorsurgery
Any major surgery within 28 days prior to the first dose of GSK525762 and fulvestrant,majorsurgery
Any major surgery within 4 weeks of study treatment. Participants must have recovered from the effects of major surgery or significant traumatic injury at least 14 days before the first dose of study treatment.,majorsurgery
At least 21 days must have elapsed or complete healing of incision must have occurred (whichever occurs sooner) after major surgery which will be defined per investigator discretion.,majorsurgery
At least 4 weeks must have elapsed since any major surgery prior to registration.,majorsurgery
"Has had major surgery (not including placement of central lines) within 7 days prior to study entry or is planned to have major surgery during the course of the study (major surgery may be defined as any invasive operative procedure in which an extensive resection is performed, e.g. a body cavity is entered, organs are removed, or normal anatomy is altered. In general, if a mesenchymal barrier is opened (pleural cavity, peritoneum, meninges), the surgery is considered major)",majorsurgery
Has had major surgery in the past 4 weeks.,majorsurgery
"Have undergone major surgery, other than diagnostic surgery, within 2 weeks prior to Day 1",majorsurgery
Inadequate recovery from toxicity and/or complications from a major surgery before starting therapy.,majorsurgery
Major surgery (as deemed by the Investigator) for any reason OR not fully recovered from surgery within 4 weeks prior to the start of study treatment.,majorsurgery
Major surgery (as defined by the Investigator),majorsurgery
"Major surgery (as defined by the investigator) within 28 days prior to first dose of MEDI4736 or tremelimumab or still recovering from prior surgery. Local procedures (eg, placement of a systemic port, core needle biopsy, and prostate biopsy) are allowed if completed at least 24 hours prior to the administration of the first dose of study treatment.",majorsurgery
"Major surgery (e.g., GI surgery) within 6 weeks before first dose of study treatment or incomplete wound healing from any prior surgery. Patients with clinically relevant ongoing complications (per investigator assessment) from prior surgery are not eligible.",majorsurgery
"Major surgery (e.g., intra-thoracic, intra-abdominal or intra-pelvic) within 4 weeks prior (2 weeks for resection of brain metastases) to starting INC280 or who have not recovered from side effects of such procedure. Video-assisted thoracic surgery (VATS) and mediastinoscopy will not be counted as major surgery and patients can be enrolled in the study >= 1 week after the procedure",majorsurgery
"Major surgery (eg, GI surgery, removal or biopsy of brain metastasis) within 8 weeks before first dose of study treatment, except prior nephrectomy within 6 weeks before first dose. Complete wound healing from major surgery must have occurred 3 weeks before first dose and from minor surgery (eg, simple excision, tooth extraction) at least 10 days before first dose. Subjects with clinically relevant ongoing complications from prior surgery are not eligible.",majorsurgery
"Major surgery (i.e., laparotomy), open biopsy, or significant traumatic injury <= 4 weeks prior to registration; minor surgery <= 2 weeks prior to registration; insertion of a vascular access device is not considered major or minor surgery in this regard",majorsurgery
Major surgery [excluding Central Venous Access Device (CVAD) replacement and bone marrow aspiration and non-open biopsy] within the last 7 days prior to enrollment that may be associated with a risk of bleeding. Open biopsy is considered a major surgery.,majorsurgery
Major surgery <= 1 week prior to randomization,majorsurgery
Major surgery <= 14 days before study registration,majorsurgery
Major surgery <= 14 days before study registration.,majorsurgery
Major surgery <= 14 days prior to C1D1.,majorsurgery
Major surgery <= 14 days prior to registration,majorsurgery
Major surgery <= 14 days prior to registration or has not recovered from major side effects (tumor biopsy is not considered as major surgery),majorsurgery
Major surgery <= 14 days prior to study registration,majorsurgery
Major surgery <= 2 weeks prior to registration,majorsurgery
Major surgery <= 28 days prior to registration.,majorsurgery
Major surgery <= 3 weeks of study treatment.,majorsurgery
Major surgery <= 3 weeks prior to registration or failure to adequately recover from surgery.,majorsurgery
"Major surgery <= 4 weeks from registration. NOTE: Diagnostic laparoscopy (without other intervention) and/or biopsies (needle aspirate, core biopsy, open biopsy, etc&hellip;) are not considered major surgery",majorsurgery
Major surgery <= 4 weeks prior to enrollment (other than diagnostic surgery or surgical spacer placement in preparation for radiation treatment).,majorsurgery
Major surgery <= 4 weeks prior to registration,majorsurgery
Major surgery <= 4 weeks prior to registration (the surgical incision should be fully healed prior to drug administration or radiation therapy),majorsurgery
Major surgery <= 4 weeks prior to registration.,majorsurgery
Major surgery or significant trauma within 28 days before the start of study treatment.,majorsurgery
Major surgery within 14 days before study registration.,majorsurgery
Major surgery within 14 days of registration and patients must have recovered from any effects of any major surgery.,majorsurgery
Major surgery within 14 days prior to start of study treatment,majorsurgery
Major surgery within 28 days before the start of study intervention (excluding prior diagnostic biopsy).,majorsurgery
Major surgery within 28 days prior to planned start of treatment,majorsurgery
Major surgery within 28 days prior to study day 1.,majorsurgery
Major surgery within 28 days prior to the first study treatment.,majorsurgery
Major surgery within 3 months of the first dose of cabozantinib if there were no wound healing complications or within 6 months of the first dose of cabozantinib if there were wound complications,majorsurgery
Major surgery within 3 weeks of starting the study or patient has not recovered from any effects of any major surgery,majorsurgery
Major surgery within 3 weeks prior to first study drug administration.,majorsurgery
Major surgery within 4 weeks before randomization.,majorsurgery
"Major surgery within 4 weeks of the first dose of study drug; following major surgeries > 4 weeks prior to the first dose of study drug, all surgical wounds must be healed and free of infection or dehiscence.",majorsurgery
Major surgery within 4 weeks prior to first dose of TAB001 or still recovering from prior surgery,majorsurgery
Major surgery within 4 weeks prior to lymphodepletion; subjects shouldhave been fully recovered from any surgical related toxicities.,majorsurgery
Major surgery within 6 weeks of enrollment,majorsurgery
Major surgery within 6 weeks prior to randomization.,majorsurgery
Major surgery within four weeks before C1D1.,majorsurgery
Major surgery within four weeks before first IMP administration.,majorsurgery
Major surgery within the previous 4 weeks (the surgical incision should be fully healed prior to the first dose of TAS-120).,majorsurgery
Major surgery without full recovery or major surgery within 3 weeks prior to planned randomization,majorsurgery
"Major surgery, other than diagnostic surgery, within 2 weeks prior to Cycle 1 Day 1, without complete recovery.",majorsurgery
"Major surgery, other than diagnostic surgery, within 4 weeks prior to Cycle 1 Day 1, without complete recovery.",majorsurgery
"Major surgery, other than diagnostic surgery, within 4 weeks prior to the first dose of test drug, minor surgery including diagnostic surgery within 2 weeks (14 days) excluding central IV port placements and needle aspirate/core biopsies, to ensure that wound healing has occurred. Radio frequency ablation or transcatheter arterial chemoembolization within six 6 weeks prior to the first dose of test drug.",majorsurgery
Major surgical procedure (as defined by the investigator) within 28 days prior to the first dose of study drug,majorsurgery
"Major surgical procedure (including open biopsy, significant traumatic injury, etc.) within 28 days, or anticipation of the need for major surgical procedure during the study, and minor surgical procedure (excluding placement of a vascular access device) within 7 days prior to study enrollment.",majorsurgery
Major surgical procedure <= 21 days.,majorsurgery
Major surgical procedure <= 28 days prior to registration or anticipation of need for a major surgical procedure during the course of the study,majorsurgery
"Major surgical procedure other than for diagnosis within 4 weeks prior to initiation of study treatment, or anticipation of need for a major surgical procedure during the course of the study",majorsurgery
"Major surgical procedure within 28 days prior to cycle 1, day 1 or anticipation of need for a major surgical procedure during the course of the study with the exception of the planned breast cancer surgery that is part of the trial design.",majorsurgery
"Major surgical procedure within 28 days prior to Cycle 1, Day 1 or anticipation of need for a major surgical procedure during the course of the study.",majorsurgery
"Major surgical procedure, laparoscopic procedure, or open biopsy within 28 days prior to enrollment.",majorsurgery
"Major surgical procedure, open biopsy, or significant traumatic injury <= 28 days prior to registration ( <= 56 days for hepatectomy, open thoracotomy, major neurosurgery) or anticipation of need for major surgical procedure during the course of the study",majorsurgery
"Major surgical procedure, other than for diagnosis, within 28 days prior to initiation of study treatment, or anticipation of need for non-protocol-mandated major surgical procedure during the study",majorsurgery
"Major surgical procedure, other than for diagnosis, within 4 weeks prior to initiation of study treatment, or anticipation of need for a major surgical procedure during the study",majorsurgery
No major surgery <= 4 weeks before pre-registration.,majorsurgery
No planned major surgery within 4 weeks of first dose of CBT-101.,majorsurgery
"Non-study related minor surgical procedure within < 5 days, or major surgical procedure within < 21 days, prior to first dose of rucaparib; in all cases, the patient must be sufficiently recovered and stable before treatment administration",majorsurgery
"Non-study related minor surgical procedure within < 5 days, or major surgical procedure within < 21 days, prior to first dose of study drug; in all cases, the patient must be sufficiently recovered and stable before treatment administration",majorsurgery
Participants must not have had any major surgery within 4 weeks of study treatment administration. Participants must have recovered from the effects of a major surgery or significant traumatic injury at least 14 days before the first dose of study treatment.,majorsurgery
Patient had major surgery within 4 weeks of starting the study or patient has not recovered from any effects of any major surgery.,majorsurgery
"Patient has had a major surgical procedure within 14 days of the first dose of study drug (procedures such as central venous catheter placement, tumor needle biopsy, and feeding tube placement are not considered major surgical procedures).",majorsurgery
Patient must not have had major surgery within 2 weeks of starting study treatments and patients must have recovered from any effects of any major surgery,majorsurgery
"Patients must have completed any major surgery at least 12 weeks prior to registration and any minor surgery (including uncomplicated tooth extractions) at least 28 days prior to registration; complete wound healing from major surgery must have occurred at least 28 days prior to registration, and complete wound healing from minor surgery must have occurred at least 10 days prior to registration",majorsurgery
Prior major surgery within 4 weeks of starting study drug administration.,majorsurgery
Radiotherapy or major surgery within 2 weeks prior to first dose of study drug.,majorsurgery
Recent major surgery within 4 weeks prior to first BFCR4350A infusion:,majorsurgery
Subject has had a major surgical procedure <= 28 days prior to the first dose of study drug.,majorsurgery
Subject with major surgery within 8 weeks up to the enrollment date. Subject must have completely recovered from any previous surgery immediately up to the enrollment date.,majorsurgery
Subject without complete recovery from a major surgical procedure <= 14 days prior to the first dose of study treatment.,majorsurgery
Subjects who have had major surgery within the 28-days from the screening,majorsurgery
Subjects who have not recovered adequately from any toxicity and/or complications from major surgery prior to starting therapy.,majorsurgery
Surgery with local anesthesia - 3 days,majorsurgery
All patients must have either t(11;14) by karyotype or fluorescent in-situ hybridization (FISH) or positive immunohistochemistry (IHC) for cyclin D1,mantle-cell
Confirmed diagnosis of mantle cell lymphoma with CD20 positivity and chromosome translocation t(11;14) and/or overexpress cyclin D1 in tissue biopsy,mantle-cell
"Confirmed diagnosis of mantle cell lymphoma with CD20 positivity and chromosome translocation t(11;14), (q13",mantle-cell
"Confirmed diagnosis of mantle cell lymphoma with CD20 positivity and chromosome translocation t(11;14), (q13;q32) and/or overexpress cyclin D1 in tissue biopsy",mantle-cell
"Confirmed diagnosis of previously treated relapsed/refractory patients MCL with CD5+, CD23-, CD20+ and chromosome translocation t(11;14), (q13;q32) and/or overexpress cyclin D1 in tissue biopsy (blastoid/pleomorphic morphology, complex karyotype is acceptable).",mantle-cell
"Diagnosis of mantle cell lymphoma (MCL) must include morphology and expression of either cyclin D1 in association with other relevant markers (eg, CD19, CD20, CD5) or evidence of t(11;14) as assessed by cytogenetics, fluorescent in situ hybridization (FISH), or polymerase chain reaction (PCR)",mantle-cell
"for subjects with MCL (confirmed with cyclin D1 expression or evidence of t(11;14) by cytogenetics, fluorescent in situ hybridization (FISH) or polymerase chain reaction (PCR): relapsed or refractory disease after at least 1 prior regimen with chemo-immunotherapy (prior auto-HSCT is allowable)",mantle-cell
Group 3: with only MCL with t(11;14) or overexpression of cyclin D1,mantle-cell
"MCL (diagnosis must be confirmed with cyclin D1 expression or evidence of t(11;14) by cytogenetics, fluorescent in situ hybridization [FISH], or PCR) with relapsed or refractory disease after at least 1 prior line of MCL therapy",mantle-cell
"MCL cohort: Mantle cell lympohma (diagnosis must be confirmed with cyclin D1 expression or evidence of t(11;14) by cytogenetics, fluorescent in situ hybridization [FISH], or PCR) with relapsed or refractory disease ",mantle-cell
"MCL cohort: MCL (diagnosis must be confirmed with cyclin D1 expression or evidence of t(11;14) by cytogenetics, fluorescent in situ hybridization [FISH], or PCR) with relapsed or refractory disease after at least 1 prior line of MCL therapy",mantle-cell
Newly diagnosed MCL: Confirmed diagnosis of MCL with CD20 and cyclin D1 positivity in tissue biopsy; patients must have never received any prior therapy for their disease,mantle-cell
"Pathologically confirmed MCL (in tumor tissue), with  either overexpression of cyclin D1 in association with other relevant markers (eg, CD19, CD20, PAX5, CD5) or evidence of t(11;14) as assessed by cytogenetics, fluorescent in situ hybridization (FISH), or polymerase chain reaction (PCR)",mantle-cell
"Pathologically confirmed MCL (in tumor tissue), with documentation of either overexpression of cyclin D1 in association with other relevant markers (eg, CD19, CD20, PAX5, CD5) or evidence of t(11;14) as assessed by cytogenetics, fluorescent in situ hybridization (FISH), or polymerase chain reaction (PCR)",mantle-cell
"Pathologically confirmed MCL, with documentation of a chromosome translocation t(11;14)(q13;q32) and/or overexpression of cyclin D1 in association with other relevant markers (eg, CD5, CD19, CD20, PAX5) .",mantle-cell
"Pathologically confirmed MCL, with documentation of chromosome translocation t(11;14)(q13;q32) and/or overexpression of cyclin D1 in association with other relevant markers (eg, CD5, CD19, CD20, PAX5).",mantle-cell
"Pathologically confirmed MCL, with documentation of monoclonal CD20+ B cells that have a chromosome translocation t(11;14)(q13;q32) and/or overexpress cyclin D1.",mantle-cell
"Patients must have histologically confirmed (biopsy-proven) diagnosis of mantle cell lymphoma (MCL), with documented cyclin D1 (BCL1) expression by immunohistochemical stains and/or t(11;14) by cytogenetics or FISH.",mantle-cell
"Patients must have histologically confirmed (biopsy-proven) diagnosis of mantle cell lymphoma (MCL), with documented cyclin D1 (BCL1) expression by immunohistochemical stains and/or t(11;14) by cytogenetics or FISH.26",mantle-cell
"Patients must have histologically confirmed mantle cell lymphoma, with cyclin D1 by immunohistochemical stains and/or t(11;14) by cytogenetics or FISH",mantle-cell
"Patients must have histologically confirmed mantle cell lymphoma, with cyclin D1 by immunohistochemical stains and/or t(11;14) by cytogenetics or FISH. The proliferation rate, using Ki-67 or MIB-1, should also be determined, but is not required until Step 1 registration. Patients may register to Step 0 without a documented Ki-67 index.",mantle-cell
"Patients must have histologically confirmed mantle cell lymphoma, with documented cluster of differentiation (CD19) or CD20 expression and cyclin D1 (BCL1) by immunohistochemical stains and/or t(11;14) by cytogenetics or fluorescence in situ hybridization (FISH",mantle-cell
"Patients must have histologically confirmed mantle cell lymphoma, with documented cluster of differentiation (CD19) or CD20 expression and cyclin D1 (BCL1) by immunohistochemical stains and/or t(11;14) by cytogenetics or fluorescence in situ hybridization (FISH); the diagnosis must be confirmed by formal hematopathology review at the enrolling center, including assessment of Ki-67 proliferation index ( <= 30% versus > 30% versus ?indeterminate? Ki-67 index)",mantle-cell
"Patients must have untreated histologically confirmed mantle cell lymphoma, with cyclin D1 (BCL1) expression by immunohistochemical stains and/or t(11;14) by cytogenetics or fluorescent in situ hybridization (FISH)",mantle-cell
"Patients must have untreated histologically confirmed mantle cell lymphoma, with cyclin D1 (BCL1) expression by immunohistochemical stains and/or t(11;14) by cytogenetics or fluorescent in situ hybridization (FISH) on involved tissue biopsy.",mantle-cell
"Patients must have untreated histologically confirmed mantle cell lymphoma, with cyclin D1 (BCL1) expression by immunohistochemical stains and/or t(11;14) by cytogenetics or fluorescent in situ hybridization (FISH). ",mantle-cell
"Patients must have untreated histologically confirmed mantle cell lymphoma, with cyclin D1 (BCL1) expression by immunohistochemical stains and/or t(11;14) by cytogenetics or fluorescent in situ hybridization (FISH). The diagnosis must be confirmed by formal hematopathology review at the enrolling center.",mantle-cell
"Relapsed or refractory, pathologically proven mantle cell lymphoma. Must have a current or prior tissue sample that is IHC positive for cyclin D 1 or that is positive by FISH or cytogenetics for t(11;14).",mantle-cell
Subjects must have histologically or cytologically confirmed MCL as defined by the World Health Organization. All patients must have either t(11;14) by karyotype or fluorescent in-situ hybridization (FISH) or positive immunohistochemistry (IHC) for cyclin D1.,mantle-cell
">= 1 measurable lesion per Response Evaluation Criteria In Solid Tumors (RECIST) Version 1.1 that has not been previously treated with locoregional therapy. A participant with a lesion(s) that has previously been treated with locoregional therapy is also eligible, if the lesion has documented progression after locoregional treatment and is measureable.",measurable
1-3 liver lesions measurable on CT/MRI or PET/CT performed within 6 weeks prior to study entry,measurable
"A minimum of 1 measurable Target Lesion that can be accurately measured by calipers, computed tomography (CT) or magnetic resonance imaging (MRI) consisting of at least one of the following:",measurable
"All patients must have measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1; measurable disease is defined as at least one target lesion that can be accurately measured in at least one dimension (longest diameter to be recorded); each lesion must be >= 10 mm when measured by computed tomography (CT), magnetic resonance imaging (MRI), or caliper measurement by clinical exam; or >= 20 mm when measured by chest x-ray; lymph nodes must be >= 15 mm in short axis when measured by CT or MRI; all imaging studies must be performed within 28 days prior to registration",measurable
"All patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as greater than or equal to 20 mm with conventional techniques or as greater than or equal to 10 mm with spiral CT scan.",measurable
All subjects must have measurable disease in 2-dimensions on MRI scan of the brain; disease should be consistently measured with the two largest perpendicular dimensions,measurable
Any measurable residual disease at the time of screening for the study documented in at least one of the following ways:,measurable
At least 1 measurable disease lesion as defined by RECIST 1.1,measurable
At least 1 measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST 1.1).,measurable
At least 1 measurable lesion.,measurable
At least 1 measurable tumor lesion,measurable
At least 1 measurable tumor lesion per RECIST v1.1 (exception: subjects in Part 1 are not required to present with measurable disease),measurable
At least 1 site of measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1,measurable
At least 1 site of radiographically measurable disease by RECIST 1.1,measurable
At least one additional lesion that is measurable and is not intended for injection (to allow an assessment of systemic antitumor effect). These lesions not intended for injection may be located in any metastatic site.,measurable
At least one endoscopically measurable tumor 6 - 10mm in diameter. Adequate hepatic and renal function. Patient or authorized proxy needs to have signed the informed consent form.,measurable
At least one measurable extra-CNS lesion based upon RECIST version 1.1.,measurable
At least one measurable lesion as defined by RECIST 1.1,measurable
"At least one measurable lesion or evaluable disease. Measurable disease is defined as lesions that can be accurately measured in at least one dimension (longest diameter to be recorded) as >= 10 mm with CT scan, as >= 20 mm by chest x-ray, or >= 10 mm with calipers by clinical exam.",measurable
"At least one measurable target lesion, as defined by RECIST v1.1",measurable
At least one radiologically measurable target lesion per RECIST version 1.1,measurable
"At least one site of disease outside of the liver that is seen on standard imaging (e.g. CT, bone scan, MRI, FDG PET/CT); patients with measurable or nonmeasurable disease are allowed.",measurable
"Contrast-enhanced computed tomography (CT) scans of the neck, chest, abdomen and pelvis are required; a whole body positron emission tomography (PET)/CT scan with diagnostic quality images and intravenous iodinated contrast may be used in lieu of a contrast enhanced CT of the neck, chest, abdomen and pelvis; contrast may be omitted if the treating investigator believes that exposure to contrast poses an excessive risk to the patient; patients must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1; all measurable lesions must be assessed within 28 days prior to registration; tests to assess non-measurable disease must be performed within 42 days prior to registration; all disease must be assessed and documented on the Baseline Tumor Assessment Form (RECIST 1.1)",measurable
Disease in the liver must be measurable by computed tomography (CT) and/or magnetic resonance imaging (MRI).,measurable
Disease is measurable or evaluable as defined by RECIST (1.1 or original version) or other tumor response criteria from an MSKCC IRB-approved clinical research protocol.,measurable
"Disease may be measurable (by Response Evaluation Criteria in Solid Tumors [RECIST] 1.1 criteria) or non-measurable but must be present in at least one non-liver site, where presence is defined as 1.5 cm or greater and visualized on PET/CT with [18F]-fluorodeoxyglucose (FDG); patients with effusion only disease or disease only in the liver are not eligible for the study",measurable
Disease must be measurable by RECIST 1.1.,measurable
Disease must be measurable with at least 1 uni dimensional measurable lesion by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.,measurable
"Disease status: Subjects must have measurable or evaluable disease, by RECIST v1.1 ± Curie Scale Criteria or RANO/RANO-BM",measurable
Dose expansion only: Subjects must have at least one measurable site of disease according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria; this lesion must be outside a previously irradiated area,measurable
"Evidence of measurable disease (per Response Evaluation Criteria in Solid Tumors version 1.1 [RECIST 1.1]) outside of the peritoneal cavity (ex: mediastinal lymphadenopathy, parenchymal liver metastasis, or symptomatic pleural effusion proven or suspected to be due to cancer)",measurable
For non-measurable disease:,measurable
For Part 1: Participant must have evaluable disease. For Part 2: Participant must have measurable disease according to Response Criteria in Solid Tumors (RECIST) v1.1,measurable
For patients enrolled in Arm B (first stage of phase II of TRC102 and pemetrexed) measurable disease is required according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria for patients with solid tumors and modified RECIST criteria as described by Byrne and Novak for patients with malignant pleural mesothelioma; pleural effusion and ascites are not considered measurable disease,measurable
"For patients enrolled in the Dose Escalation Phase, one or more tumors measurable on radiograph or CT scan, or evaluable disease defined as non-measurable lesions per RECIST v. 1.1 (e.g., malignant ascites). All patients enrolled to the Randomized Study Phase must have measurable disease only.",measurable
"For patients with measurable disease, progression by the RECIST criteria.",measurable
"Has at least one measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI), according to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1.",measurable
Has measurable disease,measurable
Has measurable disease based on either RECIST 1.1 for solid tumors or RANO for CNS tumors,measurable
"Has measurable disease, defined as at least 1 tumor that fulfills the criteria for a target lesion according to RECIST 1.1, or lymphoma that fulfills the Deauville PET Criteria",measurable
Have at least one measurable lesion of >= 2 cm by conventional methods or >= 1 cm on spiral CT,measurable
Have evidence of measurable or unmeasurable disease.,measurable
Have measurable disease,measurable
Have measurable disease based on immune related response criteria (irRC) criteria,measurable
Have measurable disease based on RECIST 1.1,measurable
Have measurable disease based on RECIST 1.1.,measurable
Have measurable disease based on RECIST 1.1. for patients with solid malignancies or evaluable disease as assessed by bone scan and/or PET scan. Patients with advanced or metastatic prostate cancer can have either androgen-sensitive or castration-resistant disease.,measurable
Have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1,measurable
Have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.,measurable
Have measurable disease per RECIST version 1.1.,measurable
Have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria present,measurable
Have measurable disease. Patients must have clinically and/or radiographically documented measurable primary disease according to RECIST 1.1. At least one site of disease must be unidimensionally measurable. All radiology scans must be performed within 28 days prior to registration,measurable
"Have on CT imaging done within 28 days of Day 1 findings consistent with advanced ccRCC, including at least one extra-renal measurable target lesion meeting the criteria of RECIST version 1.1.",measurable
Have one measurable lesion of at least 1 cm outside the planned radiation field (defined as not receiving direct beam from any of the treatment portals).,measurable
Have residual disease following surgical resection that is measurable by RECIST v1.1,measurable
Have tumor lesions considered measurable by the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1,measurable
INCLUSION CRITERIA FOR STRATUM C: All subjects must have measurable disease in 2-dimensions on MRI scan of the brain and/or spine; disease should be consistently measured with the two largest perpendicular dimensions,measurable
Measurable disease,measurable
"Measurable disease - Patients must have measurable disease, which includes lesions that can be accurately measured in at least one dimension (longest diameter to be recorded) as >= 2 cm with conventional techniques OR >= 1 cm by spiral CT scan",measurable
"Measurable disease (i.e., present with at least one measurable lesion per RECIST, version 1.1.",measurable
Measurable disease according to RECIST criteria,measurable
Measurable disease according to RECIST v1.1 and obtained by imaging within 28 days prior to registration for protocol therapy. Disease in an irradiated field as the only site of measurable disease is acceptable only if there has been clear progression since completion of radiation treatment.,measurable
Measurable disease according to RECIST v1.1 that has been confirmed by computed tomography (CT) or magnetic resonance imaging (MRI) within 4 weeks prior to Cycle 1/Day 1 (C1/D1).,measurable
Measurable disease according to Response Criteria in Solid Tumors (RECIST) version 1.1.,measurable
Measurable disease after diagnostic biopsy,measurable
Measurable disease as defined by any of the following:,measurable
Measurable disease as defined by irRC or RECIST 1.1 criteria,measurable
Measurable disease as defined by RECIST v1.1 criteria. Baseline measurements and evaluation of ALL sites of disease must be obtained within 4 weeks prior to Enrollment.,measurable
Measurable disease as per RECIST 1.1,measurable
Measurable disease as per RECIST v1.1 criteria,measurable
measurable disease based on central protein assessment,measurable
"Measurable disease based on RECIST 1.1 (Or based on IWG [Cheson, 2007] [i.e., measurement must be > 15 mm in longest diameter or > 10 mm in short axis] for rrcHL participants)",measurable
Measurable disease based on RECIST v1.1.,measurable
Measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.,measurable
Measurable disease by CT or MRI per response evaluation criteria in solid tumors version 1.1 (RECIST 1.1) criteria,measurable
Measurable disease by IMWG as defined by at least one of the following:,measurable
Measurable disease by physical examination or imaging as defined by RECIST v1.1 criteria or evaluable disease as defined by Gynecologic Cancer Intergroup (GCIG) CA125 criteria.,measurable
Measurable disease by RECIST 1.1,measurable
Measurable disease by RECIST criteria,measurable
Measurable disease by RECIST v 1.1 criteria or non- measurable disease that is clinically evaluable (bone only disease allowed if evaluable),measurable
Measurable disease by RECIST v1.1,measurable
Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1 or other tumor-specific criteria or disease assessable by physical exam or other methods if not measurable by RECIST,measurable
Measurable disease by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) and Immune related Response Criteria (irRC).,measurable
"Measurable disease defined as lesions that can be accurately measured in at least one dimension (longest diameter to be recorded) as >= 10 mm with CT scan or MRI, as >= 20 mm by chest x-ray, or >= 10 mm with calipers by clinical exam.",measurable
Measurable disease defined as lesions that can be accurately measured in at least one dimension (longest diameter to be recorded) by ultrasound or mammogram.,measurable
Measurable disease defined by any of following: Serum M-protein > 1 g/dL,measurable
measurable disease includes at least one of the following criteria,measurable
"Measurable disease is defined at least one lesion that can be accurately measured in at least one dimension (longest dimension to be recorded); each  target  lesion must be >= 20 mm when measured by conventional techniques, including palpation, plain x-ray, computed tomography (CT), and magnetic resonance imaging (MRI), or >= 10 mm when measured by spiral CT",measurable
"Measurable disease M protein component in serum (at least 0.5 g/dL) and/or urine (if present), ( >= 0.2 g excreted in a 24 hour collection sample).",measurable
Measurable disease of multiple myeloma as defined by at least ONE of the following:,measurable
Measurable disease on MRI scan.,measurable
Measurable disease on preoperative imaging,measurable
Measurable disease outlined in RECIST 1.1,measurable
Measurable disease per RECIST 1.1 criteria,measurable
Measurable disease per RECIST 1.1. See Section 10 for the evaluation of measurable disease.,measurable
Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST 1.1),measurable
Measurable disease per Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1,measurable
Measurable disease within the past 4 weeks defined by any one of the following:,measurable
"Measurable disease, as defined by RECIST v1.1",measurable
"Measurable disease, as indicated by one or more of the following:",measurable
"Measurable disease, defined as >= 1 lesions that can be accurately measured in >= 1 dimensions as >= 20 mm with conventional techniques or as >= 10 mm with spiral CT scan",measurable
"Measurable disease, defined as a lesion that can be accurately measured in at least one dimension",measurable
"Measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as > 20 mm with conventional techniques or as > 10 mm with spiral computed tomography (CT) scan, Magnetic resonance imaging (MRI), or calipers by clinical exam. See Section 13.",measurable
"Measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as >= 20 mm ( >= 2 cm) with conventional techniques or as >= 10 mm ( >= 1 cm) with spiral computed tomography (CT) scan, magnetic resonance imaging (MRI), or calipers by clinical exam",measurable
"Measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension by Response Evaluation Criteria in Solid Tumors (RECIST) criteria 1.1",measurable
Measurable disease:,measurable
Measurable disease: >= 50% increase in the sum of the cross products of all measurable lesions or the development of new measurable lesions; the short axis of a target lymph node must be at least 15 mm by spiral CT to be considered a target lesion,measurable
Measurable metastatic disease by RECIST criteria,measurable
Measurable or evaluable disease per Response Evaluation Criteria in Solid Tumors (RECIST),measurable
"Measurable or evaluable indicator lesion(s) as defined by RECIST v1.1. Patients without RECIST measurable disease will be eligible for enrollment to  Other  cohort provided their disease can be evaluated using another accepted response criteria (e.g. Gynecologic Cancer InterGroup (GCIG) CA125 Response Criteria, PET Response Criteria in Solid Tumors (PERCIST).",measurable
Measurable or non-measurable (but evaluable disease) according to RECIST v1.1.,measurable
Measurable or non-measurable (but evaluable) disease as defined via RECIST 1.1,measurable
Measurable or nonmeasurable disease by RECIST criteria (at least one target or nontarget lesion),measurable
Measurable or non-measurable disease by Response Evaluation Criteria in Solid Tumor (RECIST) 1.1 will be allowed,measurable
Measurable or non-measurable disease per RECIST criteria 1.1,measurable
"Measurable plasmacytoma; if plasmacytoma measurement is the only measurable disease, subject eligibility must be reviewed with lead principal investigator (PI) prior to signing consent",measurable
Measurable target tumors using standard imaging techniques (RECIST v. 1.1 criteria).,measurable
Measureable disease with CT or MRI,measurable
Multiple myeloma monoclonal for Kappa-light chain with measurable disease after receiving at least one chemotherapy regimen,measurable
Must have measurable disease defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded as > 20 mm with conventional techniques or > 10 mm with spiral CT scanning).,measurable
Must have measurable or evaluable disease,measurable
Must have one or more tumors measurable on radiographic imaging as defined by the Response Evaluation Criteria in Solid Tumors (RECIST). Patients with evaluable but not measurable disease per RECIST criteria may be enrolled with the approval of the medical monitor.,measurable
One measurable site of disease (according to RECIST criteria) or bone disease by NaF PET/CT,measurable
One or more tumors measurable on CT scan.,measurable
Participants must have measurable disease according to RECIST,measurable
Participants must have measurable disease by RECIST version 1.1.,measurable
"Participants must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as >= 20 mm with conventional techniques or as >= 10 mm with spiral computed tomography (CT) scan, magnetic resonance imaging (MRI), or calipers by clinical exam; scans must have been performed within 4 weeks prior to registration; Note: for participants with Kaposi sarcoma, the following apply: at least five measurable cutaneous KS lesions or any number of lesions with systemic unresectable disease with no previous local radiation, surgical, or intralesional cytotoxic therapy that would prevent response assessment",measurable
"Patient has measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) guidelines (version 1.1, 2009) for advanced solid tumors or RANO criteria (2010) for brain tumors.",measurable
Patient much have measurable disease as defined by RECIST 1.1.,measurable
Patient must have measurable disease defined by RECIST 1.1 criteria.,measurable
Patients in Part 2 extension must have at least one measurable lesion as defined by modified Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria,measurable
Patients must have at least 1 measurable metastatic lesion by RECIST1.1 criteria.,measurable
Patients must have at least one biopsiable and measurable metastatic melanoma lesions >= 1 cm (Turnstile II),measurable
"Patients must have at least one biopsiable measurable metastatic melanoma, lesion >= to 1 cm (Turnstile II)",measurable
Patients must have at least one lesion that meets the definition of measurable disease by RECIST 1.1,measurable
Patients must have measurable disease,measurable
"Patients must have measurable disease (RECIST 1.1). Measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded). Each lesion must be greater than or equal to 10 mm when measured by CT, MRI or caliper measurement by clinical exam; or greater than or equal to 20 mm when measured by chest x-ray. Lymph nodes must be greater than or equal to 15 mm in short axis when measured by CT or MRI.",measurable
Patients must have measurable disease according to International Myeloma Working Group (IMWG) criteria; measurable disease includes at least one of the following criteria:,measurable
"Patients must have measurable disease according to the standard Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, computed tomography (CT) scans or magnetic resonance imaging (MRI)s used to assess the measurable disease must have been completed within 28 days prior to study drug initiation",measurable
"Patients must have measurable disease as defined by RECIST v1.1 (at least one lesion >= 10mm in at least one dimension when assessed by CT or MRI, or a cutaneous lesion with clearly defined margins that measures >= 10 mm in at least one dimension)",measurable
Patients must have measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1,measurable
"Patients must have measurable disease as defined by the International Uniform Response Criteria,defined as any of the following:",measurable
"Patients must have measurable disease as defined by World Health Organization (WHO) criteria: at least 1 lesion that can be accurately measured in at least 1 dimension (longest diameter to be recorded). Each lesion must be > 1.0cm when measured by CT, MRI, or caliper measurement by clinical exam; or > 2.0cm when measured by chest x-ray. Lymph nodes must be > 1.5cm in short axis when measured by CT or MRI",measurable
Patients must have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1,measurable
Patients must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1,measurable
Patients must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria; baseline measurements and evaluations of all sites of disease must be obtained within 4 weeks prior to randomization and must be acquired by multiphasic computed tomography (CT) or contrast magnetic resonance imaging (MRI),measurable
"Patients must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, defined as at least one lesion that can be accurately measured in at least one dimension >= 10 mm ( >= 1 cm) by computed tomography (CT) imaging or magnetic resonance imaging (MRI) within 42 days prior to registration; the CT from a combined positron emission tomography (PET)/CT may be used only if it is of diagnostic; laboratory parameters are not acceptable as the only evidence of disease",measurable
"Patients must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, defined as at least one lesion that can be accurately measured in at least one dimension >= 10 mm ( >= 1 cm) by computed tomography (CT) imaging or magnetic resonance imaging (MRI) within 28 days prior to start of protocol therapy; the CT from a combined positron emission tomography (PET)/CT may be used if it is of diagnostic quality; laboratory parameters are not acceptable as the only evidence of disease",measurable
Patients must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteria,measurable
Patients must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1,measurable
"Patients must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST), defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as >= 20 mm by chest x-ray or as >= 10 mm with computed tomography (CT) scan, magnetic resonance imaging (MRI), or calipers by clinical exam",measurable
Patients must have measurable disease defined as at least one of the following:,measurable
"Patients must have measurable disease documented by computed tomography (CT) or magnetic resonance imaging (MRI); the CT from a combined positron emission tomography (PET)/CT may be used to document only non-measurable disease unless it is of diagnostic quality; measurable disease must be assessed within 28 days prior to sub-study registration; pleural effusions, ascites and laboratory parameters are not acceptable as the only evidence of disease; non-measurable disease must be assessed within 42 days prior to sub-study registration; all disease must be assessed and documented on the Baseline Tumor Assessment Form; patients whose only measurable disease is within a previous radiation therapy port must demonstrate clearly progressive disease (in the opinion of the treating investigator) prior to registration",measurable
"Patients must have measurable disease in the brain, defined as at least one lesion that can be accurately measured in at least one dimension as >= 10 mm by brain magnetic resonance imaging (MRI); MRI of the brain (with and without gadolinium enhancement) is to be performed using standard 5-mm slices with 2.5-mm spacing for comparison to subsequent MRI scans",measurable
Patients must have measurable disease in the pancreas; computed tomography (CT) scans or magnetic resonance imaging (MRIs) used to assess measurable disease must have been completed within 28 days prior to registration; all disease must be assessed and documented on the baseline tumor assessment form,measurable
"Patients must have measurable disease with at least one lesion whose longest diameter can be accurately measured as >= 2.0 cm with conventional techniques or as >= 1.0 cm with spiral computed topography (CT); if spiral CT is used, it must be used for both pre- and post- treatment tumor assessments",measurable
"Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as > 20 mm with conventional techniques or as > 10 mm with spiral CT scan, MRI, or calipers by clinical exam. See Section 11 for the evaluation of measurable disease.",measurable
"Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as >= 20 mm ( >= 2 cm) with conventional techniques or as >= 10 mm ( >= 1 cm) with spiral computed tomography (CT) scan, magnetic resonance imaging (MRI), or calipers by clinical exam",measurable
"Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as >= 20 mm with conventional techniques or as >= 10 mm with spiral CT scan, magnetic resonance imaging (MRI), or calipers by clinical exam",measurable
"Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as >= 20 mm with conventional techniques or as >= 10 mm with spiral computed tomography (CT) scan, magnetic resonance imaging (MRI), or calipers by clinical exam",measurable
"Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for nonnodal lesions and short axis for nodal lesions). Nodal lesions must be (Bullet) 15mm by CT scan or MRI. Non nodal lesions must be > 10 mm with CT scan or MRI.",measurable
"Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as >= 20 mm with conventional techniques or as >= 10 mm with spiral computed tomography (CT) scan",measurable
"Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as >= 20 mm with conventional techniques or as >= 10 mm with spiral computed tomography (CT) scan for the evaluation of measurable disease (Response Evaluation Criteria in Solid Tumors version 1.1 [RECIST v1.1])",measurable
"Patients must have measurable disease, defined by RECIST 1.1",measurable
"Patients must have measurable disease, defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1",measurable
"Patients must have measurable disease, per RECIST 1.1. Subjects with evaluable, but not measurable disease will be eligible for Phase 1.",measurable
Patients must have measurable disease; all sites of disease must be evaluated within 4 weeks prior to randomization,measurable
Patients must have measurable or evaluable disease for the dose escalation portion of the study and measurable disease for the expanded cohort portion of the study (except for patients in the CNS metastases and leptomeningeal cohorts).,measurable
Patients must have measurable primary tumor (undetectable NSCLC primary tumor is ineligible),measurable
"Patients must have radiographically measurable disease (with the exception of neuroblastoma), Measurable disease is defined as the presence of at least one lesion on magnetic resonance imaging (MRI) or computed tomography (CT) scan that can be accurately measured with the longest diameter a minimum of 10 mm in at least one dimension (CT scan slice thickness no greater than 5 mm).",measurable
"Patients with at least one measurable liver tumor, with size > 1cm (modified RECIST criteria)",measurable
Patients with measurable disease defined as at least one of the following:,measurable
"Phase 2: Patients must have measurable disease based on RECIST 1.1 criteria, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as > 20 mm with conventional techniques or as > 10 mm with spiral CT scan or MRI (except for lymph nodes, which must be > 15 mm).",measurable
Phase I (Cohorts A through S) and Phase II: Evaluable or measurable disease per RECIST version 1.1,measurable
"Phase I (Cohorts T, and T2): Greater than or equal to ( >= ) 1 bi-dimensionally measurable lesion on computed tomography (CT) scan",measurable
PHASE I: Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1,measurable
PHASE IB: Measurable disease according to RECIST v1.1,measurable
"PHASE IB: Patients in the expansion cohort must have a measurable site of disease according to RECIST (v 1.1) that has not been previously irradiated, or evidence of at least 20% progression in a previously irradiated lesion, and assessed by imaging within 28 days prior to registration for protocol therapy",measurable
Phase II cohorts only: patients must have measurable disease according to RECIST v.1.1 criteria. Patients enrolled in Ph Ib cohorts must have evaluable disease,measurable
Phase II study: measurable disease by RECIST 1.1 criteria; if archival tumor sample is not available tumor sample from fresh biopsy is acceptable,measurable
Phase II: Patients must have measurable disease. Phase II temporarily suspended as requested by the FDA due to IND Safety Report of 07 October 2016,measurable
Presence of at least one measurable lesion according to RECIST v.1.1,measurable
Presence of at least one measurable lesion according to RECIST v1.1.,measurable
"Presence of measurable disease (RECIST 1.1): At least one lesion, not previously irradiated, that can be accurately measured at baseline as >= 10 mm in the longest diameter (except lymph nodes which must have short axis >= 15 mm) with computed tomography (CT) or magnetic resonance imaging (MRI) and which is suitable for accurate repeated measurements.",measurable
Presence of measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 or Lugano Classification for subjects with DLBCL.,measurable
Previously irradiated sites of tumor may be considered measurable if there is radiographic progression at that site subsequent to the time of completing radiation.,measurable
Progression of bidimensionally measurable soft tissue or nodal metastasis assessed within one month prior to registration by a CT scan or MRI.,measurable
Radiation therapy must be completed at least 2 weeks prior to study entry; radiated lesions may not serve as measurable disease unless they have been radiated over 12 months prior to enrollment,measurable
Radiographically evaluable or measurable solid tumor target lesion(s).,measurable
Radiographically measurable disease by RECIST v1.1,measurable
Radiographically measurable disease per RECIST 1.1.,measurable
Radiologically measurable and clinically evaluable disease,measurable
Radiologically-measurable disease,measurable
RECIST defined measurable disease is not required,measurable
RECIST-defined measurable disease,measurable
"STEP I: Patients must have measurable or evaluable disease as defined by having one or more of the following, obtained within 28 days prior to randomization:",measurable
Subject has measurable disease according to RECIST v1.1 criteria prior to lymphodepletion.,measurable
Subject in Phase 2 only: must have measurable disease per RECIST 1.1.,measurable
Subject must have measurable disease per Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1 or disease evaluable by assessment of tumor antigens including but not limited to cancer antigen (CA-125) and prostate-specific antigen (PSA).,measurable
Subjects must have at least one measurable lesion as defined by RECIST v1.1,measurable
"Subjects must have either measurable (the presence of at least one lesion that can be accurately measured in at least one dimension with the longest diameter at least 20 mm. With spiral CT scan, lesions must be at least 10 mm.) or evaluable disease (the presence of at least one lesion that cannot be accurately measured in at least one dimension. Such lesions may be evaluable by nuclear medicine techniques, immunocytochemistry techniques, tumor markers or other reliable measures.)",measurable
Subjects must have measurable and accessible disease.,measurable
Subjects must have measurable disease,measurable
"Subjects must have measurable disease (by RECIST 1.1), defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as >= 20 mm with conventional techniques or as >= 10 mm with spiral CT scan",measurable
Subjects must have measurable disease according to RECIST (version 1.1),measurable
Subjects must have measurable liver tumors and lesions that are suitable for injection.,measurable
"Target Lesion(s) must have measurable disease, defined as a unidimensionally measurable lesion >= 1.0 cm in longest diameter by helical CT; the maximum diameter of Target Lesion(s) shall be <= 4.9 cm.",measurable
"the disease must be measurable, defined as clinically or radiographically measureable target lesion in the breast that is >= 1 cm in diameter",measurable
There must be documentation that the patient has evidence of measurable metastatic breast cancer that is accessible to biopsy at study entry.,measurable
"Tumor size is clinically at least 1 cm in greatest diameter (palpable or by imaging) and/or with involved lymph node. In case of inflammatory disease, the extent of inflammation may be the measurable lesion.",measurable
Tumor to be irradiated is measurable by RECIST 1.1 or PRC,measurable
< 60 years with  premature menopause  or  premature ovarian failure  manifest itself with secondary amenorrhea for at least 1 year and follicle stimulating hormone (FSH) and estradiol levels in the postmenopausal range according to institutional standards; or,menopause
< 60 years with  premature menopause  or  premature ovarian failure&rdquo; manifest itself with secondary amenorrhea for at least 1 year and follicle stimulating hormone (FSH) and estradiol levels in the postmenopausal range according to institutional standards; or,menopause
Age < 60 and amenorrhea > 12 consecutive months and documented follicle stimulating hormone (FSH) level within post-menopausal range according to institutional standard.,menopause
"Age < 60 and amenorrhea for 12 or more months (in the absence of chemotherapy, tamoxifen, toremifene, or ovarian suppression) and FSH and/or estradiol in the postmenopausal range per local normal range.",menopause
"Age < 60 years AND have had cessation of regular menses for at least 12 consecutive months with no alternative pathological or physiological cause and have serum levels of estradiol and follicle-stimulating hormone within the laboratory's reference range for postmenopausal females Or pre- or perimenopausal and amenable to being treated with the luteinizing hormone-releasing hormone (LHRH) agonist goserelin Patients must have commenced treatment with goserelin or an alternative LHRH agonist at least 28 days prior to first dose of treatment. If patients have received an alternative LHRH agonist prior to study entry, they must switch to goserelin for the duration of the trial.",menopause
"Age < 60 years with amenorrhea >= 1 year since last menses with no alternative pathological or physiological cause (including ongoing or recent chemotherapy, treatment with tamoxifen or toremifene, or a GnRH agonist), and serum estradiol and follicle stimulating hormone (FSH) level within the laboratory reference range for post-menopausal women",menopause
"Age < 60 years with no menses for > 1 year with FSH and estradiol levels within postmenopausal range, according to institutional standard",menopause
"Age < 60 years with no menses for > 1 year with FSH and estradiol levels within postmenopausal range, according to institutional standard.",menopause
"Age < 60 years with tamoxifen or toremifene therapy within the last 12 months, with documentation of 12 months of amenorrhea prior to tamoxifen or toremifene therapy and serum estradiol and FSH levels within the laboratory reference range for post-menopausal women",menopause
"All women will, by definition, be considered menopausal due to surgical removal of both ovaries prior to trial enrollment.",menopause
Any menopausal status:,menopause
"Are postmenopausal for at least 1 year before the screening visit, OR",menopause
"Be either: Postmenopausal, defined as:",menopause
chemotherapy-induced menopause with > 1 year interval since last menses.,menopause
Current use of systemic or topical exogenous estrogen or progesterone (menopausal hormone replacement therapy [HRT]).,menopause
"Female subjects must be post-menopausal women, defined by 1 of the following criteria:",menopause
Female subjects must be postmenopausal women.,menopause
"Females must be postmenopausal ( > 12 months without menses) or surgically sterile (i.e., by hysterectomy and/or bilateral oophorectomy).",menopause
"Females with hormonally-induced menopause (ie, requiring ongoing hormone suppression) are not eligible",menopause
For all Parts except Part F and H: Participants must have either post-menopausal status or pre-menopausal status if continuing or beginning ovarian suppression with a luteinizing hormone-releasing hormone (LHRH) agonist such as goserelin.,menopause
"has not been naturally postmenopausal for at least 24 consecutive months (e.g., has had menses at any time in the preceding 24 consecutive months.",menopause
"has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months).",menopause
"If on tamoxifen or toremifene with in the past 14 days, plasma estradiol and FSH must be in the premenopausal range per local normal range; or",menopause
"If patient is taking tamoxifen or toremifene and age < 60, then FSH and plasma estradiol levels should be in post-menopausal range per local normal range.",menopause
"In case of therapy induced amenorrhea, plasma estradiol and/or FSH must be in the premenopausal range per local normal range.",menopause
"In case of women, both premenopausal and postmenopausal patients are allowed to be included in this study; menopausal status is relevant for the requirement of goserelin or leuprolide to be used concomitantly with alpelisib in combination with fulvestrant or letrozole.",menopause
"In premenopausal women, serum estradiol level in postmenopausal range <= 7 days prior to registration.",menopause
"In the absence of 12 months of amenorrhea, FSH measurements indicating post-menopausal status must be documented in patient's medical history",menopause
"Is postmenopausal, defined as no menses for at least 12 months without an alternative medical cause; a high follicle-stimulating hormone (FSH) level consistently in the postmenopausal range (30 mIU/mL or higher) may be used to confirm a postmenopausal state in women not using hormonal contraception or hormonal replacement therapy; however, in the absence of 12 months of amenorrhea, a single FSH measurement is insufficient to confirm a postmenopausal state; or",menopause
Is post-menopausal.,menopause
or is menopausal (age >= 50 years with amenorrhea for >= 6 months,menopause
Participants must be fully postmenopausal.,menopause
Patient is postmenopausal woman defined as either:,menopause
Patient is premenopausal defined as either:,menopause
"Patient must be post-menopausal based on either a history of an oophorectomy, or >= 1 year of amenorrhea. An elevated serum gonadotropin level and estradiol level in the postmenopausal range (as locally defined) can be used to confirm menopausal status in a subject with < 1 year of amenorrhea.",menopause
"Patients must not have remaining ovarian function to be included. In women who have at least one retained ovary, menopause must be confirmed with laboratory confirmation. Women who have ovarian function are eligible but must be placed on hormonal suppression. Menopause must be confirmed with laboratory confirmation, to include an estradiol level as this is assessed within 8 weeks of patient having been on tamoxifen.",menopause
Postmenopausal (defined as at least 1 year without menses) prior to screening; or,menopause
"Postmenopausal (defined as at least 12 months with no menses without an alternative medical cause; in women < 45 years of age, a high follicle stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a postmenopausal state in women not using hormonal contraception or hormonal replacement therapy;In the absence of 12 months of amenorrhea, a single FSH measurement is insufficient); OR",menopause
Postmenopausal by history with no menses for 1 year and confirmed by FSH (using local reference ranges,menopause
postmenopausal by history with no menses for 1 year and confirmed by FSH (using local reference ranges); or,menopause
Post-menopausal defined as:,menopause
"Postmenopausal for at least 1 year before the screening visit, or",menopause
Postmenopausal for at least 1 year prior to registration,menopause
"Postmenopausal is defined as at least 12 months with no menses without an alternative medical cause; in women < 45 years of age a high follicle stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a post -menopausal state in women not using hormonal contraception or hormonal replacement therapy. In the absence of 12 months of amenorrhea, a single FSH measurement is not sufficient.",menopause
"Postmenopausal woman (i.e., surgically sterile with a hysterectomy and/or bilateral oophorectomy OR >= 12 months of amenorrhea and at least 50 years of age)",menopause
Post-menopausal women defined as aged more than 50 years and amenorrhoeic for at least 12 months following cessation of all exogenous hormonal treatment.,menopause
Postmenopausal women defined as:,menopause
Postmenopausal* (defined as at least 1 year without any menses) prior to screening; or,menopause
Pre- or postmenopausal. Postmenopausal women are defined as:,menopause
"Pre-menopausal females with one of the following: Documented tubal ligation, Documented hysteroscopic tubal occlusion procedure with follow-up confirmation of bilateral tubal occlusion, Hysterectomy, Documented Bilateral Oophorectomy",menopause
"Pre-menopausal women receiving ovarian function suppression (goserelin, leuprolide, etc.).",menopause
Premenopausal/perimenopausal women must have ovarian function suppression.,menopause
Surgical menopause with bilateral oophorectomy.,menopause
Women must be postmenopausal.,menopause
> 200 mg of monoclonal protein in the urine on 24 hour electrophoresis,m-protein
> 200 mg of monoclonal protein in the urine on 24-hour electrophoresis,m-protein
>= 0.5 g/dL monoclonal protein (M-protein) on serum protein electrophoresis,m-protein
>= 200 mg of monoclonal protein in the urine on 24 hour electrophoresis,m-protein
>= 200 mg of monoclonal protein in the urine on 24-hour electrophoresis,m-protein
>= 200 mg of monoclonal protein on a 24 hour urine protein electrophoresis (within 28 days prior to randomization).,m-protein
>= 200 mg/24 hrs of monoclonal protein (M-protein) on a 24 hour urine protein electrophoresis,m-protein
25% increase in serum M-protein from lowest response value during (or after) last therapy and/or absolute increase in serum M-protein of > or equal to 0.5 g/dL,m-protein
25% increase in serum M-protein from the lowest response value during (or after) last therapy and/or absolute increase in serum M-protein of >= 0.5 g/dL,m-protein
25% increase in urine M-protein from lowest response value during (or after) last therapy and/or absolute increase in urine M-protein of > or equal to 200 mg/24h,m-protein
25% increase in urine M-protein from the lowest response value during (or after) last therapy and/or absolute increase in urine M-protein of >= 200 mg/24 h,m-protein
a serum M protein > 0.5 g/dL measured by serum protein electrophoresis (SPEP),m-protein
M-protein (serum and/or urine protein electrophoresis (sPEP or uPEP)): sPEP >= 0.5 g/dL or uPEP >= 200 mg/24 hours,m-protein
M-protein (serum and/or urine protein electrophoresis (sPEP or uPEP)): sPEP >= 0.5 g/dL or uPEP >= 200 mg/24 hours; and/or,m-protein
M-protein (serum protein electrophoresis [sPEP] or urine protein electrophoresis [uPEP]): sPEP >= 0.5 g/dL or uPEP >= 200 mg/24 hours,m-protein
M-protein (serum protein electrophoresis [sPEP] or urine protein electrophoresis [uPEP]): sPEP >= 0.5 g/dL or uPEP >= 200 mg/24 hours and/or,m-protein
M-protein (serum protein electrophoresis [sPEP] or urine protein electrophoresis [uPEP]): sPEP >= 0.5 g/dL or uPEP >= 200 mg/24 hours; and/or,m-protein
Serum M protein >= 0.5 g/dL ( >= 5 g/L),m-protein
serum monoclonal component >= 0.5 g/dL,m-protein
serum monoclonal component >= 0.5 g/dL; or,m-protein
Serum monoclonal paraprotein (M-protein) level greater than or equal to ( >= ) 1.0 gram per deciliter (g/dL,m-protein
Serum monoclonal paraprotein (M-protein) level greater than or equal to ( >= ) 1.0 gram per deciliter (g/dL); or,m-protein
Serum monoclonal protein (M-protein) >= 0.5 g/dL ( >= 5 g/L),m-protein
Serum monoclonal protein >= 0.5 g/dL (see Section 11.1 for definition),m-protein
Serum monoclonal protein >= 1.0 g by protein electrophoresis,m-protein
Serum monoclonal protein >= 1.0 g/dL,m-protein
Serum monoclonal protein >= 1.0 g/dL by protein electrophoresis,m-protein
Serum M-protein > 0.5 g/dL,m-protein
serum M-protein > 0.5g/dl and/or,m-protein
Serum M-protein > 1 g/dL,m-protein
Serum M-protein >= 0.5 g/dL,m-protein
Serum M-protein >= 0.5 g/dL ( >= 5 g/L),m-protein
"Serum M-protein >= 0.5 g/dL or for IgA myeloma, an elevated IgA level by quantitative IgA nephelometry",m-protein
Serum M-protein >= 1 g/dL,m-protein
Serum M-protein >= 1.0 g/dL ( >= 10 g/L,m-protein
Serum M-protein >= 1.0 g/dL ( >= 10 g/L); OR,m-protein
Serum M-protein >= 500 mg/dL ( >= 5 g/L) on serum protein electrophoresis (SPEP).,m-protein
Serum M-protein >= 500 mg/dL ( >= 5 g/L) on SPEP.,m-protein
Serum M-protein greater or equal to 0.5 g/dL,m-protein
Serum M-protein greater or equal to 1.0 g/dL,m-protein
Serum M-protein greater than or equal to 1 g/dL,m-protein
Serum M-protein greater than or equal to 1 g/dL; OR,m-protein
Serum M-protein level >= 3 gm/dL,m-protein
Sserum M protein > 0.5 g/dl measured by serum protein electrophoresis,m-protein
urinary M protein excretion > 200 mg/24 hours,m-protein
Urine M protein >= 200 mg/24 hours,m-protein
Urine M-protein > 200 mg/24 h,m-protein
urine M-protein > 200 mg/24 hours and/or,m-protein
Urine M-protein > 200 mg/24h,m-protein
Urine M-protein >= 200 mg / 24h,m-protein
Urine M-protein >= 200 mg in a 24-hour collection,m-protein
Urine M-protein >= 200 mg/24 h on urine protein electrophoresis (UPEP).,m-protein
Urine M-protein >= 200 mg/24 hour,m-protein
Urine M-protein >= 200 mg/24 hours,m-protein
Urine M-protein >= 200 mg/24 hours on UPEP.,m-protein
Urine M-protein >= 200 mg/24 hours; OR,m-protein
Urine M-protein >= 200 mg/24 hr,m-protein
Urine M-protein >= 200 mg/24 hrs,m-protein
Urine M-protein greater or equal to 200 mg/24 h,m-protein
Urine M-protein greater than or equal to 200 mg/24 hours,m-protein
Urine M-protein greater than or equal to 200 mg/24 hours; OR,m-protein
Urine M-protein level >= 200 milligram per 24 hours (mg/24 hours,m-protein
Urine M-protein level >= 200 milligram per 24 hours (mg/24 hours); or,m-protein
Urine protein 2+ or less,m-protein
"Abdominal imaging is required only if ALT, AST or Alkaline Phosphatase is elevated or if there are signs or symptoms of metastatic disease",multlabs
"Absolute neutrophil count (ANC) < 1.5x10^9/L, platelet count < 100x10^9/L, or hemoglobin < 9.0 g/dL. Blood transfusion within 1 week prior to enrollment for the purpose of increasing the likelihood of eligibility is not allowed",multlabs
"Absolute neutrophil count (ANC) > 750/mm3 (µL) / platelet count > 40,000/mm^3 (µL)",multlabs
"Absolute neutrophil count (ANC) >= 1000/mm3 and platelet count >= 75,000/mm3, without growth factor or transfusion support",multlabs
"Absolute neutrophil count >= 1,500/mcl - Platelets >= 100,000/mcl",multlabs
"Absolute neutrophils count (ANC) >= 1.5x10^9/L, platelets >= 100x10^9/L, hemoglobin > 9 g/dL (without transfusion or erythropoiesis stimulating agents dependency).",multlabs
Adequate bone marrow function defined as: absolute neutrophil count (ANC) >= 1.0x10^9 cells/L and platelets >= 50x10^9 cells/L in absence of bone marrow involvement,multlabs
"Adequate bone marrow function: absolute neutrophil count (ANC) >= 1,000/mL; hemoglobin >= 8.5 g/dL, platelets >= 75,000/mL",multlabs
"Adequate hematopoietic function: total white blood cell (WBC) count >= 1500/mm3, absolute neutrophil count (ANC) >= 1000/mm3, hemoglobin (Hb) >= 10.0 g/dL, and platelet count >= 75,000/mm3.",multlabs
"Alanine amino transferase (ALT) < 2.5 X ULN, with normal bilirubin.",multlabs
"alkaline phosphatase (ALP), alanine aminotransferase (ALT) or aspartate aminotransferase (AST) < 5.0 X ULN",multlabs
ALT (SGPT) = alanine aminotransferase (serum glutamic pyruvic transaminase); AST (SGOT) = aspartate aminotransferase (serum glutamic oxaloacetic transaminase); GFR = glomerular filtration rate; ULN = upper limit of normal. a Criteria must be met without erythropoietin dependency and without packed red blood cell (pRBC) transfusion within last 2 weeks. b Creatinine clearance (CrCl) should be calculated per institutional standard. Note: This table includes eligibility-defining laboratory value requirements for treatment; laboratory value requirements should be adapted according to local regulations and guidelines for the administration of specific chemotherapies,multlabs
ALT = alanine aminotransferase; ANC = absolute neutrophil count; AST = aspartate aminotransferase; ULN = upper limit of normal,multlabs
"Aspartate aminotransferase (AST) < 2.5 X ULN, with normal bilirubin. NOTE: Concomitant elevations in bilirubin and AST above 1.5 x ULN (upper limit of normal) is not permitted.",multlabs
"Aspartate aminotransferase (AST/SGOT), alanine amino-transferase (ALT/SGPT) and alkaline phosphatase <= 2.5x ULN. If liver metastases are present, then <= 5x ULN is allowed.",multlabs
"AST, ALT, and alkaline phosphatase (ALP) <= 2.5 x upper limit of normal (ULN) with the following exceptions:",multlabs
"At least one cytopenia (ANC < 1800/µL or platelet count < 100,000/µL or hemoglobin [Hgb] < 10 g/dL)",multlabs
"Bone Marrow: Absolute neutrophil count (ANC) >= 1,500/mm3; Platelets >= 100,000/mm3; Hemoglobin >= 9.0 g/dL",multlabs
"Bone scans (with x-rays of abnormal areas) are required only if alanine aminotransferase (ALT), aspartate aminotransferase (AST) or Alkaline Phosphatase is elevated or if there are signs or symptoms of metastatic disease",multlabs
"For subjects with liver metastases: Total bilirubin <= 3.0 x ULN, AST/ ALT <= 5 x ULN",multlabs
Have serum creatinine < 2.0 mg/dl and SGOT or SGPT < 3 times upper limits of normal <= 120 days prior to registration,multlabs
"Hematologic: Absolute neutrophil count (ANC) >= 1.5x10^9/L, platelets >= 100x10^9/L, and hemoglobin >= 8 g/dL. Patients may receive erythrocyte transfusions to achieve this hemoglobin level at the discretion of the investigator. Initial study treatment must not begin earlier than the day after the erythrocyte transfusion.",multlabs
"Hematological Absolute neutrophil count (ANC) >= 1,500 /mcL Platelets >= 100,000 / mcL Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or EPO dependency (within 7 days of assessment) Renal Serum creatinine OR Measured or calculated creatinine clearance (CrCL; GFR can also be used in place of creatinine or CrCl) <= 1.5 X upper limit of normal (ULN) OR",multlabs
Hemoglobin >= 10 g/dL ANC >= 1.5x10^9/L,multlabs
"hemoglobin >= 8.5 g/dL, platelets >= 75,000/mL",multlabs
"Hepatic: Bilirubin <= 1.5 times upper limits of normal (ULN), alanine aminotransferase (ALT) <= 3.0 times ULN.",multlabs
"Inadequate bone marrow function defined by absolute neutrophil count (ANC) < 1000 cells/mm^3 in the absence of growth factor support (Neupogen within 7 days or Neulasta within 14 days) and platelet count < 50,000 cells/mm^3, in the absence of transfusion support (platelet transfusion within 7 days).",multlabs
Inadequate hepatic function defined by AST and/or ALT > 2.5 x upper limit of normal (ULN) and total bilirubin > 1.5 x ULN (unless due to Gilbert&rsquo;s syndrome and direct bilirubin is <= 1.5 x ULN).,multlabs
"laboratory levels of total bilirubin, ALT, and AST within normal range, assessed within 30 days of consenting to the treatment phase.",multlabs
"Leukocytes >= 3,000/microliter (mcL), absolute neutrophil count >= 1,500/mcL, platelets >= 100,000/mcL",multlabs
Liver dysfunction manifested by SGTP (ALT) > 5X Upper limit of normal (ULN) and/or Aspartate aminotransferase (AST) > 5 X ULN and/or direct (conjugated) bilirubin > 2X ULN,multlabs
"No cytopenias - absolute neutrophil count (ANC) < 1000 or platelets < 100,000",multlabs
Patient has total bilirubin < 2x the upper limit of normal (ULN; unless elevated bilirubin is attributed to Gilbert's Syndrome) and both alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 3x ULN.,multlabs
Serum Albumin >= 2.8g/dLSerum total bilirubin < 2.5 mg/dL (42 _mol/L),multlabs
Serum aspartate aminotransferase (AST) > 3 x the upper limit of normal (ULN) or serum total bilirubin > 2 mg/dL (except for patients in whom hyperbilirubinemia is attributed to Gilbert's syndrome),multlabs
Serum creatinine <= 1.5 mg/dL or a measured creatinine clearance >= 60 mL/min; and Negative serum &beta;-hCG (human chorionic gonadotropin) test in women of childbearing potential (defined as women <= 50 years of age or > 50 years of age with a history of amenorrhea for <= 12 months prior to study entry).,multlabs
Total bilirubin must be < 2 X ULN within 2 weeks prior to registration - Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) <= 2.5 X institutional upper limit of normal within 2 weeks prior to registration,multlabs
"WBC > 2.0x10^3/uL Platelets > 50,000/uL Bilirubin < 2.0 mg/dL Creatinine < 2.0 mg/dL AST/ALT < 3.0 x ULN",multlabs
WBC > 2.5 x 10^9/L with an ANC > 1.5 x 10^9/L and off G-CSF for 3 days,multlabs
"WBC > 3000/mm3, platelets > 100,000 mm3.",multlabs
"WBC >= 2000/uL, ANC >= 1500/uL, PLT >= 100,000/uL, HGB >= 8 g/dL",multlabs
"WBC >= 3000/µL Neutrophils >= 1500/ µL Platelets >= 100,000/µL Hemoglobin >= 9.0 g/dL (may have been transfused) Creatinine <= 1.5 mg/dL AST/ALT <= 2.5 X ULN for subject with no liver metastases",multlabs
"WBC >= 3000/mcl Absolute neutrophil count (ANC) >= 1500/mcl Platelet count >= 100,000/mcl SGOT, SGPT, and alkaline phosphatase <= 2.5 X upper limit of normal (ULN) Bilirubin <= 1.5 X ULN Creatinine <= institutional ULN",multlabs
"WBC count <= 25,000 cells/mm��?? (25 x 10 exp 9/L); use of leukapheresis or hydroxyurea (48 hours) before venetoclax initiation is allowed to achieve this entry criterion.",blood-count
White blood cell (WBC) count >= 2.5x10^9/L (2.5 x 10^9/L is equivalent to 2.5 x 10^3/µL and 2.5 x K/µL and 2.5 x 10^3/cumm and 2500/µL) OR absolute neutrophil count (ANC) >= 1.5 x 10^9/L (1.5 x 10^9/L is equivalent to 1.5 x 10^3/µL and 1.5 x K/µL and 1.5 x 10^3/cumm and 1500/µL),multlabs
White blood cell (WBC) count >= 2000/µL,blood-count
White blood cell (WBC) count >= 2000/µL.,blood-count
White blood cells (WBC) > 2.5 x 10^9/L with an absolute neutrophile count (ANC) > 1.5 x 10^9/L and off G-CSF or GM-CSF for 10 days or Neulasta for 21 days,multlabs
"White blood cells (WBC) > 3000, Hemoglobin ( Hgb) > 9, platelets > 100000 within 30 days of consent",multlabs
<= grade 2 peripheral neuropathy,neuropathy
> Grade 1 peripheral neuropathy within 14 days before enrollment.,neuropathy
>= Grade 3 peripheral neuropathy within 14 days before enrollment.,neuropathy
Absence of significant neuropathy ( >= CTCAE Grade 2).,neuropathy
Autoimmune (demyelinating) neuropathy,neuropathy
Baseline grade > 2 peripheral neuropathy,neuropathy
Baseline neuropathy > grade,neuropathy
Baseline neuropathy of > grade 2,neuropathy
Baseline of grade 2 or worse peripheral sensory neuropathy,neuropathy
Baseline peripheral neuropathy/paresthesia grade >= 1.,neuropathy
Clinically significant peripheral neuropathy at the time of study entry. Patients with pre-existing peripheral neuropathy will be allowed to receive single agent DKN-01,neuropathy
CTCAE Gr >= 2 neuropathy,neuropathy
CTCAE grade 3 or higher peripheral neuropathy,neuropathy
"CTCAE v.4.03, Grade > 2 peripheral neuropathy",neuropathy
Current Grade > 1 peripheral neuropathy.,neuropathy
"Current use of other adjuvant pharmacologic interventions (e.g., duloxetine, gabapentin, pregabalin, venlafaxine) with known or hypothesized effectiveness for treatment or prevention of peripheral neuropathy at study entry.",neuropathy
Evidence of clinically significant peripheral neuropathy as defined by patient report of frequent numbness or tingling in the hands or feet.,neuropathy
Evidence of peripheral neuropathy of any grade within 28 days prior to initiation of dosing.,neuropathy
EXCEPTION: Grade 1 peripheral (sensory) neuropathy that has been stable for at least 3 months since completion of prior treatment,neuropathy
Existing neuropathy must be no greater than Grade 1.,neuropathy
Family history of a genetic/familial neuropathy.,neuropathy
Family history of genetic/familial neuropathy.,neuropathy
For Cohort B: Has peripheral neuropathy Common Terminology Criteria for Adverse Events >= 2 except due to trauma,neuropathy
Grade > 2 neuropathy,neuropathy
Grade >= 2 peripheral neuropathy as defined by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.0 criteria (cisplatin),neuropathy
Grade >= 2 peripheral neuropathy within 14 days prior to initiation of therapy,neuropathy
Grade 2 or greater neuropathy [Applies to Phase 1]. Grade 3 or greater neuropathy [Applies to Phase 2].,neuropathy
Grade 2 or higher peripheral neuropathy.,neuropathy
Grade 3 or worse peripheral neuropathy as defined by CTCAE v4.1.,neuropathy
Grade II or higher neuropathy,neuropathy
"Has any unresolved toxicity >= Grade 2 from previous anticancer therapy except for stable chronic toxicities ( <= Grade 2) not expected to resolve, such as stable Grade 2 peripheral neuropathy.",neuropathy
Has peripheral neuropathy CTCAE >= 2 except due to trauma.,neuropathy
Have significant baseline neuropathies,neuropathy
History of peripheral neuropathy prior to receiving neurotoxic chemotherapy.,neuropathy
"if Grade 2 neuropathies have been stable for at least 3 months since completion of prior treatment, patient is eligible.",neuropathy
Motor peripheral neuropathy = grade 0 (per CTCAE v. 4.0),neuropathy
Neurologic function: neuropathy (sensory and motor) less than or equal to Common Terminology Criteria for Adverse Events (CTCAE) grade 1,neuropathy
Neuropathy ( >= grade 2 CTCAE),neuropathy
Neuropathy (sensory and motor) less than or equal to CTCAE grade 1,neuropathy
Neuropathy > Grade 3.,neuropathy
Neuropathy caused by cisplatin,neuropathy
No >= grade 2 sensory peripheral neuropathy,neuropathy
No baseline peripheral sensory neuropathy >= grade 2,neuropathy
No grade >= 2 peripheral motor or sensory neuropathy,neuropathy
No peripheral neuropathy > grade 2 at baseline.,neuropathy
Non-tolerable > Grade 2 neuropathy or evidence of unstable neurological symptoms within 4 weeks of Cycle 1 Day 1.,neuropathy
Ongoing grade 2 or higher peripheral neuropathy.,neuropathy
Ongoing sensory or motor neuropathy Grade >= 2.,neuropathy
"Patient has >= grade 2 peripheral neuropathy, or grade 1 with pain on clinical examination during the screening period",neuropathy
Patient has >= grade 3 peripheral neuropathy or grade 2 with pain on clinical examination during the screening period.,neuropathy
"Patient has >= grade 3 peripheral neuropathy, or grade 2 with pain on clinical examination during the screening period",neuropathy
"Patient has >= Grade 3 peripheral neuropathy, or Grade 2 with pain on clinical examination during the screening period.",neuropathy
Patients must have < grade 2 neuropathy (sensory/motor) within 7 days prior to registration,neuropathy
Patients must have < Grade 2 pre-existing peripheral neuropathy (per CTCAE 4.03).,neuropathy
Patients must not have > grade 2 neuropathy and/or POEMS.,neuropathy
Patients must not have a history of peripheral neuropathy of Grade 2 or greater by Common Terminology Criteria for Adverse Events (CTCAE) 5.0. In CTCAE version 5.0 Grade 2 sensory neuropathy is defined as  moderate symptoms; limiting instrumental activities of daily living (ADLs),neuropathy
"Patients must not have CTCAE >= Grade 2 neuropathy (cranial, motor or sensory) within 14 days prior to registration.",neuropathy
Patients must not have grade 2 or greater peripheral sensory neuropathy.,neuropathy
Patients must not have grade 2 or higher peripheral neuropathy per CTCAE.,neuropathy
Patients must not have grade 3 or higher peripheral neuropathy or history of grade 3 or higher peripheral neuropathy. Patients with familial demyelinating disease like Charcot-Marie-Tooth disease are also excluded.,neuropathy
Patients must not have grade 3 or higher peripheral neuropathy or history of grade 3 peripheral neuropathy. Patients with familial demyelinating diseases like Charcot-Marie-Tooth disease also excluded.,neuropathy
Patients must not have peripheral neuropathy >= Grade 2.,neuropathy
Patients with > Grade 1 neuropathy at screening,neuropathy
Patients with >= grade 2 baseline neuropathy,neuropathy
Patients with >= grade 2 neuropathy,neuropathy
Patients with a peripheral neuropathy > grade 1,neuropathy
Patients with active >= Common Terminology Criteria for Adverse Events (CTCAE) version (v.) 4 grade 2 neuropathy are ineligible,neuropathy
patients with grade >= 2 neuropathy will be evaluated on a case-by-case basis after consultation with the study physician,neuropathy
Patients with Grade 2 or higher peripheral neuropathy.,neuropathy
Patients with peripheral neuropathy must have < grade 2 at date of registration.,neuropathy
Patients with preexisting grade II peripheral neuropathy,neuropathy
Peripheral neuropathy <= CTC AE grade 2.,neuropathy
Peripheral neuropathy > grade 1,neuropathy
Peripheral neuropathy >= grade 3 on clinical examination or grade 2 with pain during the screening period,neuropathy
Peripheral neuropathy >= Grade 3 on clinical examination or Grade 2 with pain during the screening period.,neuropathy
Peripheral neuropathy >= Grade 3 on clinical examination or grade 2 with pain within 30 days prior to C1D1.,neuropathy
Peripheral neuropathy >= Grade 3 or >= Grade 2 with pain within 2 weeks prior to first dose.,neuropathy
Peripheral neuropathy grade 0 or 1 by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0,neuropathy
Peripheral Neuropathy greater than Grade 1,neuropathy
Peripheral Neuropathy greater than Grade 1 for Arm B receiving nab-paclitaxel,neuropathy
Peripheral sensory neuropathy at the thumbs bilaterally that interferes with function and/or activities of daily living,neuropathy
Peripheral sensory neuropathy Grade >= 2.,neuropathy
Peripheral sensory or motor neuropathy must have resolved to Grade <= 2.,neuropathy
Preexisting neuropathy is not allowed from any cause.,neuropathy
Pre-existing neuropathy of >= Grade 2.,neuropathy
Pre-existing peripheral neuropathy > Grade 1 (using CTCAE v 4.3 criteria),neuropathy
Presence of >= grade 2 peripheral neuropathy.,neuropathy
Previous diagnosis of diabetic or other peripheral neuropathy.,neuropathy
Sensory or motor neuropathy >= grade 2.,neuropathy
Sensory peripheral neuropathy <= Grade 1 (per CTCAE v. 4.0) Motor peripheral neuropathy = Grade 0 (per CTCAE v. 4.0),neuropathy
Sensory peripheral neuropathy grade 4 within 14 days of enrollment,neuropathy
"Significant neuropathy (grades 3-4, or grade 2 with pain) at the time of the first dose and/or within 14 days before enrollment",neuropathy
Significant neuropathy > Grade 2 at the time of first dose or within 14 days of enrollment,neuropathy
Subject has a history of >= Grade 3 peripheral neuropathy.,neuropathy
Subjects with <= grade 2 neuropathy are an exception to this criterion and may qualify for the study,neuropathy
Subjects with peripheral neuropathy >= Grade 2,neuropathy
Uncontrolled neuropathy Grade 2 or greater regardless of cause.,neuropathy
"Uncontrolled neuropathy grade 2 or greater, regardless of cause",neuropathy
With sensory or motor neuropathy of NCI CTCAE Grade >= 3.,neuropathy
(Male subjects must agree to use contraception during the study for 180 days after administration of study drug).,no-pregnancy-nursing
(WOCBP) as defined in Appendix 3: Contraceptive Guidance and Pregnancy Testing or A WOCBP who agrees to follow the contraceptive guidance in Appendix 3: Contraceptive Guidance and Pregnancy Testing during the treatment period and for at least 180 days (corresponding to time needed to eliminate any study treatment(s) [pembrolizumab and or any active combination] plus 30 days [a menstruation cycle] for study treatments with risk of genotoxicity) after the last dose of study treatment.,no-pregnancy-nursing
) patient must have negative pregnancy test within 72 hours of beginning treatment if WOCBP,no-pregnancy-nursing
"**True abstinence is acceptable when this is in line with the preferred and usual lifestyle of the subject. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception.",no-pregnancy-nursing
*A female of childbearing potential (FCBP) is a female who:,no-pregnancy-nursing
*Female of reproductive potential is any sexually mature female who:,no-pregnancy-nursing
"*True abstinence is acceptable when it is in line with the preferred and usual lifestyle of the subject. [Periodic abstinence (e.g., calendar, ovulation, symptothermal, postovulation methods) and withdrawal are not acceptable methods of contraception.]",no-pregnancy-nursing
"*True abstinence is acceptable when this is in line with the preferred and usual lifestyle of the subject. [Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception].",no-pregnancy-nursing
Highly effective forms of birth control include:,no-pregnancy-nursing
"[Periodic abstinence (e.g., calendar, ovulation, symptothermal, postovulation methods) and withdrawal are not acceptable methods of contraception.]",no-pregnancy-nursing
100% commitment to abstinence,no-pregnancy-nursing
"14 days and again within 24 hours prior to starting cycle 1 of lenalidomide; further, they must either commit to complete abstinence (true abstinence is acceptable when this is in line with the preferred and usual lifestyle of the subject; periodic abstinence [e.g., calendar, ovulation, symptothermal or post ovulation methods] and withdrawal are not acceptable methods of contraception) from heterosexual intercourse or begin TWO acceptable methods of birth control: one highly effective method and one additional effective method AT THE SAME TIME, at least 28 days before starting lenalidomide; while taking lenalidomide, during dose interruptions, and for at least 28 days after the last dose of lenalidomide; FCBP must also agree to ongoing pregnancy testing; men must agree to use a latex condom during sexual contact with a FCBP, even if they have had a successful vasectomy; a FCBP is a female who:",no-pregnancy-nursing
30 days after the last dose of venetoclax Male subjects must also agree to refrain from sperm donation until 90 days after the last dose of protocol treatment,no-pregnancy-nursing
30 days after the last dose of venetoclax Male subjects must also agree to refrain from sperm donation until 90 days after the last dose of protocol treatment.,no-pregnancy-nursing
"A female is eligible if she is not pregnant or breastfeeding, and at least one of the following conditions applies:",no-pregnancy-nursing
A female of childbearing potential (FCBP) for this study is defined as a female who:,no-pregnancy-nursing
A female of childbearing potential (FCBP) is a female who:,no-pregnancy-nursing
A female of childbearing potential is a sexually mature female who has not undergone a hysterectomy or bilateral oophorectomy and has not been naturally postmenopausal for at least 12 consecutive months.,no-pregnancy-nursing
A female of childbearing potential is a sexually mature female who:,no-pregnancy-nursing
"A female of childbearing potential is any woman, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria:",no-pregnancy-nursing
"A female of child-bearing potential is defined as any female who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) or who is not postmenopausal. Menopause is defined clinically as 12 months of amenorrhea in a female over 45 in the absence of other biological or physiological causes. In addition, females under the age of 55 must have a documented serum follicle stimulating hormone (FSH) level less than 40 mIU/mL.",no-pregnancy-nursing
"A female of child-bearing potential is defined as any female who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) or who is not postmenopausal.; menopause is defined clinically as 12 months of amenorrhea in a female over 45 in the absence of other biological or physiological causes; in addition, females under the age of 55 must have a documented serum follicle stimulating hormone (FSH) level less than 40 mIU/mL.",no-pregnancy-nursing
"A female of child-bearing potential is defined as any female who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) or who is not postmenopausal; menopause is defined clinically as 12 months of amenorrhea in a female over 45 in the absence of other biological or physiological causes; in addition, females under the age of 55 must have a documented serum follicle stimulating hormone (FSH) level less than 40 mIU/mL",no-pregnancy-nursing
A female of childbearing potential must avoid pregnancy while taking study drug(s) and for at least 30 days after the last dose of study drug. Females must commit to one of the methods of birth control described in the protocol.,no-pregnancy-nursing
A female of reproductive potential is a sexually mature female who: has not undergone a hysterectomy or bilateral oophorectomy,no-pregnancy-nursing
A female of reproductive potential is a sexually mature female who: has not undergone a hysterectomy or bilateral oophorectomy; or has not been naturally postmenopausal for at least 24 consecutive months (i.e. has had menses at any time in the preceding 24 consecutive months).,no-pregnancy-nursing
"A female participant is eligible to participate if she is not pregnant (as confirmed by a negative serum human chorionic gonadotrophin [hCG] test), not nursing, and at least one of the following conditions apply: Reproductive potential: participants must agree to follow one of the options and the duration specified in protocol; Non-reproductive potential defined as",no-pregnancy-nursing
"A female participant is eligible to participate if she is not pregnant (see Appendix 3) not breastfeeding, and at least one of the following conditions applies:",no-pregnancy-nursing
"A female participant is eligible to participate if she is not pregnant (see Appendix 3: Contraceptive Guidance and Pregnancy Testing), not breastfeeding, and at least one of the following conditions applies:",no-pregnancy-nursing
"A female participant is eligible to participate if she is not pregnant (see Appendix 5), not breastfeeding, and at least one of the following conditions applies:",no-pregnancy-nursing
"A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies:",no-pregnancy-nursing
A female patient is eligible to participate if she is not pregnant and at least one of the following conditions apply:,no-pregnancy-nursing
A female patient who is pregnant or breast-feeding,no-pregnancy-nursing
A female subject is eligible to participate if she is not pregnant or lactating and at least 1 of the following conditions applies:,no-pregnancy-nursing
"A female who is pregnant or breastfeeding or planning to become pregnant or breastfeed during treatment and for an additional 48 hours (Period 1) or 96 hours (Period 2), respectively, after the last dose of blinatumomab (Female subjects of childbearing potential should only be included in the study after a confirmed menstrual period and a negative highly sensitive urine or serum pregnancy test).",no-pregnancy-nursing
A male participant must agree to use a contraception during the treatment period and for at least 120 days after the final dose of study treatment and refrain from donating sperm during this period.,no-pregnancy-nursing
A male participant must agree to use a contraception during the treatment period and for at least 120 days after the last dose of study treatment. Participants must refrain from donating sperm during this period.,no-pregnancy-nursing
A male participant must agree to use a contraceptive as detailed in Appendix 5 of this protocol during the treatment period and for at least 120 days after the last dose of study treatment and refrain from donating sperm during this period.,no-pregnancy-nursing
A male participant must agree to use contraception during the intervention period and for at least 150 days after the last dose of study drug and refrain from donating sperm during this period.,no-pregnancy-nursing
"A male participant must agree to use contraception during the treatment period and for at least 100 days thereafter, including refraining from donating sperm during this period.",no-pregnancy-nursing
"A male participant must agree to use contraception, as detailed in Appendix 3:",no-pregnancy-nursing
A male participant with female partner of child bearing potential must agree to use one of the methods of contraception for the duration specified in protocol.,no-pregnancy-nursing
"A male patient must agree not to donate sperm starting at screening and throughout the study period, and for at least 120 days after the final study drug administration.",no-pregnancy-nursing
"A male patient with female partner(s) of child-bearing potential must agree to use contraception during the treatment period, and for at least 120 days after the final study drug administration.",no-pregnancy-nursing
A male subject must not donate sperm during the treatment period and for at least 6 months after the final study drug administration.,no-pregnancy-nursing
A male subject with female partner(s) of child-bearing potential must agree to use contraception during the treatment period and for at least 6 months after the final study drug administration.,no-pregnancy-nursing
"A man who is sexually active with a woman of childbearing potential must agree to use a condom with spermicidal foam/gel/film/cream/suppository and his partner must also be practicing a highly effective method of contraception (ie, established use of oral, injected or implanted hormonal methods of contraception; placement of an intrauterine device [IUD] or intrauterine system [IUS]).",no-pregnancy-nursing
A negative pregnancy test (if female of childbearing potential).,no-pregnancy-nursing
A negative pregnancy test (if female),no-pregnancy-nursing
A negative pregnancy test (if female).,no-pregnancy-nursing
"A negative pregnancy test will be required for all women of child bearing potential. Females of child bearing potential should agree to practice 2 effective methods of contraception, at the same time, from the time of signing the informed consent form through 90 days after the last dose of study drug and must also adhere to the guidelines of any treatment-specific pregnancy prevention program, if applicable, or agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject. (Periodic abstinence [e.g., calendar, ovulation, symptothermal, postovulation methods] and withdrawal are not acceptable methods of contraception.). Breast-feeding is not permitted.",no-pregnancy-nursing
A negative serum or urine pregnancy test at screening.,no-pregnancy-nursing
A negative serum pregnancy test for all female subjects (except those of non-childbearing potential) within 10 to 14 days prior to initiating therapy and a negative urine pregnancy test within 24 hours for all female subjects (except those of non-childbearing potential) at baseline prior to the first dose of study drug.,no-pregnancy-nursing
"A negative serum pregnancy test for all female subjects of childbearing potential at the screening visit and a negative urine pregnancy test for all female subjects of childbearing potential on Day 1, before the first dose of study drug.",no-pregnancy-nursing
A negative serum pregnancy test within 14 days of study Day 0 for females of childbearing potential,no-pregnancy-nursing
"A negative serum pregnancy test within 14 days of study Day 0, for females of childbearing potential",no-pregnancy-nursing
A positive serum pregnancy test due to fertility preservation will not be an exclusion after physician review,no-pregnancy-nursing
A sexually active male patient with female partner(s) who are of childbearing potential is eligible if:,no-pregnancy-nursing
A urine pregnancy test may be performed if the serum pregnancy result is not available before dosing.,no-pregnancy-nursing
A WOCBP Subjects who may become pregnant or who are sexually active with a partner who could become pregnant are agrees to use an effective form of barrier contraception during the study and for at least 60 days in monotherapy (for the pembrolizumab combination please see supplement DEC for the pregnancy criteria) for female subjects (Male subjects must agree to use contraception during the study for 180 days after administration of study drug).,no-pregnancy-nursing
A WOCBP Subjects who may become pregnant or who are sexually active with a partner who could become pregnant are agrees to use an effective form of barrier contraception during the study and for at least 60 days in monotherapy and 180 days after the last dose of study treatment for female subjects.,no-pregnancy-nursing
A WOCBP who agrees to follow the contraceptive guidance during the intervention period and for at least 150 days after the last dose of study intervention.,no-pregnancy-nursing
A WOCBP who agrees to follow the contraceptive guidance in Appendix 5 during the treatment period and for at least 120 days after the last dose of study treatment.,no-pregnancy-nursing
A WOCBP who has a positive pregnancy test prior to treatment.,no-pregnancy-nursing
"A WOCBP who has a positive urine pregnancy test (e.g. within 72 hours) prior to treatment. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.",no-pregnancy-nursing
A WOCBP who has a positive urine pregnancy test within 24 hours before the first dose of study treatment.,no-pregnancy-nursing
"A WOCBP who has a positive urine pregnancy test within 72 hours before the first dose of study treatment (see Appendix 5). If the urine test cannot be confirmed as negative, a serum pregnancy test will be required. Note: in the event that 72 hours have elapsed between the screening pregnancy test and the first dose of study treatment, another pregnancy test (urine or serum) must be performed and must be negative in order for subject to start receiving study medication.",no-pregnancy-nursing
"A WOCBP who has a positive urine pregnancy test within 72 hours before the first dose of study treatment. If the urine test cannot be confirmed as negative, a serum pregnacy test is required.",no-pregnancy-nursing
"A WOCBP who has a positive urine pregnancy test within 72 hours prior to first dose of study drug. (see Appendix C). If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.",no-pregnancy-nursing
"A WOCBP who has a positive urine pregnancy test within 72 hours prior to treatment allocation. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.",no-pregnancy-nursing
"A woman is considered to be of childbearing potential if she is post-menarcheal, has not reached a post-menopausal state ( >= 12 continuous months of amenorrhea with no identified cause other than menopause), and has not undergone surgical sterilization (removal of ovaries and/or uterus).",no-pregnancy-nursing
"A woman is considered to be of childbearing potential if she is postmenarcheal, has not reached a postmenopausal state ( >= 12 continuous months of amenorrhea with no identified cause other than menopause), and has not undergone surgical sterilization (removal of ovaries and/or uterus).",no-pregnancy-nursing
"A woman is considered to be of childbearing potential if she is postmenarcheal, has not reached a postmenopausal state ( >= 12 continuous months of amenorrhea with no identified cause other than menopause), and has not undergone surgical sterilization (removal of ovaries and/or uterus). The definition of childbearing potential may be adapted for alignment with local guidelines or requirements.",no-pregnancy-nursing
"A woman of child bearing potential (WOCBP) who has a positive urine pregnancy test within 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required. Note: in the event that 72 hours have elapsed between the screening pregnancy test and the first dose of study treatment, another pregnancy test (urine or serum) must be performed and must be negative in order for subject to start receiving study medication",no-pregnancy-nursing
A woman of childbearing potential is a sexually mature woman who:,no-pregnancy-nursing
"A woman of child-bearing potential is any female (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:",no-pregnancy-nursing
A woman of childbearing potential must have a negative serum (β-human chorionic gonadotropin [β-hCG]) at screening.,no-pregnancy-nursing
abstain from sex during study participation and for 60 days after the last dose of TTI-621,no-pregnancy-nursing
"Abstinence (relative to heterosexual activity) can be used as the sole method of contraception if it is consistently employed as the subject's preferred and usual lifestyle and if considered acceptable by local Regulatory Agencies and ERCs/IRBs. Periodic abstinence (e.g., calendar, ovulation, sympto-thermal, post-ovulation methods, etc.) and withdrawal are not acceptable methods of contraception.",no-pregnancy-nursing
Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the participant.,no-pregnancy-nursing
Acceptable forms of contraception:,no-pregnancy-nursing
"Acceptable forms of secondary contraception, when used along with a barrier method:",no-pregnancy-nursing
"Acceptable methods of contraception are condoms with contraceptive foam, oral, implantable or injectable contraceptives, contraceptive patch, intrauterine device, diaphragm with spermicidal gel, or a sexual partner who is surgically sterilized or post-menopausal.",no-pregnancy-nursing
Active Pregnancy,no-pregnancy-nursing
"Additionally, male subjects (including those who are vasectomized) whose partners are pregnant or might be pregnant must agree to use condoms for the duration of the study and for 90 days following completion of therapy",no-pregnancy-nursing
Adequate Contraception,no-pregnancy-nursing
"Adequate forms of contraception are double-barrier methods (condoms with spermicidal jelly or foam and diaphragm with spermicidal jelly or foam), oral depo provera, or injectable contraceptives, intrauterine devices, and tubal ligation",no-pregnancy-nursing
"Administration of atezolizumab and/or ABT-888 may have an adverse effect on pregnancy and poses a risk to the human fetus, including embryo-lethality. Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for at least 5 months (150 days) after the last dose of study agent. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and for at least 5 months (150 days) after completion of atezolizumab and/or ABT-888 administration.",no-pregnancy-nursing
"Administration of atezolizumab may have an adverse effect on pregnancy and poses a risk to the human fetus, including embryo-lethality; women of child-bearing potential and men must agree to use adequate contraception (non-hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 5 months (150 days) after the last dose of atezolizumab/placebo and 7 months after the last dose of trastuzumab and pertuzumab; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.",no-pregnancy-nursing
"Administration of study drugs (pembrolizumab, paclitaxel, carboplatin) may have an adverse effect on pregnancy and poses a risk to the human fetus, including embryo-lethality. Women of childbearing potential (WOCBP) must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) from up to 14 days prior to Step 2 registration (for oral contraceptives), during treatment, and for 120 days after the last dose of study medication. Should a woman become pregnant or suspect she is pregnant while she is participating in this study, she should inform her treating physician immediately. Patients will be considered of nonreproductive potential if they are either:",no-pregnancy-nursing
Adolescent women/young women of childbearing potential must have a negative highly sensitive serum or urine beta-human chorionic gonadotropin (beta-hCG) pregnancy test at Screening before enrollment/randomization. Adolescent/young women who are pregnant or breastfeeding are ineligible for this study,no-pregnancy-nursing
"Adult subjects of child bearing potential must agree to use double barrier contraceptive measure, oral contraception or avoidance of intercourse during the study and for 6 months after last study dose is received.",no-pregnancy-nursing
Age < 18 yr; Porphyria; pregnant or breast-feeding.,no-pregnancy-nursing
Agree not to donate sperm during the course of this study or within 180 days after receiving their last dose of study drug,no-pregnancy-nursing
Agree not to donate sperm during the course of treatment period of this study or within 120 days after receiving the last dose of the study drug,no-pregnancy-nursing
Agree not to try to become pregnant during the study and for 6 months after the final study drug administration,no-pregnancy-nursing
Agree not to try to become pregnant during the study and for at least 6 months after the final study drug administration,no-pregnancy-nursing
Agree to abstain from breastfeeding during study participation and for at least 1 year post-bb2121 infusion and until CAR T cells are no longer present by qPCR on two consecutive tests.,no-pregnancy-nursing
Agree to abstain from breastfeeding during study participation and for at least 1-year post-bb2121 infusion,no-pregnancy-nursing
"Agree to abstain from breastfeeding during study participation and for at least 3 months after the last dose of JCAR017 or until CAR T cells are no longer present by qPCR on 2 consecutive tests, whichever is later.",no-pregnancy-nursing
Agree to abstain from breastfeeding during study participation:,no-pregnancy-nursing
Agree to abstinence (if in line with the usual preferred lifestyle of the patient) or to use a male condom starting at screening and continue throughout study treatment and for at least 6 months after the final study drug administration. If the male patient has not had a vasectomy or is not sterile as defined below their female partner(s) is utilizing 1 form of highly effective birth control† per locally accepted standards starting at screening and continuing throughout study treatment and for at least 6 months after the male patient receives their final study drug administration.,no-pregnancy-nursing
"Agree to ongoing urine pregnancy testing, if clinically indicated, during the course of the study.",no-pregnancy-nursing
"Agree to practice 1 highly effective method and 1 additional effective (barrier) method of contraception at the same time, from the time of signing the informed consent through 1 month after the last dose of copanlisib, or 5 months after the last dose of nivolumab, whichever is later, or",no-pregnancy-nursing
"Agree to practice 1 highly effective method and 1 additional effective (barrier) method of contraception at the same time, from the time of signing the informed consent through 4 months after the last dose of study drug, OR",no-pregnancy-nursing
"Agree to practice effective barrier contraception during the entire study treatment period and through 1 month after the last dose of copanlisib, OR",no-pregnancy-nursing
"Agree to practice effective barrier contraception during the entire study treatment period and through 120 days after the last dose of study drug, OR",no-pregnancy-nursing
"Agree to practice effective barrier contraception during the entire study treatment period and through 180 days after the last dose of study drug, or",no-pregnancy-nursing
"Agree to practice effective barrier contraception during the entire study treatment period and through 4 months after the last dose of study drug, OR",no-pregnancy-nursing
Agree to practice effective barrier contraception during the entire study treatment period and through 90 days after the last dose of study drug,no-pregnancy-nursing
"Agree to practice effective barrier contraception during the entire study treatment period and through 90 days after the last dose of study drug, OR",no-pregnancy-nursing
Agree to practice effective barrier contraception during the entire study treatment period and through 90 days after the last dose of study drug; or,no-pregnancy-nursing
Agree to practice effective barrier contraception during the entire study Treatment period and through 90 days after the last dose of study therapy; OR,no-pregnancy-nursing
Agree to practice effective barrier contraception during the entire trial treatment period and through 90 days after the last dose of trial drug; OR,no-pregnancy-nursing
"Agree to practice highly effective barrier contraception (use condoms) during the entire study treatment period and through 120 days after the last dose of study drug. For subjects (who have not undergone vasectomy) with female partners of childbearing potential, the subject and his partner must, in addition to condoms, use highly effective contraceptive measures when engaging in sexual intercourse throughout the treatment period and for at least 120 days after the last dose of study drug (ie, oral contraceptive and condoms; intrauterine device and condoms; diaphragm with spermicide and condoms; other forms of contraception must be approved by the medical monitor) OR Agree to practice true abstinence during the entire study treatment period and through 120 days after the last dose of study drug",no-pregnancy-nursing
"Agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject (periodic abstinence [eg, calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal are not acceptable methods of contraception)",no-pregnancy-nursing
"Agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject NOTE: periodic abstinence (eg, calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception",no-pregnancy-nursing
"Agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject. (Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal are not acceptable methods of contraception).",no-pregnancy-nursing
"Agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject. (Periodic abstinence (eg, calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal are not acceptable methods of contraception)",no-pregnancy-nursing
"Agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject. (Periodic abstinence [e.g., calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal are not acceptable methods of contraception).",no-pregnancy-nursing
"Agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject. (Periodic abstinence [eg, calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal are not acceptable methods of contraception.)",no-pregnancy-nursing
"Agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject; (periodic abstinence (eg, calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal are not acceptable methods of contraception)",no-pregnancy-nursing
"Agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject; (periodic abstinence (eg, calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal are not acceptable methods of contraception).",no-pregnancy-nursing
"Agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject; (Periodic abstinence [e.g., calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal are not acceptable methods of contraception)",no-pregnancy-nursing
"Agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject; (periodic abstinence [eg, calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal are not acceptable methods of contraception)",no-pregnancy-nursing
"Agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject; (periodic abstinence [eg, calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal are not acceptable methods of contraception).",no-pregnancy-nursing
"Agree to practice true abstinence, when is in line with the preferred and usual lifestyle of the subject. Periodic abstinence (e.g., calendar, ovulation, symptothermal, postovulation methods), withdrawal, spermicides only, and lactational amenorrhea are not acceptable methods of contraception. Female and male condoms should not be used together",no-pregnancy-nursing
"Agree to practice true abstinence, when this is in line with the preferred and usual ifestyle of the patient. (Periodic abstinence [eg, calendar, ovulation, symptothermal, postovulation methods], withdrawal, spermicides only, and lactational amenorrhea are not acceptable methods of contraception. Female and male condoms should not be used together).",no-pregnancy-nursing
"Agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the participant. (Periodic abstinence [example, calendar, ovulation, symptothermal, postovulation methods], withdrawal, spermicides only, and lactational amenorrhea are not acceptable methods of contraception. Female and male condoms should not be used together.)",no-pregnancy-nursing
"Agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the patient. (Periodic abstinence [eg, calendar, ovulation, symptothermal, postovulation methods], withdrawal, spermicides only, and lactational amenorrhea are not acceptable methods of contraception. Female and male condoms should not be used together);",no-pregnancy-nursing
"Agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the patient. (Periodic abstinence [eg, calendar, ovulation, symptothermal, postovulation methods], withdrawal, spermicides only, and lactational amenorrhea are not acceptable methods of contraception. Female and male condoms should not be used together).",no-pregnancy-nursing
"Agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the patient. (Periodic abstinence [eg, calendar, ovulation, symptothermal, postovulation methods], withdrawal, spermicides only, and lactational amenorrhea are not acceptable methods of contraception. Female and male condoms should not be used together.);",no-pregnancy-nursing
"Agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the patient. (Periodic abstinence [eg, calendar, ovulation, symptothermal, postovulation methods], withdrawal, spermicides only, and lactational amenorrhea are not acceptable methods of contraception. Female and male condoms should not be used together); AND",no-pregnancy-nursing
"Agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the patient. (Periodic abstinence [eg, calendar, ovulation, symptothermal, postovulation methods], withdrawal, spermicides only, and lactational amenorrhea are not acceptable methods of contraception. Female and male condoms should not be used together.); AND",no-pregnancy-nursing
"Agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the subject (Periodic abstinence [e.g., calendar, ovulation, symptothermal, post-ovulation methods for the female partner] withdrawal, spermicides only, and lactational amenorrhea are not acceptable methods of contraception. Female and male condoms should not be used together.).",no-pregnancy-nursing
"Agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the subject. (Periodic abstinence [e.g., calendar, ovulation, symptothermal, postovulation methods for the female partner] and withdrawal are not acceptable methods of contraception. Female and male condoms should not be used together.)",no-pregnancy-nursing
"Agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the subject. (Periodic abstinence [eg, calendar, ovulation, symptothermal, post-ovulation methods] withdrawal, spermicides only, and lactational amenorrhea are not acceptable methods of contraception. Female and male condoms should not be used together.).",no-pregnancy-nursing
"Agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the subject; (periodic abstinence [e.g., calendar, ovulation, symptothermal, post-ovulation methods for the female partner] withdrawal, spermicides only, and lactational amenorrhea are not acceptable methods of contraception; female and male condoms should not be used together)",no-pregnancy-nursing
"Agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the subject; (periodic abstinence [eg, calendar, ovulation, symptothermal, post-ovulation methods] withdrawal, spermicides only, and lactational amenorrhea are not acceptable methods of contraception; female and male condoms should not be used together)",no-pregnancy-nursing
"Agree to use at least 2 effective contraceptive methods (1 highly effective method in combination with a barrier method; oral, injectable, or implantable hormonal contraceptive; tubal ligation; intra-uterine device; barrier contraceptive with spermicide; or vasectomized partner), one of which must be barrier, from signing the ICF, throughout the study, and or up to 8 weeks following the last dose of TJ011133.",no-pregnancy-nursing
Agree to use contraceptive measures during study protocol participation (when age appropriate),no-pregnancy-nursing
Agree to use effective contraception until 30 days following the last dose of investigational product and have a male partner who uses a condom or,no-pregnancy-nursing
"Agreement by females of childbearing potential and sexually active males to use an effective method of contraception (hormonal or barrier method of birth control or abstinence) prior to study entry and for up to 90 days post-HCT; should a woman become pregnant or suspect that she is pregnant while participating on the trial, she should inform her treating physician immediately",no-pregnancy-nursing
"Agreement by females of childbearing potential and sexually active males to use an effective method of contraception (hormonal or barrier method of birth control or abstinence) prior to study entry and for up to d90 post-HCT. Should a woman become pregnant or suspect that she is pregnant while participating on the trial, she should inform her treating physician immediately",no-pregnancy-nursing
"Agreement of men AND women-of-child-bearing-potential to use adequate contraception (hormonal or barrier method of birth control or abstinence) prior to study entry and for six months following duration of study participation; should a woman become pregnant or suspect that she is pregnant while participating on the trial, she should inform her treating physician immediately",no-pregnancy-nursing
"Agreement to remain abstinent (refrain from heterosexual intercourse) or use a contraceptive method with a failure rate of < 1% per year during the treatment period and for at least 30 days afte rthe last dose of venetoclax or 18 months after the last dose of rituximab, whichever is longer",no-pregnancy-nursing
Agreement to remain abstinent (refrain from heterosexual intercourse) or use a contraceptive method with a failure rate of 1% per year as outlined below.,no-pregnancy-nursing
"Agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating sperm, as defined below",no-pregnancy-nursing
"Agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating sperm, as defined below:",no-pregnancy-nursing
"Agreement to remain abstinent or use adequate contraception, among women or men of childbearing potential",no-pregnancy-nursing
Agreement to use contraception during the study and for 30 days after the last dose of study drugs if sexually active and able to bear or beget children.,no-pregnancy-nursing
"Agreement to use highly effective forms of contraception during the study and 90 days after the last dose of acalabrutinib, 6 months after the last dose of bendamustine, or 12 months after the last dose of rituximab, whichever is longest .",no-pregnancy-nursing
Agreement to use highly effective methods of contraception that alone or in combination resulting in a failure rate of a Pearl index of less than 1% per year when used consistently and correctly throughout the course of the study. Such methods include: Combined (estrogen and progestogen containing) hormonal contraception: Oral; Intravaginal; Transdermal; Progestogen-only hormonal contraception associated with inhibition of ovulation: Oral; Injectable hormonal contraception; Implantable hormonal contraception; Placement of an intrauterine device (IUD); Placement of an intrauterine hormone-releasing system (IUS); Bilateral tubal occlusion; Vasectomized partner; Sexual Abstinence.,no-pregnancy-nursing
Agreement to utilize effective contraceptive methods during the study (for one year),no-pregnancy-nursing
Agrees to protocol-defined use of effective contraception,no-pregnancy-nursing
Agrees to use a condom (even men with vasectomies) and another effective method of birth control if he is having sex with a woman of childbearing potential or agrees to use a condom if he is having sex with a woman who is pregnant while on study drug and for 3 months following the last dose of study drug. Must also agree not to donate sperm during the study and for 3 months after receiving the last dose of study drug.,no-pregnancy-nursing
"Agrees to use adequate contraception. Acceptable contraceptive methods, when used consistently and in accordance with both the product label and the instructions of the physician, are as follows:",no-pregnancy-nursing
Agrees to use an adequate method of contraception during the study and until 3 months after the last treatment.,no-pregnancy-nursing
Agrees to use contraception during study treatment,no-pregnancy-nursing
All females of childbearing potential (not surgically sterilized and between menarche and 1 year post menopause) must have a blood test to rule out pregnancy within 2 weeks prior to registration.,no-pregnancy-nursing
"All females of childbearing potential must have a blood or urine pregnancy test within 72 hours prior to randomization to rule out pregnancy. A female of childbearing potential is any woman, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria:",no-pregnancy-nursing
"All females of childbearing potential must have a blood test or urine study with a minimum sensitivity 25 IU/L or equivalent units of HCG within 2 weeks prior to registration to rule out pregnancy. A female of childbearing potential is any woman, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria:",no-pregnancy-nursing
"All females of childbearing potential must have a blood test or urine study within 14 days prior to Step 2 Registration to rule out pregnancy. A female of childbearing potential is any woman, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria:",no-pregnancy-nursing
All females of childbearing potential must have a blood test or urine study within 2 weeks prior to registration to rule out pregnancy,no-pregnancy-nursing
All females of childbearing potential must have a blood test or urine study within 2 weeks prior to registration to rule out pregnancy.,no-pregnancy-nursing
"All females of childbearing potential must have a blood test or urine study within 2 weeks prior to registration to rule out pregnancy. A female of childbearing potential is any woman, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria:",no-pregnancy-nursing
"All females of childbearing potential must have a blood test or urine study within 24 hours prior to enrollment to rule out pregnancy. A female of childbearing potential is any woman, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria:",no-pregnancy-nursing
All females of childbearing potential must have a blood test or urine study within 7 days prior to starting treatment to rule out pregnancy.,no-pregnancy-nursing
All male and female subjects must follow all requirements defined in the Pregnancy Prevention Program (v5.1). See Appendix D for CC-220 Pregnancy Prevention Plan for Subjects in Clinical Trials.,no-pregnancy-nursing
"All participants who are able to have children must practice effective birth control while on study. Acceptable forms of birth control for female patients include: birth control pills, patches, or injections, intrauterine device (IUD), diaphragm with spermicide, or condom with spermicide. Acceptable forms of birth control for male patients include condom with spermicide. If female participant becomes pregnant during the study, she will be taken off this study. If male participant fathers a child while on study, he must immediately notify his doctor",no-pregnancy-nursing
"All participants who are able to have children must practice effective birth control while on study. Acceptable forms of birth control for female patients include: hormonal birth control, intrauterine device, diaphragm with spermicide, condom with spermicide, or abstinence, for the length of the study. If the participant is a female and becomes pregnant or suspects pregnancy, she must immediately notify her doctor. If the participant becomes pregnant during this study, she will be taken off this study. Men who are able to have children must use effective birth control while on the study. If the male participant fathers a child or suspects that he has fathered a child while on the study, he must immediately notify his doctor.",no-pregnancy-nursing
"All patients must agree to use effective contraception while on study, and all patients must agree to undergo counseling sessions every 28 days about pregnancy precautions and risks of fetal exposure",no-pregnancy-nursing
All patients must be counseled at a minimum of every 28 days about pregnancy precautions and risks of fetal exposure.,no-pregnancy-nursing
All patients must practice a highly effective method of birth control,no-pregnancy-nursing
All patients of reproductive potential (heterosexually active men and women) must agree to a use of a barrier method of contraception and a second method of contraception and men must agree not to donate sperm during the study and for 4 weeks after receiving the last dose of study treatment.,no-pregnancy-nursing
All sexually active WCBP and all sexually active male subjects (even if he has undergone a successful vasectomy) must agree to use effective methods of birth control for at least 1 year post bb21217 infusion (heterosexual contact only).,no-pregnancy-nursing
"All study participants must be registered into the mandatory POMALYST (pomalidomide) Risk Evaluation and Mitigation Strategy (REMS®) program, and be willing and able to comply with the requirements of the POMALYST REMS® program",no-pregnancy-nursing
All study participants must be registered into the mandatory Revlimid REMSR program and be willing and able to comply with the requirements of the REMSR program.,no-pregnancy-nursing
"All study participants must be registered into the mandatory Revlimind REMS program and be willing to comply with its requirements. Per standard Revlimid REMS program requirements, all physicians who prescribe lenalidomide for research subjects enrolled into this trial, must be registered in, and must comply with, all requirements of the Revlimid REMS program.",no-pregnancy-nursing
All study participants must be willing to be registered into the mandatory pomalidomide (POMALYST&reg;) Risk Evaluation and Mitigation Strategy (REMS&reg;) program and be willing and able to comply with the requirements of the POMALYST REMS&reg; program.,no-pregnancy-nursing
"All subjects must agree to refrain from donating blood while on study treatment, during dose interruptions and for at least 28 days following the last dose of study treatment.",no-pregnancy-nursing
All subjects with preserved reproductive potential must agree to practice abstinence or employ contraceptive measures for the duration of treatment and for 4 weeks following final dosing. All male subjects are considered to have reproductive potential. Female subjects of reproductive potential are those who:,no-pregnancy-nursing
"All subjects with reproductive potential must agree to use effective contraceptive measures (e.g., oral contraceptives, intrauterine device, or double barrier method of condom and spermicide) during the study and for 3 months following the last dose of study drug.",no-pregnancy-nursing
"All women of childbearing potential must agree to use an effective barrier method of contraception, as described in Appendix 4, during the treatment period and for at least 1 month after discontinuation of the study drug. Male subjects should use effective barrier method of contraception during the treatment period and for at least 1 month after discontinuation of the study drug",no-pregnancy-nursing
"Alternatively, female subjects must be of non-reproductive potential (i.e., post-menopausal by history: >= 60 years old and no menses for >= 1 year without an alternative medical cause; OR history of hysterectomy, OR history of bilateral tubal ligation, OR history of bilateral oophorectomy).",no-pregnancy-nursing
an intrauterine device,no-pregnancy-nursing
And have a negative serum pregnancy test at screening,no-pregnancy-nursing
And have a negative urine or serum pregnancy test within 7 days prior to Day 1 (Females with false positive results and documented verification of negative pregnancy status are eligible for participation),no-pregnancy-nursing
"And if heterosexually active, agree to abstinence (if in line with the usual preferred lifestyle of the patient) or consistently use a condom plus 1 form of highly effective birth control† per locally accepted standards starting at screening and throughout the study period and for at least 6 months after the final study drug administration",no-pregnancy-nursing
And men who are unwilling to use birth control while taking the drug and for 4 months after stopping treatment.,no-pregnancy-nursing
"and must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control, one highly effective method and one additional effective method AT THE SAME TIME at least 28 days before she starts taking pomalidomide",no-pregnancy-nursing
"And, if heterosexually active, agree to consistently use highly effective contraception per locally accepted standards in addition to a barrier method starting at screening and throughout the study period and for 6 months after the final study drug administration.",no-pregnancy-nursing
"And, not breast feeding at any time during the study.",no-pregnancy-nursing
Any of the following * Pregnant women * Nursing women * Men or women of childbearing potential who are unwilling to employ adequate contraception during treatment and 8 weeks following the completion of treatment,no-pregnancy-nursing
"Any of the following because this study involves agents that have known or potential genotoxic or mutagenic, and teratogenic effects:",no-pregnancy-nursing
"Any of the following because this study involves an agent that has known genotoxic, mutagenic and teratogenic effects:",no-pregnancy-nursing
"Any of the following because this study involves an agent where the genotoxic, mutagenic and teratogenic effects are unknown:",no-pregnancy-nursing
"Any of the following because this study involves an agent whose genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn are unknown:",no-pregnancy-nursing
"Any of the following because this study involves an investigational agent whose genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn are unknown:",no-pregnancy-nursing
"Are not pregnant or breastfeeding, and at least one of the following conditions applies:",no-pregnancy-nursing
Are pregnant and/or nursing,no-pregnancy-nursing
"Are pregnant and/or nursing, or refuse to use appropriate contraceptives during the course of the study and for at least 30 days after the last dose of study drug",no-pregnancy-nursing
"Are pregnant and/or nursing, or refuse to use appropriate contraceptives during the course of the study and for at least 30 days after the last dose of study drug.",no-pregnancy-nursing
Are pregnant or breastfeeding,no-pregnancy-nursing
Are pregnant or breastfeeding.,no-pregnancy-nursing
Are pregnant or nursing,no-pregnancy-nursing
Are pregnant or nursing.,no-pregnancy-nursing
"As therapeutic agents used in this trial may be harmful to a fetus, women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for at least one year post-allo HCT. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in the study, she should inform her treating physician immediately.",no-pregnancy-nursing
"at least 2 effective methods of contraception, including male condom, female condom, cervical cap, diaphragm, or contraceptive sponge OR",no-pregnancy-nursing
Avoid conceiving for 8 weeks after the last dose of TJ011133.,no-pregnancy-nursing
"Azoospermic males are exempt from contraceptive requirements. WOCBP who are continuously not heterosexually active are also exempt from contraceptive requirements, and still must undergo pregnancy testing as described in this section. Investigators shall counsel WOCBP, and male participants who are sexually active with WOCBP, on the importance of pregnancy prevention and the implications of an unexpected pregnancy. Investigators shall advise on the use of highly effective methods of contraception, which have a failure rate of < 1% when used consistently and correctly (see Appendix 4).",no-pregnancy-nursing
Azoospermic males are required to use a condom for the duration of the study.,no-pregnancy-nursing
"Based on findings in animals, ivabradine may cause fetal harm when administered to a pregnant woman. For this reason, women of child-bearing potential must agree to use adequate contraception.",no-pregnancy-nursing
"Be nonfertile or agree to use an adequate method of contraception. Sexually active patients and their partners must use an effective method of contraception (hormonal or barrier method of birth control, or abstinence) prior to study entry and for the duration of study participation and for at least 30 days after the last study drug dose. Should a woman become pregnant or suspect that she is pregnant while participating in this study, she should inform her treating physician immediately.",no-pregnancy-nursing
"Be nonfertile or agree to use an adequate method of contraception. Sexually active patients and their partners must use an effective method of contraception (hormonal or barrier method of birth control; or abstinence) prior to study entry and for the duration of study participation including for 30 days after the last dose of study drug (see Section 4.6.3). Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.",no-pregnancy-nursing
Be nonfertile or agree to use an adequate method of contraception. Sexually active patients and their partners must use an effective method of contraception associated with a low failure rate during and for 6 months after completion of study therapy (see Section 4.7.3).,no-pregnancy-nursing
Be of non-childbearing potential:,no-pregnancy-nursing
"Because of the risks of drug treatment to the developing fetus, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) for the duration of study participation, and for four months following completion of study therapy. Should a woman become pregnant or suspect she is pregnant while participating in this study or if she is the partner of a male participant in this study and becomes pregnant while he is participating in this study, she should inform her or her partner's treating physician immediately as well as her obstetrician. Female study patients who become pregnant must immediately discontinue treatment with any study therapy. Male patients should avoid impregnating a female partner. Male study patients, even if surgically sterilized, (i.e. post-vasectomy) must agree to one of the following: practice effective barrier contraception during the entire study treatment period and through 4 months after the last dose of study drug, or completely abstain from sexual intercourse",no-pregnancy-nursing
"Because the effects of Zydelig on the developing human fetus are unknown, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Participants must agree to use contraception for at least 30 days after the last dose of Zydelig. Women of childbearing potential is defined as women who continues to have menstrual periods, have not had a tubal ligation, or the removal of fallopian tubes, ovaries or uterus.",no-pregnancy-nursing
"Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with CUDC-907, breastfeeding mothers are not eligible.",no-pregnancy-nursing
"Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with nivolumab, breastfeeding should be discontinued if the mother is treated with nivolumab.",no-pregnancy-nursing
"Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with pembrolizumab, breastfeeding must be discontinued if the mother is treated with pembrolizumab",no-pregnancy-nursing
"Before study enrollment, women of child bearing potential must be advised of the importance of avoiding pregnancy during study participation and the potential risk factors for an unintentional pregnancy; the subject must sign an informed consent form documenting this discussion; women of child-bearing potential (WOCBP) and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; women of childbearing potential MUST have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin [HCG]) within 24 hours prior to the start of nivolumab with or without ipilimumab; the minimum sensitivity of the pregnancy test must be 25 IU/L or equivalent units of HCG; if the pregnancy test is positive, the subject must not receive nivolumab with or without ipilimumab and must not be enrolled in the study",no-pregnancy-nursing
"Before the first dose of the study intervention(s), if using hormonal contraception",no-pregnancy-nursing
"Before the first dose of the study intervention(s), if using hormonal contraception:",no-pregnancy-nursing
"Bortezomib and clofarabine have both been assigned to pregnancy category D by the FDA. For this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation and for at least 3 months after dosing with study drugs ceases. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 3 months after completion of study drug administration.",no-pregnancy-nursing
Both female and male patients of reproductive potential must agree to avoid pregnancy or impregnating a partner (respectively) while receiving drug and for 120 days after last dose of study drug.,no-pregnancy-nursing
Both women (of childbearing potential) and men must agree to use a medically acceptable method of contraception throughout the treatment period and for 6 months after discontinuing study treatment.,no-pregnancy-nursing
"Breast feeding (if lactating, must agree not to breast feed while taking lenalidomide). Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with lenalidomide, breastfeeding should be discontinued if the mother is treated with lenalidomide.",no-pregnancy-nursing
Breast feeding after pregnant,no-pregnancy-nursing
Breast feeding or pregnant,no-pregnancy-nursing
Breast feeding women.,no-pregnancy-nursing
Breast-feeding,no-pregnancy-nursing
Breastfeeding females,no-pregnancy-nursing
"Breastfeeding mothers are not eligible, because there is an unknown risk for adverse events in nursing infants secondary to treatment of the mother with ALRN-6924.",no-pregnancy-nursing
"Breastfeeding mothers are not eligible, because there is an unknown risk for adverse events in nursing infants secondary to treatment of the mother with BMS-986158.",no-pregnancy-nursing
Breastfeeding or pregnant,no-pregnancy-nursing
Breastfeeding or pregnant (intention to become) females or participation in other clinical trials,no-pregnancy-nursing
"Breast-feeding or pregnant women, or patients for whom there is a risk of conception and who are unable or unwilling to use appropriate contraception (for male and female patients up to 4 months after end of ibrutinib.)",no-pregnancy-nursing
Breastfeeding or pregnant.,no-pregnancy-nursing
Breast-feeding woman,no-pregnancy-nursing
Breast-feeding women,no-pregnancy-nursing
Breastfeeding.,no-pregnancy-nursing
Cervical cap (additional effective method.,no-pregnancy-nursing
Cervical cap (always used with spermicide),no-pregnancy-nursing
"Child-bearing potential as defined in Section 6.10.2.2, and agrees to use one of the contraception methods as described in Appendix 4, from the time of the screening pregnancy test until 7 months after the last dose of study medication.",no-pregnancy-nursing
Childbearing potential defined as not being surgically sterilized (men and women) or have not been free from menses for > 1 year (women only),no-pregnancy-nursing
Childbearing potential defined as not being surgically sterilized or have not been free from menses for > 1 year,no-pregnancy-nursing
"Childbearing potential, including any individual who has had a negative serum pregnancy test, <= 7 days prior to randomization.",no-pregnancy-nursing
"Combined (estrogen and progesterone containing: oral, intravaginal, transdermal) and progesterone-only (oral, injectable, implantable) hormonal contraception associated with inhibition of ovulation.",no-pregnancy-nursing
"Combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, or transdermal)",no-pregnancy-nursing
Combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation:,no-pregnancy-nursing
"commit to continued abstinence from heterosexual intercourse, or agree to use and be able to comply with the use of double-barrier contraception",no-pregnancy-nursing
"Commitment from male and female subjects of reproductive potential to use, from the time of screening through 60 days after the last dose of TTI-621, either:",no-pregnancy-nursing
Committed to using a highly effective method of contraception (refer to Section 6.5) with their partner during treatment and for 6 months following the last dose of study drug,no-pregnancy-nursing
Committed to using an effective method of contraception (refer to Section 6.4) with their partner during treatment and for 6 months following the last dose of rucaparib,no-pregnancy-nursing
Complete abstinence is defined as complete avoidance of heterosexual intercourse and is an acceptable form of contraception for all study drugs; acceptable alternate methods of highly effective contraception must be discussed in the event that the subject chooses to forego complete abstinence,no-pregnancy-nursing
"Complete and true sexual abstinence defined as abstinence when it is in line with the preferred and usual lifestyle of the subject. Subjects in this study should refrain from heterosexual intercourse during and upon completion of the study and for at least 4.5 months after the last dose of study drug. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods), declaration of abstinence for the duration of exposure to study drug, and withdrawal are not acceptable methods of contraception. Non-child-bearing potential defined as pre-menopausal females with a documented tubal ligation or hysterectomy; or postmenopausal defined as 12 months of spontaneous amenorrhea (in questionable cases, a blood sample with simultaneous follicle-stimulating hormone > 40 mIU/mL and estradiol < 40 pg/mL [< 147 pmol/L] is confirmatory). Females on hormone replacement therapy (HRT) and whose menopausal status is in doubt will be required to use one of the contraception methods outlined for women of child-bearing potential if they wish to continue their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of post-menopausal status prior to study enrollment. For most forms of HRT, at least 2 to 4 weeks will elapse between the cessation of therapy and the blood draw; this interval depends on the type and dosage of HRT. Following confirmation of their post-menopausal status, they can resume use of HRT during the study without use of a contraceptive method.",no-pregnancy-nursing
Condoms (male or female) with or without a spermicidal agent,no-pregnancy-nursing
Consistent and correct usage of established hormonal contraceptives that inhibit ovulation,no-pregnancy-nursing
Continued sexual activity in men or women of childbearing potential who are unwilling to practice adequate contraception during the study,no-pregnancy-nursing
Contraception Requirements:,no-pregnancy-nursing
Contraception Subjects of child bearing or child fathering potential must be willing to practice birth control from the time of enrollment on this study and for four (4) months after receiving the preparative lymphodepletion regimen.,no-pregnancy-nursing
Contraception Subjects of child bearing or child fathering potential must be willing to practice birth control from the time of enrollment on this study and for four (4) months after receiving the preparative regimen or for as long as CD19/CD22-CAR T cells are detectable in peripheral blood.,no-pregnancy-nursing
Contraception Subjects of child-bearing or child-fathering potential must be willing to practice birth control from the time of enrollment on this study and for four (4) months after receiving the preparative regimen.,no-pregnancy-nursing
Contraception:,no-pregnancy-nursing
Contraception: Women of child-bearing potential must agree to use an effective method of birth control during treatment and for 3 months after receiving their last dose of study drug. Fertile men must also agree to use an acceptable method of birth control while on study drug and for at least 3 months after last dose.,no-pregnancy-nursing
"Contraceptive Guidance and Pregnancy Testing) for at least 180 days, (corresponding to time needed to eliminate any study treatment(s) [pembrolizumab and or any active combination] plus an additional 90 days [a spermatogenesis cycle] for study treatments where there is risk of clinically relevant genotoxicity) after the last dose of study treatment and refrain from donating sperm during this period.",no-pregnancy-nursing
contraceptive sponge (nulliparous women only),no-pregnancy-nursing
Contraceptive use by males or females will be consistent with local regulations on contraception methods for those participating in clinical studies.,no-pregnancy-nursing
Current or planned pregnancy or lactation in women of child bearing age (confirmed by negative pregnancy test prior to start of therapy).,no-pregnancy-nursing
Currently breastfeeding.,no-pregnancy-nursing
"Currently pregnant, nursing, or planning to become pregnant during the course of the study.",no-pregnancy-nursing
"Definition of childbearing potential: for this study, a female subject is considered of childbearing potential until becoming post-menopausal unless permanently sterile or with medically documented ovarian failure; women are considered to be in a postmenopausal state when >= 54 years of age with cessation of previously occurring menses for >= 12 months without an alternative cause; women of any age with amenorrhea of >= 12 months may also be considered post-menopausal if their follicle stimulating hormone (FSH) level is in the post-menopausal range and they are not using hormonal contraception or hormonal replacement therapy; permanent sterilization in females includes hysterectomy, bilateral oophorectomy, or bilateral salpingectomy in a female subject of any age; permanent sterilization in males include bilateral orchiectomy or medical documentation of alternative explanation",no-pregnancy-nursing
Diaphragm (additional effective method),no-pregnancy-nursing
Diaphragm (always used with spermicide),no-pregnancy-nursing
"Documented surgically sterile (e.g., hysterectomy, bilateral salpingectomy, bilateral oophorectomy, bilateral tubal occlusion) *Those who are amenorrheic due to an alternative medical cause are not considered postmenopausal and must follow the criteria for childbearing potential patients",no-pregnancy-nursing
DONOR: Females must not be pregnant or lactating,no-pregnancy-nursing
DONOR: Pregnant women,no-pregnancy-nursing
"Double-barrier method: male condom plus diaphragm or vaginal cap with spermicide (contraceptive sponge, jellies or creams)",no-pregnancy-nursing
"Due to the teratogenic potential of these agents, pregnant or nursing patients may not be enrolled",no-pregnancy-nursing
"Due to unknown effects of this therapy on a fetus, pregnant women are excluded from this research. The male partner should use a condom. Females of child-bearing potential should use of at least two forms of contraception unless female has had a hysterectomy or tubal ligation.",no-pregnancy-nursing
"duration of study participation and for at least 3 months after dosing with study drugs ceases. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician",no-pregnancy-nursing
"During the study, and for 3 months after receiving the last dose of daratumumab, a woman must agree not to donate eggs (ova, oocytes) and men must agree not to donate sperm for the purposes of assisted reproduction.",no-pregnancy-nursing
"Effective method of contraception defined as: Hormonal contraceptives (oral, injectable, patch, intrauterine devices), male partner sterilization, or total abstinence from heterosexual intercourse, when this is the preferred and usual lifestyle of the patient",no-pregnancy-nursing
Efficient contraception for women.,no-pregnancy-nursing
"Either commit to true abstinence* from heterosexual contact (which must be reviewed on a monthly basis and source documented) or agree to use, and be able to comply with two forms of contraception: one highly effective, and one additional effective (barrier) measure of contraception without interruption 28 days prior to starting investigational product, during the study treatment (including dose interruptions), and for at least 28 days after the last dose of CC-220 or 90 days after the last dose of DARA (for Cohort E) or BTZ (for Cohort F), whichever is longer. Contraception requirements are detailed in Appendix D.",no-pregnancy-nursing
"Either commit to true abstinence* from heterosexual contact (which must be reviewed on a monthly basis and source documented) or agree to use, and be able to comply with, effective contraception without interruption. Contraception methods must include 1 highly effective and 1 additional effective (barrier) method of contraception from screening until at least 12 months after the JCAR017 infusion and until CAR T cells are no longer present by qPCR on 2 consecutive tests, whichever is later (Arm B) and until 12 months after the last chemotherapy (Arm A).",no-pregnancy-nursing
"Either commit to true abstinence* from heterosexual contact or agree to use, and be able to comply with, effective measures of contraception without interruption, from screening through at least 1 year following last bb2121 infusion. Contraception methods must include 1 highly effective and 1 additional effective (barrier) method of contraception from screening until at least 12 months following bb2121 infusion",no-pregnancy-nursing
"Either commit to true abstinence** from heterosexual contact or agree to use, and be able to comply with, effective measures of contraception without interruption, from screening through at least 1 year following last bb2121 infusion. Contraception methods must include 1 highly effective and 1 additional effective (barrier) method of contraception from screening until at least 12 months following bb2121 infusion and until CAR T cells are no longer present by qPCR on two consecutive tests",no-pregnancy-nursing
"Either practice true abstinence2 from heterosexual contact (which must be reviewed on a monthly basis and source documented) or agree to use, and be able to comply with, effective measures of contraception without interruption. Contraception methods must include 1 highly effective and 1 additional effective (barrier) method of contraception from screening, during study treatment until:",no-pregnancy-nursing
"ELIGIBILITY FOR LYMPHODEPLETION CHEMOTHERAPY: Negative serum pregnancy test within 2 weeks before lymphodepletion chemotherapy for women of childbearing potential, defined as those who have not been surgically sterilized or who have not been free of menses for at least 1 year",no-pregnancy-nursing
Established intrauterine device (IUD) or intrauterine hormone releasing system (IUS),no-pregnancy-nursing
Evidence of post-menopausal status or negative urinary or serum pregnancy test for female pre-menopausal patients. A definition of post-menopausal is provided in Section 5.3.,no-pregnancy-nursing
"Examples of contraceptive methods with a failure rate of < 1% per year include bilateral tubal ligation, male sterilization, hormonal contraceptives that inhibit ovulation, hormone-releasing intrauterine devices, and copper intrauterine devices",no-pregnancy-nursing
"Expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment.",no-pregnancy-nursing
"FCPB must have a negative urine or serum pregnancy test within 7 days prior to registration, and be willing to adhere to the scheduled pregnancy testing as required in the Revlimid Risk Evaluation and Mitigation Strategies (REMS®) program",no-pregnancy-nursing
"Female and male patients of child-producing potential must agree to avoid becoming pregnant or impregnating a partner, respectively, during the study*, and until at least 120 days after the last dose of derazantinib.",no-pregnancy-nursing
"Female and male patients of child-producing potential must agree to avoid becoming pregnant or impregnating a partner, respectively, during the study, and until at least 120 days after the last dose of derazantinib.",no-pregnancy-nursing
Female and male patients who are fertile must agree to use an effective form of contraception with their sexual partners from randomization through 4 months after the end of treatment,no-pregnancy-nursing
Female condom,no-pregnancy-nursing
Female donors of child-bearing potential must have a negative serum or urine beta-HCG test within three weeks of mobilization,no-pregnancy-nursing
Female of childbearing potential (FOCBP) must have a negative pregnancy test <= 7 days prior to registration on study,no-pregnancy-nursing
Female of childbearing potential must have a negative serum beta-human chorionic gonadotropin (HCG) pregnancy test result within 3 days of first study dose; female patients who are surgically sterilized or who are > 45 years old and have not experienced menses for > 2 years may have beta-HCG pregnancy test waived,no-pregnancy-nursing
Female of childbearing potential or male with a female partner of childbearing potential unwilling to use a highly effective method of contraception,no-pregnancy-nursing
Female of childbearing potential: negative urine or serum pregnancy test,no-pregnancy-nursing
"Female of childbearing potential: negative urine or serum pregnancy test within 72 hours prior to receiving the first dose of study medication (within 14 days prior to day 1 of protocol therapy). If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.",no-pregnancy-nursing
"Female of childbearing potential: negative urine or serum pregnancy test, performed within 14 days prior to day 1 of protocol therapy",no-pregnancy-nursing
"Female of childbearing potential: negative urine or serum pregnancy test; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required (to be performed within 10 business days prior to day 1)",no-pregnancy-nursing
Female of childbearing potential? (Yes or No),no-pregnancy-nursing
Female only: pregnant or lactating,no-pregnancy-nursing
Female or male participant of reproductive potential must agree to use an effective contraceptive method throughout duration of study treatment.,no-pregnancy-nursing
Female participant who is post-menarchal must have a negative urine or serum pregnancy test.,no-pregnancy-nursing
Female participants must agree not to breastfeed or donate ova throughout the study drug treatment period and for 6 months after the final study drug administration.,no-pregnancy-nursing
Female participants must not be breastfeeding or pregnant.,no-pregnancy-nursing
"Female participants of child bearing age must have negative pregnancy test, abstain or use contraception for 120 days after last dose of pembrolizumab",no-pregnancy-nursing
Female participants of childbearing age must not be lactating due to theoretical potential harm to the infant from exposure to radiation.,no-pregnancy-nursing
"Female participants of childbearing potential (defined as a sexually mature woman who has not undergone surgical sterilization or who has not been naturally postmenopausal for at least 12 consecutive months for women > 55 years of age) must have a negative urine or serum pregnancy test within 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.",no-pregnancy-nursing
Female participants of childbearing potential (WOCBP) must have a negative urine or serum pregnancy test within 7 days before Day 1 (first dose of study medication).,no-pregnancy-nursing
Female participants of childbearing potential must agree to use adequate methods of contraception starting with the first dose of study therapy through 60 days after the last dose of study therapy.,no-pregnancy-nursing
Female participants of childbearing potential should have a negative urine or serum pregnancy test within 72 hours prior to receiving the first dose of study medication,no-pregnancy-nursing
Female participants who are lactating and breastfeeding or have a positive serum pregnancy test during the screening period or a positive urine pregnancy test on Day 1 before first dose of study drug.,no-pregnancy-nursing
"Female participants who are not of child-bearing potential and female participants of child-bearing potential who have a negative serum pregnancy test within 3 days prior to initial trial treatment. Female participants of child-bearing potential and all male partners, and male participants must consent to use a medically acceptable method of contraception throughout the study period and for a minimum of 1 year after the last dose of rituximab and for a minimum of 4 months after the last dose of umbralisib.",no-pregnancy-nursing
"Female participants who are not pregnant or breastfeeding, and who are either not a woman of childbearing potential (WOCBP), or are a WOCBP who agrees to use approved contraception during the treatment period and for at least 120 days (or longer, if required by the drug label of chemotherapy received by the participant on study) after the last dose of study treatment",no-pregnancy-nursing
"Female participants: A female participant is eligible to participate if she is not pregnant (see Appendix C), not breastfeeding, and at least one of the following conditions applies:",no-pregnancy-nursing
Female participants: Agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods and refrain from donating eggs.,no-pregnancy-nursing
Female partner of a male study subject should use a highly effective method of contraception while the male partner is receiving the study agent and for 12 weeks after the final dose of the study therapy,no-pregnancy-nursing
Female partners (of childbearing potential) of male subjects must also use a highly effective method of contraception throughout this period (Appendix A).,no-pregnancy-nursing
Female partners of male subjects participating in the study may use hormone based contraceptives as one of the acceptable methods of contraception,no-pregnancy-nursing
"Female patient (of childbearing potential) is not breastfeeding, has a negative serum pregnancy test within 72 hours prior to taking study treatment, and agrees to abstain from activities that could result in pregnancy from enrollment through 180 days after the last dose of study treatment; or",no-pregnancy-nursing
"Female patient must agree not to breastfeed or donate ova starting at screening and throughout the study period, and for at least 180 days after the final study drug administration.",no-pregnancy-nursing
"Female patient must agree not to breastfeed or donate ova starting at screening and throughout the study period, and for at least 6 months after the final study drug administration.",no-pregnancy-nursing
Female patient who is of childbearing potential must have a negative serum pregnancy test result within 1 week prior to starting study drugs.,no-pregnancy-nursing
"Female patient who is of childbearing potential willing to use a highly effective contraceptive measure while participating on study, or willing to agree with the true abstinence from heterosexual intercourse during the entire study treatment period and for 3 months after the last administration of study drug (Appendix J)",no-pregnancy-nursing
"Female patients (unless postmenopausal for at least 1 year before the screening visit, or surgically sterilized), agree to practice two (2) effective methods of contraception at the same time, or agree to completely abstain from heterosexual intercourse, from the time of signing the informed consent through 12 months post-transplant (see Section 2.6.4 for definition of postmenopausal)",no-pregnancy-nursing
Female patients capable of reproduction and male patients who have partners capable of reproduction must agree to use an effective contraceptive method during the course of the study and for 2 months following the completion of their last treatment,no-pregnancy-nursing
"Female patients enrolled in the study, who are not free from menses for > 2 years, post hysterectomy / oophorectomy, or surgically sterilized, must be willing to use either 2 adequate barrier methods or a barrier method plus a hormonal method of contraception to prevent pregnancy or to abstain from sexual activity throughout the study, starting with visit 1 through 4 weeks after the last dose of study therapy. Approved contraceptive methods include for example; intra uterine device, diaphragm with spermicide, cervical cap with spermicide, male condoms, or female condom with spermicide. Spermicides alone are not an acceptable method of contraception.",no-pregnancy-nursing
"Female patients enrolled in the study, who are not free from menses for > 2 years, post hysterectomy / oophorectomy, or surgically sterilized, must be willing to use either 2 adequate barrier methods or a barrier method plus a hormonal method of contraception to prevent pregnancy or to abstain from sexual activity throughout the study, starting with visit 1 through 4 weeks after the last dose of study therapy. Approved contraceptive methods include for example; intra uterine device, diaphragm with spermicide, cervical cap with spermicide, male condoms, or female condom with spermicide. Spermicides alone are not an acceptable method of contraception. Male participants need to agree to use an adequate method of contraception",no-pregnancy-nursing
female patients must agree to use a highly effective birth control method while on study and for at least 1 month after your last dose of study drug(s).,no-pregnancy-nursing
Female patients must be either postmenopausal (no menstrual period for a minimum of 12 months) or surgically sterile upon entry into the study. Female patients of childbearing potential must have a negative pregnancy test upon entry into this study and agree to use a highly effective method of contraception from Screening until 1 month following administration of gemcitabine:,no-pregnancy-nursing
"Female patients must be postmenopausal (See Section 3.1c.2) or have a negative urine or serum pregnancy test within 14 days prior to registration. Female patients of childbearing potential and male patients with partners of childbearing potential, who are sexually active, must agree to the use of two highly effective forms of contraception during protocol treatment (Groups 1 and 2) and for 6 months following the last dose of olaparib (Group 1).",no-pregnancy-nursing
Female patients must be willing to use two adequate barrier methods of contraception to prevent pregnancy or agree to abstain from heterosexual activity throughout the study or be post menopausal (free from menses > two years or surgically sterilized).,no-pregnancy-nursing
Female patients must be willing to use two adequate barrier methods of contraception to prevent pregnancy or agree to abstain from heterosexual activity throughout the study or be post-menopausal (free from menses > two years or surgically sterilized),no-pregnancy-nursing
Female patients must either be of non-reproductive potential or must have a negative serum pregnancy test upon study entry.,no-pregnancy-nursing
Female patients must have negative beta-human chorionic gonadotropin (HCG) pregnancy test (all women of child bearing-potential must have test performed),no-pregnancy-nursing
Female patients must use two highly effective contraceptive measures. All methods of contraception (with the exception of total abstinence) should be used in combination with the use of a condom by a male sexual partner for intercourse. Female patients must not be breast-feeding and must have a negative pregnancy test prior to start of dosing if of childbearing potential or must have evidence of non-childbearing potential by fulfilling one of the following criteria at screening:,no-pregnancy-nursing
Female patients of child-bearing potential (pre-menopausal and not surgically sterilized) who are breast-feeding or have a positive blood beta-human chorionic gonadotropin (β-HCG) pregnancy test at Screening,no-pregnancy-nursing
"Female patients of child-bearing potential and male patients with sexual partners of child-bearing potential who are unwilling to follow strict contraception requirements before entry and throughout the study, up to and including the 30-day non-treatment follow-up period Examples of acceptable contraception methods include:",no-pregnancy-nursing
Female patients of childbearing potential are not eligible unless a negative pregnancy test result has been obtained within 7 days prior to enrollment.,no-pregnancy-nursing
Female patients of childbearing potential are not eligible unless a negative pregnancy test result has been obtained.,no-pregnancy-nursing
"Female patients of childbearing potential must agree to use a highly effective method of birth control during and for 4 weeks after completion of study. Women are considered to be of childbearing potential unless it is documented that they are over the age of 60 OR postmenopausal by history with no menses for 1 year and confirmed by FSH (using local reference ranges) OR have a history of hysterectomy and/or bilateral oophorectomy OR have a history of bilateral tubal ligation. Highly effective methods of birth control include hormonal birth control (oral, intravaginal, transdermal, implantable, or intrauterine), IUDs, vasectomy, or any double-barrier methods (combination of male condom and spermicide with either cap, diaphragm, or sponge).",no-pregnancy-nursing
Female patients of childbearing potential must agree to use a highly effective method of birth control during and for 4 weeks after completion of study. Women are considered to be of childbearing potential unless it is documented that they are:,no-pregnancy-nursing
Female patients of childbearing potential must agree to use acceptable methods of contraception.,no-pregnancy-nursing
"Female patients of childbearing potential must agree to use acceptable methods of contraception. For additional inclusion criteria, please see the specific appendix for each study drug (Appendices 6?��?��???��?��??��?��???11).",no-pregnancy-nursing
"Female patients of childbearing potential must agree to use acceptable methods of contraception. For additional inclusion criteria, please see the specific appendix for each study drug (Appendices 6-11).",no-pregnancy-nursing
"Female patients of childbearing potential must agree to use acceptable methods of contraception. For additional inclusion criteria, please see the specific appendix for each study drug (Appendix 6 through 10).",no-pregnancy-nursing
"Female patients of child-bearing potential must agree to use dual methods of contraception (including one highly effective and one effective method of contraception [as defined in Section 6.9.2.2]) and have a negative serum pregnancy test at Screening, and male patients must use an effective barrier method of contraception if sexually active with a female of child-bearing potential. For both male and female patients, effective methods of contraception must be used throughout the study and for 3 months following the last dose.",no-pregnancy-nursing
"Female patients of child-bearing potential must agree to use dual methods of contraception and have a negative serum pregnancy test at screening, and male patients must use an effective barrier method of contraception if sexually active with a female of child-bearing potential; acceptable methods of contraception are condoms with contraceptive foam, oral, implantable or injectable contraceptives, contraceptive patch, intrauterine device, diaphragm with spermicidal gel, or a sexual partner who is surgically sterilized or post-menopausal; for both male and female patients, effective methods of contraception must be used throughout the study and for three months following the last dose",no-pregnancy-nursing
"Female patients of child-bearing potential must have a negative pregnancy test and be non-lactating and use at least one form of contraception as approved by the Investigator for 4 weeks prior to initiating study treatment and continuing for 6 months after the last dose of study drug. For the purposes of this study, child-bearing potential is defined as all female patients unless they are post-menopausal for at least 3 years or surgically sterile.",no-pregnancy-nursing
"Female patients of child-bearing potential must have a negative pregnancy test and be non-lactating and use at least one form of contraception as approved by the Investigator for 4 weeks prior to initiating study treatment and continuing for 6 months after the last dose of study drug. For the purposes of this study, child-bearing potential is defined as  all female patients unless they are post-menopausal for at least 3 years or surgically sterile .",no-pregnancy-nursing
Female patients of childbearing potential must have a negative pregnancy test at screening and within 24 hours of dosing. It is recommended that female caregivers of childbearing potential have a negative pregnancy test within one week of dosing.,no-pregnancy-nursing
"Female patients of childbearing potential must have a negative pregnancy test upon study entry. This is not required for female patients who are of non-reproductive potential (i.e., post-menopausal by history - defined as: no menses for greater than or equal to 1 year; OR, history of hysterectomy; OR, history of bilateral tubal ligation; OR, history of bilateral oophorectomy).",no-pregnancy-nursing
Female patients of childbearing potential must have a negative pregnancy test within 24 hours of dosing,no-pregnancy-nursing
Female patients of childbearing potential must have a negative pregnancy test within 24 hours of enrollment,no-pregnancy-nursing
Female patients of childbearing potential must have a negative pregnancy test within 7 days of the start of treatment and must agree to use an effective method of contraception during the trial,no-pregnancy-nursing
"Female patients of childbearing potential must have a negative serum beta-human chorionic gonadotropin (β-hCG) pregnancy test within 28 days prior to the start of study drug. For clinical sites in the UK and Germany, pregnancy testing must occur within 7 days prior to the start of study drug.",no-pregnancy-nursing
Female patients of childbearing potential must have a negative serum or urine pregnancy test and if sexually active must agree to contraceptive requirements outlined in Section 10.6.12.2. Male patients who are sexually active with heterosexual partners of childbearing potential must agree to contraceptive requirements and sperm donation restrictions outlined in Section 10.6.12.2.,no-pregnancy-nursing
Female patients of childbearing potential must have a negative serum or urine pregnancy test within 3 days prior to initiating dosing. Male and female subjects with reproductive potential must agree to use acceptable contraceptive methods until the end of study visit.,no-pregnancy-nursing
Female patients of childbearing potential must have a negative serum pregnancy test (beta-human chorionic gonadotropin [hCG]) within 2 weeks of protocol entry,no-pregnancy-nursing
Female patients of childbearing potential must have a negative serum pregnancy test (BhCG) within 2 weeks of protocol entry.,no-pregnancy-nursing
Female patients of childbearing potential must have a negative serum pregnancy test (human chorionic gonadotropin [hCG]) within 2 weeks of protocol entry,no-pregnancy-nursing
Female patients of childbearing potential must have a negative serum pregnancy test at screening and a negative (serum or urine) pregnancy test within 72 hours before the first dose of study drug.,no-pregnancy-nursing
Female patients of childbearing potential must have a negative serum pregnancy test during screening.,no-pregnancy-nursing
Female patients of childbearing potential must have a negative urine or serum pregnancy test confirmed prior to enrollment.,no-pregnancy-nursing
"Female patients of childbearing potential must have a negative urine or serum pregnancy within 72 hours before receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required",no-pregnancy-nursing
"Female patients of childbearing potential must have a serum pregnancy test prior to randomization. Patients must not be pregnant or nursing due to the potential teratogenic side effects of the protocol treatment. Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of protocol treatment, and for 5 months (150 days) after the last dose of all study drugs. A woman is considered to be of  reproductive potential  if she has had a menses at any time in the preceding 12 consecutive months.",no-pregnancy-nursing
Female patients of childbearing potential must not be pregnant. Male and female subjects with reproductive potential must agree to use acceptable contraceptive methods until the end of study visit.,no-pregnancy-nursing
"Female patients of childbearing potential who are sexually active and male patients who are sexually acitive and have female partners must agree to use a highly effective method of contraception with their partners during exposure to defibrotide and for 1 week after the last dose of defibrotide. Highly effective methods of contraception that may be used by the patient include abstinence (when this is in line with the preferred and usual lifestyle of the patient [periodic abstinence, eg, calendar, post-ovulation, symptothermal methods, and withdrawal are not acceptable methods]), combined (estrogen- and progestogen-containing) hormonal contraception associated with inhibition of ovulation (ie, birth control pills, patches, vaginal ring), progestogen-only hormonal contraception associated with inhibition of ovulation (ie, progestin implant or injection), intrauterine device (IUD), intrauterine hormone-releasing system (IUS), surgical sterilization, and vasectomy ( > 6 months before study Day 1). Surgically sterile woman and men and post-menopausal women (ie, women with > 2 years of amenorrhea) do not need to use contraception.",no-pregnancy-nursing
"Female patients of reproductive potential must agree and commit to the use of a highly effective method of contraception, as determined to be acceptable by the investigator, from the time of informed consent until 28 days after the last dose of the investigational product. Male patients must agree and commit to use a barrier method of contraception while on treatment and for 3 months after the last dose of the investigational product.",no-pregnancy-nursing
Female patients who are both lactating and breastfeeding or have a positive serum pregnancy test during the screening period or a positive urine pregnancy test on day 1 before first dose of study drug,no-pregnancy-nursing
Female patients who are both lactating and breastfeeding or have a positive serum pregnancy test during the screening period or a positive urine pregnancy test on day 1 before first dose of TAK-659,no-pregnancy-nursing
Female patients who are currently in pregnancy,no-pregnancy-nursing
"Female patients who are currently in pregnancy, or unwilling to use acceptable methods of contraception or refrain from pregnancy if of childbearing potential or currently breastfeeding. Male patients who are unwilling to follow the contraception requirements described in this protocol.",no-pregnancy-nursing
Female patients who are currently pregnant or nursing,no-pregnancy-nursing
Female patients who are currently pregnant.,no-pregnancy-nursing
"Female patients who are lactating and breastfeeding or have a positive serum pregnancy test during the screening period, or male or female patients of reproductive potential who are not employing an effective method of birth control.",no-pregnancy-nursing
Female patients who are lactating and breastfeeding or have a positive serum pregnancy test during the Screening period.,no-pregnancy-nursing
Female patients who are lactating or have a positive serum pregnancy test during the screening period,no-pregnancy-nursing
Female patients who are lactating or have a positive serum pregnancy test during the screening period.,no-pregnancy-nursing
Female patients who are lactating or pregnant,no-pregnancy-nursing
"Female patients who are not of child-bearing potential and female patients of child-bearing potential who have a negative serum pregnancy test within 3 days prior to Cycle 1, Day 1.",no-pregnancy-nursing
Female patients who are not surgically sterile or postmenopausal (for at least 1 year) must practice at least one of the following methods of birth control throughout the duration of study participation and for at least 12 months after study treatment:,no-pregnancy-nursing
Female patients who are not surgically sterile or postmenopausal (for at least 1 year) must practice at least one of the following methods of birth control throughout the duration of study participation and for at least 5 months after study treatment:,no-pregnancy-nursing
Female patients who are nursing or have a positive pregnancy test during screening are not eligible,no-pregnancy-nursing
"Female patients who are of non-reproductive potential (i.e., post-menopausal by history - no menses for greater than or equal to 1 year; OR history of hysterectomy; OR history of bilateral tubal ligation; OR history of bilateral oophorectomy). Female patients of childbearing potential must have a negative serum pregnancy test upon study entry.",no-pregnancy-nursing
"Female patients who are postmenopausal for at least 1 year before the screening visit, or are surgically sterile. Female patients of childbearing potential should agree to practice 2 effective methods of contraception, at the same time, from the time of signing the informed consent through 4 months after the last dose of study drug, or agree to completely abstain from heterosexual intercourse.",no-pregnancy-nursing
Female patients who are pregnant (as per institutional practice) or lactating,no-pregnancy-nursing
Female patients who are pregnant are not eligible; pregnancy tests must be obtained in girls who are post menarchal,no-pregnancy-nursing
"Female patients who are pregnant or breast feeding, or adults of reproductive potential who are not using effective birth control methods. Women of child bearing potential (WOCBP) or male study participants of reproductive potential must agree to use double barrier birth control method of contraception during the course of the study treatment period and for 3 months after completing study treatment. WOCBP are defined as sexually mature women who have not undergone a hysterectomy or who are not postmenopausal (no menses) for at least 12 consecutive months. WOCBP must have a negative urine or serum pregnancy test within 14 days prior to administration of treatment.",no-pregnancy-nursing
Female patients who are pregnant or breast-feeding,no-pregnancy-nursing
Female patients who are pregnant or breastfeeding or male or female patients of reproductive potential who are not willing to employ effective birth control from screening to 90 days after the last dose of durvalumab monotherapy.,no-pregnancy-nursing
Female patients who are pregnant or breastfeeding or male or female patients of reproductive potential who are not willing to employ effective birth control from screening to 90 days after the last dose of IP.,no-pregnancy-nursing
"Female patients who are pregnant or breastfeeding or male or female patients of reproductive potential who are not willing to employ highly effective birth control from screening to 6 months after the last dose of study treatment. Not engaging in sexual activity, per the patient's preferred and usual lifestyle, for the total duration of the treatment and washout periods is an acceptable practice.",no-pregnancy-nursing
"Female patients who are pregnant or breastfeeding, or male or female patients of reproductive potential who are not willing to employ effective birth control from screening to 90 days after the last dose of durvalumab monotherapy or 180 days after the last dose of durvalumab plus tremelimumab combination therapy. Not engaging in sexual activity, as per the patient's preferred and usual lifestyle, for the total duration of the treatment and washout periods is an acceptable practice.",no-pregnancy-nursing
Female patients who are pregnant or breast-feeding.,no-pregnancy-nursing
"Female patients who are pregnant or breast-feeding. Confirmation that the subject is not pregnant must be established by a negative serum beta-human chorionic gonadotropin (beta-hCG) pregnancy test result obtained during screening. Pregnancy testing is not required for post-menopausal or surgically sterilized women. Male or female patients, who are sexually active and of the child bearing age, must be willing to practice accepted birth control measures",no-pregnancy-nursing
Female patients who are pregnant or lactating are not eligible to receive treatment but can be followed for natural history.,no-pregnancy-nursing
Female patients who are pregnant or lactating.,no-pregnancy-nursing
Female patients who are pregnant since fetal toxicities and teratogenic effects have been noted for several of the study drugs. A pregnancy test is required for female patients of childbearing potential.,no-pregnancy-nursing
"Female patients who are pregnant, breast-feeding or male or female patients of reproductive potential who are not employing an effective method of birth control.",no-pregnancy-nursing
"Female patients who are pregnant, breast-feeding, or planning to become pregnant",no-pregnancy-nursing
"Female patients who are pregnant, nursing, or lactating.",no-pregnancy-nursing
Female patients who are pregnant. Pregnancy tests must be obtained in girls who are post menarchal.,no-pregnancy-nursing
Female patients who are sexually active and of reproductive potential are not eligible unless they agree to use an effective contraceptive method for the duration of their study participation and for 8 months after the last dose of InO.,no-pregnancy-nursing
Female patients who intend to donate eggs (ova) during the course of this study or 4 months after receiving their last dose of study drug(s),no-pregnancy-nursing
"Female patients who: are postmenopausal for at least 1 year before the screening visit, OR are surgically sterile, OR if they are of childbearing potential, agree to practice 2 effective methods of contraception, at the same time, from the time of signing the informed consent through 4 months after the last dose of study drug, or agree to completely abstain from heterosexual intercourse",no-pregnancy-nursing
Female patients with infants must agree not to breastfeed their infants while on the study.,no-pregnancy-nursing
Female patients with infants must agree not to breastfeed their infants while on this study.,no-pregnancy-nursing
"Female patients: if they are of childbearing potential (except if postmenopausal for at least 1 year before the screening visit, OR are surgically sterile), agree to one of the following:",no-pregnancy-nursing
"Female patients: if they are of childbearing potential, agree to one of the following:",no-pregnancy-nursing
"Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy) or tubal ligation at least six weeks before taking study treatment. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment; male sterilization (at least 6 months prior to screening). For female subjects on the study, the vasectomized male partner should be the sole partner for that subject.",no-pregnancy-nursing
"Female subject is either post-menopausal, surgically sterilized, or willing to use an acceptable method of birth control (i.e. a hormonal contraceptive, intra-uterine device, diaphragm with spermicide, condom with spermicide, or abstinence) for the duration of the study",no-pregnancy-nursing
"Female subject is either post-menopausal, surgically sterilized, or willing to use and acceptable method of birth control (i.e., a hormonal contraceptive, intra-uterine device, diaphragm with spermicide, condom with spermicide, or abstinence) for the duration of the study; women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 24 hours prior to the start of nivolumab",no-pregnancy-nursing
"Female subject is post-menopausal (no menstrual period for a minimum of 12 months) or surgically sterilized and has a negative serum pregnancy test upon entry. Women of childbearing potential (WOCBP) must use an oral or implanted contraceptive, a double barrier method of birth control or an intrauterine device upon enrollment through 3 months after receiving the last dose of IP. Male subject is surgically sterile or is willing to use contraception upon enrollment through 3 months after receiving the last dose of IP.",no-pregnancy-nursing
"Female subject must agree not to breastfeed starting at screening and throughout the study period, and for 6 months after the final study drug administration.",no-pregnancy-nursing
"Female subject must not donate ova starting at screening and throughout the study period, and for 6 months after the final study drug administration.",no-pregnancy-nursing
"Female subject of childbearing potential must agree to use adequate contraception during the study. Adequate contraception is defined by the concomitant use of two effective methods of contraception from the time of informed consent until 150 days after treatment discontinuation. The two contraception methods can be comprised of two barrier methods, or a barrier method plus a hormonal method or an intrauterine device that meets < 1% failure rate for protection from pregnancy in the product label. Female subjects of non-childbearing potential are those who are postmenopausal greater than 1 year or who have had a bilateral tubal ligation or hysterectomy or bilateral oophorectomy. Female subjects must refrain from egg cell donation while on study treatment and for at least 150 days after the last dose of investigational product.",no-pregnancy-nursing
Female subject of childbearing potential should have a negative serum pregnancy at screening.,no-pregnancy-nursing
Female subject of childbearing potential should have a negative serum pregnancy within 72 hours prior to receiving the first dose of study medication.,no-pregnancy-nursing
"Female subject of childbearing potential should have a negative urine or serum pregnancy at screening and within 24 hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required",no-pregnancy-nursing
"Female subject of childbearing potential should have a negative urine or serum pregnancy prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.",no-pregnancy-nursing
"Female subject of childbearing potential should have a negative urine or serum pregnancy test within 72 hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required",no-pregnancy-nursing
"Female subject of childbearing potential should have a negative urine or serum pregnancy within 2 weeks prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.",no-pregnancy-nursing
"Female subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of DCBA. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.",no-pregnancy-nursing
Female subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication.,no-pregnancy-nursing
"Female subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required",no-pregnancy-nursing
"Female subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.",no-pregnancy-nursing
"Female subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.Female subjects of childbearing potential must be willing to use an adequate method of contraception - Contraception, for the course of the study through 120 days after the last dose of study medication. Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject.",no-pregnancy-nursing
"Female subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required",no-pregnancy-nursing
"Female subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to registration; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required",no-pregnancy-nursing
"Female subjects (unless postmenopausal for at least 1 year before the screening visit, or surgically sterilized), agree to practice two (2) effective methods of contraception at the same time, or agree to completely abstain from heterosexual intercourse, from the time of signing of the informed consent through 12 months post-transplant",no-pregnancy-nursing
"Female subjects must be either post-menopausal, surgically sterilized, or willing to use an acceptable method of birth control (i.e. a hormonal contraceptive, intra-uterine deice, diaphragm with spermicide, condom with spermicide, or abstinence) beginning prior to study entry, for the duration of the study, and for six months duration of study participation; should a woman become pregnant or suspect that she is pregnant while participating on the trial, she should inform her treating physician immediately",no-pregnancy-nursing
"Female subjects must be either post-menopausal, surgically sterilized, or willing to use an acceptable method of birth control (i.e. a hormonal contraceptive, intra-uterine device, diaphragm with spermicide, condom with spermicide, or abstinence) beginning prior to study entry, for the duration of the study, and for six months following last dose of avelumab/utomilumab; should a woman become pregnant or suspect that she is pregnant while participating on the trial, she should inform her treating physician immediately",no-pregnancy-nursing
"Female subjects must be postmenopausal ( > 12 months without menses) or surgically sterile (ie, by hysterectomy and/or bilateral oophorectomy) or must be using effective contraception (ie, oral contraceptives, intrauterine device, double barrier method of condom and spermicide) and agree to continue use of contraception for 30 days after their last dose of assigned study treatment. Abstinence is also an acceptable form of contraception.",no-pregnancy-nursing
"Female subjects must not donate, or retrieve for their own use, ova from the time of Screening and throughout the study treatment period, and for at least 4.5 months after the final study drug administration.",no-pregnancy-nursing
"Female subjects of childbearing potential (FCBP) must have a negative serum or urine pregnancy test with a sensitivity of at least 25 mIU/mL within 10 14 days and again within 24 hours prior to prescribing Revlimid for Cycle 1 (prescriptions must be filled within 7 days as required by Revlimid REMSTM) and must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control, one highly effective method and one additional effective method AT THE SAME TIME, at least 28 days before she starts taking Revlimid. FCBP must also agree to ongoing pregnancy testing.",no-pregnancy-nursing
"Female subjects of childbearing potential (FCBP) must have a negative serum pregnancy test. NOTE: FCBP is defined as premenopausal and not surgically sterilized. FCBP must agree to use effective birth control or to abstain from heterosexual activity throughout the study, starting at the first dose of chemotherapy for at least 12 months thereafter or 4 months after there is no evidence of persistence or gene modified cells are in the subject's blood, whichever is longer. FCBP must also agree to refrain from egg donation, storage, or banking during these same time periods. Effective contraceptive methods include intra-uterine device, oral and injectable hormonal contraception, or 2 adequate barrier methods (e.g., diaphragm with spermicide, cervical cap with spermicide, or female condom with spermicide). Spermicides alone are not an adequate method of contraception; or",no-pregnancy-nursing
Female subjects of childbearing potential (FCBP*) must:,no-pregnancy-nursing
"Female subjects of childbearing potential (i.e., not surgically sterile or postmenopausal) who are sexually active with a non-sterilized male partner must use >= 1 highly effective method of contraception from the time of screening and must agree to continue using such precautions for 2 days after the last dose of study treatment. Contraception measures and restrictions on sperm donation are not required for male subjects.",no-pregnancy-nursing
"Female subjects of childbearing potential (Section 5.7.2) must be willing to use an adequate method of contraception as outlined in Section 5.7.2 - Contraception, for the course of the study through 120 days after the last dose of study medication.",no-pregnancy-nursing
Female subjects of childbearing potential and male subjects must agree to use acceptable method(s) of contraception from enrollment through at least 12 months after CTX110 infusion.,no-pregnancy-nursing
"Female subjects of childbearing potential must agree to use a highly effective method of birth control during and for 4 weeks after completion of study. Women are considered to be of childbearing potential unless it is documented that they are over the age of 60 OR postmenopausal by history with no menses for 1 year and confirmed by FSH (using local reference ranges) OR have a history of hysterectomy and/or bilateral oophorectomy OR have a history of bilateral tubal ligation. Highly effective methods of birth control include hormonal birth control (oral, intravaginal, transdermal, implantable, or intrauterine), intrauterine devices (IUDs), vasectomy, or any double-barrier methods (combination of male condom and spermicide with cap, diaphragm, or sponge).",no-pregnancy-nursing
"Female subjects of childbearing potential must be surgically sterile, be post-menopausal (for at least 1 year prior to screening visit), or must have a negative pregnancy test within 3 days prior to cycle 1 day 1 and agree to use medically acceptable contraception throughout the study period and for 4 months after the last dose of either study drug. Men of reproductive potential may not participate unless they agree to use medically acceptable contraception throughout the study period and for 4 months after the last dose of either study drug",no-pregnancy-nursing
"Female subjects of childbearing potential must be surgically sterile, be post-menopausal (per institutional guidelines), or must have a negative pregnancy test within 3 days prior to cycle 1 day 1 and agree to use medically acceptable contraception throughout the study period and for 4 months after the last dose of either study drug. Men of reproductive potential may not participate unless they agree to use medically acceptable contraception throughout the study period and for 4 months after the last dose of either study drug",no-pregnancy-nursing
"Female subjects of childbearing potential must be surgically sterile, be post-menopausal (per institutional guidelines), or must have a negative serum pregnancy test within 7 days prior to cycle 1 day 1 and agree to use medically acceptable contraception throughout the study period and for 4 months after the last dose of either study drug. Men of reproductive potential may not participate unless they agree to use medically acceptable contraception throughout the study period and for 4 months after the last dose of either study drug",no-pregnancy-nursing
"Female subjects of childbearing potential must be willing to abstain from heterosexual activity or to use 2 forms of effective methods of contraception from the time of informed consent until 6 months after study treatment discontinuation. The two contraception methods can be comprised of two barrier methods, or a barrier method plus a hormonal method or an intrauterine device that meets < 1% failure rate for protection from pregnancy in the product label.",no-pregnancy-nursing
Female subjects of childbearing potential must be willing to use an adequate method of contraception,no-pregnancy-nursing
Female subjects of childbearing potential must be willing to use an adequate method of contraception &ndash; Contraception for the course of the study through 120 days after the last dose of study medication.,no-pregnancy-nursing
"Female subjects of childbearing potential must be willing to use an adequate method of contraception as outlined - contraception, for the course of the study through 120, corresponding to time needed to eliminate any Merck study treatment(s) and/or any active comparator/combination, plus 30 days (a menstruation cycle) for study treatments with risk of genotoxicity days after the last dose of study medication.",no-pregnancy-nursing
Female subjects of childbearing potential must be willing to use an adequate method of contraception as outlined in Section 5.4.3 - Contraception for the course of the study through 120 days after the last dose of study medication.,no-pregnancy-nursing
Female subjects of childbearing potential must be willing to use an adequate method of contraception for the course of the study through 120 days after the last dose of study medication.,no-pregnancy-nursing
Female subjects of childbearing potential must be willing to use an adequate method of contraception for the course of the study through 120 days after the last dose of study medication; Note: abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject,no-pregnancy-nursing
Female subjects of childbearing potential must be willing to use an adequate method of contraception for the course of the trial through 120 days after the last dose of trial treatment,no-pregnancy-nursing
"Female subjects of childbearing potential must be willing to use an adequate method of contraception, for the course of the study through 120 days after the last dose of study medication. Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject.",no-pregnancy-nursing
Female subjects of childbearing potential must be willing to use an adequate method of contraception. Contraception should be used for the course of the study through 120 days after the last dose of study medication.,no-pregnancy-nursing
"Female subjects of childbearing potential must be willing to use an adequate method of contraception. Subjects must adhere to the contraception requirement from the day of study medication initiation, (or 14 days prior to the initiation of study medication for oral contraception) throughout the entire study, and up 120 days after the last dose of trial therapy.",no-pregnancy-nursing
"Female subjects of childbearing potential must be willing to use an adequate method of contraception; contraception, for the course of the study through 120 days after the last dose of study medication",no-pregnancy-nursing
Female subjects of childbearing potential must have a negative plasma pregnancy test upon study entry,no-pregnancy-nursing
Female subjects of childbearing potential must have a negative plasma pregnancy test upon study entry.,no-pregnancy-nursing
Female subjects of childbearing potential must have a negative plasma pregnancy test upon study entry. See section on Pregnancy and Reproduction.,no-pregnancy-nursing
Female subjects of child-bearing potential must have a negative serum pregnancy test within 14 days of the first day of drug dosing.,no-pregnancy-nursing
"Female subjects of childbearing potential must have a negative serum pregnancy test within 72 hours prior to cell procurement. Note: Females are considered of childbearing potential unless they are surgically sterile (have undergone a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or they are naturally postmenopausal for at least 12 consecutive months. Documentation of postmenopausal status must be provided.",no-pregnancy-nursing
Female subjects of childbearing potential must have a negative urine/serum pregnancy test upon study entry. Women as well are not advised to breastfeed during treatment with bortezomib and for 2 months after treatment.,no-pregnancy-nursing
Female subjects of childbearing potential must have negative results for pregnancy test.,no-pregnancy-nursing
"Female subjects of childbearing potential must not be pregnant at screening. Females of childbearing potential are defined as premenopausal females capable of becoming pregnant (ie, females who have had any evidence of menses in the past 12 months, with the exception of those who had prior hysterectomy). However, women who have been amenorrheic for 12 or more months are still considered to be of childbearing potential if the amenorrhea is possibly due to prior chemotherapy, antiestrogens, low body weight, ovarian suppression or other reasons.",no-pregnancy-nursing
"Female subjects of childbearing potential must not be pregnant at screening. Females of childbearing potential are defined as premenopausal females capable of becoming pregnant; i.e., females who have had any evidence of menses in the past 12 months, with the exception of those who had prior hysterectomy). However, women who have been amenorrheic for 12 or more months are still considered to be of childbearing potential if the amenorrhea is possibly due to prior chemotherapy, antiestrogens, low body weight, ovarian suppression or other reasons.",no-pregnancy-nursing
Female subjects of childbearing potential must:,no-pregnancy-nursing
"Female subjects of childbearing potential should be willing to use 2 methods of birth control or be surgically sterile, or abstain from heterosexual activity for the course of the study through 120 days after the last dose of study medication (Reference Section 5.5.3). Subjects of childbearing potential are those who have not been surgically sterilized or have not been free from menses for > 1 year.",no-pregnancy-nursing
"Female subjects of childbearing potential should be willing to use 2 methods of birth control or be surgically sterile, or abstain from heterosexual activity for the course of the study through 120 days after the last dose of study medication. Subjects of childbearing potential are those who have not been surgically sterilized or have not been free from menses for > 1 year.",no-pregnancy-nursing
Female subjects of childbearing potential should have a negative serum pregnancy (beta-human chorionic gonadotropin) within 7 days prior to receiving the first dose of trial treatment and should not be lactating,no-pregnancy-nursing
Female subjects of childbearing potential should have a negative serum pregnancy <= 7 days prior to registration.,no-pregnancy-nursing
Female subjects of childbearing potential should have a negative urine or serum pregnancy test (β-hCG) within 72 hours prior to receiving the first dose of study medication.,no-pregnancy-nursing
"Female subjects of childbearing potential should have a negative urine or serum pregnancy test within 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.",no-pregnancy-nursing
Female subjects of childbearing potential who are sexually active and male subjects who are sexually active and have female partners of childbearing potential must agree to use a highly effective method of contraception with their partners during exposure to defibrotide and for 30 days after the last dose of defibrotide.,no-pregnancy-nursing
"Female subjects of childbearing potential who are sexually active with a nonsterilized male partner must use at least one highly effective method of contraception (see Section 10.2 for definition of females of childbearing potential and for a description of highly effective methods of contraception) post-screening, and must agree to continue using such precautions for 90 days after the final dose of investigational product. It is strongly recommended for the male partner of a female subject to also use male condom plus spermicide throughout this period. Cessation of contraception after this point should be discussed with a responsible physician. Periodic abstinence, the rhythm method, and the withdrawal method are not acceptable methods of contraception.",no-pregnancy-nursing
"Female subjects who are not of child-bearing potential, and female subjects of child-bearing potential who have a negative serum pregnancy test within 3 days prior to Cycle 1, Day 1. Female subjects of child-bearing potential, and male partners must consent to use a medically acceptable method of contraception throughout the study period and for 30 days after the last dose of ublituximab or umbralisib or venetoclax. Men of reproductive potential may not participate unless they agree to use medically acceptable contraception.",no-pregnancy-nursing
"Female subjects who are not pregnant, breastfeeding, or considering becoming pregnant during the study or for approximately 6 months after the last dose of study drug (venetoclax and gilteritinib).",no-pregnancy-nursing
"Female subjects who are of non-reproductive potential (i.e., post-menopausal by history - no menses for >= 1 year; OR history of hysterectomy; OR history of bilateral tubal ligation; OR history of bilateral oophorectomy). Female subjects of childbearing potential must have a negative serum pregnancy test upon study entry",no-pregnancy-nursing
"Female subjects who are of non-reproductive potential (i.e., post-menopausal by history - no menses for >= 1 year; OR history of hysterectomy; OR history of bilateral tubal ligation; OR history of bilateral oophorectomy). Female subjects of childbearing potential must have a negative serum pregnancy test upon study entry.",no-pregnancy-nursing
"Female subjects who are of non-reproductive potential (i.e., post-menopausal by history - no menses for >= 1 year; OR history of hysterectomy; OR history of bilateral tubal ligation; OR history of bilateral oophorectomy); female subjects of childbearing potential must have a negative urine/serum pregnancy test upon study entry",no-pregnancy-nursing
"Female subjects who are of non-reproductive potential (i.e., post-menopausal by history -no menses for >= 1 year; OR history of hysterectomy; OR history of bilateral tubal ligation; OR history of bilateral oophorectomy). Female subjects of childbearing potential must have a negative serum pregnancy test upon study entry.",no-pregnancy-nursing
Female subjects who are pregnant or breastfeeding,no-pregnancy-nursing
Female subjects who are pregnant or breast-feeding,no-pregnancy-nursing
Female subjects who are pregnant or breastfeeding.,no-pregnancy-nursing
Female who is breastfeeding or pregnant or female of childbearing potential or male with a female partner of childbearing potential unwilling to use a highly effective method of contraception,no-pregnancy-nursing
"Female who is not pregnant, breastfeeding, or considering becoming pregnant during the course of this study or for at least 30 days after the last dose of venetoclax.",no-pregnancy-nursing
"Female who is not pregnant, breastfeeding, or considering becoming pregnant during the study and for at least 30 days after the last dose of study drug.",no-pregnancy-nursing
Female: Pregnant or breastfeeding.,no-pregnancy-nursing
Females must agree to abstain from breastfeeding during study participation,no-pregnancy-nursing
"Females must be postmenopausal ( > 12 months without menses) or surgically sterile (ie, by hysterectomy and/or bilateral oophorectomy) or, if sexually active, must be using effective contraception (ie, oral contraceptives, intrauterine device, double barrier method of condom and spermicide) and agree to continue use of contraception for 30 days after their last dose of study drug.",no-pregnancy-nursing
Females must not be breast-feeding for 1 month after last dose,no-pregnancy-nursing
Females must not be breast-feeding.,no-pregnancy-nursing
Females must not be pregnant or lactating. Women of child-bearing potential must use a highly effective method of contraception throughout their study participation and for at least 6 months following the last dose of study drug.,no-pregnancy-nursing
Females must not breastfeed for 1 month after last dose.,no-pregnancy-nursing
Females of child bearing potential (FCBP) must have a negative serum or urine pregnancy test within 72 hours of D1 of IP.,no-pregnancy-nursing
Females of child bearing potential and sexually active males must agree to use adequate birth control during study treatment,no-pregnancy-nursing
Females of child bearing potential and sexually active males must agree to use adequate birth control during study treatment.,no-pregnancy-nursing
Females of child bearing potential must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 24 hours prior to the start of nivolumab.,no-pregnancy-nursing
Females of child bearing potential must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin [HCG]),no-pregnancy-nursing
Females of child bearing potential must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin [HCG]) within 24 hours prior to the start of nivolumab,no-pregnancy-nursing
Females of childbearing potential,no-pregnancy-nursing
Females of childbearing potential (CBP) must have a negative serum pregnancy test within one week of enrollment. Women should avoid pregnancy while receiving study treatment. Males and females must agree to use adequate birth control during participation in this trial and for 3 months after completing therapy.,no-pregnancy-nursing
Females of childbearing potential (FCBP) must agree to use two reliable forms of contraception simultaneously or have or will have complete abstinence from heterosexual intercourse during the following time periods related to this study:,no-pregnancy-nursing
"Females of childbearing potential (FCBP) must either abstain from sexual intercourse for the duration of their participation in the study or agree to use TWO acceptable methods of birth control, one highly effective method and one additional effective method AT THE SAME TIME for:",no-pregnancy-nursing
"Females of childbearing potential (FCBP) must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control: one highly effective method and one additional effective method AT THE SAME TIME, at least 28 days before starting lenalidomide, during lenalidomide therapy, during dose interruptions, and for at least 28 days following discontinuation of lenalidomide therapy",no-pregnancy-nursing
Females of childbearing potential (FCBP) must have a negative serum or urine pregnancy test,no-pregnancy-nursing
"Females of childbearing potential (FCBP) must have a negative serum or urine pregnancy test (within 30 days of initiation of protocol therapy) and must be willing to use acceptable methods of birth control during and after the study consistent with local regulations regarding the use of birth control methods for subjects participating in clinical trials. Men must agree to use a latex condom during sexual contact with a female of childbearing potential even if they have had a successful vasectomy. Men must agree to not donate sperm during and after the study. For females, these restrictions apply for 1 month after the last dose of study drug. For males, these restrictions apply for 3 months after the last dose of study drug",no-pregnancy-nursing
Females of childbearing potential (FCBP) must have a negative serum or urine pregnancy test and must be willing to use acceptable methods of birth control during the study and for 30 days after the last dose of study treatment.,no-pregnancy-nursing
"Females of childbearing potential (FCBP) must have a negative serum or urine pregnancy test and must be willing to use acceptable methods of birth control during the study and for 90 days after the last dose of study treatment; acceptable methods of birth control include condoms with birth control foam, birth control pills, implantable or injectable birth control, birth control patch, intrauterine device (IUD), or diaphragm with spermicidal gel; male patients must use an effective barrier method of contraception (i.e. , condoms with birth control foam or diaphragm with spermicidal gel) during the study and for 90 days following the last dose of study treatment if sexually active with a female of childbearing potential; contraception must be in place at least 2 weeks prior to initiating study treatment; a female of childbearing potential is a sexually mature woman who:",no-pregnancy-nursing
Females of childbearing potential (FCBP) must have a negative serum or urine pregnancy test and willing to use highly effective methods of birth control. A female of childbearing potential is a sexually mature woman who:,no-pregnancy-nursing
"Females of childbearing potential (FCBP) must have a negative serum or urine pregnancy test with a sensitivity of at least 25 mIU/mL within 10-14 days and again within 24 hours prior to starting cycle 1 of lenalidomide; further, they must either commit to complete abstinence (true abstinence is acceptable when this is in line with the preferred and usual lifestyle of the subject; periodic abstinence [e.g., calendar, ovulation, symptothermal or post ovulation methods] and withdrawal are not acceptable methods of contraception) from heterosexual intercourse or begin TWO acceptable methods of birth control: one highly effective method and one additional effective method AT THE SAME TIME, at least 28 days before starting lenalidomide; while taking lenalidomide, during dose interruptions, and for at least 28 days after the last dose of lenalidomide; FCBP must also agree to ongoing pregnancy testing; men must agree to use a latex condom during sexual contact with a FCBP, even if they have had a successful vasectomy; a FCBP is a female who:",no-pregnancy-nursing
"Females of childbearing potential (FCBP) must have a negative serum or urine pregnancy test with a sensitivity of at least 25 mIU/mL within 10-14 days prior to registration. FCBP must agree to have a second pregnancy test within 24 hours prior to starting Cycle 1. Further, FCBP must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control: one highly effective method and one additional effective method AT THE SAME TIME, at least 28 days before starting lenalidomide. FCBP must also agree to ongoing pregnancy testing and must agree to not become pregnant for at least 3 months after the last dose of study treatment. A FCBP is a female who:",no-pregnancy-nursing
"Females of childbearing potential (FCBP) must have a negative serum or urine pregnancy test with a sensitivity of at least 25 mIU/mL within 14 days prior to and again within 1 day before starting lenalidomide and must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control, one highly effective method and one additional effective method AT THE SAME TIME, at least 28 days before she starts taking lenalidomide. Females of reproductive potential must adhere to the scheduled pregnancy testing as required in the Revlimid REMS program. Men must agree to use a latex condom during sexual contact with a FCBP even if they have had a vasectomy. All subjects must be counseled at a minimum of every 28 days about pregnancy precautions and risks of fetal exposure. Risks of Fetal Exposure, Pregnancy Testing Guidelines and Acceptable Birth Control",no-pregnancy-nursing
Females of childbearing potential (FCBP) must have a negative serum or urine pregnancy test with a sensitivity of at least 50 mIU/mL within 10-14 days prior to study entry,no-pregnancy-nursing
Females of childbearing potential (FCBP) must have a negative serum or urine pregnancy test with a sensitivity of at least 50 mIU/mL within 24 hours prior to the initiation of the study and they must agree to ongoing pregnancy testing and to practice contraception,no-pregnancy-nursing
"Females of childbearing potential (FCBP) must have a negative serum or urine pregnancy test within 10 - 14 days prior to and again within 24 hours prior to starting REVLIMID��?��??��?��???��?��?? and must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control, one highly effective method and one additional effective method AT THE SAME TIME, at least 28 days before she starts taking REVLIMID��?��??��?��???��?��??. FCBP must also agree to ongoing pregnancy testing.",no-pregnancy-nursing
"Females of childbearing potential (FCBP) must have a negative serum pregnancy test within 3 days prior to day 1 of treatment. NOTE: Females are considered of child bearing potential unless they are surgically sterile (have undergone a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or are postmenopausal (at least 12 consecutive months with no menses without an alternative medical cause).",no-pregnancy-nursing
Females of childbearing potential (FCBP) must:,no-pregnancy-nursing
Females of childbearing potential (FCBP)1 must:,no-pregnancy-nursing
Females of childbearing potential (FCBP)† must have a negative serum pregnancy test and agree to use appropriate methods of birth control,no-pregnancy-nursing
Females of child-bearing potential (FOCBP) and men who are sexually active with FOCBP must agree to follow instructions for method(s) of contraception for the duration of treatment and the designated post-treatment period.,no-pregnancy-nursing
Females of child-bearing potential (FOCBP) must have a negative pregnancy test within # days prior to registration on study,no-pregnancy-nursing
Females of childbearing potential (FOCBP) must have a negative urine or serum pregnancy test within 7 days prior to registration on study.,no-pregnancy-nursing
"Females of childbearing potential [A woman is considered to be of childbearing potential if she is postmenarcheal, has not reached a postmenopausal state ( >= 12 continuous months of amenorrhea with no identified cause other than menopause), and has not undergone surgical sterilization (removal of ovaries and/or uterus)] must have a negative serum or urine beta human chorionic gonadotrophin (b-hCG) pregnancy test result within 14 days prior to the first dose of treatment and must agree to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods with a failure rate of < 1% per year during the treatment period and for 6 months following the last dose of the study drugs. Examples of contraceptive methods with a failure rate of < 1% per year include bilateral tubal ligation, male sterilization, hormonal contraceptives that inhibit ovulation, hormone-releasing intrauterine devices, and copper intrauterine devices.",no-pregnancy-nursing
Females of childbearing potential and males must agree to use an acceptable form of contraception per institutional practices.,no-pregnancy-nursing
"Females of childbearing potential and males must be willing to abstain from heterosexual activity (abstinence) or use effective methods of contraception as described in Section 5.5 from the time of informed consent until 120 days after treatment discontinuation. NOTE: Females are considered of child bearing potential unless they are surgically sterile (have undergone a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or they are naturally postmenopausal for at least 12 consecutive months",no-pregnancy-nursing
"Females of childbearing potential and non-sterile males must agree to use highly effective methods of birth control throughout the course of study and at least up to 90 days after last dosing, or 18 months after the last dose of obinutuzumab, whichever is longer.",no-pregnancy-nursing
Females of childbearing potential and non-sterilized male subjects with female partners of childbearing potential must use effective methods of contraception from screening to 180 days after the final dose of study treatment (see Appendix A),no-pregnancy-nursing
"Females of childbearing potential are defined as those who are not surgically sterile (i.e., bilateral tubal ligation, bilateral oophorectomy, or complete hysterectomy) or postmenopausal (defined as at least 12 months with no menses confirmed by follicle-stimulating hormone [FSH] levels. FSH testing will be conducted at the Screening visit to confirm post-menopausal status).",no-pregnancy-nursing
"Females of childbearing potential are defined as those who are not surgically sterile (ie, have not undergone bilateral tubal ligation, bilateral oophorectomy, or complete hysterectomy) or those who are not postmenopausal (defined as 12 months with no menses without an alternative medical cause). The following age-specific requirements apply to the definition of postmenopausal:",no-pregnancy-nursing
Females of childbearing potential must be on acceptable form of birth control per instutional standard.,no-pregnancy-nursing
"Females of childbearing potential must be willing to abstain from heterosexual activity or to use 2 forms of effective methods of contraception from the time of informed consent until 24 weeks (6 months) after treatment discontinuation. The two contraception methods can be comprised of two barrier methods, or a barrier method plus a hormonal method or an intrauterine device that meets < 1% failure rate for protection from pregnancy in the product label.",no-pregnancy-nursing
"Females of childbearing potential must have 2 negative pregnancy tests, agree to ongoing pregnancy testing during the study, and sexually active female and male subjects must be willing to use an effective method to avoid pregnancies.",no-pregnancy-nursing
Females of child-bearing potential must have a negative pregnancy test because of the potentially dangerous/unknown effects on the fetus.,no-pregnancy-nursing
Females of childbearing potential must have a negative pregnancy test within 30 days prior to enrollment. Females who are postmenopausal for at least 1 year (defined as more than 12 months since last menses) or who are surgically sterilized do not require this test.,no-pregnancy-nursing
"Females of childbearing potential must have a negative serum or urine beta human chorionic gonadotrophin (β-hCG) pregnancy test result within 7 days prior to the first dose of SGN-LIV1A and must agree to use 2 effective contraceptive methods during the study and for an extended time after the last dose of study drug (Parts A and C: 6 months following the last dose of SGN-LIV1A and Part B: 7 months following the last dose of combination therapy with SGN-LIV1A and trastuzumab). Examples of effective contraception methods include, but are not limited to, the following: non-hormonal intrauterine device (IUD), condoms, diaphragm, tubal ligation (injections, implants), barrier methods, vasectomy (for male partners), or complete abstinence. Barrier methods include male and female condoms, diaphragms, and spermicides (creams or gels that contain a chemical to kill sperm) (Appendix F).",no-pregnancy-nursing
Females of childbearing potential must have a negative serum or urine beta human chorionic gonadotrophin (beta-hCG) pregnancy test result within 24 hours prior to the first dose of treatment and must agree to use a highly effective contraception method during the study and for 23 weeks following the last dose of the study drugs. Females of non- childbearing potential are those who are postmenopausal greater than 1 year or who have had a bilateral tubal ligation or hysterectomy. Males who have partners of childbearing potential must agree to use an effective contraceptive method during the study and for 31 weeks following the last dose of study drugs. Men must agree not to donate sperm during and for 3 months after the last dose of study drug. Women who are pregnant or breastfeeding are ineligible for this study,no-pregnancy-nursing
"Females of childbearing potential must have a negative serum or urine beta human chorionic gonadotropin (beta-hCG) pregnancy test result within 14 days prior to the first dose of study drugs and must agree to use an effective contraception method during the study and for 30 days following the last dose of study drug; females of non-childbearing potential are those who are postmenopausal greater than 1 year or who have had a bilateral tubal ligation or hysterectomy; appropriate methods of birth control include the following: any 2 of the following methods used together: birth control implants, injections, or pills (except for progesterone only pills), intrauterine device (IUD), vasectomy, tubal ligation, barrier method (female or male condom with spermicide, cervical cap with spermicide, diaphragm with spermicide); male condom with spermicide and diaphragm; male condom with spermicide and cervical cap; unacceptable methods of birth control include using no birth control, withdrawal, rhythm method, vaginal sponge, any barrier method that does not use spermicide, progesterone only pills, and using male and female condoms at the same time",no-pregnancy-nursing
Females of childbearing potential must have a negative serum or urine pregnancy test,no-pregnancy-nursing
Females of childbearing potential must have a negative serum or urine pregnancy test (females who have undergone surgical sterilization or who have been postmenopausal for at least 2 years are not considered to be of childbearing potential,no-pregnancy-nursing
Females of childbearing potential must have a negative serum or urine pregnancy test (females who have undergone surgical sterilization or who have been postmenopausal for at least 2 years are not considered to be of childbearing potential),no-pregnancy-nursing
Females of childbearing potential must have a negative serum or urine pregnancy test (females who have undergone surgical sterilization or who have been postmenopausal for at least 2 years are not considered to be of childbearing potential) Ability to understand and the willingness to sign a written informed consent document.,no-pregnancy-nursing
Females of childbearing potential must have a negative serum or urine pregnancy test (females who have undergone surgical sterilization or who have been postmenopausal for at least 2 years are not considered to be of childbearing potential).,no-pregnancy-nursing
Females of childbearing potential must have a negative serum or urine pregnancy test (females who have undergone surgical sterilization or who have been post-menopausal for at least 2 years are not considered to be of childbearing potential).,no-pregnancy-nursing
Females of childbearing potential must have a negative serum or urine pregnancy test result within 7 days prior to the first dose of study treatment. Women of child-bearing age must agree to use an effective contraception method during the study and for at least 6 months following the last dose of study drug.,no-pregnancy-nursing
Females of childbearing potential must have a negative serum or urine pregnancy test result within 72 hours prior to the first dose of nivolumab and must agree to follow instructions for method(s) of contraception for the duration of treatment with nivolumab and for 7 months following their last dose of study drug. Females of non-childbearing potential are those who are postmenopausal greater than 1 year or who have had a bilateral tubal ligation or hysterectomy.,no-pregnancy-nursing
"Females of childbearing potential must have a negative serum pregnancy test during Screening and must not be breastfeeding or intending to become pregnant during the study. Female patients will be considered to be of childbearing potential unless they have undergone permanent contraception or are postmenopausal. Postmenopausal is defined as at least 12 months without menses with no other medical reasons (e.g., chemical menopause due to anticancer treatment).",no-pregnancy-nursing
"Females of childbearing potential must have a negative serum pregnancy test within 14 days prior to registration. NOTE: Females are considered of child bearing potential unless they are surgically sterile (have undergone a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or they are naturally postmenopausal for at least 12 consecutive months.",no-pregnancy-nursing
"Females of childbearing potential must have a negative serum pregnancy test within 7 days prior to registration. NOTE: Females are considered of child bearing potential unless they are surgically sterile (have undergone a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or they are naturally postmenopausal for at least 12 consecutive months",no-pregnancy-nursing
"Females of childbearing potential must have a negative serum pregnancy test within 72 hours prior to registration. NOTE: If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required. NOTE: breast milk cannot be stored for future use while the mother is being treated on study",no-pregnancy-nursing
"Females of childbearing potential must have a negative serum pregnancy test within three days (72 hours) prior to initiating study treatment. NOTE: Females are considered of child bearing potential unless they are surgically sterile (have undergone a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or they are naturally postmenopausal for at least 12 consecutive months.",no-pregnancy-nursing
"Females of childbearing potential must not be pregnant or nursing, and have a negative pregnancy test within 28 days prior to registration. Women/men of reproductive potential must have agreed to use an effective contraceptive method while receiving study drug and for women until 6 months after receiving the last dose of study drug or, for men, until 7 months after receiving the last dose of study drug. A woman is considered to be of  reproductive potential  if she has had menses at any time in the preceding 12 consecutive months. In addition to routine contraceptive methods,  effective contraception  also includes heterosexual celibacy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy, bilateral oophorectomy or bilateral tubal ligation. However, if at any point a previously celibate patient chooses to become heterosexually active during the time period for use of contraceptive measures outlined in the protocol, he/she is responsible for beginning contraceptive measures.",no-pregnancy-nursing
Females of childbearing potential should avoid becoming pregnant and use highly effective contraception while on treatment and for at least 1 month and 1 week after finishing treatment.,no-pregnancy-nursing
Females of childbearing potential should have a negative serum or urine pregnancy test <= 72 hours prior to re-registration,no-pregnancy-nursing
"Females of childbearing potential who are not abstinent and intend to be sexually active with a nonsterilized male partner must have used at least one highly effective method of contraception (see Section Appendix A for definition of females of childbearing potential and for a description of highly effective methods of contraception) from the time of screening throughout the total duration of the drug treatment and the drug washout period (6 months after the last dose of durvalumab). Non-sterilized male partners of a female subject of childbearing potential must use a male condom plus spermicide throughout this period. Cessation of contraception after this point should be discussed with a responsible physician. Periodic abstinence, the rhythm method, and the withdrawal method are not acceptable methods of contraception. Female subjects should refrain from breastfeeding or egg donation throughout this period.",no-pregnancy-nursing
"Females of childbearing potential who are sexually active with a non-sterilized male partner must use a highly effective method of contraception (Table 4.1.2-1) from the time of screening, and must agree to continue using such precautions for 90 days (MEDI4736 and tremelimumab monotherapy) or 180 days (MEDI4736 combined with tremelimumab) after the final dose of investigational product(s). Male partners of a female subject must use male condom plus spermicide (or male condom in countries where spermicides are not approved or available) throughout these period. Cessation of contraception after this point should be discussed with a responsible physician. Not engaging in sexual activity for the total duration of the study and the drug washout period is an acceptable practice; however, occasional abstinence, the rhythm method, and the withdrawal method are not acceptable methods of contraception. Female subjects should refrain from breastfeeding throughout these periods.",no-pregnancy-nursing
"Females of childbearing potential who are sexually active with a nonsterilized male partner must use effective contraception from time of screening, and must agree to continue using such precautions for 90 days after the final dose of TAB001; cessation of birth control after this point should be discussed with a responsible physician. Periodic abstinence, the rhythm method, and the withdrawal method are not acceptable methods of birth control. Females of childbearing potential are defined as those who are not surgically sterile (i.e.bilateral tubal ligation, bilateral oophorectomy, or complete hysterectomy) or postmenopausal (defined as at least 12 months with no menses confirmed by folliclestimulating hormone [FSH] levels. FSH testing will be conducted at the Screening visit to confirm post-menopausal status).",no-pregnancy-nursing
"Females of childbearing potential who are sexually active with a nonsterilized male partner must use effective contraception from time of screening, and must agree to continue using such precautions for 90 days after the final dose of TAB004; cessation of birth control after this point should be discussed with a responsible physician. Periodic abstinence, the rhythm method, and the withdrawal method are not acceptable methods of birth control.",no-pregnancy-nursing
"Females of reproductive potential (defined as all females physiologically capable of becoming pregnant) must agree to use one highly effective method of contraception and one additional effective method of contraception from at least 28 days prior to beginning study therapy, during study therapy including dose interruptions, and for 1 year after the last dose of study therapy (see Section 5.3)",no-pregnancy-nursing
Females of reproductive potential are willing and able to adhere to the scheduled pregnancy testing as required by Celgene?s REVLIMID REMS program,no-pregnancy-nursing
Females of reproductive potential enrolled in the lenalidomide cohort must adhere to the scheduled pregnancy testing as required in the Revlimid Risk Evaluation and Mitigation Strategy (REMS) program,no-pregnancy-nursing
Females of reproductive potential must adhere to the scheduled pregnancy testing as required in the lenalidomide REMS® program. (Please see study schema for further details),no-pregnancy-nursing
Females of reproductive potential must adhere to the scheduled pregnancy testing as required in the Revlimid REMS program,no-pregnancy-nursing
Females of reproductive potential must adhere to the scheduled pregnancy testing as required in the Revlimid REMS® program.,no-pregnancy-nursing
"Females of reproductive potential must adhere to the scheduled pregnancy testing as required in the Revlimid REMS® program. Females of childbearing potential (FCBP) must have a negative serum or urine pregnancy test with a sensitivity of at least 50 mIU/mL within 10 - 14 days and again within 24 hours prior to prescribing lenalidomide for Cycle 1 (prescriptions must be filled within 7 days). FCBP must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control, one highly effective method and one additional effective method AT THE SAME TIME, at least 28 days before and continue for at least 28 days after the last dose of lenalidomide (or 2 days after the last dose of acalabrutinib, whichever is longer). FCBP must also agree to ongoing pregnancy testing. Men must agree to use a latex condom during sexual activity with a FCBP through one week post last dose even if they have had a successful vasectomy. Men must also agree to refrain from sperm donation during the same timeframe. See Appendix: Risks of Fetal Exposure, Pregnancy Testing Guidelines and Acceptable Birth Control Methods.",no-pregnancy-nursing
Females of reproductive potential must adhere to the scheduled pregnancy testing as required in the Revlimid REMSR program.,no-pregnancy-nursing
Females of reproductive potential must have a negative serum beta human chorionic gonadotropin (β-hCG) pregnancy test result at Screening and within 48 hours prior to the first dose of lymphodepleting chemotherapy,no-pregnancy-nursing
"Females of reproductive potential who are pregnant or lactating, and males or females not willing to use a highly effective form of contraception from Screening through the end of the study",no-pregnancy-nursing
"Females of reproductive potential who are pregnant or lactating, and males or females not willing to use a highly effective form of contraception from Screening through the end of the study.",no-pregnancy-nursing
Females of reproductive potential* must be willing to adhere to the scheduled pregnancy testing as required in the POMALYST REMS&reg; program.,no-pregnancy-nursing
Females only: Pregnant or breastfeeding,no-pregnancy-nursing
Females only: pregnant or breastfeeding.,no-pregnancy-nursing
Females or males of childbearing potential must be willing to use adequate methods of contraception as outline in section 9.9b or abstain from heterosexual activity for the course of th study through 120 days after last dose of study medication,no-pregnancy-nursing
Females planning to become pregnant during the course of the study.,no-pregnancy-nursing
Females planning to become pregnant while on study through 110 days after receiving the last dose of study drug.,no-pregnancy-nursing
Females planning to become pregnant while on study through 120 days after receiving the last dose of study drug.,no-pregnancy-nursing
Females planning to become pregnant while on study through 75 days after receiving the last dose of study drug.,no-pregnancy-nursing
Females who are breastfeeding.,no-pregnancy-nursing
Females who are currently pregnant or breastfeeding,no-pregnancy-nursing
Females who are lactating/breastfeeding or who plan to breastfeed while on study through 110 days after receiving the last dose of study drug.,no-pregnancy-nursing
Females who are lactating/breastfeeding or who plan to breastfeed while on study through 120 days after receiving the last dose of study drug.,no-pregnancy-nursing
Females who are lactating/breastfeeding or who plan to breastfeed while on study through 3 months after receiving the last dose of study drug.,no-pregnancy-nursing
Females who are lactating/breastfeeding or who plan to breastfeed while on study through 75 days after receiving the last dose of study drug.,no-pregnancy-nursing
"Females who are not of childbearing potential (i.e., who are postmenopausal or surgically sterile) and azoospermic males do not require contraception",no-pregnancy-nursing
"Females who are not of childbearing potential (i.e., who are postmenopausal or surgically sterile) and azoospermic males do not require contraception.",no-pregnancy-nursing
"Females who are not of child-bearing potential, and females of child-bearing potential (FCBP) who have a negative serum pregnancy test within 3 days prior to initial trial treatment. Males of reproductive potential may not participate unless they agree to use medically acceptable contraception. FCBP and all male partners, and male subjects must consent to use a medically acceptable method of contraception throughout the study period and for 4 months after the last dose of study drug",no-pregnancy-nursing
Females who are pregnant (positive HCG) or lactating.,no-pregnancy-nursing
Females who are pregnant (positive serum beta human chorionic gonadotropin beta [β HCG]) or uninterruptible breastfeeding,no-pregnancy-nursing
Females who are pregnant or breast feeding at the time of study entry are not eligible,no-pregnancy-nursing
Females who are pregnant or breastfeeding,no-pregnancy-nursing
Females who are pregnant or breast-feeding,no-pregnancy-nursing
Females who are pregnant or breast-feeding are not eligible.,no-pregnancy-nursing
Females who are pregnant or breastfeeding or planning to become pregnant or breastfeed during treatment and for an additional 30 days or longer after chemotherapy treatment discontinuation if required by prescribing information for chemotherapy agents received during the study.,no-pregnancy-nursing
Females who are pregnant or lactating,no-pregnancy-nursing
Females who are pregnant or lactating.,no-pregnancy-nursing
Females who are pregnant or lactating; and fertile male patients and female patients of childbearing potential who are unwilling or unable to use highly effective methods of contraception for the duration of the study and for at least 6 months after the last dose of study medication.,no-pregnancy-nursing
"Females who are pregnant or nursing. Pregnant individuals are excluded from this study because copanlisib and nivolumab have the potential to cause fetal harm based on relevant animal studies (Refer to the appropriate prescribing information). Because there is an unknown but potential risk for adverse events in nursing infants, breast-/chest-feeding should be discontinued prior to treatment with copanlisib and nivolumab.",no-pregnancy-nursing
"Females who are pregnant, lactating, or intend to become pregnant",no-pregnancy-nursing
"Females who are pregnant, lactating, or intend to become pregnant during their participation in the study.",no-pregnancy-nursing
Females who are pregnant.,no-pregnancy-nursing
Females who have undergone surgical sterilization or who have been post-menopausal for at least 2 years are not considered to be of childbearing potential.,no-pregnancy-nursing
Females with a positive pregnancy test or planning to become pregnant while on study through 3 months after receiving the last dose of study drug.,no-pregnancy-nursing
Females with a positive pregnancy test.,no-pregnancy-nursing
"Fertile female patients must use effective double-method contraception for >= 28 days before, during, and for >= 28 days after completion of study therapy",no-pregnancy-nursing
"Fertile male and female patients must be willing to use a contraceptive method before, during and for at least two months after the T cell infusion",no-pregnancy-nursing
"Fertile male and female patients must be willing to use a contraceptive method before, during, and for at least two months after the T cell infusion",no-pregnancy-nursing
"Fertile male and female patients must be willing to use an effective contraceptive method before, during, and for at least 4 months after the CAR T cell infusion",no-pregnancy-nursing
"Fertile male patients must use effective contraception during and for >= 28 days after completion of study therapy, even if they have had a successful vasectomy",no-pregnancy-nursing
"Fertile males, defined as all male subjects physiologically capable of conceiving offspring, must use a condom during study treatment and for 12 weeks after study discontinuation and should not father a child in this period.",no-pregnancy-nursing
Fertile men and women unwilling to use contraceptive techniques during and for 12 months following treatment,no-pregnancy-nursing
Fertile men must agree to use an effective method of birth control during the study and for up to 6 months after the last dose of study drug.,no-pregnancy-nursing
Fertile men or women of childbearing potential unless,no-pregnancy-nursing
Fertile men or women unwilling to use contraceptive techniques during and for 12 months following treatment,no-pregnancy-nursing
Fertile men unwilling to practice contraceptive methods during the study period.,no-pregnancy-nursing
Fertile patients must use effective contraception,no-pregnancy-nursing
Fertile patients must use effective contraception during and for 12 months after completion of therapy,no-pregnancy-nursing
"For a female of childbearing potential (FCBP), a negative pregnancy test must be confirmed before enrolment. An FCBP must commit to take highly effective contraceptive precautions without interruption during the study and for 3, 6 or 12 months after the last dose of MOR00208, BEN or RTX respectively, whichever is later. An FCBP must refrain from breastfeeding and donating blood or oocytes during the course of the study and for 3, 6 or 12 months after the last dose of MOR00208, BEN or RTX respectively, whichever is later. Restrictions concerning blood donations apply as well to females who are not of childbearing potential.",no-pregnancy-nursing
"For all male patients except those enrolling in the atezolizumab arm: must be willing to use acceptable methods of contraception. For additional inclusion criteria, please see the specific appendix for each study drug (Appendices 6-11).",no-pregnancy-nursing
for at least 28 days after discontinuation from the study. Men must agree to use a latex condom during sexual contact with a FCBP even if the participants have had a successful vasectomy. FCBP must be referred to a qualified provider of contraceptive methods if needed. FCBP must have a negative serum pregnancy test at screening.,no-pregnancy-nursing
for at least 28 days after the last dose of protocol treatment (FCBP who are assigned to Arm A and receive daratumumab must extend this contraception requirement to 3 months after the last dose of protocol treatment). Women must also agree to not breastfeed during this same time period. Men must agree to either abstain from sexual intercourse for the duration of their participation in the study or use a latex condom during sexual contact with a FCBP while participating in the study and for 28 days after the last dose of protocol treatment even if they have had a successful vasectomy. Men must also agree to abstain from donating sperm while on study treatment and for 28 days after the last dose of protocol treatment even if they have had a successful vasectomy. Both women and men must both agree to abstain from donating blood during study participation and for at least 28 days after the last dose of protocol treatment.,no-pregnancy-nursing
"For both male and female subjects, willingness to use adequate contraception",no-pregnancy-nursing
"For female individuals of childbearing potential and male individuals of reproductive potential, willingness to use a protocol- recommended method of contraception",no-pregnancy-nursing
"For female patients of childbearing potential and male patients with partners of childbearing potential agreement (by patient and/or partner) to use highly effective form(s) of contraception (i.e., one that results in a low failure rate [< 1% per year] when used consistently and correctly) and to continue its use for 6 months after trial completion.",no-pregnancy-nursing
"For female patients of childbearing potential and male patients with partners of childbearing potential, agreement (by patient and partner) to use a highly effective form(s) of contraception, that results in a low failure rate ( < 1% per year) when used consistently and correctly, starting during the screening period, continuing throughout the entire study period, and for 90 days after taking the last dose of study drug. Such methods include: oral hormonal contraception (combined estrogen/ progestogen, or progestogen-only), associated with inhibition of ovulation together with a barrier method (eg, diaphragm, always containing a spermicide); intrauterine device (IUD), intrauterine hormone-releasing system (IUS), bilateral tubal ligation, vasectomized partner (on the understanding that this is the only one partner during the whole study duration), or sexual abstinence. Oral contraception should always be combined with an additional contraceptive method (ie, barrier method) because of a potential interaction with the study drug. The same rules are valid for male patients involved in this clinical trial if they have a partner of childbirth potential. Male patients must always use a condom. A woman is considered to be of childbearing potential if she is postmenarcheal, has not reached a postmenopausal state (ie, >= 12 continuous months of amenorrhea with no identified cause other than menopause), and has not undergone surgical sterilization (removal of the ovaries and/or uterus).",no-pregnancy-nursing
"For female patients of childbearing potential and male patients with partners of childbearing potential, agreement (by patient and/or partner) to use highly effective form(s) of contraception (i.e., one that results in a low failure rate [< 1% per year] when used consistently and correctly) and to continue its use for 90 days after the last dose of zanubrutinib or venetoclax AND for 18 months after the last dose of obinutuzumab (whichever date is later)",no-pregnancy-nursing
"For female patients participating in the study, the vasectomized male partner should be the sole partner for that patient",no-pregnancy-nursing
"For female subjects of childbearing potential, a negative serum pregnancy test.",no-pregnancy-nursing
"For female subjects of childbearing potential, a negative urine or serum pregnancy test prior to the start of study therapy.",no-pregnancy-nursing
For female subjects of childbearing potential:,no-pregnancy-nursing
For female subjects of childbearing potential: Is pregnant or nursing,no-pregnancy-nursing
"For females of childbearing potential, a negative pregnancy test must be documented prior to randomization",no-pregnancy-nursing
"For females of childbearing potential, a negative serum or urine pregnancy test must be documented at screening, prior to pre-conditioning and confirmed before receiving the first dose of study treatment.",no-pregnancy-nursing
"For females of childbearing potential, a negative serum pregnancy test within 14 days of study Day 0",no-pregnancy-nursing
"For females of childbearing potential, a negative serum pregnancy test within 7 days of study treatment",no-pregnancy-nursing
"For females of child-bearing potential, negative serum or urine pregnancy test within 14 days prior to study registration",no-pregnancy-nursing
"For females of reproductive potential and men: The effects of vorinostat on the developing human fetus are unknown. For this reason and because histone deacetylase inhibitor agents as well as other therapeutic agents used in this trial (e.g., tacrolimus and methotrexate) are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation and for 4 months after completion of vorinostat administration.",no-pregnancy-nursing
"For fertile female patients, a negative pregnancy test result at enrollment",no-pregnancy-nursing
"For male subjects who can father a child and are having intercourse with females of childbearing potential who are not using adequate contraception, willingness to use an effective method of contraception from the start of study therapy until >= 3 months after the last dose of cirmtuzumab and >= 1 month after the last dose of ibrutinib, whichever is later, and to refrain from sperm donation from the start of study therapy until >= 3 months after administration of the final dose of either of the study drugs.",no-pregnancy-nursing
For males who can father a child and are having intercourse with females of childbearing potential who are not using adequate contraception:,no-pregnancy-nursing
"For males, it must be agreed that that two acceptable methods of contraception are used.",no-pregnancy-nursing
"For men and women of child-bearing potential, willing to use adequate contraception (e.g., latex condom, cervical cap, diaphragm, abstinence, etc.) for the entire duration of the study.",no-pregnancy-nursing
"For men and women of child-producing potential, the use of effective contraceptive methods during the study",no-pregnancy-nursing
"For men and women of child-producing potential, the use of effective contraceptive methods during the study and up to 6 months after the last dose of TRK-950",no-pregnancy-nursing
"For men and women of child-producing potential, use of effective contraceptive methods during the study. NOTE: All women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; or abstinence) prior to study entry and for the duration of study participation. Should a man father a child, or a woman become pregnant or suspect she is pregnant while participating in this study, he or she should inform the treating physician immediately.",no-pregnancy-nursing
"For men and women of child-producing potential, willingness to use of effective contraceptive methods during the study. If female (or female partner of male patient), was either not of childbearing potential (defined as postmenopausal for >= 1 year or surgically sterile [bilateral tubal ligation, bilateral oophorectomy or hysterectomy]) or practicing one of the following medically acceptable methods of birth control and agreed to continue with the regimen throughout the duration of the study:",no-pregnancy-nursing
"For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use a condom, and agreement to refrain from donating sperm, as defined below:",no-pregnancy-nursing
"For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use a condom, and agreement to refrain from donating sperm, as defined below: With female partners of childbearing potential or pregnant female partners, men must remain abstinent or use a condom during the treatment period for 6 months after the last dose of nab-paclitaxel, pemetrexed, carboplatin, or cisplatin, whichever is later, to avoid exposing the embryo. Men must refrain from donating sperm during this same period. The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception.",no-pregnancy-nursing
For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures and agreement to refrain from donating sperm,no-pregnancy-nursing
"For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures and agreement to refrain from donating sperm, as defined below: With female partners of childbearing potential or pregnant female partners, men must remain abstinent or use a condom during the treatment period and for at least 180 days after the last dose of study treatment. Men must refrain from donating sperm during this same period. The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception.",no-pregnancy-nursing
"For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating sperm, as defined below:",no-pregnancy-nursing
"For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating sperm, as outlined for each specific treatment arm (see Appendices 7-14)",no-pregnancy-nursing
"For men: Compliant with a medically-approved contraceptive regimen during and for 3 months after the treatment period or documented to be surgically sterile; men whose sexual partners are of child-bearing potential must agree to use 2 methods of contraception prior to study entry, during the study, and for 3 months after the treatment period",no-pregnancy-nursing
"For patients of child bearing potential: negative urine or serum pregnancy test within 72 hours prior to Step 2 registration. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test is required.",no-pregnancy-nursing
FOR PDX-GUIDED THERAPY THROUGH ONGOING TRIALS AT MD ANDERSON OR OFF-PROTOCOL WITH STANDARD OF CARE (PART 2): Women of childbearing potential (WCBP) must have a negative serum or urine pregnancy test. Men must agree not to father a child and agree to use a condom if his partner is of child-bearing potential.,no-pregnancy-nursing
"For teratogenic drugs when there is chance of DDI with hormonal contraceptive such that the contraception may not be reliable, then an alternate method with < 1% failure rate per year must be used.",no-pregnancy-nursing
"For WOCBP and for men, agreement to use a highly effective contraceptive method from the time of screening throughout the study until 5 months (WOCBP) or 6 months (men) after administration of the last dose of any study medication. Highly effective contraceptive methods consist of prior sterilization, intrauterine device (IUD), intrauterine hormone releasing system (IUS), oral or injectable contraceptives, barrier methods, and/or true sexual abstinence.",no-pregnancy-nursing
For women of childbearing potential (WCBP): a negative serum β-human chorionic gonadotropin (βhCG) pregnancy test must be performed within 1 week before randomization (WCBP defined as a sexually mature woman who has not undergone surgical sterilization or who has not been naturally post-menopausal for at least 24 consecutive months [women <= 55 years] or 12 consecutive months [women > 55 years]).,no-pregnancy-nursing
For women of childbearing potential only: a negative urine or serum pregnancy test done <= 7 days prior to pre-registration is required.,no-pregnancy-nursing
"For women of childbearing potential only: Negative pregnancy test <= 10-14 days prior to registration; NOTE: the patient must have an additional negative pregnancy test <= 24 hours prior to receiving the initial prescription of lenalidomide, per requirements of the REVLIMID Risk Evaluation and Mitigation Strategies (REMS) program",no-pregnancy-nursing
For women of childbearing potential only: negative urine or serum pregnancy test done <= 7 days prior to registration,no-pregnancy-nursing
"For women of childbearing potential*, negative serum pregnancy test within 7 days of enrollment in Part A or randomization in Part B.",no-pregnancy-nursing
"For women of childbearing potential, a negative serum or urine pregnancy test with sensitivity less than 50 mIU/m within 72 hours before the start of study medication.",no-pregnancy-nursing
For women of childbearing potential:,no-pregnancy-nursing
For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use a contraceptive method with a failure rate of < 1% per year during the treatment period and for at least 1 week after the last dose of study drug,no-pregnancy-nursing
For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use a contraceptive method with a failure rate of < 1% per year during the treatment period and for at least 24 months after the last dose of study drug,no-pregnancy-nursing
"For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use a contraceptive method with a failure rate of < 1% per year during the treatment period and for at least 30 days after the last dose of venetoclax or 18 months after the last dose of rituximab, whichever is longer.",no-pregnancy-nursing
"For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use a contraceptive method with a failure rate of < 1% per year during the treatment period and for at least 30 days after the last dose of venetoclax or 18 months after the last dose of obinutuzumab, whichever is longer",no-pregnancy-nursing
For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use a contraceptive method with a failure rate of < 1% per year during the treatment period and for at least 6 months after the last dose of study treatment,no-pregnancy-nursing
For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use an acceptable contraceptive method during the treatment period and for at least 1 month after the last dose of study drug,no-pregnancy-nursing
For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use an acceptable contraceptive method during the treatment period and for at least 7 months after the last dose of study treatment,no-pregnancy-nursing
For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures as outlined for each specific treatment arm (see Appendices 7-14),no-pregnancy-nursing
"For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, as defined below:",no-pregnancy-nursing
For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods as defined below:,no-pregnancy-nursing
For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods that result in a failure rate of < 1% per year during the treatment period and for at least 5 months after the last dose of study treatment:,no-pregnancy-nursing
"For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods with a failure rate of < 1% per year during the treatment period and for 5 months after the last dose of atezolizumab, 30 days after the last dose of nab-paclitaxel, or 6 months after the last dose of pemetrexed, carboplatin, or cisplatin, whichever is later A woman is considered to be of childbearing potential if she is postmenarcheal, has not reached a postmenopausal state ( >= 12 continuous months of amenorrhea with no identified cause other than menopause), and has not undergone surgical sterilization (removal of ovaries and/or uterus). Examples of contraceptive methods with a failure rate of < 1% per year include bilateral tubal ligation, male sterilization, hormonal contraceptives that inhibit ovulation, hormone-releasing intrauterine devices, and copper intrauterine devices. The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception.",no-pregnancy-nursing
"For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods, and agreement to refrain from donating eggs, as defined below: Women must remain abstinent or use contraceptive methods with a failure rate of < 1% per year during the treatment period and for 5 months after the final dose of atezolizumab. Women must refrain from donating eggs during this same period.",no-pregnancy-nursing
"For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods, and agreement to refrain from donating eggs, as defined below: Women must remain abstinent or use contraceptive methods with a failure rate of < 1% per year during the treatment period and for 5 months after the final dose of atezolizumab. Women must refrain from donating eggs during this same period. A woman is considered to be of childbearing potential if she is postmenarcheal, has not reached a postmenopausal state ( >= 12 continuous months of amenorrhea with no identified cause other than menopause), and has not undergone surgical sterilization (removal of ovaries and/or uterus). The definition of childbearing potential may be adapted for alignment with local guidelines or requirements. Examples of contraceptive methods with a failure rate of < 1% per year include bilateral tubal ligation, male sterilization, hormonal contraceptives that inhibit ovulation, hormone-releasing intrauterine devices, and copper intrauterine devices. The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception.",no-pregnancy-nursing
"For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use non-hormonal contraceptive methods with a failure rate of < 1% per year during the treatment period and for 28 days after the last dose of study drug. Women must refrain from donating eggs during this same period. A woman is considered to be of childbearing potential if she is postmenarcheal, has not reached a postmenopausal state ( >= 12 continuous months of amenorrhea with no identified cause other than menopause), and has not undergone surgical sterilization (removal of ovaries and/or uterus). Examples of non-hormonal contraceptive methods with a failure rate of < 1% per year include bilateral tubal ligation, male sterilization, and copper intrauterine devices. The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception.",no-pregnancy-nursing
"For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use of contraceptive methods that result in a failure rate of < 1% per year during the treatment period and for at least 180 days after the last study treatment. A woman is considered to be of childbearing potential if she is post-menarchal, has not reached a postmenopausal state ( >= 12 continuous months of amenorrhea with no identified cause other than menopause), and has not undergone surgical sterilization (removal of ovaries and/or uterus). Examples of contraceptive methods with a failure rate of < 1% per year include bilateral tubal ligation, male sterilization, hormonal contraceptives that inhibit ovulation, hormone-releasing intrauterine devices and copper intrauterine devices. The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g. calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception.",no-pregnancy-nursing
"For women who are not postmenopausal ( >= 12 consecutive months of non-therapy-induced amenorrhea) or surgically sterile (absence of ovaries and/or uterus): agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods that result in a failure rate of < 1% per year during the treatment period and for at least 18 months after the last dose of obinutuzumab, for at least 3 months after the last dose of bendamustine or according to institutional guidelines for CHOP or CVP chemotherapy, whichever is longer",no-pregnancy-nursing
For women: Compliant with a medically-approved contraceptive regimen during and for 3 months after the treatment period or documented to be surgically sterile or postmenopausal,no-pregnancy-nursing
"GENERAL EXCLUSION CRITERIA FOR SUBPROTOCOLS: Pregnant or breast-feeding women will not be entered on this study due to risks of fetal and teratogenic adverse events as seen in animal/human studies, or because there is currently no available information regarding human fetal or teratogenic toxicities; pregnancy tests must be obtained in females who are post-menarchal; males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method",no-pregnancy-nursing
has been reported to cause fetal death and/or congenital abnormalities. Confirmation that the subject is not pregnant must be established by a negative serum β-human chorionic gonadotropin (β-hCG) pregnancy test result obtained during screening. Pregnancy testing is not required for post-menopausal or surgically sterilized women.,no-pregnancy-nursing
Has evidence of post-menopausal status or negative urinary or serum pregnancy test for female pre-menopausal patients.,no-pregnancy-nursing
"has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time during the preceding 24 consecutive months). Men must agree to use a latex condom during sexual contact with a FCBP, even if they have had a successful vasectomy, during the study treatment and for 3 months after the last dose of study treatment.",no-pregnancy-nursing
"Has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months).",no-pregnancy-nursing
"has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (ie, has had menses at any time in the preceding 24 consecutive months) and must:",no-pregnancy-nursing
has not been naturally postmenopausal (not having menstrual cycles due to cancer therapy does not rule out childbearing potential) for at least 24 consecutive months.,no-pregnancy-nursing
has not undergone a hysterectomy or bilateral oophorectomy,no-pregnancy-nursing
has not undergone a hysterectomy or bilateral oophorectomy; or,no-pregnancy-nursing
Have a history of hysterectomy and/or bilateral oophorectomy,no-pregnancy-nursing
Have a history of hysterectomy and/or bilateral oophorectomy; or,no-pregnancy-nursing
"has not undergone a hysterectomy or bilateral therapy does not rule out childbearing potential) for at least 24 consecutive months (ie, has had menses at any time in the preceding 24 consecutive months). FCBP participating in the study must:",no-pregnancy-nursing
Has used a depot contraceptive or extended-cycle oral contraceptive for least 28 days and has a documented negative pregnancy test using a highly sensitive assay.,no-pregnancy-nursing
"Have 2 negative pregnancy tests as verified by the Investigator prior to starting study therapy. She must agree to ongoing pregnancy testing during the course of the study, and after end of study treatment. This applies even if the subject practices true abstinence* from heterosexual contact",no-pregnancy-nursing
Have a female partner who is NOT of childbearing potential.,no-pregnancy-nursing
Have a male partner who is vasectomized.,no-pregnancy-nursing
"Have a negative beta-human chorionic gonadotropin (β-hCG) pregnancy test at time of study entry and within 14 days prior to planned first dose of investigational product, and",no-pregnancy-nursing
Have a negative pregnancy test (if female of childbearing potential),no-pregnancy-nursing
Have a negative pregnancy test (if female of childbearing potential).,no-pregnancy-nursing
"Have a negative pregnancy test as verified by the Investigator prior to starting study therapy. She must agree to ongoing pregnancy testing during the course of the study, and after end of study treatment. This applies even if the subject practices true abstinence* from heterosexual contact.",no-pregnancy-nursing
"Have a negative pregnancy test as verified by the Investigator, one negative serum beta human chorionic gonadotropin (β-hCG) pregnancy test result at screening, prior to LD chemotherapy. This applies even if the subject practices true abstinence** from heterosexual contact",no-pregnancy-nursing
"Have a negative pregnancy test as verified by the Investigator, one negative serum beta human chorionic gonadotropin [&beta;-hCG] pregnancy test result at screening, prior to LD chemotherapy. This applies even if the subject practices true abstinence* from heterosexual contact",no-pregnancy-nursing
"Have a negative pregnancy test, as required by local regulations, on W1D1 before the first dose of study intervention.",no-pregnancy-nursing
"have a negative serum beta human chorionic gonadotropin (&beta;-hCG) pregnancy test, as verified by the Investigator, at screening and Baseline; and",no-pregnancy-nursing
"have a negative serum beta human chorionic gonadotropin (β-hCG) pregnancy test, as verified by the Investigator, at screening and Baseline; and",no-pregnancy-nursing
"Have a negative serum or highly sensitive urine pregnancy test, as required by local regulations, within 24 hours before the first dose of study intervention. If a urine test cannot be confirmed as negative (e.g., an ambiguous result), a serum pregnancy test is required.",no-pregnancy-nursing
Have a negative serum pregnancy test (sensitivity of at least 25 mIU/mL) at Screening; and have a negative serum or urine pregnancy test (Investigator's discretion) within 72 hours prior to Cycle 1 Day -1 of study treatment (note that the screening serum pregnancy test can be used as the test prior to Day -1 study treatment if it is performed within the prior 72 hours).,no-pregnancy-nursing
have a negative serum pregnancy test at screening and before Betalutin injection,no-pregnancy-nursing
Have a negative serum pregnancy test performed within 28 days before starting lymphodepleting chemotherapy,no-pregnancy-nursing
Have negative pregnancy test(s) as verified by the Investigator. This applies even if the subject practices true abstinence2 from heterosexual contact:,no-pregnancy-nursing
have not been rendered surgically sterile (having undergone hysterectomy and/or bilateral salpingo-oophorectomy). Female subjects of reproductive potential must have a negative serum pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin ([hCG]) within 7 days of first day of drug dosing.,no-pregnancy-nursing
Have the ability to become pregnant (or already pregnant or lactating/breastfeeding).,no-pregnancy-nursing
"Have two negative pregnancy tests as verified by the Investigator prior to starting study treatment. She must agree to ongoing pregnancy testing during the course of the study, and after end of study treatment. This applies even if the subject practices true abstinence* from heterosexual contact",no-pregnancy-nursing
"Highly effective contraception (i.e., methods with a failure rate of less than 1 % per year) for both male and female subjects if the risk of conception exists (Note: The effects of the trial treatment on the developing human fetus are unknown; thus, women of childbearing potential and men must agree to use highly effective contraception, defined in Appendix 9.3 or as stipulated in national or local guidelines. Highly effective contraception must be used for the duration of trial treatment, and at least for 60 days after stopping trial treatment or 6 months after stopping chemotherapy [or per label]. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this trial, the treating physician should be informed immediately).",no-pregnancy-nursing
Highly effective contraception methods include:,no-pregnancy-nursing
Highly Effective Contraceptive Methods include:,no-pregnancy-nursing
"Highly effective methods of contraception are described in Table 4.1.2-1. A highly effective method of contraception is defined as one that results in a low failure rate (ie, less than 1% per year) when used consistently and correctly. Note that some contraception methods are not considered highly effective (eg, male or female condom with or without spermicide; female cap, diaphragm, or sponge with or without spermicide; non-copper containing intrauterine device; progestogen-only oral hormonal contraceptive pills where inhibition of ovulation is not the primary mode of action [excluding Cerazette ?��?��????��?��?? /desogestrel which is considered highly effective]; and triphasic combined oral contraceptive pills); not all of these methods are approved or available in Japan (see Table 4.1.2-1).",no-pregnancy-nursing
"Highly effective methods of contraception are described in Table 4.1.2-1. A highly effective method of contraception is defined as one that results in a low failure rate (ie, less than 1% per year) when used consistently and correctly. Note that some contraception methods are not considered highly effective (eg, male or female condom with or without spermicide; female cap, diaphragm, or sponge with or without spermicide; non-copper containing intrauterine device; progestogen-only oral hormonal contraceptive pills where inhibition of ovulation is not the primary mode of action [excluding Cerazette ��?��??��?��???��?��?? /desogestrel which is considered highly effective]; and triphasic combined oral contraceptive pills); not all of these methods are approved or available in Japan (see Table 4.1.2-1).",no-pregnancy-nursing
"Highly effective methods of contraception are described in Table 4.1.2-1. A highly effective method of contraception is defined as one that results in a low failure rate (ie, less than 1% per year) when used consistently and correctly. Note that some contraception methods are not considered highly effective (eg, male or female condom with or without spermicide; female cap, diaphragm, or sponge with or without spermicide; non-copper containing intrauterine device; progestogen-only oral hormonal contraceptive pills where inhibition of ovulation is not the primary mode of action [excluding Cerazette ?��?��????��?��???��?��????��?��??? /desogestrel which is considered highly effective]; and triphasic combined oral contraceptive pills); not all of these methods are approved or available in Japan (see Table 4.1.2-1).",no-pregnancy-nursing
"Highly effective methods of contraception that result in a low failure rate (i.e., < 1% per year) when used consistently and correctly include combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, or transdermal), progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, or implantable), intrauterine device, intrauterine hormone-releasing system, bilateral tubal occlusion, vasectomized partner, or sexual abstinence",no-pregnancy-nursing
"Hormonal contraception methods, including pills, patches, rings, or injections except progestin-only containing pills (i.e.,  Mini-pill )",no-pregnancy-nursing
"Hormonal contraceptives (oral, parenteral, transdermal or vaginal ring) for at least 3 months prior to study drug administration; if the subject is currently using a hormonal contraceptive, she should also use a barrier method during this study and for 1 month after study completion",no-pregnancy-nursing
"Hormonal methods of contraception including combined oral contraceptive pills, vaginal ring, injectables, implants and intrauterine devices (IUDs) such as Mirena by WOCBP subject or male subject's WOCBP partner",no-pregnancy-nursing
"Hormone-based contraception: Established use of oral, injected, or implanted hormonal methods of contraception",no-pregnancy-nursing
"If a WOCBP, use a highly effective contraceptive method (i.e., with a failure rate of < 1% per year), preferably with low user dependency, as described in Appendix 3 for the following time periods:",no-pregnancy-nursing
"If a WOCBP, use a highly effective contraceptive method (i.e., with a failure rate of < 1% per year), preferably with low user dependency, as described in Appendix 3Contraception for the following time periods:",no-pregnancy-nursing
"If a woman of child bearing potential (WOCBP), the patient has a negative serum or urine pregnancy test within 1 week prior to SL-401 treatment (intervals shorter than 1 week are acceptable, if required by institutional guidelines).",no-pregnancy-nursing
"If any of the following exist at screening, subject will not be eligible for trial because this trial involves an investigational agent whose genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn are unknown:",no-pregnancy-nursing
"If female of childbearing potential (Section 5.7.2), be willing to use an adequate method of contraception as outlined in Section 5.7.2 - Contraception, for the course of the study through 120 days after the last dose of study medication.",no-pregnancy-nursing
"If female of childbearing potential (Section 5.7.2), have a negative urine or serum pregnancy test within 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.",no-pregnancy-nursing
"If female of child-bearing potential, must not be pregnant or be breastfeeding and required to have a negative urine or serum pregnancy test within 3 days prior to the first dose of study drug.",no-pregnancy-nursing
"If female subject, then subject should be non-pregnant, non-lactating.",no-pregnancy-nursing
"If female with reproductive potential, must have a negative serum pregnancy test prior to the start of study therapy. Females of reproductive potential, as well as fertile men and their female partners of reproductive potential, must agree to use 2 effective forms of contraception.",no-pregnancy-nursing
"If female, patient is breastfeeding.",no-pregnancy-nursing
"If female, subject must be either postmenopausal or permanently surgically sterile or, for women of childbearing potential, practicing at least 1 protocol-specified method of birth control that is effective from study Day 1 through at least 6 months after the last dose of study drug.",no-pregnancy-nursing
"If female, subject must be either postmenopausal, OR permanently surgically sterile OR for women of childbearing potential practicing at least 2 protocol-specified methods of birth control that are effective from at least 30 days before starting study drugs through at least 30 days after the last dose of any study drug.",no-pregnancy-nursing
"If female, the patient is pregnant or lactating.",no-pregnancy-nursing
"If male and sexually active with a WCBP, must agree to use highly effectivecontraception such as latex condom plus partner use of a highly effective contraceptivemethod during the study treatment period and for 7 months after last investigational studytreatment (see Appendix 4)",no-pregnancy-nursing
"If male subject with a female partner(s) of childbearing potential, must agree to use an adequate method of contraception as outlined in Section 5.7.2 - Contraception, starting with the first dose of study therapy through 120 days after the last dose of study therapy. Males with pregnant partners must agree to use a condom; no additional method of contraception is required for the pregnant partner.",no-pregnancy-nursing
"If male, and subject is sexually active with female partner(s) of childbearing potential, he must agree, from Study Day 1 through 30 days after the last dose of study drug, to practice the protocol-specified contraception.",no-pregnancy-nursing
"If of childbearing potential (male or female), agrees to practice an effective form of contraception during study treatment and for at least 3 months following last treatment.",no-pregnancy-nursing
"If of childbearing potential (males and females), willing to use an effective form of contraception such as latex condom, hormonal birth control, intrauterine device or double barrier method during chemotherapy treatment and for at least six months thereafter.",no-pregnancy-nursing
"If of childbearing potential, must agree to use adequate contraception during the treatment period and for at least 120 days after the last dose of study treatment.",no-pregnancy-nursing
"If of childbearing potential, negative pre-treatment urine or serum pregnancy test.",no-pregnancy-nursing
"If of child-bearing potential, subject must use a highly effective method of contraception, such as combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation, progestogen-only hormonal contraception associated with inhibition of ovulation, intrauterine device, intrauterine hormone-releasing system, bilateral tubal occlusion, vasectomised partner or sexual abstinence. Both females and male subjects with female partners of child-bearing potential must agree to use a highly effective method of contraception for 2 weeks prior to screening, during, and at least 28 days after last dose of trial medication for females and 90 days for males. Female subjects must have a negative serum or urine pregnancy test within 72 hours prior to start of trial medication.",no-pregnancy-nursing
"If of child-bearing potential, subject must use a highly effective method of contraception, such as combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation, progestogen-only hormonal contraception associated with inhibition of ovulation, intrauterine device, intrauterine hormone-releasing system, bilateral tubal occlusion, vasectomised partner or sexual abstinence. Both females and male subjects with female partners of child-bearing potential must agree to use a highly effective method of contraception for 2 weeks prior to screening, during, and at least 28 days after last dose of trial medication for females and 90 days for males. Female subjects must have a negative serum or urine pregnancy test within 72 hours prior to start of trial medication. and not breast feeding at any time during the study.",no-pregnancy-nursing
"If of child-bearing potential, subject must use an adequate method of contraception consisting of two-barrier method or one barrier method with a spermicide or intrauterine device. Both females and male subjects with female partners of child-bearing potential must agree to use an adequate method of contraception for 2 weeks prior to screening, during, and at least 4 weeks after last dose of trial medication. Female subjects must have a negative serum or urine pregnancy test within 72 hours prior to start of trial medication.",no-pregnancy-nursing
"If of reproductive potential, agrees to avoid harvesting ova or sperm, and to use a protocol-defined form of contraception or avoid intercourse, during and upon completion of the study, and for at least 3 months after the last dose of study drug",no-pregnancy-nursing
"If of reproductive potential, negative pregnancy test and willing to use effective birth control method",no-pregnancy-nursing
"If the patient is a woman of child-bearing potential (WOCBP), she has had a negative serum or urine pregnancy test within 2 weeks prior to treatment.",no-pregnancy-nursing
"If the risk of conception exists, male patients must use a form of barrier contraception approved by the Investigator during the study and for 6 months after the last dose of study drug.",no-pregnancy-nursing
"If the subject is vasectomized, he must still use a condom (with or without spermicide), but his female partner is not required to use contraception.",no-pregnancy-nursing
"If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required",no-pregnancy-nursing
If they are of childbearing potential,no-pregnancy-nursing
"If they are of childbearing potential, agree to practice 1 highly effective method and 1additional effective (barrier) method of contraception at the same time, from the time of signing of the informed consent form (ICF) through 90 days after the last dose of study drug (whichever is longer), or",no-pregnancy-nursing
"If they are of childbearing potential, agree to practice 1 highly effective method of contraception and 1 additional effective (barrier) method at the same time, for 4 weeks before signing the informed consent through 90 days after the last dose of study therapy; OR",no-pregnancy-nursing
"If they are of childbearing potential, agree to practice 1 highly effective method of contraception and 1 additional effective (barrier) method at the same time, from the time of signing the informed consent through 180 days after the last dose of study drug, OR",no-pregnancy-nursing
"If they are of childbearing potential, agree to practice 2 effective methods of contraception, at the same time, from the time of signing the informed consent form through 90 days after the last dose of study drug",no-pregnancy-nursing
"If they are of childbearing potential, agree to practice 2 effective methods of contraception, at the same time, from the time of signing the informed consent form through 90 days after the last dose of study drug, OR",no-pregnancy-nursing
If they are of childbearing potential:,no-pregnancy-nursing
"If using treatment with rituximab, women of childbearing potential should continue to use effective contraceptive methods for 12 months following treatment with rituximab.",no-pregnancy-nursing
"If women of childbearing potential (WCBP), willing to undergo pregnancy testing andagrees to use at least 1 highly effective contraceptive method during the study treatmentperiod and for 5 months after last investigational study treatment (see Appendix 4)",no-pregnancy-nursing
"immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 3 months after completion of study drug administration.",no-pregnancy-nursing
"Immune-modulating drugs (IMiDs) including Revlimid are known to be teratogenic and potential embryo-fetal harm can be seen with use of venetoclax and ibrutinib. The effects of obinutuzumab on the developing human fetus is unknown. For these reasons, women of child-bearing potential and men must agree to use adequate contraception as described below. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.",no-pregnancy-nursing
"In addition to having a negative pregnancy test confirmed at screening, all female participants of child bearing potential must have a negative pregnancy test confirmed within 48 hours prior to dosing with the study drug.",no-pregnancy-nursing
"In addition to the user-independent, highly effective method of contraception, a male or female condom with or without spermicide is required, example, condom with spermicidal foam/gel/film/cream/suppository. Male condom and female condom should not be used together (due to risk of failure with friction)",no-pregnancy-nursing
"In agreement to use an effective barrier method of birth control (hormonal or barrier method of birth control; abstinence) to avoid pregnancy during the study and for a minimum of 30 days after study treatment, for all male and female patients who are fertile",no-pregnancy-nursing
"In female, a negative pregnancy test if experiencing menstrual periods",no-pregnancy-nursing
"In women of childbearing potential (if randomized to Arm B), agree to have 2 negative pregnancy tests before initiating therapy, with 1 or both being a serum test (the first test should be performed within 10-14 days before; the second, within 24 hours before); then have a negative pregnancy test weekly during the first month and monthly thereafter in women with regular menstrual cycles or every 2 weeks thereafter in women with irregular menstrual cycles; and have a negative pregnancy test 4 weeks after the last dose of study therapy.",no-pregnancy-nursing
"Inability or refusal to practice effective contraception during therapy or the presence of pregnancy or active breastfeeding. Because there is no significant preclinical information regarding the risks to a fetus or a newborn infant, all pregnant or breastfeeding woman will be excluded from participation in this trial",no-pregnancy-nursing
Inability or refusal to practice effective contraception during therapy. Men and women of childbearing potential must use an effective method of birth control or abstinence during treatment and for 4 months after completion of the treatment.,no-pregnancy-nursing
Inability or unwillingness to use effective birth control.,no-pregnancy-nursing
Individual is not pregnant or breastfeeding (female individuals only) and is willing to use birth control from the time of consent through 6 months following chimeric antigen receptor (CAR) T cell infusion (both male and female individuals).,no-pregnancy-nursing
Individual/or persons who are pregnant,no-pregnancy-nursing
Individuals of both genders of child-bearing potential who are not willing to practice birth control from the time of consent through 6 months after the completion of KTE-X19,no-pregnancy-nursing
Individuals of both genders who are not willing to practice birth control from the time of consent through 6 months after the completion of conditioning chemotherapy,no-pregnancy-nursing
"Individuals of non-childbearing potential, or individual of childbearing potential with negative serum pregnancy test <= 7 days prior to randomization and willing to practice total abstinence or use a highly effective method of contraception, as outlined in item c below:",no-pregnancy-nursing
"Individuals of non-childbearing potential, or individual of childbearing potential with negative serum pregnancy test <= 7 days prior to randomization and willing to practice total abstinence or use a highly effective method of contraception, as outlined in item  c  below:",no-pregnancy-nursing
Individuals of reproductive potential and their partners willing to practice total abstinence or use a highly effective method of contraception (failure rate < 1% per year) during treatment and for 6 months following the last dose of rucaparib.,no-pregnancy-nursing
"Individuals who are pregnant or breast feeding or who become pregnant while enrolled on this trial will be excluded from participation, due to the unknown effects of PLX3397 on a growing fetus or newborn child.",no-pregnancy-nursing
Individuals/or persons of childbearing potential who are unwilling to employ adequate contraception.,no-pregnancy-nursing
Individuals/or persons who are nursing,no-pregnancy-nursing
Intrauterine device,no-pregnancy-nursing
Intrauterine device (IUD),no-pregnancy-nursing
Intrauterine device (IUD) or intrauterine hormone-releasing system (IUS).,no-pregnancy-nursing
Intrauterine device (IUD) or intrauterine system (IUS) with a documented failure rate of less than 1% per year,no-pregnancy-nursing
Intrauterine device (IUD) progesterone T,no-pregnancy-nursing
Intrauterine device (non-progesterone T),no-pregnancy-nursing
Intrauterine device.,no-pregnancy-nursing
intra-uterine devices (IUDs),no-pregnancy-nursing
Intrauterine hormone-releasing system,no-pregnancy-nursing
Investigators shall counsel WOCBP and male participants who are sexually active with WOCBP on the importance of pregnancy prevention and the implications of an unexpected pregnancy. Investigators shall advise on the use of highly effective methods of contraception (Appendix 4) which have a failure rate of < 1% when used consistently and correctly.,no-pregnancy-nursing
Is a female patient who is pregnant or breastfeeding or male or female patient of reproductive potential who are not willing to employ effective birth control from screening to 120 days after the last dose of study treatment,no-pregnancy-nursing
"Is breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of study treatment.",no-pregnancy-nursing
"Is pregnant or breast feeding, or expecting to conceive or father children within the projected duration of the trial, starting with the screening visit through 120 days after the last dose of treatment.",no-pregnancy-nursing
Is pregnant or breastfeeding,no-pregnancy-nursing
"Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of trial treatment.",no-pregnancy-nursing
"Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 120 days for females and 120 days for males after the last dose of study treatment.",no-pregnancy-nursing
"Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 180 days after the last dose of study treatment.",no-pregnancy-nursing
"Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the trial, starting with the screening visit through 120 days (or longer, if required by the drug label of chemotherapy received by the participant on study) after the last dose of trial treatment",no-pregnancy-nursing
"Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the trial, starting with the screening visit through 180 days after the last dose of trial treatment.",no-pregnancy-nursing
"Is pregnant or breastfeeding, or expecting to conceive a child within the projected duration of the trial, starting with the prescreening or screening visit through 120 days after the last dose of trial treatment",no-pregnancy-nursing
"Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of study treatment",no-pregnancy-nursing
"Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of trial treatment.",no-pregnancy-nursing
"Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the study.",no-pregnancy-nursing
"Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment",no-pregnancy-nursing
"Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment (roughly two and a half years after enrollment).",no-pregnancy-nursing
"Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment.",no-pregnancy-nursing
"Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 23 weeks for females and 31 weeks for males after the last dose of trial treatment.",no-pregnancy-nursing
"Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 90 days after the last dose of trial treatment",no-pregnancy-nursing
"Is pregnant or breast-feeding, or expecting to conceive or father children within the projected duration of the trial, starting with the screening visit until 120 days after the last dose of trial treatment.",no-pregnancy-nursing
"Is pregnant or breastfeeding, or planning to become pregnant.",no-pregnancy-nursing
Is pregnant or lactating,no-pregnancy-nursing
"Is pregnant, lactating, has been pregnant within the last 2 years, or is planning to attempt to become pregnant or impregnate someone during this study or within 90 days after dosing of study drug.",no-pregnancy-nursing
Known pregnancy or breast-feeding.,no-pregnancy-nursing
Known to be pregnant or planning to continue nursing,no-pregnancy-nursing
Lactating female,no-pregnancy-nursing
Lactating female patients must agree not to nurse a child while on this trial,no-pregnancy-nursing
Lactating females,no-pregnancy-nursing
Lactating females are not eligible unless they agree not to breastfeed their infants.,no-pregnancy-nursing
Lactating females are not eligible unless they have agreed not to breastfeed their infant.,no-pregnancy-nursing
Lactating females are not eligible unless they have agreed not to breastfeed their infants,no-pregnancy-nursing
Lactating females must agree to discontinue nursing,no-pregnancy-nursing
Lactating females who plan to breastfeed,no-pregnancy-nursing
Lactating females who plan to breastfeed their infants.,no-pregnancy-nursing
"Lactating females, unless they have agreed not to breastfeed their infants.",no-pregnancy-nursing
Lactating females.,no-pregnancy-nursing
Lactating or pregnant,no-pregnancy-nursing
Lactating or pregnant women confirmed by a positive hCG laboratory test.,no-pregnancy-nursing
Lactating or pregnant women.,no-pregnancy-nursing
Lactating or pregnant.,no-pregnancy-nursing
Male and female patients must agree to use a highly reliable method of birth control.,no-pregnancy-nursing
"Male and female patients must agree to use highly effective methods of birth control. A  highly effective method of birth control  is defined as a method that has a low failure rate (i.e., less than 1% per year) when used consistently and correctly and includes implants, injectables, birth control pills with two hormones, some intrauterine devices (IUDs). Male subject cannot use highly effective methods and are required to use barrier. The specific guidelines are as follows:",no-pregnancy-nursing
"Male and female patients of child bearing potential must be willing to use contraception (i.e., condoms, birth control) while on study and until 3 months after the last dose of study drug is taken.",no-pregnancy-nursing
"Male and female patients of childbearing potential and at risk for pregnancy must agree to use a highly effective method of contraception throughout the study and for a minimum of 8 months (females) and 5 months (males) after the last dose of assigned treatment. A patient is of childbearing potential if, in the opinion of the Investigator, he/she is biologically capable of having children and is sexually active. Female subjects of nonchildbearing potential must meet at least 1 of the following criteria:",no-pregnancy-nursing
Male and female patients of child-bearing potential must agree to use an effective method of contraception approved by the investigator during the study.,no-pregnancy-nursing
"Male and female subjects of child bearing potential must agree to use an effective method of birth control to avoid pregnancy throughout the transplant procedure, while on immunosuppression, and if the subject experiences any chronic GvHD.",no-pregnancy-nursing
Male and female subjects of reproductive potential must agree to use both a highly effective method of birth control and barrier method during the period of therapy and for 30 days after the last dose of study drug for females and 90 days for males.,no-pregnancy-nursing
Male and female subjects of reproductive/childbearing potential must agree to use a highly effective form of contraception or avoid intercourse during and upon completion of the study and for at least 4.5 months after the last dose of study drug. Methods considered as highly effective methods of contraception include: Proprietary and Confidential,no-pregnancy-nursing
"Male and female subjects who agree to use both a highly effective method of birth control (e.g., implants, injectables, combined oral contraceptives, some intrauterine devices [IUDs], complete abstinence , or sterilized partner) and a barrier method (e.g., condoms, vaginal ring, sponge, etc) during the period of therapy; female patients of reproductive potential who are not surgically sterile must practice adequate birth control for a minimum of twelve months post-treatment; male patients who are not surgically sterile must practice adequate birth control for a minimum of three months post-treatment",no-pregnancy-nursing
"Male and female subjects who agree to use both a highly effective method of birth control (eg, implants, injectables, combined oral contraceptives, some intrauterine devices [IUDs], complete abstinence , or sterilized partner) and a barrier method (eg., condoms, vaginal ring, sponge, etc) during the period of therapy and for 30 days after the last dose of study drug for females and 90 days for males. OR Female subjects who are of non-reproductive potential (ie, post-menopausal by history - no menses for >= 1 year; OR history of hysterectomy; OR history of bilateral tubal ligation; OR history of bilateral oophorectomy)",no-pregnancy-nursing
"Male and female subjects who agree to use highly effective methods of birth control (e.g., condoms, implants, injectables, combined oral contraceptives, some intrauterine devices (IUDs), sexual abstinence, or sterilized partner) during the period of therapy and for 30 days after the last dose of study drug",no-pregnancy-nursing
"Male and female subjects who agree to use highly effective methods of birth control (e.g., condoms, implants, injectables, combined oral contraceptives, some intrauterine devices [IUDs], sexual abstinence, or sterilized partner) during the period of therapy and for 90 days after the last dose of study drug",no-pregnancy-nursing
"Male and female subjects who agree to use highly effective methods of birth control (e.g., implants, injectables, combined oral contraceptives, some intrauterine devices [IUDs], sexual abstinence, or sterilized partner) and a barrier method (e.g., condoms, vaginal ring, sponge, etc) during the period of therapy and for 30 days after the last dose of study drug for females and 90 days for males",no-pregnancy-nursing
"Male and female subjects who are not surgically sterile or postmenopausal must be willing to use medically acceptable methods of birth control from the first dose of study drug to 30 days after the last dose of study drug. Sexually active men, and women using oral contraceptive pills, should also use barrier contraception.",no-pregnancy-nursing
Male and non-pregnant females >= 18 years old,no-pregnancy-nursing
Male condom (additional effective method),no-pregnancy-nursing
Male condoms with spermicide,no-pregnancy-nursing
"Male or female patients of child-bearing potential must agree to use double barrier contraception, condoms, sponge, foams, jellies, diaphragm or intrauterine device, contraceptives (oral or parenteral), Implanon®, injectables, or other measures to avoid pregnancy during the study and for 90 days after the last day of treatment. Post-menopausal females ( > 50 years old and without menses for > 1 year) and women who are surgically postmenopausal are exempt from this criterion.",no-pregnancy-nursing
"Male or female patients of child-producing potential must agree to comply with one of the following until at least 120 days after the last dose of derazantinib: Abstinence from heterosexual activity, Using (or having their partner use) an acceptable method of contraception during heterosexual activity. Highly effective methods of contraception are: an intrauterine device (IUD), vasectomy of a female patient's male partner, a contraceptive rod implanted into the skin, combined (estrogen- and progestogen-containing) or progestogen-only hormonal contraception associated with inhibition of ovulation (oral contraceptive pill [estrogen/progestin pill or progestin-only pill]contraceptive skin patch/implant, vaginal contraceptive ring, or subcutaneous contraceptive injection)",no-pregnancy-nursing
"Male or female subjects of child-producing potential must agree to use double-barrier contraceptive measures, oral contraception, or avoidance of intercourse during the study and for 90 days after the last dose of ARQ 087",no-pregnancy-nursing
"Male or female with reproductive potential, must be willing to use an approved contraceptive method (for example, intrauterine device (IUD), birth control pills, or barrier device) during and for 3 months after discontinuation of study treatment. Women of childbearing potential must have a negative serum pregnancy test within 7 days prior to randomization.",no-pregnancy-nursing
"Male or non-pregnant, non-lactating female patient at least 18 years of age at the time of consent",no-pregnancy-nursing
"Male or non-pregnant, non-lactating female patients age >= 18 years",no-pregnancy-nursing
"Male participants (even if surgically sterilized), and their partners who are women of childbearing potential must be using highly effective contraception in addition to a barrier method throughout the study drug treatment period and for 127 days after the final study drug administration.",no-pregnancy-nursing
Male participants are eligible if vasectomized or if they agree to the use of barrier contraception in combination with other methods during the study treatment period and for >= 90 days after the last dose of BGB-3111.,no-pregnancy-nursing
Male participants are eligible to participate if they agree to the following during the intervention period and for at least 4 months after the last dose of study intervention:,no-pregnancy-nursing
Male participants must agree to use an adequate method of contraception starting with the first dose of study therapy through 60 days after the last dose of study therapy.,no-pregnancy-nursing
"Male participants must agree to use approved contraception during the treatment period and for at least 120 days (or longer, if required by the drug label of chemotherapy received by the participant on study) after the last dose of study treatment and refrain from donating sperm during this period",no-pregnancy-nursing
Male participants must agree to use contraception during the treatment period and for at least 12 months (for participants who received cyclophosphamide) or 6 months (for participants who did not receive cyclophosphamide) after the last dose of study treatment and refrain from donating sperm during this period.,no-pregnancy-nursing
Male participants must not donate sperm throughout the study drug treatment period and for 127 days after the final study drug administration.,no-pregnancy-nursing
Male participants of reproductive potential must agree to use an adequate method of contraception starting with the first dose of study medication through 120 days after the last dose of study medication,no-pregnancy-nursing
"Male participants, even if surgically sterilized (that is, status postvasectomy) must agree to 1 of the following:",no-pregnancy-nursing
Male participants: A male participant must agree to use a contraception as detailed in Appendix C of this protocol during the treatment period and for at least five months after the final CMP-001 and pembrolizumab dose and refrain from donating sperm during this period.,no-pregnancy-nursing
Male participants: agreement to remain abstinent (refrain from heterosexual intercourse) or use a condom and agreement to refrain from donating sperm.,no-pregnancy-nursing
Male partner sterilization (at least 6 months prior to screening). For female patients on the study the vasectomized male partner should be the sole partner for that patient.,no-pregnancy-nursing
"Male partner sterilization (at least 6 months prior to screening). For female patients, the vasectomized male partner (in whom the surgical success of vasectomy has been assessed) should be the sole partner for that patient",no-pregnancy-nursing
"Male partner sterilization (vasectomy with documentation of azoospermia) prior to the female subject's entry into the study, and this male is the sole partner for that subject",no-pregnancy-nursing
Male partner sterilization (with appropriate post-vasectomy documentation of the absence of sperm in the ejaculate,no-pregnancy-nursing
"Male partner sterilization (with appropriate post-vasectomy documentation of the absence of sperm in the ejaculate). For female patients participating in the study, the vasectomized male partner should be the sole partner for that patient.",no-pregnancy-nursing
"Male patient must not donate sperm starting at screening and throughout the study period, and for at least 6 months after the final study drug administration.",no-pregnancy-nursing
"Male patient who is surgically sterile, or male patient who is willing to agree with the true abstinence (refrain from heterosexual intercourse) or who uses barrier contraceptive measures during the entire study treatment period and for 3 months after the last administration of study drug, and agree to refrain from donating sperm during the entire study treatment period and for 3 months after the last administration of study drug (Appendix J)",no-pregnancy-nursing
Male patient with a pregnant or breastfeeding partner(s) must agree to abstinence or use a condom for the duration of the pregnancy or time their partner is breastfeeding throughout the study period and for at least 6 months after the final study drug administration.,no-pregnancy-nursing
"Male patient with a pregnant or breastfeeding partner(s) must agree to remain abstinent or use a condom for the duration of the pregnancy or time partner is breastfeeding throughout the treatment period, and for at least 120 days after the final study drug administration.",no-pregnancy-nursing
"Male patients (even if surgically sterilized), of partners of women of childbearing potential must agree to one of the following: practice effective barrier contraception (see Section 2.6.4 for list of barrier methods), or abstain from heterosexual intercourse from the time of signing the informed consent through 12 months post-transplant",no-pregnancy-nursing
"Male patients and their partners, who are sexually active and of childbearing potential, must agree to the use of two highly effective forms of contraception in combination, throughout the period of taking study treatment and for 3 months after last dose of study drug(s) to prevent pregnancy in a partner.",no-pregnancy-nursing
Male patients are considered not to be of child-producing potential if they have azoospermia (whether due to vasectomy or an underlying medical condition).,no-pregnancy-nursing
Male patients must agree to use a barrier method of contraception or agree to abstain from heterosexual activity for the duration of the study,no-pregnancy-nursing
Male patients must agree to use a barrier method of contraception or agree to abstain from heterosexual activity for the duration of the study.,no-pregnancy-nursing
Male patients must agree to use condoms during intercourse throughout study drug therapy and the following 12 months.,no-pregnancy-nursing
Male patients must be either surgically sterile or agree to use a double-barrier contraception method from Screening until 1 month post-gemcitabine administration.,no-pregnancy-nursing
Male patients must be willing to refrain from sperm donation for 6 months following the last dose of CPX-351and must use adequate contraception throughout the entire study period and for 6 months following the last dose of CPX-351.,no-pregnancy-nursing
"Male patients must be willing to use acceptable methods of contraception. For additional inclusion criteria, please see the specific appendix for each study drug (Appendix 6 through 10).",no-pregnancy-nursing
Male patients must refrain from donating sperm during their participation in the study and until 6 months after the last treatment.,no-pregnancy-nursing
Male patients must use an effective barrier method of contraception during the study and for 30 days following the last dose of study treatment if sexually active with a female of childbearing potential.,no-pregnancy-nursing
Male patients taking lenalidomide must not donate sperm,no-pregnancy-nursing
Male patients who are committed to undertaking the following measures for the duration of the study and after the last dose of rucaparib for the time period specified:,no-pregnancy-nursing
Male patients who are committed to undertaking the following measures for the duration of the study and after the last dose of study drug for the time period specified:,no-pregnancy-nursing
"Male patients who are sexually active must be willing to use a double barrier contraceptive method upon study enrollment, during the course of the study, and for 1 month after the last study drug infusion.",no-pregnancy-nursing
Male patients who intend to donate sperm during the course of this study or 4 months after receiving their last dose of study drug(s),no-pregnancy-nursing
Male patients with a female partner of childbearing potential must use a condom and ensure that an additional form of contraception is also used during treatment and until 6 months after last study drug administration.,no-pregnancy-nursing
"Male patients with female partners must have had a prior vasectomy or agree to use an adequate method of contraception (i.e., double barrier method: condom plus spermicidal agent) starting with the first dose of study therapy through 24 weeks (6 months) after the last dose of study therapy.",no-pregnancy-nursing
"Male patients with female partners of childbearing potential and women patients of childbearing potential are required to use two forms of acceptable contraception, including one barrier method, during their participation in the study and for 7 months following last dose of study drug. Male patients must also refrain from donating sperm during their participation in the study and for 7 months following last dose of study drug.",no-pregnancy-nursing
"Male patients with female partners of child-bearing potential must be willing to use two forms of acceptable contraception, including one barrier method, during their participation in this study and for 6 months after stopping study treatment. Female partners of child-bearing potential of male patients must use at least one of the two forms of acceptable contraception.",no-pregnancy-nursing
"Male patients with female partners of childbearing potential, and female patients of childbearing potential must agree to use effective birth control. Effective birth control and cessation of lactation must be complied at least 2 weeks prior to first study drug administration, during the trial participation, and for 3 months after the last dose of study drug",no-pregnancy-nursing
Male patients with partners of childbearing potential must take appropriate precautions to avoid fathering a child from screening until 90 days after discontinuation of study treatment and use appropriate barrier contraception or true abstinence,no-pregnancy-nursing
Male patients with partners of childbearing potential must take appropriate precautions to avoid fathering a child from screening until 90 days after discontinuation of study treatment and use appropriate barrier contraception or true abstinence. See Section 4.1.1.,no-pregnancy-nursing
"Male patients, even if surgically sterilized (i.e., status post-vasectomy) must:",no-pregnancy-nursing
"Male patients, even if surgically sterilized (i.e., status post-vasectomy), must agree to one of the following:",no-pregnancy-nursing
"Male patients, even if surgically sterilized (i.e., status post-vasectomy), must agree to one of the following: practice effective barrier contraception during the entire study treatment period and through 90 days after the last dose of study drug, or must also adhere to the guidelines of any treatment-specific pregnancy prevention program, if applicable, or agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject. (Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal are not acceptable methods of contraception.)",no-pregnancy-nursing
"Male patients, even if surgically sterilized (i.e., status post-vasectomy), must:",no-pregnancy-nursing
"Male patients, even if surgically sterilized (i.e., status post-vasectomy), who agree to practice effective barrier contraception during the entire study treatment period and through 4 months after the last dose of study drug.",no-pregnancy-nursing
"Male patients, even if surgically sterilized (i.e., status post-vasectomy), who:",no-pregnancy-nursing
"Male patients, even if surgically sterilized (i.e., status post-vasectomy), who: agree to practice effective barrier contraception during the entire study treatment period and through 4 months after the last dose of study drug, or agree to completely abstain from heterosexual intercourse",no-pregnancy-nursing
"Male patients, even if surgically sterilized (ie, status postvasectomy) who:",no-pregnancy-nursing
"Male patients, even if surgically sterilized (ie, status post-vasectomy), must agree to one of the following:",no-pregnancy-nursing
"Male patients, even if surgically sterilized (ie, status postvasectomy), who:",no-pregnancy-nursing
"Male patients: even if surgically sterilized (i.e., status post-vasectomy), must agree to one of the following:",no-pregnancy-nursing
"Male patients: even if surgically sterilized (ie, status post-vasectomy), must agree to one of the following:",no-pregnancy-nursing
"Male sterilization (at least 6 months prior to screening), the vasectomized male partner should be the sole partner for that patient",no-pregnancy-nursing
Male sterilization (at least 6 months prior to screening). For female patients on the study the vasectomized male partner should be the sole partner for that patient,no-pregnancy-nursing
Male sterilization (at least 6 months prior to screening). The vasectomized male partner should be the sole partner for that subject,no-pregnancy-nursing
Male subject agrees to use an acceptable method of contraception for the duration of the study,no-pregnancy-nursing
Male subject with a pregnant or breastfeeding partner(s) must agree to remain abstinent or use a condom for the duration of the pregnancy or time partner is breastfeeding throughout the study period and for 6 months after the final study drug administration.,no-pregnancy-nursing
"Male subjects (even if surgically sterilized), of partners of women of childbearing potential must agree to one of the following: practice effective barrier contraception, or abstain from heterosexual intercourse from the time of signing the informed consent through 12 months post-transplant",no-pregnancy-nursing
Male subjects agree to use an adequate method of contraception starting with the first dose of study therapy through 31 weeks after the last dose of study therapy,no-pregnancy-nursing
Male subjects agree to use an adequate method of contraception starting with the first dose of study therapy through 31 weeks after the last dose of study therapy.,no-pregnancy-nursing
Male subjects must agree not to donate sperm for at least 90 days after the last dose of study treatment.,no-pregnancy-nursing
Male subjects must agree to practice contraception,no-pregnancy-nursing
"Male subjects must agree to use an acceptable method of contraception beginning prior to study entry, for the duration of the study, and for six months following duration of study participation",no-pregnancy-nursing
"Male subjects must agree to use an acceptable method of contraception beginning prior to study entry, for the duration of the study, and for six months following last dose of avelumab/utomilumab",no-pregnancy-nursing
"Male subjects must also agree to refrain from sperm donation, storage, or banking during these same time periods.",no-pregnancy-nursing
"Male subjects must be willing to use condoms from the time of treatment initiation until 7 months after treatment discontinuation. For a non-pregnant FCBP partner, contraception recommendations should also be considered.",no-pregnancy-nursing
"Male subjects must not freeze or donate sperm starting at Screening and throughout the study period, and at least 4.5 months after the final study drug administration. Preservation of sperm should be considered prior to enrolment in this study. Proprietary and Confidential",no-pregnancy-nursing
"Male subjects must, even if surgically sterilized (ie, status post-vasectomy):",no-pregnancy-nursing
"Male subjects of childbearing potential (Section 5.7.1) must agree to use an adequate method of contraception as outlined in Section 5.7.1- Contraception, starting with the first dose of study therapy through 120 days after the last dose of study therapy.",no-pregnancy-nursing
"Male subjects of childbearing potential (Section 9.8.2) must agree to use an adequate method of contraception as outlined in Section 9.8.2- Subjects must adhere to the contraception requirement from the day of study medication initiation, (or 14 days prior to the initiation of study medication for oral contraception) throughout the entire study, and up 120 days after the last dose of trial therapy.",no-pregnancy-nursing
Male subjects of childbearing potential must agree to use an adequate method of contraception,no-pregnancy-nursing
"Male subjects of childbearing potential must agree to use an adequate method of contraception - Contraception, starting with the first dose of study therapy through 120 days after the last dose of study therapy.",no-pregnancy-nursing
"Male subjects of childbearing potential must agree to use an adequate method of contraception as outlined in Section 5.4.3- Contraception, starting with the first dose of study therapy through 120 days after the last dose of study therapy.",no-pregnancy-nursing
Male subjects of childbearing potential must agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapy,no-pregnancy-nursing
Male subjects of childbearing potential must agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapy.,no-pregnancy-nursing
Male subjects of childbearing potential must agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapy; Note: abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject,no-pregnancy-nursing
"Male subjects of childbearing potential must agree to use an adequate method of contraception, starting with the first dose of study therapy through 120 days after the last dose of study therapy. Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject.",no-pregnancy-nursing
Male subjects of childbearing potential must agree to use an adequate method of contraception.,no-pregnancy-nursing
"Male subjects of childbearing potential must agree to use an adequate method of contraception. Contraception, starting with the first dose of study therapy through 120 days after the last dose of study therapy.",no-pregnancy-nursing
Male subjects of childbearing potential must be willing to use an adequate method of contraception for the course of the trial through 120 days after the last dose of trial treatment,no-pregnancy-nursing
Male subjects should agree to use an adequate method of barrier contraception starting with the first dose of study therapy through 120 days after the last dose of study therapy,no-pregnancy-nursing
Male subjects should agree to use an adequate method of contraception starting with the first dose of study medication until 120 days after the final dose of study medicine. Abstinence is acceptable if this is the established and preferred contraceptive method for the subject.,no-pregnancy-nursing
Male subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapy,no-pregnancy-nursing
Male subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapy.,no-pregnancy-nursing
Male subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapy; males must refrain from donating sperm during study participation and for 120 days after the last dose of study medication,no-pregnancy-nursing
Male subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 7 months following the last dose of nivolumab. Males must refrain from donating sperm during study participation and for 7 months after the last dose of nivolumab.,no-pregnancy-nursing
Male subjects should agree to use two methods of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapy,no-pregnancy-nursing
"Male subjects who are sexually active must agree, from Study Day 1 through at least 4 months after the last dose of study drug, to practice protocol-specified methods of contraception. Male subjects must agree to refrain from sperm donation from initial study drug administration through at least 4 months after the last dose of study drug (venetoclax and gilteritinib). Concomitant Medications",no-pregnancy-nursing
Male subjects with a female partner of childbearing potential must:,no-pregnancy-nursing
Male subjects with female partners must have azoospermia from a prior vasectomy or underlying medical condition or agree to use an acceptable method of contraception during treatment and for 30 days.,no-pregnancy-nursing
"Male subjects with female partners must have had a prior vasectomy or agree to use an adequate method of contraception (i.e., double barrier method: condom plus spermicidal agent) starting with the first dose of study therapy through 150 days after the last dose of study therapy. Male subjects should agree to refrain from sperm donation while receiving study treatment and for at least 150 days after the last dose of study treatment.",no-pregnancy-nursing
"Male subjects with female partners of childbearing potential must agree to use an adequate method of contraception for 2 weeks prior to screening, during, and at least for 4 weeks after last dose of trial medication.",no-pregnancy-nursing
"Male subjects, even if surgically sterilized (i.e. statue post vasectomy) must agree to 1 of the following: Practice effective barrier contraception during the entire study therapy, or agree to completely abstain from heterosexual intercourse",no-pregnancy-nursing
"Male subjects: even if surgically sterilized (i.e., status post-vasectomy), must agree to one of the following:",no-pregnancy-nursing
Male who is not considering fathering a child or donating sperm during the study and for at least 30 days after the last dose of study drug.,no-pregnancy-nursing
Male: use an adequate method of contraception starting with the first dose of study therapy through 90 days after the last dose of study therapy,no-pregnancy-nursing
Male: Use two effective methods of contraception (barrier method) or abstain from heterosexual activity with the first dose of study therapy through 120 days post last dose of pembrolizumab.,no-pregnancy-nursing
Male: use two effective methods of contraception (barrier method) or abstain from heterosexual activity with the first dose of study therapy through 7 months post last dose of nivolumab,no-pregnancy-nursing
"Males and females of reproductive potential who are unwilling to practice an acceptable method(s) of effective birth control while on study through 3 months after receiving the last dose of study drug. Acceptable methods of effective birth control include sexual abstinence (males, females); vasectomy; bilateral tubal ligation/occlusion; or a condom with spermicide (men) in combination with barrier methods (diaphragm, cervical cap, or cervical sponge), hormonal birth control or IUD (females).",no-pregnancy-nursing
"Males and females of reproductive potential who are unwilling to practice highly effective method(s) of birth control while on study through 110 days (females) and 170 days (males) after receiving the last dose of study drug. Highly effective methods of birth control include sexual abstinence (males, females); vasectomy; bilateral tubal ligation/occlusion; or a condom with spermicide (males) in combination with hormonal birth control or intrauterine device (IUD) (females).",no-pregnancy-nursing
"Males and females of reproductive potential who are unwilling to practice highly effective method(s) of birth control while on study through 75 days (females) and 135 days (males) after receiving the last dose of study drug. Highly effective methods of birth control include sexual abstinence (males, females); vasectomy; bilateral tubal ligation/occlusion; or a condom with spermicide (males) in combination with hormonal birth control or intrauterine device (IUD) (females).",no-pregnancy-nursing
Males must abstain from sex with WCBP or use an adequate method of contraception from the time of informed consent through the Day 55 Visit and for 90 days after the last dose of study drug (LUT014).,no-pregnancy-nursing
"Males must agree to always use a latex or synthetic condom during any sexual contact with females of reproductive potential while taking LEN and for up to 4 weeks after discontinuing LEN, even if they have undergone a successful vasectomy. Male patients taking LEN must not donate sperm.",no-pregnancy-nursing
"Males must agree to refrain from donating sperm while on study treatment, during dose interruptions and for at least 90 days following last dose of study treatment.",no-pregnancy-nursing
"Males must agree to use a condom (a latex condom is recommended) during sexual contact with a pregnant female or a female of childbearing potential and will avoid donation of sperm or having a female partner conceive from the time of signing the ICF, while participating in the study, during dose interruptions, and for at least 8 weeks following TJ011133 discontinuation, even if he has undergone a successful vasectomy (Appendix 2).",no-pregnancy-nursing
Males must agree to use an acceptable form of contraception per institutional practices.,no-pregnancy-nursing
Males must be willing to abstain from donating sperm or semen from the time of informed consent until 90 days after treatment discontinuation.,no-pregnancy-nursing
"Males must use an effective barrier method of contraception without interruption during the study and for 3, 6 or 12 months after the last dose of MOR00208, BEN or RTX respectively, whichever is later, if the patient is sexually active with an FCBP. Males must refrain from donating blood or sperm during study participation and for 3, 6 or 12 months after the last dose of MOR00208, BEN or RTX respectively, whichever is later.",no-pregnancy-nursing
"Males or females of reproductive potential may not participate unless they have agreed to practice 1 highly effective and 1 additional effective (barrier) method of contraception at the same time during the entire study treatment period and through 4 months after the last dose of study drug, or agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the subject; periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods), withdrawal, spermicides only, and lactational amenorrhea are not acceptable methods of contraception",no-pregnancy-nursing
Males receiving lenalidomide must agree to use a latex condom during any sexual contact with FCBPs even if they have undergone a successful vasectomy,no-pregnancy-nursing
Males who are sexually active with partners of child-bearing potential must be willing to abstain from heterosexual activity or adhere to contraception from the time of written consent until 7 months after treatment discontinuation.,no-pregnancy-nursing
Males who are sexually active with WOCBP must agree to follow instructions for method(s) of contraception (Appendix 4) for the duration of treatment with study,no-pregnancy-nursing
"Males who are sexually active with WOCBP must agree to follow instructions for method(s) of contraception (Appendix 4) for the duration of treatment with study treatment(s) and for a total of 7 months posttreatment completion. In addition, male participants must be willing to refrain from sperm donation during this time.",no-pregnancy-nursing
"Males who are sexually active with WOCBP must agree to follow instructions for method(s) of contraception and fetal protection (see Appendix 4) for the duration of treatment with study treatment(s) plus approximately 5 half-lives of the study treatment, plus the duration of sperm turnover (90 days), for a total of 7 months post-treatment completion. In addition, male participants must be willing to refrain from sperm donation during this time.",no-pregnancy-nursing
Males who are sexually active with WOCBP must agree to follow instructions for method(s) of contraception for the duration of treatment with study drug (s) plus 93 days after finishing the last dose,no-pregnancy-nursing
Males who are unwilling to abstain from sperm donation while on study through 135 days after receiving the last dose of study drug.,no-pregnancy-nursing
Males who are unwilling to abstain from sperm donation while on study through 180 days after receiving the last dose of study drug.,no-pregnancy-nursing
Males who are unwilling to abstain from sperm donation while on study through 3 months after receiving the last dose of study drug.,no-pregnancy-nursing
"Males who have not had a successful vasectomy (confirmed azoospermia) or they and their female partners do not meet the criteria above (i.e., not of childbearing potential or practicing highly effective contraception throughout the study period, for 1 week after study drug discontinuation and for an additional 3 months after). No sperm donation is allowed during the study period, for 1 week after study drug discontinuation and for an additional 3 months after.",no-pregnancy-nursing
Males who have partners of childbearing potential must agree to use an effective barrier contraceptive method for 1 year after the last dose of study therapy and should not donate semen or sperm during the entire study period (see Section 5.3),no-pregnancy-nursing
Males who have partners of childbearing potential must agree to use an effective barrier contraceptive method for at least 6 months after the last dose of huJCAR014,no-pregnancy-nursing
Males who have partners of childbearing potential must agree to use an effective contraceptive method during the study and for 30 days following the last dose of study drug,no-pregnancy-nursing
Males who have partners of childbearing potential must agree to use an effective contraceptive method during the study and for 6 months following the last dose of study drug.,no-pregnancy-nursing
Males who have partners of reproductive potential must agree to use an effective barrier contraceptive method for 90 days after the last dose of study therapy (durvalumab or JCAR014),no-pregnancy-nursing
Man who agrees to take appropriate precautions to avoid fathering children (with at least 99% certainty) from screening through safety follow-up. Permitted methods that are at least 99% effective in preventing pregnancy (see Appendix A) should be communicated to the subject and their understanding confirmed.,no-pregnancy-nursing
"Men and women of childbearing potential (WOCBP) who are sexually active must agree to adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for at least 120 days after the last dose of pembrolizumab. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.",no-pregnancy-nursing
Men and Women of childbearing potential on appropriate contraception,no-pregnancy-nursing
"Men and women of reproductive potential must agree to follow accepted birth control methods for the duration of the study. Female subject is either post-menopausal or surgically sterilized or willing to use an acceptable method of birth control (i.e., a hormonal contraceptive, intra-uterine device, diaphragm with spermicide, condom with spermicide, or abstinence) for the duration of the study. Male subject agrees to use an acceptable method for contraception for the duration of the study.",no-pregnancy-nursing
"Men and women of reproductive potential must agree to follow accepted birth control methods for the duration of the study; female subject is either post-menopausal or surgically sterilized or willing to use an acceptable method of birth control (i.e., a hormonal contraceptive, intra-uterine device, diaphragm with spermicide, condom with spermicide, or abstinence) for the duration of the study; male subject agrees to use an acceptable method for contraception for the duration of the study",no-pregnancy-nursing
"Men and women of reproductive potential must agree to use a reliable method of birth control during the treatment, and women should do so for a period of 1 year following the transplant.",no-pregnancy-nursing
"Men must agree and commit to use a barrier method of contraception while on treatment and for 3 months after the last dose of trastuzumab, fulvestrant, or neratinib monotherapy; and 6 months after the last dose of paclitaxel. Women of child-bearing potential must agree and commit to the use of a highly effective double-barrier method of contraception (eg, a combination of male condom with an intravaginal device such as the cervical cap, diaphragm, or vaginal sponge with spermicide) or a non-hormonal method, from the signing of the informed consent until:",no-pregnancy-nursing
Men must agree to take appropriate precautions to avoid fathering children (with at least 99% certainty) from screening through 90 days after the last dose of study drug(s)/treatment and must refrain from donating sperm during this period. Permitted methods that are at least 99% effective in preventing pregnancy (see Appendix A) should be communicated to the participants and their understanding confirmed.,no-pregnancy-nursing
men must agree to use a latex condom during sexual contact even if they have had a successful vasectomy,no-pregnancy-nursing
Men must agree to use a latex condom during sexual contact with a female of childbearing potential (FCBP) even if they have had a successful vasectomy.,no-pregnancy-nursing
Men must agree to use a latex condom during sexual contact with a female of child-bearing potential even if they have had a successful vasectomy,no-pregnancy-nursing
"Men must agree to use a latex condom during sexual contact with a woman of childbearing potential even if they have had a successful vasectomy. All patients must be counseled at a minimum of every 28 days about pregnancy precautions and risks of fetal exposure. Should a woman become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician immediately.",no-pregnancy-nursing
Men must agree to use a latex condom during sexual contact with females of child bearing potential even if they have had a successful vasectomy,no-pregnancy-nursing
"Men must agree to use a latex or synthetic condom during sexual contact with a pregnant female or a female who can become pregnant, for the duration of the study and for at least 4 weeks after the last drug administration, even if they have undergone a successful vasectomy.",no-pregnancy-nursing
Men must be willing to use effective and reliable method of contraception for at least 6 months after T cell infusion,no-pregnancy-nursing
Men must wear a condom when engaging in any activity that allows for passage of ejaculate to another person. Male participants should also be advised of the benefit for a female partner to use a highly effective method of contraception as condom may break or leak,no-pregnancy-nursing
Men or women not using effective contraception,no-pregnancy-nursing
Men or women of childbearing potential who are unwilling to employ adequate contraception,no-pregnancy-nursing
"men or women of childbearing potential who are unwilling to employ adequate contraception (e.g., hormonal or barrier method of birth control; abstinence) for the duration of study treatment and for 4 months after the last dose of study therapy. (See Section 6.6.3)",no-pregnancy-nursing
Men or women of childbearing potential who are unwilling to employ adequate contraception (per protocol).,no-pregnancy-nursing
Men or women of childbearing potential who are unwilling to employ adequate contraception during treatment and 8 weeks after intravesical administration of MV-NIS.,no-pregnancy-nursing
Men or women of childbearing potential who are unwilling to employ adequate contraception for at least three months after completing study treatment,no-pregnancy-nursing
Men or women of childbearing potential who are unwilling to employ adequate contraception starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment,no-pregnancy-nursing
"Men or women of childbearing potential who are unwilling to employ adequate contraception Symptomatic, untreated, or uncontrolled central nervous system (CNS) metastases or seizure disorder; NOTE: Patients with treated CNS metastases without evidence of progression and without uncontrolled symptoms or need for steroids may enroll Human immunodeficiency virus (HIV)-positive patients receiving combination anti-retroviral therapy are excluded because of possible pharmacokinetic interactions with oral investigational agents Unwilling or unable to, comply with the protocol",no-pregnancy-nursing
Men or women of childbearing potential who are unwilling to employ adequate contraception.,no-pregnancy-nursing
"Men treated or enrolled on this protocol must agree to use 2 adequate methods of contraception starting with the screening visit, for the duration of study participation, and through 120 days after the last dose of MK-3475 administration",no-pregnancy-nursing
"Men who are sexually active with WOCBP must use any contraceptive method with a failure rate of less than 1% per year. Men receiving nivolumab, and who are sexually active with WOCBP will be instructed to adhere to contraception for a period of 31 weeks after the last dose of investigational product, even if they have had a vasectomy. Women who are not of childbearing potential (ie, who are postmenopausal or surgically sterile as well as azoospermic men do not require contraception). See Note below for definition of WOCBP.",no-pregnancy-nursing
Men who are sexually active with WOCBP must use any contraceptive method with a failure rate of less than 1% per year. Men receiving study drugs and who are sexually active with WOCBP will be instructed to adhere to contraception for a period of 7 months after the last dose of investigational product. See Section 5.4.1 of the protocol for methods of contraception.,no-pregnancy-nursing
"Men who are sexually active with WOCBP must use any contraceptive method with a failure rate of less than 1% per year; men receiving nivolumab and who are sexually active with WOCBP will be instructed to adhere to contraception for a period of 31 weeks after the last dose of investigational product; women who are not of childbearing potential (i.e., who are postmenopausal or surgically sterile) as well as azoospermic men do not require contraception",no-pregnancy-nursing
Men who are sterile (including vasectomy confirmed by post vasectomy semen analysis) OR agree to use a condom with spermicide and to not donate sperm during the study and for at least 30 days following last dose of Oraxol,no-pregnancy-nursing
"Men who are unwilling to use a condom (even if they have undergone a prior vasectomy) while having intercourse with any woman, while taking the drug and for 30 days after stopping treatment.",no-pregnancy-nursing
"Men who are unwilling to use a condom (even if they have undergone a prior vasectomy) while having intercourse with any woman, while taking the drug and for 4 weeks after stopping treatment",no-pregnancy-nursing
"Men who are unwilling to use a condom (even if they have undergone a prior vasectomy) while having intercourse with any woman, while taking the drug and for 4 weeks after stopping treatment.",no-pregnancy-nursing
Men who have a female partner of childbearing potential must be willing to use 2 highly effective forms of contraception throughout protocol therapy and for at least an additional 3 months after the last dose of protocol-specified therapy; men who have a pregnant partner must be willing to use a condom during sexual activity throughout protocol therapy and for 3 months after the last dose of protocol-specified therapy,no-pregnancy-nursing
"Men who partner with a woman of childbearing potential, unless they agree to use effective, dual contraceptive methods (i.e., a condom, with female partner using oral, injectable, or barrier method) while on study drug and for 3 months afterward.",no-pregnancy-nursing
Men with female partners of childbearing potential should use effective contraception during treatment with InO and for at least 5 months after the last dose of InO.,no-pregnancy-nursing
"methods of contraception (Appendix 4), which have a failure rate of < 1% when used consistently and correctly.",no-pregnancy-nursing
"MK-3475 (pembrolizumab) and KW-0761 (mogamulizumab) may have adverse effects on a fetus in utero; furthermore, it is not known if MK-3475 (pembrolizumab) or KW-0761 (mogamulizumab) has transient adverse effects on the composition of sperm; patients are excluded from this study if pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the trial, starting with the screening visit through 180 days after the last dose of trial treatment",no-pregnancy-nursing
must agree to abstain from breastfeeding during study participation and for at least 1 year post-bb21217 infusion and until CAR T cells are no longer present by qPCR on 2 consecutive tests.,no-pregnancy-nursing
"Must agree to practice 2 effective methods of contraception from the time of signing the informed consent form through 120 days after the last dose of study therapy, or agree to completely abstain from heterosexual intercourse",no-pregnancy-nursing
"Must also adhere to the guidelines of any treatmentspecific pregnancy prevention program, if applicable; OR",no-pregnancy-nursing
must also agree to ongoing pregnancy testing,no-pregnancy-nursing
Must be willing to implement contraception throughout the study and for 8 weeks after intravesical administration of MV-NIS.,no-pregnancy-nursing
must have a negative serum pregnancy test with a sensitivity of at least 50 mIU/mL within 10-14 days prior to and again within 24 hours prior to prescribing pomalidomide for cycle 1,no-pregnancy-nursing
Must not donate sperm for at least 12 months following last bb2121 infusion and until CAR T cells are no longer present by qPCR on two consecutive tests.,no-pregnancy-nursing
Natural family planning (rhythm method) or breastfeeding,no-pregnancy-nursing
Negative β-human chorionic gonadotropin (hCG) pregnancy test for female patients of child-bearing potential <= 7 days before starting neratinib therapy.,no-pregnancy-nursing
Negative Beta HCG in woman with child-bearing potential.,no-pregnancy-nursing
Negative beta human chorionic gonadotropin (HCG) test in a woman with child bearing potential defined as not post-menopausal for 24 months or no previous surgical sterilization and willing to ongoing pregnancy testing while on treatment with lenalidomide,no-pregnancy-nursing
Negative beta-human chorionic gonadotropin (&beta;-HCG) pregnancy test within 7 days prior to start of study drug for women of childbearing potential.,no-pregnancy-nursing
Negative beta-human chorionic gonadotropin (β-HCG) pregnancy test within 7 days prior to start of study drug for women of childbearing potential.,no-pregnancy-nursing
Negative beta-human chorionic gonadotropin (β-HCG) pregnancy test within 7 days prior to start of study drugs on C1D1 for women of childbearing potential,no-pregnancy-nursing
Negative blood or urine pregnancy test at screening,no-pregnancy-nursing
Negative blood pregnancy test result obtained during screening if the patient is sexually mature woman who has not undergone a hysterectomy or ovary removal or has not been naturally postmenopausal for at least 24 consecutive months.,no-pregnancy-nursing
Negative pregnancy test,no-pregnancy-nursing
"Negative pregnancy test (serum or urine) done <= 14 days prior to registration, for persons of childbearing potential only.",no-pregnancy-nursing
Negative pregnancy test (serum or urine) within 14 days prior to Step 1 registration for women of child bearing potential.,no-pregnancy-nursing
"Negative pregnancy test done < 7 days prior to registration, for women of childbearing potential only",no-pregnancy-nursing
"Negative pregnancy test done <= 10-14 days before registrationdays prior to registration, for women of childbearing potential only",no-pregnancy-nursing
"Negative pregnancy test done <= 14 days prior to C1D1, for women of childbearing potential only.",no-pregnancy-nursing
"Negative pregnancy test done <= 14 days prior to registration, for persons of childbearing potential only.",no-pregnancy-nursing
"Negative pregnancy test done <= 7 days prior to registration, for persons of childbearing potential only",no-pregnancy-nursing
"Negative pregnancy test done <= 7 days prior to registration, for persons of childbearing potential only.",no-pregnancy-nursing
"Negative pregnancy test done <= 7 days prior to registration, for women of childbearing potential only",no-pregnancy-nursing
"Negative pregnancy test done <= 7 days prior to registration, for women of childbearing potential only.",no-pregnancy-nursing
"Negative pregnancy test done <= 7 days prior to registration, for women of childbearing potential only; Note: patients must agree to adequate birth control during the study and for up to 6 months after discontinuation of study medication",no-pregnancy-nursing
"Negative pregnancy test done <= days prior to registration, for persons of childbearing potential only.",no-pregnancy-nursing
"Negative pregnancy test done at screening and ? 3 days (72 hours) prior to registration, for women of childbearing potential",no-pregnancy-nursing
Negative pregnancy test for female patients of childbearing potential.,no-pregnancy-nursing
Negative pregnancy test for females of childbearing potential.,no-pregnancy-nursing
Negative pregnancy test for persons of child-bearing potential,no-pregnancy-nursing
Negative pregnancy test for women of childbearing potential; subjects of childbearing potential are those who have not been surgically sterilized or have not been free from menses for > 1 year,no-pregnancy-nursing
Negative pregnancy test in a woman with child bearing potential.,no-pregnancy-nursing
Negative pregnancy test in women of child-bearing potential,no-pregnancy-nursing
Negative pregnancy test in women of childbearing potential .,no-pregnancy-nursing
Negative pregnancy test performed <= 7 days prior to registration (women of childbearing potential only),no-pregnancy-nursing
"Negative pregnancy test results available as defined by urine or blood human chorionic gonadotropin (hCG) test during Screening and within 7 days of Cycle 1, Day 1 in women of childbearing potential (defined as women <= 50 years of age or history of amenorrhea for <= 12 months prior to study entry.",no-pregnancy-nursing
Negative pregnancy testing (if applicable),no-pregnancy-nursing
Negative serum β hCG (human chorionic gonadotropin) test in women of childbearing potential,no-pregnancy-nursing
Negative serum beta-HCG pregnancy test done <= 7 days prior to re-registration for women of childbearing potential only.,no-pregnancy-nursing
Negative serum beta-human chorionic gonadotropin (beta-hCG) test (women of childbearing potential only),no-pregnancy-nursing
Negative serum beta-human chorionic gonadotropin (HCG) pregnancy test done <= 7 days prior to registration/randomization for women of childbearing potential only.,no-pregnancy-nursing
Negative serum or urine &beta;-HCG in women of child-bearing potential <= 7 days prior to registration.,no-pregnancy-nursing
Negative serum or urine β-HCG in women of child-bearing potential <= 7 days prior to registration.,no-pregnancy-nursing
Negative serum or urine β-hCG pregnancy test at screening for patients of childbearing potential.,no-pregnancy-nursing
Negative serum or urine beta-human chorionic gonadotropin (HCG) test (female patient of childbearing potential only) within two weeks of registration,no-pregnancy-nursing
Negative serum or urine pregnancy test at screening for women of childbearing potential (WOCBP),no-pregnancy-nursing
"Negative serum or urine pregnancy test done <= 7 days prior to registration and repeated prior to dosing on day 1 of each cycle, for individuals of childbearing potential only.",no-pregnancy-nursing
"Negative serum or urine pregnancy test done <= 7 days prior to registration, for persons of childbearing potential only",no-pregnancy-nursing
"Negative serum or urine pregnancy test done <= 7 days prior to registration, for women of childbearing potential only; Note: a woman of childbearing potential (WOCBP) is defined as any female who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) and is not postmenopausal; menopause is defined as 12 months of amenorrhea in a woman over age 45 years in the absence of other biological or physiological causes",no-pregnancy-nursing
Negative serum or urine pregnancy test result for females of child bearing potential,no-pregnancy-nursing
Negative serum pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 7 days prior to registration in women of child-bearing potential (WOCBP).,no-pregnancy-nursing
Negative serum pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin [HCG]) within 7 days prior to registration in women of child-bearing potential (WOCBP),no-pregnancy-nursing
Negative serum pregnancy test <= 7 days prior to first study drug dose.,no-pregnancy-nursing
Negative serum pregnancy test <= 7 days prior to registration for women of childbearing potential,no-pregnancy-nursing
Negative serum pregnancy test at the time of enrollment for females of childbearing potential,no-pregnancy-nursing
"Negative serum pregnancy test done <= 14 days prior to randomization, for women of childbearing potential only.",no-pregnancy-nursing
Negative serum pregnancy test done <= 7 days prior to registration for women of childbearing potential only.,no-pregnancy-nursing
"Negative serum pregnancy test done <= 7 days prior to registration, for persons of childbearing potential only",no-pregnancy-nursing
"Negative serum pregnancy test done <= 7 days prior to registration, for persons of childbearing potential only.",no-pregnancy-nursing
"Negative serum pregnancy test done <= 7 days prior to registration, for women of childbearing potential only",no-pregnancy-nursing
"Negative serum pregnancy test done <= 7 days prior to registration, for women of childbearing potential only.",no-pregnancy-nursing
"Negative serum pregnancy test for female patients of childbearing age and potential (as defined by MSKCC Standards & Guidelines), from assays obtained < 2 weeks prior to study enrollment. Patients will be advised against having unprotected sexual intercourse from the time of the negative serum pregnancy test until after completing their participation in the study.",no-pregnancy-nursing
Negative serum pregnancy test for females of childbearing age (11-55 years) and/or lack child-bearing potential,no-pregnancy-nursing
Negative serum pregnancy test for women of childbearing potential,no-pregnancy-nursing
Negative serum pregnancy test for women of childbearing potential <= 7 days prior to registration; Note: a second pregnancy test may be required <= 72 hours prior to receiving the first dose of study medication,no-pregnancy-nursing
Negative serum pregnancy test for women of childbearing potential <= 7 days prior to registration; Note: a second pregnancy test may be required <= 72 hours prior to receiving the first dose of study medication.,no-pregnancy-nursing
"Negative serum pregnancy test in females. Male and female patients with reproductive potential must use an approved contraceptive method if appropriate (for example, abstinence, oral contraceptives, implantable hormonal contraceptives, or double barrier methods) during, and for 3 months after the last dose of 765IGF-MTX.",no-pregnancy-nursing
Negative serum pregnancy test in women of childbearing potential.,no-pregnancy-nursing
Negative serum pregnancy test result for females of child bearing potential,no-pregnancy-nursing
Negative serum pregnancy test within 14 days of registration for pre-menopausal women of childbearing potential.,no-pregnancy-nursing
"Negative serum pregnancy test within 14 days prior to the first dose of study therapy for women of child-bearing potential (WCBP), defined as a sexually mature woman who has not undergone a hysterectomy or who has not been naturally post-menopausal for at least 24 consecutive months (i.e., who has had menses any time in the preceding 24 consecutive months). Sexually active WCBP and male subjects must agree to use adequate methods to avoid pregnancy (oral, injectable, or implantable hormonal contraceptive; tubal ligation; intra-uterine device; barrier contraceptive with spermicide; or vasectomized partner) throughout the study and for 28 days after the completion of study treatment.",no-pregnancy-nursing
"Negative serum pregnancy test within 2 weeks before enrollment for women of childbearing potential, defined as those who have not been surgically sterilized or who have not been free of menses for at least 1 year",no-pregnancy-nursing
Negative serum pregnancy test within 7 days prior to Cycle 1/Day 1 for women of childbearing potential.,no-pregnancy-nursing
Negative serum pregnancy test within 7 days prior to study treatment in women of childbearing potential. Women who are not of childbearing potential and who are considered to be postmenopausal ( >= 12 months of non-therapy amenorrhea) or surgically sterile (absence of ovaries and/or uterus) are not required to have a pregnancy test.,no-pregnancy-nursing
"Negative serum pregnancy test within 72 hours prior to lymphodepletion or documentation that the subject is post-menopausal. Post-menopausal status must be confirmed with documentation of absence of menses for > 1 year, or documentation of surgical menopause involving bilateral oophorectomy.",no-pregnancy-nursing
Negative serum pregnancy test within 72 hours prior to procurement and again 72 hours prior to infusion,no-pregnancy-nursing
"Negative serum pregnancy test within 72 hours prior to procurement or documentation that the subject is post-menopausal. Post-menopausal status must be confirmed with documentation of absence of menses for > 1 year, or documentation of surgical menopause involving bilateral oophorectomy.",no-pregnancy-nursing
Negative serum pregnancy test within 72 hours prior to procurement or documentation that the subject is post-menopausal. Post-menopausal status must be confirmed with documentation of absence of menses for > 1 year.,no-pregnancy-nursing
Negative serum pregnancy test within one week prior to registration for females of childbearing potential,no-pregnancy-nursing
"Negative serum pregnancy tests (for female patients) (performed locally) at Screening prior to treatment with study drug, and as required by local guidelines.",no-pregnancy-nursing
Negative serum pregnancy within 7 days of cell infusion (does not need to be repeated if pre-lymphodepletion pregnancy test is within window).,no-pregnancy-nursing
Negative serum pregnancy within 7 days of cell product administration (does not need to be repeated if pre-lymphodepletion pregnancy test is within window).,no-pregnancy-nursing
"Negative urine or serum pregnancy test done <= 14 days prior to registration, for persons of childbearing potential only.",no-pregnancy-nursing
"Negative urine or serum pregnancy test done <= 7 days prior to registration, for women of childbearing potential only",no-pregnancy-nursing
Negative urine or serum pregnancy test for females of child bearing potential within 7 days prior to registration,no-pregnancy-nursing
Negative urine or serum pregnancy test for females of child bearing potential within 7 days prior to registration:,no-pregnancy-nursing
Negative urine or serum pregnancy test for women of childbearing potential,no-pregnancy-nursing
Negative urine or serum pregnancy test for women of childbearing potential.,no-pregnancy-nursing
Negative urine or serum pregnancy test for women of childbearing potential. All women of childbearing potential must agree to use an effective barrier method of contraception (either an intrauterine device (IUD) or double barrier method using condoms or a diaphragm plus spermicide) during the treatment period and for at least 1 month after discontinuation of the study drugs. Male subjects should use effective barrier method of contraception during the treatment period and for at least 3 months after discontinuation of the study drugs.,no-pregnancy-nursing
"Negative urine or serum pregnancy test performed <= 7 days prior to registration, for women of child bearing potential only",no-pregnancy-nursing
"Negative urine or serum pregnancy test result for females of child bearing potential; females of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation and for 23 weeks after the last dose of study drug; males who are the sexual partners of a female of child-bearing potential must use any contraceptive method with a failure rate of less than 1% per year for the duration of study participation and for a period of 31 weeks after the last dose of study drug; these periods of required use of contraception have been calculated using the upper limit of the half-life for nivolumab (25 days) and are based on the protocol requirement that females of child-bearing potential use contraception for 5 half-lives plus 30 days and males who are the sexual partners of females of child-bearing potential use contraception for 5 half-lives plus 90 days.",no-pregnancy-nursing
"Negative urine pregnancy test done <= 7 days prior to registration, for women of childbearing potential only",no-pregnancy-nursing
Negative urine pregnancy test for females of child bearing age.,no-pregnancy-nursing
No breast-feeding,no-pregnancy-nursing
"Non-childbearing potential (i.e., physiologically incapable of becoming pregnant), including any female individual who has had the following:",no-pregnancy-nursing
Non-childbearing potential defined in Section 6.10.2.1,no-pregnancy-nursing
Non-lactating and no patients known to be pregnant,no-pregnancy-nursing
"Nonpregnant and non-breastfeeding: Effects on a developing human fetus of phase 2 agents under study at the recommended therapeutic dose are unknown. For this reason and because these agents may be teratogenic, women of child-bearing potential must agree to use adequate contraception (double barrier methods of birth control or abstinence) prior to study entry and for the duration of study treatment phase. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her study physician immediately. If a participant is of child-bearing potential (women are considered not of childbearing potential if they are at least one year postmenopausal and/or surgically sterile), she must have documented negative serum or negative urine pregnancy tests within 14 days of entry to screening phase.",no-pregnancy-nursing
Non-pregnant and non-lactating.,no-pregnancy-nursing
Non-pregnant and non-nursing. Women and men of reproductive potential should agree to use an effective means of birth control,no-pregnancy-nursing
Non-pregnant and non-nursing; pregnant and nursing patients may not be enrolled; women and men of reproductive potential must agree to use acceptable forms of contraception during the study,no-pregnancy-nursing
Non-pregnant.,no-pregnancy-nursing
"Nonsterilized male subjects who are not abstinent and intend to be sexually active with a female partner of childbearing potential must use a male condom with spermicide from the time of screening throughout the total duration of the drug treatment and the drug washout period (6 months after the last dose of durvalumab). Periodic abstinence, the rhythm method, and the withdrawal method are not acceptable methods of contraception. Male subjects should refrain from sperm donation throughout this period.",no-pregnancy-nursing
"Non-sterilized male subjects who are sexually active with a female partner of childbearing potential must use a highly effective method of contraception (see Table 4.1.2-1) from Day 1 through 90 days (MEDI4736 and tremelimumab monotherapy) or 180 days (MEDI4736 combined with tremelimumab) after receipt of the final dose of investigational product(s). Not engaging in sexual activity for the total duration of the study and the drug washout period is an acceptable practice; however, occasional abstinence, the rhythm method, and the withdrawal method are not acceptable methods of contraception. Male subjects should refrain from sperm donation throughout these periods. Female partners of a male subject must use a highly effective method of contraception throughout these periods.",no-pregnancy-nursing
"Nonsterilized male subjects who are sexually active with a female partner of childbearing potential must use a male condom plus spermicide post-screening and for 90 days after receipt of the last dose of investigational product. It is strongly recommended for the female partner of a male subject to also use a highly effective method of contraception throughout this period, as described in Section 10.2. In addition, male subjects must refrain from sperm donation while on study and for 90 days after the final dose of investigational product.",no-pregnancy-nursing
Nonsterilized males who are sexually active with a female partner of childbearing potential must use effective contraception (see Table 4.1-1) from Day 1 and for 90 days after receipt of the final dose of TAB001.,no-pregnancy-nursing
Nonsterilized males who are sexually active with a female partner of childbearing potential must use effective contraception from Day 1 and for 90 days after receipt of the final dose of TAB004.,no-pregnancy-nursing
Non-vasectomized male patients must comply with at least one of the following methods of birth control throughout the duration of study participation and for at least 12 months after study treatment:,no-pregnancy-nursing
Non-vasectomized male patients must comply with at least one of the following methods of birth control throughout the duration of study participation and for at least 3 months after study treatment:,no-pregnancy-nursing
Not a woman of childbearing potential,no-pregnancy-nursing
Not a woman of childbearing potential (WOCBP),no-pregnancy-nursing
Not a woman of childbearing potential (WOCBP) as defined in Appendix 3,no-pregnancy-nursing
Not a woman of childbearing potential (WOCBP) as defined in Appendix 5 OR,no-pregnancy-nursing
Not a woman of childbearing potential (WOCBP) as defined in Appendix C OR,no-pregnancy-nursing
Not a woman of childbearing potential (WOCBP) OR,no-pregnancy-nursing
Not a woman of childbearing potential (WOCBP) OR - WOCBP who agrees to follow the contraceptive guidance throughout the treatment period and for at least 6 months after the final study drug administration.,no-pregnancy-nursing
Not a woman of childbearing potential (WOCBP); or,no-pregnancy-nursing
not be pregnant,no-pregnancy-nursing
Not breast feeding,no-pregnancy-nursing
Not breast feeding at any time during the study.,no-pregnancy-nursing
Not breast feeding.,no-pregnancy-nursing
Not donate sperm.,no-pregnancy-nursing
"Not of childbearing potential: premenarchal; postmenopausal ( > 45 years of age with amenorrhea for at least 12 months); permanently sterilized (eg, bilateral tubal occlusion [which includes tubal ligation procedures as consistent with local regulations], hysterectomy, bilateral salpingectomy, bilateral oophorectomy); or otherwise be incapable of pregnancy",no-pregnancy-nursing
Not pregnant - females of childbearing potential must have a negative pregnancy test within 7 days of apheresis,no-pregnancy-nursing
Not pregnant and not nursing,no-pregnancy-nursing
"Not pregnant and not nursing, because this study involves an agent that has known genotoxic, mutagenic and teratogenic effects; therefore, for women of childbearing potential only, a negative serum pregnancy test must be obtained within 14 days prior to registration",no-pregnancy-nursing
"Not pregnant and not nursing, because this study involves an investigational agent whose genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn are unknown.",no-pregnancy-nursing
"Not pregnant and not nursing, because this study involves an investigational agent whose genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn are unknown. Therefore, for women of childbearing potential only, a negative pregnancy test done <= 7 days prior to registration is required. A female of childbearing potential is a sexually mature female who:",no-pregnancy-nursing
Not Pregnant and Not Nursing.,no-pregnancy-nursing
"Not pregnant and not nursing; for women of childbearing potential only, a negative serum pregnancy test must be obtained within 14 days prior to registration.",no-pregnancy-nursing
"Not pregnant and not nursing; for women of childbearing potential only, a negative urine or serum pregnancy test done <= 7 days prior to registration is required.",no-pregnancy-nursing
Not pregnant as confirmed by negative serum or urine pregnancy test within 14 days prior to enrollment (if female).,no-pregnancy-nursing
Not pregnant or breastfeeding.,no-pregnancy-nursing
Not pregnant or breast-feeding.,no-pregnancy-nursing
Not pregnant or lactating,no-pregnancy-nursing
Not pregnant or nursing,no-pregnancy-nursing
"Not pregnant or nursing, with negative pregnancy test; timeline: within 3 weeks prior to start of trial",no-pregnancy-nursing
Not pregnant or nursing.,no-pregnancy-nursing
Not pregnant.,no-pregnancy-nursing
"Not pregnant. If female with child bearing potential, must be confirmed by negative serum or urine pregnancy test within 14 days prior to enrollment.",no-pregnancy-nursing
Not pregnant; agreeable to contraception,no-pregnancy-nursing
Nursing individuals,no-pregnancy-nursing
Nursing persons,no-pregnancy-nursing
Nursing persons.,no-pregnancy-nursing
Nursing women,no-pregnancy-nursing
Nursing women (lactating females are eligible provided that they agree not to breast feed while taking lenalidomide),no-pregnancy-nursing
Nursing women unwilling to stop breast feeding,no-pregnancy-nursing
nursing women who are unwilling to discontinue nursing,no-pregnancy-nursing
Nursing women.,no-pregnancy-nursing
"Of childbearing potential and agree to practice 2 effective methods of contraception, at the same time, from the time of signing the informed consent form through 90 days after the last dose of study drug",no-pregnancy-nursing
"Of childbearing potential and agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject NOTE: periodic abstinence (eg, calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception",no-pregnancy-nursing
"Of childbearing potential and practicing effective method(s) of birth control consistent with local regulations regarding the use of birth control methods for subjects participating in clinical studies, as described below:",no-pregnancy-nursing
Of non-child-bearing potential (surgically sterilized or at least 2 years post-menopausal); or,no-pregnancy-nursing
"one highly effective method of contraception, including hormonal contraceptives (e.g., combined oral contraceptives, patch, vaginal ring, injectables, and implants), intrauterine device (IUD) or intrauterine system (IUS), vasectomy, or tubal ligation OR",no-pregnancy-nursing
"Or, if of childbearing potential",no-pregnancy-nursing
Oral contraception containing progestins only,no-pregnancy-nursing
"Palifermin has had embryotoxic and fetotoxic effects in animal studies. For this reason and because the other therapeutic agents used in this trial are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of active study therapy. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.",no-pregnancy-nursing
Participant is breast feeding or pregnant.,no-pregnancy-nursing
"Participant is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the screening visit through 120 days after the last dose of trial treatment.",no-pregnancy-nursing
Participant is pregnant or breastfeeding.,no-pregnancy-nursing
Participants must agree to use appropriate contraception.,no-pregnancy-nursing
"Participants must not be planning to conceive or father children within the projected duration of the trial, starting with the pre-screening/screening visit through 120 days after the last dose of pembrolizumab.",no-pregnancy-nursing
Participants must use highly effective birth control throughout the study.,no-pregnancy-nursing
"Participants of child-bearing or child-fathering potential must agree to use adequate contraception (hormonal birth control; intrauterine device; double barrier method; or total abstinence) throughout their participation, including up until 30 days after last dose of CUDC-907.",no-pregnancy-nursing
"Participants of child-bearing or child-fathering potential must agree to use adequate contraception (hormonal birth control; intrauterine device; double barrier method; or total abstinence) throughout their participation, including up until 30 days after last dose of ALRN-6924.",no-pregnancy-nursing
Participants of childbearing or child-fathering potential must agree to use adequate contraception throughout their participation following the guidance in Appendix H.,no-pregnancy-nursing
Participants of childbearing potential are those who have not been surgically sterilized or have not been free from menses for > 1 year without an alternative medical cause.,no-pregnancy-nursing
"Participants of child-bearing potential must agree to use adequate contraceptive methods (e.g., hormonal or barrier method of birth control; abstinence) prior to study entry; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately",no-pregnancy-nursing
Participants of childbearing potential must have a negative serum beta-human chorionic gonadotropin at screening and:,no-pregnancy-nursing
Participants of reproductive potential must agree to use and utilize an adequate method of contraception throughout treatment and for at least 8 weeks after T cell infusion,no-pregnancy-nursing
Participants who are pregnant or lactating,no-pregnancy-nursing
"Partner and/or patient must use a method of birth control with adequate barrier protection, deemed acceptable by the principle investigator during the study and for 3 months after last study drug administration.",no-pregnancy-nursing
Partner's vasectomy,no-pregnancy-nursing
Partner's vasectomy.,no-pregnancy-nursing
"Patient (of childbearing potential) is not breastfeeding, has a negative serum pregnancy test within 72 hours prior to taking study drug, and agrees to abstain from activities that could result in pregnancy from Screening through 180 days after the last dose of study drug, or is of nonchildbearing potential. Note: A urine pregnancy test may be performed if the serum pregnancy test is not available before dosing.",no-pregnancy-nursing
Patient agrees to use acceptable form of contraception during the study and for up to 30 days after last study drug dose if female partner is of childbearing potential,no-pregnancy-nursing
Patient is currently pregnant. Patient must agree to use two forms of birth control if they are of child-bearing potential.,no-pregnancy-nursing
Patient is female and is pregnant or breastfeeding.,no-pregnancy-nursing
Patient is known to be pregnant.,no-pregnancy-nursing
Patient is not actively breastfeeding (or has agreed to discontinue breastfeeding before the initiation of protocol therapy).,no-pregnancy-nursing
Patient is not pregnant,no-pregnancy-nursing
"Patient is pregnant or breast feeding, or planning to become pregnant while enrolled in the study, up to End of Study (EOS) visit.",no-pregnancy-nursing
"Patient is pregnant or breast feeding, or planning to become pregnant while enrolled in the study, up to the End of Study (EOS) visit.",no-pregnancy-nursing
"Patient is pregnant or breast feeding, or planning to become pregnant while enrolled in the study, up to the End of Study visit",no-pregnancy-nursing
Patient is pregnant or breast feeding.,no-pregnancy-nursing
Patient is pregnant or breastfeeding,no-pregnancy-nursing
Patient is pregnant or breast-feeding,no-pregnancy-nursing
Patient is pregnant or breast-feeding or intending to become pregnant during the course of the study or within 6 months after the last dose of the study drugs.,no-pregnancy-nursing
"Patient is pregnant or breastfeeding, or expecting to conceive children within the projected duration of the study drug or within the 180 day period after the last dose of study drug.",no-pregnancy-nursing
Patient is pregnant or breast-feeding.,no-pregnancy-nursing
Patient is pregnant or lactating and does not agree to stop breastfeeding.,no-pregnancy-nursing
"Patient is pregnant or lactating, where pregnancy is defined as state of a female after conception and until the termination of gestation, confirmed by a positive human chorionic gonadotrophin (hCG) lab test.",no-pregnancy-nursing
"Patient is willing to practice 2 forms of contraception, one of which must be a barrier method, from study entry until at least 30 days after the last dose of poziotinib.",no-pregnancy-nursing
patient must follow pregnancy testing requirements as outlined in the POMALYST REMS program,no-pregnancy-nursing
Patient of childbearing potential who is unwilling to employ adequate contraception.,no-pregnancy-nursing
Patient who does not apply highly effective contraception during the treatment with alpelisib and through the duration as defined below after the final dose of alpelisib,no-pregnancy-nursing
Patient wishes to become pregnant.,no-pregnancy-nursing
Patients able to father a child must agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapy.,no-pregnancy-nursing
"Patients must be 18 years or older. Patients must not be pregnant and, if of child-bearing age, must take precautions not to become pregnant.",no-pregnancy-nursing
"Patients must be willing and able to adhere to pomalidomide-related risk mitigation activities if randomized to the pom+dex arm (e.g., REMS, pregnancy prevention programs).",no-pregnancy-nursing
Patients must be willing to use contraception if they have childbearing potential,no-pregnancy-nursing
"Patients must not be pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment",no-pregnancy-nursing
"Patients must not be pregnant or nursing, due to the teratogenic potential of the drugs used on this study. Women/men of reproductive potential must have agreed to use an effective contraceptive method. A woman is considered to be of  reproductive potential  if she has had menses at any time in the preceding 12 consecutive months. In addition to routine contraceptive methods,  effective contraception also includes (but is not limited to) heterosexual celibacy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy, bilateral oophorectomy, bilateral tubal ligation, or vasectomy. However, if at any point a previously celibate patient chooses to become heterosexually active during the time period for use of contraceptive measures outlined in the protocol, he/she is responsible for beginning contraceptive measures. Women must agree to avoid breast-feeding and women of child-bearing potential (WOCBP) must agree to use highly effective contraception while receiving study drug and for a period of 31 weeks after the last dose of study drug. Sexually-active men must agree to use a condom while receiving study drug and for 31 weeks after the last dose of study drug. Vasectomized men must also agree to use a condom to avoid delivering drug in the seminal fluid.",no-pregnancy-nursing
"Patients must not be pregnant or nursing. Women/men of reproductive potential must have agreed to use an effective contraceptive method. A woman is considered to be of  reproductive potential  if she has had menses at any time in the preceding 12 consecutive months. In addition to routine contraceptive methods,  effective contraception  also includes heterosexual celibacy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy, bilateral oophorectomy or bilateral tubal ligation. However, if at any point a previously celibate patient chooses to become heterosexually active during the time period for use of contraceptive measures outlined in the protocol, he/she is responsible for beginning contraceptive measures.",no-pregnancy-nursing
"Patients must not be pregnant or nursing. Women/men of reproductive potential must have agreed to use an effective contraceptive method. A woman is considered to be of reproductive potential if she has had menses at any time in the preceding 12 consecutive months. In addition to routine contraceptive methods, effective contraception also includes heterosexual celibacy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy, bilateral oophorectomy or bilateral tubal ligation. However, if at any point a previously celibate patient chooses to become heterosexually active during the time period for use of contraceptive measures outlined in the protocol, he/she is responsible for beginning contraceptive measures.",no-pregnancy-nursing
"Patients must not be pregnant or nursing; women/men of reproductive potential must have agreed to use an effective contraceptive method; a woman is considered to be of  reproductive potential  if she has had menses at any time in the preceding 12 consecutive months; in addition to routine contraceptive methods,  effective contraception  also includes heterosexual celibacy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy, bilateral oophorectomy or bilateral tubal ligation; however, if at any point a previously celibate patient chooses to become heterosexually active during the time period for use of contraceptive measures outlined in the protocol, he/she is responsible for beginning contraceptive measures",no-pregnancy-nursing
"Patients must not be pregnant or nursing; women/men of reproductive potential must have agreed to use an effective contraceptive method; a woman is considered to be of reproductive potential if she has had menses at any time in the preceding 12 consecutive months; in addition to routine contraceptive methods, effective contraception also includes (but is not limited to) heterosexual celibacy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy, bilateral oophorectomy, bilateral tubal ligation, or vasectomy; however, if at any point a previously celibate patient chooses to become heterosexually active during the time period for use of contraceptive measures outlined in the protocol, he/she is responsible for beginning contraceptive measures",no-pregnancy-nursing
"Patients of both genders at a fertile age, including those women having their last menstruation within the two previous years, must follow effective contraceptive measures.",no-pregnancy-nursing
Patients of child-bearing or child-fathering potential must be willing to practice birth control from the time of enrollment on this study and for four months after receiving the preparative regimen.,no-pregnancy-nursing
Patients of childbearing or child-fathering potential must be willing use an effective method of contraception while being treated on this study and for 4 months after the last cell infusion.,no-pregnancy-nursing
"Patients of childbearing potential must be willing to use 2 methods of birth control or be surgically sterile, or abstain from heterosexual activity for the course of the study through 120 days after the last dose of study medication.",no-pregnancy-nursing
Patients of childbearing potential must have a negative pregnancy test (serum or urine),no-pregnancy-nursing
Patients of childbearing potential must have a negative urine or serum pregnancy test <= 7 days prior to registration.,no-pregnancy-nursing
Patients of childbearing potential must practice an effective method of birth control while participating on this study to avoid possible damage to the fetus.,no-pregnancy-nursing
Patients of childbearing potential or their partners of childbearing potential must be willing to practice an approved method of birth control during treatment and for 12 months after receiving the last protocol-related therapy.,no-pregnancy-nursing
"Patients of reproductive potential agree to use birth control throughout their participation in this study, and for 28 days following study termination.",no-pregnancy-nursing
Patients of reproductive potential and their partners must agree to use an effective ( > 90% reliability) form of contraception during the study and for 4 weeks following the last study drug administration.,no-pregnancy-nursing
Patients of reproductive potential must agree to follow the contraception requirements outlined in Section 6.8.11.,no-pregnancy-nursing
Patients of reproductive potential must agree to use an effective contraceptive method during participation in this trial.,no-pregnancy-nursing
Patients that are pregnant or breast feeding,no-pregnancy-nursing
Patients who are breastfeeding must agree to discontinue breastfeeding before receiving olaparib due to potential risk for adverse events in nursing infants secondary to treatment of the mother with olaparib.,no-pregnancy-nursing
Patients who are pregnant,no-pregnancy-nursing
Patients who are pregnant or actively nursing an infant are not eligible,no-pregnancy-nursing
Patients who are pregnant or breast feeding; breastfeeding should be discontinued if the mother is treated with selinexor,no-pregnancy-nursing
Patients who are pregnant or breastfeeding,no-pregnancy-nursing
Patients who are pregnant or breastfeeding.,no-pregnancy-nursing
Patients who are pregnant or breast-feeding.,no-pregnancy-nursing
Patients who are pregnant or lactating,no-pregnancy-nursing
Patients who are pregnant or lactating.,no-pregnancy-nursing
Patients who are pregnant or nursing,no-pregnancy-nursing
Patients who are pregnant.,no-pregnancy-nursing
Patients who are pregnant; pregnancy test is required for female patients of childbearing potential,no-pregnancy-nursing
Patients with child bearing potential must have a negative serum pregnancy test within 7 days of the first dose of study drug.,no-pregnancy-nursing
"Patients, both females and males, of childbearing/reproductive potential must agree to use adequate contraception while included in the trial and for 6 months after the last infusion of enapotamab vedotin (see Appendix V).",no-pregnancy-nursing
"Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception.",no-pregnancy-nursing
"Periodic abstinence (e.g., calendar, ovulation, symptothermal, or post-ovulation methods) and withdrawal are not acceptable methods of contraception.",no-pregnancy-nursing
Persons able to become pregnant must be willing to adhere to the scheduled pregnancy testing as required in the REVLIMID Risk Evaluation and Mitigation Strategy (REMS) program,no-pregnancy-nursing
"Persons able to father a child: even if surgically sterilized (i.e., status post-vasectomy), must agree to one of the following:",no-pregnancy-nursing
Persons of childbearing potential who are unwilling to employ adequate contraception,no-pregnancy-nursing
Persons of childbearing potential who are unwilling to employ adequate contraception Any of the following prior therapies:,no-pregnancy-nursing
Persons of childbearing potential who are unwilling to employ adequate contraception for at least 3 months after the last dose of the study drug.,no-pregnancy-nursing
Persons of childbearing potential who are unwilling to employ adequate contraception.,no-pregnancy-nursing
Persons of childbearing potential who are unwilling to employ highly effective contraception,no-pregnancy-nursing
"Persons of childbearing potential, agree to one of the following:",no-pregnancy-nursing
Placement of an intrauterine device or intrauterine system,no-pregnancy-nursing
Positive beta HCG in female of child-bearing potential defined as not postmenopausal for 24 months or no previous surgical sterilization or lactating females.,no-pregnancy-nursing
Positive pregnancy test for women of childbearing age.,no-pregnancy-nursing
Positive serum or urine beta human chorionic gonadotropin (HCG) test in females of childbearing potential within 3 weeks of registration,no-pregnancy-nursing
"Positive serum pregnancy test (ie, urine human chorionic gonadotropin) at screening.",no-pregnancy-nursing
Positive serum pregnancy test at screening visit.,no-pregnancy-nursing
Positive serum pregnancy test for females,no-pregnancy-nursing
Positive serum pregnancy test in females of child-bearing potential or current breastfeeding,no-pregnancy-nursing
"Positive urine pregnancy test (i.e., urine human chorionic gonadotropin [β-hCG]) at screening.",no-pregnancy-nursing
"Positive urine pregnancy test (i.e., urine human chorionic gonadotropin) at screening.",no-pregnancy-nursing
Positive urine pregnancy test within 72 hours prior to the initiation of study treatment,no-pregnancy-nursing
"Positive urine pregnancy test within 72 hours prior to the initiation of study treatment. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.",no-pregnancy-nursing
Post-menarchal females and males who are sexually active with women of childbearing potential who are not employing/willing to employ an effective method of birth control.,no-pregnancy-nursing
Postmenopausal or evidence of non-childbearing status for women of childbearing potential: negative urine or serum pregnancy test within 28 days and within 72 hours of study treatment and confirmed prior to receiving treatment on this study. Patients with positive results will be removed from the study. Postmenopausal is defined as:,no-pregnancy-nursing
"Practice 2 effective methods of contraception, at the same time, from the time of signing the informed consent form through 120 days after the last dose of study drug, AND must also adhere to the guidelines of any treatment-specific pregnancy prevention program, if applicable, OR",no-pregnancy-nursing
"Practice 2 effective methods of contraception, at the same time, from the time of signing the informed consent form through 90 days after the last dose of study drug, AND must also adhere to the guidelines of any treatment-specific pregnancy prevention program, if applicable, OR",no-pregnancy-nursing
"Practice 2 effective methods of contraception, at the same time, from the time of signing the informed consent form through 90 days after the last dose of study drug, OR",no-pregnancy-nursing
"Practice 2 effective methods of contraception, at the same time, from the time of signing the informed consent form through 90 days after the last dose of trial drug; AND",no-pregnancy-nursing
"Practice 2 effective methods of contraception, at the same time, from the time of signing the informed consent form through 90 days after the last dose of trial drug; AND Must also adhere to the guidelines of any treatment specific pregnancy prevention program, if applicable; OR",no-pregnancy-nursing
"Practice true abstinence* (which must be reviewed on a monthly basis and source documented) or agree to use a condom during sexual contact with a pregnant female or a female of childbearing potential while participating in the study, during dose interruptions and for at least 90 days following the last dose of study treatment, even if he has undergone a successful vasectomy.",no-pregnancy-nursing
"Practice true abstinence* (which must be reviewed on a monthly basis) or agree to use a condom during sexual contact with a pregnant female or a female of childbearing potential while participating in the study, during dose interruptions and for 12 months after the JCAR017 infusion even if he has undergone a successful vasectomy and until CAR T cells are no longer present by qPCR on 2 consecutive tests, whichever occurs last (Arm B) and for 12 months after the last chemotherapy (Arm A).",no-pregnancy-nursing
"Practice true abstinence* (which must be reviewed on a monthly basis) or agree to use a condom during sexual contact with a pregnant female or a female of childbearing potential while participating in the study, during dose interruptions and for at least 12 weeks (approximately 5 times the mean terminal half-life of luspatercept based on multiple-dose PK data) following investigational product discontinuation, even if he has undergone a successful vasectomy.",no-pregnancy-nursing
"Practice true abstinence* (which must be reviewed on a monthly basis) or agree to use a condom during sexual contact with a pregnant female or a female of childbearing potential** while participating in the study, during dose interruptions and for at least 12 weeks (approximately 5 times the mean terminal half-life of luspatercept based on multiple-dose PK data) following investigational product discontinuation, even if he has undergone a successful vasectomy",no-pregnancy-nursing
"Practice true abstinence* or agree to use a condom during sexual contact with a pregnant female or a female of childbearing potential for at least one year post BB2121 infusion, even if he has undergone a successful vasectomy. Subjects will be followed from screening until at least 1 year following last bb2121 infusion.",no-pregnancy-nursing
"Practice true abstinence2 or agree to use a condom during sexual contact with a pregnant female or a female of childbearing for at least 1 year post bb2121 infusion, even if he has undergone a successful vasectomy from screening until at least 1 year following last bb2121 infusion and until CAR T cells are no longer present by qPCR on two consecutive tests.",no-pregnancy-nursing
"Practice true abstinence2 or agree to use a condom during sexual contact with a pregnant female or a female of childbearing potential while participating in the study, during dose interruptions even if he has undergone a successful vasectomy, until:",no-pregnancy-nursing
"Practicing 2 methods of contraception, including one highly effective method (ie, established use of oral, injected or implanted hormonal methods of contraception; placement of an intrauterine device [IUD] or intrauterine system [IUS], AND, a second method, (eg, condom with spermicidal foam/gel/film/cream/suppository or occlusive cap [diaphragm or cervical/vault caps] with spermicidal foam/gel/film/cream/suppository) Subjects must agree to continue contraception throughout the study and continuing through 6 months after the last dose of study drug.",no-pregnancy-nursing
"Practicing true abstinence (when this is in line with the preferred and usual lifestyle of the subject), which is defined as refraining from heterosexual intercourse during the entire period of the study, including up to 6 months after the last dose of study drug is given. Periodic abstinence (calendar, symptothermal, post-ovulation methods) is not considered an acceptable contraceptive method. or",no-pregnancy-nursing
"Pre- or post-menopausal women are eligible If premenopausal, patient must be willing to comply with pregnancy requirements laid out in Section 5.5 and agrees with GnRH agonist therapy for ovarian suppression during the study.",no-pregnancy-nursing
Pregnancy,no-pregnancy-nursing
Pregnancy (by self-report of pregnancy status),no-pregnancy-nursing
Pregnancy (positive beta human chorionic gonadotropin [HCG] test in a woman with child bearing potential defined as not post-menopausal for 12 months or no previous surgical sterilization) or currently breast-feeding; pregnancy testing is not required for post-menopausal or surgically sterilized women,no-pregnancy-nursing
Pregnancy (positive serum or urine pregnancy test) or breast feeding.,no-pregnancy-nursing
"Pregnancy and Breastfeeding There have been no human studies of InO in pregnant women and no reports of exposure in utero. Based on nonclinical safety studies, InO has the potential to impair human male and female fertility and to adversely affect human embryo-fetal development. Women of childbearing potential should be advised to avoid becoming pregnant while receiving InO. There is no information regarding the presence of InO in human milk, the effects on the breast-fed infant, or the effects on milk production. Because of the potential for adverse reactions in breast-fed infants, women should not breast-feed during treatment with InO and for at least 2 months after the final dose.",no-pregnancy-nursing
Pregnancy or active breastfeeding,no-pregnancy-nursing
Pregnancy or breast feeding,no-pregnancy-nursing
Pregnancy or breast feeding women,no-pregnancy-nursing
Pregnancy or breast feeding women.,no-pregnancy-nursing
Pregnancy or breast feeding.,no-pregnancy-nursing
Pregnancy or breastfeeding,no-pregnancy-nursing
Pregnancy or breast-feeding,no-pregnancy-nursing
Pregnancy or breastfeeding women.,no-pregnancy-nursing
"Pregnancy or breastfeeding, or intention of becoming pregnant during study treatment or within 5 months after last dose of atezolizumab, 30 days after the last dose of nab-paclitaxel, or 6 months after last dose of pemetrexed, carboplatin, or cisplatin Women of childbearing potential must have a negative serum pregnancy test result within 14 days prior to initiation of study treatment.",no-pregnancy-nursing
"Pregnancy or breastfeeding, or intention of becoming pregnant during the study",no-pregnancy-nursing
Pregnancy or breastfeeding.,no-pregnancy-nursing
Pregnancy or breast-feeding.,no-pregnancy-nursing
Pregnancy or Breast-Feeding: No information is available regarding human fetal or teratogenic toxicities. Pregnancy tests must be obtained in girls who are post-menarchal. Males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method.,no-pregnancy-nursing
Pregnancy or Breast-Feeding: Pregnant patients are ineligible for this study due to the unknown teratogenic effects of this agent. Pregnancy tests must be obtained in females of childbearing potential prior to enrollment.,no-pregnancy-nursing
"Pregnancy or breastfeeding; (females of childbearing potential must have a negative serum or urine beta human chorionic gonadotropin [beta-hCG] pregnancy test result within 7 days prior to the first dose of brentuximab vedotin; females with false positive results and documented verification that the patient is not pregnant are eligible for participation; females of non-childbearing potential are those who are postmenopausal greater than 1 year or who have had a bilateral tubal ligation or hysterectomy; females of childbearing potential and males who have partners of childbearing potential must agree to use 2 effective contraceptive methods during the study and for 6 months following the last dose of brentuximab vedotin or 8 months following the last dose of nivolumab, whichever is later)",no-pregnancy-nursing
Pregnancy or breastfeeding; a pregnancy test must be performed within 7 days prior to ibrutinib initiation in women of childbearing potential; pregnant women; breastfeeding must be discontinued because of unknown but potential risks in the nursing infant,no-pregnancy-nursing
Pregnancy or lactation,no-pregnancy-nursing
pregnancy or lactation (for females),no-pregnancy-nursing
pregnancy or lactation (for females). Pregnancy and lactation will affect cfDNA quality relative to the evaluation of tumor specific alterations.,no-pregnancy-nursing
Pregnancy or lactation (for females); pregnancy test will have been completed as per standard of care prior to treatment and does not need to be repeated for this study,no-pregnancy-nursing
Pregnancy or lactation at the time of randomization or intention to become pregnant during the study.,no-pregnancy-nursing
Pregnancy or lactation at the time of study entry. (Note: Pregnancy testing must be performed within 2 weeks prior to randomization according to institutional standards for women of childbearing potential.),no-pregnancy-nursing
Pregnancy or lactation at the time of study registration; (Note: Pregnancy testing according to institutional standards for women of childbearing potential must be performed within 2 weeks prior to study registration),no-pregnancy-nursing
Pregnancy or lactation or intending to become pregnant during study,no-pregnancy-nursing
Pregnancy or lactation.,no-pregnancy-nursing
Pregnancy or men whose female partners are pregnant,no-pregnancy-nursing
Pregnancy or nursing or unwilling to take adequate birth control during therapy,no-pregnancy-nursing
Pregnancy or nursing patients will be excluded from the study.,no-pregnancy-nursing
Pregnancy or nursing.,no-pregnancy-nursing
Pregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception during treatment and for 180 days after the completion of all treatment. This exclusion is necessary because the treatment involved in this study may be significantly teratogenic. Women who are breastfeeding are also excluded.,no-pregnancy-nursing
Pregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception for the duration of study treatment and for 180 days after the last dose of study drug (Arm 2); this exclusion is necessary because the treatment involved in this study may be significantly teratogenic.,no-pregnancy-nursing
Pregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception; this exclusion is necessary because the treatment involved in this study may be significantly teratogenic.,no-pregnancy-nursing
"Pregnancy test (urine or serum beta-HCG) done within 72 hours before randomization must be negative (for women of childbearing potential only). If urine pregnancy results are positive or cannot be confirmed as negative, a serum pregnancy test will be required.",no-pregnancy-nursing
Pregnancy Test Females of childbearing potential must have a negative serum or urine pregnancy test (females who have undergone surgical sterilization or who have been postmenopausal for at least 2 years are not considered to be of childbearing potential),no-pregnancy-nursing
"Pregnancy, positive serum HCG within 28 days of enrollment, or breast-feeding",no-pregnancy-nursing
Pregnancy.,no-pregnancy-nursing
Pregnancy. Lactating females must cease expression of milk prior to signing consent to be eligible.,no-pregnancy-nursing
"Pregnant and breastfeeding women are excluded from this study. Pregnant women are excluded in this study because ibrutinib is a tyrosine kinase inhibitor with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with ibrutinib, breastfeeding should be discontinued if the mother is treated with ibrutinib.",no-pregnancy-nursing
Pregnant and lactating women,no-pregnancy-nursing
Pregnant and lactating women are excluded,no-pregnancy-nursing
"Pregnant and lactating women will not be eligible; women of childbearing potential should have a negative pregnancy test prior to entering on the study and be willing to practice methods of contraception. Women do not have childbearing potential if they have had a hysterectomy or are postmenopausal without menses for 12 months. In addition, men enrolled on this study should understand the risks to any sexual partner of childbearing potential and should practice an effective method of birth control",no-pregnancy-nursing
"Pregnant and lactating women will not be eligible; women of childbearing potential should have a negative pregnancy test prior to entering on the study and be willing to practice methods of contraception; women do not have childbearing potential if they have had a hysterectomy or are postmenopausal without menses for 12 months; in addition, men enrolled on this study should understand the risks to any sexual partner of childbearing potential and should practice an effective method of birth control",no-pregnancy-nursing
Pregnant and nursing women. A negative serum pregnancy test during screening and a negative pregnancy test within 72 hours prior to the first dose must be documented before CD19 t haNK for Infusion is administered to a female subject of child-bearing potential.,no-pregnancy-nursing
Pregnant and nursing: female patients must have a negative serum pregnancy test within 72 hours prior to initiating protocol therapy and be practicing an effective form of contraception during protocol therapy and for at least 4 weeks following completion of protocol therapy,no-pregnancy-nursing
Pregnant and/or breastfeeding.,no-pregnancy-nursing
Pregnant and/or breastfeeding. Women of childbearing potential must have a negative pregnancy test within 14 days of study entry.,no-pregnancy-nursing
Pregnant and/or breastfeeding. Women of childbearing potential must have a negative serum pregnancy test within 14 days of study entry.,no-pregnancy-nursing
Pregnant and/or lactating women.,no-pregnancy-nursing
Pregnant and/or nursing females.,no-pregnancy-nursing
Pregnant breastfeeding.,no-pregnancy-nursing
Pregnant female patients; breastfeeding female patients; fertile male patients and female patients of childbearing potential who are unwilling or unable to use 2 highly effective methods of contraception as outlined in this protocol for the duration of the study and for at least 28days after the last dose of investigational product.,no-pregnancy-nursing
Pregnant female subjects; breastfeeding female subjects; fertile male subjects and female subjects of childbearing potential who are unwilling or unable to use highly effective contraception as outlined in this protocol for the duration of the study and for a minimum of 8 months (females) and 5 months (males) after the last dose of investigational product,no-pregnancy-nursing
Pregnant female.,no-pregnancy-nursing
Pregnant females,no-pregnancy-nursing
Pregnant females (Lactating females must agree not to breast feed while taking ibrutinib,no-pregnancy-nursing
"Pregnant females, as documented by a serum beta human chorionic gonadotropin (β-hCG) pregnancy test consistent with pregnancy, obtained within 7 days prior to the first dose of study drug. Females with β-hCG values that are within the range for pregnancy but are not pregnant (false-positives) may be enrolled with written consent of the Sponsor, after pregnancy has been ruled out. Females of non-childbearing potential (postmenopausal for more than 1 year; bilateral tubal ligation; bilateral oophorectomy; hysterectomy) do not require a serum β-hCG test.",no-pregnancy-nursing
Pregnant females. (Lactating females must agree not to breast feed while taking the study medications).,no-pregnancy-nursing
Pregnant individuals,no-pregnancy-nursing
Pregnant or a lactating female,no-pregnancy-nursing
Pregnant or breast feeding,no-pregnancy-nursing
Pregnant or breast feeding females,no-pregnancy-nursing
Pregnant or breast feeding women,no-pregnancy-nursing
Pregnant or breast feeding.,no-pregnancy-nursing
"Pregnant or breast feeding. For males and females of child-producing potential, inability to use effective contraceptive methods during the study",no-pregnancy-nursing
Pregnant or breast feeding. Refer to section 4.4 for further details,no-pregnancy-nursing
Pregnant or breast feeding. The agents used in this study include Pregnancy Category D: known to cause harm to a fetus. Females of childbearing potential must have a blood test or urine study within 14 days prior to registration to rule out pregnancy.,no-pregnancy-nursing
Pregnant or breast feeding. The agents used in this study include Pregnancy Category D: known to cause harm to a fetus. Females of childbearing potential must have a negative pregnancy test prior to starting therapy.,no-pregnancy-nursing
Pregnant or breast feeding. The agents used in this study may be teratogenic to a fetus and there is no information on the excretion of agents into breast milk. Females of childbearing potential must have a blood test or urine study within 14 days prior to study enrollment to rule out pregnancy.,no-pregnancy-nursing
Pregnant or breastfeeding,no-pregnancy-nursing
Pregnant or breast-feeding,no-pregnancy-nursing
Pregnant or breastfeeding - methotrexate is Pregnancy Category X - has been reported to cause fetal death and/or congenital abnormalities. Confirmation that the subject is not pregnant must be established by a negative serum β-human chorionic gonadotropin (β-hCG) pregnancy test result obtained during screening. Pregnancy testing is not required for post-menopausal or surgically sterilized women.,no-pregnancy-nursing
Pregnant or breastfeeding - The agents used in this study include those that fall under Pregnancy Category D - have known teratogenic potential. For elotuzumab arm: Women of child bearing potential must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 14 days of study treatment start (24 hours prior to the start of elotuzumab),no-pregnancy-nursing
"Pregnant or breast-feeding (lactating) woman or woman who plans to become pregnant or breast-feed during the study or within 90 days after the last dose of gevokizumab. Pregnancy is defined as the state after conception and until the termination of gestation, confirmed by a positive hCG laboratory test",no-pregnancy-nursing
Pregnant or breastfeeding (NOTE: breast milk cannot be stored for future use while the mother is being treated on study),no-pregnancy-nursing
Pregnant or breastfeeding (NOTE: breast milk cannot be stored for future use while the mother is being treated on study).,no-pregnancy-nursing
Pregnant or breastfeeding female,no-pregnancy-nursing
Pregnant or breastfeeding females,no-pregnancy-nursing
Pregnant or breast-feeding females,no-pregnancy-nursing
Pregnant or breast-feeding females (lactating females must agree not to breast feed while taking the investigational agents).,no-pregnancy-nursing
Pregnant or breastfeeding females.,no-pregnancy-nursing
Pregnant or breast-feeding females.,no-pregnancy-nursing
Pregnant or breast-feeding females; (lactating females must agree not to breast-feed while taking lenalidomide),no-pregnancy-nursing
Pregnant or breast-feeding or intending to become pregnant during the study,no-pregnancy-nursing
"Pregnant or breast-feeding patients. WOCBP must have a serum pregnancy test performed a maximum of 7 days before the start of study treatment, and a negative result must be documented before the start of study treatment.",no-pregnancy-nursing
"Pregnant or breast-feeding patients. Women of childbearing potential must have a pregnancy test performed a maximum of 7 days before start of treatment, and a negative result must be documented before start of treatment",no-pregnancy-nursing
"Pregnant or breast-feeding patients. Women of childbearing potential must have a serum pregnancy test performed a maximum of 7 days before start of treatment, and a negative result must be documented before start of treatment",no-pregnancy-nursing
Pregnant or breastfeeding women,no-pregnancy-nursing
Pregnant or breast-feeding women,no-pregnancy-nursing
Pregnant or breast-feeding women are excluded,no-pregnancy-nursing
Pregnant or breastfeeding women are excluded from this study,no-pregnancy-nursing
"Pregnant or breastfeeding women are excluded from this study because CAR-T cell therapy may be associated with the potential for teratogenic or abortifacient effects. Women of child bearing potential must have a negative serum pregnancy test. Because there is an unknown, but potential risk for adverse events in nursing infants secondary to treatment of the mother with CAR-T cells, breastfeeding should be discontinued. These potential risks may also apply to other agents used in this study.",no-pregnancy-nursing
"Pregnant or breastfeeding women are excluded from this study because Jakafi is inhibitor of the Jak-1 and Jak-2 kinases with the potential for teratogenic or abortifacient effects. Because there is an unknown, but potential risk for adverse events in nursing infants secondary to treatment of the mother with Jakafi, breastfeeding should be discontinued if the mother is treated with Jakafi. These potential risks may also apply to other agents used in this study.",no-pregnancy-nursing
Pregnant or breastfeeding women are excluded from this study.,no-pregnancy-nursing
Pregnant or breastfeeding women are excluded from this study; breastfeeding should be discontinued if the mother is treated with carfilzomib,no-pregnancy-nursing
Pregnant or breastfeeding women will be excluded from participation in this trial,no-pregnancy-nursing
Pregnant or breast-feeding women will not be entered on this study because there is currently no available information regarding human fetal or teratogenic toxicities; pregnancy tests must be obtained in girls who are post-menarchal; males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method for the duration of study treatment and for one week after the last dose of ensartinib,no-pregnancy-nursing
Pregnant or breast-feeding women will not be entered on this study because there is not yet available information regarding human fetal or teratogenic toxicities; pregnancy tests must be obtained in girls who are post-menarchal,no-pregnancy-nursing
"Pregnant or breast-feeding women will not be entered on this study due to risks of fetal and teratogenic adverse events as seen in animal studies; pregnancy tests must be obtained in girls who are post-menarchal; males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method, while receiving study treatment and for 3 months after the last dose of JNJ-42756493 (erdafitinib); male subjects (with a partner of child-bearing potential) must use a condom with spermicide when sexually active and must not donate sperm from the first dose of study drug until 5 months after the last dose of study drug",no-pregnancy-nursing
"Pregnant or breast-feeding women will not be entered on this study due to risks of fetal and teratogenic adverse events as seen in animal/human studies. Pregnancy tests must be obtained in girls who are post-menarchal. Males or females of reproductive potential may not participate unless they have agreed to use two methods of birth control- a medically accepted barrier method of contraceptive method (e.g., male or female condom) and a second effective method of birth control- during protocol therapy and for at least 4 months after the last dose of XL184. Abstinence is an acceptable method of birth control.",no-pregnancy-nursing
Pregnant or breast-feeding women will not be entered on this study due to risks of fetal and teratogenic adverse events as seen in animal/human studies; pregnancy tests must be obtained in girls who are post-menarchal; males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method for the duration of study treatment,no-pregnancy-nursing
"Pregnant or breast-feeding women will not be entered on this study due to risks of fetal and teratogenic adverse events as seen in animal/human studies; pregnancy tests must be obtained in girls who are post-menarchal; males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method for the duration of study treatment; females study participants of child-bearing potential and their partners, should agree to use highly effective forms of contraception for at least 3 weeks after the last dose of palbociclib; male study participants should avoid fathering a child, donating sperm, and should agree to use highly effective forms of contraception for at least 3 months after the last dose of palbociclib",no-pregnancy-nursing
Pregnant or breast-feeding women will not be entered on this study due to risks of fetal and teratogenic adverse events as seen in animal/human studies; pregnancy tests must be obtained in girls who are post-menarchal; women of child-bearing potential and their partners should agree to use two (2) highly effective forms of contraception throughout study participation and for at least one (1) month after the last dose of olaparib; male study participants should avoid fathering a child or donating sperm during the study and for three (3) months after the last dose of olaparib,no-pregnancy-nursing
Pregnant or breast-feeding women will not be entered on this study.,no-pregnancy-nursing
Pregnant or breast-feeding women will not be entered on this study; pregnancy tests must be obtained in girls who are post-menarchal; males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method for the duration of study treatment,no-pregnancy-nursing
Pregnant or breast-feeding women will not be entered on this study; pregnancy tests must be obtained in girls who are post-menarchal; males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method while receiving study treatment and for 3 months after the last dose of LY3023414,no-pregnancy-nursing
"Pregnant or breast-feeding women will not be entered on this study; pregnancy tests must be obtained in girls who are post-menarchal; males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method, for the duration of study treatment and for 6 months after the last dose of vemurafenib",no-pregnancy-nursing
"Pregnant or breast-feeding women will not be entered on this study; pregnancy tests must be obtained in girls who are post-menarchal; males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive use two effective methods of birth control- including a medically accepted barrier method of contraceptive method (e.g., male or female condom) for the entire period in which they are receiving protocol therapy; abstinence is an acceptable method of birth control",no-pregnancy-nursing
Pregnant or breastfeeding women.,no-pregnancy-nursing
Pregnant or breast-feeding women.,no-pregnancy-nursing
Pregnant or breastfeeding women: positive pregnancy test within 7 days of starting treatment.,no-pregnancy-nursing
"Pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial through 120 days after the last dose of study medication",no-pregnancy-nursing
"Pregnant or breastfeeding, or intending to become pregnant during the study",no-pregnancy-nursing
"Pregnant or breastfeeding, or intending to become pregnant during the study or within 12 months after the last dose of study drug",no-pregnancy-nursing
"Pregnant or breastfeeding, or intending to become pregnant during the study or within 3 months after the last dose of study drug.",no-pregnancy-nursing
Pregnant or breastfeeding.,no-pregnancy-nursing
Pregnant or breast-feeding.,no-pregnancy-nursing
Pregnant or breastfeeding. NOTE: breast milk cannot be stored for future use while the mother is being treated on study.,no-pregnancy-nursing
Pregnant or breast-feeding. Refer to section 4.4 for further detail.,no-pregnancy-nursing
Pregnant or breastfeeding. The agents used in this study include Pregnancy Category D: known to cause harm to a fetus. Females of childbearing potential must have a negative pregnancy test prior to starting therapy.,no-pregnancy-nursing
Pregnant or breastfeeding: Females of childbearing potential must have a blood test or urine study within 14 days prior to registration to rule out pregnancy,no-pregnancy-nursing
Pregnant or lactating,no-pregnancy-nursing
Pregnant or lactating donor,no-pregnancy-nursing
pregnant or lactating female,no-pregnancy-nursing
Pregnant or lactating female.,no-pregnancy-nursing
Pregnant or lactating females,no-pregnancy-nursing
Pregnant or lactating females are ineligible as many of the medications used in this protocol could be harmful to unborn children and infants.,no-pregnancy-nursing
Pregnant or lactating females.,no-pregnancy-nursing
Pregnant or lactating individuals.,no-pregnancy-nursing
"Pregnant or lactating or is expecting to conceive children or breastfeed within the projected duration of the trial, starting with the screening visit through 120 days after the last dose of trial treatment",no-pregnancy-nursing
Pregnant or lactating patients.,no-pregnancy-nursing
Pregnant or lactating subjects.,no-pregnancy-nursing
Pregnant or lactating women,no-pregnancy-nursing
Pregnant or lactating women are excluded from this study,no-pregnancy-nursing
Pregnant or lactating women are not eligible,no-pregnancy-nursing
"Pregnant or lactating women or is expecting to conceive children or breastfeed within the projected duration of the trial, starting with the screening visit through 120 days after the last dose of trial treatment.",no-pregnancy-nursing
Pregnant or lactating women or women of childbearing potential and male participants who are sexually active and not willing/able to use medically acceptable forms of contraception; this exclusion is necessary because the radiation treatment involved in this study may be significantly teratogenic.,no-pregnancy-nursing
Pregnant or lactating women.,no-pregnancy-nursing
Pregnant or lactating women. The safety of this therapy on unborn children is not known. Female study participants of reproductive potential must have a negative serum or urine pregnancy test performed within 48 hours before infusion.,no-pregnancy-nursing
Pregnant or lactating women. Women and men of childbearing age should use effective contraception while on this study and continue for 1 year after all treatment is finished,no-pregnancy-nursing
Pregnant or lactating women. Women and men of childbearing age should use effective contraception.,no-pregnancy-nursing
"Pregnant or lactating, or intending to become pregnant during the study",no-pregnancy-nursing
"Pregnant or lactating, or intending to become pregnant during the study Women of childbearing potential must have a negative serum pregnancy test result within 21 days prior to initiation of study drug.",no-pregnancy-nursing
"Pregnant or lactating, or intending to become pregnant during the study.",no-pregnancy-nursing
"Pregnant or lactating, or intending to become pregnant or father children within the projected duration of the trial starting with the screening visit through 5 months after the last dose of checkpoint inhibitor and/or DNA vaccine",no-pregnancy-nursing
Pregnant or lactating.,no-pregnancy-nursing
Pregnant or lactating. The effects of the immunosuppressive medications that could be required to treat GHVD are likely to be harmful to a fetus. The effects upon breast milk are also unknown and may be harmful to an infant.,no-pregnancy-nursing
Pregnant or nursing,no-pregnancy-nursing
"Pregnant or nursing (lactating women), where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test",no-pregnancy-nursing
"Pregnant or nursing (lactating women), where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test.",no-pregnancy-nursing
Pregnant or nursing (lactating) women,no-pregnancy-nursing
"Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive human chorionic gonadotropin (hCG) laboratory test",no-pregnancy-nursing
"Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive human chorionic gonadotropin (hCG) laboratory test.",no-pregnancy-nursing
Pregnant or nursing (lactating) women.,no-pregnancy-nursing
Pregnant or nursing female participants,no-pregnancy-nursing
Pregnant or nursing females,no-pregnancy-nursing
Pregnant or nursing females are excluded from this study.,no-pregnancy-nursing
Pregnant or nursing females are not eligible.,no-pregnancy-nursing
Pregnant or nursing females.,no-pregnancy-nursing
Pregnant or nursing patients.,no-pregnancy-nursing
Pregnant or nursing women,no-pregnancy-nursing
Pregnant or nursing women are excluded from this study because the safety of metformin in pregnancy has not been established.,no-pregnancy-nursing
Pregnant or nursing women.,no-pregnancy-nursing
Pregnant or nursing women. Men or women may not participate unless they have agreed to use effective contraception during treatment and for 12 months following completion of therapy,no-pregnancy-nursing
"Pregnant or nursing women. NOTE: If a woman became pregnant or suspects she is pregnant while participating in this study, she must inform her treating physician immediately.",no-pregnancy-nursing
"Pregnant or nursing women. NOTE: Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; or abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.",no-pregnancy-nursing
Pregnant or nursing women; men or women of reproductive potential may not participate unless they have agreed to use an effective contraceptive method,no-pregnancy-nursing
Pregnant or planning to become pregnant in the next 6 mos/breastfeeding,no-pregnancy-nursing
Pregnant participants will not be entered on this study given that the effects of BMS-986158 on the developing human fetus are unknown. Female participants of childbearing potential must have a documented negative pregnancy exam within 24 hours prior to dosing.,no-pregnancy-nursing
Pregnant participants will not be entered on this study given that the effects of CUDC-907 on the developing human fetus are unknown.,no-pregnancy-nursing
Pregnant patients cannot participate in the substudy,no-pregnancy-nursing
Pregnant persons,no-pregnancy-nursing
Pregnant persons or persons of reproductive ability who are unwilling to use effective contraception,no-pregnancy-nursing
Pregnant persons.,no-pregnancy-nursing
Pregnant women,no-pregnancy-nursing
"Pregnant women and women who are lactating. Triplex risks to pregnant women are unknown. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with the administered vaccine, also breastfeeding should be discontinued if the mother is enrolled on this study",no-pregnancy-nursing
Pregnant women and women who are lactating; breastfeeding should be discontinued if the mother is enrolled on this study,no-pregnancy-nursing
Pregnant women are excluded from this study,no-pregnancy-nursing
"Pregnant women are excluded from this study because ABT-888 and atezolizumab are have the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with ABT-888 and atezolizumab, breastfeeding should be discontinued if the mother is treated with ABT-888 and atezolizumab.",no-pregnancy-nursing
"Pregnant women are excluded from this study because APR-246 has not been studied in pregnant patients. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with APR 246, breastfeeding should be discontinued if the mother is treated with APR-246.",no-pregnancy-nursing
"Pregnant women are excluded from this study because bortezomib and clofarabine have been assigned to pregnancy category D by the FDA. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with the study drugs, breastfeeding should be discontinued prior to the first dose of study drug and women should refrain from nursing throughout the treatment period and for 3 months following the last dose of study drug.",no-pregnancy-nursing
"Pregnant women are excluded from this study because carfilzomib is a PI with the potential for abortifacient effects. Because there is an unknown but potential risk for AEs in nursing infants secondary to treatment of the mother with CB-839 HCl, carfilzomib, and dexamethasone, breastfeeding should be discontinued if the mother is treated with this drug combination.",no-pregnancy-nursing
"Pregnant women are excluded from this study because CDX-1127 (varlilumab) and nivolumab are agents with the potential for teratogenic or abortifacient effects; because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with CDX-1127 (varlilumab) or nivolumab, breastfeeding should be discontinued if the mother is treated with CDX-1127 (varlilumab) or nivolumab",no-pregnancy-nursing
"Pregnant women are excluded from this study because copanlisib and nivolumab are agents with the potential for teratogenic or abortifacient effects; because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with copanlisib or nivolumab, breastfeeding should be discontinued for 1 month after last dose if the mother is treated with copanlisib or nivolumab",no-pregnancy-nursing
"Pregnant women are excluded from this study because ivabradine is an agent with the potential for teratogenic effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with ivabradine, breastfeeding should be discontinued if the mother is treated with ivabradine.",no-pregnancy-nursing
Pregnant women are excluded from this study because lenalidomide is a Category X agent with the potential for teratogenic or abortifacient effects. These potential risks may also apply to other agents used in this study.,no-pregnancy-nursing
"Pregnant women are excluded from this study because LMP744 is an agent with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with LMP744, breastfeeding should be discontinued if the mother is treated.",no-pregnancy-nursing
"Pregnant women are excluded from this study because LY3214996 and ibrutinib are agents with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with LY3214996 or ibrutinib, breastfeeding should be discontinued if the mother is treated with LY3214996 or ibrutinib. A negative serum pregnancy test is required for women of childbearing potential prior to the first dose of study medication.",no-pregnancy-nursing
"Pregnant women are excluded from this study because M6620 (VX-970) as a DNA-damage response (DDR) inhibitor may have the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with M6620 (VX-970), breastfeeding should be discontinued if the mother is treated with M6620 (VX-970). These potential risks also apply to the other agents used in this study, such as carboplatin and gemcitabine.",no-pregnancy-nursing
"Pregnant women are excluded from this study because MK-3475 (pembrolizumab) is an agent with the potential for teratogenic or abortifacient effects; because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with MK-3475 (pembrolizumab), breastfeeding should be discontinued if the mother is treated with MK-3475 (pembrolizumab); these potential risks may also apply to KW-0761 (mogamulizumab)",no-pregnancy-nursing
"Pregnant women are excluded from this study because navitoclax, dabrafenib, and trametinib may have teratogenic or abortifacient effects; because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with the study drugs, breastfeeding should be discontinued if the mother is treated with the study drugs",no-pregnancy-nursing
"Pregnant women are excluded from this study because neratinib (and other agents on study) is an agent with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk of adverse events in nursing infants secondary to treatment of the mother with neratinib, breastfeeding should be discontinued if the mother is treated with neratinib. Negative urine pregnancy test is required for women of childbearing potential within 4 weeks of planned treatment start.",no-pregnancy-nursing
Pregnant women are excluded from this study because nivolumab is an IgG monoclonal antibody with the potential for teratogenic or abortifacient effects.,no-pregnancy-nursing
"Pregnant women are excluded from this study because of the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with the targeted agent, breastfeeding should be discontinued if the mother is treated with the targeted agent.",no-pregnancy-nursing
"Pregnant women are excluded from this study because of the potential for teratogenic or abortifacient effects; because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother, breastfeeding should be discontinued",no-pregnancy-nursing
"Pregnant women are excluded from this study because of the potential for teratogenic or abortifacient effects; because there is an unknown but potential risk of adverse events in nursing infants secondary to treatment of the mother, breastfeeding should be discontinued",no-pregnancy-nursing
"Pregnant women are excluded from this study because of the potential teratogenic or abortifacient effects; because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother, breastfeeding should be discontinued",no-pregnancy-nursing
"Pregnant women are excluded from this study because olaparib and AT13387 are agents with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with AT13387 or olaparib, breastfeeding should be discontinued if the mother is treated with olaparib or AT13387.",no-pregnancy-nursing
"Pregnant women are excluded from this study because paclitaxel, doxorubicin, and cyclophosphamide have the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk of adverse events in nursing infants secondary to treatment of the mother with these agents, breastfeeding should be discontinued if the mother is treated on study. These potential risks may also apply to other agents used in this study.",no-pregnancy-nursing
"Pregnant women are excluded from this study because palifermin has been shown to be embryotoxic and fetotoxic in animal studies. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with palifermin, breastfeeding should be discontinued for the duration of active study therapy. These potential risks may also apply to other agents used in this study.",no-pregnancy-nursing
"Pregnant women are excluded from this study because personalized neoantigen peptides and poly-ICLC are agents with unknown risks to the developing fetus. Because there is an unknown but potential risk of adverse events in nursing infants secondary to treatment of the mother with personalized neoantigen peptides and poly-ICLC, nursing women are excluded from this study.",no-pregnancy-nursing
"Pregnant women are excluded from this study because rituximab is an agent with known potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with rituximab or umbralisib, breastfeeding should be discontinued if the mother is treated with rituximab or umbralisib. These potential risks may also apply to other agents used in this study.",no-pregnancy-nursing
"Pregnant women are excluded from this study because study therapy can cause fetal harm. Because there is potential risk for adverse events in nursing infants secondary to treatment of the mother with study therapy, breastfeeding should be discontinued if the mother is treated with study drugs.",no-pregnancy-nursing
"Pregnant women are excluded from this study because the effects of the study drugs on the developing fetus are unknown. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with the study drugs, breastfeeding should be discontinued prior to the first dose of study drug and women should refrain from nursing throughout the treatment period and for 3 months following the last dose of study drug.",no-pregnancy-nursing
"Pregnant women are excluded from this study because the study agents have the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with the study agents, breastfeeding should be discontinued.",no-pregnancy-nursing
"Pregnant women are excluded from this study because vorinostat is a histone deacetylase inhibitor agent with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with vorinostat, breastfeeding should be discontinued if the mother is treated with vorinostat. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.",no-pregnancy-nursing
"Pregnant women are excluded from this study because VX-970 as a DNA-damage response (DDR) inhibitor may have the potential for teratogenic or abortifacient effects. Further, radiation therapy is known to have the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with VX-970, breastfeeding should be discontinued if the mother is treated with VX-970.",no-pregnancy-nursing
"Pregnant women are excluded from this study because XL184 and nivolumab are agents with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with XL184 and nivolumab, breastfeeding should be discontinued if the mother is treated with XL184 and nivolumab.",no-pregnancy-nursing
"Pregnant women are excluded from this study due to the potential toxicity in pre-clinical reproductive studies; in addition, there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with MEDI-570; breastfeeding should be discontinued if the mother is treated with MEDI-570",no-pregnancy-nursing
"Pregnant women are excluded from this study. Because there is an unknown but potential risk for AEs in nursing infants secondary to treatment of the mother with tamoxifen, breastfeeding should be discontinued by nursing mothers who agree to participate in the study.",no-pregnancy-nursing
Pregnant women are excluded from this study; breastfeeding should be discontinued,no-pregnancy-nursing
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with any of these agents.,no-pregnancy-nursing
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with atezolizumab,no-pregnancy-nursing
"Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with atezolizumab, gemcitabine, and oxaliplatin",no-pregnancy-nursing
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with atezolizumab.,no-pregnancy-nursing
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with CDX-1127 (varlilumab) or nivolumab .,no-pregnancy-nursing
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with indium In 111 (111In-) and 90Y-basiliximab-DOTA,no-pregnancy-nursing
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with these agents,no-pregnancy-nursing
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with VX-970; these potential risks may also apply to other agents used in this study,no-pregnancy-nursing
Pregnant women are excluded from this study; breastfeeding should be discontinued; these potential risks may also apply to other agents used in this study,no-pregnancy-nursing
"Pregnant women may not participate in this study because with cabozantinib, nivolumab, and ipilimumab have potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with cabozantinib, nivolumab, and ipilimumab, breastfeeding should be discontinued if the mother is treated with these agents.",no-pregnancy-nursing
"Pregnant women or nursing mothers are not eligible for this trial. Patients of child bearing potential must use adequate contraception (contraceptive pill, or intrauterine device ((IUD)), or two mechanical barriers).",no-pregnancy-nursing
Pregnant women or women of reproductive ability who are unwilling to use 2 effective methods of contraception from the time of signing the informed consent form through 90days after the last dose of study drug,no-pregnancy-nursing
Pregnant women or women of reproductive ability who are unwilling to use effective contraception,no-pregnancy-nursing
Pregnant women or women of reproductive ability who are unwilling to use highly effective contraception.,no-pregnancy-nursing
Pregnant women or women of reproductive ability who are unwilling to use two effective methods of contraception from the time of signing the informed consent form through 4 months after the last dose of study drug,no-pregnancy-nursing
Pregnant women will be excluded.,no-pregnancy-nursing
"pregnant women, children, prisoners, institutionalized individuals",no-pregnancy-nursing
"Pregnant women, or women of childbearing potential without a negative pregnancy test (serum or urine) within 7 days prior to randomization, irrespective of the method of contraception used, are excluded from this study because the effect of palbociclib on a developing fetus is unknown. Breastfeeding must be discontinued prior to study entry.",no-pregnancy-nursing
"Pregnant women, or women of childbearing potential without a negative pregnancy test (serum or urine) within 7 days prior to registration, irrespective of the method of contraception used, are excluded from this study because the effect of palbociclib on a developing fetus is unknown. Breastfeeding should be discontinued prior to study entry.",no-pregnancy-nursing
"Pregnant women, or women who intend to become pregnant during the study are excluded from this study because of potential teratogenic effects associated with acalabrutinib, R-CHOP, and/or DA-EPOCH-R",no-pregnancy-nursing
"Pregnant women, or women who intent to become pregnant during the study, are excluded from this study because Revlimid has known teratogenic effects and venetoclax, ibrutinib and obinutuzumab are agents with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with these agents, breastfeeding should be discontinued if the mother is treated on study.",no-pregnancy-nursing
"Pregnant women, women planning to become pregnant and women that are nursing.",no-pregnancy-nursing
"Pregnant, intending to become pregnant, or breastfeeding",no-pregnancy-nursing
"Pregnant, lactating, or intending to become pregnant during the study",no-pregnancy-nursing
"Pregnant, planning to become pregnant, or nursing",no-pregnancy-nursing
Pregnant/nursing.,no-pregnancy-nursing
"Progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable)",no-pregnancy-nursing
Progestogen-only hormonal contraception associated with inhibition of ovulation:,no-pregnancy-nursing
"RANDOMIZED PHASE II (ARMS K AND L): Women must not be pregnant or breast-feeding due to risk of fetal harm by the chemotherapeutic agents prescribed in this protocol; all females of childbearing potential must have a blood test or urine study within 24 hours prior to enrollment to rule out pregnancy; a female of childbearing potential is any woman, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria:",no-pregnancy-nursing
"RANDOMIZED PHASE II (ARMS K AND L): Women of childbearing potential (WOCBP) and sexually active males must either abstain from sexual intercourse for the duration of their participation in the study or agree to use both double barrier contraception and birth control pills or implants for at least one week prior to the start of the study drug and continuing for 5 months after the last dose of study drug (for female patients) and for 7 months after the last dose of study drug (for male patients who are sexually active with WOCBP); should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she (or the participating partner) should inform the treating physician immediately",no-pregnancy-nursing
"RECIPIENT: Agreement by females of childbearing potential and males with partners of childbearing potential to use effective contraception (hormonal or barrier method or abstinence) prior to study entry and for up to 90 days post-HCT. Should a woman become pregnant or suspect that she is pregnant while participating on the trial, she should inform her treating physician immediately",no-pregnancy-nursing
RECIPIENT: Negative serum or urine beta-human chorionic gonadotropin (HCG) test (female patient of childbearing potential only) within two weeks of registration,no-pregnancy-nursing
RECIPIENT: Pregnant women and women who are lactating. The risks of CMV-MVA-Triplex to pregnant women are unknown. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother. Breastfeeding should be discontinued if the mother is enrolled on this study,no-pregnancy-nursing
Recommendation is for 2 effective contraceptive methods during the study,no-pregnancy-nursing
refrain from breast feeding and donating oocyte,no-pregnancy-nursing
Refrain from donating sperm,no-pregnancy-nursing
Refrain from donating sperm.,no-pregnancy-nursing
Refrain from sperm donation:,no-pregnancy-nursing
REGISTRATION TO STEP 2 ELIGIBILITY CRITERIA: Pregnant women are excluded from this study; breastfeeding should be discontinued,no-pregnancy-nursing
"Serum or urine pregnancy test must be negative within 7 days of randomization in women of childbearing potential. Pregnancy testing does not need to be pursued in patients who are judged as postmenopausal before randomization, as determined by local practice, or who have undergone bilateral oophorectomy, total hysterectomy, or bilateral tubal ligation. Women of childbearing potential and male patients randomized into the study must use adequate contraception for the duration of protocol treatment and for 6 months after the last treatment with palbociclib if they are in Arm A and for 7 months after last treatment with trastuzumab if in either Arm A or Arm B. Adequate contraception is defined as one highly effective form (i.e. abstinence, (fe)male sterilization OR two effective forms (e.g. non-hormonal IUD and condom / occlusive cap with spermicidal foam / gel / film / cream / suppository).",no-pregnancy-nursing
"Serum or urine pregnancy test must be negative within 7 days of starting study treatment in women of childbearing potential. Women of childbearing potential and men with female partners who are able to become pregnant are required to use a highly effective form of barrier contraception for the duration of the study and for 90 days after the last dose of study drug. Adequate contraception is defined as abstinence or two forms non hormonal contraception, which is a combination of two forms of the following:",no-pregnancy-nursing
"Serum pregnancy test (for females of childbearing potential) negative at screening, and negative serum or urine pregnancy test at baseline prior to treatment administration.",no-pregnancy-nursing
Sexual abstinence (reliability to be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient).,no-pregnancy-nursing
sexual abstinence in accordance with an individual's lifestyle,no-pregnancy-nursing
"Sexual abstinence, which is defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatments; the reliability of sexual abstinence must be evaluated in relation to the duration of the trial and the preferred and usual lifestyle of the subject.",no-pregnancy-nursing
Sexually active females of child bearing potential and males with partners of child bearing potential must agree to use effective contraception during therapy and for 4 months after completion of therapy,no-pregnancy-nursing
Sexually active females of childbearing potential and males with partners of child-bearing potential must agree to use adequate birth control during study treatment.,no-pregnancy-nursing
"Sexually active fertile subjects and their partners must agree to use medically accepted methods of contraception (eg, barrier methods, including male condom, female condom, or diaphragm with spermicidal gel) during the course of the study and for 5 months after the last dose of study treatment.",no-pregnancy-nursing
"Sexually active male and female patients of childbearing potential must agree to use an effective method of birth control (e.g., barrier methods with spermicides, oral or parenteral contraceptives and/or intrauterine devices) during the entire duration of the study and for 6 months after final administration of MCLA-128.",no-pregnancy-nursing
Sexually active male subjects must use a barrier method of contraception during the study and agree to continue the use of male contraception for at least 30 days after the last dose of study drug.,no-pregnancy-nursing
"Sexually active male unless he uses a condom during intercourse while taking chemotherapy drug(s) and for 6 months after stopping chemotherapy treatment, and should not father a child in this period or as per the local label. A condom is required to be used also by a vasectomized man in order to prevent potential delivery of the standard of care anti-cancer drugs via seminal fluid. Note: Sexually active male patients and their partners who are women of childbearing potential should follow the contraception recommendations and any other precautionary",no-pregnancy-nursing
"Sexually active males must agree to use a condom during sexual contact with a pregnant female or a female of child-bearing potential (FCBP) for the course of the study through to 18 months after the last dose of obinutuzumab, 28 days after the last dose of lenalidomide and 30 days after the last dose of venetoclax, whichever is longer, even if he has undergone a successful vasectomy.",no-pregnancy-nursing
Sexually active males unless they use a condom during intercourse while taking drug and for 30 days after stopping study treatment and should not father a child in this period.,no-pregnancy-nursing
Sexually active males unless they use a condom during intercourse while taking drug and for 7 days after stopping treatment and should not father a child in this period. A condom is required to be used also by vasectomized men as well as during intercourse with a male partner in order to prevent delivery of the drug via semen.,no-pregnancy-nursing
Sexually active males unless they use a condom during intercourse while taking the drug and for 21 days after stopping treatment and should not father a child in this period; Note: A condom is required to be used also by vasectomized men in order to prevent delivery of the drug via seminal fluid,no-pregnancy-nursing
Sexually active males.,no-pregnancy-nursing
Sexually active men not using birth control if their partners are women of reproductive age.,no-pregnancy-nursing
Sexually active patients must be willing to utilize one of the more effective birth control methods during the study and for 3 months after the study is concluded. The male partner should use a condom.,no-pregnancy-nursing
Sexually active patients must be willing to utilize one of the more effective birth control methods during the study and for 6 months after ATL infusion. The male partner should use a condom.,no-pregnancy-nursing
Sexually active patients must be willing to utilize one of the more effective birth control methods during the study and for 6 months after the study is concluded. The male partner should use a condom.,no-pregnancy-nursing
Sexually active patients must be willing to utilize one of the more effective birth control methods for 6 months after the ATL infusion. Male partner should use a condom.,no-pregnancy-nursing
Sexually active patients must be willing to utilize one of the more effective birth control methods for 6 months after the CTL infusion. The male partner should use a condom.,no-pregnancy-nursing
Sexually active patients of reproductive potential are not eligible unless they agree to use an effective contraceptive method for the duration of treatment and for 3 months after stopping treatment,no-pregnancy-nursing
Sexually active patients of reproductive potential are not eligible unless they have agreed to use an effective contraceptive method for the duration of their study participation.,no-pregnancy-nursing
Sexually active patients of reproductive potential who have not agreed to use an effective contraceptive method for the duration of their study participation,no-pregnancy-nursing
Sexually active patients of reproductive potential who have not agreed to use an effective contraceptive method for the duration of their study participation.,no-pregnancy-nursing
"Sexually active subjects (men and women) must agree to use medically accepted barrier methods of contraception (e.g., male or female condom) during the course of the study and for 4 months after the last dose of study drug(s), even if oral contraceptives are also used. All subjects of reproductive potential must agree to use both a barrier method and a second method of birth control during the course of the study and for 4 months after the last dose of study drug(s).",no-pregnancy-nursing
"Sexually active women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study treatment and for the duration of study treatment; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately",no-pregnancy-nursing
"Sexually active women of child-bearing potential with a non-sterilized male partner and sexually active men must agree to use 2 methods of adequate contraception (hormonal plus barrier or 2 barrier forms) OR abstinence prior to study entry, for the duration of study participation, and for 3 months following last dose of study drugs.",no-pregnancy-nursing
"Should a female of child-bearing potential become pregnant or suspect she is pregnant while she or her partner is participating in this study, she (or the participating partner) should inform the treating physician immediately",no-pregnancy-nursing
"Should a female of child-bearing potential become pregnant or suspect she is pregnant while she or her partner is participating in this study, she (or the participating partner) should inform the treating physician immediately.",no-pregnancy-nursing
"Should a woman become pregnant or suspect she is pregnant while she is participating in this study, she should inform her treating physician immediately.",no-pregnancy-nursing
"Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she (or the participating partner) should inform the treating physician immediately; if, following initiation of the investigational product, it is subsequently discovered that a study subject is pregnant or may have been pregnant at the time of investigational product exposure, including during at least 6 half-lives after product administration, the investigational product will be permanently discontinued in an appropriate manner (e.g., dose tapering if necessary for subject safety); the investigator must immediately notify BMS of this event and record the pregnancy on the Pregnancy Surveillance Form (not an severe adverse event [SAE] form); initial information on a pregnancy must be reported immediately to BMS, and the outcome information provided once the outcome is known; completed Pregnancy Surveillance Forms must be forwarded to BMS according to SAE reporting procedures; any pregnancy that occurs in a female partner of a male study participant should be reported to the sponsor. Information on this pregnancy will be collected on the Pregnancy Surveillance Form; protocol-required procedures for study discontinuation and follow-up must be performed on the subject unless contraindicated by pregnancy (e.g., X-ray studies); other appropriate pregnancy follow-up procedures should be considered if indicated. In addition, the investigator must report and follow-up on information regarding the course of the pregnancy, including perinatal and neonatal outcome. Infants should be followed for a minimum of 8 weeks",no-pregnancy-nursing
"Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately",no-pregnancy-nursing
"Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.",no-pregnancy-nursing
"Should a woman become pregnant or suspect that she is pregnant while she or her partner is participating in this study, she should inform the treating physician immediately.",no-pregnancy-nursing
"Subject is a female who is pregnant, nursing or breastfeeding, or who intends to become pregnant during the participation in the study.",no-pregnancy-nursing
"Subject is a female who is pregnant, nursing, or breastfeeding 27. For a subject randomized to Treatment Arm B and will be on a POM- or LEN-containing regimen; unable or unwilling to undergo protocol required thromboembolism prophylaxis.",no-pregnancy-nursing
"Subject is a female who is pregnant, nursing, or breastfeeding, or who intends to become pregnant during participation in the study.",no-pregnancy-nursing
"Subject is a female who is pregnant, nursing, or breastfeeding, or who intends to become pregnant during the participation in the study.",no-pregnancy-nursing
Subject is a woman who is pregnant or breastfeeding or planning to become pregnant while enrolled in this study or within 6 months after the last dose of investigational product.,no-pregnancy-nursing
"Subject is a woman who is pregnant, or breast-feeding, or planning to become pregnant while enrolled in this study or within 6 months after the last dose of study drug.",no-pregnancy-nursing
Subject is pregnant or breastfeeding (Note: breast milk cannot be stored for future use while the mother is being treated on the study. Subject must abstain from breastfeeding for 150 days after end of study).,no-pregnancy-nursing
"Subject is pregnant or breastfeeding, or planning to become pregnant while enrolled in the study, up to the EOS visit.",no-pregnancy-nursing
Subject is pregnant or lactating (Note: Breast milk cannot be stored for future use while the mother is being treated on study).,no-pregnancy-nursing
Subject is pregnant or lactating and does not agree to stop breastfeeding.,no-pregnancy-nursing
Subject is pregnant or lactating.,no-pregnancy-nursing
Subject is pregnant.,no-pregnancy-nursing
Subjects (women of child-bearing potential and males) must be willing to use viable contraception method that is deemed effective by the investigator throughout the treatment period and for at least three months following the last dose of study drug. Postmenopausal women must have been amenorrheic for at least 12 months to be considered of non-childbearing potential.,no-pregnancy-nursing
Subjects (women of child-bearing potential and males) must be willing to use viable contraception method that is deemed effective by the investigator throughout the treatment period and for at least three months following the last dose of study drug. Postmenopausal women must have been amenorrhoeic for at least 12 months to be considered of non-childbearing potential.,no-pregnancy-nursing
Subjects must agree to use appropriate contraception.,no-pregnancy-nursing
Subjects must agree to use barrier contraceptive methods throughout the study period up until at least 90 days post last palbociclib dose.,no-pregnancy-nursing
"Subjects must not be pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the screening visit through 120 days after the final dose of study medication.",no-pregnancy-nursing
Subjects of both genders of child-bearing potential who are not willing to practice birth control from the time of consent through 6 months after the completion of KTE-C19,no-pregnancy-nursing
Subjects of both genders of child-bearing potential who are not willing to practice birth control from the time of consent through 6 months after the completion of KTE-X19,no-pregnancy-nursing
Subjects of both genders who are not willing to practice birth control from the time of consent through 6 months after the completion of axicabtagene ciloleucel,no-pregnancy-nursing
"Subjects of both genders who are not willing to practice birth control from the time of consent through 6 months after the completion of conditioning chemotherapy or axicabtagene ciloleucel infusion, whichever is longer.",no-pregnancy-nursing
Subjects of child bearing or child fathering potential must be willing to practice birth control from the time of enrollment on this study and for four (4) months after receiving the preparative regimen; females of child bearing potential must have a negative pregnancy test,no-pregnancy-nursing
Subjects of childbearing potential are those who have not been surgically sterilized or have not been free from menses for > 1 year.,no-pregnancy-nursing
"Subjects of child-bearing potential who are not willing to practice birth control from the time of consent through 6 months after the administration of conditioning chemotherapy or KTE-X19, whichever is longer.",no-pregnancy-nursing
"Subjects of reproductive potential and their partners must agree to either to abstain continuously from heterosexual intercourse or to use 2 methods of reliable birth control simultaneously to begin 4 weeks prior to initiating treatment with LEN until 28 days after the last dose of MT-3724 or LEN. The investigator or a designated associate should advise the subject how to achieve adequate contraception. The following birth control methods may be considered: one highly effective form of contraception - tubal ligation, IUD, hormonal (birth control pills, injections, hormonal patches, vaginal rings, or implants), or partner's vasectomy, and one additional effective contraceptive method - male latex or synthetic condom, diaphragm, or cervical cap.",no-pregnancy-nursing
Subjects of reproductive potential and their partners must agree to either to abstain continuously from heterosexual intercourse or to use a reliable birth control method between signing the informed consent until 6 months following the last dose of MT-3724 or GEMOX. The investigator or a designated associate should advise the subject how to achieve adequate contraception. The following birth control methods may be considered as adequate,no-pregnancy-nursing
"Subjects of reproductive potential must agree to use acceptable birth control methods, as described in protocol Section 4.3.",no-pregnancy-nursing
Subjects who are of childbearing potential must have a negative serum pregnancy test at Screening and within 96 hours before Week 1 dosing.,no-pregnancy-nursing
Subjects who are pregnant or intend to become pregnant during participation in the study.,no-pregnancy-nursing
"Subjects who have a positive serum human chorionic gonadotropin (hCG), are pregnant or lactating are ineligible",no-pregnancy-nursing
"The effects of abiraterone, olaparib or the combination of both on the developing human fetus at the recommended therapeutic dose are unknown. Men must agree to use adequate contraception prior to study entry, for the duration of study participation and for at least 3 months thereafter.",no-pregnancy-nursing
"The effects of brentuximab vedotin and ibrutinib on the developing fetus is unknowm; for this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control or abstinence) prior to study entry and for six months following duration of study participation; should a woman become pregnant or suspect that she is pregnant while participating on the trial, she should inform her treating physician immediately",no-pregnancy-nursing
The effects of cabozantinib and nivolumab on the developing human fetus are unknown. Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test at screening. WOCBP must agree to use adequate contraception (barrier method of birth control or abstinence) prior to study entry and for the duration of study participation. WOCBP should use an adequate method to avoid pregnancy for 7 months after the last dose of investigational drug. Women must not be breastfeeding.,no-pregnancy-nursing
"The effects of CAR-37 T cells on the developing human fetus are unknown. For this reason, women of child-bearing potential and men with partners of childbearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to leukapheresis and until 6 months post CAR-37 infusion. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men with partners of childbearing potential treated or enrolled on this protocol must also agree to use adequate contraception prior to the study and until 4 months after last CAR-37 T cells administration.",no-pregnancy-nursing
"The effects of Carfilzomib on the developing human fetus are unknown. For this reason and because chemotherapeutic agents used in this study are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (double barrier method of birth control or abstinence) 2 weeks prior to initiation of treatment, for the duration of study participation and for 3 months after completing treatment. Should a woman become pregnant or suspect that she is pregnant while she or her partner is participating in this study, she should inform the treating physician immediately. Men must agree to refrain from sperm donation for at least 90 days after the last dose of carfilzomib.",no-pregnancy-nursing
"The effects of CB-839 HCl on the developing human fetus are unknown. For this reason and because carfilzomib caused embryo-fetal toxicity in pregnant rabbits at doses lower than the recommended dose, women of child-bearing potential and men must agree to use two effective methods of contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and 4 months after completion of CB-839 HCl, carfilzomib, and dexamethasone administration. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of CB-839 HCl, carfilzomib, and dexamethasone administration.",no-pregnancy-nursing
"The effects of copanlisib and nivolumab on the developing human fetus are unknown. For this reason, and because the study drugs used in this trial are known to be teratogenic, females of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation and for 5 months after the last dose of study drug. Males who are the sexual partners of a female of child-bearing potential must use any contraceptive method with a failure rate of less than 1% per year for the duration of study participation and for a period of 7 months after the last dose of study drug. These periods of required use of contraception have been calculated using the upper limit of the half-life for nivolumab (25 days) and are based on the protocol requirement that females of child-bearing potential use contraception for 5 months and males who are the sexual partners of females of child-bearing potential use contraception for 7 months.",no-pregnancy-nursing
"The effects of copanlisib and nivolumab on the developing human fetus are unknown; for this reason, and because the study drugs used in this trial are known to be teratogenic, females of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation and for 5 months after the last dose of study drug; males who are the sexual partners of a female of child-bearing potential must use any contraceptive method with a failure rate of less than 1% per year for the duration of study participation and for a period of 7 months after the last dose of study drug; these periods of required use of contraception have been calculated using the upper limit of the half-life for nivolumab (25 days) and are based on the protocol requirement that females of child-bearing potential use contraception for 5 months and males who are the sexual partners of females of child-bearing potential use contraception for 7 months",no-pregnancy-nursing
"The effects of ibrutinib and TEDDI-R on the developing human fetus are unknown. For this reason, male and female patients must agree to use highly effective methods of birth control. A highly effective method of birth control is defined as a method that has a low failure rate (i.e., less than 1% per year) when used consistently and correctly and includes implants, injectables, birth control pills with two hormones, some intrauterine devices (IUDs). Male subject cannot use highly effective methods and are required to use barrier. The specific guidelines are as follows:",no-pregnancy-nursing
"The effects of ibrutinib on the developing human fetus are unknown. For this reason and because tyrosine kinase inhibitors as well as other therapeutic agents used in this trial may be teratogenic, women of non-reproductive potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry.",no-pregnancy-nursing
"The effects of ibrutinib or LY3214996 on the developing human fetus are unknown. For this reason and because anti-cancer agents are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of ibrutinib or LY3214996 administration.",no-pregnancy-nursing
"The effects of LMP744 on the developing human fetus are unknown. For this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Women and men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of LMP744 administration.",no-pregnancy-nursing
"The effects of MEDI-570 on the developing human fetus are unknown; for this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, during the study participation, and for 3 months after the last dose of the drug; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately; men treated or enrolled on this protocol must have either had a prior vasectomy or agree to use effective contraception prior to the study, during the study, and for 3 months after the last dose of the drug; males should avoid fathering children during and for at least three months after therapy is completed",no-pregnancy-nursing
"The effects of MK-3475 (pembrolizumab) in combination with KW-0761 (mogamulizumab) on the developing human fetus are unknown; for this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation, and 6 months after completion of MK-3475 (pembrolizumab) in combination with KW-0761 (mogamulizumab) administration; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately; men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 6 months after completion of MK-3475 (pembrolizumab) in combination with KW-0761 (mogamulizumab) administration",no-pregnancy-nursing
"The effects of navitoclax, dabrafenib, and trametinib on the developing human fetus are unknown; for this reason, women of child-bearing potential and men with partners of childbearing potential must agree to use adequate contraception (barrier method of birth control, or abstinence; hormonal contraception is not allowed due to drug-drug interactions which can render hormonal contraceptives ineffective) prior to study entry, for the duration of study participation, and for 4 months after completion of study drug administration; should a woman become pregnant or suspect she is pregnant while she is participating in this study, she should inform her treating physician immediately; based on studies in animals, it is also known that dabrafenib may cause damage to the tissue that makes sperm; this may cause sperm to be abnormal in shape and size and could lead to infertility, which may be irreversible; safety and efficacy of the combination of dabrafenib and trametinib in pediatric populations have not been investigated; dabrafenib or trametinib-dabrafenib combination should not be administered to pediatric populations outside clinical trials",no-pregnancy-nursing
"The effects of NeoVax and poly-ICLC on the developing human fetus are unknown. For this reason, women of childbearing potential (WOCBP) must have a negative pregnancy test (minimum sensitivity 25 IU/L or equivalent of HCG) before entry onto the trial and within 7 days prior to start of study medication. It is the investigators' responsibility to repeat the pregnancy test should start of treatment be delayed.",no-pregnancy-nursing
"The effects of NeoVax and poly-ICLC on the developing human fetus are unknown. For this reason, women of childbearing potential (WOCBP) must have a negative pregnancy test (serum) before entry onto the trial and within 7 days prior to start of study vaccination.",no-pregnancy-nursing
"The effects of neratinib, capecitabine, and T-DM1 on the developing human fetus are not known. For this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.",no-pregnancy-nursing
"The effects of nivolumab and ipilimumab on the developing human fetus are unknown; for this reason and because other therapeutic agents used in this trial are known to be teratogenic, women of childbearing potential (WOCBP) and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; WOCBP should use an adequate method to avoid pregnancy for 6 months after the last dose of investigational drug; women of childbearing potential must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropic [HCG]) within 72 hours prior enrollment and the start of nivolumab; women must not be breastfeeding; men who are sexually active with WOCBP must use any contraceptive method with a failure rate of less than 1% per year; men receiving nivolumab and who are sexually active with WOCBP will be instructed to adhere to contraception for a period of 31 weeks after the last dose of investigational product; women who are not of childbearing potential (i.e., who are postmenopausal or surgically sterile as well as azoospermic men) do not require contraception; WOCBP receiving nivolumab will be instructed to adhere to contraception for a period of 6 months after the last dose of investigational product; men receiving nivolumab and who are sexually active with WOCBP will be instructed to adhere to contraception for a period of 31 weeks after the last dose of investigational product; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she (or the participating partner) should inform the treating physician immediately",no-pregnancy-nursing
"The effects of olaparib in combination with AT13387on the developing human fetus are unknown. For this reason and because olaparib and AT13387 are anti-neoplastic small molecule inhibitors, which are agents that are potentially teratogenic, women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 3 months after the last dose of study drugs. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of olaparib and/or AT13387 administration.",no-pregnancy-nursing
"The effects of pembrolizumab on the developing human fetus are unknown. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.",no-pregnancy-nursing
"The effects of rifaximin on the developing human fetus are unknown. For this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of rifaximin administration",no-pregnancy-nursing
"The effects of ruxolitinib on the developing human fetus are unknown. For this reason women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry until completion of chemotherapy. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.",no-pregnancy-nursing
"The effects of study drug on the developing human fetus are unknown. For this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the",no-pregnancy-nursing
"The effects of the candidate chemoprevention agents on the developing human fetus remain incompletely defined. However, study participants will be women who have gone through a bi-lateral oophorectomy procedure(see Section 3.22).",no-pregnancy-nursing
"The effects of the drugs used for cancer treatment on the developing human fetus are unknown. For this reason and because of the possibility that the agents are teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.",no-pregnancy-nursing
"The effects of tisagenlecleucel T cells on the developing human fetus are unknown. For this reason, women of child-bearing potential and men with partners of childbearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to leukapheresis for at least 1-year post tisagenlecleucel infusion and until CAR T cells are no longer present by qPCR on two consecutive tests. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men with partners of childbearing potential treated or enrolled on this protocol must also agree to use adequate contraception prior to leukapheresis and until 4 months after tisagenlecleucel T cells administration.",no-pregnancy-nursing
"The effects of topical 4-OHT gel on the developing human fetus at the recommended therapeutic dose are unknown. However, oral tamoxifen is Pregnancy Category D-positive evidence of human fetal risk. For this reason, and because triphenylethylene antiestrogens, including tamoxifen, are known to be teratogenic, women of childbearing potential and their male partners must agree to use TWO effective forms of birth control (abstinence is not an allowed method) prior to study entry and for the duration of study participation, and for two months following the last dose of study medications. Effective birth control methods are: copper IUD [intrauterine device], diaphragm/cervical cap/shield, spermicide, contraceptive sponge, condoms. Women of childbearing potential must have a negative pregnancy test within five days before starting study medications. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her study physician immediately.",no-pregnancy-nursing
"The effects of trastuzumab, capecitabine, and neratinib on the developing human fetus are unknown. For this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.",no-pregnancy-nursing
"The following are acceptable contraceptive methods: bilateral tubal ligation; male sterilization; hormonal contraceptives; hormone-releasing intrauterine devices; copper intrauterine devices; male or female condom with or without spermicide; and cap, diaphragm, or sponge with spermicide.",no-pregnancy-nursing
The following are examples of highly effective and additional effective methods of contraception:,no-pregnancy-nursing
The Investigator evaluates the effectiveness of the contraceptive method in relationship to the first dose of study intervention.,no-pregnancy-nursing
"The investigator or a designated associate is requested to advise the patient how to achieve highly effective birth control (failure rate of less than 1%), e.g. intrauterine device (IUD), intrauterine hormone-releasing system (IUS), bilateral tubal occlusion, vasectomized partner and sexual abstinence",no-pregnancy-nursing
"The patient (either male or female) agrees to use acceptable contraceptive methods for the duration of time in the study, and to continue to use acceptable contraceptive methods for 2 months after the last SL-401 infusion.",no-pregnancy-nursing
The patient is pregnant or breast feeding or plans to become pregnant within 6 months of IP administration.,no-pregnancy-nursing
The patient is pregnant or breast feeding.,no-pregnancy-nursing
The patient must agree to use a condom (even men with vasectomies) and another effective method of birth control if he is having sex with a woman of childbearing potential or agree to use a condom if he is having sex with a woman who is pregnant while on study drug and for 3 months following the last dose of study drug.,no-pregnancy-nursing
"The patient, if of childbearing potential, must have a negative serum pregnancy test and be using a medically acceptable form of contraception (eg, hormonal birth control, double-barrier method) or abstinence.",no-pregnancy-nursing
"The potential for all study treatments to be excreted in breast milk of nursing mothers is unknown. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with acalabrutinib, breastfeeding must be discontinued.",no-pregnancy-nursing
The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient.,no-pregnancy-nursing
"The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g. calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception",no-pregnancy-nursing
"The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or post-ovulation methods) and withdrawal are not acceptable methods of contraception.",no-pregnancy-nursing
"The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception",no-pregnancy-nursing
"The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception.",no-pregnancy-nursing
"The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception. For information regarding specific testing methodologies and allowable identified mutations, see Appendix 5.",no-pregnancy-nursing
"The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception. For male subjects: Agree that during the period specified above, men will not father a child. Subjects must be surgically sterile (e.g, vasectomy) or use contraceptive methods that result in a failure rate of < 1% per year during the treatment period and for at least 5 months after the last dose of study treatment.",no-pregnancy-nursing
The subject must also not donate sperm during the study and for 6 months after receiving the last dose of study drug.,no-pregnancy-nursing
The use of condoms by male patients is required unless the female partner is permanently sterile. Female subjects of childbearing potential must have a negative plasma pregnancy test upon study entry,no-pregnancy-nursing
"Therefore, for women of childbearing potential only, a negative pregnancy test done <= 14 days prior to registration is required.",no-pregnancy-nursing
"Therefore, for women of childbearing potential only, a negative pregnancy test done <= 7 days prior to registration is required.",no-pregnancy-nursing
"This study involves: 1)an investigational agent whose genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn are unknown; and teratogenic effects on the developing fetus and newborn are unknown; and 2) an agent that has known genotoxic, mutagenic, and teratogenic effects.",no-pregnancy-nursing
Those with female partners of childbearing potential may be enrolled if they are:,no-pregnancy-nursing
"Total abstinence (when this is in line with the preferred and usual lifestyle of the patient). Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception",no-pregnancy-nursing
"Total abstinence (when this is in line with the preferred and usual lifestyle of the subject. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception",no-pregnancy-nursing
"Total abstinence when this is in line with the preferred and usual lifestyle of the patient. Periodic abstinence (e.g. calendar, ovulation, symptothermal, postovulation methods) and withdrawal are not acceptable methods of contraception.",no-pregnancy-nursing
"Total abstinence when this is in line with the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception",no-pregnancy-nursing
"Total abstinence when this is in line with the preferred and usual lifestyle of the patient; periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception",no-pregnancy-nursing
"Treatment Arm A (for subjects who take no bridging therapy or DVd as bridging therapy): One negative serum β-subunit of human chorionic gonadotropin [βhCG] pregnancy test result at screening, and another prior to LD chemotherapy.",no-pregnancy-nursing
"Treatment Arm B (for subjects on DPd or IRd): Two negative pregnancy tests prior to starting study treatment. She must agree to ongoing pregnancy testing during the course of the study, and after end of study treatment.",no-pregnancy-nursing
Treatment Arm B (for subjects on DVd): One negative pregnancy test prior to starting study treatment. Pregnancy testing during the course of the study should be done if clinically indicated.,no-pregnancy-nursing
True abstinence is acceptable when it is in line with the preferred and usual lifestyle of the subject.,no-pregnancy-nursing
"True abstinence is acceptable when this is in line with the preferred and usual lifestyle of the subject. In contrast, periodic abstinence (eg, calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception.",no-pregnancy-nursing
"True abstinence is acceptable when this is in line with the preferred and usual lifestyle of the subject. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception.",no-pregnancy-nursing
"True abstinence, when in line with the preferred and usual lifestyle of the patient, is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of study participation and for 1 month post-gemcitabine administration. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the clinical study and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, and post-ovulation method) and withdrawal are not acceptable methods of contraception; and",no-pregnancy-nursing
"True abstinence: When this is the line with the preferred and usual lifestyle of the subject. Periodic abstinence (e.g. calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception",no-pregnancy-nursing
Unacceptable forms of contraception for women of childbearing potential:,no-pregnancy-nursing
Unwilling to employ adequate contraception.,no-pregnancy-nursing
Use a male condom,no-pregnancy-nursing
"Use a male condom: When having sexual intercourse with a WOCBP, who is not currently pregnant, and advise her to use a highly effective contraceptive method with a failure rate of < 1% per year, as described in Appendix 3, since a condom may break or leak.",no-pregnancy-nursing
use an effective barrier method of contraception if sexually active with FCBP,no-pregnancy-nursing
"Use of an effective means of contraception for female patients of child-bearing potential, and all male partners.",no-pregnancy-nursing
Use of an effective means of contraception for women of childbearing potential and men with partners of childbearing potential.,no-pregnancy-nursing
"Use of oral (estrogen and progesterone), injected or implanted combined hormonal methods of contraception or placement of an intrauterine device (IUD) or intrauterine system (IUS) or other forms of hormonal contraception that have comparable efficacy (failure rate < 1%), for example hormone vaginal ring or transdermal hormone contraception In case of use of oral contraception women should have been stable on the same pill for a minimum of 3 months before taking study treatment.",no-pregnancy-nursing
"Use of oral (estrogen and progesterone), injected or implanted hormonal methods of contraception or other forms of hormonal contraception that have comparable efficacy (failure rate < 1%, when used correctly), for example hormone vaginal ring or transdermal hormone contraception or placement of an intrauterine device (IUD) or intrauterine system (IUS)",no-pregnancy-nursing
"use of oral, injected or implanted hormonal methods of contraception or other forms of hormonal contraception that have comparable efficacy (failure rate < 1%), for example hormone vaginal ring or transdermal hormone contraception",no-pregnancy-nursing
"Use of oral, injected or implanted hormonal methods of contraception or placement of an intrauterine device (IUD) or intrauterine system (IUS), or other forms of hormonal contraception that have comparable efficacy (failure rate < 1%), for example hormone vaginal ring or transdermal hormone contraception",no-pregnancy-nursing
"Use of oral, injected or implanted hormonal methods of contraception or placement of an intrauterine device (IUD) or intrauterine system (IUS), or other forms of hormonal contraception that have comparable efficacy (failure rate < 1%), for example hormone vaginal ring or transdermal hormone contraception. In case of use of oral contraception women should have been stable on the same pill for a minimum of 3 months before taking study treatment. Women are considered post-menopausal and not of child bearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g., age appropriate, history of vasomotor symptoms) or have had surgical bilateral oophorectomy (with or without hysterectomy), total hysterectomy or tubal ligation at least six weeks ago. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment is she considered not of child bearing potential",no-pregnancy-nursing
Using (or having their partner use) an acceptable method of contraception during heterosexual activity. Acceptable methods of contraception are***:,no-pregnancy-nursing
"using an adequate measure of contraception such as oral contraceptives, intrauterine device, or barrier method of contraception in conjunction with spermicidal jelly",no-pregnancy-nursing
Vasectomized male subject or vasectomized partner of female subjects,no-pregnancy-nursing
"Vasectomy (a vasectomy is a highly effective contraception method provided the absence of sperm has been confirmed. If not, an additional highly effective method of contraception should be used)",no-pregnancy-nursing
Vasectomy is an acceptable method for a male subject or male partner of a female subject.,no-pregnancy-nursing
vasectomy of a female patient's male partner,no-pregnancy-nursing
"Vulnerable subjects - pregnant women, children, prisoners, institutionalized individuals",no-pregnancy-nursing
WCBP must agree to abstain from sex or use an adequate method of contraception from the time of informed consent through the Day 55 Visit and for 90 days after the last dose of study drug (LUT014),no-pregnancy-nursing
"When having sexual intercourse with a WOCBP, who is not currently pregnant, and advise her to use a highly effective contraceptive method with a failure rate of < 1 % per year, as described in Appendix 3Contraception, since a condom may break or leak",no-pregnancy-nursing
Willigness to use contraception,no-pregnancy-nursing
"Willing to be registered into the mandatory REVLIMID REMS program, and willing and able to comply with the requirements of the REVLIMID REMS program",no-pregnancy-nursing
Willing to comply with study procedures. Patients with reproductive potential must agree to use effective contraception and to not donate sperm during the study and for at least 3 months following the last dose of study treatment.,no-pregnancy-nursing
Willing to employ adequate and appropriate birth control if applicable,no-pregnancy-nursing
Willing to employ adequate contraception from the time of registration through 6 months after the final vaccine cycle.,no-pregnancy-nursing
Willing to follow strict birth control measures,no-pregnancy-nursing
Willing to follow strict birth control measures as detailed in Section 9.9i.,no-pregnancy-nursing
"Willing to follow strict birth control measures as outlined in the protocol. Female subjects: If they are of childbearing potential, agree to one of the",no-pregnancy-nursing
"Willing to follow strict birth control measures as outlined in the protocol. Female subjects: If they are of childbearing potential, agree to one of the following:",no-pregnancy-nursing
Willing to follow strict birth control measures as suggested below,no-pregnancy-nursing
Willing to follow strict birth control measures as suggested by the study,no-pregnancy-nursing
Willing to follow the requirements of the {Revlimid&reg;/Pomalyst&reg;} REMS program.,no-pregnancy-nursing
Willing to use 2 acceptable forms of effective contraception from enrollment through 6 months post treatment if the female partner is of childbearing potential (defined as premenopausal women who have not been sterilized).,no-pregnancy-nursing
Willing to use adequate contraception while on the study and until 120 days after the last dose of study drug,no-pregnancy-nursing
"Willingness by both males, and female patients of child bearing potential, to use contraception by a method that is deemed effective by the investigator, throughout the treatment period and for at least three months following the last dose of study drug Postmenopausal women must be amenorrheal for at least 12 months to be considered of non-childbearing potential. All partners must have the same willingness for contraception methods throughout the treatment period and for at least three months following the last dose of study drug as well.",no-pregnancy-nursing
"Willingness of male and female patients, if sexually active, to use an effective barrier method of contraception during the study and for 3 months following the last dose of study drug",no-pregnancy-nursing
"Willingness of men and women of reproductive potential to observe conventional and effective birth control for the duration of treatment and for 3 months following the last dose of study treatment; this may include barrier methods, such as condom or diaphragm with spermicidal gel.",no-pregnancy-nursing
Willingness of men and women of reproductive potential to observe conventional and effective birth control.,no-pregnancy-nursing
"Willingness of sexually active participants to use adequate contraception; both men and women of child-bearing potential treated or enrolled on this study must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) before study entry, for the duration of study participation, 90 days after completion of ibrutinib, and 12 months after the last dose of rituximab, whichever comes last; men who only have sex with other men do not need to use contraception specifically for this study (should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately)",no-pregnancy-nursing
Willingness to avoid pregnancy or fathering children based on the following criteria:,no-pregnancy-nursing
Willingness to avoid pregnancy or fathering children.,no-pregnancy-nursing
Willingness to follow pregnancy precautions,no-pregnancy-nursing
Willingness to not donate sperm or oocytes during the entire study treatment period and after treatment discontinuation,no-pregnancy-nursing
Willingness to use contraception by a method that is deemed effective by the investigator by both males and female patients of child bearing potential (postmenopausal women must have been amenorrheal for at least 12 months to be considered of non-childbearing potential) and their partners throughout the treatment period and for at least three months following the last dose of study drug.,no-pregnancy-nursing
Willingness to use contraception if childbearing potential,no-pregnancy-nursing
"With female partners of childbearing potential or pregnant female partners, men must remain abstinent or use a condom during the treatment period and for 60 days after the final dose of mosunetuzumab, 5 months after the final dose of polatuzumab vedotin, 3 months after the final dose of rituximab, 6 months after the final dose of cyclophosphamide, doxorubicin, prednisone, or vincristine, and 60 days after the final dose of tocilizumab, as applicable, to avoid exposing the embryo. Men must refrain from donating sperm during this same period",no-pregnancy-nursing
"With female partners of childbearing potential or pregnant female partners, men must remain abstinent or use a condom during the treatment period and for at least 3 months after the last dose of study drug to avoid exposing the embryo. Men must refrain from donating sperm during this same period.",no-pregnancy-nursing
"With female partners of childbearing potential or pregnant female partners, men must remain abstinent or use a condom during the treatment period and for at least 6 months after the last dose of study treatment to avoid exposing the embryo. Men must refrain from donating sperm during this same period.",no-pregnancy-nursing
"With female partners of childbearing potential or pregnant female partners, men must remain abstinent or use a condom during the treatment period and for at least 60 days after the last dose of BFCR4350A and tocilizumab (if applicable) to avoid exposing the embryo. Men must refrain from donating sperm during this same period",no-pregnancy-nursing
"With female partners of childbearing potential, men must remain abstinent or use a condom plus an additional contraceptive method that together result in a failure rate of < 1% per year during the treatment period and for at least 6 months after the last dose of rituximab. Men must refrain from donating sperm during this same period.",no-pregnancy-nursing
"With female partners of childbearing potential, men must remain abstinent or use a condom plus an additional contraceptive method that together result in a failure rate of < 1% per year during the treatment period and for at least 6 months after the last dose of obinutuzumab. Men must refrain from donating sperm during this same period",no-pregnancy-nursing
"With female partners of childbearing potential, men must remain abstinent or use a condom plus an additional contraceptive method that together result in a failure rate of < 1% per year during the treatment period and for at least 7 months after the last dose of study treatment. Men must refrain from donating sperm during this same period.",no-pregnancy-nursing
"With female partners of childbearing potential, men must remain abstinent or use a condom plus an additional contraceptive method that together result in a failure rate of less than 1% per year as noted below. Men must refrain from donating sperm during this same period.",no-pregnancy-nursing
"With pregnant female partners, men must remain abstinent or use a condom as noted below to avoid exposing the embryo.",no-pregnancy-nursing
"With pregnant female partners, men must remain abstinent or use a condom during the treatment period and for at least 6 months after the last dose of obinutuzumab to avoid exposing the embryo",no-pregnancy-nursing
"With pregnant female partners, men must remain abstinent or use a condom during the treatment period and for at least 6 months after the last dose of rituximab to avoid exposing the embryo",no-pregnancy-nursing
"With pregnant female partners, men must remain abstinent or use a condom during the treatment period and for at least 6 months after the last dose of rituximab to avoid exposing the embryo.",no-pregnancy-nursing
"With pregnant female partners, men must remain abstinent or use a condom during the treatment period and for at least 7 months after the last dose of study treatment to avoid exposing the embryo.",no-pregnancy-nursing
"WOCBP and men who are sexually active with WOCBP must use adequate contraception (e.g., hormonal or 2 barrier methods with a failure rate of less than 1% per year or abstinence) prior to study entry and throughout study drug administration. WOCBP receiving nivolumab will be instructed to adhere to contraception for a period of 23 weeks after the last dose of investigational product. Men receiving nivolumab and who are sexually active with WOCBP will be instructed to adhere to contraception for a period of 31 weeks after the last dose of investigational product.",no-pregnancy-nursing
WOCBP and sexually active fertile men with WOCBP partners who are unwilling or unable to use acceptable contraception method to avoid pregnancy.,no-pregnancy-nursing
"WOCBP and sexually active, non-sterile men must be willing to use acceptable method of contraception. WOCBP must agree to not get pregnant and sexually active, non-sterile men must agree not to impregnate a woman for at least 18 weeks after the last dose of nivolumab",no-pregnancy-nursing
WOCBP defined as not being surgically sterilized or have not been free from menses for > 1 year,no-pregnancy-nursing
"WOCBP include any female who has experienced menarche and who has not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation or bilateral oophorectomy) or is not postmenopausal (defined as amenorrhea > 12 consecutive months); or women on hormone replacement therapy (HRT) with documented serum follicle stimulating hormone (FSH) level > 35 mIU/mL. Even women who are using oral, implanted or injectable contraceptive hormones or mechanical products such as an IUD or barrier methods (diaphragm, condoms, spermicides) to prevent pregnancy or practicing abstinence or where partner is sterile (e.g., vasectomy), should be considered to be of child-bearing potential.",no-pregnancy-nursing
WOCBP must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 2 weeks prior to the start of study drug. Women who undergo fertility preservation within 2 weeks of beginning chemotherapy are expected to have false-positive pregnancy tests and therefore testing may be waived for these patients.,no-pregnancy-nursing
WOCBP must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 24 hours prior to the start of study drug. Women who undergo fertility preservation within 2 weeks of beginning chemotherapy are expected to have false-positive pregnancy tests and therefore testing may be waived for these patients.,no-pregnancy-nursing
WOCBP must have a negative serum or urine pregnancy test within 5 days prior to enrollment.,no-pregnancy-nursing
WOCBP who has a positive urine pregnancy test within 72 hours before the first dose of study treatment,no-pregnancy-nursing
WOCBP: Pregnant or breastfeeding,no-pregnancy-nursing
Woman of child-bearing potential must have negative pregnancy tests during the screening period and before starting study treatment.,no-pregnancy-nursing
Woman of childbearing potential who has a negative serum pregnancy test at screening and before the first dose on Day 1 who agrees to take appropriate precautions to avoid pregnancy (with at least 99% certainty) from screening through safety follow-up. Permitted methods that are at least 99% effective in preventing pregnancy should be communicated to the subject and their understanding confirmed,no-pregnancy-nursing
Woman of childbearing potential who has a negative serum pregnancy test at screening and before the first dose on Day 1 who agrees to take appropriate precautions to avoid pregnancy (with at least 99% certainty) from screening through safety follow-up. Permitted methods that are at least 99% effective in preventing pregnancy (see Appendix A) should be communicated to the subject and their understanding confirmed.,no-pregnancy-nursing
"Woman of childbearing potential, defined as a woman physiologically capable of becoming pregnant, unless she is using highly effective methods of contraception during treatment with gevokizumab and for at least 90 days after stopping gevokizumab. Highly effective contraception methods include:",no-pregnancy-nursing
Woman of reproductive potential must agree to use highly effective methods of birth control during the period of therapy and for 30 days after the last dose of the study drug. Men who are sexually active must agree to use highly effective contraception during the period of therapy and for 3 months after the last dose.,no-pregnancy-nursing
"Woman with child bearing potential must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control, one highly effective method and one additional effective method AT THE SAME TIME, at least 4 weeks before she starts taking lenalidomide",no-pregnancy-nursing
"Women and men must use adequate birth control while taking part in this study (such as a condom or diaphragm with contraceptive cream/jelly, birth control pills, Norplant, abstinence (no sexual intercourse) or surgical sterilization.",no-pregnancy-nursing
"Women are considered of reproductive potential unless they have undergone hysterectomy and/or surgical sterilization (at least 6 weeks following a bilateral oophorectomy, bilateral tubal ligation, or bilateral tubal occlusive procedure that has been confirmed in accordance with the device's label) or achieved postmenopausal status (defined as cessation of regular menses for greater than 12 consecutive months in women at least 45 years of age).",no-pregnancy-nursing
Women currently pregnant or breastfeeding.,no-pregnancy-nursing
Women must agree to avoid breast-feeding and women of child-bearing potential (WOCBP) must agree to use highly effective contraception while receiving study drug and for a period of 31 weeks after the last dose of study drug; sexually-active men must agree to use a condom while receiving study drug and for 31 weeks after the last dose of study drug; vasectomized men must also agree to use a condom to avoid delivering drug in the seminal fluid,no-pregnancy-nursing
Women must not be breastfeeding,no-pregnancy-nursing
Women must not be breastfeeding.,no-pregnancy-nursing
"Women must not be pregnant due to potential harm to the fetus from daratumumab and lenalidomide. All females of childbearing potential (FCBP) must have a blood test or urine study with a sensitivity of at least 25 mIU/mL within 10-14 days prior to the first dose of lenalidomide and again within 24 hours prior to the first dose of lenalidomide. FCBP must also agree to ongoing pregnancy testing while on treatment. A female of childbearing potential is any woman, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria:",no-pregnancy-nursing
Women must not be pregnant or breast-feeding,no-pregnancy-nursing
"Women must not be pregnant or breast-feeding and must not become pregnant or breastfeed during protocol therapy and for at least 3 months after protocol therapy; woman of childbearing potential must abstain from sexual activity or be willing to use 2 highly effective forms of contraception throughout protocol therapy and for at least an additional 3 months after the last dose of protocol-specified therapy; all females of childbearing potential must have a blood test or urine study within 2 weeks prior to registration to rule out pregnancy; a female of childbearing potential is any woman, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria: has not undergone a hysterectomy or bilateral oophorectomy; or has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)",no-pregnancy-nursing
"Women must not be pregnant or breast-feeding because, based on the mechanism of action, crizotinib may cause fetal harm when administered during pregnancy. In animal studies, teratogenicity was not evident, but embryotoxic and fetotoxic effects were noted in rats at crizotinib exposures similar to and above those observed in humans at the recommended clinical dose.",no-pregnancy-nursing
"Women must not be pregnant or breast-feeding due to potential harm to the fetus from cisplatin, carboplatin, etoposide, temozolomide and/or capecitabine. All females of childbearing potential must have a blood test or urine study within 2 weeks prior to randomization to rule out pregnancy. A female of childbearing potential is any woman, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria:",no-pregnancy-nursing
Women must not be pregnant or breast-feeding due to potential harm to the fetus or infant from ALK inhibitors and the unknown risk. Women of childbearing potential and sexually active males must agree to use an accepted and effective method of contraception or to abstain from sexual intercourse for the duration of their participation in the study.,no-pregnancy-nursing
Women must not be pregnant or breast-feeding due to risk of fetal harm by the chemotherapeutic agents prescribed in this protocol.,no-pregnancy-nursing
"Women must not be pregnant or breast-feeding due to risk of fetal harm by the chemotherapeutic agents prescribed in this protocol. All females of childbearing potential must have a blood test or urine study within 2 weeks prior to registration to rule out pregnancy. A female of childbearing potential is any woman, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria:",no-pregnancy-nursing
"Women must not be pregnant or breast-feeding due to risk of fetal harm by the chemotherapeutic agents prescribed in this protocol. All females of childbearing potential must have a blood test or urine study within 7 days prior to starting treatment to rule out pregnancy. A female of childbearing potential is any woman, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria:",no-pregnancy-nursing
"Women must not be pregnant or breast-feeding due to risk of fetal harm by the chemotherapeutic agents prescribed in this protocol; all females of childbearing potential must have a blood test or urine study within 2 weeks prior to registration to rule out pregnancy; a female of childbearing potential is any woman, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria:",no-pregnancy-nursing
Women must not be pregnant or breast-feeding due to the potential for congenital abnormalities and of harm to nursing infants due to the treatment regimens used.,no-pregnancy-nursing
"Women must not be pregnant or breast-feeding due to the potential harm to an unborn fetus and possible risk for adverse events in nursing infants with the treatment regimens being used. Patients must also not expect to conceive or father children from the time of registration, while on study treatment, and until 12 months after the last dose of study treatment. All females of childbearing potential must have a blood test or urine study within 2 weeks prior to randomization to rule out pregnancy. A female of childbearing potential is any woman, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria: has achieved menarche at some point, has not undergone a hysterectomy or bilateral oophorectomy; or has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months).",no-pregnancy-nursing
Women must not be pregnant or breast-feeding due to unknown and potentially harmful effects of nivolumab on the developing fetus or child.,no-pregnancy-nursing
"Women must not be pregnant or breast-feeding since this study involves investigational agents whose genotoxic, mutagenic, and teratogenic effects on the developing fetus and newborn are unknown. All females of childbearing potential must have a blood test within 2 weeks prior to registration to rule out pregnancy. A female of childbearing potential is any woman, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria:",no-pregnancy-nursing
Women must not be pregnant or breastfeeding since we do not know the effects of ixazomib and ibrutinib on the fetus or breastfeeding child. All sexually active females of childbearing potential must have a blood test to rule out pregnancy within 2 weeks prior to registration.,no-pregnancy-nursing
"Women must not be pregnant or breast-feeding. All females of childbearing potential must have a blood test or urine study within 7 days prior to FES PET/CT scan and [18F]-fluorodeoxyglucose (FDG)-PET/CT scan to rule out pregnancy; a female of childbearing potential is any woman, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria:",no-pregnancy-nursing
"Women must not be pregnant or breastfeeding. Females of childbearing potential who are sexually active with a non-sterilized male partner and sexually active men must agree to use 2 methods of adequate contraception (hormonal plus barrier or 2 barrier forms) prior to study entry, for the duration of study participation, and for 12 months after last dose of therapy. Method of contraception must be documented.",no-pregnancy-nursing
Women must not be pregnant or breast-feeding; all females of childbearing potential must have a serum or urine pregnancy test to rule out pregnancy within 2 weeks prior to registration,no-pregnancy-nursing
Women must not be pregnant or breast-feeding; all females of childbearing potential must have a serum or urine pregnancy test to rule out pregnancy within 2 weeks prior to registration -,no-pregnancy-nursing
Women must not be pregnant or breast-feeding; all females of childbearing potential must have a serum or urine pregnancy test to rule out pregnancy within 2 weeks prior to registration - REGISTRATION TO STEP 2 ELIGIBILITY CRITERIA: Pregnant women are excluded from this study; breastfeeding should be discontinued,no-pregnancy-nursing
Women must remain abstinent or use contraceptive methods with a failure rate of < 1% per year during the treatment period and for at least 3 months after the last dose of BFCR4350A and tocilizumab (if applicable).,no-pregnancy-nursing
"Women not of reproductive potential are female patients who are postmenopausal or permanently sterilized (e.g., tubal occlusion, hysterectomy, bilateral salpingectomy).",no-pregnancy-nursing
"Women of child bearing potential (WCBP), defined as a sexually mature woman not surgically sterilized or not post-menopausal for at least 24 consecutive months if <= 55 years or 12 months if > 55 years, must have a negative serum pregnancy test within 72 hours prior to the first dose of study drug and must agree to use highly effective methods of birth control throughout the study. Highly effective methods of contraception include total abstinence, sterilization of patient and/or patient's partner, or use of combination of two methods, including barrier methods (double barrier method is acceptable), IUD or IUS, and hormonal implants or combined oral contraceptives (see Appendix F).",no-pregnancy-nursing
Women of child bearing potential (WOCBP) must have a negative serum or β-human chorionic gonadotropin (β-hCG) at screening or evidence of surgical sterility or evidence of post-menopausal status. Post-menopausal status is defined as any of the following: natural menopause with menses > 1 year ago; radiation or chemotherapy inducted oophorectomy with menses > 1 year ago and follicle stimulating hormone (FSH) level in the menopausal range.,no-pregnancy-nursing
"Women of child bearing potential and male partners of women of child bearing potential must agree to use two medically accepted methods of contraception, one of them being a barrier method during the study and for 7 months after last study drug administration.",no-pregnancy-nursing
Women of child bearing potential and sexually active males with partners of child bearing potential must agree to use adequate birth control for the duration of treatment,no-pregnancy-nursing
Women of child bearing potential must agree to use 2 methods of reliable contraception simultaneously,no-pregnancy-nursing
Women of child bearing potential only: Negative urine or serum pregnancy test,no-pregnancy-nursing
Women of child bearing potential who are pregnant or breastfeeding because of the potentially dangerous effects of the preparative chemotherapy on the fetus or infant.,no-pregnancy-nursing
Women of child bearing potential who are pregnant or breastfeeding; females who have undergone surgical sterilization or who have been postmenopausal for at least 2 years are not considered to be of childbearing potential,no-pregnancy-nursing
Women of child bearing potential who are unwilling to employ adequate contraception from the time of registration through 6 months after the final vaccine cycle.,no-pregnancy-nursing
Women of childbearing age must have a negative pregnancy test and all sexually active participants must agree to use effective contraception during study treatment,no-pregnancy-nursing
"Women of childbearing age must undergo a serum pregnancy test with negative results before screening, and are willing to use effective and reliable method of contraception (Section 10.8) for at least 6 months after T cell infusion",no-pregnancy-nursing
Women of child-bearing potential,no-pregnancy-nursing
Women of child-bearing potential (according to recommendations of the Clinical Trial Facilitation Group [CTFG]) must not be pregnant or breastfeeding and must have a negative pregnancy test at screening.,no-pregnancy-nursing
Women of childbearing potential (defined as all women physiologically capable of becoming pregnant) must agree to both of the following:,no-pregnancy-nursing
"Women of childbearing potential (i.e., not postmenopausal for at least 12 months or surgically sterile) must have a negative serum pregnancy test result at screening, within 14 days prior to the first study drug administration",no-pregnancy-nursing
"Women of child-bearing potential (i.e., women who are pre-menopausal or not surgically sterile) must use accepted contraceptive methods (abstinence, intrauterine device [IUD], oral contraceptive or double barrier device) during the study and must have a negative serum or urine pregnancy test within 2 weeks prior to treatment initiation.",no-pregnancy-nursing
"Women of child-bearing potential (i.e., women who are pre-menopausal or not surgically sterile) must use accepted contraceptive methods (abstinence, intrauterine device [IUD], oral contraceptive(s), intrauterine hormone releasing system (IUS), bilateral tubal occlusion or vasectomized partner) during and for 6 months of the study and must have a negative serum or urine pregnancy test within 1 week prior to treatment initiation, at the end of systemic exposure and between the cycles if the menstrual period is delayed by over 30 days.",no-pregnancy-nursing
Women of childbearing potential (not postmenopausal for at least one year or not surgically incapable of bearing children) must agree not to become pregnant for the duration of the study.,no-pregnancy-nursing
Women of childbearing potential (WCBP) must:,no-pregnancy-nursing
"Women of child-bearing potential (WCBP), defined as a sexually mature woman who has not undergone a hysterectomy or tubal ligation or who has not been naturally postmenopausal for at least 24 consecutive months, must have a negative serum pregnancy test prior to treatment. All sexually active WCBP and all sexually active male subjects must agree to use highly effective methods of birth control through one year post bb2121 infusion.",no-pregnancy-nursing
"Women of child-bearing potential (WCBP), defined as a sexually mature woman who has not undergone a hysterectomy, bilateral oophorectomy, or tubal ligation or who has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months, must:",no-pregnancy-nursing
"Women of childbearing potential (WOCBP) and fertile men must agree to use adequate contraception when sexually active from signing of the ICF for the full study until at least 6 months after the last study drug administration. For all male patients, prior to treatment, advice should be sought for conserving sperm due to the chance of irreversible infertility as a consequence of treatment. Genetic consultation is recommended if the patient wishes to have children after ending treatment. The investigator or a designated associate is requested to advise the patient how to achieve highly effective birth control. Highly effective (failure rate of less than 1% per year) contraception methods include:",no-pregnancy-nursing
"Women of child-bearing potential (WOCBP) and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study treatment, and for at least 18 months after the last dose of obinutuzumab. The effects of rhIL-15 and obinutuzumab on the developing human fetus are unknown. Additionally, CD20-depleting agents are known to produce opportunistic infections, causing fetal B-cell depletion in animal studies, and may be teratogenic. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.",no-pregnancy-nursing
"Women of childbearing potential (WOCBP) and men must agree to use effective contraception when sexually active. This applies for the time period between signing of the informed consent form and 30 days (for WOCBP) and 90 days (for men) after the last administration of study treatment. A woman is considered of childbearing potential, i.e. fertile, following menarche and until becoming post-menopausal unless permanently sterile. Permanent sterilization methods include but are not limited to hysterectomy, bilateral salpingectomy and bilateral oophorectomy. A postmenopausal state is defined as no menses for continuous 12 months without an alternative medical cause. A high follicle stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a post-menopausal state in women not using hormonal contraception or hormonal replacement therapy.",no-pregnancy-nursing
"Women of childbearing potential (WOCBP) and men must agree to use effective contraception when sexually active. This applies for the time period between signing of the informed consent form and 6 months (180 days) for WOCBP and for men after the last administration of study treatment. NOTE: A woman is considered of childbearing potential, (i.e., fertile), following menarche and until becoming post-menopausal unless permanently sterile. Permanent sterilization methods include but are not limited to hysterectomy, bilateral salpingectomy and bilateral oophorectomy. A postmenopausal state is defined as no menses for continuous 12 months without an alternative medical cause. A high follicle stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a post-menopausal state in women not using hormonal contraception or hormonal replacement therapy. The investigator or a designated associate is requested to advise the patient how to achieve highly effective birth control (failure rate of less than 1%), e.g., intrauterine device (IUD), intrauterine hormone-releasing system (IUS), bilateral tubal occlusion, vasectomized partner and sexual abstinence. The use of condoms by male patients is required unless the female partner is permanently sterile.",no-pregnancy-nursing
"Women of childbearing potential (WOCBP) and sexually active males must either abstain from sexual intercourse for the duration of their participation in the study or agree to use both double barrier contraception and birth control pills or implants for at least one week prior to the start of the study drug and continuing for 5 months after the last dose of study drug (for female patients) and for 7 months after the last dose of study drug (for male patients who are sexually active with WOCBP). Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she (or the participating partner) should inform the treating physician immediately.",no-pregnancy-nursing
"Women of childbearing potential (WOCBP) and sexually active males must either abstain from sexual intercourse for the duration of their participation in the study or agree to use both single barrier contraception and birth control pills or implants for at least one week prior to the start of the study drug and continuing for 5 months after the last dose of study drug (for female patients) and for 7 months after the last dose of study drug (for male patients who are sexually active with WOCBP); should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she (or the participating partner) should inform the treating physician immediately",no-pregnancy-nursing
"Women of childbearing potential (WOCBP) and sexually active males must either abstain from sexual intercourse for the duration of their participation in the study or agree to use both single barrier contraception and birth control pills or implants for at least one week prior to the start of the study drug and continuing for 5 months after the last dose of study drug (for female patients) and for 7 months after the last dose of study drug (for male patients who are sexually active with WOCBP). Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she (or the participating partner) should inform the treating physician immediately.",no-pregnancy-nursing
"Women of childbearing potential (WOCBP) is defined as any female who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) or who is not postmenopausal. Menopause is defined clinically as 12 months of amenorrhea in a woman over age 45 in the absence of other biological or physiological causes. In addition, women under the age of 55 must have a documented serum follicle stimulating hormone (FSH) level less than 40 mIU/mL.",no-pregnancy-nursing
Women of childbearing potential (WOCBP) is defined as any female who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) or who is not postmenopausal; menopause is defined clinically as 12 months of amenorrhea in a woman over 45 in the absence of other biological or physiological causes,no-pregnancy-nursing
Women of childbearing potential (WOCBP) must agree to follow instructions for method(s) of contraception for the duration of treatment with study treatments BMS-813160 plus 5 half-lives of study treatment plus 30 days (duration of ovulatory cycle) for a total of 5 months post-treatment completion (see Appendix 4).,no-pregnancy-nursing
Women of childbearing potential (WOCBP) must agree to use a highly effective method of contraception from the time of giving informed consent until at least 16 weeks after the last dose of Camidanlumab Tesirine. Men with female partners who are of childbearing potential must agree to use a highly effective method of contraception from the time of giving informed consent until at least 16 weeks after the participants receives his last dose of Camidanlumab Tesirine.,no-pregnancy-nursing
"Women of childbearing potential (WOCBP) must agree to use an adequate method of contraception during the study and until 3 months after the last treatment. Males must be surgically or biologically sterile or agree to use an adequate method of contraception during the study until 3 months after the last treatment. Adequate methods of contraception include: total abstinence when this is in line with the preferred and usual lifestyle of the subject; periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception.",no-pregnancy-nursing
Women of child-bearing potential (WOCBP) must agree to use an effective method(s) of contraception during treatment and during the post treatment follow-up period,no-pregnancy-nursing
Women of child-bearing potential (WOCBP) must have a negative pregnancy test (urine or serum) within 7 days prior to administration of the first dose of TAS-120. Female patients are not considered to be of child-bearing potential if they have a history of hysterectomy or are post-menopausal defined as no menses for 12 months without an alternative medical cause. Both males and females of reproductive potential must agree to use effective birth control during the study prior to the first dose and for 6 months after the last dose. Section 8.7.1 provides a list of effective contraceptive methods for this protocol.,no-pregnancy-nursing
Women of childbearing potential (WOCBP) must have a negative serum beta-HCG pregnancy test result within seven days from start of treatment,no-pregnancy-nursing
Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) during screening and within 48 hours prior to the first dose of nivolumab.,no-pregnancy-nursing
"Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 24 hours prior to the start of nivolumab. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required. Female subjects of childbearing potential should agree to ongoing pregnancy testing, to be performed prior to each dosing of ipilimumab and nivolumab. See Note below for definition of WOCBP.",no-pregnancy-nursing
Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 24 hours prior to the start of study treatment.,no-pregnancy-nursing
Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin [HCG]) within 24 hours prior to the start of study treatment.,no-pregnancy-nursing
Women of child-bearing potential (WOCBP) must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin) within 24 hours prior to the start of study treatment. An extension up to 72 hours prior to the start of study treatment is permissible in situations where results cannot be obtained within the standard 24-hour window.,no-pregnancy-nursing
Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test (minimum sensitivity of 25 IU/L or equivalent units of human chorionic gonadotropin) performed at screening and within 24 hours of first dose of investigational treatment. See Section 5.4.1 of the protocol for definition of childbearing potential.,no-pregnancy-nursing
"Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test with a sensitivity of at least 50 mIU/ml, <= 14 days prior to registration and within 24 hours of starting pomalidomide. In addition, must either commit to continue abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control, one highly effective method and one additional effective method AT THE SAME TIME, at least 28 days before she starts taking pomalidomide. WOCBP must also agree to ongoing pregnancy testing. Men must agree to use a latex condom during sexual contact with a WOCBP even if they have had a vasectomy. In addition, women of childbearing potential (WOCBP) receiving nivolumab will be instructed to adhere to contraception for a period of 5 months after the last dose of nivolumab. Men receiving nivolumab and who are sexually active with WOCBP will be instructed to adhere to contraception for a period of 7 months after the last dose of nivolumab. All patients must be counseled at a minimum of every 28 days about pregnancy precautions and risks of fetal exposure",no-pregnancy-nursing
"Women of child-bearing potential (WOCBP) must have a negative serum pregnancy test at Screening ( <= 7 days prior to 1st study drug dose) and must agree to use an effective form of contraception from the time of the negative pregnancy test up to 6 months after the last dose of study drug. Effective forms of contraception include abstinence, hormonal contraceptive in conjunction with a barrier method, or a double barrier method. Women of non-child-bearing potential may be included if they are either surgically sterile or have been postmenopausal for >= 1 year.",no-pregnancy-nursing
Women of childbearing potential (WOCBP) must have a negative serum pregnancy test within the 7 days prior to study drug administration.,no-pregnancy-nursing
Women of childbearing potential (WOCBP) must use appropriate method(s) of contraception. WOCBP should use an adequate method to avoid pregnancy for 23 weeks (30 days plus the time required for nivolumab to undergo five half-lives) after the last dose of investigational drug.,no-pregnancy-nursing
Women of child-bearing potential (WOCBP) not practicing an effective method(s) of contraception.,no-pregnancy-nursing
Women of childbearing potential (WOCBP) only: Negative urine or serum pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin [HCG]),no-pregnancy-nursing
Women of child-bearing potential (WOCBP) should be advised to avoid becoming pregnanct and men should be advised not to father a child while receiving treatment with azacitidine. All men and women of child-bearing potential must use acceptable methods of birth control throughout the study.,no-pregnancy-nursing
Women of childbearing potential (WOCBP): negative urine or serum pregnancy test,no-pregnancy-nursing
Women of childbearing potential (WOCBP): negative urine or serum pregnancy test (to be performed within14 days prior to day 1 of protocol therapy unless otherwise stated),no-pregnancy-nursing
"Women of childbearing potential (WOCBP): negative urine or serum pregnancy test; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required",no-pregnancy-nursing
Women of childbearing potential (WOCP) must have a negative pregnancy test result prior to enrollment. WOCP and men whose partners are WOCP must agree to use a highly effective method of birth control during the study and for 6 months following the last dose of study drug. A highly effective method of birth control is defined as one which results in a low failure rate (less than 1% per year).,no-pregnancy-nursing
"Women of childbearing potential and all men (and their female partners of childbearing potential) who are sexually active must agree to use adequate method of contraception at study entry, during treatment and for at least 9 months (270 days) following the last dose of study drug.",no-pregnancy-nursing
"Women of childbearing potential and male patients should use effective contraception during treatment with MM-398 and for 90 days following the final dose of veliparib and MM-398 for both female and male patients; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.",no-pregnancy-nursing
Women of child-bearing potential and men must agree to use adequate contraception (double barrier method of birth control or abstinence) 4 weeks prior to study entry and for the duration of study participation. Women of child-bearing age must have documented negative pregnancy test prior to start of lympho-depleting regimen.,no-pregnancy-nursing
"Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control or abstinence) prior to study entry and for six months following duration of study participation; should a woman become pregnant or suspect that she is pregnant while participating on the trial, she should inform her treating physician immediately",no-pregnancy-nursing
"Women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control, abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician immediately.",no-pregnancy-nursing
"Women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control, abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician immediately. Men must agree and commit to use a barrier method of contraception while on treatment and for 3 months after the last dose of the investigational product (see Section 6.3).",no-pregnancy-nursing
"Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) after study entry and for the duration of study participation. The effects of FLT on the developing human fetus are unknown. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately. A screening urine human chorionic gonadtropin (hCG) (pregnancy test) will be administered in Nuclear Medicine to women of childbearing potential before each FLT scan and pregnant women will be stopped from participating further in this study.",no-pregnancy-nursing
"Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately",no-pregnancy-nursing
"Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately; men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 6 months after completion of VX-970 administration",no-pregnancy-nursing
"Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, during the treatment portion of the study, and for a minimum of 8 after the last dose of study drug; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately",no-pregnancy-nursing
"Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and 30 days after completion of rhIL-15 and avelumab administration. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.",no-pregnancy-nursing
"Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 180 days after the last dose of paclitaxel; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.",no-pregnancy-nursing
"Women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 4 months after completion of study; should a woman become pregnant or suspect while she or her partner is participating in this study, she should inform her treating physician immediately",no-pregnancy-nursing
"Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 5 months (150 days) after the last dose of study agent; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately",no-pregnancy-nursing
"Women of child-bearing potential and men must agree to use adequate contraception (hormonal, barrier method or abstinence) prior to study entry and for the duration of study participation",no-pregnancy-nursing
Women of child-bearing potential and men must agree to use adequate contraception (see below) for at least 90 days prior to study entry and for the duration of study participation.,no-pregnancy-nursing
Women of child-bearing potential and men must agree to use adequate contraception for the duration of study participation and for 120 days after the last treatment with nivolumab.,no-pregnancy-nursing
Women of child-bearing potential and men must agree to use adequate contraception prior to study entry and for the duration of study participation.,no-pregnancy-nursing
"Women of child-bearing potential and men must agree to use adequate contraception prior to the start of treatment, for the duration of treatment, and for 5 months after last dose of study treatment",no-pregnancy-nursing
Women of child-bearing potential and men must agree to use adequate contraception.,no-pregnancy-nursing
"Women of childbearing potential and men must agree to use contraceptive methods as described in Section 5.7 prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician immediately.",no-pregnancy-nursing
"Women of childbearing potential and men who are able to father a child must agree to use an effective method of contraception (eg, oral contraceptives, double-barrier methods such as a condom and a diaphragm, intrauterine device, Norplant, Depo-Provera) during the study and for 12 months following administration of the study drug",no-pregnancy-nursing
"Women of childbearing potential and men who are able to father a child, must agree to use an effective contraception method during study and for 12 months following study drug administration",no-pregnancy-nursing
"Women of childbearing potential and men who are sexually active must be practicing a highly effective method of birth control during and after the study consistent with local regulations regarding the use of birth control methods for subjects participating in clinical trials. Men must agree to not donate sperm during and after the study. For females, these restrictions apply for 1 month after the last dose of study drug. For males, these restrictions apply for 3 months after the last dose of study drug",no-pregnancy-nursing
"Women of childbearing potential and men who are sexually active must be practicing a highly effective method of birth control during and after the study consistent with local regulations regarding the use of birth control methods for subjects participating in clinical trials; men must agree to not donate sperm during and after the study; for females, these restrictions apply for 1 month after the last dose of study drug; for males, these restrictions apply for 3 months after the last dose of study drug",no-pregnancy-nursing
"Women of childbearing potential and men who are sexually active must be practicing a highly effective method of birth control during and after the study consistent with local regulations regarding the use of birth control methods for subjects participating in clinical trials. Men must agree to not donate sperm during and after the study. For females, these restrictions apply for 1 month after the last dose of study drug. For males, these restrictions apply for 3 months after the last dose of study drug.",no-pregnancy-nursing
"Women of childbearing potential and men who are sexually active must be practicing a highly effective method of birth control during and after the study consistent with local regulations regarding the use of birth control methods for subjects participating in clinical trial. Men must agree to not donate sperm during and after the study. For females, these restrictions apply for 30 days month after the last dose of study drug. For males, these restrictions apply for 120 days after the last dose of study drug.",no-pregnancy-nursing
"Women of childbearing potential and men who are sexually active must be practicing a highly effective method of birth control during and after the study consistent with local regulations regarding the use of birth control methods for subjects participating in clinical trials. Men must agree to not donate sperm during and after the study. For females, these restrictions apply for 3 months after Venetoclax and 12 months after Rituximab For males, these restrictions apply for 3 months after the last dose of study drug.",no-pregnancy-nursing
"Women of childbearing potential and men who are sexually active must be practicing a highly effective method of birth control during and after the study consistent with local regulations regarding the use of birth control methods for subjects participating in clinical trials; men must agree to not donate sperm during and after the study; for sexually active women of childbearing potential, these restrictions apply for 5 months after the last dose of study drug; for sexually active men, these restrictions apply for 7 months after the last dose of study drug",no-pregnancy-nursing
"Women of childbearing potential and men who are sexually active must be practicing a highly effective method of birth control during and after the study consistent with local regulations regarding the use of birth control methods for subjects participating in clinical trials; men must agree to not donate sperm during and after the study; for females, these restrictions apply for 12 months after last dose of obinutuzumab, or 1 month after the last dose of ibrutinib, whichever is later; for males, these restrictions apply for 12 months after the last dose of obinutuzumab or 3 months after the last dose of ibrutinib, whichever is later",no-pregnancy-nursing
Women of childbearing potential and men who partner with a woman of childbearing potential must agree to use highly effective contraceptive methods for the duration of the study and for 3 months after the lastdose of CA-4948,no-pregnancy-nursing
"Women of child-bearing potential and men with partners of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 30 days following completion of therapy. Should a woman or partner become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician and the investigator immediately.",no-pregnancy-nursing
Women of childbearing potential and sexually active males must be strongly advised to practice abstinence or use an accepted and effective method of contraception.,no-pregnancy-nursing
Women of childbearing potential and sexually active males must be strongly advised to use accepted and highly effective method(s) of contraception or to abstain from sexual intercourse for the duration of their participation in the study and for:,no-pregnancy-nursing
Women of childbearing potential and sexually active males must be strongly advised to use an accepted and effective method of contraception or to abstain from sexual intercourse during the treatment period and for 31 weeks after the last nivolumab infusion.,no-pregnancy-nursing
Women of childbearing potential and sexually active males must be strongly advised to use an accepted and effective method of contraception or to abstain from sexual intercourse for the duration of their participation in the study and for 12 months post rituximab treatment.,no-pregnancy-nursing
Women of childbearing potential and sexually active males must be strongly advised to use an accepted and effective method of contraception or to abstain from sexual intercourse for the duration of their participation in the study.,no-pregnancy-nursing
Women of childbearing potential and sexually active males must use an accepted and effective method of contraception or to abstain from sexual intercourse for the duration of their participation in the study,no-pregnancy-nursing
"Women of childbearing potential and sexually active males must use an accepted and highly effective method of contraception or to abstain from sexual intercourse for the duration of their participation in the study and for 30 days after the last dose of venetoclax. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she (or the participating partner) should inform the treating physician immediately.",no-pregnancy-nursing
"Women of childbearing potential and sexually active males must use an accepted and highly effective method(s) of contraception or abstain from sexual intercourse for the duration of their participation in the study and for 3 months after the last dose of daratumumab or 30 days after the last dose of venetoclax, whichever is longer. Male patients must also agree not to donate sperm for the duration of their participation in the study for 3 months after the last dose of daratumumb or 30 days after the last dose of venetoclax whichever is longer.",no-pregnancy-nursing
"Women of childbearing potential and sexually active males must use an accepted and highly effective method(s) of contraception or abstain from sexual intercourse for the duration of their participation in the study and for 3 months after the last dose of daratumumab or 30 days after the last dose of venetoclax, whichever is longer. Male patients must also agree not to donate sperm for the duration of their participation in the study for 3 months after the last dose of daratumumab or 30 days after the last dose of venetoclax, whichever is longer.",no-pregnancy-nursing
Women of childbearing potential and sexually active males must use an effective contraception method during treatment and for three months after completing treatment.,no-pregnancy-nursing
Women of childbearing potential as defined in Appendix 2 must:,no-pregnancy-nursing
"Women of childbearing potential include women who have experienced menarche and who have not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or are not postmenopausal. Post menopause is defined as amenorrhea >= 12 consecutive months.",no-pregnancy-nursing
Women of childbearing potential must,no-pregnancy-nursing
"Women of childbearing potential must agree to undergo pregnancy testing within 14 days of study entry and agree to use adequate contraception (barrier method of birth control, abstinence, not hormonal) prior to study entry and for the duration of study participation as well as chemical LHRH Agonist with goserelin. Should a woman become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician immediately.",no-pregnancy-nursing
"Women of child-bearing potential must agree to use 2 reliable methods of contraception beginning 4 weeks prior to the initiation of treatment, during therapy, and for at least 4 weeks after the last drug administration.",no-pregnancy-nursing
"Women of child-bearing potential must agree to use 2 reliable methods of contraception beginning 4 weeks prior to the initiation of treatment, during therapy, and for at least 4 weeks after the last drug administration. 1094P17AUG.003 Amendment 2 - August 22, 2017",no-pregnancy-nursing
Women of childbearing potential must agree to use acceptable methods of birth control starting with the screening visit and up to 120 days after the last dose of study treatment,no-pregnancy-nursing
Women of childbearing potential must agree to use an effective contraception method during the study and for 60 days following the last dose of study drug. Women of non- childbearing potential are those who are postmenopausal greater than 1 year or who have had a bilateral tubal ligation or hysterectomy. Men who have partners of childbearing potential must agree to use an effective contraceptive method during the study and for 60 days following the last dose of study drug,no-pregnancy-nursing
"Women of child-bearing potential must agree to use an effective method of birth control on trial, as the safety of metformin in pregnancy has not been established. An effective method of birth control includes surgical sterilization of woman or her partner, abstinence, or two barrier methods (e.g. condom plus diaphragm); or hormonal methods of birth control (oral contraceptives or intrauterine device).",no-pregnancy-nursing
Women of childbearing potential must agree to use dual methods of contraception and have a negative serum pregnancy test prior to selinexor treatment. Male patients must use an effective barrier method of contraception if sexually active with a female of child-bearing potential.,no-pregnancy-nursing
Women of child-bearing potential must agree to utilize a form of birth control or agree to undergo sexual abstinence during radiation therapy.,no-pregnancy-nursing
"Women of childbearing potential must be willing and able to use adequate contraception (hormonal and barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 30 days after the last dose of study agent. Should a woman become pregnant or suspect she is pregnant while she is participating in this study, she should inform her treating physician immediately. Theoretically, CYP3A induction with tazemetostat use may result in the loss of efficacy in hormonal contraceptives, thus a barrier method of contraception must be used in addition to hormonal contraceptives due to the potential drug-drug interaction with tazemetostat.",no-pregnancy-nursing
Women of childbearing potential must be willing to use an adequate method of contraception,no-pregnancy-nursing
Women of childbearing potential must consent to use adequate contraception throughout protocol therapy; females of childbearing potential must have a negative urine pregnancy test < 7 days prior to registration.,no-pregnancy-nursing
"Women of childbearing potential must follow pregnancy testing requirements as outlined in the Revlimid REMS program material. This is defined as either committing to continued abstinence from heterosexual intercourse or beginning TWO acceptable methods of contraception (one highly effective method and one additional effective method AT THE SAME TIME) at least 28 days prior to the start of lenalidomide, for the duration of study participation, and for 28 days following the last dose of lenalidomide. Women of childbearing potential must also agree to ongoing pregnancy testing.",no-pregnancy-nursing
"Women of childbearing potential must follow pregnancy testing requirements as outlined in the Revlimid Risk Evaluation and Mitigation Strategy (REMS) program material; this is defined as either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of contraception (one highly effective method and one additional effective method (AT THE SAME TIME) at least 28 days prior to the start of lenalidomide, for the duration of study participation, and for 28 days following the last doses of brentuximab vedotin and lenalidomide; women of childbearing potential must also agree to ongoing pregnancy testing; men must agree to use a latex condom during sexual contact with a woman of childbearing potential even if they have had a successful vasectomy; all patients must be counseled at a minimum of every 28 days about pregnancy precautions and risks of fetal exposure; should a woman become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician immediately",no-pregnancy-nursing
"Women of childbearing potential must have a negative baseline blood or urine pregnancy test within 72 hours of first study therapy. Women may be neither breastfeeding nor intending to become pregnant during study participation and must agree to use effective contraceptive methods (hormonal or barrier method of birth control, or true abstinence) for the duration of study participation and in the following 90 days after discontinuation of study treatment",no-pregnancy-nursing
"Women of childbearing potential must have a negative baseline blood or urine pregnancy test within 72 hours of first study therapy. Women may be neither breastfeeding nor intending to become pregnant during study participation and must agree to use effective contraceptive methods (hormonal or barrier method of birth control, or true abstinence) for the duration of study participation and in the following 90 days after discontinuation of study treatment. See Section 4.1.1.",no-pregnancy-nursing
"Women of childbearing potential must have a negative highly sensitive serum (beta-human chorionic gonadotropin [beta-hCG]) at screening and prior to the first dose of study drug. Women must agree not to donate eggs (ova, oocytes) for the purposes of assisted reproduction during the study and for a period of 90 days after receiving the last dose of study drug",no-pregnancy-nursing
Women of childbearing potential must have a negative pregnancy test (urine or serum) and must not be lactating at the time of informed consent.,no-pregnancy-nursing
Women of childbearing potential must have a negative pregnancy test <= 7 days prior to registration.,no-pregnancy-nursing
Women of childbearing potential must have a negative pregnancy test done <= 14 days prior to registration,no-pregnancy-nursing
Women of childbearing potential must have a negative qualitative serum pregnancy test <= 14 days prior to Step 1 registration.,no-pregnancy-nursing
Women of childbearing potential must have a negative serum (beta human chorionic gonadotropin β-hCG]) or urine pregnancy test at Screening. Women who are pregnant or breastfeeding are ineligible for this study.,no-pregnancy-nursing
Women of childbearing potential must have a negative serum (beta-human chorionic gonadotropin (beta-hCG) or urine beta hCG pregnancy test at Screening. Women who are pregnant or breastfeeding are ineligible for this study.,no-pregnancy-nursing
Women of childbearing potential must have a negative serum (beta-human chorionic gonadotropin [β-hCG]) or urine pregnancy test at Screening.,no-pregnancy-nursing
"Women of childbearing potential must have a negative serum (beta-human chorionic gonadotropin [beta-hCG]) or urine pregnancy test at screening, within 24 hours of the first dose of anti-OX40 antibody, and every four weeks while on study treatment; women who are pregnant or breastfeeding are ineligible for this study",no-pregnancy-nursing
Women of childbearing potential must have a negative serum (beta-human chorionic gonadotropin [beta-hCG]) or urine pregnancy test at screening. Women who are pregnant or breastfeeding are ineligible for this study,no-pregnancy-nursing
Women of childbearing potential must have a negative serum (beta-human chorionic gonadotropin [beta-hCG]) or urine pregnancy test at Screening. Women who are pregnant or breastfeeding are ineligible for this study.,no-pregnancy-nursing
Women of childbearing potential must have a negative serum (beta-human chorionic gonadotropin [beta-hCG]) or urine pregnancy test at screening; women who are pregnant or breastfeeding are ineligible for this study,no-pregnancy-nursing
Women of childbearing potential must have a negative serum (beta-human chorionic gonadotropin [-hCG]) or urine pregnancy test at Screening. Women who are pregnant or breastfeeding are ineligible for this study.,no-pregnancy-nursing
Women of childbearing potential must have a negative serum beta-human chorionic gonadotropin or urine pregnancy test at screening.,no-pregnancy-nursing
Women of childbearing potential must have a negative serum or urine beta human chorionic gonadotropin (beta-hCG) pregnancy test result within 14 days prior to the first dose of study drugs and must agree to use an effective contraception method during the study and for 30 days following the last dose of study drug; women of non-childbearing potential are those who are postmenopausal greater than 1 year or who have had a bilateral tubal ligation or hysterectomy; men who have partners of childbearing potential must agree to use an effective contraceptive method during the study and for 30 days following the last dose of study drug,no-pregnancy-nursing
Women of childbearing potential must have a negative serum or urine pregnancy test (women who have undergone surgical sterilization or who have been postmenopausal for at least 2 years are not considered to be of childbearing potential),no-pregnancy-nursing
Women of childbearing potential must have a negative serum or urine pregnancy test within 28 days prior to initiation of treatment AND confirmed prior to initiation of treatment on Day 1.,no-pregnancy-nursing
Women of childbearing potential must have a negative serum or urine pregnancy test within 7 days prior to enrollment.,no-pregnancy-nursing
Women of childbearing potential must have a negative serum or urine pregnancy test within 72 hours prior to the first dose of pembrolizumab.,no-pregnancy-nursing
Women of child-bearing potential must have a negative serum or urine pregnancy test.,no-pregnancy-nursing
Women of childbearing potential must have a negative serum pregnancy test at screening and before the first dose on Day 1 and must agree to take appropriate precautions to avoid pregnancy (with at least 99% certainty) from screening through safety follow-up. Permitted methods that are at least 99% effective in preventing pregnancy (see Appendix A) should be communicated to the participants and their understanding confirmed.,no-pregnancy-nursing
Women of childbearing potential must have a negative serum pregnancy test at screening and must agree to take appropriate precautions to avoid pregnancy (with at least 99% certainty) from screening through 6 months after the last dose of study drug. Permitted methods that are at least 99% effective in preventing pregnancy (see Appendix A) should be communicated to the participants and their understanding confirmed.,no-pregnancy-nursing
Women of childbearing potential must have a negative serum pregnancy test before study entry and must be non-lactating; and,no-pregnancy-nursing
Women of childbearing potential must have a negative serum pregnancy test result within 21 days prior to initiation of study drug,no-pregnancy-nursing
Women of childbearing potential must have a negative serum pregnancy test result within 7 days prior to initiation of study drug.,no-pregnancy-nursing
Women of childbearing potential must have a negative serum pregnancy test result within 7 days prior to initiation of study treatment.,no-pregnancy-nursing
Women of childbearing potential must have a negative serum pregnancy test within 14 days prior to the first study treatment administration,no-pregnancy-nursing
"Women of childbearing potential must have a negative serum pregnancy test within 2 weeks prior to registration; patients that are pregnant or breast feeding are excluded; a female of childbearing potential is any woman, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria:",no-pregnancy-nursing
Women of childbearing potential must have a negative serum pregnancy test within 7 days of enrollment,no-pregnancy-nursing
Women of childbearing potential must have a negative urine or serum pregnancy test documented within 7 days prior to treatment with study drug. contraceptive guidance and collection of pregnancy information for women of childbearing potential.,no-pregnancy-nursing
Women of childbearing potential must have a negative urine pregnancy test at the screening visit,no-pregnancy-nursing
"Women of childbearing potential must have agreed to use an effective contraceptive method. A woman is considered to be of  childbearing potential  if she has had menses at any time in the preceding 12 consecutive months. In addition to routine contraceptive methods,  effective contraception  also includes heterosexual celibacy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy, bilateral oophorectomy or bilateral tubal ligation, or vasectomy/vasectomized partner. However, if at any point a previously celibate patient chooses to become heterosexually active during the time period for use of contraceptive measures outlined in the protocol, she is responsible for beginning contraceptive measures. Women of childbearing potential will have a pregnancy test to determine eligibility as part of the Pre-Study Evaluation (see Section 4.0); this may include an ultrasound to rule-out pregnancy if a false-positive is suspected. For example, when beta-human chorionic gonadotropin is high and partner is vasectomized, it may be associated with tumour production of hCG, as seen with some cancers. Patient will be considered eligible if an ultrasound is negative for pregnancy.",no-pregnancy-nursing
Women of childbearing potential must have negative pregnancy test within 24 hours of enrollment,no-pregnancy-nursing
Women of child-bearing potential must have two negative serum pregnancy tests at screening,no-pregnancy-nursing
"Women of childbearing potential must use adequate contraception from study start to one month after the last dose of protocol therapy; adequate contraception is defined as hormonal birth control, intrauterine device, double barrier method or total abstinence; men must practice complete abstinence or agree to use an adequate contraception method from study start to one month after the last dose of protocol therapy",no-pregnancy-nursing
Women of child-bearing potential must use an accepted and effective method of contraception and/or abstain from sexual intercourse while on protocol treatment and for at least 5 months after the last dose of nivolumab; sexually active males must use an accepted and effective method of contraception and/or abstain from sexual intercourse while on protocol treatment and for at least 7 months after the last dose of nivolumab,no-pregnancy-nursing
"Women of child-bearing potential participating in this study should avoid becoming pregnant, and male participants should avoid impregnating a female partner. Nonsterilized female participants of reproductive age and male participants should use effective methods of contraception through defined periods during and after study treatment as specified below. Female participants must meet 1 of the following:",no-pregnancy-nursing
Women of child-bearing potential should have a negative urine pregnancy test within 4 weeks of starting preparative regimen.,no-pregnancy-nursing
Women of child-bearing potential who are pregnant or breastfeeding because of the potentially dangerous effects of the conditioning lymphodepletion chemotherapy on the fetus or infant. Females who have undergone surgical sterilization or who have been postmenopausal for at least 2 years are not considered to be of childbearing potential.,no-pregnancy-nursing
Women of childbearing potential who are pregnant or breastfeeding because of the potentially dangerous effects of the preparative chemotherapy on the fetus or infant.,no-pregnancy-nursing
Women of child-bearing potential who are pregnant or breastfeeding because of the potentially dangerous effects of the preparative chemotherapy on the fetus or infant.,no-pregnancy-nursing
Women of child-bearing potential who are pregnant or breastfeeding because of the potentially dangerous effects of the preparative chemotherapy on the fetus or infant. Females who have undergone surgical sterilization are not considered to be of childbearing potential,no-pregnancy-nursing
Women of child-bearing potential who are pregnant or breastfeeding because of the potentially dangerous effects of the preparative chemotherapy on the fetus or infant. Females who have undergone surgical sterilization or who have been postmenopausal for at least 2 years are not considered to be of childbearing potential,no-pregnancy-nursing
Women of childbearing potential who are pregnant or breastfeeding because of the potentially dangerous effects of the preparative chemotherapy on the fetus or infant. Females who have undergone surgical sterilization or who have been postmenopausal for at least 2 years are not considered to be of childbearing potential.,no-pregnancy-nursing
Women of childbearing potential who are sexually active and not willing/able to use medically acceptable forms of contraception,no-pregnancy-nursing
"Women of childbearing potential who are sexually active should be willing and able to use medically acceptable forms of contraception for the course of the study through 120 days after the last dose of MK-3475 (pembrolizumab). Women who are not of childbearing potential (i.e., who are postmenopausal or surgically sterile, who have had a hysterectomy and/or bilateral oophorectomy) do not require contraception.",no-pregnancy-nursing
Women of childbearing potential who are unwilling to employ adequate contraception,no-pregnancy-nursing
Women of childbearing potential who are unwilling to employ adequate contraception.,no-pregnancy-nursing
"Women of childbearing potential who are unwilling to employ adequate contraception; NOTE: should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately; women of child-bearing potential and men must agree to use adequate contraception using one of the methods listed below prior to study entry, for the duration of study participation, and up to 90 days following completion of therapy:",no-pregnancy-nursing
Women of childbearing potential who currently are pregnant (Β-HCG+) or who are not practicing adequate contraception.,no-pregnancy-nursing
Women of childbearing potential who do not consent to use highly effective methods of birth control.,no-pregnancy-nursing
"Women of child-bearing potential with a negative pregnancy test (qualitative serum HCG) prior to study entry AND must be using an adequate contraception method, which must be continued for 1 week after PDT.",no-pregnancy-nursing
"Women of childbearing potential* must agree to use acceptable methods of birth control starting with the screening visit and up to 120 days after the last dose of study treatment. Recommendation is for 2 effective contraceptive methods during the study. Adequate forms of contraception are double-barrier methods (condoms with spermicidal jelly or foam and diaphragm with spermicidal jelly or foam), oral depo provera, or injectable contraceptives, intrauterine devices, and tubal ligation.",no-pregnancy-nursing
Women of childbearing potential* must have a negative urine or serum pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 72 hours prior to receiving the first dose of study medication,no-pregnancy-nursing
"Women of childbearing potential, be surgically sterile or agree to practice abstinence or utilize acceptable contraception (intrauterine, injectable, transdermal, or combination oral contraceptive) through 1-year post transplant; Males who are sexually active with women of childbearing potential must be surgically sterile or using an acceptable method of contraception (defined as barrier methods in conjunction with spermicides) from time of screening through 12 weeks after last dose of study drug",no-pregnancy-nursing
"Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during dosing and for 7 days after stopping treatment. Highly effective contraception methods include:",no-pregnancy-nursing
"Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during dosing and for at least 8 months after stopping the study medication.",no-pregnancy-nursing
"Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception throughout the study and for 3 weeks after study drug discontinuation. Highly effective contraception methods include:",no-pregnancy-nursing
"Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception throughout the study and for 8 weeks after study drug discontinuation; highly effective contraception methods include:",no-pregnancy-nursing
"Women of childbearing potential, negative pregnancy test done <= 7 days prior to registration",no-pregnancy-nursing
"Women of childbearing potential, unless they agree to use dual contraceptive methods which, in the opinion of the Principal Investigator, are effective and adequate for that subject's circumstances while on study drug and for 3 months afterward.",no-pregnancy-nursing
Women of child-bearing potential.,no-pregnancy-nursing
Women of childbearing potential: Females of childbearing potential (FCBP) must agree to use two reliable forms of contraception simultaneously or have or will have complete abstinence from heterosexual intercourse during the following time periods related to this study:,no-pregnancy-nursing
"Women of nonchildbearing potential (ie, surgically sterile with a hysterectomy and/or bilateral oophorectomy OR >= 12 months of amenorrhea and at least 50 years of age) are eligible.",no-pregnancy-nursing
"Women of nonchildbearing potential (ie, surgically sterile with a hysterectomy and/or bilateral oophorectomy OR >= 12 months of amenorrhea) are eligible.",no-pregnancy-nursing
Women of reproductive potential (defined as all women physiologically capable of becoming pregnant) must agree to use suitable methods of contraception for 90 days after the last dose of study therapy (durvalumab or JCAR014),no-pregnancy-nursing
Women of reproductive potential must agree to use highly effective methods of birth control during the period of therapy and for 30 days after the last dose of the study drug. Men who are sexually active must agree to use highly effective contraception during the period of therapy and for 3 months after the last dose.,no-pregnancy-nursing
"Women of reproductive potential must have a negative pregnancy test during the screening period within 72 hours before the start of treatment. Women not of reproductive potential are female subjects who are postmenopausal or permanently sterilized (e.g., tubal occlusion, hysterectomy,bilateral salpingectomy).",no-pregnancy-nursing
"Women of reproductive potential must have a negative pregnancy test on 2 occasions during the screening period (within 10-14 days and within 24 hours before the start of treatment). Women not of reproductive potential are female subjects who are postmenopausal or permanently sterilized (e.g., hysterectomy, bilateral salpingectomy).",no-pregnancy-nursing
Women of reproductive potential must have a negative serum beta human chorionic gonadotropin (β-HCG) pregnancy test obtained within 7 days before the start of study treatment.,no-pregnancy-nursing
Women of reproductive potential must have negative urine pregnancy test.,no-pregnancy-nursing
Women of reproductive potential† must have a negative Serum β human chorionic gonadotropin (β-HCG) pregnancy test within 1 week of C1D1. They should discuss contraception with treating provider.,no-pregnancy-nursing
"Women of reproductive potential† must have a negative serum or urine β human chorionic gonadotropin (βhCG) pregnancy test. All women of reproductive potential, all sexually active male patients, and all partners of patients must agree to use adequate methods of birth control (e.g. latex condoms) throughout the study and for 30 days after the last dose of study drug.",no-pregnancy-nursing
"Women should be using adequate contraceptive measures, should not be breast feeding and must have a negative pregnancy test before start of dosing if of child-bearing potential or must have evidence of nonchildbearing potential.",no-pregnancy-nursing
Women who are breastfeeding,no-pregnancy-nursing
Women who are breast-feeding,no-pregnancy-nursing
Women who are breast-feeding or pregnant as evidenced by positive serum or urine pregnancy test performed within 72 hours of first dosing. (Pregnant women are excluded from this study because it is not known whether IACS-010759 has the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with IACS-010759 breastfeeding should be discontinued if the mother is treated with IACS-010759.),no-pregnancy-nursing
Women who are breastfeeding.,no-pregnancy-nursing
Women who are known to be pregnant or who plan to become pregnant while on rituximab treatment,no-pregnancy-nursing
"Women who are not of childbearing potential (i.e., who are postmenopausal or surgically sterile as well as azoospermic men do not require contraception.",no-pregnancy-nursing
Women who are not postmenopausal or have not undergone hysterectomy must have a documented negative serum pregnancy test per standard MCC-VCUHS BMT Program guidelines,no-pregnancy-nursing
Women who are planning to become pregnant or breast feed during the trial,no-pregnancy-nursing
Women who are pregnant,no-pregnancy-nursing
Women who are pregnant and/or breastfeeding. Women of childbearing potential must have a negative serum or urine pregnancy test within 24 hours prior to the start of nivolumab.,no-pregnancy-nursing
Women who are pregnant and/or lactating.,no-pregnancy-nursing
Women who are pregnant are ineligible.,no-pregnancy-nursing
Women who are pregnant at Screening or prior to study drug administration.,no-pregnancy-nursing
Women who are pregnant or breast feeding,no-pregnancy-nursing
Women who are pregnant or breast feeding.,no-pregnancy-nursing
Women who are pregnant or breastfeeding,no-pregnancy-nursing
"Women who are pregnant or breastfeeding, or male or female patients of reproductive potential who are not employing two highly effective and acceptable forms of contraception throughout their participation in the study and for 90 days after last dose of study drug.",no-pregnancy-nursing
Women who are pregnant or breastfeeding.,no-pregnancy-nursing
Women who are pregnant or breast-feeding.,no-pregnancy-nursing
Women who are pregnant or breast-feeding. NOTE: A urine pregnancy test will be performed for women of child-bearing potential for Cohort A but will not be required for Cohort B as this is a registry only.,no-pregnancy-nursing
"Women who are pregnant or intending to become pregnant before, during, or within 6 months after the last dose of study drug; women who are breastfeeding; persons of childbearing potential and not willing to use a highly effective method of contraception.",no-pregnancy-nursing
Women who are pregnant or lactating,no-pregnancy-nursing
Women who are pregnant or lactating.,no-pregnancy-nursing
"Women who are pregnant or nursing (lactating), where pregnancy is defined as a state of a female after conception until the termination of gestation, confirmed by a positive serum hCG laboratory test of > 5 mIU/mL (See section on Pregnancy and Reproduction)",no-pregnancy-nursing
Women who are pregnant or nursing or plan to become pregnant or nurse during the course of the study.,no-pregnancy-nursing
"Women who are pregnant, are planning on becoming pregnant, or are breast-feeding.",no-pregnancy-nursing
"Women who are surgically sterile (ie, bilateral salpingectomy, bilateral oophorectomy, or complete hysterectomy) are eligible.",no-pregnancy-nursing
"Women who are unwilling, if not postmenopausal or surgically sterile, to abstain from sexual intercourse or employ highly effective contraception during the study drug administration period and for at least 30 days after the last dose of study drug. Men who are unwilling, if not surgically sterile, to abstain from sexual intercourse or employ highly effective contraception during the study drug administration period and for at least 90 days after the last dose of study drug. Refer to Section 9.6.1 for acceptable methods of contraception.",no-pregnancy-nursing
Women with a positive pregnancy test (serum assay) on enrollment or prior to pentamidine administration.,no-pregnancy-nursing
"Women: If you can have children, you must use a highly effective method of birth control and a barrier method, or sexual abstinence (which is defined as refraining from all aspects of sexual activity), while taking study treatment, as well as for 12 months after the last dose of rituximab.",no-pregnancy-nursing
"Women: Women of childbearing potential (WOCBP) must use a highly effective method of birth control and a barrier method, or sexual abstinence (which is defined as refraining from all aspects of sexual activity), while taking the study treatment, as well as for 12 months after the last dose of rituximab.",no-pregnancy-nursing
> 5% weight loss over the 28 days prior to consent or > 5% change in weight from consent to randomization.,notconsent
> New York Heart Association (NYHA) class II congestive heart failure at time of consent OR,notconsent
6 months have elapsed since completion of therapy prior to consent,notconsent
All acute toxic effects of any prior treatment have resolved to NCI-CTCAE v4.0 Grade 1 or less at the time of signing the Informed Consent Form (ICF).,notconsent
"All cancer treatments for another malignancy must be completed at least 3 years prior to study entry (i.e., signature date of the informed consent form).",notconsent
"Antiandrogens (e.g., bicalutamide, flutamide, nilutamide, abiraterone, enzalutamide) for > 2 months prior to consenting. Patients on 5-alpha reductase inhibitors are allowed on study.",notconsent
Are consented to the study by a protocol-specified designee who is not their longitudinal oncologist,notconsent
"Because the lists of these agents are constantly changing, it is important to regularly consult a frequently-updated list; medical reference texts such as the Physicians' Desk Reference may also provide this information; as part of the enrollment/informed consent procedures, the patient will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the patient is considering a new over-the-counter medicine or herbal product",notconsent
"Certain required laboratory values, performed within 14 days prior to consent",notconsent
Cognitively impaired patients who cannot give informed consent.,notconsent
Considered a potential transplant candidate; the attending/treating physician will determine transplant candidacy at the time of consent,notconsent
Endorsement of at least one sexual symptom (see Appendix A for eligibility screening),notconsent
Estrogen containing compounds for > 2 months prior to consenting,notconsent
"Evidence of other conditions that could interfere with subject's safety, obtaining informed consent or compliance to the study procedures, in the opinion of the investigator.",notconsent
Evidence of predominate small cell or neuroendocrine variant prostate cancer on standard of care metastatic biopsy within the past 8 weeks prior to signing consent,notconsent
"GnRH agonists or GnRH antagonists (e.g., leuprorelin, degarelix) for > 2 months prior to consenting",notconsent
"Had a prior 68Ga DOTATATE PET/CT scan (NetSpot) and a CT or MRI with or without contrast performed within 3 months before signing the consent, without interval treatment other than a somatostatin analog.",notconsent
"History of xyz positivity within 3 months prior to the date of informed consent for this study (if no test has been performed within 3 months, it must be done at screening)",notconsent
"In the phase II portion of the study, patients that have been previously treated with any systemic therapy for GIST are not permitted to enroll, with the exception of adjuvant imatinib systemic therapy or exposure to imatinib within 4 weeks of signing consent.",notconsent
Intravesical therapy within 6 weeks prior to consent (chemotherapy or immunotherapy including BCG administered directly into the bladder),notconsent
It may be initiated no more than 3 months prior to the signing of consent,notconsent
Participant is considered a legal adult by local regulation at the time of signing informed consent form (ICF).,notconsent
Participation in the treatment phase of another clinical trial within 3 months prior to consent,notconsent
"Pathologically (histologically or cytologically) proven diagnosis of HCC,(biopsies are recommended, and are to be submitted for research evaluation if patients consent)",notconsent
"Patient and his/her partner agree to use adequate contraception after providing written informed consent through 3 months after the last dose of TVB-2640, as follows:",notconsent
Patients 21 years or older scheduled for radical prostatectomy for the treatment of prostate cancer with one of the consenting surgeons at MSKCC.,notconsent
Patients are eligible if no formal unrelated donor search has been activated prior to date of consent. A formal unrelated donor search begins at the time at which samples are requested from potential National Marrow Donor Program (NMDP) donors. Patients who have started a sibling donor search or who have found a matched sibling donor are eligible.,notconsent
Patients must be enrolled on APEC14B1 and consented to Eligibility Screening on the Part A consent form prior to enrollment on AALL1131.,notconsent
Patients must have fewer than 20% marrow blasts within 60 days of consent.,notconsent
Patients must have worst pain rated as less than 4 out of 10 and should be completed within one week prior to registration,notconsent
"Patients must have worst pain rated as less than 4 out of 10 on the following question:  In the past week, how much pain have you had on a scale of 0 to 10, where 0 equals no pain and 10 means the worst pain you can imagine;   NOTE: This question regarding patient's pain should be completed within one week prior to registration; this pain item may be completed orally prior to consent up to 7 days prior to registration; it is not necessary to complete this pain item via the PROMIS website",notconsent
"Patients must receive an MRI/CT of the brain or PET/CT within 6 months of consenting. If new lesions are present, PI or his designee should make final determination regarding enrollment. (Turnstile I)",notconsent
Patients will be consented prior to the surgical evaluation/cytoreductive surgery. Patients must have less than or equal to 0.5cm residual disease at the completion of the secondary surgery to be eligible for the study.,notconsent
"Patients will be excluded if they have significant concurrent disease, illness, psychiatric disorder or social issue that would compromise patient safety or compliance with protocol treatment or required observations, interfere with consent, study participation, follow up, or interpretation of study results.",notconsent
Patients with impaired decision making capacity may participate in the study if a legal authorized representative is available to consent.,notconsent
Prior whole-lung or hemi-thorax irradiation of greater than 12 Gy received less than 6 months prior to consent (focal radiotherapy to the thorax is not an exclusion),notconsent
Subjects currently taking medications that are included in the contraindicated concurrent medications section of the Food and Drug Administration (FDA) approved indications for ketoconazole will be required to complete a seven day wash out period prior to consideration for enrollment.,notconsent
"Subjects should have a bone scan within (+/-) 4 months of signing of consent that is without evidence of metastasis. A questionable bone scan is acceptable if additional imaging studies (e.g., plain x-rays, CT, or MRI) do not confirm for metastasis.",notconsent
Subjects who are incarcerated within 6 months of signing informed consent will be excluded.,notconsent
"The benefits/risks of the induction chemotherapy regimen will be reviewed, and a second consent may be necessary if the regimen will be administered according to a separate protocol",notconsent
Use of neutropenic diet within 72 hours prior to consent,notconsent
Whole blood transfusions 120 days prior to signing consent,notconsent
"A change in antiretroviral therapy within 6 months of the start of screening (except if, after consultation with the sponsor on exclusion criterion 11.c, a change is made to avoid a potential drug-drug interaction with the study drug).",other
"A contrast-enhanced [diagnostic] CT, magnetic resonance imaging [MRI] or MRI-PET is acceptable in event that PET-CT is contraindicated, however the same modality must be utilized through the trial",other
"A core biopsy interpreted as invasive cancer meets this criterion; if no core biopsy is performed, the date of first histologic diagnosis will be the date of first surgical procedure that identifies invasive cancer (biopsy, lumpectomy or mastectomy).",other
Abdomen: CT scan with IV contrast (preferred); or MRI (acceptable),other
abdominal-pelvic(lymph node/adrenal gland),other
"Additional adjuvant chemotherapy after surgery is allowed at the discretion of the treating physician, either completed prior to randomization or planned for after completion of protocol treatment. If adjuvant chemotherapy is administered after mastectomy, the patient must be randomized at least 3 weeks but no more than 12 weeks after the last dose of adjuvant chemotherapy.",other
Agree to undergo a biopsy of at least one metastatic site to determine DNA repair defects. However:,other
"All patients must have completed neoadjuvant chemotherapy prior to mastectomy. The chemotherapy regimen is at the discretion of the treating physician but it is recommended that it include at least 4 cycles of anthracycline and/or taxane-based therapy (plus targeted therapy for patients with HER2+ disease). Response to chemotherapy is not a criterion for eligibility (both complete responders and those with residual disease are eligible). Please note that although pathologic complete response (pCR) is not required or excluded, pCR status must be determined post-surgery prior to randomization.",other
Body surface area (BSA) less than 0.85 m^2 if enrolling at dose level 1 or less than 0.53 m^2 if enrolling at dose level 2.,other
Brachial plexus previously irradiated to > 50 Gy (delivered in <= 3 Gy/fraction),other
Brainstem previously irradiated to > 50 Gy (delivered in <= 3 Gy/fraction),other
Breast MRI demonstrating a residual mass with rapid rise and washout type III kinetics.,other
"CA19-9 NOTE: in the event that a stent has been placed and biliary obstruction has been relieved, the CA19-9 should be drawn post stent placement",other
Candidate for low anterior surgical resection by laparoscopy or conventional open method,other
"Chest X-Ray, 2 view (or Chest CT, or positron emission tomography [PET]/CT) is required only if clinically indicated or recommended by NCCN guidelines.",other
"Clinically node negative patients undergoing mastectomy and sentinel lymph node biopsy (SLNB) with possible axillary lymph node dissection (ALND) if SLNB is positive. If ALND is performed during a separate operation, ARM procedure must be repeated. Clinically node negative is defined by:",other
Contraindication to both CT and MRI contrast agent.,other
Contraindication to MRI No contraindications to breast MRI,other
CYP2C8 substrates such as thiazolidinediones (glitazones) and select statins (because of expected inhibition of the metabolism of CYP2C8 substrates) by venetoclax,other
CYP2C9 substrates such as tolbutamide (because of expected inhibition of the metabolism of CYP2C9 substrates by venetoclax. It is recommended to exclude CYP2C9 substrates with a narrow therapeutic index such as phenytoin.,other
Dehydration (pre- and post-hydration is required to prevent serious renal dysfunction),other
During the intervention period.,other
Evidence for presence of inflammatory lesions and/or vasculitis on cerebral MRI.,other
"Females or males diagnosed with pathologically (histologically) proven invasive mammary carcinoma (ductal, lobular or other) of the breast who have undergone either mastectomy or lumpectomy with any type of axillary surgery or axillary sampling.",other
"For patients receiving neoadjuvant chemotherapy, clinical pre-chemo staging and post mastectomy pathological staging is required for all patients. Patients who have received neoadjuvant chemotherapy and are pathologically cT0-2 and N0 are only eligible if biopsy-proven clinically N1 or N2 disease is documented prior to the start of neoadjuvant chemotherapy. cT3N0 patients or ypT3N0 patients who receive neoadjuvant chemotherapy may be eligible based on clinical or pathological T stage, and do not require pathologically positive lymph nodes.",other
Has known current drug or alcohol abuse.,other
Having any condition that does not allow proper use of our imaging devices,other
History of known persistent proteinuria of CTCAE v5.0 grade 3 or higher ( >= 3.5 g/24 hrs).,other
History of severe asthma,other
History of severe asthma,other
"If a PET/CT is performed, a separate pancreas protocol CT is required for inclusion.",other
"If patient has splenomegaly present by palpation, spleen volume must be determined by MRI/CT at baseline.",other
"If present, prolymphocytes should be < 55%",other
"If the patient is to receive HCQ, pre-existing retinopathy",other
"If this will not be the first patient to receive a specific RT modality, the patient should be immediately randomized to Step 2 on the same day.",other
IMAGING CORRELATIVE STUDY,other
"IV contrast (e.g., CT and MRI) within 1 day [or 24 hours] of blood and/or stool collection.",other
"IV contrast (e.g., CT and MRI) within 1 day [or 24 hours] of blood collection.",other
Known alcohol or drug abuse.,other
liver,other
Mammogram in women,other
mediastinal/cervical lymph node,other
Metastasis irradiated with SBRT,other
Minimal neurologic symptoms,other
Must have had a nephrectomy (radical or partial) and must provide the cell block from the nephrectomy,other
"Must not have undergone any intervention for, or compromise of, the Ampulla of Vater",other
Need for ongoing therapeutic anticoagulation,other
osseous (bone),other
Patients are required to have no evidence of extrahepatic tumor (excluding tumor thrombus) by computed tomography (CT) or magnetic resonance imaging (MRI) scan,other
"Patients must have a whole body or limited whole body PET-CT scan performed within 42 days prior to registration. (A contrast-enhanced [diagnostic] CT, magnetic resonance imaging [MRI] or MRI-PET is acceptable in event that PET-CT is contraindicated, however the same modality must be utilized through the trial.) NOTE: All images from PET-CT, CT, MRI or MR-PET scans performed as standard of care to assess disease (within 42 days prior to registration) must be submitted and associated radiology reports must be submitted.",other
Patients must have complete history and physical examination within 28 days prior to registration.,other
"Patients must have had a bilateral mammogram or MRI within 12 months prior to registration, unless the initial surgery was a total mastectomy, in which case only a mammogram of the remaining breast is required. (Subjects with bilateral total mastectomies do not require imaging).",other
"Patients must have imaging of the chest/abdomen/pelvis, preferably with a computed tomography (CT) scan, and a bone scan within 4 weeks prior to randomization; (NOTE: if a patient is unable to receive CT contrast, a magnetic resonance imaging [MRI] of the abdomen/pelvis and non-contrast chest CT should be performed; positron emission tomography/computed tomography [PET/CT] is not an acceptable alternative).",other
"Patients must not have received prior WBRT (previous SRS/SRT done at least 4 weeks from the planned start of WBRT is acceptable). Patients planned upfront to undergo SRS/SRT/fractionated boosts or neurosurgery after WBRT are not eligible; however, these treatments/procedures can be performed once the DLT assessment has been completed, if felt clinically necessary.",other
Patients who undergo cystectomy with non-curative intent will be excluded.,other
"Patients with an implanted medical electronic device (e.g., cardiac pacemaker) remain eligible if device monitoring complies with standard of practice (e.g., Cardiology and Medical Physics evaluation, function checks and during-treatment monitoring).",other
"Planned ICU admission, abdominoperineal resection, exenteration, use of IORT, HIPEC.",other
Primary tumor irradiated with SBRT,other
"Protocol-mandated procedures (e.g., bone marrow biopsies) are permitted.",other
Radiographic evidence of major blood vessel invasion/infiltration. The degree of tumor invasion/infiltration of major blood vessels should be considered because of the potential risk of severe hemorrhage associated with tumor shrinkage/necrosis following lenvatinib therapy.,other
Requirement for hemodialysis or peritoneal dialysis.,other
Scheduled to undergo hysterectomy at Mayo Clinic.,other
"See Section 15.1 for further information, including specimen submission timepoints",other
See Section 7.1b for additional CT/MRI time points during treatment,other
Serum AFP levels of >= 100ng/mL and their non-cancerous liver tissue (if applicable) has <= 5% cells stained for AFP at any intensity by immunohistochemistry. Subjects with serum AFP levels within the normal range at the time of screening are unlikely to have AFP expressing tumors and generally should not undergo new tumor biopsy for the purpose of participating in this study.,other
"Small intestine, large intestine, or stomach previously irradiated to > 45 Gy (delivered in <= 3 Gy/fraction)",other
Sodium chloride,other
Spinal cord previously irradiated to > 40 Gy (delivered in <= 3 Gy/fraction),other
spine,other
subjects who are non-secretors will be considered on a case-by-case basis,other
"The proliferation rate, using Ki-67 or MIB-1 immunohistochemistry ( <= 30% versus > 30% versus indeterminate Ki-67 index), must be documented for a baseline tumor biopsy specimen.",other
"Tumor biopsy of new or growing or unresectable lesions demonstrating viable non-teratomatous GCT (enrollment in this study for adjuvant treatment after macroscopically complete resection of viable GCT is not allowed) In the event of an incomplete gross resection where viable GCT is found, patients will be considered eligible for the study.",other
"Unable to receive prophylactic treatment for pneumocystis, herpes simplex virus (HSV), or herpes zoster (VZV) at screening",other
Undergoing bilateral radiation,other
"Undergoing unilateral external beam radiotherapy at the Mayo Clinic - Rochester, MN or Mayo Clinic - Eau Claire, WI",other
"Viable, non-necrotic portion (arterial phase IV contrast-enhancing) that can be accurately measured at baseline as >= 10 mm in the longest diameter",other
Water for injections,other
"When CT of the chest, abdomen, and pelvis are performed, this must be with contrast per pancreas protocol. Imaging with a PET/MRI alone is acceptable on study.",other
Whole lung previously irradiated with prior V20Gy > 30% (delivered in <= 3 Gy/fraction),other
women already receiving screening breast MRIs,other
women who have been referred to genetic counseling,other
Women with a diagnosis of psychosis or severe dementia,other
Women with visual impairment,other
"A history of other malignancies (except non melanoma skin carcinoma, carcinoma in situ of the uterine cervix, non-invasive follicular thyroid neoplasm and papillary thyroid cancer) within 5 years prior to this breast cancer diagnosis.",othercancer
A malignancy except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.,othercancer
Active concurrent malignancies within the last five years other than colorectal primary except basal cell skin carcinoma and thyroid carcinoma.,othercancer
Active malignancies within 3 years except for those with a negligible risk of metastasis or death treated with expected curative outcome.,othercancer
"Active malignancy (except for RCC, definitively treated basal or squamous cell carcinoma of the skin, and carcinoma in-situ of the cervix or bladder) within the past 24 months. Participants with history of localized & low risk prostate cancer are allowed in the study if they were treated with curative intent and there is no prostate specific antigen (PSA) recurrence within the past 5 years",othercancer
Active malignancy other than ovarian cancer,othercancer
Active malignancy other than prostate cancer,othercancer
"Active malignancy within 5 years prior to current diagnosis except for in situ disease or cancer with very high curability rate (i.e. testicular cancer, etc.)",othercancer
"Active malignancy, other than NSCLC, for which systemic therapy is indicated. History of adequately treated local basal cell or squamous cell carcinoma of the skin, cervical carcinoma in situ, superficial bladder cancer, asymptomatic prostate cancer without known metastatic disease and with no requirement for therapy asides from hormonal therapy, adequately treated stage 1 or 2 cancer currently in complete remission, or any other cancer that has been in complete remission for >= 5 years is permitted.",othercancer
"Active malignancy, other than the one for which the allogeneic mPB transplant is being performed, within 12 months of enrollment, excluding superficial basal cell and carcinoma in situ cervical cancer",othercancer
active or untreated malignancy other than non-melanoma skin cancer,othercancer
Active second malignancy,othercancer
"Active secondary malignancy other than skin cancer (e.g., basal cell carcinoma or squamous cell carcinoma) that in the investigator's opinion will shorten survival to less than 1 year",othercancer
"additional, actively-treated malignancy or history of malignancy, except non-melanoma skin cancer",othercancer
"Another active malignancy <= 3 years prior to registration with the exception of non-melanotic skin cancer or carcinoma-in-situ of any type; NOTE: if there is a history of prior malignancy, they must not be receiving other specific treatment for their cancer; any malignancy considered to be indolent and that has never required therapy may allowed at the discretion of the protocol chair",othercancer
Another known malignancy other than breast cancer that is progressing or requires active treatment.,othercancer
Another primary malignancy that has not been in remission for at least 2 years. Non-melanoma skin cancer allowed.,othercancer
Any active malignancy except for non-melanoma skin cancer or in situ cervical cancer or treated cancer from which the patient has been continuously disease free for more than 5 years.,othercancer
Any concomitant or prior invasive malignancies with the following curatively treated exceptions:,othercancer
Any concurrent malignancy,othercancer
"Any cytotoxic chemotherapy, investigational agent or other anticancer drug(s) from a previous cancer treatment regimen or clinical study (other than EGFR TKI), within 14 days of the first dose of study treatment",othercancer
Any other active malignancy requiring systemic therapy,othercancer
"Any other cancer from which the patient has been disease-free for less than 5 years (except treated and cured basal-cell or squamous-cell skin cancer, superficial bladder cancer, or treated carcinoma in situ of the cervix, breast, or bladder and treated localized prostate cancer with undetectable PSA for 2 years).",othercancer
"Any other invasive cancer in the past 5 years, except basal cell skin",othercancer
Any other malignancy within last 3 years,othercancer
"Any other previous malignancies (except for cervical in situ cancers treated only by local excision, and basal and squamous cell carcinomas of the skin) within 5 years",othercancer
"Any prior history of invasive malignancy within the past 5 years except non-melanoma skin cancer, carcinoma in-situ, localized prostate cancer without biochemical recurrence following definitive treatment.",othercancer
"Co-existing or prior invasive malignancy (except non-melanomatous skin cancer), unless disease free for a minimum of 3 years; previous RT dose, date, fraction size, must be reported",othercancer
Concomitant invasive malignancy requiring treatment other than non-melanomatous skin cancer.,othercancer
"Concomitant malignancies or previous malignancies with less than a 1-year disease free interval at the time of signing consent. Potential participants with adequately resected basal or squamous cell carcinoma of the skin, or adequately resected carcinoma in situ (e.g., cervix) may enroll irrespective of the time of diagnosis.",othercancer
"Concomitant second malignancy except for non-melanoma skin cancer, and non-invasive cancer such as cervical CIS, superficial bladder cancer without local recurrence or breast CIS.",othercancer
Concurrent active malignancy other than non-melanoma skin cancer or carcinoma in situ of the cervix,othercancer
Concurrent active malignancy that requires systemic treatment.,othercancer
"Concurrent malignancy or malignancy within 3 years of randomization, with the exception of adequately treated basal cell carcinoma, squamous cell skin carcinoma, non-melanomatous skin cancer or curatively resected cervical cancer.",othercancer
"Concurrent malignancy other than cervical cancer and/or history of malignancy other than cervical cancer within 3 years of date of first planned dose of study drug (REGN2810 [cemiplimab] or IC chemo), except for tumors with negligible risk of metastasis or death, such as adequately treated cutaneous squamous cell carcinoma or basal cell carcinoma of the skin or ductal carcinoma in situ of the breast. Patients with hematologic malignancies (eg, chronic lymphocytic leukemia) are excluded.",othercancer
"Concurrent malignancy requiring active treatment with chemotherapy, immunotherapy, or radiation",othercancer
Concurrent malignancy.,othercancer
"Concurrent or previous other malignancy within 5 years of study entry with the exception of cured basal or squamous cell skin cancer, superficial bladder cancer, prostate intraepithelial neoplasm, carcinoma in-situ of the cervix, or other noninvasive or indolent malignancy.",othercancer
"Concurrent, active malignancies in addition to those being studied (other than cutaneous squamous cell carcinoma or basal cell carcinoma)",othercancer
"Criteria 5, History of other malignancy within the past 5 years prior to enrollment with some exceptions, as outlined in the protocol.",othercancer
"Current malignancy or history of a prior malignancy, as outlined in the protocol",othercancer
"Diagnosed or treated for another malignancy within 2 years of enrollment, with the exception of complete resection of basal cell carcinoma or squamous cell carcinoma of the skin, an in situ malignancy, or low-risk prostate cancer after curative therapy.",othercancer
"Diagnosed with or treated for another malignancy within 2 years before randomization, or previously diagnosed with another malignancy and have any evidence of residual, persistent, or recurrent disease. Participants with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection.",othercancer
Diagnosis of an invasive malignancy within 5 years (other than current prostate cancer or non-metastatic basal or squamous skin cancers or non-metastatic curatively treated papillary thyroid carcinoma).,othercancer
"Diagnosis of another malignancy within 2 years before first dose of study treatment, except for superficial skin cancers, or localized, low grade tumors deemed cured or with a prolonged natural history (e.g estimated overall survival > 5 years).",othercancer
Diagnosis of another malignancy within 2 years before first dose of study treatment.,othercancer
"Diagnosis of other malignancy within 2 years prior to enrollment except adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ of the bladder, breast, or cervix, or low grade (Gleason <= 6) prostate cancer",othercancer
"Diagnosis or treatment for another malignancy within 3 years of enrollment, with the exception of complete resection of basal cell carcinoma or squamous cell carcinoma of the skin, any in situ malignancy, or low-risk prostate cancer after curative therapy",othercancer
"Diagnosis or treatment for another systemic malignancy within 2 years before the first dose of study drugs, or previously diagnosed with another malignancy & have any evidence of residual disease. Potential participants with non-melanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection.",othercancer
"Disease free of prior malignancies for > 2 years with exception of currently treated basal cell, squamous cell carcinoma of the skin, or carcinoma ?in situ? of the cervix or breast",othercancer
"Disease free of prior malignancies for at least 5 years with exception of currently treated basal cell or squamous cell carcinoma of the skin, or carcinoma  in situ  of the uterus, cervix or breast.",othercancer
"Disease-free of active second/secondary or prior malignancies for >= 2 years with the exception of squamous cell carcinoma of the skin, or carcinoma in situ of the cervix or breast",othercancer
Does not have any other active malignancy other than the one for which this transplant is indicated.,othercancer
"Eligibility based on prior treatment with CIT depends on the mechanistic class of the drug and the cohort for which the participant is being considered, as described below. In addition, all criteria pertaining to adverse events attributed to prior cancer therapies must be met",othercancer
"Evidence of another malignancy, exclusive of a skin cancer that requires only local treatment",othercancer
Evidence of any other cancer within the past 5 years and < 50% probability of a 5 year survival. (Prior or concurrent diagnosis of basal cell or non-invasive squamous cell cancer of the skin is allowed).,othercancer
Evidence within 2 years of the start of study treatment of another malignancy which required systemic treatment except for cured nonmelanoma skin cancer or cured in situ cervical carcinoma,othercancer
"Exception: patients who have been disease-free for 3 years, or patients with a history of completely resected non-melanoma skin cancer and/or patients with indolent secondary malignancies, are eligible; consult the Cancer Therapy Evaluation Program (CTEP) Medical Monitor if unsure whether second malignancies meet the requirements specified above",othercancer
"Exceptions are limited exclusively to patients with the following previous malignancies, if adequately treated: basal or squamous cell carcinoma of the skin, in situ non-breast carcinoma, contra- or ipsilateral in situ breast carcinoma, stage Ia carcinoma of the cervix.",othercancer
For disease specific studies: the subject has had evidence within 2 years of the start of study treatment of another malignancy which required systemic treatment,othercancer
"For Part 2, active malignancies other than colorectal cancer.",othercancer
"Free of prior malignancies for greater than or equal to 5 years with exception of currently treated basal cell, squamous cell carcinoma of the skin, or carcinoma in situ of the cervix or breast.",othercancer
"Has a known additional malignancy that is active and/or progressive requiring treatment; exceptions include basal cell or squamous cell skin cancer, in situ cervical or bladder cancer, or other cancer for which the patient has been disease free for at least five years",othercancer
Has a known additional malignancy that is progressing or requires active treatment within 3 years from registration. Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer. Subjects with a history of prior malignancy diagnosed and treated greater than 3 years form registration may be considered with consultation of the primary investigator.,othercancer
Has a known additional malignancy that is progressing or requires active treatment; exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer,othercancer
"Has a known additional malignancy that progressed or required active treatment within the last five years. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer.",othercancer
Has any previous history of another malignancy (other than cured basal or squamous cell carcinoma of the skin or cured in situ carcinoma of the cervix or localized prostate cancer with normal prostate specific antigen) within three years of study enrollment.,othercancer
"Has history of a second malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 2 years",othercancer
Have a known additional malignancy that is progressing or required active treatment within the past 1 year.,othercancer
Have a previous history of invasive breast cancer who have completed treatment except for hormonal therapy,othercancer
"Have been diagnosed with another primary malignancy other than NSCLC, except for adequately treated non-melanoma skin cancer or cervical cancer in situ; definitively treated non-metastatic prostate cancer; or patients with another primary malignancy who are definitively relapse-free with at least 2 years elapsed since the diagnosis of the other primary malignancy",othercancer
"Have discontinued all previous cancer therapies (except nonsteroidal aromatase inhibitors for participants in Part B2), and any agents that have not received regulatory approval for any indication, for at least 21 days or 5 half lives prior to study enrollment, whichever is shorter, and recovered from the acute effects of therapy. Participants must have discontinued mitomycin-C or nitrosourea therapy for at least 42 days",othercancer
History of a different malignancy except for the following circumstances:,othercancer
History of a previous malignancy,othercancer
History of active malignancy; patients with a history of cancer that has been adequately treated and are free of disease recurrence for 3 years or more are allowed to participate; patients with non-melanoma skin cancers or carcinoma in situ of the bladder that have been adequately excised are eligible to participate,othercancer
"History of an active malignancy within the previous 5 years, except for locally curable cancers that have been apparently cured, such as low-grade thyroid carcinoma, prostate cancer not requiring treatment (Gleason grade <= 6), basal or squamous cell skin cancer, superficial bladder cancer, melanoma in situ, or carcinoma in situ of the prostate, cervix, or breast. Patients who have been free of other malignancies for >= 5 years prior to registration are eligible for this study.",othercancer
"History of an invasive malignancy (other than this prostate cancer, or basal or squamous skin cancers) in the last 5 years.",othercancer
"History of anal cancer, penile, vulvar, vaginal, or cervical cancer, or signs of any of these malignancies at baseline; participants with prior carcinoma in situ will not be considered to have prior cancer for eligibility purposes",othercancer
History of another malignancy except for:,othercancer
History of another malignancy within 3 years,othercancer
History of another malignancy within the past 2 years (some skin cancer and prostate cancers permitted),othercancer
History of another primary invasive malignancy that has not been definitively treated or in remission for less than 2 years,othercancer
History of another primary malignancy that has not been in remission for at least 3 years,othercancer
"History of another primary malignancy, leptomeningeal carcinomatosis and active primary immunodeficiency.",othercancer
History of any second malignancy in the last 5 years; subjects with prior history of in-situ cancer or basal or squamous cell skin cancer are eligible; subjects with other malignancies are eligible if they have been continuously disease free for at least 5 years,othercancer
History of colorectal cancer,othercancer
"History of invasive cancer in the last 3 years (except for appropriately treated low-rist prostate cancer, treated non-melanoma/melanoma skin cancer, appropriately treated ductal carcinoma in situ or early stage invasive carcinoma of breast and appropriately treated in-situ/early stage cervical/endometrial cancer)",othercancer
History of lung cancer,othercancer
"History of malignancy (other than MM) unless all treatment of that malignancy was completed at least 2 years before consent and the participant has no evidence of disease further exceptions are squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix, or breast, or other non-invasive lesion, that in the opinion of the investigator, with concurrence with the sponsor's medical monitor, is considered cured with minimal risk of recurrence within 3 years",othercancer
"History of malignancy other than breast cancer within 2 years prior to screening, with the exception of those with a negligible risk of metastasis or death",othercancer
"History of malignancy other than gastric or gastroesophageal junction carcinoma within 2 years prior to screening, with the exception of those with a negligible risk of metastasis or death",othercancer
"History of malignancy other than non-melanoma skin cancer or carcinoma in situ (e.g. cervix, bladder, breast) unless disease free for at least 3 years",othercancer
History of non-breast malignancies (except for in situ cancers treated only by local excision and basal cell and squamous cell carcinomas of the skin) within 5 years prior to study entry.,othercancer
"History of other cancer < 5 years prior to consent (except non-melanoma skin cancer or carcinoma in situ of the uterine cervix) or receiving other specific treatment for this cancer (monoclonal antibody, small molecule pathway inhibitor)",othercancer
"History of other clinically active malignancy within 5 years of enrollment, except for tumors with a negligible risk for metastasis or death, such as adequately controlled basal-cell carcinoma, adequately controlled, non-metastatic squamous-cell carcinoma of the skin, or carcinoma in situ of the cervix or breast.",othercancer
"History of other invasive malignancy that is currently active and/or has been treated within 12 months prior to enrollment (notable exceptions include: basal cell carcinoma, squamous cell carcinoma of the skin, localized prostate cancer, in situe carcinomas of the cervix and breast, and superficial bladder cancers [non-muscle invasive]).",othercancer
History of other malignancies (except for adequately treated basal or squamous cell carcinoma or carcinoma in situ) within the last 3 years.,othercancer
"History of other malignancies, except: adequately treated non-melanoma skin cancer or lentigo maligna , curatively treated in-situ cancer, or other solid tumors curatively treated with no evidence of disease for > 5 years following the end of treatment and which, in the opinion of the treating physician, do not have a substantial risk of recurrence of the prior malignancy.",othercancer
"History of other malignancy is permitted provided it has been definitively treated with no evidence of recurrence within the past 2 years (Exception: Definitively treated non-melanoma skin cancer, lobular cancer in situ, and cervical cancer in situ within 2 years are permitted). Cohort Specific Phase 1b Criteria (monotherapy and combination therapy)",othercancer
History of other malignancy within the past 2 years prior to first dose of AMG 757 with exceptions,othercancer
History of other primary malignancy requiring systemic treatment <= 3 years prior to registration; patients must not be receiving chemotherapy or immunotherapy for another cancer; patients must not have another active malignancy requiring active treatment; EXCEPTIONS: Non-melanotic skin cancer or carcinoma-in-situ of the cervix,othercancer
"History of previous cancer, except for squamous cell or basal-cell carcinoma of the skin, or any in situ carcinoma that has been completely resected, requiring therapy within the previous 2 years.",othercancer
"History of prior cancers except for those that have been curatively treated, with no evidence of cancer currently (provided all chemotherapy was completed > 6 months prior and/or bone marrow transplant > 2 years prior to first dose of rucaparib).",othercancer
History of prior malignancy except,othercancer
"History of prior malignancy other than ovarian that has not been in remission for > 5 years, with the exception of basal cell or squamous cell carcinoma or cervical carcinoma in situ on biopsy",othercancer
History of prior malignancy within 2 years that requires/ed treatment. Patients who are considered NED from a malignancy may be considered on a case by case basis.,othercancer
"History of prior malignancy. However, cancer survivors who have undergone potentially curative therapy may be considered for stem cell donation on a case-by-case basis. Risk/benefit of the transplant and the possibility of transmitting viable tumor cells at the time of transplantation will be discussed with the patient.",othercancer
"History of prior to concomitant malignancies (other than fully excised non-melanoma skin cancer, cured in situ cervical carcinoma, early stage bladder cancer or DCIS of breast) within 3 years of study entry",othercancer
"History of prior treated malignancies, other than breast cancer, that are now stable, are in remission, and do not require active therapy, are acceptable.",othercancer
"If subject has prior malignancy, must be without any evidence of disease of that prior malignancy for at least 2 years (excludes skin cancers that may have been excised within that 2 year period).",othercancer
"In patients with a prior history of invasive malignancy, less than five years in complete remission.",othercancer
Individuals with a history of a different malignancy are ineligible except for the following circumstances.,othercancer
"Individuals with a history of a different malignancy are ineligible except for the following circumstances. Individuals with a history of other malignancies are eligible if they have been disease-free for at least 3 years and are deemed by the investigator to be at low risk for recurrence of that malignancy. Individuals with the following cancers are eligible if diagnosed and treated within the past 3 years: cervical cancer in situ, and basal cell or squamous cell carcinoma of the skin.",othercancer
"Individuals with a history of a second malignancy are ineligible except for the following circumstances. Individuals with a history of other malignancies are eligible if they have been disease-free for at least 5 years and are deemed by the investigator to be at low risk for recurrence of that malignancy. Individuals with the following cancers are eligible if diagnosed and treated within the past 5 years: cervical cancer in situ, and non-melanoma cancer of the skin. Participants with other cancers diagnosed within the past 5 years and felt to be at low risk of recurrence should be discussed with the study sponsor to determine eligibility.",othercancer
individuals with a history of invasive malignancy are eligible if they have been disease-free for at least 2 years and are deemed by the investigator to be at low risk for recurrence of that malignancy,othercancer
"Individuals with a history of other malignancies are eligible if they have been disease-free for at least 3 years and are deemed by the investigator to be at low risk for recurrence of that malignancy, or",othercancer
Individuals with other active malignancies that require concurrent chemotherapy are ineligible,othercancer
Invasive malignancy or history of invasive malignancy other than disease under study within the last 2 years.,othercancer
known active invasive malignancy other than the lung cancer under therapy (non-melanoma skin cancer or carcinoma in situ of the cervix or bladder are exempted),othercancer
"Known additional malignancy that is progressing or has required active treatment within the past 3 years. Note: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (e.g. breast carcinoma, cervical cancer in situ) that have undergone potentially curative therapy are not excluded.",othercancer
Known additional malignancy that is progressing or requires active treatment,othercancer
"Known additional malignancy that is progressing or requires active treatment excepting basal cell carcinoma of the skin, squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer. A history of prostate cancer that was treated with definitive intent (surgically or through radiation therapy) is acceptable provided that the following criteria are met: Stage T2N0M0 or lower; Gleason score <= 7 and prostatic-specific antigen (PSA) undetectable for at least 1 year while off androgen deprivation therapy that was either treated with definitive intent or untreated in active surveillance that has been stable for the past year prior to study allocation",othercancer
"Known additional malignancy that progressed or required active treatment within the last 2 years. Exceptions include basal cell carcinoma of the skin, squamous cell cancer (SqCC) of the skin that has undergone potentially curative therapy, or in situ cervical cancer.",othercancer
"Known history of a hematologic malignancy, malignant primary brain tumor or malignant sarcoma, or of another malignant primary solid tumor (other than that under study), unless the patient has undergone potentially curative therapy with no evidence of that disease for 3 years.",othercancer
Known past or current malignancy other than the inclusion diagnosis.,othercancer
"Malignancies (other than AML) requiring active therapy or diagnosed within the last year, with the exception of non-melanoma skin cancer which can be treated or in situ malignancies (such as cervical, breast, prostate, etc.)",othercancer
"Malignancies other than breast cancer within 5 years prior to treatment initiation (except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, or Stage I uterine cancer)",othercancer
"Malignancies other than NSCLC within 5 years prior to randomization, with the exception of those with a negligible risk of metastasis or death treated expected curative outcome",othercancer
"Malignancies other than pancreatic carcinoma within 2 years prior to study start, with the exception of those with a negligible risk of metastasis or death treated with expected curative outcome (such as adequately treated carcinoma in situ of the cervix, basal or squamous cell skin cancer, localized prostate cancer treated surgically with curative intent, ductal carcinoma in situ treated surgically with curative intent)",othercancer
"Malignancies other than the disease under study <= 5 years prior to Cycle 1, Day 1, with the exception of those with a negligible risk of metastasis or death and with expected curative outcome (such as adequately treated carcinoma in situ of the cervix, basal or squamous cell skin cancer, localized prostate cancer treated surgically with curative intent, or ductal carcinoma in situ treated surgically with curative intent) or undergoing active surveillance per standard-of-care management (e.g., chronic lymphocytic leukemia Rai Stage 0, prostate cancer with Gleason score <= 6, and prostate-specific antigen [PSA] <= 10 mg/mL, etc.)",othercancer
"Malignancies other than the disease under study within 5 years prior to Cycle 1, Day 1, with the exception of those with a negligible risk of metastasis or death and with expected curative outcome (such as adequately treated carcinoma in situ of the cervix, basal or squamous cell skin cancer, localized prostate cancer treated surgically with curative intent, or ductal carcinoma in situ treated surgically with curative intent) or undergoing active surveillance per standard-of-care management (e.g., chronic lymphocytic leukemia Rai Stage 0, prostate cancer with Gleason score <= 6, and prostate-specific antigen [PSA] <= 10 mg/mL, etc.)",othercancer
"Malignancies other than urothelial cancer within 5 years prior to Cycle 1 Day 1, with the exception of those with a negligible risk of metastasis or death treated with expected curative outcome (such as adequately treated carcinoma in situ of the cervix, basal or squamous cell skin cancer, or ductal carcinoma in situ treated surgically with curative intent) or localized prostate cancer treated with curative intent and absence of prostate-specific antigen (PSA) relapse or incidental prostate cancer (T1/T2a, Gleason score <= 3 + 4, and PSA <= 0.5 ng/mL undergoing active surveillance and treatment naive)",othercancer
More than 5 years since prior invasive malignancy unless non melanoma skin cancer or in-situ cancer,othercancer
No active malignancy except for non-melanoma skin cancer or in situ cervical cancer or treated cancer from which the patient has been continuously disease free for more than 5 years.,othercancer
"No active prior malignancy within 3 years of registration (with the exception of non-melanoma skin cancer, in-situ cancers, or Rai stage 0 chronic lymphocytic leukemia [CLL]); if patient is disease free from a prior malignancy between 3-5 years, special consideration can be requested; in these cases, if the risk of recurrence at 5 years is less than 20%, and in the opinion of the investigator the prior malignancy will not affect the patient's outcome in light of newly diagnosed pancreatic cancer, the patient may be eligible; this will require principle investigator (PI) review and approval on a case by case basis, and approval will be documented in the medical record; all patients who have been disease free from a prior malignancy for at least 5 years will be eligible",othercancer
"No concurrent malignancy, except for nonmelanoma skin lesions",othercancer
No currently active second malignancy,othercancer
No evidence (within 5 years) of prior malignancies (except successfully treated basal cell or squamous cell carcinoma of the skin).,othercancer
No history of other cancer (except non-melanoma skin cancer or in situ breast cancer or cervix cancer) unless the tumor was successfully treated with curative intent at least 2 years before trial entry.,othercancer
No other active malignancies (other than treated non-melanoma skin cancer or treated in situ cancer) within the past year,othercancer
No other active malignancy,othercancer
No other active malignancy within 2 years.,othercancer
No other cancer in previous 2 years with the exception of non-invasive skin cancers,othercancer
No other malignancy within the past 5 years except for nonmelanoma skin cancer (the disease-free interval from any prior malignancy must be continuous),othercancer
"No other prior malignancy except adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or stage I or II cancer from which the patient is in complete remission for the past 5 years",othercancer
"No prior history of other malignancies within past 5 year (besides breast cancer as per 3.1.1). Individuals with the following cancers are eligible if diagnosed and treated within the past 5 years: ductal carcinoma in situ of the breast, cervical cancer in situ, and basal cell or squamous cell carcinoma of the skin. No concurrent malignancy or other serious medical condition as deemed by the investigator.",othercancer
"No prior malignancy allowed except cervical cancer in situ, adequately treated basal cell or squamous cell carcinoma of skin or treated low risk prostate cancer",othercancer
"No prior malignancy is allowed except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancers for which the patient has been disease-free for at least 5 years",othercancer
No prior malignancy is allowed except:,othercancer
"No prior or concurrent malignancy is allowed except for: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, localized or locally advanced prostate cancer definitively treated without recurrence or with biochemical recurrence only, or any other cancer fully treated or from which the subject has been disease-free for at least 2 years.",othercancer
No second malignancies other than non-melanoma skin cancers or cervical carcinoma in situ,othercancer
Or any other cancer from which the subject has been disease-free for 3 years.,othercancer
"Other active invasive malignancy; history of non-invasive malignancies such as ductal carcinoma in situ of the breast, non-melanomatous carcinoma of the skin, is allowed, as is history of other invasive malignancy that is in remission for >= 5 years after treatment with curative intent",othercancer
"Other active malignancies requiring oncologic treatment (Note: non-melanoma skin cancer, superficial bladder cancer etc. are eligible)",othercancer
Other active malignancy,othercancer
"Other active malignancy <= 5 years prior to pre-registration; EXCEPTIONS: non-melanotic skin cancer or carcinoma-in-situ of the cervix; NOTE: if there is a history or prior malignancy, they must not be receiving other specific treatment, i.e., other hormonal therapy, for their cancer",othercancer
Other active malignancy requiring concurrent intervention.,othercancer
Other active malignancy. Participants with history of prior malignancy treated with curative intent who achieved complete response (CR) more than 2 years before study entry are eligible. This exclusion rule does not apply to non?melanoma skin tumors and in?situ cervical cancer,othercancer
Other cancer for which the patient has been disease free for >= 3 years.,othercancer
"Other invasive malignancy <= 5 years prior to registration. Exceptions are colonic polyps, non-melanoma skin cancer, ductal carcinoma in situ, bladder carcinoma in situ, or carcinoma-in-situ of the cervix.",othercancer
"Other malignancies diagnosed within the past five years (other than curatively treated cervical cancer in situ), non melanoma skin cancer, superficial bladder tumors Ta (non invasive tumor) and TIS (carcinoma in situ)",othercancer
Other malignancies within the past 3 years except for adequately treated carcinoma of the cervix or basal or squamous cell carcinomas of the skin.,othercancer
"Other malignancies, either currently active or diagnosed in the last 5 years, except for adequately treated in situ carcinoma of the cervix and basal or squamous cell skin carcinoma",othercancer
Other malignancy requiring systemic therapy within the last 3 years (except non melanoma skin cancer or low-grade superficial bladder cancer),othercancer
"Other malignancy within the last 5 years except for the following, which are permitted:",othercancer
"Other malignancy, except non-melanoma skin cancer, that is active or has a >= 30% probability of recurrence within 12 months",othercancer
Part II: Individuals with a history of a different malignancy are ineligible except for the following circumstances:,othercancer
Participant has or has had other cancer(s) within 3 years of study,othercancer
"Participant has prior malignancies, except lobular breast carcinoma in situ, fully resected basal cell or squamous cell carcinoma of skin or treated cervical carcinoma in situ.",othercancer
Participants must not have a current or prior invasive malignancy within the past 6 months,othercancer
"Participants with a history of a second primary malignancy. Exceptions include: patients with a history of malignancies that were treated curatively and have not recurred within 3 years prior to study entry; resected basal and squamous cell carcinomas of the skin, and completely resected carcinoma in situ of any type.",othercancer
Participants with concomitant or previous malignancies within the last 5 years are excluded from the study.,othercancer
Participants with current or previous history of invasive breast cancer.,othercancer
Participants with history of breast cancer in the past 5 years.,othercancer
Participants with history of prior malignancy treated with curative intent who achieved complete response (CR) more than 2 years before study entry are eligible,othercancer
Participants with known additional malignancy that is progressing or required active treatment within the last 2 years,othercancer
Participants with presence of other active malignancy within 2 years of study entry,othercancer
Patient has a concurrent invasive malignancy or a prior invasive malignancy whose treatment was completed within 2 years before PICF signature,othercancer
"Patient has a concurrent malignancy or malignancy within 3 years prior to Cycle 1 Day 1, with the exception of adequately treated basal or squamous cell carcinoma or curatively resected cervical cancer.",othercancer
"Patient has a history of another malignancy within 2 years prior to starting study treatment, except for cured basal cell carcinoma of the skin or excised carcinoma in situ of the cervix",othercancer
"Patient has a known presence or history of malignancy of other organ system within the 5 years before study start, with the exception of non-melanoma skin cancer; very low or low-risk prostate cancer; or patients who have been disease free for at least 2 years following stage 1 or 2 cancer",othercancer
Patient must not have a concurrent active malignancy for which they are receiving treatment,othercancer
"Patient with other malignancy that contains a non-synonymous mutation, insertion, or deletion in the TP53 gene determined previously or at screening",othercancer
patients are not considered to have a  currently active  malignancy if they have completed therapy for a prior malignancy and disease free from prior malignancies for > 2 years,othercancer
Patients being actively treated for a secondary malignancy,othercancer
Patients diagnosed or treated for malignancy other than HCC are not eligible unless they meet one of the following exceptions:,othercancer
Patients may not have a  currently active  second malignancy other than non-melanoma skin cancers. Patients are not considered to have a  currently active  malignancy if they have completed therapy and are considered by their physician to be at less than 30% risk of relapse.,othercancer
Patients must not have other active malignancies other than non-melanoma skin cancers or superficial bladder cancer; subjects with a history of other cancers who have been adequately treated and have been recurrence-free for >= 3 years are eligible,othercancer
Patients must not have received treatment for another malignancy within 3 years of enrollment,othercancer
Patients receiving any other standard or investigational treatment for their hematologic malignancy other than supportive care,othercancer
Patients receiving palliative radiation are eligible for this study. Palliative radiation is allowed during treatment as well. Patients with a known additional malignancy that is progressing or requires active treatment within the past 5 years are excluded. Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer.,othercancer
Patients who have a history of another primary malignancy unless the patient has been disease free for >= 3 years,othercancer
"Patients who have a history of other malignancies except for basal cell or squamous cell skin cancer, in situ cervical cancer, unless they have been disease-free for at least three years. Patients may have dual primaries of ovarian and endometrial cancer, superficial bladder, or localized prostate cancer.",othercancer
Patients with a  currently active  second invasive malignancy other than non-melanoma skin cancers. Patients are not considered to have a  currently active  malignancy if they have completed therapy and have been free of disease for >= 1 years.,othercancer
Patients with a history of any malignancy are ineligible except for the following circumstances:,othercancer
Patients with a history of invasive breast cancer,othercancer
Patients with a history of invasive second malignancy who are disease free for > 2 years.,othercancer
"Patients with a history of malignancy who have been adequately treated and have been disease-free for at least 1 year, and",othercancer
Patients with a history of prior malignancy within 5 years of study entry with the exception of curatively treated non-melanomatous skin cancer or carcinoma in situ of the cervix or breast,othercancer
Patients with a known concurrent malignancy that is progressing or requires active treatment; exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or carcinoma in situ of the cervix,othercancer
Patients with a malignancy other than that of epithelial origin,othercancer
"Patients with a prior history of a second malignancy are eligible provided they have been treated with curative intent and have been free of disease greater than three years. There will be no exclusion for patients with a history of basal cell carcinoma, squamous cell skin cancer, superficial bladder cancer, or other in situ carcinoma that has been adequately treated.",othercancer
"Patients with a second, clinically active, cancer. Patients with second cancers which have been treated with curative intent and/or are currently inactive are allowed.",othercancer
Patients with another active malignancy that requires treatment excluding non-melanoma skin cancers,othercancer
Patients with another active malignancy will not be eligible except for:,othercancer
"Patients with any concurrent active malignancies as defined by malignancies requiring any therapy other than expectant observation or hormonal therapy, with the exception of squamous and basal cell carcinoma of skin",othercancer
"Patients with any evidence of another malignancy within the last five years (except non-melanoma skin cancer) Patients with a known sensitivity to cisplatin, Mitomycin C, or Adriamycin. Patients with significant co-morbid medical conditions that would prevent the patient from completing treatment on this protocol, per Investigator discretion.",othercancer
Patients with any other concomitant or prior invasive malignancies are ineligible. Patients with prior history of pneumonitis and/or interstitial lung disease will be excluded.,othercancer
Patients with any prior history of lung cancer may not participate in this study.,othercancer
"Patients with evidence of another malignancy, exclusive of a skin cancer that requires only local treatment, should not be enrolled on this protocol",othercancer
Patients with history of other cancers should be free of disease for at least 2 years,othercancer
"Patients with history of second malignancies in remission may be eligible if there is clinical evidence of disease stability off cytotoxic chemotherapy, documented by imaging, tumor marker studies, etc., at screening",othercancer
"Patients with other active malignancies are ineligible for this study, other than localized malignancies",othercancer
"Patients with other active, current primary malignancies, other than carcinoma in situ of the cervix or non-melanoma skin cancer",othercancer
Patients with other cancer types must have received at least one prior cancer therapy,othercancer
"Patients with other documented malignancies within past year aside from synchronous or metachronous multiple cancers with a disease-free period of <= 5 years (excluding carcinoma in situ, mucosal carcinoma, or other such carcinomas curatively treated with local therapy)",othercancer
Patients with other malignancies are not eligible,othercancer
"Patients with previous malignancies (except non-melanoma skin cancers, and the following in situ cancers: bladder, gastric, colon, cervical/dysplasia, melanoma, or breast) are excluded unless definitive therapy has been completed at least 1 year prior to study entry and the patient is now without evidence of disease from that malignance and no additional therapy is required or anticipated to be required during the study period.",othercancer
"Patients with prior cancers, except: those diagnosed >= 5 years ago with no evidence of disease relapse and clinical expectation of relapse of less than 5%; prior successfully treated Level 1 cutaneous melanomas >= 2 years ago; or non-melanoma skin cancer; or carcinoma in situ of the cervix",othercancer
"Patients with prior malignancies, including pelvic cancer, are eligible if they have been disease free for > 5 years; patients with prior in situ carcinomas are eligible provided there was complete removal",othercancer
Patients with second primary cancer (exceptions defined in the protocol).,othercancer
"Persons having colorectal disease (e.g., ulcerative colitis or colectomy), personal history of colorectal cancer or colorectal disease, end-stage or life threatening diseases or, those known to be under hospice care or living in a skilled nursing facility may be excluded.",othercancer
PRE-REGISTRATION: Active malignancy (other than melanoma) or malignancy <= 3 years prior to pre-registration.,othercancer
Presence of active malignancy other than disease under study,othercancer
Presence of concomitant malignancy requiring chemotherapy or any malignancy (except basal and squamous cell carcinoma of the skin) for which the patient received chemotherapy within 6 months prior to enrollment,othercancer
"Presence of other active cancers; patients with stage I cancer who have received definitive local treatment within the last 3 years, and whom are considered unlikely to recur, are eligible; all patients with previously treated in-situ carcinoma (i.e., non-invasive) are eligible, as are patients with prior non-melanoma skin cancers",othercancer
"Previous malignancies (except non-melanoma skin cancers, and in situ bladder, gastric, colorectal, endometrial, cervical/dysplasia, melanoma, or breast cancers) unless complete remission was achieved at least 2 years prior to study entry and no additional therapy is required during the study period.",othercancer
Previous malignancy (except for non-melanomatous skin cancer) < 5 years,othercancer
Previous malignancy confined and surgically resected (or treated with other modalities) with curative intent,othercancer
"Previous malignancy within 2 years of the first dose of derazantinib, except curatively treated or low grade malignancies such as non-melanoma skin cancer, carcinoma in-situ of the breast, cervix, and superficial bladder tumors",othercancer
"Previous malignancy, other than basal cell or squamous cell carcinoma of the skin or in situ carcinoma of the cervix, from which the patient has been disease free for less than 5 years",othercancer
Previous malignant disease (other than the target malignancy to be investigated in this study) within the last 3 years,othercancer
Previous malignant disease being disease-free for less than 5 years (except carcinoma in situ (CIS) of the cervix and non-melanoma skin cancer).,othercancer
Previous or concurrent malignancy (excluding non-basal cell carcinoma of skin or carcinoma in situ of the uterine cervix) unless the tumor was treated with curative intent more than 2 years prior to study entry,othercancer
Previous or concurrent malignancy with the following exceptions:,othercancer
"Previously untreated or concurrent cancer that is distinct in primary site or histology except cervical cancer in-situ, treated ductal carcinoma in situ of the breast, curatively treated non-melanoma skin carcinoma, noninvasive aerodigestive neoplasms or superficial bladder tumor",othercancer
"Prior active malignancy within the previous 3 years except for locally curable cancers such as basal or squamous skin cancer, superficial bladder, low risk prostate cancer, breast, or cervix cancer. If other prior malignancy was active within prior 3 years, enrollment requires approval of a principal investigator.",othercancer
prior cancer at other sites (including most of oral cavity) or larynx are not exclusions,othercancer
Prior cancer treatment must be completed at least 28 days or 5 half-lives (whichever is shorter) prior to first dose of study drug. Subjects must have recovered from all reversible acute toxic effects of the regimen (other than alopecia) to <= Grade 1 or baseline.,othercancer
Prior history of another malignancy with a life expectancy of < 3 years.,othercancer
"Prior history of any other malignancy within the last 2 years, other than skin basal cell or cutaneous superficial squamous cell carcinoma that has not metastasized and superficial bladder cancer.",othercancer
Prior history of breast cancer; prior DCIS is allowable as long as participant is not taking endocrine therapy and has at least 1 breast that has not been irradiated.,othercancer
Prior history of invasive breast cancer,othercancer
"Prior history of invasive cancer within 5 years of study entry or history of metastatic cancer; exceptions include non-metastatic, curatively treated basal and squamous cell carcinoma of the skin",othercancer
"Prior history of invasive HPV-related anogenital cancer (cervical, vaginal, vulvar, penile, or anal cancer), or oropharyngeal cancer (base of tongue, tonsil); prior cancer at other sites (including most of oral cavity) or larynx are not exclusions",othercancer
Prior history of invasive malignancy within the last 2 years,othercancer
"Prior history of malignancies, other than MM, unless the subject has been free of the disease for more than 5 years. Allowed exceptions include the following:",othercancer
"Prior history of other malignancy, provided that he/she has been free of disease for >= 3 years, with the exception of in-situ carcinoma of the cervix or completely resected basal cell carcinoma of the skin.",othercancer
"Prior invasive malignancy (except non-melanomatous skin cancer, curatively resected thyroid papillary carcinoma, and invasive and non-invasive cancers related to the breast cancer) unless disease free for a minimum of 3 years",othercancer
Prior invasive malignancy of other histology currently requiring treatment.,othercancer
"Prior invasive malignancy unless disease free for a minimum of 3 years (oral cavity, or non-melanomatous skin cancer are all permissible)",othercancer
"Prior invasive malignancy, except non-melanoma skin cancer, carcinoma in-situ of the bladder or head and neck region, unless disease free for a minimum of 2 years",othercancer
"Prior malignancies (except non-melanoma skin cancers, and the following in situ cancers: bladder, gastric, colon, endometrial, cervical/dysplasia, melanoma, or breast) unless a complete remission was achieved at least 2 years prior to study entry.",othercancer
Prior malignancies within 3 years of registration (with the exception of non- melanomatous skin cancer),othercancer
Prior malignancies.,othercancer
Prior malignancy (except non melanoma skin cancer) within 3 years,othercancer
"Prior malignancy (including invasive or ductal in-situ breast cancer) within 5 years prior to randomization, except curatively treated basal cell carcinoma of the skin and carcinoma in situ of the cervix.",othercancer
"Prior malignancy <= 5 years prior to registration (except non-melanotic skin cancer or carcinoma-in-situ of the cervix) (must be disease free for a minimum of 5 years); if there is a history of prior malignancy, patient must not be receiving other specific treatment (other than hormonal therapy) for cancer",othercancer
"Prior malignancy active within the previous 2 years except for locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer or carcinoma in situ of the cervix, breast, or prostate cancer.",othercancer
Prior malignancy active within the previous 3 years except for locally curable cancers that have been apparently cured.,othercancer
"Prior malignancy active within the previous year except for locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer or carcinoma in situ of the cervix, breast, or prostate cancer.",othercancer
Prior malignancy completely excised or removed and patient has been continuously disease free for > 5 years OR,othercancer
"Prior malignancy except for the following: adequately treated basal cell or squamous cell skin cancer, in-situ cervical cancer, thyroid cancer (except anaplastic) or any cancer from which the patient has been disease-free for 2 years",othercancer
Prior malignancy requiring therapy within the last 12 months (excluding non-melanoma skin cancer,othercancer
"Prior malignancy, with the exception of curatively treated squamous cell or basal carcinoma of the skin or in situ cervical cancer, unless there is a 3-year disease-free interval",othercancer
"Prior or concurrent known additional malignancy of any site unless disease free for 5 years. Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer, Stage T1a well differentiated prostatic carcinoma in men (Gleason = 3+3, PSA < 5)",othercancer
"Prior or concurrent malignancy except for: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, localized or locally advanced prostate cancer definitively treated without recurrence or with biochemical recurrence only, or any other cancer fully treated or from which the subject has been disease-free for at least 2 years.",othercancer
Research participants with presence of other active malignancy,othercancer
"Second malignancy unless in remission for 2 years, except for non-melanomatous skin cancer, carcinoma in situ of the cervix treated with curative intent.",othercancer
Second primary malignancy that has not been in remission for greater than 3 years. Exceptions that do not require a 3-year remission include: non-melanoma skin cancer; cervical carcinoma in situ on biopsy or squamous intraepithelial lesion on Papanicolaou (PAP) smear; localized prostate cancer (Gleason score < 6); or resected melanoma in situ.,othercancer
"Second primary malignancy, other than in situ malignancies or adequately treated basal cell carcinoma of the skin or other malignancy treated at least 2 years previously with no evidence of recurrence",othercancer
Secondary cancer diagnosis within the past 5 years.,othercancer
"STEP I: Patients with a history of prior malignancy are eligible provided they were treated with curative intent and do not require active therapy (currently treated basal cell, squamous cell carcinoma of the skin, or carcinoma ?in situ? of the cervix or breast are not excluded)",othercancer
"Subject has a history of other malignancies within 2 years prior to study entry, with exceptions as described in the protocol.",othercancer
"Subject has history of another malignancy within 3 years before the first dose of study drug, or any evidence of residual disease from a previously diagnosed malignancy. Subjects with nonmelanoma skin cancer, localized prostate cancer treated with curative intent with no evidence of progression, low-risk or very low-risk (per standard guidelines) localized prostate cancer under active surveillance/watchful waiting without intent to treat, or carcinoma in situ of any type (if complete resection was performed) are allowed.",othercancer
"Subject has other serious medical illness, including a second malignancy, or psychiatric illness that could, in the Investigator's opinion, potentially interfere with the completion of treatment according to this protocol.",othercancer
"Subject has prior malignancies, except resected basal cell carcinoma or treated cervical carcinoma in situ. Cancer treated with curative intent >= 5 years previously will be allowed. Cancer treated with curative intent < 5 years previously will not be allowed.",othercancer
"Subjects with a second malignancy or any other cancer at least 3 years following definitive treatment with no evidence of disease, except for adequately treated basal cell or squamous cell skin cancer.",othercancer
Subjects with second malignancies in addition to myeloma if the second malignancy has required therapy in the last 3 years or is not in complete remission,othercancer
the only prior malignancy was cervical cancer in situ and/or basal cell or squamous cell carcinoma of the skin,othercancer
The patient has a history of prior malignancy but has been disease free for < 2 years prior to enrollment,othercancer
"The patient has an active second malignancy other than curatively resected basal cell or squamous cell carcinoma of the skin, in situ carcinoma of the bladder, or other cancers for which they are treated with curative intent with no active disease in the 3 years prior to enrollment.",othercancer
Acute pancreatitis with elevation of amylase OR lipase >= 3x the upper limit of normal AND at least 1 of: abdominal pain consistent with acute pancreatitis OR imaging findings consistent with acute pancreatitis.,pancreatitits
"Adult patients with benign pancreas disorders such as pancreatitis with imaging within 12 months (CT, MRI, EUS) documenting no cancer.",pancreatitits
"Clinical or laboratory evidence of pancreatitis, based on discretion of treating physician.",pancreatitits
Current or past history of pancreatitis,pancreatitits
Evidence of clinically significant pancreatitis as determined by the investigator,pancreatitits
Has a history of acute or chronic pancreatitis,pancreatitits
Has acute pancreatic abnormalities (acute pancreatitis or trauma).,pancreatitits
Have a history of >= Grade 3 pancreatitis.,pancreatitits
History of >= Grade 2 pancreatitis,pancreatitits
History of acute or chronic pancreatitis,pancreatitits
History of acute pancreatitis within 1 year of screening or past medical history of chronic pancreatitis,pancreatitits
History of acute pancreatitis within 1 year of screening or past medical history of pancreatitis,pancreatitits
History of acute pancreatitis within 1 year of study entry or history of chronic pancreatitis,pancreatitits
History of acute pancreatitis within 1 year of study or history of chronic pancreatitis.,pancreatitits
History of acute pancreatitis within 1 year of study screening or history of chronic pancreatitis.,pancreatitits
History of acute pancreatitis within 6 months prior to screening,pancreatitits
History of chronic pancreatitis.,pancreatitits
History of diverticulitis or pancreatitis within 12 weeks of registration,pancreatitits
History of pancreatitis,pancreatitits
History of pancreatitis.,pancreatitits
"History of recent clinical pancreatitis, according to revised Atlanta criteria, within 3 months of randomization.",pancreatitits
Known history of acute or chronic pancreatitis,pancreatitits
Known history of acute or chronic pancreatitis (history of acute pancreatitis with no recurrent events in the prior 24 months are permitted),pancreatitits
Known history of acute or chronic pancreatitis <= 6 months prior to registration/randomization,pancreatitits
Known history of acute or chronic pancreatitis.,pancreatitits
No radiologic or clinical evidence of pancreatitis,pancreatitits
Pancreatitis that is active or within the preceding 3 months which in the judgment of the endoscopist would make tumor injection likely to trigger severe recurrent pancreatitis.,pancreatitits
"Participants with a history of acute pancreatitis, chronic pancreatitis, or any ongoing pancreatic disease not considered related to ALL.",pancreatitits
Participants with clinical or radiographic evidence of pancreatitis are excluded,pancreatitits
"Patient has not recovered (i.e, still at > Grade 1) from drug-induced pancreatitis or has a history of drug-induced pancreatitis.",pancreatitits
Patient must not have acute pancreatitis or a history of chronic pancreatitis,pancreatitits
"Patients with active or chronic pancreatitis based on lipase elevation, symptoms, and radiographic findings",pancreatitits
Patients with acute pancreatitis in the immediate 2 weeks prior to the procedure.,pancreatitits
Patients with chronic pancreatitis,pancreatitits
Predisposing characteristics for acute pancreatitis in the last month prior to randomization.,pancreatitits
Prior episode of pancreatitis.,pancreatitits
Prior pancreatitis that was symptomatic or required medical intervention <= 6 months prior to registration (known toxicity of pembrolizumab),pancreatitits
The patient has a history of pancreatitis.,pancreatitits
An Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1 (Appendix C).,perfstatus
An ECOG performance status of 2,perfstatus
"An ECOG performance status score of <= 1 for Cohort 1, or <= 2 for Cohort 2.",perfstatus
Eastern Collaborative Oncology Group (ECOG) performance status of 0-1,perfstatus
Eastern Cooperative Oncology Group (ECOG) 0-1.,perfstatus
Eastern Cooperative Oncology Group (ECOG) performance score of 0 or 1,perfstatus
Eastern Cooperative Oncology Group (ECOG) performance score of 0-2.,perfstatus
"Eastern Cooperative Oncology Group (ECOG) performance status (ECOG performance status [PS]) of 0, 1 or 2",perfstatus
Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) <= 2 (Appendix I).,perfstatus
Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1,perfstatus
Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 or 1 (Appendix 1).,perfstatus
Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1.,perfstatus
"Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1 or 2",perfstatus
"Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1, 2",perfstatus
"Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1, 2.",perfstatus
"Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1, or 2 at registration.",perfstatus
"Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, or 1",perfstatus
Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0-1,perfstatus
Eastern Cooperative Oncology Group (ECOG) performance status (PS) of <= 2.,perfstatus
"Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0, 1, or 2",perfstatus
Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-1.,perfstatus
Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 3 or 4,perfstatus
Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0 or 1 at enrollment.,perfstatus
Eastern Cooperative Oncology Group (ECOG) performance status <= 1.,perfstatus
Eastern Cooperative Oncology Group (ECOG) performance status <= 2 (Karnofsky >= 60%).,perfstatus
Eastern Cooperative Oncology Group (ECOG) performance status <= 2 and minimum life expectancy of at least 4 weeks,perfstatus
Eastern Cooperative Oncology Group (ECOG) performance status <= 2.,perfstatus
Eastern Cooperative Oncology Group (ECOG) performance status 0 - 1.,perfstatus
Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 (Appendix F),perfstatus
Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 (Karnofsky >= 80%),perfstatus
"Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 on Day 1 of Cycle 1 (see Appendix C, ECOG Performance Status).",perfstatus
Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.,perfstatus
"Eastern Cooperative Oncology Group (ECOG) Performance Status 0 to 1 and adequate bone marrow, renal, and liver functions.",perfstatus
"Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2",perfstatus
"Eastern Cooperative Oncology Group (ECOG) Performance Status 0, 1, or 2.",perfstatus
Eastern Cooperative Oncology Group (ECOG) performance status 0-1,perfstatus
Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1 or Karnofsky Performance Status 70-100.,perfstatus
Eastern Cooperative Oncology Group (ECOG) performance status 0-1.,perfstatus
Eastern Cooperative Oncology Group (ECOG) performance status 0-2,perfstatus
Eastern Cooperative Oncology Group (ECOG) performance status 0-2 (Appendix A),perfstatus
Eastern Cooperative Oncology Group (ECOG) performance status 0-2 assessed within 90 days of enrollment,perfstatus
"Eastern Cooperative Oncology Group (ECOG) performance status and/or other performance status 0, 1, or 2",perfstatus
Eastern Cooperative Oncology Group (ECOG) Performance Status from 0 (asymptomatic) to 3 (symptomatic and in bed > 50% of the day),perfstatus
Eastern Cooperative Oncology Group (ECOG) Performance Status grade 0 or 1 or Karnofsky performance status >= 70 (Appendix 6),perfstatus
"Eastern Cooperative Oncology Group (ECOG) Performance Status grade of 0, 1, or 2.",perfstatus
Eastern Cooperative Oncology Group (ECOG) performance status of <= 1,perfstatus
Eastern Cooperative Oncology Group (ECOG) performance status of <= 1.,perfstatus
Eastern Cooperative Oncology Group (ECOG) performance status of <= 2 (Appendix F),perfstatus
Eastern Cooperative Oncology Group (ECOG) Performance Status of <= 2.,perfstatus
Eastern cooperative oncology group (ECOG) performance status of 0 or 1,perfstatus
Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 9. Subjects must have at least one previously irradiated tumor lesion that can be measured by RECIST v1.1.,perfstatus
"Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 Amendment 4, 11 June 2018",perfstatus
Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.,perfstatus
Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1,perfstatus
Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.,perfstatus
Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2,perfstatus
"Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2 (Appendix 6)",perfstatus
"Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2 (see Appendix B)",perfstatus
Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.,perfstatus
Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1.,perfstatus
Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 to 1 (See Appendix 5 for definitions).,perfstatus
"Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1 or 2.",perfstatus
"Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1, or 2.",perfstatus
Eastern Cooperative Oncology Group (ECOG) performance status: 0-2,perfstatus
Eastern Cooperative Oncology Group (ECOG) PS of 0 to 1 at study entry and Day 1 of treatment with M7824.,perfstatus
Eastern Cooperative Oncology Group (ECOG) PS of 0 to 1.,perfstatus
Eastern Cooperative Oncology Group (ECOG) status of 0-2.,perfstatus
Eastern Cooperative Oncology Group (ECOG) status of 1 or 0.,perfstatus
Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1.,perfstatus
Eastern Cooperative Oncology Group performance status 0 to 1.,perfstatus
Eastern Cooperative Oncology Group performance status of 0 to 2,perfstatus
ECOG (Zubrod) Performance Status 0-1,perfstatus
ECOG performance score 0-3,perfstatus
ECOG performance score of 0 or 1.,perfstatus
ECOG Performance Status (PS) 0,perfstatus
ECOG Performance Status (PS) 0 or 1 (Appendix I).,perfstatus
ECOG Performance Status (PS) 0 or 1 (form is available on the ACCRU web site).,perfstatus
ECOG Performance Status (PS) 0 or 1.,perfstatus
"ECOG Performance Status (PS) 0, 1 or 2 (Appendix II).",perfstatus
"ECOG Performance Status (PS) 0, 1 or 2.",perfstatus
"ECOG Performance Status (PS) 0, 1, or 2 (Appendix A)",perfstatus
"ECOG Performance Status (PS) 0, 1, or 2 (Appendix I) at registration.",perfstatus
"ECOG performance status (PS) 0, 1, or 2 (see Appendix I).",perfstatus
"ECOG performance status (PS) 0, 1, or 2.",perfstatus
"ECOG Performance Status (PS) 0, 1.",perfstatus
"ECOG performance status (PS) 0, or 1 (Appendix I).",perfstatus
ECOG Performance Status (PS) of 0 or 1).,perfstatus
ECOG performance status (PS) of 0 or 1.,perfstatus
"ECOG performance status (PS) of 0, 1, or 2.",perfstatus
"ECOG Performance Status (PS) of 0, 1, or 2. (Form is available on the ACCRU web site https://www.accru.org/accru/forms/NonProtocolSpecificForms/index.html)",perfstatus
ECOG performance status (PS) score 0-1.,perfstatus
ECOG Performance Status (PS; Appendix 3) 0 to 1.,perfstatus
ECOG performance status <= 1 (Appendix 2).,perfstatus
ECOG performance status <= 1 (Karnofsky >= 70%; see Appendix A),perfstatus
ECOG performance status <= 1 (see Appendix A),perfstatus
"ECOG performance status <= 2 (Karnofsky >= 60%, see Appendix A).",perfstatus
ECOG performance status <= 2 (see Appendix A).,perfstatus
ECOG Performance Status 0 - 2 (asymptomatic to symptomatic but capable of self-care) within 45 days prior to randomization.,perfstatus
ECOG performance status 0 or 1,perfstatus
"ECOG performance status 0 or 1 (Karnofsky > 60%, see Appendix A).",perfstatus
ECOG performance status 0 or 1 (Refer to Appendix IV).,perfstatus
ECOG performance status 0 or 1 (see Appendix A).,perfstatus
ECOG Performance Status 0 to 1,perfstatus
ECOG performance status 0 to 2,perfstatus
"ECOG performance status 0, 1 or 2.",perfstatus
ECOG performance status 0-1 (appendix I) documented within 90 days prior to randomization,perfstatus
ECOG performance status 0-1 (appendix II) assessed within 90 days of randomization.,perfstatus
ECOG performance status 0-2 (see Appendix A) (all cohorts),perfstatus
ECOG performance status 0-2 (see Appendix A).,perfstatus
ECOG performance status 0-2.,perfstatus
ECOG performance status of <= 1,perfstatus
ECOG Performance Status of <= 1 within 60 days prior to Step 1 registration,perfstatus
ECOG performance status of 0 or 1,perfstatus
ECOG performance status of 0 to 2.,perfstatus
"ECOG performance status of 0, 1 or 2 (Appendix A).",perfstatus
"ECOG performance status of 0, 1 or 2 (appendix III).",perfstatus
"ECOG Performance Status of 0, 1 or 2 within 14 days prior to registration",perfstatus
"ECOG Performance Status of 0, 1, or 2 (see Appendix A).",perfstatus
ECOG Performance Status of 0-2 (see Appendix 3),perfstatus
ECOG performance status of 0-2.,perfstatus
ECOG performance status score >= 2.,perfstatus
ECOG Performance Status: 0 or 1.,perfstatus
"ECOG Performance Status: 0, 1, or 2",perfstatus
ECOG PS > 2.,perfstatus
ECOG status of 0-2 (Appendix A: Performance Status Criteria).,perfstatus
Has adequate performance status: Eastern Co-operative Oncology Group (ECOG) performance status (PS) 0-1,perfstatus
"Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, as assessed within 10 days prior to initiation of study treatment.",perfstatus
Has an Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 to 1.,perfstatus
Have a performance status of <= 1 on the Eastern Cooperative Oncology Group (ECOG) scale (refer to Attachment 6).,perfstatus
Have a performance status of 0 or 1 on Eastern Cooperative Oncology Group (ECOG) Performance Scale,perfstatus
Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.,perfstatus
Have Eastern Cooperative Oncology Group (ECOG) Performance Status grade of 0 or 1.,perfstatus
Karnofsky >= 70% (Eastern Cooperative Oncology Group [ECOG] performance status 0-1),perfstatus
Karnofsky performance >= 70%,perfstatus
Karnofsky Performance Score (KPS) >= 70%.,perfstatus
Karnofsky performance status >= 70%.,perfstatus
Karnofsky performance status >= 80%,perfstatus
Karnofsky performance status of 50 (or ECOG/WHO equivalent).,perfstatus
Karnofsky performance status of 70-100 within 90 days prior to Step 1 registration,perfstatus
Lansky (age < 16 years at the time of assent/consent) or Karnofsky (age >= 16 years at the time of assent/consent) performance status >= 80 at screening,perfstatus
Participant has an Eastern Cooperative Oncology Group (ECOG) performance status score > 2.,perfstatus
Participant has Karnofsky performance status score < 70% (APPENDIX F).,perfstatus
Participants must have an Eastern Cooperative Oncology Group performance status <= 1 (see Appendix 7).,perfstatus
Patient has an Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 and has a life-expectancy of more than 6 months.,perfstatus
Patient has an ECOG performance status of 0 or 1.,perfstatus
Patient has Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-1.,perfstatus
Patient has ECOG (Eastern Cooperative Oncology Group) Performance Status <= 2.,perfstatus
"Patient must have a GOG performance status of 0, 1, or 2 or equivalent (Appendix A).",perfstatus
Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status <= 2.,perfstatus
"Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2.",perfstatus
Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.,perfstatus
Patient must have Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1.,perfstatus
"Patients must have a Lansky or Karnofsky performance status score of >= 50, corresponding to ECOG categories 0, 1 or 2. Use Karnofsky for patients > 16 years of age and Lansky for patients <= 16 years of age. Patients who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score.",perfstatus
"Patients must have a Lansky or Karnofsky performance status score of >= 50, corresponding to ECOG categories 0, 1 or 2. Use Karnofsky for patients > 16 years of age and Lansky for patients <= 16 years of age. Patients who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score (see https://members.childrensoncologygroup.org/prot/reference_materials.asp).",perfstatus
"Patients must have a performance status corresponding to Eastern Cooperative Oncology Group (ECOG) scores of 0, 1, or 2; use Karnofsky for patients > 16 years of age and Lansky for patients <= 16 years of age",perfstatus
Patients must have a performance status of 0-2 by Zubrod criteria,perfstatus
Patients must have a performance status of 3 or greater by Zubrod criteria,perfstatus
Patients must have a Zubrod performance status of 0 - 1 within 28 days prior to randomization (see Section 10.5).,perfstatus
Patients must have a Zubrod Performance Status of 0 or 1. (See Section 10.4),perfstatus
Patients must have a Zubrod performance status of 0-2,perfstatus
Patients must have a Zubrod Performance Status of 0-2 (see Section 10.10).,perfstatus
Patients must have a Zubrod performance status score of 0-2 (2 is included here because such patients are typically > 70 years old and cannot tolerate surgery).,perfstatus
Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 within 28 days prior to registration.,perfstatus
Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-3 (restricted to ECOG performance status [PS] 0-2 if age > 70 years),perfstatus
Patients must have an ECOG (Eastern Cooperative Oncology Group) performance status 0 or 1.,perfstatus
Patients must have an ECOG performance status of 0 to 2.,perfstatus
Performance status of ECOG 0 or 1.,perfstatus
"Performance Status Patients must have a performance status corresponding to ECOG scores of 0, 1, or 2",perfstatus
"Performance Status Patients must have a performance status corresponding to ECOG scores of 0, 1, or 2. Use Karnofsky for patients > 16 years of age and Lansky for patients <= 16 years of age. Patients who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score.",perfstatus
Performance status sufficient to undergo RC (in the opinion of the enrolling urologist).,perfstatus
Performance status: ECOG performance status 0-1.,perfstatus
Subject has an Eastern Cooperative Oncology Group (ECOG) performance score of <= 2.,perfstatus
Subject must have ECOG performance status 0 or 1 (Attachment 1).,perfstatus
"Subject should have an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.",perfstatus
Subjects having ECOG Performance Status of 0 to 1.,perfstatus
Subjects must have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2. (see Appendix E),perfstatus
Subjects with an ECOG performance status greater than or equal to 3.,perfstatus
The patient has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.,perfstatus
The patient has an ECOG PS of 0-2.,perfstatus
The patient must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1,perfstatus
The patient must have an ECOG performance status of 0 or 1 (see Appendix A).,perfstatus
The subject has an Eastern Cooperative Oncology Group (ECOG) performance status of <= 2.,perfstatus
Zubrod performance score 0-1.,perfstatus
Zubrod performance status <= 2 within 30 days prior to registration,perfstatus
"Zubrod Performance Status 0, 1, or 2 within 30 days prior to registration",perfstatus
"Zubrod performance status 0, 1, or 2.",perfstatus
Zubrod performance status 0-2 within 30 days prior to Step 1 registration,perfstatus
"Obtained <= 14 days prior to registration: Platelet count >= 100,000/mm^3",platelet
"Patient must have a platelet count of > 100,000/mm^3",platelet
"Platelet (PLT) >= 100,000/uL",platelet
"Platelet >= 100,000/ mm^3",platelet
Platelet >= 100x10^3μL ( >= 100x10^9/L) without transfusion within 2 weeks of the first study drug administration,platelet
"Platelet >= 50,000 cells/mm3 for patients who have bone marrow plasmacytosis < 50% or >= 30,000 cells/mm3 for patients who have bone marrow plasmacytosis of >= 50%",platelet
"Platelet Count (PLT) >= 100,000/μL",platelet
"Platelet Count (untransfused) >= 30,000/mm^3.",platelet
"Platelet count < 100,000/uL without full-dose anticogulation therapy",platelet
"Platelet count < 150,000/uL with ongoing full-dose anticoagulation therapy",platelet
Platelet count < 50 000 cells/μL (50x10^9/L) (without platelet transfusion in the previous 7 days).,platelet
"Platelet count < 50,000 mm3 in the absence of transfusion support (platelet transfusion within 7 days of screening)",platelet
"Platelet count >= 100,000 cells/mm^3 (pre-registration cycle).",platelet
"Platelet count >= 100,000/mm^3 or >= 100 x 10^9/L (must be >= 7 days after most recent transfusion).",platelet
"Platelet count >= 75,000/ mm^3 ( >= 75*10^ 9/L); a value of >= 50,000/ mm^3 ( >= 50*10^ 9/L) may be acceptable for participants with > 50% of plasma cells in bone marrow, after discussion with the sponsor",platelet
Platelet count measurment > 100x10^9/L,platelet
"Platelet count must be >= 100,000/mm^3 (within 14 days prior to randomization).",platelet
Platelet counts of < 50 x 10^9/L in at least 2 blood counts prior to randomization.,platelet
"Platelets: >= 50,000/mm3. For subjects with > 50% myeloma involvement in the marrow, a platelet count of >= 30,000 mm3 is allowed. Subjects may not have received a platelet transfusion within 72 hours prior to the platelet count used for eligibility",platelet
"PLT >= 10,000/μL (transfusion to get platelets >= 10,000 is allowed)",platelet
"PLT >= 75,000/ul (Platelet transfusions to help patients meet eligibility criteria are not allowed within 3 days prior to study drug dosing for any dosing day)",platelet
Untransfused platelet count >= 75000/mL.,platelet
"Ascites, pleural effusion, or pericardial fluid requiring drainage in the last 4 weeks prior to registration",pleural-effusion
Clinically significant ascites or pleural effusions.,pleural-effusion
Clinically significant pleural effusion causing symptoms or needing intervention,pleural-effusion
"Clinically significant third space fluid accumulation (i.e., ascites requiring drainage or pleural effusion that is either requiring drainage or associated with shortness of breath).",pleural-effusion
"Evidence of fluid retention at screening (including, for example, peripheral edema, pleural effusion, or ascites on physical or radiological examination) or history of severe capillary leak syndrome",pleural-effusion
"Greater than minimal, exudative, or cytologically positive pleural effusions.",pleural-effusion
Has symptomatic ascites or pleural effusion. A participant who is clinically stable following treatment for these conditions (including therapeutic thoraco- or paracentesis) is eligible.,pleural-effusion
Has symptomatic ascites or pleural effusion. A subject who is clinically stable following treatment for these conditions (including therapeutic thoraco- or paracentesis) is eligible.,pleural-effusion
Have ascites and/or clinically significant pleural effusion.,pleural-effusion
"If a pleural effusion is present, the following criteria must be met to exclude malignant involvement (incurable T4 disease):",pleural-effusion
"malignant fluid collections (e.g., ascites, pleural effusions)",pleural-effusion
"No ascites, effusions or significant edema.",pleural-effusion
No clinically significant pleural effusion,pleural-effusion
"Participants with exudative pleural effusions are excluded, regardless of cytology.",pleural-effusion
"Patients must not have active pericardial effusion, ascites or pleural effusion of any grade based on chest x-ray and echocardiogram within 28 days prior to registration. Exception: If the effusion is suspected to be related to the leukemia, the patient may have pericardial effusion <= Grade 2 or pleural effusion <= Grade 1.",pleural-effusion
Patients presenting with a pleural effusion will be eligible if thoracentesis is cytologically negative and non-bloody or if pleural fluid is too small a volume to effectively sample by thoracentesis and does not show increased metabolic activity on CT/PET imaging.,pleural-effusion
Patients with a history of documented significant pleural or pericardial effusions.,pleural-effusion
"Patients with malignant pleural effusions that do notresolve after first-line systemic therapy. Patients with pleural effusions that have become too small for thoracentesis at the time of registration would be permitted on study, indicating a significant response to first-line systemic therapy",pleural-effusion
Pleural effusion requiring drainage <= 12 months prior to registration,pleural-effusion
Pleural effusion requiring drainage <= 12 months prior to registration.,pleural-effusion
Pleural effusions or ascites.,pleural-effusion
Previous cytologic confirmation of malignant pleural effusion or ascites if that is the planned source of fresh specimen collection for study participation,pleural-effusion
"Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequently)",pleural-effusion
Evidence of interstitial lung disease or active noninfectious pneumonitis.,pneumonitis
Has a history of (non-infectious) pneumonitis /interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease that requires steroids.,pneumonitis
Has a history of (noninfectious) pneumonitis that required steroids or has current pneumonitis.,pneumonitis
Has a history of (non-infectious) pneumonitis that required steroids or has current pneumonitis.,pneumonitis
Has a history of non-infectious pneumonitis that required treatment with steroids or has current pneumonitis.,pneumonitis
Has a known history of interstitial lung disease.,pneumonitis
"Has evidence of interstitial lung disease or active, non-infectious pneumonitis.",pneumonitis
"Has known history of or any evidence of active, non-infectious pneumonitis",pneumonitis
"Has known history of, or any evidence of active, non-infectious pneumonitis.",pneumonitis
History of acute pneumonitis.,pneumonitis
"History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan",pneumonitis
"History of idiopathic pulmonary fibrosis, organizing pneumonia (eg, bronchiolitis obliterans), drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computerized tomography (CT) scan. History of radiation pneumonitis in the radiation field (fibrosis) is permitted.",pneumonitis
"History of idiopathic pulmonary fibrosis, pneumonitis (including drug induced), organizing pneumonia (i.e., bronchiolitis obliterans, cryptogenic organizing pneumonia, etc.), or evidence of active pneumonitis on screening chest computed tomography (CT) scan; note: History of radiation pneumonitis in the radiation field (fibrosis) is permitted",pneumonitis
"History of idiopathic pulmonary fibrosis, pneumonitis (including drug induced), organizing pneumonia (i.e., bronchiolitis obliterans, cryptogenic organizing pneumonia, etc.), or evidence of active pneumonitis on screening chest CT scan:",pneumonitis
"History of non-infectious pneumonitis that required steroids, or current pneumonitis.",pneumonitis
History of pneumonitis or other interstitial lung disease,pneumonitis
"History of, or any evidence of, active non-infectious pneumonitis.",pneumonitis
"History or any evidence of interstitial lung disease such as idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug induced or active noninfectious pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest CT scan",pneumonitis
Interstitial lung disease or its history.,pneumonitis
Interstitial lung disease that is symptomatic or may interfere with the detection or management of suspected treatment-related pulmonary toxicity.,pneumonitis
Interstitial pneumonia or extensive and symptomatic interstitial fibrosis of the lung,pneumonitis
"Known history of, or any evidence of active non-infectious pneumonitis.",pneumonitis
"Known history of, or any evidence of active, non-infectious pneumonitis.",pneumonitis
"Known interstitial lung disease, interstitial fibrosis, or history of tyrosine kinase inhibitor-induced pneumonitis.",pneumonitis
No current pneumonitis or prior history of non-infectious pneumonitis that required steroids within the previous 5 years.,pneumonitis
No known interstitial fibrosis or interstitial lung disease.,pneumonitis
Participants must not have interstitial lung disease that is symptomatic or may interfere with the detection or management of suspected treatment-related pulmonary toxicity.,pneumonitis
Patients must not have known interstitial lung disease that is symptomatic or may interfere with the detection or management of suspected drug-related pulmonary toxicity,pneumonitis
Patients with known and confirmed diagnosis of interstitial lung disease (ILD).,pneumonitis
Patients with non-infectious pneumonitis.,pneumonitis
Patients with ongoing pneumonitis at screening or with a history of non-infectious pneumonitis that required steroids.,pneumonitis
Patients with symptomatic interstitial lung disease,pneumonitis
"Presence of clinically [symptomatic interstitial lung disease] or interstitial pneumonitis, including radiation pneumonitis (ie, affecting activities of daily living or requiring therapeutic intervention).",pneumonitis
"Presence or history of interstitial lung disease or interstitial pneumonitis, including clinically significant radiation pneumonitis (i.e., affecting activities of daily living or requiring therapeutic intervention).",pneumonitis
Prior or current pneumonitis,pneumonitis
A subject who meets all of the following criteria may be included in the study:,preamble-nolabs
"All institutional, FDA, and NCI requirements for human studies must be met.",preamble-nolabs
"All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human subjects research must be met",preamble-nolabs
Any of the following within 28 days before the first dose of study treatmentF,preamble-nolabs
Any of the following within 6 months before the first dose of study treatment:,preamble-nolabs
Any of the following:,preamble-nolabs
Both Studies:,preamble-nolabs
Diagnosis requirement for phase I patients:,preamble-nolabs
Dose Escalation Segment,preamble-nolabs
Enrollment closed,preamble-nolabs
Exceptions,preamble-nolabs
Has met at least one of the following indications for treatment:,preamble-nolabs
"Has primary liver cancer or hepatic metastasis, provided that at the screening visit the following criteria are met",preamble-nolabs
Meets one of the sets of the following criteria:,preamble-nolabs
Must meet criteria for one option below:,preamble-nolabs
Other protocol defined criteria could apply,preamble-nolabs
Other protocol defined inclusion criteria could apply.,preamble-nolabs
Other protocol defined inclusion/exclusion criteria could apply.,preamble-nolabs
Other protocol defined inclusion/exclusion criteria may apply,preamble-nolabs
Participants must have met all criteria to be enrolled on the main protocol for receipt of neratinib in Section,preamble-nolabs
Patient had at least one of the following:,preamble-nolabs
Patient having received:,preamble-nolabs
Patient meets all entry criteria for the assigned Sub-Protocol.,preamble-nolabs
Patient met one or more exclusion criteria for participation in the Sub-Protocol.,preamble-nolabs
Patients enrolled in the Phase 1a study must:,preamble-nolabs
Patients enrolled in the Phase 1b study must meet criteria for one of the following tumor types:,preamble-nolabs
Patients in all treatment arms except atezolizumab must meet the following criteria for study entry (note that all inclusion criteria for patients in the atezolizumab arm have been moved to A11-4.1.1 and some may differ from related criteria in the list below):,preamble-nolabs
Patients may have received either:,preamble-nolabs
Patients must have met eligibility criteria for the screening step 0.,preamble-nolabs
Patients should meet the following:,preamble-nolabs
Patients who have had or are planning to have the following invasive procedures are not eligible:,preamble-nolabs
Patients will be ineligible for this study if they meet any one of the following criteria:,preamble-nolabs
Regulatory Criteria,preamble-nolabs
Should meet all of the following criteria for prior therapy:,preamble-nolabs
Subjects with one of the following cohort specific requirements:,preamble-nolabs
The following requirements apply:,preamble-nolabs
The subject has experienced any of the following within 3 months before the first dose of study treatment:,preamble-nolabs
Treatment period,preamble-nolabs
> 2 lines of prior chemotherapy in the metastatic setting,priortherapy
> 2 prior regimens containing cytotoxic chemotherapy in the metastatic setting.,priortherapy
"> 4 weeks since prior radiation, surgery or chemotherapy",priortherapy
a platinum-based regimen,priortherapy
All lesions should be treatable by EBRT while meeting normal tissue constraints,priortherapy
Allowable transplant preparative regimens are the following:,priortherapy
An anthracycline containing regimen,priortherapy
"Any anticancer therapy within 14 days prior to the first dose of study drug, including: small molecules, immunotherapy, chemotherapy, monoclonal antibody therapy, radiotherapy or any other agents to treat cancer ",priortherapy
Any number of prior lines of chemotherapy in the metastatic setting is allowed.,priortherapy
"Any other prior therapy directed at the malignant tumor, including chemotherapy, biologic/targeted therapy and immunologic therapy, must be discontinued at least 3 weeks prior to study treatment initiation.",priortherapy
"Any other therapy directed at treating the cancer including chemotherapy, biologic/targeted agents, and immunologic agents, must be discontinued at least 3 weeks prior to enrollment.",priortherapy
"Any prior chemotherapy, immunotherapy, radiation therapy or surgeries must have been completed at least 3 weeks prior to initiation of study medication.",priortherapy
"At least 2 weeks from prior chemotherapy or radiation therapy to time of start of treatment, except for hydroxyurea or corticosteroid therapy, which may be continued through Cycle 1",priortherapy
"At least 2 weeks or 5 half-lives, whichever is shorter, must have elapsed after prior chemotherapy or small molecule targeted therapy",priortherapy
"At least 2 weeks washout period post chemotherapy, any prior protocol therapy, lapatinib, other targeted or biologic therapy, or radiation therapy is required prior to study entry",priortherapy
At least 28 days since the last chemotherapy or immunotherapy prior to the first dose; at least 14 days since the last radiation prior to the first dose (exception: palliative radiotherapy for pain can be used greater than or equal to ( >= ) 7 days prior to or after infusion),priortherapy
At least one prior chemotherapy,priortherapy
"At least one prior regimen of chemotherapy, with no maximum number of chemotherapy cycles",priortherapy
"At the time of enrollment, subjects may not have had any prior systemic therapy for breast cancer, including chemotherapy, hormonal therapy or targeted biologic therapy. Similarly, chemotherapy or biologic therapy must not be part of the subsequent treatment plan.",priortherapy
Bone/soft tissue directed palliative radiotherapy within 4weeks,priortherapy
Chemotherapy < 3 weeks prior to registration,priortherapy
Chemotherapy <= 21 days prior to first administration of study treatment and/or monoclonal antibody <= 6 weeks prior to first administration of study treatment,priortherapy
Chemotherapy <= 3 weeks prior to registration,priortherapy
Chemotherapy <= 3 weeks prior to study entry,priortherapy
Chemotherapy <= 4 weeks prior to registration,priortherapy
Chemotherapy administered for the currently diagnosed breast cancer prior to randomization,priortherapy
"Chemotherapy is not administered prior to, during, and for >= 21 days after completion of radiotherapy (for patients receiving brachytherapy boost)",priortherapy
Chemotherapy must have been completed at least 7 days prior to leukapheresis,priortherapy
Chemotherapy within 5 years prior to registration. Hormonal therapy is allowable if the disease free interval is >= 5 years.,priortherapy
"Chemotherapy, radiation therapy, or immunotherapy within 4 weeks prior to first dosing of study drug (6 weeks for nitrosoureas); concomitant hormonal therapies for breast cancers are allowed",priortherapy
Completion of prior chemotherapy systemic anticancer therapy at least 2 weeks prior to study entry,priortherapy
"Concurrent treatment with any anticancer agent, including chemotherapy, immunotherapy, or biologic therapy. In breast cancer patients, concurrent use of hormonal therapy (but not trastuzumab) is acceptable provided hormonal therapy was initiated more than 30 days prior to treatment on this study.",priortherapy
Cytotoxic chemotherapy within 21 days prior to enrolment.,priortherapy
"Cytotoxic chemotherapy, immunotherapy, or radiotherapy within 28 days (42 days in cases of mitomycin C, nitrosourea, lomustine) prior to enrollment.",priortherapy
"Disease must be amenable to TACE and anticipated to require no more than 4 TACE treatments to treat sites of disease within a <= 16-week period (Permitted modalities are DEB-TACE or cTACE (using an emulsion of Lipiodol® and a permitted chemotherapeutic agent as per institutional practice, followed by embolizing agents).",priortherapy
"Had surgery, chemotherapy, or radiation therapy within 28 days prior to receiving study drug",priortherapy
Has had prior systemic cancer cytotoxic chemotherapy within the past four weeks at the time of the start of the lymphodepletion regimen.,priortherapy
Has previously received at least 2 prior regimens for advanced disease and were refractory to or unable to tolerate their last prior therapy.,priortherapy
"Has received prior targeted small molecule therapy, radiation therapy or systemic chemotherapy for urothelial bladder cancer including neoadjuvant chemotherapy. Prior intravesical chemotherapy or intravesical immunotherapy is permissible, however, no prior intravesical therapy is permitted within 4 weeks of study enrollment; adjuvant therapy is not permitted.",priortherapy
"Has received the prohibited therapy (e.g., concurrent anti-cancer therapy including but not limited to: chemotherapy, radiation, hormonal, or immunotherapy) <= 14 days prior to first planned dose of AC0010MA.",priortherapy
Have completed Transurethral Resection of Bladder Tumor (TURBT) procedure,priortherapy
"His/her last dose of prior chemotherapy, immunotherapy or radiation is at least 2 weeks out from PBMC collection",priortherapy
History of prior chemotherapy,priortherapy
"Hormonal therapy, radiation therapy, biologic therapy, chemotherapy or other systemic antitumor therapy for pancreatic cancer within 14 days prior to Cycle 1 Day 1",priortherapy
"If research participant is undergoing leukapheresis the last dose of prior chemotherapy, immunotherapy or radiation must be at least 2 weeks before the leukapheresis procedure",priortherapy
Immunotherapy not specified in this protocol,priortherapy
INCLUSION CRITERIA FOR STRATUM C: Patients must have received prior radiotherapy and/or chemotherapy with the following exceptions:,priortherapy
More than 2 prior chemotherapy regimens for the current malignancy; full dose chemotherapy used in conjunction with concurrent radiation therapy will be included as prior therapy,priortherapy
"More than one line of prior chemotherapy for metastatic or locally advanced disease, with the following exception:",priortherapy
More than one prior chemotherapy-containing line(re-challenge with the same initial regimen is not allowed),priortherapy
Must have completed prior chemotherapy or radiation therapy at least 2 weeks prior to registration,priortherapy
Must have had at least one standard treatment with one of the following regimens:,priortherapy
Must have progressed on at least 1 prior chemotherapy regimen for the treatment of advanced breast cancer; there is no upper limit on the number of prior therapies,priortherapy
Must have received first line chemotherapy. No upper limit for the number of prior therapies,priortherapy
Neoadjuvant chemotherapy must be held for at least 3 weeks prior to surgery,priortherapy
"Neoadjuvant chemotherapy or radiation therapy prior to prostatectomy, including focal ablation techniques (HiFu)",priortherapy
No chemotherapy or study drugs for > 3 weeks prior to starting study.,priortherapy
No history of chemotherapy for cancer within 6 months prior to registration,priortherapy
No limitation on the number of prior chemotherapy regimens that the patient may have received prior to study entry.,priortherapy
No more than 3 prior chemotherapy regimens.,priortherapy
No other chemotherapy or radiation therapy within 14 days prior to registration,priortherapy
No prior chemotherapy,priortherapy
No prior chemotherapy or surgery for rectal cancer,priortherapy
"No prior chemotherapy, irradiation, or definitive therapeutic surgery (eg, mastectomy or lumpectomy or axillary dissection) for this malignancy; patients who have had a prior sentinel lymph node biopsy for this malignancy are eligible",priortherapy
"No prior chemotherapy, radiation therapy, or breast resection within 6 months of study entry",priortherapy
"No prior chemotherapy, radiation therapy, or surgery for this malignancy will be allowed; prior endoscopic procedures for superficial disease (endoscopic mucosal resection, cryotherapy, photodynamic therapy, etc.) will not exclude a patient; prior dilatation is also allowed",priortherapy
No prior cytotoxic chemotherapy for metastatic disease; prior immunotherapy is permitted,priortherapy
No prior or concurrent cytotoxic chemotherapy for prostate cancer,priortherapy
"No prior prostate cancer therapy such as: prostatectomy, cryotherapy, chemotherapy or hyperthermia.",priortherapy
No prior radiotherapy or chemotherapy (except for the chemotherapy described in the bullet above) for SCLC,priortherapy
"No prior receipt of systemic treatment (chemotherapy, targeted therapy, or immunotherapy) for the lesion under consideration of treatment",priortherapy
No prior systemic chemotherapy,priortherapy
No prior systemic chemotherapy for the current cervical cancer,priortherapy
One line of cytotoxic chemotherapy (must be completed >= 4 weeks prior to Cycle 1 Day -2).,priortherapy
One line of prior chemotherapy for advanced/metastatic disease is permissible.,priortherapy
"Participants who have received prior neo-adjuvant, radiotherapy, adjuvant chemotherapy, or chemoradiotherapy with curative intent for non-metastatic disease must have experienced a treatment-free interval of at least 6 months from randomization since the last dose of chemotherapy and/or radiotherapy",priortherapy
Patient has received routine therapy as follows:,priortherapy
Patient may have had any number of prior chemotherapy regimens in the adjuvant/neoadjuvant and/or metastatic setting (including none),priortherapy
"Patient may receive treatment after tissue collection; however, lack of response must be documented prior to Step 1; the following restrictions apply:",priortherapy
Patient must NOT have a history of > 1 line of administered chemotherapy for metastatic disease and must be off chemotherapy for a minimum of 2 weeks; prior chemotherapy in the adjuvant setting is allowed,priortherapy
"Patients currently receiving anticancer therapies (including chemotherapy, radiation therapy, hormonal, or antibody-based therapy); prior treatment should have a washout period of 28 days or 4 1/2 half-lives (7 days), whichever is shorter",priortherapy
Patients may have received only one prior chemotherapy regimen for metastatic disease provided treatment was completed >= 3 weeks prior to randomization,priortherapy
Patients may have received prior chemotherapy.,priortherapy
Patients may have received prior systemic chemotherapy. Such therapy must have been completed at least 5 years prior to study entry and the patient has no evidence of disease subsequent to such therapy. Patients must not have received neoadjuvant chemotherapy for the present disease.,priortherapy
Patients may not have received chemotherapy prior to enrollment on ANBL00B1 and procurement of study-related tissues with the following exception:,priortherapy
"Patients must be at least 28 days post cytotoxic chemotherapy, and/or monoclonal antibody therapy (excluding bone-directed therapy), prior to enrollment",priortherapy
Patients must have completed last chemotherapy >= 3 weeks or radiotherapy >= 2 weeks prior to receiving study drugs,priortherapy
Patients must have had at least 4 months of prior systemic chemotherapy.,priortherapy
Patients must have received at least one but no more than three prior systemic treatment regimens and for whom single-agent chemotherapy is appropriate as the next line of treatment,priortherapy
Patients must have received prior induction chemotherapy for at least 2 months and up to 8 months; at least three weeks should have elapsed after the last chemotherapy,priortherapy
Patients must not have received chemotherapy and/or radiation therapy within 2 weeks of start of protocol treatment; hydroxyurea is allowed up to 48 hours prior to starting therapy in the setting of rapidly proliferating disease,priortherapy
Patients should not have received chemotherapy or radiation therapy (localized radiation therapy is allowed to non-evaluable sites) between prior 123I-MIBG scan and 18F-MFBG administration.,priortherapy
Patients who are candidates for and willing to receive intensive induction chemotherapy,priortherapy
"Patients who have had any prior chemotherapy, or endocrine therapy for the treatment of breast cancer or any other cancer",priortherapy
Patients who have had chemotherapy or biological cancer therapy within 2 weeks prior to the first dose of study drug,priortherapy
"Patients who have had prior chemotherapy, immunotherapy, targeted therapy, or radiotherapy within 1 month of enrollment",priortherapy
Patients who have received a final dose of any of the following treatments/procedures within the following minimum interval before the first dose of TAK-169:,priortherapy
"Patients who have received chemotherapy within 3 weeks prior to the initiation of study treatment, or endocrine therapy within 2 weeks prior to the initiation of study treatment.",priortherapy
Patients who have received prior chemotherapy for endometrial cancer.,priortherapy
Patients who received less than 4 weeks of therapy and were unable to continue therapy due to toxicity will be allowed to participate,priortherapy
Patients with any prior chemotherapy regimens are eligible,priortherapy
Patients with prior chemotherapy for this cancer,priortherapy
"Previous treatment with radiotherapy, cytotoxic chemotherapy, or immunotherapeutic agents in the 4 weeks prior to study drug administration (Cycle 1 Day 1)",priortherapy
Prior chemotherapy completed < 7 days prior to planned study entry,priortherapy
Prior chemotherapy in the adjuvant setting is allowed,priortherapy
Prior chemotherapy is acceptable if last dose given >= 3 weeks prior to registration to this study. [Note: no chemotherapy to be given after resection of liver lesions prior to treatment on this study.],priortherapy
Prior chemotherapy or hormone therapy,priortherapy
Prior chemotherapy or radiotherapy,priortherapy
"Prior chemotherapy, biologic therapy, and/or radiotherapy allowed",priortherapy
Prior chemotherapy.,priortherapy
Prior cytotoxic chemotherapy and/or radiation therapy within 4 weeks of treatment,priortherapy
Prior radiation therapy or chemotherapy within 2 weeks or major surgical procedure within 4 weeks of the first dose of study treatment.,priortherapy
"Prior radiation therapy, chemotherapy, or surgery in patients requiring flap reconstruction in the head and neck region.",priortherapy
Prior receipt of induction chemotherapy followed by referral for concurrent chemoradiation is allowed,priortherapy
"Prior surgery (not including TURP), cryosurgery, radiofrequency ablation, chemotherapy or radiation for PCa",priortherapy
"Prior systemic (example [e.g.], chemotherapy) or local (e.g. radical prostatectomy, cryotherapy) treatment for prostate cancer",priortherapy
Prior systemic chemotherapy (for lung cancer) and/or thoracic/neck radiotherapy for any reason and/or surgical resection of present cancer,priortherapy
Prior systemic chemotherapy for any reason.,priortherapy
Prior systemic chemotherapy within the last three years.,priortherapy
"Prior systemic chemotherapy, targeted small molecule therapy, or radiation therapy for bladder cancer.",priortherapy
Prior therapy with any systemic therapy (chemotherapy or biologic therapy) within twenty-eight days prior to study entry,priortherapy
Prior Therapy: At least 2 weeks should have elapsed since any biologic therapy. Three weeks should have elapsed since last dose of chemotherapy.,priortherapy
"Prior treatment of this cancer including: Surgery, Radiation, Chemotherapy",priortherapy
"Radiation, chemotherapy, immunotherapy or any other systemic anticancer therapy <= 2 weeks prior to initiation of therapy",priortherapy
"Radiation, chemotherapy, or immunotherapy or any other anticancer therapy <= 2 weeks prior to cycle 1 day 1",priortherapy
Recent prior chemotherapy:,priortherapy
Recent prior therapy: Systematic chemotherapy less than 2 weeks prior to infusion.,priortherapy
Regimen A (FT516 monotherapy):,priortherapy
"Stable or progressive disease after, or was unable to tolerate, at least one line of prior anticancer therapy for this disease. NOTE: For patients with stable disease, it is strongly encouraged to confirm the presence of active disease (eg, demonstrating FDG avidity via PET or repeat biopsy).",priortherapy
Subject has received at least 2 but no greater than 4 prior MM regimens.,priortherapy
Subject is expected to require another form of antineoplastic therapy while on study treatment.,priortherapy
The last dose of chemotherapy or radiation must have been administered at least 4 weeks prior to liver surgery.,priortherapy
"The last dose of prior chemotherapy, immunotherapy or radiation must be at least 2 weeks before the leukapheresis procedure",priortherapy
The patient has been treated with radio- or toxin-immunoconjugates within 70 days of the first dose of the study drug.,priortherapy
"The patient must have completed adjuvant chemotherapy within at least 6 months, but no more than 36 months prior to initial study scan.",priortherapy
The subject and her physician must agree to 6 cycles (a total of up to 8 cycles will be allowed) of one of the standard of care regimens allowed on this protocol. These regimens (starting dosage) include:,priortherapy
"The subject has had preoperative chemotherapy, immunotherapy, or radiation therapy within the 30 days prior to Lymphoseek administration",priortherapy
There is no limit to the number of prior chemotherapy regimens received. Patients must have received at least one line of prior systemic chemotherapy for advanced unresectable and/or metastatic disease.,priortherapy
"There is no upper limit on prior chemotherapy, targeted therapy, or endocrine therapy.",priortherapy
Treatment with low dose chemotherapy concurrent with radiation within 14 days prior to study entry,priortherapy
Treatment with surgery or chemotherapy within 21 days prior to study entry (42 days for nitrosoureas or mitomycin C),priortherapy
Proteinuria at Screening as demonstrated by urinalysis with proteinuria >= 2+ (patients discovered to have >= 2+ proteinuria on dipstick urinalysis at baseline should undergo a 24-hour urine collection and must demonstrate <= 1g of protein in 24 hours to be eligible).,proteinuria 
Subjects with proteinuria > 1+ on urine dipstick testing will undergo 24-hour urine collection for quantitative assessment of proteinuria. Subjects with urine protein >= 1 g/24 h will be ineligible.,proteinuria 
"Urinary protein is <= 1+ on dipstick of routine urinalysis or urine protein-to-creatinine ratio <= 1 mg/mL (assessed by local laboratory). Note: if urine dipstick or routine analysis indicate proteinuria >= 2+ or urine protein-to creatinine ratio is > 1mg/mL, then a 24-hour urine must be collected and must demonstrate < 1 gram of urine protein (assessed by local laboratory).",proteinuria 
Urine dipstick for proteinuria < 2+ (patients discovered to have >= 2+ proteinuria on dipstick urinalysis at baseline should undergo a 24 hour urine collection and must demonstrate <= 1g of protein in 24 hours to be eligible).,proteinuria 
Urine dipstick protein >= 2+ and 24-hour urine protein >= 1.0 g/24-h. Patients with greater than 1+ proteinuria on urinalysis must undergo a 24-hour urine collection,proteinuria 
Urine dipstick proteinuria < 2+ or urine protein/creatinine (UPC) ratio <= 1.0,proteinuria 
Activated partial thromboplastin (aPTT) and prothrombin time (PT) <= 1.5 x ULN.,ptinrptt
Adequate coagulation function defined as international normalized ratio (INR) or prothrombin time (PT) <= 1.5 X ULN unless the participant is receiving anticoagulant therapy and activated partial thromboplastin time (aPTT) <= 1.5 X ULN unless the participant is receiving anticoagulant therapy.,ptinrptt
Coagulation function as follows: Prothrombin time (PT)/ international normalized ratio (INR) and partial thromboplastin time (PTT) < 1.5 x institutional upper limit of normal.,ptinrptt
Cohort 2 (MTD) only: prothrombin time (PT)/international normalized ratio (INR) <= 1.5 x ULN (only if muscle biopsy has not been waived),ptinrptt
International normalized ratio (INR or prothrombin time (PT) Activated partial thromboplastin time (aPTT) < 1.5 x ULN unless participant is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants,ptinrptt
International normalized ratio (INR) <= 1.5 or prothrombin time (PT) <= 1.5 x ULN.,ptinrptt
International Normalized Ratio (INR) or Prothrombin Time (PT) <= 1.5 X IULN unless subject is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of intended use of anticoaculants,ptinrptt
"International Normalized Ratio (INR) or Prothrombin Time (PT) <= 1.5 X ULN unless receiving anticoagulant therapy, as long as PT or PTT is within therapeutic range of intended use of anticoagulants",ptinrptt
International normalized ratio (INR) OR prothrombin time (PT) Activated partial thromboplastin time (aPTT) <= 1.5 x ULN unless participant is receiving anticoagulant therapy as long as PT or aPTT is within therapeutic range of intended use of anticoagulants,ptinrptt
International normalized ratio (INR) or prothrombin time (PT) and activated partial thromboplastin time (aPTT) <= 1.5 x ULN unless patient is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants.,ptinrptt
International normalized ratio (INR) or prothrombin time (PT) or partialthromboplastin time (PTT) <= 1.5 x ULN,ptinrptt
"International normalized Ratio (INR), Prothrombin Time (PT) or Activated Partial Thromboplastin time (aPTT) <= 1.5 X ULN unless the subject is receiving anticoagulant therapy as long as PT or aPTT is within therapeutic range of intended use of anticoagulants.",ptinrptt
International normalized ratio (INR)/prothrombin time (PT) <= 1.5 obtained <= 14 days prior to registration,ptinrptt
International normalized ratio of prothrombin time (INR) within 28 days before randomization must be <= ULN for the lab. Patients who are therapeutically treated with an agent such as warfarin may participate if they are on a stable dose and no underlying abnormality in coagulation parameters exists per medical history. (See Section 5.6.9 for coumarin-derivative drug/drug interactions).,ptinrptt
International normalized ratio/Prothrombin time and activated partial thromboplastin time <= 1.5 x ULN,ptinrptt
"Patients not receiving anti-coagulant therapy must have prothrombin time (PT) and international normalized ratio (INR) <= 1.5 x ULN within 14 days prior to randomization; for laboratories that do not report an ULN for the INR assay, use <= 1.5 as the value for the ULN; patients receiving anti-coagulants should have a baseline INR assessed, but the value does not affect eligibility.",ptinrptt
Prothrombin and Partial Thromboplastin Times <= 1.2 xnormal,ptinrptt
"Prothrombin time (PT) - international normalized ratio (INR) and partial thromboplastin time (PTT) <= 1.5 x ULN. Patients on a stable, maintenance regimen of anticoagulant therapy for at least 30 days prior to study drug administration may have PT/INR measurements > 1.5 x ULN if, in the opinion of the Investigator, the patient is suitable for the study. An adequate rationale must be provided to the Sponsor prior to enrollment.",ptinrptt
Prothrombin time (PT) and partial thromboplastin time (PTT) <= 1.5 X ULN after correction of nutritional deficiencies that may have contributed to prolonged PT/PTT.,ptinrptt
Prothrombin time (PT) within 1.5x normal limits,ptinrptt
prothrombin time (PT)/ International Normalized Ratio (INR) and partial thromboplastin time (PTT) test < 1.3 x ULN,ptinrptt
"Prothrombin time (PT)/ international normalized ratio (INR), partial thromboplastin time (PTT) < 1.3 x upper limit of normal (ULN)",ptinrptt
Prothrombin time (PT)/ international normalized ration (INR) < 1.5 x ULN and partial thromboplastin time (PTT) (activated [a]PTT) < 1.5 x ULN.,ptinrptt
Prothrombin time (PT)/international normalized ratio (INR) < 1.5 x ULN and partial thromboplastin time (PTT) (activated partial thromboplastin time [aPTT]) < 1.5 x ULN (obtained <= 14 days prior to registration).,ptinrptt
Prothrombin time (PT)/international normalized ratio (INR) and partial thromboplastin time (PTT) < 1.3 x upper limit of normal (ULN),ptinrptt
Prothrombin time (PT)/international normalized ratio (INR)/partial thromboplastin time (PTT) <= 1.5 x ULN OR if a subject is receiving anticoagulant therapy and PT or PTT is within therapeutic range of intended use of coagulants for 7 days prior to receiving study treatment,ptinrptt
Prothrombin time 11 to 15 seconds,ptinrptt
The subject has prothrombin time (PT)/INR or partial thromboplastin time (PTT) tes >= 1.3 X the laboratory ULN within 7 days before the first dose of study treatment.,ptinrptt
"A clinically significant ECG abnormality, including a marked baseline prolonged QTcF (QT corrected for heart rate using Fridericia's formula) interval (e.g., a repeated demonstration of a QTc interval > 480 ms).",qtcf
Baseline corrected QT interval (QTcF) < 480 ms.,qtcf
Baseline QTcF interval >= 450 msec,qtcf
Corrected QT interval calculated by the Fridericia formula (QTcF) > 500 ms per electrocardiogram (ECG) within 28 days before first dose of study treatment (see Section 5.6.4 for Fridericia formula).,qtcf
Fridericia's corrected QT interval (QTcF) > 470 ms on ECG conducted during Screening.,qtcf
Fridericia's correction formula (QTcF) interval at screening < 450 msec (using Fridericia? s correction),qtcf
"Have a corrected QT interval (QTcF, Fridericia's method) of > 450 msec in men and 470 msec in women",qtcf
"Inability to determine the QT interval on screening (QTcF, using Fridericia? s correction)",qtcf
Known congestive heart failure (Grade III or IV as classified by the New York Heart Association); and/ or a known decreased cardiac ejection fraction of < 45%. A baseline QT interval as corrected by Fridericia's formula (QTcF) > 480 msec or a complete left bundle branch block (defined as a QRS interval >= 120 msec in left bundle branch block form).,qtcf
Mean QT interval corrected for heart rate (QTc) >= 470 ms calculated from 3 electrocardiograms (ECGs) using Fridericia&rsquo;sCorrection.,qtcf
Not applicable per Protocol Revision 04. QT interval corrected for heart rate using Fridericia's formula (QTcF) prolongation > 480 msec.,qtcf
Participant has a Fridericia-corrected QT interval (QTcF) > 450 msec (average of triplicate determinations) per central read.,qtcf
Participant has a QTcF interval > 450 msec (average of triplicate determinations) by central read.,qtcf
Patients must have QTcF (by Fridericia calculation) < 480/msec based on EKG performed within 28 days prior to registration. QTcF = QT/(RR)0.33 (QTcF = QT interval divided by the cube root of the RR [heart rate] in seconds),qtcf
QT corrected by Fridericia's formula (QTcF) interval at screening < 450msec (using Fridericia?s correction),qtcf
QT interval corrected for heart rate using Fridericia's formula (QTcF) <= 500 msec,qtcf
QT interval corrected with Fridericia's formula >= 480 ms,qtcf
"QT interval with Fridericia's correction (QTcF) > 470 milliseconds (Vandenberk 2016). The QTcF should be calculated as the arithmetic mean of the QTcF on triplicate ECGs. In the case of potentially correctible causes of QT prolongation, (e.g., medications, hypokalemia), the triplicate ECG may be repeated once during Screening and that result may be used to determine eligibility.",qtcf
QTcF <= 450 ms,qtcf
QTcF > 450 msec for men and QTcF > 460 msec for women.,qtcf
QTcF interval >= 470 ms.,qtcf
QT-interval corrected according to Fridericia's formula (QTcF) <= 450 ms on electrocardiogram (ECG) at Screening,qtcf
"Screening 12-lead ECG showing a baseline QT interval as corrected by Fridericia's formula (QTcF) > 480 msec (NOTE: If QTcF > 480 msec, then this must be confirmed based on average QTcF value from at least 3 manually over-read 12-lead ECGs performed over a short period of time [ie, within 30 minutes]).",qtcf
Subject does not have a corrected QT interval of > 450 ms (as calculated using QT interval corrected for heart rate using Fridericia's formula [QTcF]).,qtcf
"The subject has a corrected QT interval calculated by the Fridericia formula (QTcF) > 500 ms within 28 days before randomization. Note: if initial QTcF is found to be > 500 ms, two additional EKGs separated by at least 3 minutes should be performed. If the average of these three consecutive results for QTcF is <= 500 ms, the subject meets eligibility in this regard.",qtcf
All races and ethnic groups are eligible for this study,race-gender-ethnic
Both men and women and members of all races and ethnic groups are eligible for this trial.,race-gender-ethnic
"Both men and women and members of all races and ethnic groups are eligible for this trial. Because of the epidemiology of breast cancer, it is anticipated that the vast majority of participants in this trial will be female.",race-gender-ethnic
Both men and women of all races and ethnic groups are eligible for this study,race-gender-ethnic
Both men and women of all races and ethnic groups are eligible for this study.,race-gender-ethnic
Both men and women of all races and ethnic groups are eligible for this trial,race-gender-ethnic
Both men and women of all races and ethnic groups are eligible for this trial.,race-gender-ethnic
"Both men and women of all races and ethnic groups are eligible for this trial. Because breast cancer predominantly affects females, it is anticipated that male enrollment will be < 5% of the overall study population.",race-gender-ethnic
Both men and women of all races and ethnic groups are eligible.,race-gender-ethnic
"Both men and women, and members of all races and ethnic groups are eligible for this trial.",race-gender-ethnic
INCLUSION CRITERIA FOR STRATUM C: All races and ethnic groups are eligible for this study,race-gender-ethnic
Inclusion of Women and Minorities Both males and females of all races and ethnic groups are eligible for this study.,race-gender-ethnic
Inclusion of Women and Minorities Both men and women and members of all races and ethnic groups are eligible for this trial.,race-gender-ethnic
Individuals of all races and ethnic groups are eligible for this trial.,race-gender-ethnic
Individuals of all races and ethnic groups are eligible for this trial. There is no bias towards age or race in the clinical trial outlined. This trial is open to the accrual of women only.,race-gender-ethnic
Individuals of all races and ethnic groups are eligible for this trial. There is no bias towards age or race in the clinical trial outlined. This trial is open to the accrual of women. TBCRC-XXX./MC1831,race-gender-ethnic
Members of all races and ethnic groups are eligible for this trial,race-gender-ethnic
Men of all races and ethnic groups are eligible for this trial. Women are excluded as prostate cancer does not exist in this population.,race-gender-ethnic
"This study will be available to all eligible patients regardless of race or ethnic group. Because this is a clinical trial in primary peritoneal, ovarian and fallopian tube malignancies, all patients in this study will be women.",race-gender-ethnic
Women and members of all races and ethnic groups are eligible for this trial,race-gender-ethnic
Women and men of all races and ethnic groups are eligible for this trial.,race-gender-ethnic
"Women of all races and ethnic groups are eligible for this trial. Men are not included since DCIS of the breast is exceedingly rare in men, and there are no data regarding skin penetration of 4-OHT though male chest wall skin (which is thicker and hairier than female chest wall skin).",race-gender-ethnic
3rd or greater remission ALL.,remission
Acute biphenotypic or bilineal leukemia in CR1,remission
Acute leukemias in second (2nd) or subsequent remission,remission
Acute leukemias of ambiguous lineage in >= 1st remission,remission
Acute lymphoblastic leukemia (ALL) not in CR1,remission
Acute lymphocytic leukemia in first or subsequent remission,remission
Acute lymphoid leukemia in 1st or 2nd morphological remission. ALL with any morphological evidence of disease will not be eligible.,remission
Acute myeloid leukemia in first or subsequent remission,remission
"Adequately managed stage 0 (carcinoma in situ), I, or II basal cell or squamous cell carcinoma from which the patient is currently in complete remission.",remission
AML and ALL in 1st complete remission (CR1),remission
AML in >= 2nd remission,remission
AML in CR2 or subsequent.,remission
"AML not in CR1 (including patients with morphologic CR but with incomplete recovery, CRi)",remission
"AML patients in first complete remission (CR) (CR1) or first complete remission with incomplete blood count recovery (CRi) after induction and consolidation chemotherapy; except young ( < 60 years) AML patients in European LeukemiaNet favorable group; (the current trial will exclude young favorable group AML patients), patients could receive any cycle consolidation or no consolidation per the discretion by the treating physician",remission
Biphenotypic/undifferentiated leukemias in first (1st) or subsequent complete remission (CR),remission
Burkitt's lymphoma in CR2 or subsequent CR.,remission
"Busulfan dose may be adjusted according to pharmacokinetics targeting a daily AUC of 5000 µmol-min/L, per institution standard of practice.",other
Complete second remission (CR2).,remission
CR2 or CR3,remission
CR2 or CR3 with either:,remission
CR2 or higher,remission
Disease status: B-ALL in first (CR1) or second remission (CR2),remission
Greater than 1 cycle of induction therapy required to achieve remission,remission
Hodgkin's or Non-Hodgkin's lymphoma in 2nd or greater remission or with persistent disease.,remission
"if the patient is in remission from induction therapy, he/she will receive post-remission therapy",remission
Initial partial remission AML ( < 20% blasts in the bone marrow).,remission
Large Cell NHL > CR2/> PR2: Patients in CR2/PR2 with initial short remission ( < 6 months) are eligible.,remission
Large cell NHL > CR2/> second partial response (PR2):,remission
"Lymphoplasmacytic Lymphoma, Mantle-Cell Lymphoma, Prolymphocytic Leukemia are eligible after initial therapy in CR1+ or PR1+.",remission
"patients beyond second remission have to be in complete remission (CR) at transplant to be eligible, or",remission
Patients in CR1 or CR2 after blinatumomab treatment.,remission
Patients in CR1 or CR2 after CAR-T cellular therapy.,remission
Patients in CR2/PR2 with initial short remission ( < 6 months) are eligible,remission
Patients in first remission are eligible,remission
Patients must have achieved CR or Cri within 2 cycles of Induction/Re-Induction with blinatumomab.,remission
Patients who are pre-HCT NGS-MRD negative (CR1/CR2) who received inotuzumab ozogamicin therapy before proceeding to HCT.,remission
Recipients with AML in CR1 must have one of the following:,remission
"Recurrence of disease after a first complete remission (CR1) and not eligible for a second course of induction therapy, or",remission
"Recurrence of disease after a second complete remission (CR2), or",remission
Second complete remission (CR2) or third complete remission (CR3),remission
second or greater remission,remission
Second or greater remission AML,remission
Secondary AML in 1st remission,remission
Secondary AML in remission,remission
subjects must be in CNS remission at the time of protocol enrollment if there is a history of CNS involvement,remission
Such disease treated into remission is permitted,remission
Time to complete remission > 4 weeks,remission
Acute lymphoblastic leukemia in high risk first complete remission (CR1) as defined by at least one of the following:,remissionriskfeatures
Acute lymphoid leukemia (ALL) in first complete remission (CR1) with high risk for relapse including:,remissionriskfeatures
Acute myelogenous leukemia in high risk CR1 as defined by at least one of the following:,remissionriskfeatures
Acute myeloid leukemia (AML) in CR1 with high risk features (European Leukemia Network [ELN]) at presentation,remissionriskfeatures
Acute myeloid leukemia (AML) in CR1 with high risk features defined as:,remissionriskfeatures
"Acute Myeloid Leukemia (AML): high risk CR1 (as evidenced by preceding MDS, high risk cytogenetics, >= 2 cycles to obtain CR, erythroblastic or megakaryocytic leukemia, FLT-3 ITD +; CR2+. All patients must be in CR as defined by hematological recovery, AND < 5% blasts by light microscopy within the bone marrow with a cellularity of >= 15%.",remissionriskfeatures
Acute myeloid leukemia in first remission with any of the following high risk features defined as:,remissionriskfeatures
Acute myeloid leukemia: high risk CR1 as evidenced by:,remissionriskfeatures
AML in CR1 with intermediate-risk features,remissionriskfeatures
AML in first complete remission (CR1) with high-risk features defined as > 1 cycle of induction therapy required to achieve remission OR preceding MDS or myeloproliferative disease,remissionriskfeatures
Any of the high risk features listed in CR1,remissionriskfeatures
"Complete Remission (CR1) with poor-risk cytogenetics or molecular markers (e.g. Flt 3 mutation, 11q23, del 5, del 7, complex cytogenetics)",remissionriskfeatures
"Complete remission (first complete remission [CR1]) with poor-risk cytogenetics or molecular markers (e.g. fms-related tyrosine kinase 3 [Flt 3] mutation, 11q23, del 5, del 7, complex cytogenetics)",remissionriskfeatures
first complete remission with high-risk features defined as:,remissionriskfeatures
High risk acute myelogenous leukemia (AML) in CR1 or greater,remissionriskfeatures
High-risk CR1 including:,remissionriskfeatures
Patients with high risk AML in CR1 or after first relapse or with primary refractory disease or minimal residual disease.,remissionriskfeatures
"Pre-B ALL patients in CR1 with high-risk features such as adverse cytogenetics including t(9;22), t(4;11) or other MLL rearrangements, t(8",remissionriskfeatures
"Acute leukemia, primary refractory or beyond CR1, or minimal residual disease (MRD) positivity.",rrr
All patients must have received at least one prior therapy - 1 cycle of cytarabine containing regimen or 2 cycles of hypomethylating agent - before determination of refractory status (defined as response duration less than 3 months or no response),rrr
AML in 1st relapse ,rrr
are in relapse to standard therapy following an initial response,rrr
Are relapsed or refractory to at least 1 line of chemotherapy,rrr
Arm B: patients' tumor must be either refractory to or progressed on one of the above agents,rrr
Biochemically recurrent prostate cancer with PSA doubling time <= 9 months at the time of randomization.,rrr
Biopsy proven relapsed disease,rrr
Diagnosis of recurrent or refractory CD19+ leukemia,rrr
"Diagnosis of relapsed/refractory advanced malignancies. Specifically: relapsed refractory refractory acute myeloid leukemia that have failed one line of prior therapy, myelodysplastic syndrome that have failed hypomethylating agents, myelofibrosis that have failed ruxolitinib or are ineligible for this therapy.",rrr
Disease must be refractory to or intolerant of at least first-line chemotherapy which contains 5-fluorouracil or gemcitabine,rrr
Disease progression or relapsed <= 12 months after ASCT (must have biopsy proven recurrence in relapsed subjects).,rrr
Documented active disease requiring treatment per respective NCCN guideline that is relapsed or refractory defined as:,rrr
"Early relapsed leukemia, defined as the re-appearance of leukemia after the achievement of remission and within one year of diagnosis, OR",rrr
"Evidence of biochemical (PSA) or clinical relapse following local primary intervention with curative intent, such as surgery, radiation therapy, cryotherapy, or high-frequency ultrasound and not a candidate for salvage treatment by surgery; or",rrr
For gynecologic cancer cohort only recurrent or progressive disease within 30 days of the last dose of weekly paclitaxel or nab-paclitaxel.,rrr
Has AML or ALL and failed any prior induction therapy regimen or have relapsed after prior therapy,rrr
Has either refractory to or intolerant of at least one proteasome inhibitor and a least one immunomodulatory drug.,rrr
Locally recurrent and unresectable lesions will be allowed only if the entire tumor is clearly delineated and measurable by RECIST 1.1 criteria.,rrr
"MM patients that are relapsed or have refractory disease from at least 3 regimens or lines of therapy including an IMID and a proteasome inhibitor, are eligible for enrollment provided they fulfill the other eligibility criteria:",rrr
"Must be refractory to lenalidomide, defined as having received at least 2 consecutive cycles of lenalidomide as a single agent or within a lenalidomide-containing regimen and having had PD during treatment with or within 60 days after the last dose of lenalidomide. The starting dose of lenalidomide should have been 25 mg (or as low as 10 mg in the case of renal function impairment or other safety concern), and the final dose should have been a minimum of 10 mg.",rrr
Must have had a relapse or PD after having received 2 or more prior lines of systemic therapy,rrr
Must have relapsed or refractory acute lymphoblastic leukemia (ALL) or relapsed or refractory lymphoblastic lymphoma (LL). Refractory is defined as persistent disease after at least 2 courses of chemotherapy.,rrr
"Only patients who are relapsed, refractory, or intolerant of standard AML therapy will be eligible for Part 1 (minimum of 1 prior line of AML-directed therapy)",rrr
"Participant in dose escalation or dose optimization cohort must have received at least one prior systemic therapy, and must have relapsed or progressed after, or failed to respond to any/all available effective therapy or therapies.",rrr
"Participants must have received, and then progressed, relapsed, or been intolerant to at least 2 standard treatment regimens with proven survival benefit in the advanced or metastatic setting according to tumor type, if such a therapy exists",rrr
Participants must have relapsed or refractory cancer.,rrr
"Participants who are refractory to a PD-1/PD-L1 agent, with tumor types such as melanoma, NSCLC, platinum-pretreated head and neck cancer, second line bladder and RCC.",rrr
Pathologic evidence of local/regional breast tumor recurrence,rrr
"Patient must have recurrent, measurable disease by RECIST v1.1.",rrr
"Patients are considered relapsed, when they progress greater than 8 weeks from their last dose of treatment.",rrr
"Patients must have CD19+ B cell malignancy with relapsed or refractory disease, defined as below:",rrr
"Patients must have histologically confirmed MM by MSKCC pathologist, with MM cells expressing BCMA, previously treated with 2+ prior lines of therapy including an IMiD and a PI, either with refractory, persistent, or progressive disease",rrr
"Patients must have platinum-resistant/refractory (i.e., platinum-free interval < 6 months) recurrent or persistent histologically confirmed epithelial (non-mucinous) ovarian, fallopian tube, or primary peritoneal cancer.",rrr
"Patients who relapse within 6 months of adjuvant cisplatin based concurrent chemoradiation, or neoadjuvant cisplatin based therapy can be considered eligible without an additional course of platinum chemotherapy for relapsed disease",rrr
Patients with platinum resistant disease or platinum sensitive disease that is past the first or second recurrence.,rrr
Platinum resistant or refractory disease as defined by progression of disease on a platinum-containing regimen or recurrence of disease within 180 days of previous platinum treatment.,rrr
Primary or recurrent disease eligible,rrr
Primary refractory disease (i.e. never responded ( >= MR) to any prior therapy),rrr
Primary refractory non-M3 AML,rrr
"Received 2-4 prior lines of therapy, including lenalidomide and a PI, either sequential or in the same line, and is refractory (relapsed and refractory or refractory) to both the last line of therapy and to lenalidomide ( >= 10 mg) administered within 18 months prior to randomization. Refractory to lenalidomide is defined as progression while on lenalidomide therapy or within 60 days of last dose, following at least 2 cycles of lenalidomide with at least 14 doses of lenalidomide per cycle.",rrr
recurred within <= 12 months on at least 1 line of ET and 1 cyclin-dependent kinase (CDK)4/6 inhibitor in the adjuvant setting.,rrr
Recurrence of the same primary cancer within any timeframe; OR,rrr
Recurrent breast cancer.,rrr
"Recurrent or progressive ovarian cancer, primary peritoneal cancer or fallopian tube cancer after prior treatment with platinum and taxanes",rrr
"Recurrent, persistent, or progressive epithelial ovarian, fallopian tube, or primary peritoneal cancer after treatment with bilateral oophorectomy and either cisplatin or carboplatin and either paclitaxel, albumin-bound paclitaxel, or docetaxel; histologic confirmation of the primary tumor is required; eligible histologies include serous, endometrioid, clear cell, mucinous, transitional cell, undifferentiated, or mixed carcinoma",rrr
"Refactory to or relapsed after at least 1 prior biologic agent (e.g. Ibrutinib, idelalisib, venetoclax, except a single agent anti-CD20 monoclonal antibody) requiring further treatment",rrr
Refractoriness to their most recent lenalidomide-containing regimen and proteasome inhibitor-containing regimen.,rrr
Refractory / relapsed AML following >= 1 prior therapies (Arms 4a & 5a),rrr
Refractory disease after frontline chemo-immunotherapy,rrr
"Refractory leukemia, defined as persistent leukemia after at least two courses of induction chemotherapy, OR",rrr
Refractory or intolerant to platinum and pemetrexed systemic therapy,rrr
Refractory or Relapsed Acute Myelogenous Leukemia (AML) meeting at least one of the following:,rrr
"Refractory or relapsed after at least 1 prior biologic agent (e.g. lenalidomide, ibrutinib, idelalisib)",rrr
Refractory or relapsed after at least 2 lines of chemoimmunotherapy (including at least one course of anti-CD20 antibody),rrr
Refractory to at least 1 prior induction chemotherapy,rrr
Refractory to or relapsed after 1 or more prior chemoimmunotherapies with at least one containing an anthracycline and CD20 directed therapy,rrr
"Refractory to or relapsed after at least 2 prior chemo or chemoimmunotherapy (e.g. FCR, BR) requiring further treatment",rrr
Refractory to platinum and pemetrexed systemic therapy,rrr
Refractory: failure to achieve complete response (CR) (minimal residual disease [MRD]-negative) at the end of induction,rrr
Relapse after initial complete or partial response or hematological improvement (according to 2006 IWG criteria) observed after at least four cycles of azacitidine or decitabine administered during the past 3 years OR,rrr
Relapse is defined as having progressive disease after achieving an objective response after at least 2 cycles of DNMTi therapy,rrr
Relapsed acute leukemia with <= 5% blasts in the bone marrow prior to transplantation (i.e. CR2 or greater).,rrr
Relapsed after at least 1 prior multiagent systemic chemotherapy that included induction and consolidation,rrr
Relapsed AML,rrr
Relapsed disease after at least 2 line of therapy,rrr
"Relapsed leukemia that is refractory to at least one course of salvage therapy (i.e., therapy given after the relapse has occurred), OR",rrr
"Relapsed or refractory acute leukemia in second or subsequent remission, with remission defined as < 5% bone marrow blasts morphologically",rrr
Relapsed or refractory AML (including AML in CR2),rrr
"Relapsed or refractory AML patients with at least 5% blasts by bone marrow biopsy or aspirate, or at least 1% blasts in peripheral blood, not likely to benefit from standard salvage chemotherapy.",rrr
"Relapsed or refractory AML, who require salvage therapy",rrr
Relapsed or refractory B-cell ALL (patients with Burkitt's lymphoma/leukemia are not eligible),rrr
Relapsed or refractory B-cell NHL meeting all of the following criteria:,rrr
Relapsed or refractory disease,rrr
"Relapsed/refractory AML ( >= 20% blasts in bone marrow or extramedullary leukemia) or newly diagnosed AML patients who are not candidates for (age >= 70 years; adverse cytogenetics, e.g., as defined by the Medical Research Council [MRC] Prognostic Groupings; secondary AML; organ dysfunction arising from significant co-morbidities not directly linked to leukemia; Eastern Cooperative Oncology Group [ECOG] = 2) or not willing to undergo intensive chemotherapy; Note that both relapsed/refractory and newly diagnosed AML patients will be eligible for the dose escalation part of the study, but only newly diagnosed patients will be eligible for the dose expansion cohort",rrr
Relapsed/refractory AML following 7+3 (or similar cytarabine containing induction chemotherapy for AML) disease detected by one of the following methods:,rrr
Relapsed: recurrence of disease after achieving CR,rrr
Second or greater relapse,rrr
"Subjects must have disease that has relapsed and/or refractory after their most recent therapy, with progressive disease (PD) being defined as an increase of 25% from the lowest response value in any one or more of the following:",rrr
Subjects with myeloma that is relapsed and/or refractory to KRd when used in combination defined as progression of disease while on therapy or within 60 days of completing therapy,rrr
The patient has recurrent ipsilateral breast cancer.,rrr
"AML relapse > 6 months since autologous or allogeneic stem cell transplantation, provided there is no active graft-versus-host disease (GVHD) > grade 1; no treatment with high dose steroids for GVHD (up to 20 mg prednisolone or equivalent); no treatment with immunosuppressive drugs with the exception of low dose cyclosporine and tacrolimus (blood levels of 0.5-0.6 ug/mL)",rrsct
Any hematologic malignancy relapsed or with persistent disease after allogeneic hematopoietic stem cell transplant,rrsct
Any relapse after allogeneic hematopoietic stem cell transplantation (HSCT) and >= 4 months from stem cell transplant (SCT) at enrollment OR,rrsct
Participants may enter if they have received a prior autologous stem cell transplant and this therapy produced a remission that lasted greater than 18 months before progression of disease,rrsct
Patient must meet one of the following criteria: a/ patient refractory to one or two standard induction regimens b/ patients with a first untreated relapse within 2 years of documentation of complete remission. Patients relapsing after allogeneic stem cell transplantation are eligible if more than 6 months after transplantation and without signs of active GVHD.,rrsct
Patients relapsing after allogeneic stem cell transplantation are eligible if more than 6 months after transplantation and without signs of active GVHD,rrsct
Patients who have relapsed after standard autologous stem cell infusion are eligible as long as they meet all inclusion criteria and no exclusion criteria. These patients must be out more than 6 months from cell infusion to be eligible for enrollment.,rrsct
Patients with evidence of relapsed or refractory AML or MDS following allogeneic stem cell transplantation,rrsct
Patients with prior allogeneic stem cell transplant who experience relapse of AML are eligible if they are off of immunosuppressive therapy and without any evidence of graft-versus-host disease (GVHD),rrsct
"Patients with refractory or relapsed JMML must have had at least one cycle of intensive frontline therapy or at least 2 cycles of a deoxyribonucleic acid (DNA) demethylating agent with persistence of disease, defined by clinical symptoms or the presence of a clonal abnormality; frontline therapy is defined as one cycle of intravenous chemotherapy that includes of any of the following agents: fludarabine, cytarabine, or any anthracycline but specifically excludes oral 6-mercaptopurine; frontline therapy will also include any conditioning regimen as part of a stem cell transplant; patients who transform to AML at any point with more than 20% blasts are not eligible for this trial",rrsct
"Patients with relapsed or primary refractory AML; patients with relapsed AML after allogeneic stem cell transplantation, including those who have received donor lymphocyte infusions, are eligible if they have no active graft versus host disease (GVHD) and are off immunosuppression",rrsct
Patients with relapsed/refractory AML are eligible if they are not eligible for potentially curative therapy such as effective salvage therapy or hematopoietic stem cell transplantation or who refuse these options at the time of enrollment.,rrsct
Refractory to or intolerant of lenalidomide maintenance following first autologous stem cell transplantation. Refractory is defined as disease relapse/progression on therapy or within 60 days of completing therapy. Intolerance is defined as the inability to administer >= 10 mg per day due to toxicity.,rrsct
"Refractory/relapsed AML following >= 1 prior therapies and are deemed by the investigator not to be candidates for standard therapy, including re-induction with cytarabine or other established chemotherapy regimens for patients with AML (patients who are suitable for standard re-induction chemotherapy or hematopoietic stem cell transplantation and willing to receive it are excluded)",rrsct
Relapse > 6 months since autologous or allogeneic stem cell transplantation provided:,rrsct
Relapse after a prior autologous stem cell transplant (ASCT),rrsct
"Relapse after allogeneic or autologous stem cell transplantation (first relapse after stem cell transplant would be eligible, regardless of prior duration of remission)",rrsct
Relapse after allogeneic or autologous stem cell transplantation (requirement for second relapse does not apply post-transplant),rrsct
relapse after autologous stem cell transplantation,rrsct
Relapse at >= 2 months after first related donor haploidentical stem cell transplantation.,rrsct
relapsed after hematopoietic stem cell transplantation (HSCT),rrsct
Relapsed AML after stem cell transplantation. 90 days (since stem cell infusion) must have elapsed between transplant and emergence of recurrent AML OR,rrsct
"relapsed and refractory multiple myeloma (RRMM): subjects who have received at least 2 prior regimen, were responsive to at least 1 prior regimen (as defined by IMWG criteria) and then are refractory to their most recent therapy ( <= 25% response or progression during therapy or within 60 days after completion of therapy). Prior therapies for subjects with PRMM or RRMM must include an immunomodulatory drug (IMiD) and a proteasome inhibitor as separate lines or a combined line of therapy. If prior therapy includes autologous stem cell transplantation (ASCT), then the succession of induction/ASCT/maintenance therapies will be considered as one line of therapy altogether. Subjects who have relapsed after ASCT or are unable to receive ASCT are eligible. The interval from ASCT to entry in the study must be >= 12 weeks.",rrsct
relapsed disease at least 4 months after allogeneic stem cell transplantation with no evidence of active graft versus host disease and no availability of donor lymphocyte infusion,rrsct
relapsed disease at least 60 days after autologous stem cell transplantation,rrsct
relapsed disease between 2-18 months of 1st autologous stem cell transplantation,rrsct
Relapsed disease within 18 months of prior autologous stem cell transplant (ASCT),rrsct
Relapsed Hodgkin lymphoma unable to achieve 2nd remission or Very Good Partial Response (VGPR) and therefore ineligible to receive autologous hematopoietic stem cell transplant (auto-HSCT),rrsct
"Relapsed or refractory after two or more lines of therapy, including a CD20 antibody and an anthracycline, and the patient is ineligible for autologous stem cell transplantation, if an aggressive or highly aggressive lymphoma.",rrsct
Relapsed or refractory disease after allogeneic hematopoietic stem cell transplant (allo-HSCT),rrsct
Relapsed or refractory disease after allogeneic transplant provided individual is at least 100 days from stem cell transplant at the time of enrollment,rrsct
Relapsed or refractory disease after allogeneic transplant provided individuals is at least 100 days from stem cell transplant at the time of enrollment,rrsct
Relapsed or refractory disease after allogeneic transplant provided subject is at least 100 days from stem cell transplant at the time of enrollment and off of immunosuppressive medications for at least 4 weeks prior to enrollment,rrsct
Subjects must have undergone a prior ASCT for multiple myeloma and have progressed within 365 days of stem cell infusion. Progression is defined according to IMWG criteria49.,rrsct
"Subjects who have undergone autologous stem cell transplantation (SCT) with disease progression or relapse following SCT are eligible; subjects who have undergone allogeneic SCT will be eligible if, in addition to meeting other eligibility criteria, they are at least 100 days post transplant, they have no evidence of graft versus host disease (GVHD) and have been without immunosuppressive agents for at least 30 days",rrsct
"The patient must either have relapsed refractory multiple myeloma (RRMM) after receiving prior lines of anti-myeloma treatments that included at least lenalidomide (Revlimid?��?��????��?��???��?��????��?��??), pomalidomide (Pomalyst?��?��????��?��???��?��????��?��??), bortezomib (Velcade?��?��????��?��???��?��????��?��??), carfilzomib (Kyprolis?��?��????��?��???��?��????��?��??), and daratumumab (Darzalex?��?��????��?��???��?��????��?��??) (refractory MM is defined as the development of disease progression during therapy with an anti-myeloma regimen or within 60 days of the last dose of an anti-myeloma regimen or the achievement of less than a partial response (PR) after greater than or equal to 2 cycles; for relapsing patients the duration from the last dose of the last prior treatment regimen to relapse must be less than or equal to 12 months); OR have multiple myeloma that is refractory to or has relapsed within 1 year of receiving high-dose therapy [HDT]/autologous stem cell transplantation [ASCT] in first- or second-line (refractory is defined as the achievement of less than a PR at the Day 90 to 100 post-ASCT response assessment)",rrsct
Allogeneic stem cell transplant is indicated as management of underlying hematologic malignancy.,sctelig
Any patients eligible for allogeneic stem cell transplantation (allo-SCT) and willing to undergo allo-SCT as determined at time of screening for trial; patients who are ineligible or not interested in undergoing allo-SCT will be eligible for the trial,sctelig
"Availability of appropriate, willing, human leukocyte antigen (HLA)-matched related stem cell donor",sctelig
Be deemed eligible for an allogenic stem cell transplantation as per institutional guidelines of the Blood and Marrow Transplantation Program at John Theurer Cancer Center at Hackensack University Medical Center,sctelig
Be deemed eligible for an autologous stem cell transplantation according to the institutional guidelines of the Blood and Marrow Transplantation Program at John Theurer Cancer Center at Hackensack University Medical Center,sctelig
"Be eligible for apheresis, as determined by the Stem Cell Transplant team",sctelig
"Cohort I, Ph-negative Patients Only: Patients must not be candidates for allogeneic hematopoietic stem cell transplant; NOTE: Subjects up to age 70 years who are considered fit for allogeneic hematopoietic stem cell transplant, should be considered for enrollment on E1910, in order to avoid competing with that study; if a patient is considered unfit for intensive chemotherapy at the time of initial diagnosis, but subsequently achieves a complete remission (CR), then it will be left to the treating physician's discretion to consider hematopoietic stem cell transplant (HSCT)",sctelig
Current eligibility for ASCT,sctelig
Declined or ineligible for potentially curative options such as allogeneic stem cell transplant.,sctelig
Either not eligible or unwilling to proceed with hematopoietic stem cell transplantation (HSCT),sctelig
Eligible for Autologous Hematopoietic stem cell transplantation according at the investigator discretion.,sctelig
"Eligible for, have a suitable donor and are willing to undergo Hematopoietic Stem Cell Transplantation (HSCT)",sctelig
"Eligible patient are not currently considered candidates for, or have declined, stem cell transplantation at the time of enrollment.",sctelig
Eligible to receive a reduced-intensity allogeneic hematopoietic stem cell transplantation (alloSCT).,sctelig
Ineligible for allogeneic stem cell transplant,sctelig
Is eligible for intensive chemotherapy and/or allogeneic stem cell transplantation. The reason a participant is not eligible for intensive chemotherapy and/or allogeneic stem cell transplantation may consist of one or more of the following factors:,sctelig
Meets standard eligibility requirements for high dose chemotherapy with autologous stem cell rescue (COHORT 1) or allogeneic hematopoietic stem cell transplant (COHORT 2) and has signed consent for those procedures,sctelig
"Not a candidate for stem cell transplant (HSCT), at least one re-induction attempt required",sctelig
"Not a candidate for, or refusing treatment with hematopoietic stem cell transplantation",sctelig
not be eligible for or willing to proceed with allogeneic stem cell transplant or for whom allogeneic stem cell transplant is not considered standard of care,sctelig
Not eligible for autologous hematopoietic stem cell transplant (auto-HSCT),sctelig
Participant is candidate for hematopoietic stem cell transplants at the time of enrollment.,sctelig
"Participant is considered a suitable candidate for HCT and has an acceptable source of allogeneic donor stem cells, as defined per institutional practice (allogeneic HCT for any donor source [matched sibling, unrelated donor (URD), mismatched URD, related haploidentical, or umbilical cord blood] and any graft source [umbilical cord, BM, peripheral blood (PB)], and any conditioning [myeloablative conditioning (MAC), reduced intensity conditioning (RIC), or non-myeloablative conditioning (NMA)] will be permitted).",sctelig
Participant is not a candidate to undergo intensive chemotherapy or allogeneic hematopoietic stem cell transplantation (HSCT).,sctelig
Participants must be designated to undergo reduced intensity allogeneic peripheral blood hematopoietic stem cell transplantation (HCT),sctelig
Participants must be designated to undergo reduced intensity allogeneic peripheral blood hematopoietic stem cell transplantation (HCT). Consent will be obtained prior to admission for HCT. The following HCT conditions must be planned:,sctelig
Patient eligible to bone marrow or stem cell transplant,sctelig
Patients eligible for hematopoietic stem cell transplantation,sctelig
"Patients must have either failed ASCT, or be ineligible for or not consenting to ASCT.",sctelig
Patients undergoing stem cell therapy (SCT) or those who are planned for SCT.,sctelig
Patients who are considered appropriate candidates for allogeneic hematopoietic stem cell transplantation and have one of the following diagnoses:,sctelig
"Patients who are considered appropriate candidates for myeloablative, TBI-containing allogeneic hematopoietic stem cell transplantation and have one of the following diagnoses:",sctelig
Patients who are primarily eligible for autologous stem cell transplant,sctelig
Patients who are scheduled to receive an Autologous Hematopoietic Stem Cell Transplantation (autoHSCT) are NOT eligible,sctelig
Patients who have a matched related donor who is eligible and willing to donate stem cells,sctelig
Planned peripheral blood stem cell (PBSC) or bone marrow (BM) HCT for the treatment of the following hematologic malignancies:,sctelig
Planned to undergo myeloablative allogeneic hematopoietic stem cell transplant (HCT),sctelig
"Planned/anticipated HSCT (autologous or allogeneic, with any degree of match donor); acute promyelocytic leukemia (APL; M3 or any morphologic and molecular variants, inclusive); history or current diagnosis of CNS leukemia",sctelig
Subject is a candidate for hematopoietic stem cell transplantation (HSCT).,sctelig
Subject is not a candidate to undergo allogenic hematopoietic stem cell transplantation (HSCT).,sctelig
"Subjects planning to undergo SCT prior to PD on this study (ie, these subjects should not be enrolled in order to reduce disease burden prior to transplant)",sctelig
Subjects who are considered eligible to receive and have not refused an autologous stem cell transplant,sctelig
Suitable candidate to receive allogeneic stem cell transplantation; patient is eligible for study if a suitable candidate refuses to undergo an allogeneic stem cell transplant or a suitable donor cannot be found,sctelig
suitable for allogeneic hematopoietic stem cell transplant (HSCT),sctelig
The patient must have a disease (listed below) with treatment-responsiveness that the treating transplant physician believes will benefit from an allogeneic stem cell transplant. The diseases include:,sctelig
"The patient must have a disease, listed below, with treatment responsiveness that the treating transplant physician believes will benefit from an allogeneic stem cell transplant. The diseases include:",sctelig
allogeneic hematopoietic stem cell transplant (HSCT),sctexcl
Any previous ASCT for multiple myeloma (MM),sctexcl
Gene therapy using an integrating vector Allogeneic hematopoietic stem cell transplant at any time not permitted,sctexcl
"Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study treatment, or has a history of organ transplant, including allogeneic stem cell transplant",sctexcl
Has a history of allogeneic stem cell transplantation,sctexcl
Has a known history of allogenic stem cell transplant,sctexcl
Has a medical history of allogenic stem cell transplant,sctexcl
Has a medical history of allogenic stem cell transplant or received a solid organ transplant.,sctexcl
Has ever received or is scheduled to receive an Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT),sctexcl
Has had a prior allogeneic stem cell or bone marrow transplant.,sctexcl
Has previously had a hematopoetic stem cell transplant or solid organ transplant,sctexcl
Has previously received an allogenic hematopoietic stem cell transplant.,sctexcl
Has received a prior allogeneic stem cell transplant.,sctexcl
Has received an allogeneic stem cell transplant.,sctexcl
Have had a prior allogeneic HSCT.,sctexcl
Have received allogeneic stem cell transplant.,sctexcl
"History of allogeneic bone marrow, stem cell, or solid organ transplant",sctexcl
History of allogeneic stem cell transplant for NHL,sctexcl
History of an allogeneic hematopoietic stem cell transplant.,sctexcl
History of bone marrow transplant and stem cell rescue,sctexcl
History of organ or previous autologous/allogeneic stem cell transplantation,sctexcl
History of organ or stem cell transplantation including previous history of liver transplantation,sctexcl
History of organ transplant or hematopoietic stem cell that requires use of immunosuppressives.,sctexcl
"History of organ, bone marrow, or stem cell transplantation.",sctexcl
History of solid organ or allogeneic stem cell transplant,sctexcl
History of solid organ or stem cell transplant requiring immunosuppressive medications.,sctexcl
History of solid organ or stem cell transplantation.,sctexcl
or prior allogeneic HSCT at any time,sctexcl
Organ transplant recipients including allogeneic hematopoietic stem cell transplant (HSCT).,sctexcl
Participant has previously received an allogenic stem cell transplant,sctexcl
Participant has received allogeneic HSCT or solid organ transplantation.,sctexcl
Participants with prior allogeneic stem cell or solid organ transplantation.,sctexcl
Patient has had hematopoietic stem cell transplant (HSCT) and meets any of the following:,sctexcl
Patients had prior autologous or allogeneic stem cell transplant; prior stem cell collection is allowed,sctexcl
"Patients must not have a prior autologous, syngeneic or allogeneic hematopoietic stem cell transplant.",sctexcl
Patients undergoing haploidentical allogeneic hematopoietic stem cell transplants are not eligible,sctexcl
Patients who have had allogenic hematopoietic stem cell transplant or allogenic bone marrow transplant,sctexcl
Patients who previously received an allogeneic stem cell transplant (SCT) or solid organ transplant are not eligible,sctexcl
Patients who received organ or allogeneic bone marrow or peripheral blood stem cell transplants,sctexcl
Patients with a history of organ transplant including high dose chemotherapy with autologous stem cell rescue,sctexcl
Patients with history of allogeneic hematopoeitic stem cell transplant,sctexcl
Patients with history of allogeneic stem cell transplantation,sctexcl
Patients with lymphomas: prior allogeneic SCT,sctexcl
Patients with previous allogeneic stem cell transplant (SCT) if they meet either of the following criteria:,sctexcl
Patients with previous hematopoietic stem cell transplant (HSCT),sctexcl
Patients with prior allogeneic stem cell or solid organ transplantation,sctexcl
Patients with prior stem cell transplantation or solid organ transplantation.,sctexcl
Previous allogeneic stem cell transplant,sctexcl
Previous allo-HSCT of any kind,sctexcl
Previous bone marrow or stem cell transplant.,sctexcl
Previous hematopoietic stem cell transplant (HSCT),sctexcl
Previous history of an allogeneic hematopoietic stem cell transplantation or treatment with any gene therapy-based therapeutic for cancer or investigational cellular therapy for cancer or BCMA targeted therapy,sctexcl
Previous HSCT procedure (autologous or allogeneic)Pregnancy,sctexcl
Previously received a solid organ transplant or allogeneic progenitor/stem cell transplant.,sctexcl
Prior allogeneic hematopoietic stem cell transplantation,sctexcl
Prior allogeneic HSCT,sctexcl
Prior allogeneic SCT or solid organ transplantation,sctexcl
Prior allogeneic stem cell or solid organ transplant,sctexcl
Prior allogeneic stem cell or solid organ transplantation.,sctexcl
Prior allogeneic stem cell transplant or organ graft,sctexcl
Prior allogeneic stem cell transplant.,sctexcl
Prior allogeneic stem cell transplantation or organ transplantation.,sctexcl
Prior allogeneic stem cell transplantation.,sctexcl
Prior allogeneic transplant of any solid organ or bone marrow/stem cells,sctexcl
Prior allogenic stem cell or solid organ transplant.,sctexcl
Prior allogenic stem cell transplantation,sctexcl
Prior autologous or allogeneic hematopoietic stem cell,sctexcl
Prior autologous or allogeneic stem cell transplant within defined period of initiation of therapy,sctexcl
Prior bone marrow transplants (including stem cells) except autologous stem cell transplant without immunosuppression is NOT considered an exclusion.,sctexcl
Prior bone marrow/hematopoietic stem cell transplantation,sctexcl
"Prior cell or gene therapy, excluding transfers of genetically unmodified autologous cells (eg. Hematopoietic stem cell transplantation), at any time; or prior allogeneic HSCT at any time",sctexcl
Prior hematopoietic stem cell or bone marrow transplant,sctexcl
Prior hematopoietic stem cell or bone marrow transplantation,sctexcl
Prior hematopoietic stem cell or bone marrow transplantation.,sctexcl
Prior hematopoietic stem cell transplantation,sctexcl
Prior history of allogeneic hematopoietic stem cell transplantation.,sctexcl
Prior history of stem cell transplantation,sctexcl
Prior intensive chemotherapy or stem cell transplantation for the treatment of myelodysplastic syndrome,sctexcl
Prior organ transplantation including allogenic stem cell transplantation,sctexcl
Prior receipt of > 1 autologous stem cell transplantation.,sctexcl
Prior solid organ or stem cell transplant,sctexcl
prior stem cell collection is allowed,sctexcl
Prior stem cell transplant.,sctexcl
Prior stem cell transplantation for myeloma,sctexcl
Prior stem cell transplantation or solid organ transplantation,sctexcl
Prior stem cell transplantation or solid organ transplantation.,sctexcl
Prior treatment with allogeneic stem cell transplantation.,sctexcl
Recipient of an autologous stem cell transplant.,sctexcl
Subject has received allogeneic HSCT or solid organ transplantation.,sctexcl
"To decrease sample heterogeneity (consistent with JNCI, 2013 recommendations), allogeneic-HSCT survivors will not be eligible for the study.",sctexcl
Two prior stem cell transplants of any kind,sctexcl
Undergoing myeloablative alloHSCT.,sctexcl
< 100 days from allogeneic SCT,scttime
>= 12 weeks since autologous bone marrow/stem cell transplant prior to enrollment,scttime
>= 6 weeks post last dose of myeloablative therapy and allogeneic or autologous stem cell transplant,scttime
>= 6 weeks post non-myeloablative therapy and allogeneic stem cell transplant,scttime
60 days from allogeneic SCT,scttime
Active GVHD requiring calcineurin inhibitors or steroid dosing >= 10mg/day prednisone (or equivalent) or < 3 months from allogenic hematopoietic stem cell transplant (HSCT).,scttime
"Allogeneic (non-autologous) bone marrow or stem cell transplant, or any stem cell infusion including DLI or boost infusion: >= 84 days after infusion and no evidence of GVHD.",scttime
"Allogeneic (non-autologous) bone marrow or stem cell transplant, or any stem cell infusion including donor lymphocyte infusion (DLI) or boost infusion: >= 100 days after infusion, no evidence of graft versus host disease (GVHD) and no requirement for immunosuppression",scttime
"Allogeneic (non-autologous) bone marrow or stem cell transplant, or any stem cell infusion including donor lymphocyte infusion (DLI) or boost infusion: >= 84 days after infusion and no evidence of graft versus host disease (GVHD)",scttime
Allogeneic hematopoietic stem cell transplant (HSCT) within 3 months prior to enrollment,scttime
Allogeneic hematopoietic stem cell transplant or cellular therapies (including CAR-T cells): The patient must have no evidence of graft versus host diseaseand at least 90 days must have elapsed after allogeneic stem cell infusion. At least 42 days must have elapsed after last dose of other cellular therapy.,scttime
Allogeneic hematopoietic stem cell transplant within the previous 3 months.,scttime
Allogeneic hematopoietic stem cell transplantation (Allo-HSCT) within 90 days of leukapheresis,scttime
"Allogeneic hematopoietic stem cell transplantation (HSCT) within 6 months before the start of protocol-specified therapy, or with active acute/chronic graft-versus-host disease (GvHD) requiring systemic treatment; or receiving immunosuppression for GvHD prophylaxis within 2 weeks from the start of study therapy.",scttime
Allogeneic HSCT or donor lymphocyte infusion within 90 days of leukapheresis,scttime
Allogeneic HSCT or donor lymphocyte infusion within 90 days of leukapheresis.,scttime
Allogeneic HSCT within 3 months prior to start of AMG 427 treatment.,scttime
Allogeneic HSCT within 3 months prior to start of AMG 673 treatment.,scttime
Allogeneic HSCT within three months prior to start of AMG 330 treatment,scttime
"Allogeneic stem cell transplantation at least 24 weeks prior to starting AMG-232 + KRd, and these subjects must also NOT have moderate to severe active acute or chronic graft versus host disease (GVHD)",scttime
"Allogeneic stem cell transplantation is allowed provided the patient is >= 1 year from transplant at time of registration, is not on immunosuppressive therapy to treat/prevent graft-versus-host disease, has no evidence of active graft versus host disease, and no evidence of active infection",scttime
"Allogeneic stem cell transplantation is allowed provided the patient is >= 1 year from transplant, not on immunosuppressive therapy to treat/prevent graft-versus-host disease, has no evidence of active graft-versus-host disease, and has no evidence of active graft-versus-host disease or infection.",scttime
Allo-HSCT within 60 days prior to leukapheresis or donor lymphocyte infusion (DLI) within 6 weeks prior to leukapheresis,scttime
Allowed prior allogeneic hematopoietic stem cell transplantation (allo-HCT) regardless of stem cell source; patients must be at least 3 months post allo-HCT (at time of treatment start); mismatched transplantations would be allowed,scttime
An allogenic stem cell transplant within 6 months before first dose of study drug. Participants who received an allogeneic transplant must be off all immunosuppressive medications for 6 weeks without signs of graft-versus-host disease (GVHD); and/or an autologous stem cell transplant less than or equal to ( <= ) 12 weeks before first dose of study drug,scttime
"Any bone marrow relapse > 100 days after allogeneic stem cell transplant, or",scttime
Any HSCT within 6 months prior to signing informed consent,scttime
At least 4 months since hematopoietic stem cell transplant (HSCT) with no evidence of acute graft vs host disease (GVHD).,scttime
At least 4 months since HSCT with no evidence of acute GVHD.,scttime
Autologous hematopoietic stem cell transplant (HSCT) within 6 weeks prior to enrollment,scttime
Autologous hematopoietic stem cell transplant and stem cell boost: Patients must be at least 60 days from day 0 of an autologous stem cell transplant or stem cell boost.,scttime
Autologous HSCT < 6 months prior to proposed haplo-SCT,scttime
Autologous HSCT < 6 months prior to proposed UCB transplant,scttime
Autologous HSCT within 6 weeks prior to start of AMG 427 treatment.,scttime
Autologous HSCT within 6 weeks prior to start of AMG 673 treatment.,scttime
Autologous HSCT within six weeks prior to start of AMG 330 treatment,scttime
Autologous or allogeneic stem cell or bone marrow transplant within 3 months prior to cycle 1 day 1,scttime
Autologous stem cell infusion including boost infusion: >= 42 days.,scttime
Autologous stem cell transplantation (SCT) within 100 days prior to first infusion,scttime
Autologous stem cell transplantation at least 12 weeks prior to starting AMG-232 + KRd,scttime
Autologous stem cell transplantation less than 90 days prior to study day 1,scttime
Autologous Stem-Cell Transplantation (ASCT) within 100 days prior to first study drug administration,scttime
Autologous transplant completed (referring to day of stem cell infusion) > 12 weeks prior to day 1 of treatment,scttime
"ELIGIBILITY CRITERIA - PHASE I (ARMS A, B, C): Patient may be enrolled with a prior allogeneic hematopoietic stem cell transplant (HSCT) but the transplant date must be at least 90 days before date of enrollment; patient must be off immunosuppression and without active graft versus host disease (GVHD) prior to enrollment if previous HSCT",scttime
ELIGIBILITY CRITERIA - PHASE II (ARM D): Patient may be enrolled with a prior allogeneic hematopoietic stem cell transplant (HSCT) but the transplant date must be at least 90 days before date of enrollment; patient must be off immunosuppression and without active GVHD prior to enrollment if previous HSCT,scttime
"Extensive prior radiotherapy on more than 30% of bone marrow reserves, or prior bone marrow/stem cell transplantation within 5 years from enrollment; Ongoing toxicity (except alopecia) due to a prior therapy, unless returned to baseline or Grade 1 or less",scttime
"Extensive prior RT on more than 30 percent of bone marrow reserves (by Investigator judgment), or prior bone marrow/stem cell transplantation within 5 years before study start",scttime
"For subjects with prior allogeneic stem cell transplant, no evidence of active graft-versus host disease (GVHD), and must be ? 2 weeks off immunosuppressive therapy",scttime
"Has a history of having undergone allogeneic stem cell transplantation, or any other allogeneic or xenogeneic transplant, or has undergone autologous transplantation within 90 days.",scttime
Has received allogeneic hematopoietic cell transplantation (HSCT) within 3 months of planned infusion of genetically modified T cells,scttime
"Has received allogenic hematopoietic stem cell transplantation (HSCT) within 6 months, have active graft-versus-host disease (GVHD) following transplant, or receiving immunosuppressive therapy following a transplant",scttime
"Has received Hematopoietic Stem Cell Transplantation (HSCT) within 60 days of the first dose of DS-3032b, is on immunosuppressive therapy post-HSCT at the time of screening, or has clinically significant GVHD (use of topical steroids for ongoing skin GVHD will be permitted). Has a washout period of >= 2 weeks or at least 4 half-lives (whichever is longer) from their last systemic immunosuppressive treatment for GVHD.",scttime
Has received hematopoietic stem cell transplantation (HSCT) within 60 days of the first dose of DS-3201b,scttime
Has undergone HSCT within the 2 month period prior to the first study dose,scttime
"Has undergone solid organ transplant at any time, or prior allogeneic hematopoietic stem cell transplantation within the last 5 years. (Participants who have had an allogeneic hematopoietic transplant > 5 years ago are eligible as long as there are no symptoms of Graft Versus Host Disease [GVHD].)",scttime
Have completed autologous stem cell transplant within 180 days prior to registration (see also Section 5.2a).,scttime
Hematopoietic stem cell transplant (HSCT) within 60 days of the first dose of CA-4948 for AML,scttime
Hematopoietic stem cell transplant <= 3 months prior to registration.,scttime
"Hematopoietic stem cell transplant: Patients who have experienced their relapse after a HSCT are eligible provided they have no evidence of active GVHD, no past history of grade 3 or greater GVHD, and are at least 100 days post-transplant at the time of enrollment. Patients should be off immune suppression for at least 2 weeks (excluding physiologic replacement steroids).",scttime
"Hematopoietic stem cell transplant: Patients who have experienced their relapse after a HSCT are eligible, provided they have no evidence of acute or chronic Graft-versus-Host Disease (GVHD), are not receiving GVHD prophylaxis or treatment, and are at least 90 days post-transplant at the time of enrollment.",scttime
Hematopoietic stem cell transplantation (HSCT) performed within 3 months prior to Cycle 1 Day 1.,scttime
"Hematopoietic stem cell transplantation (HSCT) within 60 days of screening, or receipt of immunosuppressive therapy for graft-versus-host disease treatment or prophylaxis within 30 days of screening, or active graft-versus-host-disease",scttime
High dose chemotherapy followed by autologous stem cell transplantation within 90 days prior to initiating study treatment,scttime
History of organ allograft (allogeneic bone marrow or stem cell transplant) within 3 months prior to first dose of study drug,scttime
"History of organ allograft (except for corneal transplant) or autologous or allogeneic bone marrow transplant, or stem cell rescue within 3 months prior to the first dose of IMP",scttime
HSCT >= 3 months from CAR-T cell infusion eligible,scttime
HSCT: greater than or equal to 56 days from stem cell transplant with no evidence of active graft vs. host disease; must be off immunosuppressive therapy for at least 4 weeks and have no active graft-versus-host disease (GVHD) at the time of entry onto this trial.,scttime
"If a research participant has undergone prior allogeneic stem cell transplant, he/she must be off all immunosuppressants for graft versus host disease (GVHD) for at least 2 weeks before undergoing leukapheresis",scttime
"If research participant is undergoing leukapheresis and the research participant has undergone prior alloSCT, two months must have elapsed since allogeneic stem cell transplant to undergo PBMC collection for T cell manufacturing",scttime
"If subject has had a hematopoietic stem cell transplant, subject must be >= 60 days post-transplant with no clinically significant GVHD requiring systemic therapy",scttime
Less than 3 months since HSCT,scttime
Less than 30 days post-allogeneic stem cell transplant.,scttime
More than 12 weeks post-transplant of your own blood forming stem cells (autologous transplant),scttime
One prior allogeneic stem cell transplant within the preceding 24 months,scttime
One prior autologous stem cell transplant within the preceding 12 months,scttime
or autologous SCT within 12 weeks prior to randomization,scttime
or participant has received autologous stem cell transplantation (ASCT) within 12 weeks before Cycle 1 Day 1,scttime
"Participants who have had a prior stem cell transplant (SCT) within 90 days prior to the first dose of study medication. Additionally, participants having undergone prior SCT must be off calcineurin inhibitor therapy for at least 28 days prior to the first dose of study medication.",scttime
Participants who have received allogeneic HSCT within 90 days prior to randomization,scttime
"Patient having received hematopoietic stem cell transplantation (HSCT) within 60 days of the first dose of DS-3032b, is on immuno-suppressive therapy post-HSCT at the time of screening, or has clinically significant GVHD (use of topical steroids for ongoing skin GVHD will be permitted)",scttime
Patient must be >= 12 weeks since autologous bone marrow/stem cell transplant prior to enrollment,scttime
"Patient must be >= 3 months from hematopoietic stem cell transplant, must not have active GVHD, and must be off all immunosuppression",scttime
Patients for whom there is the prospect of stem cell transplantation in the next 6 months in the treatment plan are excluded,scttime
Patients having undergone prior allogeneic stem cell transplant within 3 months or having active graft versus host disease,scttime
Patients must have undergone allogeneic stem cell transplant within 40-60 days before starting treatment and be self-sufficient in caloric intake along with no active graft vs. host disease,scttime
Patients that have received a chemotherapy regimen with stem cell support in the previous 6 months,scttime
"Patients who have experienced their relapse after a Hematopoietic stem cell transplantation (HSCT) are eligible, provided they have no evidence of graft-versus-host disease (GVHD) and are at least 100 days post-transplant at the time of enrollment.",scttime
"Patients who have experienced their relapse after a HSCT and are less than 100 days post-transplant at the time of enrollment, have active GVHD at time of enrollment, have past history of grade 3 or greater GVHD, Patients on immune suppression (excluding physiologic replacement steroids).",scttime
"Patients who have previously received an autologous SCT, are excluded if less than 120 days have elapsed from the time of transplant or the patient has not recovered from transplant-associated toxicities prior to the first scheduled dose of MEDI7247.",scttime
"Patients who have received allogeneic HSCT within 6 months, unless being done as a boost.",scttime
Patients who have received an allogeneic HSCT within 90 days of enrollment or are eligible for an allogeneic HSCT and have a donor (unless transplant is refused),scttime
Patients who have received autologous stem cell transplant <= 12 weeks prior to the first dose of study drug.,scttime
Patients who have received prior stem cell transplantation will be allowed to enroll as long as prior transplantation has been at least 3 months before enrollment in the trial and any transplant related toxicities have subsided to grade 1 or less,scttime
Patients who have undergone a prior allogeneic or autologous stem cell transplant within the previous six months.,scttime
"Patients who have undergone allogeneic SCT (alloSCT) are eligible if they are >= 60 days from stem cell infusion, have no evidence of graft versus host disease (GVHD) > Grade 1, and are >= 2 weeks off all immunosuppressive therapy.",scttime
"Patients who have undergone allogeneic stem cell transplant within 12 months are excluded. If allogeneic transplant was > 12 months ago, then they are not excluded as long as they are off all immunosuppression and have no signs or symptoms of active graft versus host disease.",scttime
"Patients who have undergone allogeneic stem cell transplantation and have required systemic treatment for GVHD (including but not limited to oral or parenteral corticosteroids, ibrutinib, and extracorporeal phototherapy) within the last 12 weeks",scttime
Patients who have undergone autologous stem cell transplantation (autoSCT) are eligible provided that they are >= 4 weeks from stem cell infusion.,scttime
"Patients who have undergone HSCT and have not had adequate hematologic recovery (i.e. ANC > 1000 and platelet count > 100K) or patients on immunosuppressive therapy post HSCT at the time of screening (must be off all immunosuppression therapy for at least 2 weeks), or with Grade > 2 active graft-versus-host disease (GVHD), moderate or severe limited chronic GVHD, or extensive chronic GVHD of any severity. The use of topical steroids for cutaneous GVHD is allowed and stable steroid doses less than or equal to 10 mg of prednisone daily is permitted with Medical Monitor approval.",scttime
Patients who have undergone stem cell transplant must be at least 100 days from transplant,scttime
"Patients who have undergone stem cell transplantation (SCT), autologous or allogeneic, are eligible provided that they are >= 8 weeks from stem cell infusion, have no active graft versus host disease (GVHD), are off immune suppression for at least 2 weeks, and do not have a history of veno-occlusive disease (VOD)",scttime
Patients who received a stem cell transplant <= 12 months from the start of therapy,scttime
"Patients with a history of allogeneic hematopoietic stem cell transplantation (HSCT) will be eligible if they are more than 90 days removed from the date of stem cell infusion, have no evidence of acute graft-versus-host disease (GVHD) or active chronic (grade 2-4) GVHD, and are off of all transplant-related immunosuppression for at least 2 weeks",scttime
Patients with a history of allogeneic stem cell transplantation are eligible for study participation provided the transplant was > 100 days prior to study enrollment,scttime
"Patients with history of allogeneic stem cell transplantation are eligible if at least 100 days post-transplant, if there is no evidence of active GVHD and no longer taking immunosuppressive agents for at least 30 days prior to enrollment.",scttime
Patients with prior myeloablative allogeneic stem cell transplantation < 3 months prior to proposed enrollment on study and/or >= Grade II active acute GVHD or extensive chronic GVHD.,scttime
"Previous allogeneic hematopoietic stem cell transplant within 6 months prior to enrollment, active graft versus host disease (GVHD), or requiring transplant-related immunosuppression.",scttime
"Previous allogeneic stem cell transplantation with active graft versus host disease (GVHD), or treatment with immunosuppressive therapy in the 2 months prior to study entry.",scttime
Prior allogeneic hematopoietic stem cell transplant (HSCT) with either standard or reduced intensity conditioning <= 6 months prior to starting CC-90009.,scttime
"Prior allogeneic hematopoietic stem cell transplant (HSCT) within 90 days before randomization. Patients must have completed immunosuppression therapy for treatment of graft versus host disease (GvHD) prior to enrollment. At randomization, patients must not have Grade 2 or higher acute GvHD, or extensive chronic GvHD",scttime
Prior allogeneic hematopoietic stem cell transplantation within previous 100 days (note patients with a prior alloHSCT receive nivolumab at the reduced dose of 1 mg/kg),scttime
"Prior allogeneic HSCT or allogeneic CAR-T within 6 months of Cycle 1 Day 1, or ongoing requirement for systemic graft-versus-host therapy",scttime
Prior allogeneic or ASCT within 12 weeks of initiation of therapy. Prior allogeneic stem cell transplant with active graft-versus-host disease (GVHD),scttime
Prior allogeneic stem cell transplant within 60 days or active acute Graft-vs-Host-Disease (GVHD) grade 3 or higher.,scttime
Prior allogenic bone marrow transplantation in any prior line of therapy or prior autologous SCT in the last prior line of therapy- unless the autologous SCT was performed a year or more before disease progression.,scttime
Prior autologous or allogeneic stem cell transplantation (SCT) within 12 weeks of initiation of study treatment,scttime
Prior autologous SCT in the prior 12 months.,scttime
"Prior autologous stem cell transplantation < 1 month, or allogeneic stem cell transplantation < 3 months prior to C1D1",scttime
Prior bone marrow or peripheral blood HSCT within the last 6 (six) months,scttime
"Prior Bone Marrow-Stem Cell Transplant Subjects who have undergone autologous stem cell transplant (SCT) with disease progression or relapse following SCT are eligible. Subjects who have undergone allogeneic SCT will be eligible if, in addition to meeting other eligibility criteria, they are at least 100 days post transplant, they have no evidence of Graft versus host disease (GVHD) and have been without immunosuppressive agents for at least 30 days.",scttime
Prior hematopoietic stem cell transplant within 6 months of enrollment. If the participant had an allogenic transplant there must be no apparent signs of graft versus host disease and participants must have discontinued all immunosuppressive therapies for at least 4 weeks,scttime
Prior hematopoietic stem cell transplantation within 12 weeks of the first dose of study treatment or ongoing immunosuppressive therapy for graft versus host disease,scttime
"Prior HSCT is not allowed, if it was conducted within 2 months prior to study enrollment.",scttime
Prior peripheral stem cell transplant within 12 weeks of randomization,scttime
Prior peripheral stem cell transplant within 12 weeks of study enrollment,scttime
Prior peripheral stem cell transplant within 12 weeks of the first dose of study treatment,scttime
Prior treatment with any of the following: allogeneic or syngeneic SCT within 16 weeks prior to randomization,scttime
Receipt of allogeneic hematopoietic stem cell transplant 6-12 weeks prior to enrollment,scttime
Receipt of HSCT within 60 days of the first dose of TAK-659/Ixazomib; clinically significant graft-versus-host disease (GVHD) requiring ongoing immunosuppressive therapy post HSCT at the time of screening (use of topical steroids for ongoing skin GVHD is permitted).,scttime
Received a hematopoietic stem cell transplant within the previous 2 months,scttime
Received stem cell transplant within 90 days.,scttime
"Recovered (i.e., <= grade 2 toxicity) from the reversible effects of autologous stem cell transplant (within 5 days before the first dose of the study drug)",scttime
Stem Cell Infusion without TBI: No evidence of active graft vs. host disease and at least 84 days must have elapsed after transplant and 42 days for autologous stem cell infusion after I131-MIBG therapy.,scttime
Stem Cell Infusion: At least 60 days must have elapsed from HSCT and at least 4 weeks (from first dose) must have elapsed from donor lymphocyte infusion (DLI) without conditioning.,scttime
Stem Cell Infusion: No evidence of active graft vs. host disease and at least 84 days must have elapsed after transplant or stem cell infusion.,scttime
Stem cell transplant (autologous or allogeneic) within 100 days of study treatment start,scttime
Stem cell transplant or rescue without TBI: no evidence of active graft versus (vs.) host disease and >= 3 months must have elapsed since transplant,scttime
Stem Cell Transplantation. At least 2 months post-autologous stem cell transplant or at least 3 months post-allogeneic transplant and recovered from toxicities without evidence of graft versus host disease and on stable doses of immunosuppressive medications if required.,scttime
Subject has received ASCT within 12 weeks prior to leukapheresis,scttime
Subject has received autologous stem cell transplantation (ASCT) within 12 weeks prior to randomization.,scttime
"Subject has undergone HSCT within 60 days prior to the start of study treatment, or on immunosuppressive therapy post HSCT at the time of screening, or with clinically significant graft-versus-host disease (GVHD). The use of a stable dose of oral steroid post-HSCT and/or topical steroids for ongoing skin GVHD is permitted.",scttime
"Subjects must be at least 90 days since autologous stem cell transplant, if performed.",scttime
Subjects who have received prior allogeneic stem cell transplant at least 100 days before enrollment with no signs of acute or chronic graft-versus-host disease (GVHD) will be considered eligible,scttime
"Subjects who have undergone hematopoietic stem cell transplantation (HSCT) within 60 days of the first dose of LP-108, or subjects on immunosuppressive therapy post-HSCT at the time of Screening, or with clinically significant graft-versus-host disease (GVHD). (Subjects in relapse after allogeneic transplantation must be off calcineurin inhibitors for at least 4 weeks. The use of topical steroids and/or up to 20 mg/day prednisone or equivalent systemic steroids for ongoing GVHD is permitted).",scttime
Subjects who received an allogeneic bone marrow or allogeneic peripheral blood stem cell transplant less than 12 months prior to initiation of study treatment and who have not discontinued immunosuppressive treatment for at least 4 weeks prior to initiation of study treatment and are currently dependent on such treatment.,scttime
"Subjects with a prior history of stem cell transplant (autologous and/or allogeneic) are allowed if: At least 3 months has elapsed from the time of transplant and the subject has recovered from transplant-associated toxicities prior to the first dose of GSK3326595 and For subjects with a prior history of allogeneic transplant, the subject has been off systemic immunosuppressive medications (including but not limited to: cyclosporine, tacrolimus, mycophenolate mofetil, or corticosteroids) for at least 1 month prior to the first dose of GSK3326595. Topical steroids are permitted; there are no signs or symptoms of acute graft versus host disease, other than Grade 1 skin involvement; there are no signs or symptoms of chronic graft versus host disease requiring systemic therapy.",scttime
The interval from the infusion of stem cells to time of initiation of nivolumab or ipilimumab will be at least 6 weeks (42 days),scttime
"Unless approved by the medical monitor, may not have received an allogeneic hematopoietic stem cell transplant within 6 months before treatment, or have active graft-versus-host-disease following allogeneic transplant",scttime
"Unless approved by the medical monitor, may not have received autologous hematopoietic stem cell transplant within 3 months before treatment",scttime
Who have received autologous stem cell transplant (SCT) 60 days before first infusion of TAK-573 or participants who have received allogeneic SCT 6 months before first infusion. Graft-versus-host disease that is active or requires ongoing systemic immunosuppression.,scttime
"Within 3 years post autologous stem cell transplantation (ASCT) on maintenance, or 18 months if unmaintained",scttime
Active seizure disorder uncontrolled by medication.,seizure
Any history of epilepsy or a seizure disorder or any known prior seizures.,seizure
"Concurrent use of enzyme-inducing antiepileptic drugs (EIAEDs), including phenytoin, carbamazepine, oxcarbazepine, fosphenytoin, phenobarbital, pentobarbital, or primidone",seizure
"Encephalitis, meningitis, or uncontrolled seizures in the year prior to informed consent",seizure
"Has a history of seizure or any condition that may predispose to seizure (including, but not limited to prior cerebrovascular accident, transient ischemic attack, or brain arteriovenous malformation; or intracranial masses such as a schwannoma or meningioma that is causing edema or mass effect).",seizure
"Has experienced a seizure or seizures within 6 months of signing informed consent or is currently being treated with cytochrome P450 enzyme inducing anti-epileptic drugs for seizures (use of anti-epileptic drugs to control pain is allowed in subjects not suffering from seizures unless drug is excluded due to CYP3A4 induction [e.g., phenytoin, carbamazepine, phenobarbital]).",seizure
Have a seizure disorders requiring anticonvulsant therapy,seizure
History of seizure disorder,seizure
"History of uncontrolled seizure disorder, defined as any seizure within 12 months prior to study enrollment.",seizure
More than two seizures over the last 4 weeks prior to study entry,seizure
New onset seizures (within 3 months prior to planned randomization) or poorly controlled seizures,seizure
Patients have significant neurologic disorders such as seizures or dementia or prior brain bleeding (subarachnoid or subdural hematoma within the past 3 years) and unable to safely stop full dose anticoagulation during the screening and treatment phase.,seizure
Patients must not require use of enzyme-inducing antiepileptic drugs,seizure
Patients with a history of active seizures (or a single confirmed seizure event) in the last 2 years from the time of registration.,seizure
Patients with a history of epilepsy who have had no seizures in the past 2 years while not receiving any anti-epileptic medications are allowed in the expansion cohorts only.,seizure
Patients with a history of epilepsy who have had no seizures in the past 2 years while not receiving any anti-epileptic medications are allowed.,seizure
Patients with a known seizure disorder who are receiving non-enzyme inducing anticonvulsants and have well-controlled seizures may be enrolled.,seizure
"Patients with active seizures or a history of uncontrolled seizure disorder, including focal or generalized seizure within the past year.",seizure
Patients with seizure disorder requiring medication.,seizure
Seizure disorder.,seizure
Seizure disorders requiring anticonvulsant therapy.,seizure
"Veliparib has a potential seizure risk, therefore patients with a high risk of seizures should be excluded from the protocol (e.g. those patients with an uncontrolled seizure disorder, and/or patients who have had a focal or generalized seizure within the last 12 months",seizure
"Clinically significant iron metabolism disorders (eg, sickle cell anemia)",sickle-cell
"Diagnosis of Sickle Cell Disease, Thalassemia, Diamond Blackfan Anemia or other non-malignant hematologic disorders for which a stem cell transplant is indicated",sickle-cell
"Hemoglobinopathies (e.g. Sickle Cell Disease, Thalassemia)",sickle-cell
Hemoglobinopathies (including sickle cell disease and thalassemia,sickle-cell
Hemoglobinopathies (including sickle cell disease and thalassemia),sickle-cell
"History of clinically significant sickle cell anemia, autoimmune hemolytic anemia, or idiopathic thrombocytopenic purpura",sickle-cell
"History of sickle cell anemia, auto-immune hemolytic anemia, or idiopathic thrombocytopenic purpura",sickle-cell
No history of sickle cell disease,sickle-cell
No history of sickle cell disease.,sickle-cell
"Patients with known cirrhosis, untreated B12 deficiency, thalassemia, or sickle cell anemia are not eligible as these could cause falsely elevated STM levels",sickle-cell
Patients with sickle cell anemia and other hemolytic anemia.,sickle-cell
Prior diagnosis of hemochromatosis or hemoglobinopathy (e.g. thalassemia),sickle-cell
Sickle cell disease,sickle-cell
"Sickle Cell Disease (Homozygous Hemoglobin S Disease, or Hemoglobin S β 0/+ thalassemia, or Hemoglobin SC Disease)",sickle-cell
Sickle cell disorders.,sickle-cell
"Clinical stage IA2, IB, or IIA disease (this corresponds to surgical tumor node metastasis (TNM) staging of T1-T2, N1, M0)",stage
"Clinical stage T1b-T2b, N0-Nx, M0-Mx (AJCC 6th Edition)",stage
Clinical stage T1-T2c (AJCC 7th edition) within 90 days of registration.,stage
clinical stage T2a or lower,stage
Clinical stages T1a to T2b PSA of less than 10 ng per ml,stage
Cytologically or histologically confirmed non squamous NSCLC Stage IV (including pleural effusion).,stage
Evidence of distant metastases of stage IV,stage
"Histologic diagnosis of either limited stage SCLC (LS-SCLC), or extensive stage SCLC (ES-SCLC) or neuroendocrine tumor",stage
"Histologically confirmed adenocarcinoma of the prostate, clinical stage T1b - T2b (AJCC 6th Edition, see Appendix II), NX/N0, M0.",stage
"Histologically confirmed disease (AJC Classification): Tis, T1, T2 ( <= 3.0 cm), N0, M0.",stage
"Histologically confirmed recurrent adenocarcinoma of the prostate, clinical stage T1 - T3 (AJCC 6th Edition, see Appendix II), NX/N0, M0, following prior prostate radiotherapy.",stage
"Infiltrating ductal carcinoma or DCIS, stage T0, T1, and T2 less than or equal to 3.0 cm, N0 and M0",stage
Metastatic disease not amenable to potentially curative surgery and with available archival tumor tissue or fresh tumor tissue biopsy.,stage
"M-stage determined by physical exam, CT or MRI. Bone scan not required unless clinical findings suggest possible osseous metastases.",stage
"Pathological stage 0-IIIA disease (pTis; pT1-2, N0-N2a, M0)",stage
"Patient must have clinically T1-3, N1 breast cancer at the time of diagnosis (before neoadjuvant therapy). Clinical axillary nodal involvement can be assessed by palpation, ultrasound, CT scan, MRI, PET scan, or PET/CT scan.",stage
"Patient must have clinically T1-3, N1 breast cancer at the time of diagnosis (before neoadjuvant therapy); clinical axillary nodal involvement can be assessed by palpation, ultrasound, CT scan, magnetic resonance imaging (MRI), positron emission tomography (scan, or PET/CT scan",stage
"Patients must have metastatic melanoma, uveal melanoma or stage III in-transit or regional nodal disease. (Turnstile I)",stage
"Patients must have newly diagnosed, stage IIA",stage
"Patients must have newly diagnosed, stage IIA ? IV disease and must be entered within eight weeks from surgery; they may have either measurable residual disease by Response Evaluation Criteria In Solid Tumors (RECIST) criteria, or they may have no measurable residual disease; OR, they must have biopsy-proven recurrent disease of any stage and have never received cytotoxic chemotherapy",stage
"Patients with a histologic diagnosis of squamous cell carcinoma, adenocarcinoma, or adenosquamous cell carcinoma of the cervix, stage IA1 (lymph-vascular space invasion [LVSI]+), IA2, and IB1 (tumor size [maximum visible or palpable]) <= 2 cm), any grade",stage
"Patients with a histological diagnosis of clinical stage I epithelial ovarian cancer, fallopian tube or primary peritoneal carcinoma",stage
"Patients with a histological diagnosis of epithelial ovarian cancer, fallopian tube or primary peritoneal carcinoma, clinical stage II, III or IV at diagnosis",stage
Rai Stage III/IV,stage
"Stage < T1b, T2c, T3 or T4 disease (AJCC 6th Edition, see Appendix II).",stage
"Stage T2, T3, or T4a disease",stage
Stage T3 to 4 disease,stage
"Stage T4 disease (AJCC 6th Edition, see Appendix II).",stage
Ability to swallow and retain capsules.,swallowpills
"Ability to swallow and retain oral medication, with no clinically significant gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowels",swallowpills
"Ability to swallow entrectinib intact without chewing, crushing, or opening the capsules.",swallowpills
"Ability to swallow oral medications (capsules and tablets) without chewing, breaking, crushing, opening or otherwise altering the product formulation. Patients should not have gastrointestinal illnesses that would preclude the absorption of olaparib, which is an oral agent. For the gastric cancer cohort, patients with a full or partial gastrectomy will be permitted.",swallowpills
Ability to swallow pills or capsules.,swallowpills
Able to swallow and retain oral medication,swallowpills
Able to swallow and retain oral medication and must not have any clinically significant gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowels,swallowpills
Able to swallow and retain oral medications and without gastrointestinal (GI) illnesses that would preclude absorption of cediranib or olaparib,swallowpills
Able to swallow and retain orally administered medication and does not have any clinically significant gastrointestinal abnormalities that may alter absorption,swallowpills
Able to swallow and retain orally administered medication.,swallowpills
"Able to swallow and retain orally-administered medication and does not have any clinically significant gastrointestinal abnormalities that may alter absorption, such as malabsorption syndrome, bowel obstruction, or major resection of the stomach or bowel",swallowpills
Able to swallow Metformin and Nelfinavir tablets.,swallowpills
Able to swallow or have medication administered through a gastrostomy tube (G-tube) and absorb the medication,swallowpills
Able to swallow oral formulation of drugs.,swallowpills
Able to swallow oral medication as an intact dosage form,swallowpills
Able to swallow ribociclib capsules,swallowpills
Able to swallow supplements.,swallowpills
"Able to take oral medication without crushing, dissolving or chewing tablets.",swallowpills
Able to take oral medications,swallowpills
Any active gastrointestinal dysfunction that prevents the patient from swallowing tablets or interferes with absorption of study treatment,swallowpills
"Any condition that impairs patient's ability to swallow PD 0332991 tablets (e.g., gastrointestinal tract disease resulting in an inability to take oral medication or a requirement for IV alimentation, prior surgical procedures affecting absorption)",swallowpills
"Any condition that impairs the ability to swallow or absorb oral medication (e.g., gastrointestinal tract disease resulting in an inability to take oral medication or a requirement for IV alimentation, prior surgical procedures affective absorption).",swallowpills
Are able to swallow capsules/tablets.,swallowpills
Gastrointestinal condition that could interfere with the swallowing or absorption of study medication.,swallowpills
"Gastrointestinal disease limiting the ability to swallow oral medications or absorb oral medications including refractory nausea and vomiting, chronic gastrointestinal diseases, inflammatory bowel disease; malabsorption syndromes",swallowpills
"Gastrointestinal disease that might inhibit ibrutinib absorption (e.g., malabsorption syndrome, resection of the stomach or a large portion of small bowel, or partial/complete bowel obstruction), or unable to swallow capsules",swallowpills
Gastrointestinal disorder affecting absorption or the ability to swallow tablets,swallowpills
Gastrointestinal disorder affecting the absorption or ability to swallow large pills.,swallowpills
"History of difficulty swallowing, malabsorption, active partial or complete bowel obstruction, or other chronic gastrointestinal disease or condition that may hamper compliance and/or absorption of AL3818.",swallowpills
Inability of the participant to swallow and retain oral medication,swallowpills
"Inability or unwillingness to swallow pemigatinib or significant gastrointestinal disorder(s) that could interfere with the absorption, metabolism, or excretion of pemigatinib.",swallowpills
Inability or unwillingness to swallow pills or receive IM injections,swallowpills
Inability to swallow capsules or known gastrointestinal malabsorption,swallowpills
Inability to swallow food or any condition of the upper gastrointestinal tract that precludes administration of oral medications (Valacyclovir).,swallowpills
"Inability to swallow gelatin capsules, or any medical condition that interferes with normal gastrointestinal absorption.",swallowpills
Inability to swallow medication or malabsorption condition that would alter the absorption of orally administered medications,swallowpills
"Inability to swallow oral medications (capsules and tablets) without chewing, breaking, crushing, opening or otherwise altering the product formulation. Patients should not have gastrointestinal illnesses that would preclude the absorption of pamiparib, which is an oral agent.",swallowpills
Inability to swallow pills or any significant gastrointestinal disease which would preclude the adequate oral absorption of medications,swallowpills
Inability to swallow tablets.,swallowpills
"Inability to take oral medication, or malabsorption syndrome or any other uncontrolled gastrointestinal condition (e.g., nausea, diarrhea, or vomiting) that might impair the bioavailability of H3B-8800 or absorption of vitamins.",swallowpills
"Is able to swallow and retain orally administered medication and does not have any uncontrolled gastrointestinal (GI) condition such as nausea, vomiting, or diarrhea, or any clinically significant GI abnormalities that may alter absorption such as malabsorption syndromes, hereditary fructose intolerance, glucose-galactose malabsorption, sucrose-isomaltase insufficiency, or major resection of stomach and/or bowels NOTE: Nasogastric and gastrostomy tube administration of the oral suspension formulation of study drug is permitted.",swallowpills
"Known gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of CB-839 HCl including difficulty swallowing, refractory vomiting, gastric resection or bypass, or duodenal/jejunal resection.",swallowpills
Known gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of ixazomib including difficulty swallowing,swallowpills
Known gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of ixazomib or idasanutlin including difficulty swallowing,swallowpills
Known gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of MLN9708 including difficulty swallowing.,swallowpills
Known gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of study treatment including difficulty swallowing,swallowpills
"Known impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral everolimus (e.g., inability to take oral medication or a requirement for intravenous [IV] alimentation, prior surgical procedures affecting absorption, malabsorption syndrome, and active peptic ulcer disease) are excluded; subjects with ulcerative colitis, inflammatory bowel disease, or a partial or complete small bowel obstruction are also excluded, as are any patients who cannot swallow the capsule whole",swallowpills
"Lack of physical integrity of the upper gastrointestinal tract, malabsorption syndrome or inability to swallow",swallowpills
"Medical history of difficulty swallowing, malabsorption, or other chronic gastrointestinal disease, or conditions that may hamper compliance and/or absorption of the test product",swallowpills
Must be able to tolerate oral medication or have it administered via an Nasogastric tube (NGT) or GT tube,swallowpills
No known medical condition causing an inability to swallow oral formulations of agents,swallowpills
Not Applicable as per Revised Protocol 01 - Inability to tolerate oral medication.,swallowpills
Participant is able to take an oral medication.,swallowpills
Participant is able to take oral medication.,swallowpills
Participant must be able to swallow pills and retain oral medication and must not have clinically significant gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowels.,swallowpills
Participants unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the study medication.,swallowpills
"Patient is not able to swallow oral medication and/or has impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of the study drugs (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or significant small bowel resection).",swallowpills
Patient is not able to swallow pills.,swallowpills
Patient is unable to swallow or keep down oral medication.,swallowpills
Patients must be able and willing to swallow and retain oral medication without a condition that would interfere with enteric absorption.,swallowpills
Patients must be able to swallow and retain oral medication and must not have any clinically significant gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowels.,swallowpills
Patients must be able to swallow and retain oral medications and have no known gastrointestinal disorders likely to interfere with absorption of the study medication,swallowpills
"Patients must be able to swallow and tolerate oral medications and not have gastrointestinal illnesses that would preclude absorption of AZD1775 (e.g. uncontrolled nausea, vomiting, or diarrhea; malabsorption syndrome; ulcerative disease); Note: patient may not have a percutaneous endoscopic gastrostomy (PEG) tube or be receiving total parenteral nutrition (TPN)",swallowpills
Patients must be able to swallow oral medications without crushing or chewing,swallowpills
Patients must be able to swallow pills.,swallowpills
Patients must be able to swallow tablets and have no significant impairment in gastrointestinal absorption,swallowpills
Patients must be able to swallow tablets and have no significant impairment in gastrointestinal absorption.,swallowpills
"Patients must be able to swallow tablets or capsules; a patient with any gastrointestinal disease that would impair ability to swallow, retain, or absorb drug is not eligible",swallowpills
Patients must be able to swallow whole capsules; nasogastric or gastrointestinal (G)-tube administration is not allowed,swallowpills
"Patients must be able to swallow whole tablets or capsules. Nasogastric or G-tube administration is not allowed. Any gastrointestinal disease which would impair ability to swallow, retain, or absorb drug is not allowed.",swallowpills
"Patients must be able to take oral medications (i.e., swallow pills whole); patients must not have gastrointestinal tract disease resulting in an inability to take oral medication or a requirement for intravenous (IV) alimentation, prior surgical procedures that could in the opinion of the treating investigator affect absorption, or active peptic ulcer disease; patients with intractable nausea or vomiting are not eligible",swallowpills
Patients must have the ability to swallow and retain oral medication.,swallowpills
"Patients unable to swallow oral medications, or patients with gastrointestinal conditions (e.g. malabsorption, gastric or small bowel resection, etc.) deemed to jeopardize intestinal absorption",swallowpills
Patients unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the study medication,swallowpills
Patients who are unable to swallow intact tablets are not eligible.,swallowpills
Patients who are unable to swallow pills or absorb orally administered medication.,swallowpills
"Patients with a bowel obstruction or any other gastrointestinal condition that might affect absorption of the oral drug should be excluded; this would include patients with inability to swallow and retain orally-administered medication, malabsorption syndrome, or those with a major resection of the stomach or bowels",swallowpills
"Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection",swallowpills
"Refractory nausea and vomiting, chronic gastrointestinal diseases, previous significant bowel resection, or any process that compromises the ability to swallow or absorb oral medication",swallowpills
"Refractory nausea, vomiting, or chronic gastrointestinal diseases, inability to swallow the study medication, or previous significant bowel resection that would preclude adequate absorption of HS-10296.",swallowpills
Subject is able to swallow and retain oral medication and does not have uncontrolled emesis or gastrointestinal disorders likely to interfere with absorption of the study medication,swallowpills
Subject is able to swallow and retain oral medication and does not have uncontrolled emesis.,swallowpills
Unable or unwilling to swallow study drug.,swallowpills
Unable or unwilling to swallow tablets as per dosing schedule,swallowpills
Unable or unwilling to swallow tablets.,swallowpills
Unable or unwilling to swallow the complete daily dose of derazantinib capsules,swallowpills
Unable to swallow and retain oral medication.,swallowpills
"Unable to swallow capsules or malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel, symptomatic inflammatory bowel disease or ulcerative colitis, or partial or complete bowel obstruction",swallowpills
Unable to swallow oral medications.,swallowpills
Unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the study medication.,swallowpills
Unable to swallow orally administered medication whole.,swallowpills
Castrate testosterone levels ( < 50 ng/dL) achieved by orchiectomy or maintenance on a luteinizing hormone-releasing hormone (LHRH) agonist or antagonist,testosterone-castrated
Documented castration resistant prostate cancer (mCRPC) (Note: castration will be defined by a testosterone < 50 ng/dL achieved by orchiectomy or luteinizing hormone-releasing hormone [LHRH] agonist/antagonist therapy),testosterone-castrated
Has serum testosterone levels < 50 ng/dL during screening. Patients without a history of bilateral orchiectomy are required to remain on luteinizing hormone-releasing hormone (LHRH) analog during the course of protocol therapy,testosterone-castrated
Have testosterone < 50 ng/dL. Note: Patients must continue primary androgen deprivation with an luteinizing hormone-releasing hormone (LHRH) analogue (agonist or antagonist) if they have not undergone orchiectomy,testosterone-castrated
Have testosterone level of < 50 ng/dL. Note: Patients must continue primary androgen deprivation with a luteinizing hormone-releasing hormone (LHRH) analogue (agonist or antagonist) if they have not undergone orchiectomy.,testosterone-castrated
"Maintenance of castration status, defined as serum testosterone level of less than 50 ng/dL. Patients must be surgically castrate or maintained on LHRH agonist or antagonist therapy for the duration of the study period.",testosterone-castrated
"No androgen deprivation therapy such as treatment with antiandrogens, luteinizing hormone-releasing hormone (LHRH) agonists or antagonists for at least one year prior to trial enrollment, and testosterone must be inside normal range prior to trial enrollment if there is prior history of ADT.",testosterone-castrated
Ongoing androgen deprivation therapy (ADT) with a Gonadotropin-releasing hormone (GnRH) analogue or a surgical/medical castration with testosterone level of <= 1.73nmol/L (50ng/dL),testosterone-castrated
"Ongoing androgen deprivation therapy with a luteinizing hormone-releasing hormone (LHRH)  super-agonist  or antagonist, or bilateral orchiectomy and serum testosterone level < 50 ng/dL ( < 0.5 ng/mL, < 1.7 nmol/L) at screening.",testosterone-castrated
Participants must have undergone a radical prostatectomy.,testosterone-castrated
Patient desires and is medically fit to undergo prostatectomy,testosterone-castrated
"Patients must have been surgically or medically castrated; if the method of castration was luteinizing hormone-releasing hormone (LHRH) agonists (leuprolide or goserelin) or antagonists (degarelix), then the patient must be willing to continue the use of LHRH agonists or antagonists; serum testosterone must be at castration levels ( < 50 ng/dL) within 3 months prior to registration",testosterone-castrated
"Patients must have had either orchiectomy or be on luteinizing hormone-releasing hormone (LHRH) agonist or antagonist therapy with serum testosterone < 50 ng/dL, and agree to stay on LHRH agonist or antagonist therapy during the study.",testosterone-castrated
PCa survivors that had at least 6 months of hormone therapy (i.e. ADT with testosterone lowering agents) within the past 10 years,testosterone-castrated
Testosterone < 50 ng/dL. Patients must continue primary androgen deprivation with a luteinizing hormone-releasing hormone (LHRH) analogue if they have not undergone orchiectomy.,testosterone-castrated
Testosterone <= 50 ng/dL; subjects must continue primary androgen deprivation with an luteinizing hormone-releasing hormone (LHRH) analogue (agonist or antagonist) if they have not undergone orchiectomy,testosterone-castrated
"Acute deep vein thrombosis or clinically relevant pulmonary embolism, not stable for at least 4 weeks prior to first IMP administration.",thromboembolic
Arterial thromboembolic events,thromboembolic
"Coagulopathy or any history of coagulopathy within the past 6 months, including history of deep vein thrombosis or pulmonary embolism. However, subjects with the following conditions will be allowed to participate:",thromboembolic
"Conditions that increase the risk of venous thrombosis and/or pulmonary emboli including, but not limited to: prior history of deep venous thrombosis or pulmonary emboli, atrial fibrillation, paroxysmal atrial fibrillation, known and documented thrombophilia requiring long term anticoagulation therapy, permanent intravenous indwelling catheters, severe obesity (BMI > 40).",thromboembolic
History of a pulmonary embolus (PE) or deep vein thrombosis (DVT) within the last 6 months or any known thrombophilia. Subjects stable on anti-coagulants for maintenance are eligible as long as the DVT and/or PE occurred > 6 months prior to enrollment and there is no evidence for active thrombosis. The use of low dose ASA is permitted.,thromboembolic
History of deep venous thrombosis (DVT) or pulmonary embolisms (PE) 1 <= 12 months prior to preregistration; OR Active DVT and/or PE requiring anti-coagulant therapy.,thromboembolic
History of symptomatic deep vein thrombosis or pulmonary embolism within 6 months of enrollment.,thromboembolic
History or presence within the last 3 months of Deep Vein Thrombosis (DVT) or a pulmonary embolism (PE),thromboembolic
Patient has a history of thromboembolic event(s) and is not willing to take thromboembolic prophylaxis.,thromboembolic
Patients may have a history of current or previous deep vein thrombosis or pulmonary embolism but are required to take some form of anti-coagulation as prophylaxis if they are not currently on full-dose anticoagulation.,thromboembolic
"Portal vein thrombosis involving more than intrahepatic portal vein branches: thrombosis of the right or left portal vein branch or the bifurcation, partial or complete obstruction of the portal vein trunk.",thromboembolic
"Stroke (including transient ischemic attack [TIA]), myocardial infarction (MI), or other ischemic event, or thromboembolic event (e.g., deep venous thrombosis, pulmonary embolism) within 6 months before first dose.",thromboembolic
"Stroke (including transient ischemic attack [TIA]), myocardial infarction (MI), or other ischemic event, or thromboembolic event (eg, deep venous thrombosis [DVT], pulmonary embolism) within 6 months before first dose. Subjects with a diagnosis of DVT within 6 months are allowed if stable, asymptomatic, and treated with LMWH for at least 6 weeks before first dose. Iatrogenic arterial embolization procedures such as tumor arterial embolization or splenic artery embolization are allowed.",thromboembolic
"Stroke or transient ischemic attack, or other ischemic event, or thromboembolic event (e.g., deep venous thrombosis, pulmonary embolism) within 3 months before start of study treatment.",thromboembolic
"Subject with stroke, deep venous thrombosis, pulmonary or arterial embolism within 6 months immediately up to the enrollment date.",thromboembolic
"Subjects who have had a venous thromboembolic event (e.g., pulmonary embolism or deep vein thrombosis) requiring anticoagulation and who meet any of the following criteria:",thromboembolic
Subjects with a history of venous thrombosis within the past 3 months.,thromboembolic
symptomatic pulmonary embolism.,thromboembolic
"Venous thrombotic events (e.g., deep vein thrombosis) or pulmonary arterial events (e.g., pulmonary embolism) within the 3 months before start of study drug. Patients with venous thrombotic events >= 3 months before start of study drug on stable anticoagulation therapy are eligible.",thromboembolic
"All acute toxic effects of any prior radiotherapy, chemotherapy, or surgical procedure must have resolved to grade less than or equal to ( <= ) 1, except alopecia (any grade) and Grade 2 peripheral neuropathy",toxicity
"All hematologic, gastrointestinal, and genitourinary chemotherapy toxicities must be less than grade 2 at the time study therapy is to begin. (Note: Transfusions may be used to correct hemoglobin for patients experiencing anemia from therapy who otherwise would be eligible for the study.",toxicity
"All prior treatment-related toxicities must be National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4 <= Grade 1 (except alopecia [permissible at any Grade] and peripheral neuropathy [which must be <= Grade 2]) at the time of treatment allocation. - Adequate organ function as per Hematologic, Hepatic, Renal and Cardiac Laboratory Values",toxicity
"All toxicities attributed to prior anti-cancer therapy other than alopecia and fatigue must have resolved to Grade 1 (NCI CTCAE version 4) or baseline before administration of study drug. Participants with toxicities attributed to prior anti-cancer therapy which are not expected to resolve and result in long lasting sequelae, such as peripheral neuropathy grade 2 or less, are permitted to enroll",toxicity
"All treatment-related toxicities resolved to Grade < 1 on National cancer institute Common Terminology Criteria for Adverse Events (NCI-CTCAE version 5.0) criteria (except hair loss and <= Grade 2 neuropathy, which are acceptable).",toxicity
Any grade 4 toxicity prior to start of chemoradiotherapy that may be due to induction chemotherapy.,toxicity
Any non-hematological toxicities (except for peripheral neuropathy as described in exclusion criterion #24) that patients experienced from treatments in previous clinical studies must have resolved to <= Grade 2 by Cycle 1 Day 1.,toxicity
Any systemic therapy associated toxicity should be Grade 1 or less,toxicity
"Any unresolved chronic toxicity with Common Toxicity Criteria (CTC) AE grade >= 2, from previous anticancer therapy, except for alopecia. Any unresolved toxicity National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) grade >= 2 from previous anticancer therapy with the exception of alopecia, vitiligo, and the laboratory values defined in the inclusion criteria.",toxicity
Any unresolved toxicities from previous anticancer therapy.,toxicity
"Any unresolved toxicities from prior therapy greater than Common Terminology Criteria for Adverse Events (CTCAE) Grade 1 at the time of starting IMP, with the exception of alopecia.",toxicity
"Any unresolved toxicities from prior therapy greater than Common Terminology Criteria for Adverse Events (CTCAE) grade 1 at the time of starting study treatment with the exception of alopecia and grade 2, prior platinum-therapy related neuropathy.",toxicity
"Any unresolved toxicities from prior therapy, including commercial osimertinib, greater than Common Terminology Criteria for Adverse Events (CTCAE) grade 1 at the time of starting study treatment.",toxicity
"Any unresolved toxicity ( > CTCAE grade 2) from previous anti-cancer therapy. (Subjects with irreversible toxicity that is not reasonably expected to be exacerbated by the investigational product may be included (e.g., hearing loss, peripheral neuropathy).",toxicity
Any unresolved toxicity >= Grade 2 (except stable Grade 2 peripheral neuropathy or alopecia) from previous anticancer therapy,toxicity
"Any unresolved toxicity by Common Terminology Criteria for Adverse Events Version (CTCAE v4.03) > Grade 1 from previous anti-cancer therapy (including radiotherapy), except alopecia.",toxicity
Any unresolved toxicity Common Terminology Criteria for Adverse Events (CTCAE) > Grade 2 from the prior chemoradiation therapy,toxicity
Any unresolved toxicity CTCAE Grade >= 2 from previous anticancer therapy,toxicity
"Any unresolved toxicity National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) grade >= 2 from previous anticancer therapy with the exception of alopecia, vitiligo, and the laboratory values defined in the inclusion criteria.",toxicity
"Any unresolved toxicity National Cancer Institute (NCI) CTCAE Version 4.03 Grade >= 2 from previous anticancer therapy with the exception of alopecia, vitiligo, and laboratory values defined in the inclusion criteria.",toxicity
"Any unresolved toxicity NCI CTCAE Grade >= 2 from previous anticancer therapy with the exception of alopecia, vitiligo, and the laboratory values defined in the inclusion criteria -Patients with Grade >= 2 neuropathy will be evaluated on a case-by-case basis after consultation with the Study Physician.",toxicity
"Any unresolved toxicity of NCI CTCAE Grade >= 2 from previous anticancer therapy with the exception of alopecia, vitiligo, and the laboratory values defined in the inclusion criteria.",toxicity
"At least 14 days must have elapsed since any prior systemic therapy at the time the patient starts the cyclophosphamide and fludarabine conditioning regimen, and patients' toxicities must have recovered to a grade 1 or less (except for toxicities such as alopecia or vitiligo).",toxicity
At least 3 half-lives must have elapsed since prior therapy that included a monoclonal antibody with the exception of blinatumomab. Patients must have been off blinatumomab infusion for at least 7 days and all drug related toxicity must have resolved to grade 2 or lower as outlined in the inclusion/exclusion criteria.,toxicity
Chemotherapy: A minimum of 21 days must have elapsed from the last dose and resolution of toxicity to <= grade 1 excluding <= grade 2 peripheral neuropathy or alopecia,toxicity
Chemotherapy-related hematological toxicities must have resolved to Grade 1 or less.,toxicity
"Concomitant anti-neoplastic treatment is not allowed during protocol treatment and should be completed at least 2 weeks prior to commencement of protocol treatment, with resolution of associated acute toxicities. Bisphosphonates are permitted without restriction even during protocol treatment.",toxicity
Continue to have unresolved > grade 1 toxicity from any previous treatment,toxicity
"Failure to have fully recovered (i.e., <= grade 1 toxicity) from the reversible effects of prior chemotherapy.",toxicity
"Failure to have fully recovered (i.e., <= grade 2 toxicity) from the effects of prior chemotherapy regardless of the interval since last treatment",toxicity
"Failure to recover from any immune-related toxicity from prior cancer therapy to <= Grade 1, except if previous immune-related endocrinopathy is medically managed with hormone replacement therapy only.",toxicity
Failure to recover from any other toxicity (other than immune-related toxicity) related to previous anticancer treatment to <= Grade 2.,toxicity
"Failure to recover to <= grade 1 from acute, reversible effects of prior chemotherapy, excluding alopecia regardless of interval since last treatment; (NOTE: patients with residual peripheral neuropathy are allowed)",toxicity
"Full recovery from the acute effects of prior cancer treatments, defined as effects having resolved to NCI CTCAE v4.03 Grade 0 or 1 with the exception of alopecia and certain laboratory values as listed above. Subjects with irreversible toxicity that is not reasonably expected to be exacerbated by MEDI4736 and tremelimumab may be included (eg, hearing loss, neuropathy) upon approval of the PI.",toxicity
"Grade ? 2 toxicity (other than alopecia) continuing from prior anticancer therapy, including radiation",toxicity
Grade > 1 toxicity from prior therapy (except alopecia or anorexia).,toxicity
"Had recovered from toxicities related to prior anticancer therapy to national cancer institute common terminology criteria for adverse events (NCI CTCAE), version 4.03, Grade <= 1. (Note: Treatment-related alopecia or peripheral neuropathy that are Grade > 1 are allowed if deemed irreversible.) and have adequate major organ functions.",toxicity
"Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., <= grade 1 or at baseline) from adverse events due to a previously administered agent; Note: subjects with <= grade 2 neuropathy are an exception to this criterion and may qualify for the study; Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy",toxicity
"Has not recovered (recovery is defined as Common Terminology Criteria for Adverse Events (CTCAE) version (v)4 grade <= 1 or return to baseline) from the acute toxicities of previous therapy, except treatment-related alopecia or laboratory abnormalities otherwise meeting eligibility requirements.",toxicity
Has not recovered adequately from toxicities and/or complications from surgical intervention before starting study drug.,toxicity
"Has not recovered from clinically significant toxicities as a result of prior anticancer therapy, except alopecia and infertility. Recovery is defined as <= CTCAE) Version 4.03",toxicity
Has not recovered or stabilized from any clinically significant toxicity associated with any prior procedure or anticancer therapy,toxicity
"Has persistent clinically significant toxicities (grade >= 2; per National Cancer Institute Common Terminology Criteria for Adverse Events [NCI CTCAE] version 4.03) from previous anticancer therapy (excluding alopecia which is permitted and excluding grades 2 and 3 laboratory abnormalities if they are not associated with symptoms, are not considered clinically significant by the Investigator, and can be managed with available medical therapies).",toxicity
"Has persistent, clinically significant > Grade 1 non-hematologic toxicity from prior AML therapies",toxicity
Has recovered adequately from major surgery or the toxicity and/or complications from the intervention prior to starting study treatment,toxicity
Has recovered adequately from toxicity and/or complications from surgery prior to study start,toxicity
"Has recovered from all NCI CTAE grade III-IV, non-hematologic acute toxicities from prior therapy",toxicity
"Has unresolved toxicities from previous anticancer therapy, defined as toxicities (other than alopecia) not yet resolved to NCI-CTCAE Grade <= 1, or baseline. Subjects with chronic Grade 2 toxicities may be eligible at the discretion of the Investigator and Sponsor (eg, Grade 2 chemotherapy-induced neuropathy).",toxicity
"Have recovered from toxicities related to prior anticancer therapy to national cancer institute common terminology criteria for adverse events (NCI CTCAE) v4.03 grade less than or equal to ( <= )1. (Note: treatment-related alopecia or peripheral neuropathy that are grade greater than ( > ) 1 are allowed, if deemed irreversible).",toxicity
"Have resolution of toxic effect(s) of the most recent prior chemotherapy to Grade 1 or less (except alopecia). If the patient received major surgery or radiation therapy of > 30 Gy, they must have recovered from the toxicity and/or complications from the intervention.",toxicity
"If patient has received adjuvant treatments, in particular ipilimumab and high dose interferon, any toxicities must have resolved to grade 1 or less. Grade 2 toxicities attributed to ipilimumab from autoimmune endocrinopathies that require permanent hormone replacement therapy are allowed as long as they are adequately treated. This implies that patients should be off systemic steroids for treatment of any of these or other autoimmune toxicities (e.g. colitis, rash).",toxicity
Inadequate recovery from toxicity attributed to prior anti-cancer therapy.,toxicity
NO clinically significant organ toxicity that are defined as follows:,toxicity
No CTCAE grade >= 3 non-hematologic toxicity,toxicity
Not recovered from prior-treatment toxicities to Grade <= 1.,toxicity
Ongoing acute treatment-related toxicity associated with a previous therapy greater than grade 1 except for grade 2 alopecia or neuropathy,toxicity
"Ongoing prior toxicities related to previous treatments must be recovered to < grade 2 at the time of registration (with the exception of alopecia, grade 2 peripheral neuropathy or lymphopenia)",toxicity
"Participants who have not recovered from adverse events due to prior anti-HSIL therapy (i.e., have residual toxicity > grade 1), per Common Toxicity Criteria for Adverse Events (CTCAE) v4.0",toxicity
"Patients must have recovered (i.e., improvement to Grade 1 or better) from all acute toxicities from previous therapy, excluding alopecia and vitiligo.",toxicity
Patients must have recovered from acute non hematologic toxicity (to Grade 1 or less) of all previous therapy prior to enrollment.,toxicity
"Patients recovered from acute toxicities from prior anti-cancer chemotherapy including HSCT, cytotoxic therapy, prior blinatumomab, biologic, immunotherapy, monoclonal antibody, XRT and corticosteroid therapy",toxicity
"Patients with toxicities (as a result of prior anticancer therapy) which have not recovered to baseline or stabilized, except for AEs not considered a likely safety risk (eg, alopecia, neuropathy and specific laboratory abnormalities).",toxicity
"Persistent Grade 3 or 4 toxicity from previous chemotherapy and/or radiotherapy, with the exception of alopecia.",toxicity
"Persistent toxicities ( > Common Terminology Criteria for Adverse Event (CTCAE) grade 2) caused by previous cancer therapy, excluding alopecia.",toxicity
"Presence of >= CTCAE grade 2 toxicity (except alopecia, peripheral neuropathy and ototoxicity, which are excluded if >= CTCAE grade 3) due to prior cancer therapy",toxicity
"Presence of >= CTCAE grade 2 toxicity (except alopecia, peripheral neuropathy and ototoxicity, which are excluded if >= CTCAE grade 3) due to prior therapy.",toxicity
Presence of >= grade 3 non-hematologic toxicities as per CTCAE version 5 from any previous treatment unless it is felt to be due to underlying disease.,toxicity
"Presence of National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) >= grade 2 toxicity (except alopecia, peripheral neuropathy and ototoxicity, which are excluded if >= NCI CTCAE grade 3) due to prior cancer therapy",toxicity
"Prior to randomization patients with any non-hematologic toxicity from surgery, chemotherapy and radiation therapy must have recovered to grade <= 1 with the exception of alopecia, ototoxicity and neuropathy",toxicity
"Recovered from all toxicities associated with prior treatment to acceptable baseline status (for laboratory toxicities, see below limits for inclusion) or a National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03, Grade of 0 or 1, except for toxicities not considered a safety risk (e.g., alopecia or vitiligo).",toxicity
"Recovery from >= grade 2 toxicities of prior therapy regimen to grade 1 or baseline, with the exception of anemia and lymphopenia and chronic residual toxicities that in the opinion of the investigator are not clinically relevant given the known safety/toxicity profiles of gemicitabine, sorafenib, and vorinostat (eg, alopecia, changes in pigmentation, stable endocrinopathies). Patients with <= grade 2 peripheral sensory or motor neuropathy are eligible.",toxicity
"Recovery from acute toxicity related to prior therapy, including surgery and radiation, or no treatment-related toxicity >= grade 2.",toxicity
"Recovery to baseline or <= Grade 1 CTCAE v.4.0 from toxicities related to any prior treatments, unless AE(s) are clinically nonsignificant and/or stable on supportive therapy",toxicity
"Recovery to baseline or <= Grade 1 CTCAE v4 from toxicities related to any prior treatments, unless AE(s) are clinically nonsignificant and/or stable on supportive therapy. Alopecia, sensory neuropathy Grade <= 2, or other Grade <= 2 not constituting a safety risk based on investigator's judgment are acceptable.",toxicity
Recovery to grade 1 of any clinically significant toxicity (excluding alopecia) prior to initiation of study drugs.,toxicity
"Residual toxicity from prior anticancer therapy of grade 3 or greater (CTCAE v5.0), with the exception of alopecia",toxicity
"Resolution of all related toxicities from chemo/RT to < grade 2, except alopecia.",toxicity
"Resolution of any adverse events (AEs) from prior treatments must be resolved to baseline or grade <= 1 at enrollment (with the exception of alopecia), neuropathy, and ototoxicity (i.e., AEs that are not expected to improve within the washout period)",toxicity
Significant neurotoxicity/neuropathy (Grade 3 or higher) within 14 days of first dose of study drug,toxicity
Subjects must have recovered to baseline or <= grade 1 toxicities related to any prior treatments unless AE(s) are clinically non-significant and/or stable.,toxicity
Toxicities from previous therapies that have not resolved to a grade 1 or less.,toxicity
"Toxicities of prior therapy (except alopecia) should be resolved to <= grade 1 as per National Cancer Institute (NCI)-Common Terminology Criteria for Adverse Events (CTCAE) version (v)5.0; patients with long-standing stable grade 2 neuropathy or prior grade 2 treatment-related hypothyroidism requiring treatment, provided free T4 within normal range, may be considered eligible after discussion with the study principal investigator (PI)",toxicity
Toxicities of prior therapy (excepting alopecia) should be resolved to less than or equal to Grade 1 as per CTCAE v4.0 (http://ctep.cancer.gov/protocol development/electronic_applications/ctc.htm). Patients with long-standing stable grade 2 neuropathy may be considered after discussion with the Study Chair.,toxicity
Toxicities of prior therapy (excepting alopecia) should be resolved to less than or equal to grade 1 as per CTCAE; patients with long-standing stable grade 2 neuropathy may be considered after discussion with the study chair.,toxicity
Toxicity from previous anticancer treatment that includes:,toxicity
"Toxicity related to prior treatment that has not resolved to <= Grade 1 (except alopecia, vitiligo, hearing loss, endocrinopathy managed with replacement therapy, and peripheral neuropathy which must be <= Grade 2).",toxicity
"Treatment with cytotoxic chemotherapy within previous 28 days, or failure to recover from AEs due to cytotoxic chemotherapy administered more than 28 days previous (however, ongoing neuropathy is permitted).",toxicity
Unresolved Grade 2 or higher toxicities related to previous anticancer therapy except alopecia.,toxicity
"Unresolved toxicities from prior anticancer therapy, defined as having not resolved to NCI CTCAE v4.03 Grade 0 or 1, or to levels dictated in the inclusion/exclusion criteria",toxicity
"Unresolved toxicity (i.e., > Grade 1 or above baseline) due to previously administered agents. Exception includes: subjects with <= Grade 2 neuropathy are eligible for the study.",toxicity
Unresolved toxicity >= CTCAE Grade 2 from previous anti-cancer therapy except alopecia (if applicable) unless agreed that the patient can be entered after discussion with the Medical Monitor.,toxicity
"Unresolved toxicity higher than CTCAE (version 5.0) grade 1 attributed to any prior therapy/procedure, excluding alopecia, peripheral neuropathy, and bone marrow parameters.",toxicity
Active tuberculosis,tuberculosis
"active tuberculosis (history of exposure or history of positive TB test with presence of clinical symptoms, physical or radiographic finding).",tuberculosis
"Active tuberculosis infection (clinical symptoms, physical or radiographic, and laboratory findings).",tuberculosis
Active tuberculosis OR known history of previous clinical diagnosis of tuberculosis.,tuberculosis
Active tuberculosis.,tuberculosis
Has a known history of active TB (Bacillus Tuberculosis),tuberculosis
Has a known history of active TB (Bacillus Tuberculosis).,tuberculosis
Has a known history of active tuberculosis (Bacillus tuberculosis).,tuberculosis
Has a known history of active tuberculosis (TB; Bacillus tuberculosis),tuberculosis
Has a known history of active tuberculosis.,tuberculosis
History of active TB (Bacillus Tuberculosis).,tuberculosis
History of tuberculosis or history of tuberculosis skin test (PPD) positivity.,tuberculosis
Known history of active TB (Bacillus Tuberculosis),tuberculosis
Known history of active TB (Bacillus Tuberculosis).,tuberculosis
Known history of active TB.,tuberculosis
Known history of tuberculosis,tuberculosis
Participants must not have known or suspected active tuberculosis.,tuberculosis
"Participants with active tuberculosis (history of exposure or history of positive tuberculosis test; plus presence of clinical symptoms, physical, or radiographic findings).",tuberculosis
Patient must not have a history of active tuberculosis.,tuberculosis
Patients must not have known history of tuberculosis,tuberculosis
Patients with active tuberculosis (TB) are excluded.,tuberculosis
Patients with clinically active tuberculosis.,tuberculosis
Clinical evidence of local recurrence or distant metastases.,unresectableadvanced
"Cytologically or histologically and radiologically confirmed solid tumor that is inoperable locally advanced, metastatic, or recurrent:",unresectableadvanced
Diagnosis must have been made from the biopsy of the locally recurrent or metastatic disease.,unresectableadvanced
"Has unresectable or metastatic lesions that can be safely biopsied, as deemed by the Investigator, and must consent to pre- and post-therapy biopsies. A fresh baseline tumor biopsy (fresh baseline biopsy is defined as a biopsy specimen taken during screening) is required, except if inaccessible and with Medical Monitor approval.",unresectableadvanced
"Histologic proof of metastatic or locally advanced, unresectable breast cancer.",unresectableadvanced
Histological or cytological confirmation of locally recurrent or metastatic rectal adenocarcinoma,unresectableadvanced
"Histologically confirmed invasive, recurrent, or metastatic thymic epithelial carcinoma not amenable to surgery.",unresectableadvanced
Histologically confirmed unresectable and/or recurrent/metastatic cholangiocarcinoma.,unresectableadvanced
Histologically confirmed unresectable and/or recurrent/metastatic pancreatic adenocarcinoma.,unresectableadvanced
"Histologically confirmed, chemo-refractory, locally advanced, recurrent or metastatic gastric (including GE junction), colorectal, or pancreatic adenocarcinoma.",unresectableadvanced
"Histologically or cytologically confirmed solid tumor malignancy that is advanced or metastatic (Stage IIIB or IV per the AJCC Cancer Staging Manual, 6th ed; AJCC 2002) or is surgically unresectable.",unresectableadvanced
"Pathologically documented unresectable, recurrent, or metastatic colorectal adenocarcinoma. Until sponsor's notification to the study sites, subject must be a RAS/BRAF wild-type cancer.",unresectableadvanced
"Patients must have a locally advanced and unresectable or metastatic gastroenteropancreatic neuroendocrine carcinoma that is either known or suspected to be of GI origin. Primary tumors arising from the lung, gynecologic organs or prostate are not permitted.",unresectableadvanced
"Patients must have advance, recurrent or metastatic endometrial cancer.",unresectableadvanced
Patients must have documented metastatic or locally advanced unresectable disease on CT or MR imaging CT scans or MRIs used to assess measurable disease as defined in Section 10.1. must have been completed within 28 days prior to registration. CT scans or MRIs used to assess non-measurable disease must have been completed within 42 days prior to registration. All disease must be assessed and documented on the Baseline Tumor Assessment Form.,unresectableadvanced
Patients with locally advanced surgically unresectable PDAC.,unresectableadvanced
Patients with the indicated advanced or metastatic solid tumor as follows:,unresectableadvanced
"Received prior anticancer systemic therapy for unresectable and/or metastatic disease (not including adjuvant/neo-adjuvant treatment completed at least 6 months prior to enrollment, and participants that have received treatment for locally advanced disease with trans-arterial chemoembolization or selective internal radiation therapy, if clear evidence of radiological progression is observed before enrollment).",unresectableadvanced
Stage: Locally advanced/unresectable or metastatic disease,unresectableadvanced
"Subjects must have histologically or cytologically documented NSCLC who present with locally advanced, unresectable, Stage III disease.",unresectableadvanced
"Subjects must have recurrent, unresectable, or metastatic cervical cancer and have relapsed after a platinum-containing doublet administered for treatment of advanced (recurrent, unresectable, or metastatic) disease.",unresectableadvanced
>= 3 months have elapsed since the last dose of vaccine.,vaccine-live
Administration of a live vaccine within 4 weeks prior to start of protocol therapy.,vaccine-live
Administration of a live vaccine within 6 weeks of first dose of study drug,vaccine-live
Administration of a live vaccine within 6 weeks of first dose of study drug.,vaccine-live
"Administration of a live, attenuated vaccine within 28 days before Cycle 1, Day 1 or anticipation that such a live attenuated vaccine will be required during the study",vaccine-live
"Administration of a live, attenuated vaccine within 30 days before first dose of study treatment.",vaccine-live
"Administration of a live, attenuated vaccine within 30 days before Week 1, Day 1 or anticipation that such a live attenuated vaccine will be required during the study:",vaccine-live
"Administration of a live, attenuated vaccine within 4 weeks before cycle 1, day 1 or anticipation that such a live, attenuated vaccine will be required during the study and up to 5 months after the last dose of atezolizumab",vaccine-live
"Administration of a live, attenuated vaccine within 4 weeks before Cycle 1, Day 1 or anticipation that such a live, attenuated vaccine will be required during the study and up to 5 months after the last dose of atezolizumab.",vaccine-live
"Administration of a live, attenuated vaccine within 4 weeks before cycle 1, day 1 or anticipation that such a live, attenuated vaccine will be required during the study and up to 5 months after the last dose of atezolizumab:",vaccine-live
"Administration of a live, attenuated vaccine within 4 weeks before first BFCR4350A infusion or anticipation that such a live attenuated vaccine will be required during the study.",vaccine-live
"Administration of a live, attenuated vaccine within 4 weeks before first study treatment administration or anticipation that such a live, attenuated vaccine will be required during the study.",vaccine-live
"Administration of a live, attenuated vaccine within 4 weeks before obinutuzumab infusion or anticipation that such a live attenuated vaccine will be required during the study",vaccine-live
"Administration of a live, attenuated vaccine within 4 weeks before study treatment infusion on Cycle 1 Day 1 or anticipation that such a live, attenuated vaccine will be required during the study",vaccine-live
"Administration of a live, attenuated vaccine within 4 weeks prior to initiation of study treatment or anticipation of need for such a vaccine during the study Patients must agree not to receive live, attenuated influenza vaccine (e.g., FluMist®) within 4 weeks prior to randomization, during treatment, or within 28 days following the last dose of venetoclax.",vaccine-live
"Administration of a live, attenuated vaccine within 4 weeks prior to initiation of study treatment or anticipation of need for such a vaccine during the study Patients must agree not to receive live, attenuated influenza vaccine (e.g., FluMist®) within 4 weeks prior to randomization, during treatment, or within 28 days following the last dose of venetoclax.",vaccine-live
"Administration of a live, attenuated vaccine within 4 weeks prior to initiation of study treatment or anticipation of need for such a vaccine during the study Patients must agree not to receive live, attenuated influenza vaccine (e.g., FluMist®) within 4 weeks prior to randomization, during treatment, or within 28 days following the last dose of venetoclax.",vaccine-live
"Administration of a live, attenuated vaccine within 4 weeks prior to randomization or anticipation that such vaccine will be required during the study:",vaccine-live
Administration of live vaccine within 6 weeks before randomization,vaccine-live
"Any experimental antibodies or live vaccines in the last 28 days prior to the first dose of TJ011133. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster, yellow fever, rabies, Bacillus Calmette-Guérin, and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (e.g., FluMist®) are live attenuated vaccines and are not allowed",vaccine-live
"Chronic or current active infectious disease requiring systemic antibiotics, antifungal, or antiviral treatment, and exposure to a live vaccine within 30 days of study treatment administration.",vaccine-live
Cohort 3: Subjects must be receiving acalabrutinib for at least 6 months prior to administration of the first vaccine dose,vaccine-live
Cohort 3: Subjects must be receiving acalabrutinib monotherapy for at least 6 months prior to administration of the first vaccine dose,vaccine-live
"Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette-Guérin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (eg, FluMist®) are live attenuated vaccines and are not allowed.",vaccine-live
"Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette-Guérin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (eg, FluMist®) are live attenuated vaccines and are not allowed.",vaccine-live
"Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette-Guérin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (eg, FluMist®) are live attenuated vaccines and are not allowed.",vaccine-live
"Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette-Guérin (BCG), typhoid, and intranasal influenza vaccines (eg, FluMist®) vaccine.",vaccine-live
Had received or were scheduled to receive a live virus vaccine in the period from 4 weeks prior to Dose 1 through 28 days post-second dose,vaccine-live
Has received a live attenuated vaccine within 30 days prior to enrolling in the study.,vaccine-live
Has received a live vaccine <= 30 days prior to study registration,vaccine-live
Has received a live vaccine <= 30 days prior to study registration.,vaccine-live
Has received a live vaccine within 28 days of the planned start of study drug.,vaccine-live
Has received a live vaccine within 28 days prior to first dose.,vaccine-live
Has received a live vaccine within 30 days of planned start of registration.,vaccine-live
Has received a live vaccine within 30 days of planned start of study therapy,vaccine-live
Has received a live vaccine within 30 days of planned start of study therapy.,vaccine-live
"Has received a live vaccine within 30 days of planned start of study therapy. (Note: seasonal influenza vaccines for injection are allowed as they are inactivated; however, intranasal influenza vaccines are live attenuated vaccines and are NOT allowed)",vaccine-live
"Has received a live vaccine within 30 days of planned start of study treatment. Seasonal influenza vaccines for injection are generally inactivated flu vaccines and are allowed; intranasal influenza vaccines (e.g., Flu-Mist®) are live attenuated vaccines and are NOT allowed.",vaccine-live
"Has received a live vaccine within 30 days of planned start of study treatment. Seasonal influenza vaccines for injection are generally inactivated flu vaccines and are allowed; intranasal influenza vaccines (e.g., Flu-Mist®) are live attenuated vaccines and are NOT allowed.",vaccine-live
Has received a live vaccine within 30 days of the first dose of trial treatment.,vaccine-live
Has received a live vaccine within 30 days of the planned start of study drug.,vaccine-live
Has received a live vaccine within 30 days prior to first dose,vaccine-live
Has received a live vaccine within 30 days prior to first dose of study drug.,vaccine-live
Has received a live vaccine within 30 days prior to first dose of study treatment,vaccine-live
Has received a live vaccine within 30 days prior to the first dose of pembrolizumab,vaccine-live
"Has received a live vaccine within 30 days prior to the first dose of study drug. Examples of live vaccines include, but are not limited to, the following:",vaccine-live
"Has received a live vaccine within 30 days prior to the first dose of study drug. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette-Guerin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (eg, FluMist) are live attenuated vaccines and are not allowed.",vaccine-live
"Has received a live vaccine within 30 days prior to the first dose of study drug. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette-Guérin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (eg, FluMist®) are live attenuated vaccines and are not allowed.",vaccine-live
"Has received a live vaccine within 30 days prior to the first dose of study drug. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette-Guérin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (e.g., FluMist®) are live attenuated vaccines and are not allowed.",vaccine-live
"Has received a live vaccine within 30 days prior to the first dose of study drug. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, yellow fever, rabies, Bacillus Calmette-Guérin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (eg, FluMist®) are live attenuated vaccines and are not allowed.",vaccine-live
Has received a live vaccine within 30 days prior to the first dose of study treatment.,vaccine-live
"Has received a live vaccine within 30 days prior to the first dose of study treatment. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette-Guérin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (eg, FluMist®) are live attenuated vaccines and are not allowed.",vaccine-live
"Has received a live vaccine within 30 days prior to the first dose of study treatment. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette-Guérin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (eg, FluMist®) are live attenuated vaccines and are not allowed.",vaccine-live
"Has received a live vaccine within 30 days prior to the first dose of study treatment. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette-Guérin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (eg, FluMist®) are live attenuated vaccines and are not allowed.",vaccine-live
Has received a live vaccine within 30 days prior to the first dose of trial drug.,vaccine-live
Has received a live vaccine within 30 days prior to the first dose of trial treatment,vaccine-live
Has received a live vaccine within 30 days prior to the first dose of trial treatment.,vaccine-live
Has received a live virus vaccine in 30 days preceding start of therapy.,vaccine-live
Has received a live-attenuated vaccine within 30 days prior to enrolment.,vaccine-live
Has received a live-virus vaccine within 30 days of planned treatment start. Seasonal flu vaccines that do not contain live virus are permitted.,vaccine-live
Have received any live vaccine within 14 days prior to first study drug administration,vaccine-live
Have received recent (within 4 weeks prior to randomization) live vaccination. Seasonal flu vaccines that do not contain a live virus are permitted.,vaccine-live
History of drug-induced colitis or pneumonitis; TB treatment <= 2 years prior to randomization; administration of a live or live attenuated vaccine within 6 weeks of randomization,vaccine-live
"Inactivated influenza vaccination should be given during influenza season only (approximately October to March). Patients must not receive live, attenuated influenza vaccine within 4 weeks prior to randomization or while on protocol treatment and up to 5 months after the last dose of protocol treatment.",vaccine-live
"Inactivated influenza vaccination should be given during local influenza season only. Patients must not receive live, attenuated influenza vaccine (e.g., FluMist®) at any time during the study treatment period.",vaccine-live
"Influenza vaccination should be given during influenza season (approximately October to May in the Northern Hemisphere; approximately May to October in the Southern Hemisphere). Patients must not receive live, attenuated influenza vaccine (e.g., FluMist®) at any time during the study treatment period.",vaccine-live
"Influenza vaccination should be given during influenza season (approximately October to May in the Northern Hemisphere; approximately May to October in the Southern Hemisphere). Patients must not receive live, attenuated influenza vaccine (e.g., FluMist®) at any time during the study treatment period.",vaccine-live
"Influenza vaccination should be given during influenza season (approximately October to May in the Northern Hemisphere; approximately May to October in the Southern Hemisphere). Patients must not receive live, attenuated influenza vaccine (e.g., FluMist®) at any time during the study treatment period.",vaccine-live
"Influenza vaccination should be given during influenza season only (approximately October to March). Patients must not receive live, attenuated influenza vaccine within 4 weeks prior to Cycle 1, Day 1 or at any time during the study.",vaccine-live
"Influenza vaccination should be given during influenza season only (approximately October to March); patients must not receive live, attenuated influenza vaccine within 4 weeks prior to cycle 1, day 1 or at any time during the study",vaccine-live
"Influenza vaccination should be given during influenza season only. Patients must not receive live, attenuated influenza vaccine (e.g., FluMistTM) within 4 weeks prior to Week 1, Day 1 or at any time during the study.",vaccine-live
"Influenza vaccination should be given during influenza season only; patients must not receive live, attenuated influenza vaccine within 4 weeks prior to cycle 1, day 1 or at any time during the study.",vaccine-live
Investigators should review the vaccination status of potential study patients being considered for this study and follow the U.S. Centers for Disease Control and Prevention guidelines for adult vaccination with any other non-live vaccines intended to prevent infectious diseases prior to study.,vaccine-live
Is known to have received a live vaccine within 30 days prior to the first dose of trial treatment,vaccine-live
"Is receiving any live vaccine (example, varicella, pneumococcus) within 4 weeks of initiation of study treatment.",vaccine-live
Live attenuated vaccines,vaccine-live
Live attenuated vaccines (from the time of HCT to d70 post-HCT),vaccine-live
Live attenuated vaccines within 90 days prior to leukapheresis.,vaccine-live
Live vaccine < 6 weeks prior to start of lympho-conditioning,vaccine-live
Live vaccine <= 4 weeks prior to enrollment,vaccine-live
Live vaccine <= 4 weeks prior to enrolment.,vaccine-live
Live vaccine <= 6 weeks prior to planned start of conditioning chemotherapy.,vaccine-live
Live vaccine <= 6 weeks prior to planned start of conditioning regimen,vaccine-live
Live vaccine <= 6 weeks prior to planned start of conditioning regimen.,vaccine-live
Live vaccine <= 6 weeks prior to start of conditioning regimen,vaccine-live
Live vaccine administration within 4 weeks before enrollment,vaccine-live
"Live vaccine within 30 days prior to day 1 of protocol therapy (e.g. measles, mumps, rubella, varicella, yellow fever, rabies, Bacillus Calmette?Guerin [BCG], oral polio vaccine, and oral typhoid)",vaccine-live
Live vaccine within 30 days prior to treatment initiation.,vaccine-live
Live vaccine within 30 days.,vaccine-live
Live vaccines should be avoided during study treatment and after the last study treatment until B-cell recovery to normal ranges.,vaccine-live
"Live vaccines: Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, chicken pox, shingles, yellow fever, rabies, bacillus Calmette-Guerin (BCG), and typhoid (oral) vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (e.g., Flu-Mist) are live attenuated vaccines, and are not allowed. Prior administration of intravesical BCG is allowed",vaccine-live
Live virus vaccines within 2 weeks prior to planned start of lymphodepleting chemotherapy.,vaccine-live
Live virus vaccines within 4 weeks prior to C1D1 or during rituximab therapy.,vaccine-live
Live virus vaccines within 4 weeks prior to or during study therapy.,vaccine-live
"Live, attenuated vaccine within 30 days prior to the first dose of protocol therapy",vaccine-live
Newly diagnosed MCL: Major surgery within 4 weeks or vaccination with live attenuated vaccines within 4 weeks of the first dose of study drug,vaccine-live
No exposure to the live VZV vaccine (ZOSTAVAX) within 12 months prior to vaccination,vaccine-live
"No live vaccines within 30 days prior to registration; examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, chicken pox, yellow fever, rabies, BCG, and typhoid (oral) vaccine; seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (e.g., Flu-Mist) are live attenuated vaccines and are not allowed; NOTE: no live vaccines may be administered while participating in the trial",vaccine-live
"No live vaccines within 30 days prior to the first dose of trial treatment and while participating in the trial; examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, chicken pox, yellow fever, rabies, BCG, and typhoid (oral) vaccine; seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (e.g., Flu-Mist) are live attenuated vaccines and are not allowed",vaccine-live
"Non-antibody immunotherapy (e.g., tumor vaccine), at least 42 days from last dose",vaccine-live
"Non-oncology vaccine therapies for prevention of infectious diseases (e.g., human papilloma virus vaccine) within 4 weeks of study registration. The inactivated seasonal influenza vaccine can be given to patients before treatment and while on therapy without restriction. Influenza vaccines containing live virus or other clinically indicated vaccinations for infectious diseases (i.e., pneumovax, varicella, etc.) may be permitted, but must be discussed with the sponsor investigator and may require a study drug washout period before and after administration of vaccine.",vaccine-live
Participants must not have received nononcology vaccines containing live virus for prevention of infectious diseases within 12 weeks prior to the first dose of study treatment.,vaccine-live
Patient has received live vaccine within 30 days of planned start of study therapy.,vaccine-live
"Patient must not be vaccinated with live, attenuated vaccines within 4 weeks of first dose of study drug",vaccine-live
"Patient must not be vaccinated with live, attenuated vaccines within 4 weeks of first dose of study drug.",vaccine-live
Patients have been administered live attenuated vaccine 4 weeks before leukapheresis or lymphodepletion,vaccine-live
"Patients must agree not to receive live, attenuated influenza vaccine (e.g., FluMist) within 4 weeks prior to randomization, during treatment or within 5 months following the last dose of atezolizumab/placebo.",vaccine-live
Patients must not be planning to receive live virus or live bacterial vaccines while receiving olaparib and during the 30 day follow up period.,vaccine-live
"Patients must not have received a live vaccine within 30 days prior to planned day 1 of protocol therapy (e.g. measles, mumps, rubella, varicella, yellow fever, rabies, Bacillus Calmette-Guerin [BCG], oral polio vaccine, and oral typhoid).",vaccine-live
"Patients must not have received a live, attenuated vaccine within 4 weeks prior to randomization or anticipate that such a live, attenuated vaccine will be required while on protocol treatment and up to 5 months after the last dose of protocol treatment.",vaccine-live
Patients receiving a live attenuated vaccine <= 28 days before the first dose of study drug.,vaccine-live
Patients should not have received immunization with attenuated live vaccine within one week of study entry or during study period.,vaccine-live
Patients who have received a live or attenuated vaccine within 28 days of beginning the preparative NMA-LD regimen,vaccine-live
Patients who have received a live vaccine less than or equal to 30 days prior to enrollment are ineligible.,vaccine-live
Patients who have received live attenuated vaccine within 28 days of first dose of investigational drug.,vaccine-live
Patients who have received live vaccines within the last 30 days,vaccine-live
Planned live vaccine administration after starting study drug.,vaccine-live
Planned live vaccine administration after starting study drugs (C1D1),vaccine-live
Potential subjects must not have received any vaccines for 28 days prior to administration of their first dose of MT-3724 and should not receive any vaccine during the study or within 28 days after their last dose of MT-3724. The single exception to this exclusion is for the annual influenza (flu) vaccine which can be given up to 14 days prior to first dose.,vaccine-live
"Prior chemotherapy within 3 weeks, nitrosoureas within 6 weeks, therapeutic anticancer antibodies within 4 weeks, radio- or toxin-immunoconjugates within 10 weeks, radiation therapy or other investigational agents within 3 weeks, major surgery within 4 weeks or vaccination with live attenuated vaccines within 4 weeks of the first dose of study drug.",vaccine-live
"reatment with a live, attenuated vaccine within 4 weeks prior to initiation of study treatment, or anticipation of need for such a vaccine during the course of the study or within 5 months after the final dose of atezolizumab",vaccine-live
Receipt of a live attenuated vaccine within 4 weeks prior to study drug,vaccine-live
Receipt of a live vaccine within 30 days of planned start of study drug.,vaccine-live
Receipt of a live vaccine within 30 days of receipt of study therapy.,vaccine-live
"Receipt of a live vaccine within 30 days of the start of treatment. Examples are measles, mumps, rubella, varicella, yellow fever, rabies, BCG, oral polio vaccine, and oral typhoid vaccine.",vaccine-live
Receipt of a live virus vaccine <= 2 months prior to registration.,vaccine-live
Receipt of a live virus vaccine within 28 days prior to Day 1 of Cycle 1,vaccine-live
Receipt of a live/attenuated vaccine within 30 days of first treatment. The inactivated seasonal influenza vaccine can be given to participants before treatment and while on therapy without restriction.,vaccine-live
"Receipt of any live vaccine (example, varicella, pneumococcus) within 4 weeks of initiation of study treatment.",vaccine-live
Receipt of attenuated vaccine within 2 weeks prior to starting study treatment.,vaccine-live
"Receipt of live (including attenuated) vaccines during the study, or anticipation of need for such a vaccine during the study.",vaccine-live
Receipt of live attenuated vaccination within 30 days of receiving study drug.,vaccine-live
"Receipt of live attenuated vaccination within 30 days prior to receiving study treatment. Inactivated viruses, such as those in the influenza vaccine, are permitted",vaccine-live
Receipt of live attenuated vaccination within 30 days prior to study entry,vaccine-live
Receipt of live attenuated vaccination within 4 weeks prior to study entry or within 30 days of receiving TAB004.,vaccine-live
Receipt of live attenuated vaccination within 4 weeks prior to study entry or within 4 weeks of receiving TAB001.,vaccine-live
Receipt of live attenuated vaccine within 30 days before the first dose of study treatment.,vaccine-live
Receipt of live attenuated vaccine within 30 days prior to the first dose of IP.,vaccine-live
Receipt of live attenuated vaccine within 30 days prior to the first dose of study treatment.,vaccine-live
"Receipt of live attenuated vaccine within 30 days prior to the first dose of study treatment. Note: Patients, if enrolled, should not receive live vaccine whilst receiving study treatment and up to 30 days after the last dose of study treatment.",vaccine-live
Receipt of live or live attenuated vaccine within 12 weeks prior to enrollment,vaccine-live
Receipt of live vaccination within 28 days before randomization. Seasonal flu vaccines that do not contain live virus are permitted.,vaccine-live
receipt of live vaccine within 28 days prior to registration,vaccine-live
"Receipt of live vaccines within 30 days before the first dose of trial treatment and while participating in the trial; examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, chicken pox, yellow fever, seasonal flu, H1N1 flu, rabies, bacillus Calmette-Guérin (BCG), and typhoid vaccine",vaccine-live
"Receipt of live, attenuated vaccine within 28 days prior to the first dose of durvalumab (Note: enrolled patients should not receive live vaccine during the study and for 180 days after the last dose of durvalumab)",vaccine-live
"Receipt of live, attenuated vaccine within 28 days prior to the first dose of MEDI5395 (Note: Subjects, if enrolled, should not receive live vaccine during the study and for 60 days after the last dose of MEDI5395 or 30 days after the last dose of durvalumab, whichever is longer)",vaccine-live
"Receipt of live, attenuated vaccine within 30 days prior to enrolment",vaccine-live
"Receipt of live, attenuated vaccine within 30 days prior to study entry. Enrolled patients should not receive live vaccine during the study and 30 days after the last dose of durvalumab.",vaccine-live
"Receipt of live, attenuated vaccine within 30 days prior to the first dose of investigational products (Note: Subjects, if enrolled, should not receive live vaccine during the study and 30 days after the last dose of investigational product[s]). Vaccination with a killed vaccine is permitted at any time with consultation with the medical monitor.",vaccine-live
Receipt of live-virus vaccines within 28 days prior to registration or need for live-virus vaccines at any time during study treatment.,vaccine-live
Receipt of live-virus vaccines within 28 days prior to the initiation of study treatment or need for live-virus vaccines at any time during study treatment,vaccine-live
Receipt of live-virus vaccines within 28 days prior to the initiation of study treatment or need for live-virus vaccines at any time during study treatment.,vaccine-live
Received a live vaccine <= 30 days prior to registration,vaccine-live
Received a live vaccine <= 30 days prior to registration.,vaccine-live
"Received a live vaccine <= 30 days prior to registration; Note: Seasonal influenza vaccines for injection are generally inactivated flu vaccines and are allowed; however, intranasal influenza vaccines (e.g., Flu-Mist) are live attenuated vaccines, and are not allowed; routine vaccinations, including seasonal influenza, must be given >= 2 weeks prior to registration",vaccine-live
Received a live vaccine within 28 days of study Day 1.,vaccine-live
Received a live vaccine within 30 days of planned start of study medication,vaccine-live
Received a live vaccine within 30 days of planned start of the trial treatment,vaccine-live
Received a live vaccine within 30 days of the first dose of study drugs.,vaccine-live
"Received a live vaccine within 30 days prior to the first study treatment. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette-Guérin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (e.g. FluMist) are live attenuated vaccines and are not allowed.",vaccine-live
"Received a live, attenuated vaccine within 28 days prior to randomization or anticipation that such a live attenuated vaccine will be required during the trial Note: Influenza vaccination should be given during influenza season only (approximately October to March). Subjects must not receive live, attenuated influenza vaccine (e.g., FluMistP ®) within 28 days prior to Day 0, during treatment, or within 90 days following the last dose of trial treatment.",vaccine-live
Received a vaccination with a live vaccine <= 28 days prior to randomization,vaccine-live
Received a vaccine (inactivated) <= 14 days prior to registration.,vaccine-live
Received a vaccine (inactivated) <= 2 weeks prior to registration.,vaccine-live
Received any vaccine within 7 days of planned start of study therapy,vaccine-live
"Received any vaccines except injectable flu (inactivated or recombinant) vaccine within 4 weeks before the start of treatment, or likely to require any vaccines except injectable flu vaccine at any time from the start of treatment until 28 days after the last dose of MT-3724.",vaccine-live
"Received any vaccines within 28 days of the start of treatment, or likely to require vaccines at any time from the start of treatment until 28 days after the last dose of MT-3724. Injectable flu vaccine (inactivated or recombinant) is permitted at the investigator's discretion",vaccine-live
"Received any vaccines within 28 days of the start of treatment, or likely to require vaccines at any time from the start of treatment until 28 days after the last dose of MT-3724. Injectable flu vaccine (inactivated or recombinant) is permitted at the investigator's discretion.",vaccine-live
Received live vaccine <= 30 days prior to registration,vaccine-live
"Received live vaccine <= 30 days prior to registration. NOTE: Seasonal influenza vaccines for injection are generally inactivated flu vaccines and are allowed; however intranasal influenza vaccines (e.g., Flu-Mist®) are live attenuated vaccines, and are not allowed.",vaccine-live
"Received live vaccine <= 30 days prior to registration. NOTE: Seasonal influenza vaccines for injection are generally inactivated flu vaccines and are allowed; however intranasal influenza vaccines (e.g., Flu-Mist®) are live attenuated vaccines, and are not allowed.",vaccine-live
Received live vaccine within 30 days prior to day 1 of protocol therapy.,vaccine-live
Received live vaccine within 4 weeks before Screening.,vaccine-live
Received live vaccines,vaccine-live
Received live vaccines within 30 days prior to enrollment,vaccine-live
Received live vaccines within 30 days prior to enrollment in Part A or randomization in Part B.,vaccine-live
RECIPIENT: Live attenuated vaccines,vaccine-live
"Relapsed/refractory MCL: Prior chemotherapy within 3 weeks, nitrosoureas within 6 weeks, therapeutic anticancer antibodies within 4 weeks, radio- or toxin-immunoconjugates within 10 weeks, radiation therapy or other investigational agents within 3 weeks, major surgery within 4 weeks or vaccination with live attenuated vaccines within 4 weeks of the first dose of study drug",vaccine-live
"Routine vaccinations, including seasonal influenza, should be given at least 2 weeks prior to study treatment. Vaccines are not prohibited on study, but must be given at least 6 weeks after cycle 1 and not within 7 days of treatment.",vaccine-live
"Routine vaccinations, including seasonal influenza, should be given at least 2 weeks prior to study treatment; vaccines are not prohibited on study, but must be given at least 6 weeks after cycle 1 and not within 7 days of treatment",vaccine-live
"Subject has received a live attenuated vaccine within 30 days of initiating study treatment (i.e., 30 days prior to the first dose, during treatment, and for 30 days after study treatment discontinuation). Inactivated vaccines, such as the injectable influenza vaccine, are permitted.",vaccine-live
Subject must not have received any live vaccines within 8 weeks prior to randomization.,vaccine-live
"Subject must not have received any live vaccineswithin 4 weeks before the first dose of study drug, or have an expected need for a live vaccination during study participation including at least 4 weeks after the last dose of study drug (venetoclax or gilteritinib).",vaccine-live
Subjects must not have received a live vaccine within 30 days prior to the first dose of study medication.,vaccine-live
Subjects who have received a live vaccine within last 3 months of the first administration of study drug.,vaccine-live
"The use of inactivated seasonal influenza vaccines (eg, Fluzone®) will be permitted on study without restriction.",vaccine-live
"Treatment with a live, attenuated vaccine within 4 weeks prior to initiation of study treatment, or anticipation of need for such a vaccine during atezolizumab treatment or within 5 months after the last dose of atezolizumab",vaccine-live
"Treatment with a live, attenuated vaccine within 4 weeks prior to initiation of study treatment, or anticipation of need for such a vaccine during the course of the study",vaccine-live
"Treatment with a live, attenuated vaccine within 4 weeks prior to initiation of study treatment, or anticipation of need for such a vaccine during the course of the study or within 5 months after the final dose of atezolizumab",vaccine-live
"Treatment with a live, attenuated vaccine within 4 weeks prior to initiation of study treatment, or anticipation of need for such a vaccine during the course of the study or within 5 months after the last dose of atezolizumab.",vaccine-live
"Treatment with a live, attenuated vaccine within 4 weeks prior to initiation of study treatment, or anticipation of need for such a vaccine during treatment with atezolizumab and within 5 months after the last dose of atezolizumab",vaccine-live
Use of an experimental vaccine within 2 months in the absenceof tumor response. The subject should be excluded if theirdisease is responding to an experimental vaccine given within 6 months,vaccine-live
"Use of any live vaccines against infectious diseases (e.g. influenza, varicella, pneumococcus) within 4 weeks of initiation of study treatment.",vaccine-live
Use of live vaccines against infectious diseases 4 weeks prior to first study drug administration and during study.,vaccine-live
"Vaccinated with live, attenuated vaccine within 4 weeks of first dose of study drug",vaccine-live
"Vaccinated with live, attenuated vaccines within 28 days of the first dose of the study drug",vaccine-live
"Vaccinated with live, attenuated vaccines within 4 weeks of enrollment",vaccine-live
"Vaccinated with live, attenuated vaccines within 4 weeks of enrollment.",vaccine-live
"Vaccinated with live, attenuated vaccines within 4 weeks of first dose of avelumab",vaccine-live
"Vaccinated with live, attenuated vaccines within 4 weeks of first dose of study drug",vaccine-live
"Vaccinated with live, attenuated vaccines within 4 weeks of first dose of study drug.",vaccine-live
"Vaccinated with live, attenuated vaccines within 4 weeks of randomization",vaccine-live
"Vaccinated with live, attenuated vaccines within 4 weeks of randomization.",vaccine-live
"Vaccinated with live, attenuated vaccines within 4 weeks of study entry.",vaccine-live
"Vaccination for the prevention of infectious diseases with a live vaccine during the four-week period prior to TG4050 treatment initiation planned date. Furthermore, patients should not receive any live vaccine during the period of study treatment administration.",vaccine-live
Vaccination with a live vaccine < 28 days prior to the start of treatment,vaccine-live
Vaccination with a live vaccine a minimum of 28 days prior to the start of treatment,vaccine-live
Vaccination with a live vaccine a minimum of 4 weeks prior to study enrollment,vaccine-live
"Vaccination with a live virus vaccine within 28 days prior to Day 1 of Cycle 1 or anticipation that such a live, attenuated vaccine will be required during the study",vaccine-live
Vaccination with live vaccine within 35 days prior to first dose.,vaccine-live
Vaccination with live vaccine within 35 days prior to the first dose of study drug.,vaccine-live
Vaccination with live vaccines within 28 days prior to the start of Cycle 1,vaccine-live
Vaccination within 4 weeks of the first dose of avelumab and while on study is prohibited except for administration of inactivated vaccines (e.g. inactivated influenza vaccines).,vaccine-live
Vaccination within 4 weeks of the first dose of study treatment is prohibited except for administration of inactivated vaccines.,vaccine-live
"Vaccine administration within 4 weeks of M7824 administration. Vaccination with live vaccines while on study is prohibited. Administration of inactivated vaccines is allowed (e.g., inactivated influenza vaccines).",vaccine-live
Adequate vascular access available or planned for leukapheresis procedure (either peripheral line or surgically placed line),vascaccess
Adequate vascular access for leukapheresis procedure,vascaccess
Adequate vascular access for leukapheresis procedure (either peripheral line or surgically-placed line),vascaccess
Inability to be venipunctured and/or tolerate venous access.,vascaccess
Research participant must have appropriate venous access,vascaccess
Subject either currently has central vascular access or is a candidate to receive central vascular access or peripheral vascular access for leukapheresis procedure,vascaccess
Subject either currently has central vascular access or is a candidate to receive central vascular access or peripheral vascular access for leukapheresis procedure.,vascaccess
Suitable venous access for safe drug administration and the study-required PK and pharmacodynamic sampling.,vascaccess
Suitable venous access for safe drug administration and the study-required PK and pharmacodynamics sampling.,vascaccess
Willingness to have a central venous line (peripherally inserted central catheter [PICC] or PORT),vascaccess
Willingness to have a central venous line (PICC or PORT).,vascaccess
>= 10% weight loss within the past month.,weight-loss
"Constitutional symptoms, defined as either weight loss > 10% during the prior 6 months or fever ( > 37.5��?��??��?��??��?��??C) or night sweats not attributable to other etiologies persisting for > 1 month.",weight-loss
Malabsorption with weight loss attributed to gastrointestinal tract mast infiltrates.,weight-loss
Unintentional weight loss of >= 10% within the previous 6 months,weight-loss
Unintentional weight loss of >= 10% within the previous 6 months; or,weight-loss
Unintentional weight loss of 10% or more within 6 months,weight-loss
Weight loss >= 10% within the previous 6 months,weight-loss
Weight loss of > 10% in the past 3 months,weight-loss
Active peptic ulcer disease,wound-or-ulcer
Any medical condition that requires intact wound healing capacity and is expected to endanger subject safety if wound healing capacity would be severely reduced during administration of the investigational agent,wound-or-ulcer
Complete healing of an intra-abdominal abscess must be confirmed before first dose.,wound-or-ulcer
Complete healing of an intra-abdominal abscess must be confirmed before randomization.,wound-or-ulcer
"History of abdominal fistula, GI perforation, peptic ulcer, or intra-abdominal abscess within 6 months.",wound-or-ulcer
"In addition, complete wound healing from prior surgery must be confirmed at least 28 days before the first dose of cabozantinib irrespective of the time from surgery",wound-or-ulcer
No history of fracture within 28 days of registration,wound-or-ulcer
No history of non-healing wounds or ulcers within 28 days of registration,wound-or-ulcer
"Non-healing serious wound, ulcer, or bone fracture unrelated to the primary tumor",wound-or-ulcer
"Non-healing serious wound, ulcer, or bone fracture unrelated to the primary tumor.",wound-or-ulcer
"Non-healing wound, active ulcer, or bone fracture. Patients with granulating incisions healing by secondary intention with no evidence of facial dehiscence or infection are eligible but require wound examinations every 3 weeks",wound-or-ulcer
"Ongoing serious, non-healing wound, ulcer, or bone fracture.",wound-or-ulcer
serious non-healing wound/ulcer/bone fracture within 28 days before the first dose of study treatment,wound-or-ulcer
Serious non-healing wound/ulcer/bone fracture.,wound-or-ulcer
"Serious or non-healing wound, peptic ulcer, or bone fracture within 28 days prior to initiation of study treatment",wound-or-ulcer
"Serious, non-healing wound, skin ulcer (of any grade), or bone fracture.",wound-or-ulcer
"Serious, non-healing wound, ulcer, or bone fracture",wound-or-ulcer
Subjects with a healing or open wound,wound-or-ulcer
Surgical or other wounds must be adequately healed prior to enrollment,wound-or-ulcer
"Wound healing problem, per Investigator's assessment, that would make the patient ineligible for study randomization",wound-or-ulcer
